

OS Unidentified.
 XX WO200259259-A2.
 PN
 XX 01-AUG-2002.
 PD
 XX 23-JAN-2002; 2002WO-IL00071.
 PF
 XX 23-JAN-2001; 2001US-263158P.
 PR
 XX (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
 PA
 XX Wreschner DH;
 PI
 XX WPI: 2002-599769/64.
 DR
 XX P-PSDB; ABG98328.
 DR
 XX Differential display method for identifying secreted or transmembrane
 PT protein, comprises contacting a DNA with a first primer that hybridizes
 PT to a sequence coding for a leucine-rich motif and with a second
 PT oligonucleotide primer -
 XX
 XX Disclosure; Fig 2; 37pp; English.
 PS
 XX The invention relates to a differential display comprising contacting
 CC cDNA with a first primer that hybridizes to an oligonucleic sequence
 CC coding for a leucine-rich motif, and with a second oligonucleotide primer
 CC to form a cDNA-hybrid molecule. The method comprises obtaining mRNA from
 CC at least 2 samples, synthesizing cDNA from the RNA of each sample,
 CC contacting the cDNA with a first primer that hybridizes to an
 CC oligonucleic sequence coding for a leucine-rich motif, and with a second
 CC oligonucleotide primer to form cDNA-hybrid molecules, amplifying the
 CC cDNA-hybrid molecules, detecting amplified products and comparing the
 CC amplified products from each sample to identify distinctive amplified
 CC products coding for at least one secreted or transmembrane protein. The
 CC method is useful for discovering novel secreted and/or transmembrane
 CC proteins which are important for cell processes and play an important
 CC role in determining its phenotype, and which act as mediators for the
 CC transfer of signals from external environment into the cell itself, thus
 CC modulating gene expression. Sequences ABX03792-ABX03869 represent DNA
 CC encoding secreted protein signal peptide sequences.
 XX
 SQ Sequence 18 BP; 1 A; 8 C; 5 G; 4 T; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 566 CACTGCTCCAGCGCC 582
 DB 2 CACTGCTCCAGCGCC 18
 RESULT 276
 ABS52111/c
 ID ABS52111 standard; DNA; 18 BP.
 XX
 XX ABS52111;
 AC
 XX 05-NOV-2002 (first entry)
 DT
 XX Human adipocyte Clq Tumour Necrosis Factor-like PCR primer 1.
 DE
 XX Human; NOVX; NOVX-associated disorder; cardiomyopathy; atherosclerosis;
 KW call signal processing; metabolic pathway modulation; metabolic disorder;
 KW obesity; diabetes; infectious disease; neurodegenerative disorder; acne;
 KW Alzheimer's disease; Parkinson's disease; immune disorder; cancer;
 KW haematopoietic disorder; cirrhosis; pancreatitis; learning defect;
 KW memory defect; infertility; congenital heart defect; hair growth;
 KW pigmentation disorder; endocrine disorder; respiratory disease; health;
 KW gastro-intestinal disease; reproductive; neurological disease; health;
 KW bone marrow transplantation; endocrine disease; allergy; inflammation;
 KW neurological disorder; urinary system disorder; age-related disorder;

KW neuropsychiatric disorder; EGF-related protein; SCUBE1; TEN-M4;
 KW adipocyte complement-related Clq tumour necrosis factor; out at first;
 KW beta adrenergic receptor kinase; EphA6/ehk-2; glucose transporter;
 KW type Ia membrane sushi-containing domain; butyrophilin;
 KW type Ia membrane-sushi domain containing; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200257453-A2.
 PN
 XX 25-JUL-2002.
 PD
 XX 19-DEC-2001; 2001WO-US50331.
 PF
 XX 19-DEC-2000; 2000US-265704P.
 PR
 XX 20-DEC-2000; 2000US-257314P.
 PR
 XX 02-MAY-2001; 2001US-288153P.
 PR
 XX 29-MAY-2001; 2001US-294075P.
 PR
 XX 24-JUL-2001; 2001US-307506P.
 PR
 XX 10-AUG-2001; 2001US-311590P.
 PR
 XX 10-AUG-2001; 2001US-311613P.
 PR
 XX 29-AUG-2001; 2001US-315617P.
 PR
 XX 14-SEP-2001; 2001US-322358P.
 XX
 XX (CURA-) CURAGEN CORP.
 PA
 XX Gangolli EA, Patturajan M, Vernet CAM, Malyankar UM, Kekuda R;
 XX Stone DU, Anderson D, Shinkens RA, Burgess CE, Zerhusen BD, Liu X;
 PI Spytek KA, Casman SJ, Boldog FL, Smithson G, Li L, Ji W;
 XX WPI; 2002-590744/63.
 DR
 XX Novel isolated NOVX polypeptide useful for treating cardiomyopathy,
 PT atherosclerosis, metabolic disorders, diabetes, obesity, infectious
 PT disease, anorexia, neurodegenerative disorders, Alzheimer's disease or
 PT cancer -
 XX
 XX Example 1; Page 198; 318pp; English.
 PS
 XX The present invention relates to new NOVX polypeptides. The invention is
 CC useful for treating or preventing a NOVX-associated disorder such as
 CC cardiomyopathy or atherosclerosis, where the disorder is related to cell
 CC signal processing and metabolic pathway modulation in a subject.
 CC preferably human. The invention is also useful for treating metabolic
 CC disorders (e.g. obesity), diabetes, infectious disease, neurodegenerative
 CC disorders (e.g. Alzheimer's disease, Parkinson's disease), immune
 CC disorders, haematopoietic disorders and various cancers. The molecules of
 CC the invention are also useful for treating or preventing cirrhosis,
 CC pancreatitis, learning and memory defects, infertility, congenital heart
 CC defects, acne, hair growth, pigmentation disorders, endocrine disorders,
 CC respiratory diseases, gastro-intestinal diseases, reproductive diseases,
 CC neurological diseases, bone marrow transplantation, endocrine diseases,
 CC allergy and inflammation, nephrological disorders, urinary system
 CC disorders, neuropsychiatric disorders and age-related disorders.
 CC The present nucleic acid sequence represents a PCR primer that was used
 CC in the methods of the invention.
 XX
 SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 725 AGCAGGGGGCCTGGCTG 741
 DB 18 AGCATGGCGCTGGCTG 2
 RESULT 277
 AAQ27299/c
 ID AAQ27299 standard; DNA; 19 BP.
 XX
 XX AAQ27299;
 AC

```

XX DT 25-MAR-2003 (updated)
XX DT 02-FEB-1993 (first entry)
XX DE PSPL1 primer DHAl4.
XX KW Cosmid; MalphaG#9; exon; Na, K-ATPase; in vivo splicing splasmid;
XX KW HIV-1 tat; splice site; beta-globin; ss.
XX OS Synthetic.
XX XX WO92113071-A1.
XX PN 06-AUG-1992.
XX PF 27-JAN-1992; 92WO-US00692.
XX PR 28-JAN-1991; 91US-0646664.
XX PA (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX PI Buckler AJ, Chang DD, Housman DE, Sharp PA;
XX DR WPI; 1992-284656/34.
XX XX
XX XX Isolating coding sequence from mammalian genomic DNA - by
XX PT providing fragmented DNA, inserting DNA into intron of in vivo
XX PT splicing plasmid, introducing obtd. in vivo splicing plasmid
XX PT construct into host cell, etc.
XX XX
XX PS Claim 24; Page 33; 38pp; English.
XX XX
XX CC Fragments of a mouse cosmid clone, MalphaG#9, known to contain
XX CC exon sequences of the Na, K-ATPase alpha subunit gene (Tam, S.-
XX CC Y., et al., Mol. Cell. Biol. 10:6619-6623 (1990) were used to
XX CC demonstrate that when a fragment contg. an entire exon with
XX CC flanking intron sequences (in the proper orientation) is inserted
XX CC into an intron of an in vivo splicing plasmid, the exon is retained
XX CC in the mature poly A+ cytoplasmic RNA. In vivo splicing plasmid
XX CC PSPL1 was used. The insertion site is within an intron from the
XX CC HIV-1 tat gene whose flanking exons and splice sites were substituted
XX CC for the second intron of the rabbit beta-globin gene.
XX CC Oligonucleotide pairs for PCR are represented in AAQ27298-304.
XX CC Beta-globin specific primers are SD2 and SA2 (AAQ27300-01).
XX CC The antisense primers DHAB14 and SA2 (AAQ27299 and AAQ27301) were used
XX CC as primer in the first strand cDNA synthesis reactions.
XX CC SD1 and SA1 (AAQ27302-03) are internal to the initial RNA/PCR prod.
XX CC and were used for reamplification of RNA/PCR prods.
XX CC (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 19 BP; 3 A; 5 C; 8 G; 3 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 788 CCAGTGCCTGGCTGC 804
DB 17 CCATGCGCTGGCTCAC 1

RESULT 278
AAQ47696/c
ID AAQ47696 standard; DNA; 19 BP.
XX AC AAQ47696;
XX XX
XX DT 25-MAR-2003 (updated)
XX DT 04-FEB-1994 (first entry)
XX XX
XX DE Sequence of primer CAMP-c #2 for cyclophilin associated
XX DE membrane protein (CAMP-c) cDNA.

```

```

KW Cyclophilin associated membrane protein; CAMP-c; primer; ss.
XX OS Synthetic.
XX PN WO9316183-A1.
XX PD 19-AUG-1993.
XX PF 08-FEB-1993; 93WO-US01123.
XX PR 07-FEB-1992; 92US-0832862.
XX PA (STRD ) UNIV LELAND STANFORD JUNIOR.
XX PI Friedman JS, Weissman IL;
XX DR WPI; 1993-272887/34.
XX XX
XX PT Cyclophilin C-associated membrane proteins and DNA - used for
XX PT screening for immunomodulatory agents and for diagnosis and
XX PT therapy
XX PS Example; Page 64; 105pp; English.
XX CC Primers CAMP-c #2 and CAMP-c #4 were used to screen a plasmid
XX CC cDNA library derived from AC 6 cells for cDNA clones encoding
XX CC CAMP-c. These primers amplify a fragment of approx. 250 bp.
XX CC (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 19 BP; 3 A; 6 C; 6 G; 4 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 235 CAGGCATCTGCATCTGG 251
DB 19 CAGGGATCTGCACTGG 3

RESULT 279
AAQ36444/c
ID AAQ36444 standard; DNA; 19 BP.
XX AC AAQ36444;
XX XX
XX DT 06-JUL-1999 (first entry)
XX XX
XX DE Target sequence for 2'-substituted oligonucleotide.
XX KW RNaseH; RNA cleavage; DNA cleavage; hybridisation; protein kinase C gene;
XX KW gene expression modulation; ras; raf; therapy; AIDS; atherosclerosis;
XX KW infection; cell growth; ss.
XX OS Synthetic.
XX PN WO9730067-A1.
XX PD 21-AUG-1997.
XX PF 07-FEB-1997; 97WO-US02043.
XX PR 14-FEB-1996; 96US-0011620.
XX PA (ISIS-) ISIS PHARM INC.
XX PA (NOVS ) NOVARTIS AG.
XX PI Altmann K, Cook PD, Martin P, Monia B;
XX DR WPI; 1997-424968/39.
XX XX
XX PT Oligonucleotide with RNaseH activity, which specifically hybridises
XX PT to DNA or RNA - comprises 1st and 2nd sub-sequence(s) having

```

PT 2'-O-CH2-CH2-O-CH3 and 2'-deoxy sugar moieties, useful for therapy
 XX or diagnosis
 PS Example 2; Page 21; 86pp; English.
 XX
 CC This sequence represents a target sequence used to test the
 CC oligonucleotides of the invention.
 CC The invention relates to oligonucleotides (A), which specifically
 CC linked by phosphodiester or phosphorothioate linkages, comprising a first
 CC subsequence having 2'-O-CH2-CH2-O-CH3 sugar moieties and a second
 CC subsequence having 2'-deoxy sugar moieties. (A), which has RNaseH
 CC activity for cleaving a complementary strand, can be used to modulate the
 CC expression of ras, raf and protein kinase C genes, useful in the therapy
 CC of AIDS, atherosclerosis, bacterial or other infections, or to control
 CC aberrant cell growth in humans, animals or plants. (A) can also be used
 CC diagnostically, particularly when labelled, to detect overexpression of
 CC mRNA or expression of abnormal RNA, including imaging of tissue sections,
 CC and as a research reagent. (A) has increased binding affinity for
 CC complementary strands (attributable to the 2'-O-CH2-CH2-O-CH3 sugar
 CC moiety, which overcomes the loss of affinity caused by altered intersugar
 CC links), and increased resistance to nuclease (from the modified links and
 CC the 2'-O-CH2-CH2-O-CH3 sugar moiety).
 XX
 SQ Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTTTTCTTTG 1157
 |||||
 Db 19 GCGTTTTTTTTTTG 3

RESULT 280
 AAT95586/c
 ID AAT95586 standard; DNA; 19 BP.
 XX
 AC AAT95586;
 XX
 DT 25-MAR-2003 (updated)
 DT 11-MAR-1998 (first entry)
 XX
 DE Primer for SSCP analysis of SRP19.
 XX
 KW Human; adenomatous Polyposis coli; APC; diagnosis; prognosis;
 KW neoplastic tissue; tumour tissue; tumour repressor; mutation;
 KW sporadic colorectal cancer; detection; PCR primer; SRP19;
 KW SSCP; single stranded conformation polymorphism; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US5648212-A.
 XX
 PD 15-JUL-1997.
 XX
 PF 12-AUG-1994; 94US-0289548.
 XX
 PR 16-JAN-1991; 91GB-0000962.
 PR 16-JAN-1991; 91GB-0000963.
 PR 16-JAN-1991; 91GB-0000974.
 PR 16-JAN-1991; 91GB-0000975.
 PR 08-AUG-1991; 91US-0741940.
 XX
 PA (NICA-) JAPANESE FOUND CANCER RES.
 PA (UYJO) UNIV JOHNS HOPKINS.
 PA (UTAH) UNIV UTAH.
 PA (ZENE) ZENECA LTD.
 XX
 PI Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ;
 PI Joslyn G, Kinzler K, Markham A, Nakamura Y, Thliveris A;

PI Vogelstein B, White RL;
 XX WPI; 1997-372053/34.
 XX
 PT Cancer diagnosis - by detecting mutation(s) in adenomatous polyposis
 PT coli gene
 XX
 XX Example 8; Columns 31-32; 140pp; English.
 XX
 PS The present sequence is a primer for the SSCP analysis of SRP19,
 CC which was used in the development of a novel method of diagnosing
 CC or prognosing a human adenomatous Polyposis coli (APC) gene
 CC associated neoplastic tissue. The method comprises comparing APC
 CC gene coding sequences or mRNA in a tumour tissue, to APC gene
 CC coding sequences or mRNA in a non-neoplastic tissue, where a
 CC difference indicates an APC gene associated neoplasia of the tumour
 CC tissue. APC is a tumour repressor expressed in most normal tissues.
 CC APC mutations are found in familial adenomatous polyposis and
 CC sporadic colorectal cancer patients. The method enables mutations
 CC to be detected to provide an indication of predisposition to
 CC cancer.
 CC (Updated on 25-MAR-2003 to correct PR field.)
 XX

SQ Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCGAGGCGCA 116
 |||||
 Db 17 ACAACCCGAGGCGCA 1

RESULT 281
 AAT51286/c
 ID AAT51286 standard; DNA; 19 BP.
 XX
 AC AAT51286;
 XX
 DT 11-NOV-1997 (first entry)
 DT Human AD4 gene PCR primer INT1R.
 XX
 DE Autosomal dominant early-onset Alzheimer's Disease; AD4; STM2;
 KW neurodegeneration; senile dementia; human chromosome 1;
 KW Volga German kindred; VG; yeast artificial chromosome library;
 KW expressed sequence tag database; polymerase chain reaction;
 KW PCR primer; Homo sapiens; ss.
 XX
 OS Synthetic.
 OS
 XX WO9703192-A2.
 XX
 XX 30-JAN-1997.
 XX
 XX 05-JUL-1996; 96WO-US11386.
 XX
 XX 14-AUG-1995; 95US-0002328.
 PR 07-JUL-1995; 95US-0000956.
 PR 28-JUL-1995; 95US-0001675.
 PR 11-AUG-1995; 95US-0002174.
 XX
 XX (DARW-) DARWIN MOLECULAR CORP.
 PA (GEHO) GEN HOSPITAL CORP.
 PA (VAME-) VA MEDICAL CENT.
 XX
 XX Bird TD, Galas DJ, Levy-Lahad E, Mulligan J, Schellenberg GD;
 PI Tanzi RE, Wasco W;
 XX WPI; 1997-119048/11.
 XX
 XX New Alzheimer's disease related gene, AD4 - used to develop prods.
 PT

PT for detecting pre-disposition to or for diagnosis, prevention or
 PT treatment of Alzheimer's disease
 XX
 PS Disclosure; Fig 11; 83pp; English.

XX A genetically isolated group of families with autosomal dominant
 CC early-onset Alzheimer's Disease (AD) has been studied and initial
 CC mapping analyses have predicted the AD4 locus (also known as STM2)
 CC resides on chromosome 1. The present sequence corresponds to a PCR
 CC primer which was used during the cloning procedure to isolate and
 CC sequence the AD4 gene. The group of families has been designated
 CC the Voiga German (VG) kindreds. The entire gene has been amplified
 CC from VG individuals and unaffected individuals (from VG and
 CC unrelated lineages). Sequence analysis has shown that affected
 CC individuals have a nucleotide change at codon 141 resulting in an
 CC amino acid alteration from Asn to Ile. Portions of a mutant AD4,
 CC especially one in which Asn at position 141 has been replaced by
 CC Ile, can be used in a peptide vaccine. Detection of mutant AD4, for
 CC example using antibodies specific for the protein or using nucleic
 CC acid probes specific for the mutant gene, provides a means of
 CC diagnosing Alzheimer's disease.

XX Sequence 19 BP; 6 A; 2 C; 10 G; 1 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Indels 0; Gaps 0;
 Matches 15; Conservative 0;

QY 581 CCTCGGCTGCGCCCC 597
 DB 17 CTCCTCGTCTGCCCCAC 1

RESULT 282

AAV51978
 ID AAV51978 standard; DNA; 19 BP.

AC AAV51978;

DT 02-FEB-1999 (first entry)

DE Zea mays genome reverse PCR primer #274.

XX Polymorphic marker; allele-specific; probe; amplification; PCR primer;
 KW hybridisation; plant; hybrid certification; genetic contribution;
 KW progeny; back-cross; hybrid; ancestry; corn; ss.

OS Synthetic.

OS Zea mays.

FN WO9824796-A1.

XX 11-JUN-1998.

PF 01-DEC-1997; 97WO-US21782.

XX 07-MAR-1997; 97US-0813507.

PR 02-DEC-1996; 96US-0032069.

XX (APFY-) AFFYMETRIX INC.

PI Landry BS, Lemieux B, Murigneux A, Sapolsky RJ;

XX WPI; 1998-333252/29.

XX Brassica species allele-specific oligonucleotide probes and primers
 PT - useful for plant breeding

XX Example 1; Page Page 54; 65pp; English.

XX AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
 CC Zea mays genome in order to detect polymorphic markers. Such markers can
 CC be used in the construction of allele-specific primers and probes for

CC amplification or hybridisation, e.g. to determine common or disparate
 CC ancestry between 2 or more plants, to monitor the genetic contribution
 CC of an ancestral plant, to trace the progeny of proprietary plants, in
 CC certification of a hybrid plant or to identify the progeny of a
 CC back-crossed plant with an ancestral plant.

XX Sequence 19 BP; 5 A; 6 C; 7 G; 1 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Indels 0; Gaps 0;
 Matches 15; Conservative 0;

QY 552 GGCAGGCGATGCACAC 568
 DB 1 GGCAGGCGAGGCACGAC 17

RESULT 283

AAV51979

ID AAV51979 standard; DNA; 19 BP.

AC AAV51979;

DT 02-FEB-1999 (first entry)

DE Zea mays genome reverse PCR primer #275.

XX Polymorphic marker; allele-specific; probe; amplification; PCR primer;
 KW hybridisation; plant; hybrid certification; genetic contribution;
 KW progeny; back-cross; hybrid; ancestry; corn; ss.

OS Synthetic.

OS Zea mays.

FN WO9824796-A1.

XX 11-JUN-1998.

PF 01-DEC-1997; 97WO-US21782.

XX 07-MAR-1997; 97US-0813507.

PR 02-DEC-1996; 96US-0032069.

XX (APFY-) AFFYMETRIX INC.

PI Landry BS, Lemieux B, Murigneux A, Sapolsky RJ;

XX WPI; 1998-333252/29.

XX Brassica species allele-specific oligonucleotide probes and primers
 PT - useful for plant breeding

XX Example 1; Page Page 54; 65pp; English.

XX AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
 CC Zea mays genome in order to detect polymorphic markers. Such markers can
 CC be used in the construction of allele-specific primers and probes for
 CC amplification or hybridisation, e.g. to determine common or disparate
 CC ancestry between 2 or more plants, to monitor the genetic contribution
 CC of an ancestral plant, to trace the progeny of proprietary plants, in
 CC certification of a hybrid plant or to identify the progeny of a
 CC back-crossed plant with an ancestral plant.

XX Sequence 19 BP; 5 A; 6 C; 7 G; 1 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Indels 0; Gaps 0;
 Matches 15; Conservative 0;

QY 552 GGCAGGCGATGCACAC 568
 DB 1 GGCAGGCGAGGCACGAC 17

RESULT 284

AAV56488/c
ID AAV56488 standard; DNA; 19 BP.

XX AC
XX AAV56488;
XX AC
XX 25-MAR-2003 (updated)
DT 23-NOV-1998 (first entry)
XX

XX Human DP2.5 APC primer #11.

XX Familial adenomatous polyposis coli; APC; tumour suppressor; therapy;
KW chromosome 5q21; tumorigenesis; retinoblastoma; colorectal tumour;
KW FAP; Gardner's Syndrome; GS; predisposition; primer; ss.

XX Synthetic.
OS Homo sapiens.

XX US5783666-A.

XX 21-JUL-1998.

XX 25-MAY-1995; 95US-0452655.

XX 16-JAN-1991; 91GB-0000962.

XX 16-JAN-1991; 91GB-0000963.

XX 16-JAN-1991; 91GB-0000974.

XX 16-JAN-1991; 91GB-0000975.

XX 08-AUG-1991; 91US-0741940.

XX 12-AUG-1994; 94US-0289548.

XX (CANC-) CANCER INST.

XX (UYJO) UNIV JOHNS HOPKINS.

XX (UTAH) UNIV UTAH.

XX (ZENE) ZENECA PHARM.

XX Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ;
PI Joslyn G, Kinzler K, Markham AF, Nakamura Y, Thliveris A;
PI Vogelstein B, White RL;

XX WPI; 1998-427100/36.

XX Adenomatous polyposis coli protein - useful in the treatment of
PT cancers associated with mutation(s) on human chromosome 5q21
PT
XX Example 8; Column 31-32; 102pp; English.

XX AAV56477-V56581 are primers used in the isolation of a human familial
CC adenomatous polyposis coli (APC) protein from clone DP2.5. The gene
CC for the protein is present on human chromosome 5q21 and is also referred
CC to as adenomatous polyposis coli gene. It is a tumour suppressor gene,
CC and mutations in this gene have been associated with tumorigenesis in
CC retinoblastoma and colorectal tumours, and especially familial
CC adenomatous polyposis (FAP) and Gardner's Syndrome (GS). The protein can
CC be used in therapy to replace lack of native functional protein and the
CC nucleic acids can be used for gene therapy. The nucleic acids that
CC encode them can also be used as probes and primers in detection of the
CC cancers and predisposition to it.

XX (Updated on 25-MAR-2003 to correct PR field.)

SQ Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCCGGAGCGCA 116
Db 17 ACAACCCCGGAGCGCA 1

RESULT 285

AAT96201/c

ID AAT96201 standard; DNA; 19 BP.

XX AC
XX AAT96201;

XX 25-MAR-2003 (updated)
DT 08-APR-1998 (first entry)

XX Primer for SSCP analysis of SRP19.

XX Human; adenomatous Polyposis coli; APC; diagnosis; prognosis;
KW neoplastic tissue; tumour tissue; tumour repressor; mutation;
KW sporadic colorectal cancer; detection; PCR primer; SRP19;
KW SSCP; single stranded conformation polymorphism; ss.

XX Synthetic.
OS Homo sapiens.

XX US5691454-A.

XX 25-NOV-1997.

XX 25-MAY-1995; 95US-0452654.

XX 16-JAN-1991; 91GB-0000962.

XX 16-JAN-1991; 91GB-0000963.

XX 16-JAN-1991; 91GB-0000974.

XX 16-JAN-1991; 91GB-0000975.

XX 08-AUG-1991; 91US-0741940.

XX 12-AUG-1994; 94US-0289548.

XX (CANC-) CANCER INST.

XX (ICIL) IMPERIAL CHEM IND PLC.

XX (UYJO) UNIV JOHNS HOPKINS.

XX (UTAH) UNIV UTAH.

XX Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ;
PI Joslyn G, Kinzler K, Markham AF, Nakamura Y, Thliveris A;
PI Vogelstein B, White RL;

XX WPI; 1998-017712/02.

XX Antibodies to normal and mutant adenomatous polyposis coli proteins
PT - useful for detecting genetic predisposition to cancer

XX Example 8; Columns 25-26; 107pp; English.

XX The present sequence is a primer for the SSCP analysis of SRP19,
CC which was used in the development of a novel method of diagnosing
CC or prognosing a human adenomatous Polyposis coli (APC) gene
CC associated neoplastic tissue. The method comprises comparing APC
CC gene coding sequences or mRNA in a tumour tissue, to APC gene
CC coding sequences or mRNA in a non-neoplastic tissue, where a
CC difference indicates an APC gene associated neoplasia of the tumour
CC tissue. APC is a tumour repressor expressed in most normal tissues.
CC APC mutations are found in familial adenomatous polyposis and
CC sporadic colorectal cancer patients. The method enables mutations
CC to be detected to provide an indication of predisposition to
CC cancer.

XX (Updated on 25-MAR-2003 to correct PR field.)

SQ Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCCGGAGCGCA 116
Db 17 ACAACCCCGGAGCGCA 1

RESULT 286

```

AAZ10311/c
ID AAZ10311 standard; DNA; 19 BP.
XX
AC AAZ10311;
XX
XX 20-MAR-2003 (updated)
DT 08-NOV-1999 (first entry)
XX
XX Antisense oligonucleotide which is gapped 2' modified.
XX
XX Antisense oligonucleotide; nuclease resistance; RNase H strand cleavage;
KW phosphorothioate; oligonucleotide therapeutic; AIDS; atherosclerosis; ss.
XX
XX Synthetic.
OS
XX US5955589-A.
PN
XX 21-SEP-1999.
PD
XX
XX 06-JUN-1995; 95US-0465880.
PF
XX
XX 24-DEC-1991; 91US-0814961.
PR
XX 23-DEC-1992; 92WO-US11339.
PR
XX 21-JUN-1994; 94US-0244993.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Cook PD, Monia BP;
PI
XX
XX WPI; 1999-539598/45.
DR
XX
XX Oligonucleotides eliciting RNase H activity useful for diagnosis
PT and treatment of diseases e.g AIDS or atherosclerosis
PT
XX
XX Example 2; Column 13; 34pp; English.
XX
XX The present sequence represents a phosphorothioate antisense
CC oligonucleotide which a gapped 2' modified oligonucleotide,
CC whereby one part has at least two consecutive 2'-F (2'-H) nucleotides
CC and the second part has at least five consecutive nucleotides with 2'-H
CC sugar moieties. The modified oligonucleotide has increased nuclease
CC resistance, and increased binding affinity for substrates. The
CC oligonucleotide elicits RNase H strand cleavage of specific RNAs.
CC Oligonucleotides of the invention are useful for the diagnosis, detection
CC and treatment of conditions susceptible to oligonucleotide therapeutics
CC (e.g. AIDS and atherosclerosis).
CC (Updated on 20-MAR-2003 to correct PR field.)
XX
XX Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1141 GCCTTTTCTTTTCTTTT 1157
Db 19 GCGTTTCTTTTCTTTT 3
RESULT 287
AAZ33236/c
ID AAZ33236 standard; DNA; 19 BP.
XX
XX AAZ33236;
AC
XX
XX 25-JUN-1999 (first entry)
DT
XX
XX Wheat viviparous 1 (taVP1) primer #3.
DE
XX
XX Wheat; oat; viviparous 1; VP1; afVP1; taVP1; maize; detection; PHS;
KW pre-harvest sprouting; dormant; germination; crop plant; primer; ss.
XX
XX Synthetic.
OS

```

```

OS Triticum aestivum.
XX
XX WO9915667-A1.
XX
XX 01-APR-1999.
PD
XX
XX 18-SEP-1998; 98WO-GB02835.
PF
XX
XX 19-SEP-1997; 97GB-0020060.
PR
XX
XX (PLAN-) PLANT BIOSCIENCE LTD.
PA
XX Flinham JE, Gale MD, Holdsworth MJ;
XX
XX WPI; 1999-244424/20.
DR
XX
XX New isolated oat and wheat VP1 genes, used, e.g. to impose
PT sufficient dormancy to avoid pre-harvest sprouting
PT
XX
XX Claim 56; Page 89; 120pp; English.
PS
XX
XX The present sequence represents a primer for the wheat viviparous 1 (VP1)
CC gene, which keeps mature seeds dormant and inhibits germination. The
CC present invention describes genes which are homologues of the maize
CC Viviparous 1 gene, obtained from oat Avena fatua and wheat which encode
CC polypeptides designated afVP1 and taVP1 respectively. The VP1 activity
CC keeps mature seeds dormant and inhibits germination and can be used to
CC maintain or impose sufficient intensity and duration of dormancy to
CC avoid pre-harvest sprouting (PHS) before harvest. The products can be
CC used in the production of transformed crop plants having desirable
CC primary or secondary dormancy, or after-ripening properties, and in
CC particular may be resistant to PHS.
XX
XX Sequence 19 BP; 3 A; 4 C; 11 G; 1 T; 0 other;
SQ
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 800 CTCGCTCCCTGCGACCG 816
Db 18 CTCGCACTCTGCTGCG 2
RESULT 288
AAZ05488/c
ID AAZ05488 standard; DNA; 19 BP.
XX
XX AAZ05488;
AC
XX
XX 20-APR-1999 (first entry)
DT
XX
XX 2' modified oligo used in the course of the invention.
DE
XX
XX Nuclease resistant; modified; deoxyfuranosyl moiety; infection;
KW AIDS; atherosclerosis; tumour; ss.
XX
XX Synthetic.
OS
XX
XX US5859221-A.
PN
XX
XX 12-JAN-1999.
PD
XX
XX 06-JUN-1995; 95US-0468037.
PF
XX
XX 06-JUN-1995; 95US-0468037.
PR
XX 11-JAN-1990; 90US-0463358.
PR
XX 13-AUG-1990; 90US-0566977.
PR
XX 12-AUG-1991; 91WO-US05720.
PR
XX 05-MAR-1992; 92US-0835932.
PR
XX 01-JUL-1992; 92US-0854634.
XX
XX (ISIS-) ISIS PHARM INC.
PA

```

XX Cook PD, Kawasaki AM;
 XX WPI; 1999-120005/10.
 XX Nuclease resistant oligonucleotide analogues - having nucleosides
 PT including modified deoxyfuranosyl moiety bearing 2'-substituent to
 PT increase binding affinity
 XX Example 19; Column 40; 49pp; English.
 XX The invention relates to a nuclease resistant compound that hybridises
 CC with RNA or DNA. The compound comprises covalently-bound nucleosides
 CC that individually include a ribose or deoxyribose sugar portion and a
 CC base portion, where the nucleosides are joined together by
 CC internucleoside linkages such that the base portion of the nucleosides
 CC form a mixed base sequence that is complementary to a RNA base sequence
 CC or to a DNA base sequence; and where at least 1 of the nucleosides
 CC includes a modified deoxyfuranosyl moiety bearing a 2'-substituent
 CC selected from cyano, fluoromethyl, thioalkoxyl, alkylsulphonyl,
 CC alkylsulphonyl, allyloxy and alkeneoxy groups. The nuclease resistant
 CC oligonucleotides (ONs) can bind to and modulate the activity of DNA or
 CC RNA and can be used for treating organisms having a disease characterised
 CC by the undesired production of a protein. They can be used in therapeutic
 CC or prophylactic treatment in organisms such as bacteria, yeast, protozoa,
 CC algae, plant and higher animal forms including warm-blooded animals. The
 CC ONs can also be used for treating infections, AIDS, atherosclerosis or
 CC tumours. The products can be used for detection and diagnosis. The ONs
 CC provide enhanced binding to targets. Increased binding of 2'-sugar
 CC modified sequence-specific ONs provides superior potency and specificity
 CC compared to phosphorus-modified ONs. The present sequence represents a
 CC 2' modified oligonucleotide that was used in the course of the invention.
 XX SQ Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1141 GCCTTTTTCCTTTTG 1157
 Db 19 GCGTTTTTTTTTTT 3
 RESULT 289
 AAA93490/c
 ID AAA93490 standard; DNA; 19 BP.
 AC AAA93490;
 XX 16-JAN-2001 (first entry)
 DT Human SRP19 gene exon 1 PCR primer 1.
 DE SRP19 gene; signal recognition particle protein; human; chromosome 5q21;
 XX familial adenomatous polyposis; FAP locus; Gardner's syndrome; GS;
 KW sporadic tumour; adenoma; carcinoma; cancer; lung; breast; colon; rectum;
 KW bladder; liver; sarcoma; stomach; prostate; leukaemia; lymphoma;
 KW tumour suppressor; anti-APC antibody; detection; diagnosis; prognosis;
 KW genetic predisposition; drug screening; Adenomatous Polyposis Coli;
 KW APC gene; exon; PCR primer; ss.
 XX Homo sapiens.
 OS US6114124-A.
 PN 05-SEP-2000.
 XX 25-MAY-1995; 95US-0450582.
 XX 16-JAN-1991; 91GB-0000962.
 PR 16-JAN-1991; 91GB-0000963.
 PR 16-JAN-1991; 91GB-0000974.

PR 16-JAN-1991; 91GB-0000975.
 PR 08-AUG-1991; 91US-0741940.
 PR 12-AUG-1994; 94US-0289548.
 XX (ICIL) IMPERIAL CHEM IND PLC.
 PA (UYJO) UNIV JOHNS HOPKINS.
 PA (UTAH) UNIV UTAH.
 PA (CANC-) CANCER INST.
 XX Carlsson M, Groden J, Joslyn G, Kinzler K, Markham AF, Anand R;
 PI Albertsen H, White RL, Thliveris A, Nakamura Y, Vogelstein B;
 PI Hedge PJ;
 XX WPI; 2000-565003/52.
 DR Detecting Adenomatous Polyposis Coli (APC) protein in a sample for
 PT diagnosing cancers, involves contacting the sample with antibodies that
 PT specifically bind to APC protein and detecting the complex formed -
 XX Example 8; Column 31; 125pp; English.
 XX The invention relates to a novel method for detecting Adenomatous
 CC Polyposis Coli (APC) protein in a sample. The method involves
 CC contacting the sample with antibodies which specifically binds to the
 CC 2843 amino acid form of the human APC protein, or to a mutant APC
 CC protein, and detecting an APC-antibody complex. Mutations in the APC
 CC gene play a role in tumorigenesis, indicating that it is a tumour
 CC suppressor gene. It is located on chromosome 5q21, which corresponds to
 CC the FAP (familial adenomatous polyposis) locus. FAP is an autosomal
 CC dominant inherited disease in which affected individuals develop
 CC hundreds to thousands of adenomatous polyps in the colon and rectum,
 CC some of which progress to malignancy. The FAP locus is often found to
 CC be deleted in sporadic (i.e., non-familial) adenomas and carcinomas, and
 CC chromosome 5q deletions have also been observed in tumours of the lung,
 CC breast, colon, rectum, bladder, liver, sarcomas, stomach, and prostate,
 CC and in leukaemias and lymphomas. Although the FAP locus contains
 CC several other genes such as FRR, TBL1, TB2, and MCC, it is thought that
 CC mutations in the APC gene play a key role in the development of FAP and
 CC sporadic tumours. The method is useful for detecting APC protein and its
 CC mutant forms in foetal tissue, placental tissue, amniotic fluid, blood,
 CC serum or a tumour sample. The method is useful for diagnosing or
 CC prognosing neoplastic tissue, for detecting a genetic predisposition to
 CC cancer, for detecting germline and somatic alteration of wild-type APC
 CC genes, and for testing therapeutic agents for the ability to suppress
 CC tumours. Sequences AAA93490-A93499 represent PCR primers used in an
 CC exemplification of the invention to amplify exonic regions of the human
 CC SRP19 (signal recognition particle protein) gene.
 XX SQ Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 100 ACAACCCCGAGCGCA 116
 Db 17 ACAACCCCGAGCGCA 1
 RESULT 290
 AAA84760
 ID AAA84760 standard; DNA; 19 BP.
 XX AAA84760;
 AC AAA84760;
 XX 04-DEC-2000 (first entry)
 DT Cyclin F ribozyme binding site #28.
 DE Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
 XX restenosis; ss.
 KW Mammalia.

```

XX PN WO200032765-A2.
XX PD
XX PF
XX PR 08-JUN-2000.
XX PR 06-DEC-1999; 99WO-US28772.
XX PR 04-DEC-1998; 98US-0110954.
XX PA (IMMU-) IMMUSOL INC.
XX PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX DR WPI; 2000-412314/35.
XX PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PT PCNA and Cyclin B1
XX PS Disclosure; Page 82; 109pp; English.
XX CC The present invention relates to a hairpin or hammerhead ribozyme,
XX CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX CC Representative examples of ribozyme recognition sites are given in
XX CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
XX CC inhibiting restenosis by introduction of the ribozyme into cells.
XX CC The ribozyme is resistant to endonuclease activity and hence is
XX CC efficient in restenosis treatment.
XX SQ Sequence 19 BP; 3 A; 6 C; 6 G; 4 T; 0 other;
    Query Match      1.0%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 2e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
    QY 877 GCCAAGTTCGAGGAGCT 893
    Db 3 GCCAGCTTCGAGGAGCT 19
RESULT 291
ID AAA06830/c
XX AAA06830 standard; DNA; 19 BP.
XX AC AAA06830;
XX DT 19-JUN-2000 (first entry)
XX DE Phosphorothioate oligonucleotide, SEQ ID NO:4.
XX KW Phosphorothioate; modified nucleoside; 2'-substituted;
XX KW 2'-deoxy-erythro-pentofuranosyl sugar moiety; nuclease resistant;
XX KW hybridisation; binding affinity; ss.
XX OS Synthetic.
XX FH Key
XX FT modified_base 1..19
XX FT /tag= a
XX FT /note= "Phosphorothioate linkages"
XX FT modified_base 1..3
XX FT /tag= b
XX FT /note= "Contains a 2'-O-substituent selected from
XX FT 2'-O-aminooxyethyl, 2'-O-ethylaminooxyethyl and
XX FT 2'-O-dimethylaminooxyethyl"
XX FT modified_base 18..19
XX FT /tag= c
XX FT /note= "Contains a 2'-O-substituent selected from
XX FT 2'-O-aminooxyethyl, 2'-O-ethylaminooxyethyl and
XX FT 2'-O-dimethylaminooxyethyl"
XX PN WO200008042-A1.

```

```

XX PD 17-FEB-2000.
XX PF 09-AUG-1999; 99WO-US17988.
XX PR 07-AUG-1998; 98US-0130973.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Manoharan M, Cook PD, Prakash TP, Kawasaki AM;
XX DR WPI; 2000-224020/19.
XX PT Aminoxy-modified nucleosides and oligonucleotides useful in
XX PT diagnostic, therapeutic and research reagents and for modulating the
XX PT expression of protein in organisms -
XX PS Example 40; Page 75; 195pp; English.
XX CC The invention relates to aminoxy-modified nucleosides and
XX CC oligonucleotides and to oligonucleotides that elicit RNase H for
XX CC cleavage in a complementary nucleic acid strand. It also relates to
XX CC oligonucleotides wherein at least some of the nucleotides are
XX CC functionalised to be nuclease resistant, at least some of the
XX CC nucleotides include a substituent that potentiates hybridisation of the
XX CC oligonucleotide to a complementary strand, and at least some of the
XX CC nucleotides include a 2'-deoxy-erythro-pentofuranosyl sugar moiety. The
XX CC inclusion of one or more aminoxy moieties in such oligonucleotides
XX CC provides for improved binding of such oligonucleotides to a
XX CC complementary strand. The oligonucleotides of the invention are used as
XX CC diagnostic, therapeutic or research reagents, and can be used to modulate
XX CC gene expression in organisms. The oligonucleotides containing the
XX CC modified nucleosides have increased nuclease resistance and increased
XX CC binding affinity to a complementary strand. The present sequence
XX CC represents a phosphorothioate oligonucleotide used in an exemplification
XX CC of the present invention which has 2'-substituted regions flanking a
XX CC central region. This sequence is the complement of AAA06829.
XX SQ Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;
    Query Match      1.0%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 2e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
    QY 1141 GCCTTTTTCCTTTTG 1157
    Db 19 GCGTTTTTTTTTTTG 3
RESULT 292
ID AAA23478
XX AAA23478 standard; DNA; 19 BP.
XX AC AAA23478;
XX DT 19-JUN-2000 (first entry)
XX DE Clone vc46_1 hybridisation probe, SEQ ID NO:96.
XX KW Human; secreted protein; cancer; tumour; cardiovascular disorder;
XX KW blood disorder; haemophilia; autoimmune disease; diabetes; inflammation;
XX KW infection; fungal; bacterial; viral; HIV; allergy; arthritis;
XX KW neurodegenerative disease; asthma; contraceptive; hybridisation probe;
XX KW ss.
XX OS Homo sapiens.
XX PN WO200011015-A1.
XX PD 02-MAR-2000.
XX PF 24-AUG-1999; 99WO-US19351.

```

OS	Homo sapiens.
XX	WO200014198-A2.
XX	16-MAR-2000.
XX	13-AUG-1999; 99WO-US18463.
XX	02-SEP-1998; 98US-0146218.
PR	(RESE) RESEARCH CORP TECHNOLOGIES INC.
PA	Vance DE, Walkey CJ, Cui Z;
XX	WFI; 2000-256956/22.
XX	Isolated nucleic acid molecule encoding phosphatidylethanolamine
PT	N-methyltransferase protein used to treat phosphatidylethanolamine
PT	N-methyltransferase-associated disorders such as liver cancer -
XX	Example 8; Page 57; 11lpp; English.
XX	The present sequence is that of a primer used in the PCR
CC	amplification of the open reading frame of a cDNA clone (see
CC	AAZ94150) encoding human phosphatidylethanolamine N-methyltransferase
CC	(PEMT-2, see AAY73199). The PCR product was subcloned into
CC	mammalian expression vector pCI, and PEMT-2 was expressed in
CC	rat hepatoma McArdle-RH777 cells. The invention relates to
CC	novel human PEMT2 polynucleotides and protein (see AAY79199), and
CC	to methods of using them in the treatment and diagnosis of liver
CC	disorders, such as liver cancer.
XX	Sequence 19 BP; 2 A; 7 C; 7 G; 3 T; 0 Other;
SQ	
Query Match	1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity	88.2%; Pred. NO. 2e+02;
Matches 15; Conservative	0; Mismatches 2; Indels 0; Gap
QY	715 GTGGCCCCAGCAGCGG 731
DB	18 GTAGCCCACGACCGGG 2
RESULT 294	
AAZ48149/c	
ID	AAZ48149 standard; DNA; 19 BP.
XX	AC
XX	AAZ48149;
DT	14-MAR-2000 (first entry)
DE	Oligonucleotide SEQ ID NO:33.
XX	Polyribonucleotide solid phase synthesis; diagnosis; hybridisation;
KW	protein production modulation; 2'-deoxyfuranosyl moiety; anti-HIV;
KW	antiartherosclerotic; nuclease resistant; atherosclerosis; AIDS;
KW	abnormal cell proliferation; tumour formation; ss.
XX	Synthetic.
XX	OS
PN	US6005087-A.
XX	21-DEC-1999.
PD	05-MAR-1998; 98US-0035357.
XX	06-JUN-1995; 95US-0458037.
PR	11-JAN-1990; 90US-0463358.
PR	13-AUG-1990; 90US-0566977.
PR	12-AUG-1991; 91WO-US05720.
PR	05-MAR-1992; 92US-0835932.
XX	01-JUL-1992; 92US-0854634.

PA (ISIS-) ISIS PHARM INC.
 XX Kawasaki AM, Cook PD;
 XX WPI; 2000-072074/06.
 DR Nuclease resistant oligonucleotides useful as research agents,
 PT diagnostic agents, and in the treatment of atherosclerosis and AIDS -
 PT Example 19; Column 40; 49pp; English.
 PS The present invention describes nuclease resistant oligonucleotides (I)
 CC comprising 2'-fluoro modified ribofuranosyl nucleotides. (I) comprise
 CC covalently bound nucleotides, where the nucleotides are joined together
 CC by: (a) internucleotide linkages such that the base portion of the
 CC nucleotides forms a mixed base sequence; and (b) at least one of the
 CC nucleotides includes a modified ribofuranosyl group bearing a 2'-fluoro
 CC substituent; provided that at least two of the nucleotides are 2'-fluoro
 CC modified ribofuranosyl nucleotides when the internucleotide linkages are
 CC phosphodiester nucleotides. (I) bind to their target mRNA and inhibit its
 CC expression. (I) are resistant to nuclease degradation and hybridize with
 CC appropriate strength and fidelity to its target RNA/DNA. (I) are also
 CC useful as research agents, diagnostic agents and as oligonucleotide
 CC therapeutics. (I) may be used to treat atherosclerosis following
 CC angioplasty to prevent reocclusion of the treated arteries. (I) may also
 CC be used in conjunction with AZT to treat AIDS patients. (I) have been
 CC used to modulate the expression of RAR gene, a cellular gene whose
 CC activate form has been implicated in abnormal cell proliferation and
 CC tumour formation. (I) are also used to modulate the expression of protein
 CC kinase C. (I) exhibit hybridisation properties of higher quality than
 CC phosphorous modified oligonucleotide duplexes containing
 CC methylphosphonates, phosphoranidates and phosphate triesters. The present
 CC sequence represent an oligonucleotide used in the exemplification of the
 CC present invention.
 XX
 SQ Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 86.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 1141 GCCTTTTCTTTCTTTTG 1157
 Db |||||
 19 GCGTTTTTTTTTTTG 3
 RESULT 295
 AAS11124/c
 ID AAS11124 standard; DNA; 19 BP.
 AC AAS11124;
 XX
 DT 24-OCT-2001 (first entry)
 DE Bacterial 16s RNA antisense oligomer #90.
 XX Antisense; bacterial 16s ribosomal RNA; rRNA; bacterial infection;
 KW human; food grain supplement; livestock; poultry; therapeutic; ss.
 XX Enterococcus faecium.
 OS WO200142457-A2.
 XX
 FN 14-JUN-2001.
 PD 29-NOV-2000; 2000WO-US42391.
 PF 29-NOV-1999; 99US-0168150.
 PR (AVIB-) AVI BIOPHARMA INC.
 PA Iversen PL;
 PI
 XX

DR WPI; 2001-457295/49.
 XX Antibacterial compound, useful for treating bacterial infections and as
 PT livestock and poultry food supplement, comprises antisense
 PT oligonucleotides complementary to bacterial 16S and 23S rRNA -
 XX Disclosure; Page 35; 62pp; English.
 PS AAS11035-AAS11157 represent the coding sequences of bacterial 16S
 CC ribosomal RNA (rRNA) antisense oligomers. These sequences are
 CC antibacterial compounds comprising substantially uncharged antisense
 CC oligomers containing 8-40 nucleotide subunits, including a targeting
 CC nucleic acid sequence at least 10 nucleotides in length which is
 CC complementary to a bacterial 16S or 23S rRNA nucleic acid sequence.
 CC The antisense oligomers are used for treating a bacterial infection
 CC in a human or a mammalian animal produced by Escherichia coli, Salmonella
 CC typhimurium, Pseudomonas aeruginosa, Vibrio cholera, Neisseria
 CC gonorrhoea, Helicobacter pylori, Bartonella henselae, Haemophilus
 CC influenza, Shigella dysenteriae, Staphylococcus aureus, Mycobacterium
 CC tuberculosis, Streptococcus pneumoniae, Treponema pallidum and Chlamydia
 CC trachomatis. The antibacterial compound may be used as a food grain
 CC supplement in livestock and poultry food composition.
 XX Sequence 19 BP; 4 A; 5 C; 8 G; 2 T; 0 other;
 SQ Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 685 TTTGGGAGCCAGCGGCC 701
 Db |||||
 17 TTTGGAGCCAGCGGCC 1
 RESULT 296
 AAS11035
 ID AAS11035 standard; DNA; 19 BP.
 AC AAS11035;
 XX
 DT 10-SEP-2001 (first entry)
 DE Cyclin F ribozyme binding site SEQ ID NO:2346.
 XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulvar;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
 KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;
 KW antiskinning; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX
 FN WO200130362-A2.
 XX
 PD 03-MAY-2001.
 PF 26-OCT-2000; 2000WO-US29500.
 PR 26-OCT-1999; 99US-0161532.
 PA (INMU-) INMUSOL INC.
 XX Robbins JM, Tritz R;
 PI WPI; 2001-300427/31.
 DR Treating proliferative skin or eye diseases and scarring, using
 XX

PT ribozymes that cleave RNA encoding cytokines involved in inflammation,
PT matrix metalloproteinases, growth factors and cell-cycle dependent
PT kinases -
XX
PS Example 1; Page 242; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antiproliferative,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antiscaling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative
CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 19 BP; 3 A; 6 C; 6 G; 4 T; 0 other;
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 877 GCCAAGTTCAGGAGCT 893
DB 3 GCCAGCTTCAGGAGCT 19
RESULT 297
ABS67159/c
ID ABS67159 standard; DNA; 19 BP.
AC ABS67159;
XX
XX 29-NOV-2002 (first entry)
XX
XX DP1, SRP19, DP25 gene SSCP primer #11.
XX
XX Adenomatous polyposis coli; APC; human; neoplastic tissue;
XX mutation detection; tumour; cancer;
XX single stranded conformational polymorphism; primer; ss.
XX
XX Homo sapiens.
XX
XX US6413727-B1.
XX
XX 02-JUL-2002.
XX
XX 25-MAY-1995; 95US-0449731.
XX
XX 16-JAN-1991; 91GB-0000962.
XX 16-JAN-1991; 91GB-0000963.
XX 16-JAN-1991; 91GB-0000974.
XX 16-JAN-1991; 91GB-0000975.
XX 08-AUG-1991; 91US-0741940.
XX 12-AUG-1994; 94US-0289548.
XX
XX (UJJO) UNIV JOHNS HOPKINS.
XX (UTAH) UNIV UTAH.
XX (NICA-) JAPANESE FOUND CANCER RES.
XX (ZENE) ZENECA LTD.
XX
XX Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ, Joslyn G;
XX Kinzler K, Markham AF, Nakamura Y, Thilaveris A, Vogelstein B;

PI White RL;
XX
XX WPI; 2002-641559/69.
XX
PT Method to aid in the diagnosis/prognosis of neoplastic tissues in
PT humans, by detecting somatic alteration of wild-type APC protein in
PT tumor tissue isolated from human, the alteration indicating neoplasia
PT of the tissue -
XX
PS Example 15; Column 31-32; 140pp; English.
XX
CC This invention relates to a novel method to aid in the diagnosis or
CC prognosis of a neoplastic tissue of a human. The method involves
CC detecting somatic alteration of wild-type adenomatous polyposis coli
CC protein in a tumour tissue isolated from a human (the alteration
CC indicating neoplasia of the tissue). The method of the invention
CC is useful in diagnosis or prognosis of a neoplastic tissue of a human.
CC The method is useful in detection of genetic predisposition to cancer.
CC The present sequence represents a DNA sequence used in the method
CC of the invention
XX
SQ Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCCGAGCGCA 116
DB 17 ACAACCCCGAGCGCA 1
RESULT 298
ABA81571
ID ABA81571 standard; DNA; 15 BP.
XX
XX ABA81571;
XX
XX 24-JAN-2002 (first entry)
XX
XX Human phospholipid transfer protein gene ASO probe SEQ ID NO: 20.
XX
XX Human; phospholipid transfer protein; PLTP; SNP; atherosclerosis;
XX single nucleotide polymorphism; high-density lipoprotein metabolism;
XX allele-specific oligonucleotide; probe; ss.
XX
XX Homo sapiens.
XX
XX WO200172761-A2.
XX
XX 04-OCT-2001.
XX
XX 15-MAR-2001; 2001WO-US08283.
XX
XX 24-MAR-2000; 2000US-192127P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chew A, Choi JY, Koshiy B;
XX
XX WPI; 2001-662922/76.
XX
XX Genotyping phospholipid transfer protein gene of individual for
XX haplotyping individual's gene, comprises determining identity of
XX nucleotide pair at polymorphic sites for two copies of PLTP gene
XX present in the individual -
XX
XX Claim 15; Page 13; 98pp; English.
XX
XX The present invention relates to a method for haplotyping the human
XX phospholipid transfer protein (PLTP) gene, involving determining the
XX identity of the nucleotide present at one or more of the 25 polymorphic
XX sites within the gene. This can be used to aid drug development for the

CC treatment of diseases associated with different haplotypes of the PLTP
 CC gene, possibly including atherosclerosis. The present sequence is an
 CC allele-specific probe used for detecting polymorphisms in the PLTP gene.

XX SQ Sequence 15 BP; 6 A; 2 C; 5 G; 1 T; 1 other;

Query Match 1.0%; Score 13.6; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.6e+02; Indels 0; Gaps 0;

Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 918 AAAGGAGATGGCAG 931

|||||:|||||
 2 AAAGGARATGGCAG 15

RESULT 299

ABL91860
 ID ABL91860 standard; DNA; 15 BP.

XX AC ABL91860;

XX DT 11-JUL-2002 (first entry)

XX DE Human LIPG gene allele specific oligonucleotide primer 39.

XX KW Human; ss; allele specific oligonucleotide; primer;
 KW single nucleotide polymorphism; SNP; lipase endothelial isogene; LIPG;
 KW drug screening; atherosclerosis; cardiovascular disorder;
 KW LIPG haplotyping; LIPG genotyping.

XX OS Homo sapiens.

XX PN WO200216397-A2.

XX PD 28-FEB-2002.

XX PF 17-AUG-2001; 2001WO-US26639.

XX PR 25-AUG-2000; 2000US-227825P.

XX PA (GENA-) GENAISSANCE PHARM INC.

XX PI Duda A, Kazemi A, Kliem SE, Messer C;

XX DR WPI; 2002-292055/33.

XX PT Novel genetic variants of Lipase, Endothelial isogenes, useful for
 PT improving efficiency and reliability in drug development for treating
 PT diseases associated with LIPG activity, e.g. atherosclerosis

XX PS Claim 16; Page 14; 134pp; English.

XX CC The invention comprises the DNA and amino acid sequence of the human
 CC lipase, endothelial (LIPG) isogene. Specifically, the invention relates
 CC to the discovery of 20 novel polymorphic sites within the LIPG gene. The
 CC LIPG coding sequence and protein are useful for screening drugs that can
 CC be used to treat atherosclerosis and other cardiovascular disorders. The
 CC LIPG coding sequence can also be used to haplotype and genotype the LIPG
 CC gene of an individual. The DNA sequences ABL91822 - ABL91861 represent
 CC LIPG gene allele specific oligonucleotide primers.

XX SQ Sequence 15 BP; 1 A; 4 C; 7 G; 2 T; 1 other;

Query Match 1.0%; Score 13.6; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.6e+02;

Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 534 GCAGCTGGGTGCC 547

|||||:|||||
 1 GCAGCTGGGTGCC 14

RESULT 300

AAS94583

ID AAS94583 standard; DNA; 15 BP.

XX AC AAS94583;

XX DT 14-FEB-2002 (first entry)

XX DE Human PLTP gene allele-specific oligonucleotide probe #17.

XX KW Human; phospholipid transfer protein; PLTP; haplotyping; haplotype pair;
 KW single nucleotide polymorphism; genotyping; gene therapy; drug screening;
 KW binding affinity; atherosclerosis; ss; sequencing primer; PCR primer;
 KW probe.

XX OS Homo sapiens.

XX PN WO200172966-A2.

XX PD 04-OCT-2001.

XX PF 26-MAR-2001; 2001WO-US09776.

XX PR 24-MAR-2000; 2000US-192127P.

XX PA (GENA-) GENAISSANCE PHARM INC.

XX PI Chew A, Choi JY, Koshy B;

XX DR WPI; 2002-010724/01.

XX PT New isolated polynucleotide which is polymorphic variant of
 PT phospholipid transfer protein (PLTP) gene, having any one of
 PT polymorphic sites PSI-PS25, for studying function of PLTP, and
 PT expressing PLTP protein

XX PS Claim 15; Page 70; 99pp; English.

XX CC The invention relates to single nucleotide polymorphisms in the gene
 CC encoding the human phospholipid transfer protein (PLTP). A method for
 CC haplotyping the PLTP gene in an individual comprises identifying the
 CC nucleotide at one or more polymorphic sites and determining whether one
 CC of the copies of the gene is defined by one of the PLTP haplotypes given
 CC in the specification or whether both copies are defined by a haplotype
 CC pair. This method is useful in genotyping, whereby all possible haplotype
 CC pairs can be assigned to specific genotypes. An association between a
 CC trait and a haplotype or haplotype pair of the PLTP gene can be
 CC identified by comparing the frequency of the haplotype or haplotype pair
 CC in a population exhibiting the trait with the frequency of the haplotype
 CC or haplotype pair in a reference population, where a higher haplotype
 CC frequency in the trait population indicates the trait is associated with
 CC the haplotype or haplotype pair. PLTP and its corresponding DNA are used
 CC for studying the expression and function of PLTP, for use in screening
 CC for candidate drugs to treat diseases related to PLTP activity. The
 CC sequences are also useful for studying the effect of variation on the
 CC biological activity of PLTP as well as on the binding affinity of
 CC candidate drugs targeting PLTP for treating atherosclerosis. Sequences
 CC AAS94586-AAS94691 represent allele-specific oligonucleotide probes,
 CC sequencing primers and PCR primers used for detecting PLTP gene
 CC polymorphisms.

XX SQ Sequence 15 BP; 6 A; 2 C; 5 G; 1 T; 1 other;

Query Match 1.0%; Score 13.6; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.6e+02;

Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 918 AAAGGAGATGGCAG 931

|||||:|||||
 2 AAAGGARATGGCAG 15

RESULT 301

AAC67429

ID AC67429 standard; DNA; 21 BP.
 AC AC67429;
 XX
 DT 14-FEB-2001 (first entry)
 XX
 DE Alzheimer's disease-linked mitochondrial SNP PCR primer #129.
 XX
 KW Human; mitochondrial genome; single nucleotide polymorphism; SNP;
 KW Alzheimer's disease; mtDNA; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200063441-A2.
 XX
 PD 26-OCT-2000.
 XX
 PF 19-APR-2000; 200WO-US10906.
 XX
 PR 20-APR-1999; 99US-0130447.
 PR 22-OCT-1999; 99US-0160901.
 XX
 PA (MITO-) MITOKOR.
 XX
 PI Herrnstadt C, Davis RE;
 XX
 DR WPI; 2000-672748/65.
 XX
 PT Diagnosing a subject at the risk for or having Alzheimer's disease
 PT comprises determining at least one single nucleotide polymorphism in
 PT mitochondrial DNA associated with the disease in the sample from the
 PT subject -
 XX
 PS Example 4; Page 40; 89pp; English.
 XX
 CC The present invention describes a novel method for determining the risk
 CC of or diagnosing Alzheimer's disease using single nucleotide
 CC polymorphisms (SNPs) present in an individual's mitochondrial DNA
 CC (mtDNA). In addition, the SNPs identified can be used to identify agents
 CC suitable for use in treating Alzheimer's disease. Sequences
 CC AAC67301-C67610 are PCR primers used to demonstrate the method of the
 CC invention.
 XX
 SQ Sequence 21 BP; 5 A; 2 C; 8 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.6; DB 1; Length 21;
 Best Local Similarity 80.0%; Pred. No. 2.5e+02;
 Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 268 TGGCTGATCAAGAGGAGC 287
 DB 2 TGGCTGATCAAGAGGAGTATGC 21
 RESULT 302
 AAZ57277
 ID AAZ57277 standard; DNA; 21 BP.
 XX
 AC AAZ57277;
 XX
 DT 30-MAR-2000 (first entry)
 XX
 DE Human mitochondrial DNA NADH dehydrogenase PCR primer SEQ ID NO:76.
 XX
 KW Human; mitochondrial DNA; extramitochondrial DNA; mtDNA; exmtDNA;
 KW diagnosis; quantification; detection; dystonia; Alzheimer's disease;
 KW Huntington's disease; Parkinson's disease; schizophrenia; stroke;
 KW non-insulin dependent diabetes mellitus; mitochondrial encephalopathy;
 KW lactic acidosis; myoclonic epilepsy ragged red fibre syndrome;
 KW Leber's hereditary optic neuropathy; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX

PN WO9966075-A2.
 XX
 PD 23-DEC-1999.
 XX
 PF 14-JUN-1999; 99WO-US13426.
 XX
 PR 15-JUN-1998; 98US-0097889.
 PR 15-JUN-1998; 98US-0098079.
 PR 30-APR-1999; 99US-0302681.
 XX
 PA (MITO-) MITOKOR.
 XX
 PI Herrnstadt C, Ghosh SS, Clevenger W, Fahy ED, Davis RE;
 XX
 DR WPI; 2000-097754/08.
 XX
 PT Quantification of extramitochondrial DNA for diagnosis of, e.g.
 PT Alzheimer's, Huntington's and Parkinson's disease -
 XX
 PS Disclosure; Page 32; 157pp; English.
 XX
 CC The present invention describes a method for the quantification of
 CC extramitochondrial DNA (exmtDNA) by determining the ratio of a first
 CC and second biological sample containing exmtDNA and mitochondrial DNA
 CC (mtDNA) to determine the risk or presence of a disease associated with
 CC altered mitochondrial function. The method can be used to determine
 CC the risk of or presence of a disease associated with altered
 CC mitochondrial function, especially Alzheimer's disease, Huntington's
 CC disease, Parkinson's disease, dystonia, schizophrenia, non-insulin
 CC dependent diabetes mellitus, mitochondrial encephalopathy, lactic
 CC acidosis, stroke, myoclonic epilepsy ragged red fibre syndrome and
 CC Leber's hereditary optic neuropathy. The method can also be used to
 CC identify agents suitable for treating such diseases, in particular
 CC Alzheimer's disease. AAZ57202 to AAZ57313 represent nucleotide sequences
 CC used in the exemplification of the present invention. More specifically
 CC AAZ57206 to AAZ57313 are PCR primers used in the detection of exmtDNA
 CC and mtDNA.
 XX
 SQ Sequence 21 BP; 5 A; 2 C; 8 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.6; DB 1; Length 21;
 Best Local Similarity 80.0%; Pred. No. 2.5e+02;
 Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 268 TGGCTGATCAAGAGGAGC 287
 DB 2 TGGCTGATCAAGAGGAGTATGC 21
 RESULT 303
 AAX18364
 ID AAX18364 standard; DNA; 15 BP.
 XX
 AC AAX18364;
 XX
 DT 11-MAY-1999 (first entry)
 XX
 DE RT-PCR primer of the invention SEQ ID 5.
 XX
 KW RT-PCR primer; DNA sequence determination; gene sequence analysis; ss.
 XX
 OS Synthetic.
 XX
 PN JP11032765-A.
 XX
 PD 09-FEB-1999.
 XX
 PF 18-JUL-1997; 97JP-0208312.
 XX
 PR 18-JUL-1997; 97JP-0208312.
 XX
 PA (TAKI) TAKARA SHUZO CO LTD.
 XX

DR WPI; 1999-183822/16.
 XX Peptides having at least two new nucleotides - useful as primers in
 PT RT-PCR
 PT
 XX Disclosure; Page 10; 19pp; Japanese.
 XX
 CC This sequence represents a primer of the invention. The invention relates
 CC to sequences of at least two nucleotides of formula:
 CC (X)m5'-(alpha)n-beta-N3'; or (X)m5'-(gamma)k-delta-N3'; where
 CC X = a labelled compound and/or a nucleotide with voluntary sequence;
 CC m = 0 or 1; alpha = thymine; n = natural number indicating the repetition
 CC of alpha; beta, delta = V or N; V = adenine, guanine or cytosine;
 CC N = adenine, guanine, cytosine or thymine; gamma = thymine;
 CC k = natural number of 3 or over indicating the repetition of gamma, in
 CC which thymine expressed by gamma is composed of 1/3 or less of adenine,
 CC guanine and/or cytosine. The new nucleotides are useful as primers for
 CC RT-PCR and determination of base sequences. The new sequences allow for
 CC reproductive and highly efficient analysis of gene sequences.
 XX
 SQ Sequence 15 BP; 0 A; 0 C; 2 G; 13 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1144 TTTTTCCTTTTGG 1158
 DB 1 TTTTTCCTTTTGG 15
 RESULT 304
 AAF95031
 ID AAF95031 standard; DNA; 15 BP.
 AC AAF95031;
 XX
 DT 23-MAY-2001 (first entry)
 DE Mutant capture oligonucleotide #24.
 XX
 KW Tubercle bacillus; drug sensitivity; drug resistance; rifampicin;
 KW streptomycin; kanamycin; isoniazid; ethambutol; rpoB gene; rrs gene;
 KW rpsL gene; inhA gene; katG gene; embB gene; probe; PCR primer; ss.
 XX
 OS Mycobacterium tuberculosis.
 XX
 PN EP1076099-A2.
 XX
 PD 14-FEB-2001.
 XX
 PF 02-AUG-2000; 2000EP-0306563.
 XX
 PR 03-AUG-1999; 95JP-0220357.
 XX
 PA (NISON) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 PI Suzuki Y, Nishida M, Takenishi S;
 XX
 DR WPI; 2001-246696/26.
 XX
 PT New oligonucleotides, nucleic acid probes and primers are useful for
 PT differentiating drug-resistance and determining infection with tubercle
 PT bacilli -
 XX
 PS Claim 10; Page 25; 114pp; English.
 XX
 CC The present invention relates to oligonucleotides based on nucleotide
 CC sequences obtained from both wild-type tubercle bacilli (wtTB) that are
 CC susceptible to a drug and mutant-type tubercle bacilli (mtTB) that are
 CC resistant to a drug. The drugs used in the present invention are
 CC rifampicin (RFP), streptomycin (SM), kanamycin (KM), isoniazid (INH) and

CC ethambutol (EB). The rpoB gene is responsible for resistance to RFP; the
 CC rrs gene is responsible for resistance to SM and KM; the rpsL gene is
 CC responsible for resistance to SM; the inhA gene is responsible for
 CC resistance to INH; the katG gene is responsible for resistance to INH;
 CC and the embB gene is responsible for resistance to EB. The present
 CC invention also relates to nucleic acid probes having part of a nucleotide
 CC sequence of tubercle bacilli (TB) responsible for drug resistance and
 CC primers used to generate the probes. The present sequence is an
 CC oligonucleotide of the present invention. The oligonucleotides of the
 CC present invention can be used to enable the differentiation of drug
 CC resistance and the determination of infection with tubercle bacilli
 CC simultaneously.
 XX
 SQ Sequence 15 BP; 3 A; 5 C; 5 G; 2 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 885 CCAGCAGCTGCGGTA 899
 DB 1 CCAGCAGCTGCGGTA 15
 RESULT 305
 AAF45161
 ID AAF45161 standard; RNA; 15 BP.
 AC AAF45161;
 XX
 DT 30-MAR-2001 (first entry)
 DE Antisense oligonucleotide #10.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WC200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU00693.
 XX
 PR 21-JUN-1999; 99US-0140345.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -
 XX
 PS Claim 15; Page 115; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation.
 CC inflammation and/or other disorders. The present sequence is one such
 CC antisense oligonucleotide. The method is useful for ameliorating the

CC effects of psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea,
 CC keloids, keratosis, neoplasias, scleroderma, warts, benign growths,
 CC cancers of the skin, a hyperneovascular condition such as a neovascular
 CC condition of the retina, brain or skin, growth factor-mediated
 CC malignancies, other sclerotic disease, kidney disease, hyperproliferation
 CC of the inside of blood vessels or any other hyperplasia.
 XX
 SQ Sequence 15 BP; 4 A; 5 C; 6 G; 0 U; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 552 GGCAGGCGATGCACAC 566
 |||||
 Db 1 GGCAGGCGAGGCAC 15

RESULT 306
 AAF46436/C
 ID AAF46436 standard; DNA; 15 BP.

XX AAF46436;

DT 30-MAR-2001 (first entry)

DE IGFBP2 oligonucleotide #1275.

KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.

PN WO200078341-A1.

PD 28-DEC-2000.

PF 21-JUN-2000; 2000WO-AU00693.

PR 21-JUN-1999; 99US-0140345.

PA (MURD-) MURDOCH CHILDRENS RES INST.

PI Wraight CJ, Werther GA, Edmondson SR;

DR WPI; 2001-041421/05.

PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -

XX Example 6; Page 42; 201pp; English.

XX The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-F45161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other

CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.

SQ Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 239 CATCTGCATCTGGGA 253
 |||||
 Db 15 CATCTGCAGCTGGGA 1

RESULT 307
 AAF46437/C
 ID AAF46437 standard; DNA; 15 BP.

XX AAF46437;

DT 30-MAR-2001 (first entry)

DE IGFBP2 oligonucleotide #1276.

KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.

PN WO200078341-A1.

PD 28-DEC-2000.

PF 21-JUN-2000; 2000WO-AU00693.

PR 21-JUN-1999; 99US-0140345.

PA (MURD-) MURDOCH CHILDRENS RES INST.

PI Wraight CJ, Werther GA, Edmondson SR;

DR WPI; 2001-041421/05.

PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -

XX Example 6; Page 42; 201pp; English.

XX The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-F45161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.

SQ Sequence 15 BP; 3 A; 6 C; 4 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 238 GCATCTGCATCTGGG 252
DB 15 GCATCTGCATCTGGG 1

RESULT 308
AAF46438/c
ID AAF46438 standard; DNA; 15 BP.

XX AAF46438;
XX
XX 30-MAR-2001 (first entry)
XX IGFBP2 oligonucleotide #1277.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.

XX Homo sapiens.
XX WO200078341-A1.
XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU00693.
XX 21-JUN-1999; 99US-0140345.
XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by
XX administering UV (ultra-violet) treatment (optional) and an antisense
XX nucleic acid that inhibits or reduces growth factor mediated cell
XX proliferation and/or inflammation -
XX Example 6; Page 42; 201pp; English.

XX The present invention relates to a method for ameliorating the effects
XX of skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and
XX AAF45153-F45161). The method is useful for ameliorating the effects of
XX psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids,
XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
XX skin, a hyperneovascular condition such as a neovascular condition of the
XX retina, brain or skin, growth factor-mediated malignancies, other
XX sclerotic disease, kidney disease, hyperproliferation of the inside of
XX blood vessels or any other hyperplasia.

XX Sequence 15 BP; 3 A; 6 C; 4 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 237 GCATCTGCATCTGG 251
DB 15 GCATCTGCATCTGG 1

RESULT 309
AAF46503
ID AAF46503 standard; DNA; 15 BP.

XX AAF46503;
XX
XX 30-MAR-2001 (first entry)
XX IGFBP2 oligonucleotide #1342.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.

XX Homo sapiens.
XX WO200078341-A1.
XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU00693.
XX 21-JUN-1999; 99US-0140345.
XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by
XX administering UV (ultra-violet) treatment (optional) and an antisense
XX nucleic acid that inhibits or reduces growth factor mediated cell
XX proliferation and/or inflammation -
XX Example 6; Page 42; 201pp; English.

XX The present invention relates to a method for ameliorating the effects
XX of skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and
XX AAF45153-F45161). The method is useful for ameliorating the effects of
XX psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids,
XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
XX skin, a hyperneovascular condition such as a neovascular condition of the
XX retina, brain or skin, growth factor-mediated malignancies, other
XX sclerotic disease, kidney disease, hyperproliferation of the inside of
XX blood vessels or any other hyperplasia.

XX Sequence 15 BP; 3 A; 2 C; 8 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 888 GGAGCTGCGGTACAG 902
DB 1 GGAGCTGCGGTACAG 15

```

RESULT 310
AAF49863/C
ID AAF49863 standard; DNA; 15 BP.
XX
XX
AC AAF49863;
XX
XX
DT 30-MAR-2001 (first entry)
XX
XX
DE IGF-I oligonucleotide #823.
XX
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
FN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CU, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 66; 20pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 0 A; 5 C; 5 G; 5 T; 0 other;
XX
Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 553 GCAGGCATGCACACA 567
DB 15 GCAGGCAGGCACACA 1

RESULT 311
AAF49864/C
ID AAF49864 standard; DNA; 15 BP.
XX
XX
AC AAF49864;
XX
XX
DT 30-MAR-2001 (first entry)
XX
XX
DE IGF-I oligonucleotide #824.
XX
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
FN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CU, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 66; 20pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 0 A; 5 C; 5 G; 5 T; 0 other;
XX
Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 552 GCAGGCATGCACACA 566
DB 15 GCAGGCAGGCACACA 1

RESULT 312
AAF51703/C
ID AAF51703 standard; DNA; 15 BP.
XX
XX
AC AAF51703;
XX
XX

```

DT 30-MAR-2001 (first entry)
 DE IGF-1 oligonucleotide #2663.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP-3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200078341-A1.
 XX
 XX 28-DEC-2000.
 XX
 XX 21-JUN-2000; 2000WO-AU00693.
 XX
 XX 21-JUN-1999; 99US-0140345.
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 XX Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by
 XX administering UV (ultra-violet) treatment (optional) and an antisense
 XX nucleic acid that inhibits or reduces growth factor mediated cell
 XX proliferation and/or inflammation -
 XX
 XX Example 8; Page 78; 201pp; English.
 XX
 XX The present invention relates to a method for ameliorating the effects
 XX of skin disorders. The method comprises contacting the skin with an
 XX antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 XX receptor, IGF binding protein [IGFBP]-2 or IGFBP-3), which is capable of
 XX inhibiting or reducing growth factor mediated cell proliferation,
 XX inflammation and/or other disorders. The present sequence is an
 XX oligonucleotide which can be used to design the antisense
 XX oligonucleotides of the present invention (see AAF45151 and
 XX AAF45153-45161). The method is useful for ameliorating the effects of
 XX psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
 XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 XX retina, brain or skin, growth factor-mediated malignancies, other
 XX sclerotic disease, kidney disease, hyperproliferation of the inside of
 XX blood vessels or any other hyperplasia.
 XX
 XX Sequence 15 BP; 4 A; 2 C; 6 G; 3 T; 0 other;
 XX
 XX Query Match 1.0%; Score 13.4; DB 1; Length 15;
 XX Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 158 CGCGCTGATCTCAA 172
 DB 15 CTCGCTGATCTCAA 1
 XX
 RESULT 313
 ABS97176/c
 ID ABS97176 standard; DNA; 15 BP.
 XX
 AC ABS97176;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human CYP450A2 Exon 4 and 5 sequencing primer #4.
 XX
 XX
 KW Human; ss; primer; cytochrome P450 A1; CYP450A1A1; UGT2B4; MDR1;
 KW cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW glutathione-S-transferase 12; GSTI2; 5-lipoxygenase activating protein; FLAP;
 KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile;
 KW STM; UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological; sequencing.
 XX
 OS Homo sapiens.
 XX
 FN WO200257410-A2.
 XX
 XX 25-JUL-2002.
 XX
 XX 28-NOV-2001; 2001WO-US44838.
 XX
 XX 28-NOV-2000; 2000US-0724389.
 XX
 XX (DNAS-) DNA SCI LAB INC.
 XX
 XX Guida M, Hall J;
 XX WPI; 2002-698522/75.
 XX
 XX Isolated nucleic acid molecules having polymorphisms in known human
 XX genes e.g. cytochrome p450 and cathepsin S useful as genetic linkage
 XX markers for locating, identifying and characterizing the genes
 XX responsible for disorder-related traits -
 XX
 XX Example 2; Page 101; 714pp; English.
 XX
 XX This invention relates to the sequence of an isolated nucleic acid
 XX molecule comprising at least one base variation from that of a known
 XX human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
 XX cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
 XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 XX (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 XX inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase
 XX activating protein (FLAP), glutathione-S-transferase 12 (GSTI2),
 XX histamine-N-methyl transferase (HNMT), (kallikrein 2) KLK2, nicotinamide
 XX -N-methyl transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
 XX sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 XX (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 XX transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance
 XX protein 3 (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine
 XX muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or
 XX CHMR5) sequence. The polymorphisms in the human genes cited in the
 XX invention are useful as genetic linkage markers for locating and
 XX characterising the genes that are responsible for specific traits within
 XX the genome and eventually identifying the genes responsible for a
 XX variety of disorder-related traits as a result of their e.g.,
 XX overexpression, constitutive expression, mutation or underexpression,
 XX which may be used in diagnosing and/or treating the disorders. The
 XX nucleic acid molecules comprising the polymorphic sequences contained
 XX in CYP450A1, CYP450A2, CYP4502E1, ARNT, EPHX2, GSTI2, NNMT, NQO2,
 XX NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful
 XX for screening individuals for altered drug metabolism. The polymorphic
 XX sequences contained in CYP450A1, CYP450A2, AHR, MDR1 and/or MDR3 may
 XX also be used to screen individuals for susceptibility to cancer.
 XX Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered
 XX cardiovascular function, in COX2 for altered susceptibility to
 XX colorectal tumours, in DBI or CHMR1 for altered central nervous system
 XX function, in FLAP and HNMT for altered pulmonary, immunological or

CC haematological function, in KLK2 for altered serine protease activity in
 CC the prostate, in LTF for altered immunological or haematological
 CC function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral
 CC nervous system function. The present sequence represents a sequencing
 CC primer used to sequence the polymorphic genes of the invention.

XX SQ Sequence 15 BP; 3 A; 2 C; 9 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 582 CCTCCGCTGCCCC 596
 DB 15 CCTCAGTCTGCCCC 1

RESULT 314

AA48126
 ID AAL48126 standard; DNA; 15 BP.

XX AC AAL48126;

XX DT 27-SEP-2002 (first entry)

XX DE Human neuropeptide Y allele specific primer SEQ ID NO: 50.

XX KW Human; neuropeptide Y; NPY; isogene; SNP; atherosclerosis; obesity;
 KW psychological disorder; single nucleotide polymorphism; alcoholism;
 KW antiarteriosclerotic; anorectic; PCR; primer; ss.

XX OS Homo sapiens.

XX PN WO200251857-A1.

XX PD 04-JUL-2002.

XX PF 21-DEC-2000; 2000WO-US34758.

XX PR 21-DEC-2000; 2000WO-US34758.

XX PA (GENA-) GENAISSANCE PHARM INC.

XX PI Chew A, Denton RR, Lanz EM, Nandabalan K, Stephens JC;

XX DR WPI; 2002-566671/60.

XX PT New genetic variants of the human Neuropeptide Y (NPY) gene useful for
 PT treating disorders affected by abnormal expression or function of NPY
 PT isogene e.g., atherosclerosis or obesity -

XX PS Claim 11; Page 17; 80pp; English.

XX CC The present invention provides the human neuropeptide Y (NPY) gene and
 CC single nucleotide polymorphisms (SNPs) identified therein. The sequence
 CC can be used in the treatment of disorders associated with NPY, including
 CC atherosclerosis, obesity, psychological disorders and alcoholism. The
 CC present sequence is an allele specific primer used to isolate the human
 CC NPY coding sequence.

XX SQ Sequence 15 BP; 3 A; 7 C; 2 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 639 GCTCTGCAATCCCCA 653

DB 1 GCTCTGCAATCCCCA 15

RESULT 315

AAT06918

ID AAT06918 standard; DNA; 17 BP.

XX AC AAT06918;

XX DT 04-JUL-1996 (first entry)

XX DE Chromosomal locus E15 primer #2.

XX KW prostate/colon tumour suppressor gene; allelic loss; colorectal cancers;
 KW microsatellite analysis; sequence tagged site; primer; probe; PCR;
 KW amplification; chromosome; ss.

XX OS Synthetic.

XX PN WO9532214-A1.

XX PD 30-NOV-1995.

XX PF 22-MAY-1995; 95WO-US06593.

XX PR 20-MAY-1994; 94US-0246604.

XX PA (CANG-) CANJI INC.

XX PI Bookstein R, Isaacs WB;

XX DR WPI; 1996-020526/02.

XX PT New DNA encoding a prostate tumour suppressor protein - from
 PT chromosome 8, for the diagnosis and treatment of prostatic and
 PT colorectal cancer

XX PS Disclosure; Page 86; 122pp; English.

XX CC Primers AAT06887-932 were used to analyse the breakpoints at chromosomal
 CC locus 8p22-21, contained in patients having prostate cancer, by
 CC microsatellite analysis and sequence tagged sites (STS). The region
 CC contains a prostate/colon tumour suppressor gene (PTSG). The primers
 CC and amplified fragments were used to screen a YAC library of prostate
 CC cancer DNA to isolate the PTSG (AAT06880), which can be used in the
 CC diagnosis and treatment of prostate and colorectal cancers.
 CC The primers AAT06917-8 amplify an 86 bp fragment from chromosomal locus
 CC E15.

XX SQ Sequence 17 BP; 1 A; 4 C; 6 G; 6 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 237 GGCATCTGCATCTGG 251

DB 3 GGCATCTGCATCTGG 17

RESULT 316

AAT64712

ID AAT64712 standard; DNA; 17 BP.

XX AC AAT64712;

XX DT 25-MAR-2003 (updated)

XX DT 12-FEB-1998 (first entry)

XX DE Primer E15 for mapping prostate/colon tumour suppressor gene.

XX KW Prostate/colon tumour suppressor; allelic loss; prostate cancer;
 KW colorectal cancer; microsatellite analysis; sequence tagged site;
 KW STS; amplification; chromosomal location 8q22-21; probe;
 KW primer; gene mapping; diagnosis; treatment; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN JP09098790-A.
 XX PD 15-APR-1997.
 XX PF 22-FEB-1996; 96JP-0062144.
 XX PR 22-MAY-1995; 95US-0445515.
 XX PA (CANJ-) CANJI INC.
 XX PA (UYJO) UNIV JOHNS HOPKINS.
 XX PI Isaacs WB, Bookstein R;
 XX DR WPI; 1997-275447/25.
 XX PT New prostate/colon tumour suppressor gene - mapped to a locus on
 XX PT human chromosome 8
 XX PS Disclosure; Page 26; 45pp; Japanese.
 XX CC The present primer was used in the mapping of a gene encoding 2
 CC forms of a prostate/colon tumour suppressor (P/CTS). The P/CTS gene
 CC was isolated by analysis of allelic loss in patients with prostate
 CC cancer, and was putatively located to the chromosomal location
 CC 8q22-21 via microsatellite analysis and the use of sequence tagged
 CC sites (STS). Primers and probes derived from the gene can be used
 CC to screen lambda cDNA libraries for genes encoding P/CTS form 1 and
 CC 2. The P/CTS or its cDNA can be used in the diagnosis and treatment
 CC of prostate and colorectal cancers.
 CC (Updated on 25-MAR-2003 to correct PA field.)
 CC (Updated on 25-MAR-2003 to correct PI field.)
 XX SQ Sequence 17 BP; 1 A; 4 C; 6 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 237 GGCATCTGCACTGG 251
 Db |||||
 3 GGCATCTGCTCTGG 17
 RESULT 317
 ID AAA21346
 XX AAA21346 standard; RNA; 17 BP.
 XX AC AAA21346;
 XX DT 19-JUN-2000 (first entry)
 XX DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4572.
 XX KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX OS Homo sapiens.
 XX PN WO9950403-A2.
 XX PD 07-OCT-1999.
 XX PF 24-MAR-1999; 99WO-US06507.
 XX PR 27-MAR-1998; 98US-0079678.

XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 XX DR WPI; 1999-591315/50.
 XX PT Novel ribozymes for modulating the synthesis, expression and/or
 XX PT stability of an mRNA encoding an angiogenic factors -
 XX PS Claim 55; Page 202; 305pp; English.
 XX CC The present invention describes enzymatic nucleic acid molecules with
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3.
 XX SQ Sequence 17 BP; 0 A; 2 C; 4 G; 11 U; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 20.0%; Pred. No. 2.1e+02;
 Matches 3; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
 QY 1141 GCCTTTTCTCTTT 1155
 Db |||:|||||:|:|:|
 3 GGCUUUUUUUUUUU 17
 RESULT 318
 ID AAC66363/c
 XX AAC66363 standard; DNA; 17 BP.
 XX AC AAC66363;
 XX DT 22-FEB-2001 (first entry)
 XX DE PCR primer used to amplify B. pertussis S1 DNA.
 XX KW Protection; pathogen infection; vaccination; immunisation; poliovirus;
 KW Bordetella pertussis; respiratory syncytial virus; Mycoplasma pneumoniae;
 KW meningococcus; pneumococcus; rotavirus; influenza; parainfluenza;
 KW Corynebacterium diphtheriae; Clostridium tetani; hepatitis B virus;
 KW Chlamydia pneumoniae; Chlamydia trachomatis; Moraxella catarrhalis;
 KW PCR primer; ss.
 XX OS Bordetella pertussis.
 XX PN WO200064457-A1.
 XX PD 02-NOV-2000.
 XX PF 21-APR-2000; 2000WO-US10954.

XX 23-APR-1999; 99US-0298135.
 XX (UYDA-) UNIV DALHOUSIE.
 XX Lee SF, Halperin SA;
 XX WPI; 2000-687261/67.
 XX Composition having genetically modified live oral commensal bacteria
 PT which express immunogenic fragments of mucosal pathogens, used as oral
 PT vaccines to treat host against Bordetella pertussis, poliovirus
 PT infection -
 XX Example 1; Page 25; 52pp; English.
 XX A composition for stimulating protection against infection by a pathogen,
 CC comprises a live commensal oral organism genetically modified to express
 CC multiple immunogenic fragments of the pathogen. The composition has
 CC antibacterial and antiviral activity and acts as a vaccine. The
 CC composition which is administered orally or intranasally, is used for
 CC prophylactically treating a host against infection by a pathogen such as
 CC Bordetella pertussis, respiratory syncytial virus, poliovirus, Mycoplasma
 CC pneumoniae, meningococcus, pneumococcus, rotavirus, influenza,
 CC parainfluenza, Corynebacterium diphtheriae, Clostridium tetani, hepatitis
 CC B virus, Neisseria gonorrhoeae non-typeable Haemophilus influenzae
 CC Chlamydia pneumoniae, Chlamydia trachomatis, Moraxella catarrhalis, or
 CC their combinations. The composition can also be used for chronic
 CC immunisation of a host against infection by a pathogen. The present
 CC sequence represents a PCR primer used to amplify a Bordetella pertussis
 CC DNA sequence, which is used in an example illustrating the use of the
 CC composition of the invention.
 XX Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 760 CGGTGGCGGTGGAT 774
 DB 16 CGGTGGCGGTGGAT 2
 RESULT 319
 AAF02209
 ID AAF02209 standard; DNA; 17 BP.
 XX AAF02209;
 XX AAF02209;
 XX 16-FEB-2001 (first entry)
 XX Hammerhead ribozyme substrate #504.
 DE Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX Homo sapiens.
 XX WO200061729-A2.
 XX 19-OCT-2000.
 XX 11-APR-2000; 2000WO-US09721.
 XX 12-APR-1999; 99US-0129390.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Zwick M, Pavco P, McSwiggen J;
 XX WPI; 2000-647423/62.
 DR WPI; 2000-647423/62.
 XX

PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor
 PT protein, interferon alpha and erythropoietin -
 XX Claim 37; Page 67; 164pp; English.
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
 CC transcription factor gene, IRF-2 and/or the CAAT Displacement
 CC Protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.
 XX Sequence 17 BP; 1 A; 10 C; 3 G; 3 T; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 583 CTCGGTCTGCCCCC 597
 DB 1 CTCGGTCTACCCCC 15
 RESULT 320
 AAA36112
 ID AAA36112 standard; DNA; 17 BP.
 XX AAA36112;
 XX 26-JUL-2000 (first entry)
 DE Human genomic SNP allele specific oligonucleotide SEQ ID NO:169.
 XX Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
 KW allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
 KW genomic classification; identification; DNA fingerprinting;
 KW tumour characterisation; hybridisation; ss.
 XX Homo sapiens.
 XX WO200018960-A2.
 XX 06-APR-2000.
 XX 24-SEP-1999; 99WO-US22283.
 XX 25-SEP-1998; 98US-0101757.
 XX (NASI) MASSACHUSETTS INST TECHNOLOGY.
 XX Landers JE, Jordan B, Houseman DE, Charest A;
 XX WPI; 2000-293181/25.
 XX Detection of single nucleotide polymorphisms in genomes by preparation
 PT and analysis of reduced complexity genomes, useful for genotyping,
 PT fingerprinting and determining allele frequency of SNPs -
 XX Disclosure; Page 58; 111pp; English.
 XX A method has been developed for detecting the presence or absence of a
 CC single nucleotide polymorphism (SNP) allele in a genomic sample. The
 CC method comprises preparing a reduced complexity genome (RCG) from the
 CC genomic sample and analysing the RCG for the presence or absence of a
 CC SNP allele. The method can be used to characterise a tumour, to generate
 CC a genomic pattern for an individual genome or to generate a genomic
 CC classification code for a genome. The method can be used to assess
 CC whether a subject is at risk for developing a disease or to identify a
 CC set of SNP alleles associated with a disease. The method can also be
 CC used to perform linkage analysis. AAA35944 to AAA35947 represent

CC sequences used in the exemplification of the present invention. AAA35948
CC to AAA36632 represent nucleotide sequences containing SNPs.

XX SQ Sequence 17 BP; 2 A; 0 C; 2 G; 13 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1145 TTTTCTTTTGGG 1159
|||||
Db 1 TTTTCTTTTGGG 1159

RESULT 321
AAA25574/C
ID AAA25574 standard; DNA; 17 BP.
XX AC AAA25574;
XX AA25574;
DT 19-JUL-2000 (first entry)
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2072.
KW Oestrogen receptor; c-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
OS Homo sapiens.
XX WO9954459-A2.
XX 28-OCT-1999.
XX 19-APR-1999; 99WO-US08547.
XX 20-APR-1998; 98US-0082404.
XX 23-JUN-1998; 98US-0103636.
XX (RIBO-) RIBOZYME PHARM INC.
XX Thompson JD, Beigelman L, McSwiggen JA, Karpaisky A, Bellion L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerli P;
PI Matulic-Adamic J;
XX WPI; 2000-013248/01.
XX New nucleic acids that interact, and optionally cleave, target
PT sequences, used to treat cancer -
XX Claim 77; Page 83; 148pp; English.

CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodithioate
CC link, having endonuclease activity. (A), and more generally any
CC catalytic nucleic acid (A') that modulates expression of the oestrogen
CC receptor gene, are used to treat cancer (particularly of breast or
CC endometrium), in vivo or by transforming cells ex vivo and implanting
CC treated cells, or for other conditions associated with levels of
CC oestrogen receptor. Because of the high selectivity for targeted RNA, (A)
CC can also be used to correlate inhibition of gene expression with
CC alterations in phenotype, particularly for identification of therapeutic
CC targets, and as research reagents (for RNA, in the same way that
CC restriction endonucleases are used with DNA). The combination of
CC modifications in (A) improves resistance to nucleases, binding affinity
CC and/or activity. AAA3503 to AAA24747 represent oestrogen receptor
CC hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their
CC corresponding target sequences. AAA25993 to AAA26105 represent oestrogen
CC receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent
CC their corresponding target sequences. AAA26219 to AAA26271 represent
CC other ribozyme sequences and antisense oligonucleotides used in the
CC exemplification of the present invention.

XX SQ Sequence 17 BP; 6 A; 4 C; 1 G; 6 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 71 CATGGATGAATAAT 85
|||||
Db 17 CATGGATGAATAAT 3
RESULT 322
ABA77189
ID ABA77189 standard; DNA; 17 BP.
XX AC ABA77189;
XX 24-JAN-2002 (first entry)
DE Adenosine deaminase deficiency correcting oligo SEQ ID NO: 35.
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; anticisclcking; antianaemic; haemostatic;
KW antilipemic; ss.
XX Homo sapiens.
XX WO200173002-A2.
XX 04-OCT-2001.
XX 27-MAR-2001; 2001WO-US09761.
XX 27-MAR-2000; 2000US-192176P.
XX 27-MAR-2000; 2000US-192179P.
XX 01-JUN-2000; 2000US-208538P.
XX 30-OCT-2000; 2000US-244989P.
XX (UYDE) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification -
XX Claim 7; Page 43; 294pp; English.
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting

CC oligonucleotides of the invention.

XX Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 other;

SQ Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 888 GGAGCTGCGGTACAG 902

|||||

Db 1 GGAGTGGGTACAG 15

RESULT 323

ABA77190/c

ID ABA77190 standard; DNA; 17 BP.

XX ABA77190;

DT 24-JAN-2002 (first entry)

XX Adenosine deaminase deficiency correcting oligo SEQ ID NO: 36.

DE Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;

XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;

XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;

XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;

XX haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;

XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;

XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;

XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;

XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;

XX antileptic; ss.

XX Homo sapiens.

OS WO200173002-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US09761.

XX 27-MAR-2000; 2000US-192176P.

XX 27-MAR-2000; 2000US-192179P.

XX 01-JUN-2000; 2000US-208538P.

XX 30-OCT-2000; 2000US-244989P.

XX (UYDE) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for

XX treating cystic fibrosis, comprises at least one mismatch and chemical

XX modification -

XX Claim 7; Page 43; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can

XX be used for the targeted alteration of genomic sequences, where the

XX oligonucleotide has at least one mismatch compared with the genomic

XX sequence to be altered. In particular, these sequences are directed at

XX the following genes: adenosine deaminase, p53, beta-globin,

XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A

XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus

XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and

XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases

XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,

XX haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,

XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and

CC various syndromes. The present sequence is one of the gene correcting

XX oligonucleotides of the invention.

SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 888 GGAGCTGCGGTACAG 902

|||||

Db 17 GGAGTGGGTACAG 3

RESULT 324

ABA77193

ID ABA77193 standard; DNA; 17 BP.

XX ABA77193;

DT 24-JAN-2002 (first entry)

XX Adenosine deaminase deficiency correcting oligo SEQ ID NO: 39.

DE Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;

XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;

XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;

XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;

XX haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;

XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;

XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;

XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;

XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;

XX antileptic; ss.

XX Homo sapiens.

OS WO200173002-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US09761.

XX 27-MAR-2000; 2000US-192176P.

XX 27-MAR-2000; 2000US-192179P.

XX 01-JUN-2000; 2000US-208538P.

XX 30-OCT-2000; 2000US-244989P.

XX (UYDE) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for

XX treating cystic fibrosis, comprises at least one mismatch and chemical

XX modification -

XX Claim 7; Page 43; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can

XX be used for the targeted alteration of genomic sequences, where the

XX oligonucleotide has at least one mismatch compared with the genomic

XX sequence to be altered. In particular, these sequences are directed at

XX the following genes: adenosine deaminase, p53, beta-globin,

XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A

XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus

XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and

XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases

XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,

XX haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,

XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and

CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 888 GGAGCTGCGGTACAG 902
 Db 1 GGAGTGGGTACAG 15
 RESULT 325
 ABA77194/c
 ID ABA77194 standard; DNA; 17 BP.
 XX
 AC ABA77194;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Adenosine deaminase deficiency correcting oligo SEQ ID NO: 40.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOB;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US09761.
 XX
 PR 27-MAR-2000; 2000US-192176P.
 PR 27-MAR-2000; 2000US-192179P.
 PR 01-JUN-2000; 2000US-208538P.
 PR 30-OCT-2000; 2000US-244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -
 XX
 PS Claim 7; Page 43; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOB), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,

CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 888 GGAGCTGCGGTACAG 902
 Db 17 GGAGTGGGTACAG 3
 RESULT 326
 ABA77197
 ID ABA77197 standard; DNA; 17 BP.
 XX
 AC ABA77197;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Adenosine deaminase deficiency correcting oligo SEQ ID NO: 43.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOB;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US09761.
 XX
 PR 27-MAR-2000; 2000US-192176P.
 PR 27-MAR-2000; 2000US-192179P.
 PR 01-JUN-2000; 2000US-208538P.
 PR 30-OCT-2000; 2000US-244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -
 XX
 PS Claim 7; Page 43; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOB), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases

CC such as cancer, adenosine deaminase deficiency, cystic fibrosis.
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 8 G; 4 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 888 GGAGCTGGCGTACAG 902
 DB 2 GGAGTGGCGTACAG 16
 RESULT 327
 ABA77198/c
 ID ABA77198 standard; DNA; 17 BP.
 XX
 AC ABA77198;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Adenosine deaminase deficiency correcting oligo SEQ ID NO: 44.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antickling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 XX 27-MAR-2001; 2001WO-US09761.
 XX
 XX 27-MAR-2000; 2000US-192176P.
 PR 27-MAR-2000; 2000US-192179P.
 PR 01-JUN-2000; 2000US-208538P.
 PR 30-OCT-2000; 2000US-244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX
 XX Kmiec EB, Gamper HB, Rice MC;
 PI
 XX
 XX WPI; 2001-639230/73.
 DR
 XX
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -
 XX
 XX
 XX Claim 7; Page 43; 294pp; English.
 XX
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and

CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.
 XX
 SQ Sequence 17 BP; 4 A; 8 C; 2 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 888 GGAGCTGGCGTACAG 902
 DB 16 GGAGTGGCGTACAG 2
 RESULT 328
 ABA80972/c
 ID ABA80972 standard; DNA; 17 BP.
 XX
 AC ABA80972;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3818.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antickling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 XX 27-MAR-2001; 2001WO-US09761.
 XX
 XX 27-MAR-2000; 2000US-192176P.
 PR 27-MAR-2000; 2000US-192179P.
 PR 01-JUN-2000; 2000US-208538P.
 PR 30-OCT-2000; 2000US-244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX
 XX Kmiec EB, Gamper HB, Rice MC;
 PI
 XX
 XX WPI; 2001-639230/73.
 DR
 XX
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -
 XX
 XX
 XX Claim 7; Page 251; 294pp; English.
 XX
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

CC (UTG1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.

XX SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 745 CATGTTGCTGACTTT 759
 Db 15 CATGTTGCTGACTTT 1

RESULT 329
 ABA80973
 ID ABA80973 standard; DNA; 17 BP.
 XX AC ABA80973;
 XX DT 24-JAN-2002 (first entry)
 XX DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3819.
 XX KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antileptic; ss.

XX OS Homo sapiens.
 XX PN WO200173002-A2.
 XX PD 04-OCT-2001.
 XX PF 27-MAR-2001; 2001WO-US09761.
 XX PR 27-MAR-2000; 2000US-192176P.
 XX PR 27-MAR-2000; 2000US-192176P.
 XX PR 01-JUN-2000; 2000US-208538P.
 XX PR 30-OCT-2000; 2000US-244989P.
 XX PA (UYDE) UNIV DELAWARE.
 XX PI Kmiec EB, Gampier HB, Rice MC;
 XX WPI; 2001-639230/73.
 XX PT Oligonucleotide for targeted alterations of genetic sequences and for
 XX treating cystic fibrosis, comprises at least one mismatch and chemical
 XX modification -
 XX Claim 7; Page 251; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.

XX SQ Sequence 17 BP; 3 A; 4 C; 4 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 745 CATGTTGCTGACTTT 759
 Db 3 CATGTTGCTGACTTT 17

RESULT 330
 AAF44454
 ID AAF44454 standard; DNA; 17 BP.
 XX AC AAF44454;
 XX DT 02-APR-2001 (first entry)
 XX DE Human PRO1245 reverse PCR primer SEQ ID NO:493.
 XX KW Human; secreted and transmembrane protein; PRO; cytostatic;
 KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
 KW diagnostic assay; PCR primer; hybridisation; probe; ss.
 XX OS Homo sapiens.
 XX PN WO2000073454-A1.
 XX PD 07-DEC-2000.
 XX PF 30-MAR-2000; 2000WO-US08439.
 XX PR 02-JUN-1999; 99WO-US12252.
 XX PR 23-JUN-1999; 99US-0141037.
 XX PR 07-JUL-1999; 99US-0143048.
 XX PR 20-JUL-1999; 99US-0144758.
 XX PR 26-JUL-1999; 99US-0145698.
 XX PR 28-JUL-1999; 99US-0146222.
 XX PR 17-AUG-1999; 99US-0149396.
 XX PR 15-SEP-1999; 99WO-US21090.
 XX PR 15-SEP-1999; 99WO-US21547.
 XX PR 08-OCT-1999; 99US-0158663.
 XX PR 30-NOV-1999; 99WO-US28313.
 XX PR 01-DEC-1999; 99WO-US28301.
 XX PR 16-DEC-1999; 99WO-US30095.
 XX PR 20-DEC-1999; 99WO-US30911.
 XX PR 05-JAN-2000; 2000WO-US00219.
 XX PR 06-JAN-2000; 2000WO-US00376.
 XX PR 11-FEB-2000; 2000WO-US03565.
 XX PR 18-FEB-2000; 2000WO-US04341.
 XX PR 22-FEB-2000; 2000WO-US04414.
 XX PR 24-FEB-2000; 2000WO-US04914.
 XX PR 24-FEB-2000; 2000WO-US05004.
 XX PR 02-MAR-2000; 2000WO-US05841.
 XX PR 15-MAR-2000; 2000WO-US06884.
 XX PR 20-MAR-2000; 2000WO-US07377.
 XX PA (GETH) GENENTECH INC.
 XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen MB, Goddard A, Godowski PJ;
 PI Grimaldi CJ, Gurney AL, Kijavini IU, Napier MA, Pan J, Faoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood W;

PI Zhang Z;
 XX WPI; 2001-032160/04.
 DR PRO polynucleotides used to produce polypeptides used to target
 XX bioactive molecules such as toxins, radiolabels or antibodies, to
 PT specific cells, to cause targeted cell death -
 PT
 XX Example 170; Page 544; 935pp; English.
 PS
 XX The present invention describes human secreted and transmembrane PRO
 CC proteins. The PRO proteins have cytostatic activity. The PRO proteins
 CC can be used for targeted delivery of bioactive molecules, such as
 CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
 CC sequences, and their fragments, can be used as hybridisation probes, in
 CC chromosomal and gene mapping, and in the generation of anti-sense RNA
 CC and DNA. They may also be used to produce transgenic animals which are
 CC used to develop and screen therapeutically useful reagents. The PRO
 CC nucleotide and protein sequence can be used for tissue typing and in
 CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
 CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
 CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
 CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
 CC sequences given in the exemplification of the present invention.
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 494 GTGTGACGCGCTCTTG 508
 DB 1 GTGGGCGCGCTCTTG 15
 RESULT 331
 ABV73116
 ID ABV73116 standard; DNA; 17 BP.
 XX
 AC ABV73116;
 XX
 DT 08-JAN-2003 (first entry)
 XX
 DE LGALS1 cDNA quantifying primer LGALS13.
 XX
 KW Nucleic acid sequencing; gene expression; nucleic acid amplification;
 KW LGALS1; PCR; primer; ss.
 XX
 OS Synthetic.
 XX
 PN W0200272772-A2.
 XX
 PD 19-SEP-2002.
 XX
 PF 11-MAR-2002; 2002WO-US07306.
 XX
 PR 09-MAR-2001; 2001US-274550P.
 XX
 XX (NUGE-) NUGEN TECHNOLOGIES INC.
 XX
 XX Kurn N;
 PI
 XX WPI; 2002-740809/80.
 DR
 XX Generating multiple copies of polynucleotide complementary to RNA, by
 PT amplifying RNA with composite primer, second primer, and strand
 PT displacement to generate DNA products comprising sequences
 ET complementary to RNA -
 XX
 XX Example 5; Page 105; 148pp; English.
 PS
 XX The invention relates to generating multiple copies of polynucleotide

CC complementary to RNA sequence. The method involves extending first primer
 CC hybridized to target RNA (1) with enzyme to form complex having first
 CC primer extension product (EP1) and (1), cleaving (1) from the complex,
 CC extending second primer hybridized to EP1 with enzyme to form complex,
 CC having EP1 and EP2, and cleaving RNA from the composite primer in the
 CC complex. The method is useful for sequencing RNA sequence of interest;
 CC for detecting a mutation in a target RNA using single stranded
 CC conformation polymorphism; for determining presence or absence of a
 CC sequence of interest; for producing a nucleic acid immobilized to a
 CC substrate; for characterizing an RNA sequence of interest; for
 CC determining gene expression profile in a sample; and for preparing a
 CC library. The method is also useful for differential amplification of one
 CC or more sequence of interest, and for making a cDNA library by preparing
 CC a subtractive hybridization probe. Sequences ABV73113-120 represent
 CC primer pairs used for quantification of the four specific expressed genes
 CC in either cDNA or amplification products generated using the method of
 CC the invention.
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 6 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 261 CCTGGGCTGGCTGAT 275
 DB 1 CATGGGCTGGCTGAT 15
 RESULT 332
 ABV79137
 ID ABV79137 standard; DNA; 17 BP.
 XX
 AC ABV79137;
 XX
 DT 03-JAN-2003 (first entry)
 XX
 DE Human HTPL scanning oligonucleotide SEQ ID 383.
 XX
 KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1229046-A2.
 XX
 PD 07-AUG-2002.
 XX
 PF 28-JAN-2002; 2002EP-0001167.
 XX
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 23-MAY-2001; 2001US-0864761.
 PR 09-OCT-2001; 2001US-0327898.
 XX
 XX (ABOM-) AEOMICA INC.
 XX
 XX Zhan J;
 PI
 XX WPI; 2002-676582/73.
 DR
 XX Novel isolated human testis expressed Patched like protein (HTPL),
 PT useful for identifying agonist and antagonist and specific binding
 PT partners, and for treating subjects having defects in HTPL -
 ET
 XX
 XX Example 2; Page 114; 718pp; English.
 PS
 XX

CC The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 7 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 522 CCTGCCGGAGGAGCA 536
 |||||
 Db 3 CCTGCCGGAGGAGCA 17

RESULT 333
 ABV79138
 ID ABV79138 standard; DNA; 17 BP.

XX AC ABV79138;
 XX DT 03-JAN-2003 (first entry)
 XX DE Human HTPL scanning oligonucleotide SEQ ID 384.
 XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX OS Homo sapiens.

XX FN EP1229046-A2.
 XX PD 07-AUG-2002.
 XX PF 28-JAN-2002; 2002EP-0001167.
 XX PR 30-JAN-2001; 2001WO-US00663.
 XX PR 30-JAN-2001; 2001WO-US00664.
 XX PR 30-JAN-2001; 2001WO-US00665.
 XX PR 30-JAN-2001; 2001WO-US00666.
 XX PR 30-JAN-2001; 2001WO-US00667.
 XX PR 30-JAN-2001; 2001WO-US00668.
 XX PR 23-MAY-2001; 2001US-0864761.
 XX PR 09-OCT-2001; 2001US-0327898.

XX PA (AEOM-) AEOMICA INC.

XX PI Zhan J;

XX DR WPI; 2002-676582/73.

XX Novel isolated human testis expressed Patched like protein (HTPL),
 PT useful for identifying agonist and antagonist and specific binding
 PT partners, and for treating subjects having defects in HTPL -

PS Example 2; Page 114; 718pp; English.

XX CC The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.
 XX

SQ Sequence 17 BP; 4 A; 5 C; 7 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 522 CCTGCCGGAGGAGCA 536
 |||||
 Db 2 CCTGCCGGAGGAGCA 16

RESULT 334
 ABV79139
 ID ABV79139 standard; DNA; 17 BP.

XX AC ABV79139;
 XX DT 03-JAN-2003 (first entry)
 XX DE Human HTPL scanning oligonucleotide SEQ ID 385.
 XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX OS Homo sapiens.

XX FN EP1229046-A2.
 XX PD 07-AUG-2002.
 XX PF 28-JAN-2002; 2002EP-0001167.
 XX PR 30-JAN-2001; 2001WO-US00663.
 XX PR 30-JAN-2001; 2001WO-US00664.
 XX PR 30-JAN-2001; 2001WO-US00665.
 XX PR 30-JAN-2001; 2001WO-US00666.
 XX PR 30-JAN-2001; 2001WO-US00667.
 XX PR 30-JAN-2001; 2001WO-US00668.
 XX PR 23-MAY-2001; 2001US-0864761.
 XX PR 09-OCT-2001; 2001US-0327898.

XX PA (AEOM-) AEOMICA INC.

XX PI Zhan J;

XX DR WPI; 2002-676582/73.

XX Novel isolated human testis expressed Patched like protein (HTPL),
 PT useful for identifying agonist and antagonist and specific binding


```

XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 495; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB8399), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
SQ Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 631 CTCGAGGAGCTCTGC 645
Db 16 CTCGCGGAGCTCTGC 2

RESULT 337
ABV89783/C
ID ABV89783 standard; DNA; 17 BP.
XX
AC ABV89783;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 496.
XX
KW Human; POSHL1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
FN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-0001165.
XX
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.

```

```

PR 23-MAY-2001; 2001US-0864761.
PR 10-OCT-2001; 2001US-0328205.
XX
PA (AEOM-) AROMICA INC.
XX
PI Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 496; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB8399), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
SQ Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 631 CTCGAGGAGCTCTGC 645
Db 15 CTCGCGGAGCTCTGC 1

RESULT 338
ABV90552/C
ID ABV90552 standard; DNA; 17 BP.
XX
AC ABV90552;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1265.
XX
KW Human; POSHL1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
FN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-0001165.
XX
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.

```


KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; incozyme;
 KW amberzyme.
 XX Homo sapiens.
 OS WO200188124-A2.
 FN 22-NOV-2001.
 XX 16-MAY-2001; 2001WO-US15966.
 XX 16-MAY-2000; 2000US-0572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;
 PI WPI; 2002-082995/11.
 XX Novel polynucleotide which down regulates expression of Ets-related
 PT gene, useful for treating cancer, diabetic retinopathy, macular
 PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 PT syndrome -
 XX Claim 4; Page 78; 149pp; English.
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention.
 XX Sequence 17 BP; 6 A; 5 C; 2 G; 4 U; 0 other;
 SQ
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 80.0%; Pred. No. 2.1e+02;
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 21 TTATACCAACCCAG 35
 : : |||||
 Db 2 UTAUACCAACCCAG 16
 RESULT 343
 ABK19335/C
 ID ABK19335 standard; RNA; 17 BP.
 XX
 AC ABK19335;

XX 09-APR-2002 (first entry)
 DT Human ERG Amberzyme target sequence Seq ID No 1982.
 DE
 XX
 KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnarary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; incozyme;
 KW amberzyme.
 XX Homo sapiens.
 OS WO200188124-A2.
 FN 22-NOV-2001.
 XX 16-MAY-2001; 2001WO-US15966.
 XX 16-MAY-2000; 2000US-0572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;
 PI WPI; 2002-082995/11.
 XX Novel polynucleotide which down regulates expression of Ets-related
 PT gene, useful for treating cancer, diabetic retinopathy, macular
 PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 PT syndrome -
 XX Claim 4; Page 126; 149pp; English.
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention.
 XX Sequence 17 BP; 7 A; 1 C; 6 G; 3 U; 0 other;
 SQ
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 48 TTACGATCTCTCTCA 62
 ||||| |||||

Db 16 TTAGCATCTCTCTCA 2

RESULT 344

ABT39230

ID ABT39230 standard; DNA; 17 BP.

XX AC ABT39230;

XX DT 12-JUN-2003 (first entry)

XX DT Tumour suppression related human fukutin oligo SEQ ID No 4867.

DE XX

DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

XX KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

XX KW schizophrenia; protein chip; gene therapy; tumour suppression;

XX KW human fukutin; ds.

XX OS Homo sapiens.

XX PN WO2003025175-A2.

XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB04208.

XX PR 17-SEP-2001; 2001FR-0011978.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313353/30.

XX PT New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

PT polypeptides, antibodies and transfected cells -

XX PS Disclosure; Page 603; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,

CC given in the specification, a sequence containing at least 15

CC consecutive nucleotides from the 17 mer sequence, a sequence with, after

CC optimal alignment, at least 80 % identity to the 17 mer sequence, a

CC sequence that hybridizes to them under highly stringent conditions, or

CC the complement of any of them, or the corresponding RNA. The novel

CC isolated nucleic acids of the invention are useful as probes and primers

CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,

CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,

CC and for production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the nucleic acids, cells containing the

CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and

CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in

CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and

CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression

CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 8 A; 3 C; 4 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GATCAAGAGGAGC 287

DB 1 GATCAAGAGGAGC 15

RESULT 345

ABT39985/c

ID ABT39985 standard; DNA; 17 BP.

XX AC ABT39985;

XX DT 13-JUN-2003 (first entry)

XX DT Tumour suppression related human fukutin oligo SEQ ID No 5622.

DE XX

DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

XX KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

XX KW schizophrenia; protein chip; gene therapy; tumour suppression;

XX KW human fukutin; ds.

XX OS Homo sapiens.

XX PN WO2003025175-A2.

XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB04208.

XX PR 17-SEP-2001; 2001FR-0011978.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313353/30.

XX PT New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

PT polypeptides, antibodies and transfected cells -

XX PS Disclosure; Page 691; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,

CC given in the specification, a sequence containing at least 15

CC consecutive nucleotides from the 17 mer sequence, a sequence with, after

CC optimal alignment, at least 80 % identity to the 17 mer sequence, a

CC sequence that hybridizes to them under highly stringent conditions, or

CC the complement of any of them, or the corresponding RNA. The novel

CC isolated nucleic acids of the invention are useful as probes and primers

CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,

CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,

CC and for production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and

CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in

CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and

CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression

CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 2 A; 10 C; 3 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 760 CGGTGGCGGGTGGAT 774

DB 16 CGGAGGCGGGTGGAT 2

ABX80463
 ID ABX80463 standard; DNA; 17 BP.
 XX AC ABX80463;
 XX DT 28-APR-2003 (first entry)
 XX DE Novel human secreted or transmembrane protein PRO183 DNA.
 XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
 KW cardiac insufficiency disorder; cancer; tumour; immune response;
 KW adrenal cortical capillary endothelial growth; c-fos induction;
 KW vascular endothelial growth factor inhibition; VEGF inhibition;
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
 KW retinal neurons cell survival; rod photoreceptor cell survival;
 KW retinal disorder; retinitis pigmentosa; kidney disorder;
 KW mammalian kidney mesangial cell proliferation; Berger disease;
 KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
 KW chondrocyte redifferentiation; sports injury; arthritis; gene; ds.
 XX OS Homo sapiens.
 XX US US2002132252-A1.
 XX 19-SEP-2002.
 PF 14-NOV-2001; 2001US-0990442.
 PR 05-NOV-1997; 97WO-US200069.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 06-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.

PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.
 XX (GETH) GENENTECH INC.
 XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;
 XX WPI; 2003-247083/24.
 DR P-PSDB; ABUS9182.
 XX Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
 PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
 PT are therapeutically useful for enhancing immune response and in cancer
 PT treatments -
 XX Claim 2; Fig 307; 649pp; English.
 XX The invention describes an isolated human PRO polypeptide. The PRO
 CC polypeptides are useful in detecting PRO polypeptides in a sample, in
 CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
 CC in modulating at least one biological activity of a cell expressing a PRO
 CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
 CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186

CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
 CC PRO943, PRO828, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
 CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
 CC useful for treating conditions or disorders where angiogenesis would be
 CC beneficial, e.g. wound healing and antagonist of this polypeptide are
 CC useful for treating cancerous tumours. PRO812 inhibits vascular
 CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
 CC cells and is thus useful for inhibiting endothelial cell growth in
 CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
 CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
 CC stimulated T-lymphocytes and are therapeutically useful for enhancing
 CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
 CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
 CC rod photoreceptor cells) and therefore are useful for treating retinal
 CC disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813
 CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,
 CC and therefore are useful for treating kidney disorders associated with
 CC decreased mesangial cell function such as Berger disease or Crohn's
 CC nephropathies associated with dermatitis, herpeticiformis or Crohn's
 CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
 CC proliferation and/or redifferentiation of chondrocytes in culture and
 CC are thus useful for treating sports injuries, and arthritis. This
 CC sequence represents a novel human PRO protein polynucleotide.

XX Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 494 GTGTGACGCGCTTG 508

Db 1 GTGTGACGCGCTTG 15

RESULT 347

ABX80967

ID ABX80967 standard; DNA; 17 BP.

XX AC ABX80967;

XX DT 22-APR-2003 (first entry)

XX DE Human secreted/transmembrane protein, TagMan probe #22.

XX KW Human; probe; ss; PRO; secreted; transmembrane; pharmaceutical;

XX KW diagnostic; biosensor; bioreactor; tumour; therapeutic; TagMan;

XX KW gene therapy; tumour-associated antigenic target; TAT; ADEPT;

XX KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.

XX OS Homo sapiens.

XX FN US2003027162-A1.

XX PD 06-FEB-2003.

XX PF 15-NOV-2001; 2001US-0997428.

XX PR 05-NOV-1997; 97WO-US20069.

XX PR 16-SEP-1998; 98WO-US19330.

XX PR 17-SEP-1998; 98WO-US19437.

XX PR 07-OCT-1998; 98WO-US21141.

XX PR 01-DEC-1998; 98WO-US25108.

XX PR 05-JAN-1999; 99WO-US00106.

XX PR 08-MAR-1999; 99WO-US05028.

XX PR 02-JUN-1999; 99WO-US12252.

XX PR 15-SEP-1999; 99WO-US21090.

XX PR 15-SEP-1999; 99WO-US21547.

XX PR 30-NOV-1999; 99WO-US28313.

XX PR 01-DEC-1999; 99WO-US28301.

XX PR 01-DEC-1999; 99WO-US28634.

XX PR 16-DEC-1999; 99WO-US30095.

XX PR 20-DEC-1999; 99WO-US30911.

PR 05-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065116P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088126P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088217P.
 PR 05-JUN-1998; 98US-088212P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.


```
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090245P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 22-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090423P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090433P.
PR 24-JUN-1998; 98US-090443P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 25-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-092339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096771P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.
PR 18-AUG-1998; 98US-097022P.

PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 31-AUG-1998; 98US-098014P.
PR 31-AUG-1998; 98US-098525P.
PR 16-SEP-1998; 98US-100634P.
PR 17-SEP-1998; 98US-100858P.
PR 22-DEC-1998; 98US-113296P.
PR 12-MAR-1999; 99US-123957P.
PR 23-JUN-1999; 99US-141037P.

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 494 GTGTGACGCGCTCTTG 508
Db 1 GTGGGACGCGCTCTTG 15

RESULT 348
ABX81350
ID ABX81350 standard; DNA; 17 BP.
XX
AC ABX81350;
XX
XX 22-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO183 DNA.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ds.
OS Homo sapiens.
XX
XX US2003027985-A1.
XX
XX 06-FEB-2003.
XX
XX 14-NOV-2001; 2001US-0990562.
XX
XX 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
```

PR	06-JAN-2000;	2000WO-US00376.	PR	18-JUN-1998;	98US-089801P.
PR	11-FEB-2000;	2000WO-US03565.	PR	18-JUN-1998;	98US-089907P.
PR	18-FEB-2000;	2000WO-US04341.	PR	18-JUN-1998;	98US-089908P.
PR	22-FEB-2000;	2000WO-US04414.	PR	19-JUN-1998;	98US-089947P.
PR	24-FEB-2000;	2000WO-US04914.	PR	19-JUN-1998;	98US-089948P.
PR	24-FEB-2000;	2000WO-US05004.	PR	19-JUN-1998;	98US-089952P.
PR	02-MAR-2000;	2000WO-US05841.	PR	22-JUN-1998;	98US-090246P.
PR	10-MAR-2000;	2000WO-US06319.	PR	22-JUN-1998;	98US-090252P.
PR	15-MAR-2000;	2000WO-US06884.	PR	22-JUN-1998;	98US-090254P.
PR	20-MAR-2000;	2000WO-US07377.	PR	23-JUN-1998;	98US-090349P.
PR	30-MAR-2000;	2000WO-US08439.	PR	23-JUN-1998;	98US-090355P.
PR	15-MAY-2000;	2000WO-US13358.	PR	24-JUN-1998;	98US-090429P.
PR	17-MAY-2000;	2000WO-US13705.	PR	24-JUN-1998;	98US-090431P.
PR	22-MAY-2000;	2000WO-US14042.	PR	24-JUN-1998;	98US-090435P.
PR	30-MAY-2000;	2000WO-US14941.	PR	24-JUN-1998;	98US-090444P.
PR	02-JUN-2000;	2000WO-US15264.	PR	24-JUN-1998;	98US-090445P.
PR	28-JUL-2000;	2000WO-US20710.	PR	24-JUN-1998;	98US-090472P.
PR	11-AUG-2000;	2000WO-US20231.	PR	24-JUN-1998;	98US-090540P.
PR	23-AUG-2000;	2000WO-US23522.	PR	24-JUN-1998;	98US-090542P.
PR	24-AUG-2000;	2000WO-US23328.	PR	24-JUN-1998;	98US-090557P.
PR	08-NOV-2000;	2000WO-US30952.	PR	25-JUN-1998;	98US-090676P.
PR	01-DEC-2000;	2000WO-US32678.	PR	25-JUN-1998;	98US-090678P.
PR	28-FEB-2001;	2001WO-US06520.	PR	25-JUN-1998;	98US-090690P.
PR	01-JUN-2001;	2001WO-US17800.	PR	25-JUN-1998;	98US-090694P.
PR	20-JUN-2001;	2001WO-US19692.	PR	25-JUN-1998;	98US-090695P.
PR	29-JUN-2001;	2001WO-US21066.	PR	25-JUN-1998;	98US-090696P.
PR	09-JUL-2001;	2001WO-US21735.	PR	26-JUN-1998;	98US-090862P.
PR	16-JUN-1997;	97US-049787P.	PR	26-JUN-1998;	98US-090863P.
PR	17-OCT-1997;	97US-062250P.	PR	01-JUL-1998;	98US-091360P.
PR	12-NOV-1997;	97US-065186P.	PR	01-JUL-1998;	98US-091544P.
PR	13-NOV-1997;	97US-065311P.	PR	02-JUL-1998;	98US-091478P.
PR	24-NOV-1997;	97US-066770P.	PR	02-JUL-1998;	98US-091513P.
PR	25-FEB-1998;	98US-075945P.	PR	02-JUL-1998;	98US-091628P.
PR	20-MAR-1998;	98US-078910P.	PR	02-JUL-1998;	98US-091628P.
PR	28-APR-1998;	98US-083322P.	PR	02-JUL-1998;	98US-091633P.
PR	07-MAY-1998;	98US-084600P.	PR	02-JUL-1998;	98US-091646P.
PR	28-MAY-1998;	98US-087106P.	PR	02-JUL-1998;	98US-091673P.
PR	02-JUN-1998;	98US-087607P.	PR	07-JUL-1998;	98US-091978P.
PR	02-JUN-1998;	98US-087609P.	PR	07-JUL-1998;	98US-091982P.
PR	02-JUN-1998;	98US-087759P.	PR	09-JUL-1998;	98US-092182P.
PR	03-JUN-1998;	98US-087827P.	PR	10-JUL-1998;	98US-092472P.
PR	04-JUN-1998;	98US-088021P.	PR	20-JUL-1998;	98US-093339P.
PR	04-JUN-1998;	98US-088025P.	PR	30-JUL-1998;	98US-094651P.
PR	04-JUN-1998;	98US-088026P.	PR	04-AUG-1998;	98US-095282P.
PR	04-JUN-1998;	98US-088028P.	PR	04-AUG-1998;	98US-095285P.
PR	04-JUN-1998;	98US-088029P.	PR	04-AUG-1998;	98US-095301P.
PR	04-JUN-1998;	98US-088030P.	PR	04-AUG-1998;	98US-095302P.
PR	04-JUN-1998;	98US-088323P.	PR	04-AUG-1998;	98US-095318P.
PR	05-JUN-1998;	98US-088326P.	PR	04-AUG-1998;	98US-095321P.
PR	05-JUN-1998;	98US-088327P.	PR	04-AUG-1998;	98US-095325P.
PR	05-JUN-1998;	98US-088402P.	PR	10-AUG-1998;	98US-095916P.
PR	05-JUN-1998;	98US-088421P.	PR	10-AUG-1998;	98US-095929P.
PR	09-JUN-1998;	98US-088455P.	PR	10-AUG-1998;	98US-096012P.
PR	10-JUN-1998;	98US-088734P.	PR	11-AUG-1998;	98US-096143P.
PR	10-JUN-1998;	98US-088738P.	PR	11-AUG-1998;	98US-096146P.
PR	10-JUN-1998;	98US-088742P.	PR	12-AUG-1998;	98US-096329P.
PR	10-JUN-1998;	98US-088810P.	PR	17-AUG-1998;	98US-096757P.
PR	10-JUN-1998;	98US-088810P.	PR	17-AUG-1998;	98US-096766P.
PR	10-JUN-1998;	98US-088824P.	PR	17-AUG-1998;	98US-096768P.
PR	10-JUN-1998;	98US-088826P.	PR	17-AUG-1998;	98US-096773P.
PR	11-JUN-1998;	98US-088858P.	PR	17-AUG-1998;	98US-096791P.
PR	11-JUN-1998;	98US-088861P.	PR	17-AUG-1998;	98US-096867P.
PR	12-JUN-1998;	98US-088876P.	PR	17-AUG-1998;	98US-096891P.
PR	12-JUN-1998;	98US-089105P.	PR	17-AUG-1998;	98US-096894P.
PR	16-JUN-1998;	98US-089440P.	PR	17-AUG-1998;	98US-096895P.
PR	16-JUN-1998;	98US-089512P.	PR	17-AUG-1998;	98US-096897P.
PR	16-JUN-1998;	98US-089514P.	PR	18-AUG-1998;	98US-096949P.
PR	17-JUN-1998;	98US-089532P.	PR	18-AUG-1998;	98US-096950P.
PR	17-JUN-1998;	98US-089538P.	PR	18-AUG-1998;	98US-096959P.
PR	17-JUN-1998;	98US-089598P.	PR	18-AUG-1998;	98US-096960P.
PR	17-JUN-1998;	98US-089599P.	PR	18-AUG-1998;	98US-097022P.
PR	17-JUN-1998;	98US-089600P.	PR	19-AUG-1998;	98US-097141P.
PR	17-JUN-1998;	98US-089653P.			

PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes -
PS Example 170; Page 297; 650pp; English.
XX
XX The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful in gene therapy, in chromosome
CC identification, as chromosome markers, or in generating probes. The PRO
CC polypeptides are useful as molecular markers for protein
CC electrophoresis, and the isolated nucleic acids may be used for
CC recombinantly expressing those markers. The PRO polypeptides and nucleic
CC acids may also be used in tissue typing. Anti-PRO antibodies are useful
CC in diagnostic assays for PRO, and in affinity purification of PRO from
CC recombinant cell culture or natural sources. The sequences presented in
CC CC ABX90083-ABX90468 are the genes encoding, the primers amplifying and the
CC probes detecting the PRO polynucleotides of the invention.
CC Note: The sequence data for this patent is also available in electronic
CC format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX

SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 494 GTGGGACGCGCTTG 508
||| ||||| ||||| |||||
Db 1 GTGGGACGCGCTTG 15

RESULT 350

ABX78051

ID ABX78051 standard; DNA; 17 BP.

AC ABX78051;

DT 14-APR-2003 (first entry)

DE Human PRO PCR primer #127.

XX Human; PRO; PCR; ss; cytostatic; tumour; cancer; breast; lung; stomach;
KW liver; horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT; primer;
KW antibody-dependent enzyme mediated prodrug therapy.
XX Homo sapiens.
OS
XX US2003027163-A1.
FN
XX
PD 06-FEB-2003.
XX
XX 15-NOV-2001; 2001US-0997666.
PF
XX 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US21108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.

PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06984.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23322.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 24-NOV-1997; 97US-065311P.
PR 25-FEB-1998; 97US-066770P.
PR 28-MAR-1998; 98US-075945P.
PR 28-APR-1998; 98US-078910P.
PR 07-MAY-1998; 98US-083322P.
PR 28-MAY-1998; 98US-084600P.
PR 02-JUN-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.

PR 17-JUN-1998; 98US-089553P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 19-JUN-1998; 98US-089947P.
 PR 19-JUN-1998; 98US-089948P.
 PR 19-JUN-1998; 98US-089952P.
 PR 22-JUN-1998; 98US-090246P.
 PR 22-JUN-1998; 98US-090252P.
 PR 22-JUN-1998; 98US-090254P.
 PR 23-JUN-1998; 98US-090349P.
 PR 23-JUN-1998; 98US-090355P.
 PR 24-JUN-1998; 98US-090439P.
 PR 24-JUN-1998; 98US-090431P.
 PR 24-JUN-1998; 98US-090435P.
 PR 24-JUN-1998; 98US-090444P.
 PR 24-JUN-1998; 98US-090445P.
 PR 24-JUN-1998; 98US-090472P.
 PR 24-JUN-1998; 98US-090535P.
 PR 24-JUN-1998; 98US-090540P.
 PR 24-JUN-1998; 98US-090542P.
 PR 24-JUN-1998; 98US-090557P.
 PR 25-JUN-1998; 98US-090676P.
 PR 25-JUN-1998; 98US-090678P.
 PR 25-JUN-1998; 98US-090690P.
 PR 25-JUN-1998; 98US-090694P.
 PR 25-JUN-1998; 98US-090695P.
 PR 25-JUN-1998; 98US-090696P.
 PR 26-JUN-1998; 98US-090862P.
 PR 26-JUN-1998; 98US-090863P.
 PR 01-JUL-1998; 98US-091360P.
 PR 01-JUL-1998; 98US-091544P.
 PR 02-JUL-1998; 98US-091478P.
 PR 02-JUL-1998; 98US-091519P.
 PR 02-JUL-1998; 98US-091626P.
 PR 02-JUL-1998; 98US-091628P.
 PR 02-JUL-1998; 98US-091633P.
 PR 02-JUL-1998; 98US-091646P.
 PR 02-JUL-1998; 98US-091673P.
 PR 07-JUL-1998; 98US-091978P.
 PR 07-JUL-1998; 98US-091982P.
 PR 09-JUL-1998; 98US-092182P.
 PR 10-JUL-1998; 98US-092472P.
 PR 20-JUL-1998; 98US-093339P.
 PR 30-JUL-1998; 98US-094651P.
 PR 04-AUG-1998; 98US-095282P.
 PR 04-AUG-1998; 98US-095285P.
 PR 04-AUG-1998; 98US-095301P.
 PR 04-AUG-1998; 98US-095318P.
 PR 04-AUG-1998; 98US-095321P.
 PR 04-AUG-1998; 98US-095325P.
 PR 10-AUG-1998; 98US-095916P.
 PR 10-AUG-1998; 98US-095929P.
 PR 10-AUG-1998; 98US-096012P.
 PR 11-AUG-1998; 98US-096143P.
 PR 11-AUG-1998; 98US-096146P.
 PR 12-AUG-1998; 98US-096329P.
 PR 17-AUG-1998; 98US-096757P.
 PR 17-AUG-1998; 98US-096766P.
 PR 17-AUG-1998; 98US-096768P.
 PR 17-AUG-1998; 98US-096773P.
 PR 17-AUG-1998; 98US-096791P.
 PR 17-AUG-1998; 98US-096867P.
 PR 17-AUG-1998; 98US-096891P.
 PR 17-AUG-1998; 98US-096894P.
 PR 17-AUG-1998; 98US-096895P.
 PR 17-AUG-1998; 98US-096897P.
 PR 18-AUG-1998; 98US-096899P.
 PR 18-AUG-1998; 98US-096950P.
 PR 18-AUG-1998; 98US-096959P.
 PR 18-AUG-1998; 98US-096960P.
 PR 18-AUG-1998; 98US-097022P.

PR 19-AUG-1998; 98US-097141P.
 PR 20-AUG-1998; 98US-097218P.
 PR 24-AUG-1998; 98US-097661P.
 PR 26-AUG-1998; 98US-097952P.
 PR 26-AUG-1998; 98US-097954P.
 PR 26-AUG-1998; 98US-097955P.
 PR 26-AUG-1998; 98US-097971P.
 PR 26-AUG-1998; 98US-097974P.
 PR 26-AUG-1998; 98US-097978P.
 PR 26-AUG-1998; 98US-097979P.
 PR 26-AUG-1998; 98US-097986P.
 PR 26-AUG-1998; 98US-098014P.
 PR 31-AUG-1998; 98US-098525P.
 PR 16-SEP-1998; 98US-100634P.
 PR 17-SEP-1998; 98US-100858P.
 PR 22-DEC-1998; 98US-113296P.
 PR 12-MAR-1999; 98US-123957P.
 PR 23-JUN-1999; 98US-141037P.
 PR 07-JUL-1999; 98US-143048P.
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 494 GTGTGACGGCTCTTG 508
 DB 1 GTGGGACGGCTCTTG 15
 RESULT 351
 ABX79647
 ID ABX79647 standard; DNA; 17 BP.
 AC ABX79647;
 XX
 XX 17-APR-2003 (first entry)
 DE Human secreted/transmembrane protein, TaqMan probe #22.
 XX
 KW Human; probe; ss; PRO; secreted; transmembrane; signal peptide;
 KW pharmaceutical; diagnostic; biosensor; bioresor; tumour; therapeutic;
 KW colon cancer; lung cancer; breast cancer; cancer; gene therapy; taqMan.
 XX
 OS Homo sapiens.
 XX
 PN US2002142961-A1.
 PD
 PF 03-OCT-2002.
 XX
 XX 19-NOV-2001; 2001US-0989721.
 XX
 PR 05-NOV-1997; 97WO-US20069.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 18-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.

PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-0880326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.
 (GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrera N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoi NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;
 XX WPI; 2003-155950/15.
 DR
 XX
 XX New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
 PT PRO361 or PRO846) useful as targets for therapeutic intervention in
 PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers
 PT -
 XX
 XX Example 170; Page 294; 647pp; English.
 PS
 XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC comprising a sequence without signal peptide and the nucleic acid
 CC encoding them. The polypeptides can be used to raise antibodies that
 CC specifically bind to the PRO polypeptide, for linking a bioactive
 CC molecule to a cell expressing a PRO protein and for modulating at least
 CC one biological activity of a cell. The PRO polypeptides or
 CC polynucleotides are also useful as pharmaceuticals, diagnostics,
 CC biosensors or bioreactors, for detecting or treating e.g. tumours in
 CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
 CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
 CC colon, lung or breast cancers) and diagnostic determination of the
 CC presence of these cancers. The PRO polypeptides are also useful as
 CC molecular weight markers or for chromosome identification. The PRO genes
 CC are useful as hybridisation probes or for screening libraries of human
 CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
 CC therapy, particularly for replacing a defective gene. The sequences
 CC presented in ABX79290-ABX79675 are the genes encoding, the primers
 CC amplifying and the probes detecting the PRO polynucleotides of the
 CC invention.
 CC Note: The sequence data for this patent is also available in electronic
 CC format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred.No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 494 GTGTGCGAGCGTCTTG 508
 |||||
 Db 1 GTGGCGAGCGTCTTG 15
 RESULT 352
 ABZ60185/c
 ID ABZ60185 standard; RNA; 17 BP.
 XX
 AC ABZ60185;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human K-Ras DNAzyme substrate #297.
 XX
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 PD
 PD 05-DEC-2002.
 XX
 XX 29-MAY-2002; 2002WO-US16840.
 PF
 XX 29-MAY-2001; 2001US-294140P.
 PR 06-JUN-2001; 2001US-296249P.
 PR 10-SEP-2001; 2001US-318471P.

XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX PT
XX PS Claim 58; Page 90; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 4 A; 5 C; 2 G; 6 U; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 77 ATGAATATAGCAGT 91
Db 17 ATGACTATAGCAGT 3
RESULT 353
ABZ61172
ID ABZ61172 standard; RNA; 17 BP.
XX AC ABZ61172;
XX DT 21-MAR-2003 (first entry)
XX DE Human K-Ras DNAzyme substrate #1284.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX PT
PS Claim 58; Page 109; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 7 A; 4 C; 5 G; 1 U; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 281 AGGAAGCAGCAGCAA 295
Db 1 AGGUAGCAGCAGCAA 15
RESULT 354
ABZ61566/C
ID ABZ61566 standard; RNA; 17 BP.
XX AC ABZ61566;
XX DT 21-MAR-2003 (first entry)
XX DE Human H-Ras DNAzyme target #357.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX PT
PS Claim 58; Page 117; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.

CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.

XX SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 U; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1293 TGCTCAGCGCTGGCC 1307
 DB 16 TGCTCAGCGCGCC 2

RESULT 355
 ABZ61903
 ID ABZ61903 standard; RNA; 17 BP.

XX AC ABZ61903;
 XX DT 21-MAR-2003 (first entry)
 XX DE Human H-Ras DNase target #694.

XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.

XX OS Homo sapiens.
 XX PN WO200297114-A2.

XX PD 05-DEC-2002.

XX XX 29-MAY-2002; 2002WO-US16940.

XX XX 29-MAY-2001; 2001US-294140P.

XX XX 06-JUN-2001; 2001US-296249P.

XX XX 10-SEP-2001; 2001US-318471P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Mcswiggen J;

XX XX WPI; 2003-140484/13.

XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -

XX PS Claim 58; Page 124; 185pp; English.

XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and
 CC anti-rheumatic activity. The nucleic acid molecules are useful for
 CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
 CC acids are also useful for treating breast, ovarian, colorectal, lung,
 CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
 CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.

XX SQ Sequence 17 BP; 1 A; 8 C; 5 G; 3 U; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 73.3%; Pred. No. 2.1e+02;
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 231 GCCTCAGGCATCTGC 245

Db |||:|||||:|:|
 2 GCCCAGGCCUCUGC 16

RESULT 356
 ABX64286

ID ABX64286 standard; DNA; 17 BP.

XX AC ABX64286;

XX XX 26-FEB-2003 (first entry)

XX DE Human PRO DNA PCR primer #125.

XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;
 KW genetic disorder; antibacterial; immunosuppressive; PCR; primer; ss.

XX OS Homo sapiens.

XX PN US2002103125-A1.

XX PD 01-AUG-2002.

XX XX 20-NOV-2001; 2001US-0989731.

XX XX 05-NOV-1997; 97WO-US20069.

XX XX 16-SEP-1998; 98WO-US19330.

XX XX 17-SEP-1998; 98WO-US19437.

XX XX 07-OCT-1998; 98WO-US21141.

XX XX 01-DEC-1998; 98WO-US25108.

XX XX 05-JAN-1999; 99WO-US00106.

XX XX 08-MAR-1999; 99WO-US05028.

XX XX 02-JUN-1999; 99WO-US12252.

XX XX 15-SEP-1999; 99WO-US21090.

XX XX 15-SEP-1999; 99WO-US21547.

XX XX 30-NOV-1999; 99WO-US28313.

XX XX 01-DEC-1999; 99WO-US28301.

XX XX 16-DEC-1999; 99WO-US28634.

XX XX 20-DEC-1999; 99WO-US30095.

XX XX 06-JAN-2000; 2000WO-US00219.

XX XX 11-FEB-2000; 2000WO-US03565.

XX XX 18-FEB-2000; 2000WO-US04341.

XX XX 22-FEB-2000; 2000WO-US04414.

XX XX 24-FEB-2000; 2000WO-US04914.

XX XX 02-MAR-2000; 2000WO-US05004.

XX XX 10-MAR-2000; 2000WO-US05841.

XX XX 15-MAR-2000; 2000WO-US06884.

XX XX 20-MAR-2000; 2000WO-US07177.

XX XX 30-MAR-2000; 2000WO-US08439.

XX XX 15-MAY-2000; 2000WO-US13358.

XX XX 17-MAY-2000; 2000WO-US13705.

XX XX 22-MAY-2000; 2000WO-US14042.

XX XX 30-MAY-2000; 2000WO-US14941.

XX XX 02-JUN-2000; 2000WO-US15264.

XX XX 28-JUL-2000; 2000WO-US20710.

XX XX 11-AUG-2000; 2000WO-US22031.

XX XX 23-AUG-2000; 2000WO-US23522.

XX XX 24-AUG-2000; 2000WO-US23328.

XX XX 08-NOV-2000; 2000WO-US30952.

XX XX 01-DEC-2000; 2000WO-US32678.

XX XX 28-FEB-2001; 2001WO-US06520.

XX XX 01-JUN-2001; 2001WO-US17800.

XX XX 20-JUN-2001; 2001WO-US19692.

XX XX 29-JUN-2001; 2001WO-US21056.

XX XX 09-JUL-2001; 2001WO-US21735.

XX XX 16-JUN-1997; 97US-049787P.

XX XX 17-OCT-1997; 97US-062250P.

XX XX 12-NOV-1997; 97US-085186P.

XX XX 13-NOV-1997; 97US-065311P.

XX XX 24-NOV-1997; 97US-065770P.

PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH LTD.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;

XX WFI; 2003-102117/09.

XX Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers -

XX Example 170; Page 295; 649pp; English.

XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The
 CC PRO polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides are useful for detecting other PRO polypeptides, for
 CC linking bioactive molecules to cells expressing PRO polypeptides,
 CC for modulating biological activities of cells expressing PRO
 CC polypeptides, and for identifying agonists or antagonists.
 CC The polynucleotide sequences encoding PRO polypeptides are useful as
 CC hybridisation probes, in chromosome and gene mapping, in the generation
 CC of antisense RNA and DNA, in the preparation of PRO polypeptides, for
 CC generating transgenic animals or knockout animals, to construct

CC hybridisation probes for mapping the gene which encodes the PRO
 CC polypeptide, and for the genetic analysis of individuals with genetic
 CC disorders, in gene therapy, for chromosome identification, as
 CC chromosome markers, and for generating probes for PCR, Northern
 CC analysis, Southern analysis and Western analysis. The present
 CC sequence represents a PCR primer used in the examples of the present
 CC invention.
 CC Note: The sequence data for this patent was obtained in electronic
 CC format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipdsIDentry.html.
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 494 GTGTGCGAGCGTCTTG 508

Db 1 GTGGGCGAGCGTCTTG 15

RESULT 357

ABX17250

ID ABX17250 standard; DNA; 17 BP.

AC ABX17250;

DT 04-FEB-2003 (first entry)

DE Human PRO probe #59.

XX Human; PRO; probe; ss; secreted polypeptide; transmembrane polypeptide;

KW toxin; radiolabel; cell death; gene mapping; chromosome mapping;

KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
 KW antibacterial.

XX Homo sapiens.

PN US2002123463-A1.

XX 05-SEP-2002.

XX 19-NOV-2001; 2001US-0989732.

XX 05-NOV-1997; 97WO-US20069.

XX 16-SEP-1998; 98WO-US19330.

XX 17-SEP-1998; 98WO-US19437.

XX 07-OCT-1998; 98WO-US21141.

XX 01-DEC-1998; 98WO-US25108.

XX 05-JAN-1999; 99WO-US00106.

XX 08-MAR-1999; 99WO-US05028.

XX 02-JUN-1999; 99WO-US12252.

XX 15-SEP-1999; 99WO-US21090.

XX 15-SEP-1999; 99WO-US21547.

XX 30-NOV-1999; 99WO-US28313.

XX 01-DEC-1999; 99WO-US28301.

XX 01-DEC-1999; 99WO-US28634.

XX 16-DEC-1999; 99WO-US30095.

XX 20-DEC-1999; 99WO-US30911.

XX 06-JAN-2000; 2000WO-US00219.

XX 06-JAN-2000; 2000WO-US00376.

XX 11-FEB-2000; 2000WO-US03565.

XX 18-FEB-2000; 2000WO-US04341.

XX 22-FEB-2000; 2000WO-US04414.

XX 24-FEB-2000; 2000WO-US04914.

XX 02-MAR-2000; 2000WO-US05004.

XX 02-MAR-2000; 2000WO-US05841.

XX 10-MAR-2000; 2000WO-US06319.

XX 15-MAR-2000; 2000WO-US06884.

XX 20-MAR-2000; 2000WO-US07377.

XX 30-MAR-2000; 2000WO-US08439.

XX 15-MAY-2000; 2000WO-US13358.

PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US30678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 28-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087108P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089807P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.
 (GETH) GENENTECH INC.

PA Askenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WT;
 PI Zhang Z;

XX WFI; 2003-066810/06.
 XX
 XX Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers -
 XX
 PS Example 170; Page 301; 655pp; English.
 XX

XX The invention relates to a secreted and transmembrane polypeptide, termed
 CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
 CC useful for detecting PRO polypeptides and for linking a bioactive
 CC molecule to a cell expressing the above polypeptides, where the bioactive
 CC molecule is a toxin, radiolabel or an antibody. The bioactive material
 CC causes the death of the cell. The polypeptide is useful for identifying
 CC agonists or antagonists of the PRO polypeptide, for preparing variants of
 CC PRO, as a molecular weight marker for protein electrophoresis purposes
 CC and the PRO polynucleotide is useful for recombinantly expressing those
 CC markers. The polynucleotide is also useful as a hybridisation probe, in
 CC chromosome and gene mapping, in generation of antisense RNA and DNA, in
 CC the preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, to construct hybridisation
 CC probes for mapping the gene which encodes PRO and for the genetic
 CC analysis of individuals with genetic disorders, in gene therapy, for
 CC chromosome identification, as a chromosome marker and for generating
 CC probes for PCR, Northern analysis, Southern analysis and Western
 CC analysis. This sequence represents a human PRO probe of the invention.
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. NO. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 494 GTGTGACAGCGCTTGT 508
 ||| |||||
 Db 1 GTGGGACAGCGCTTGT 15

RESULT 358
 AAQ26549/c
 ID AAQ26549 standard; DNA; 18 BP.

XX AC AAQ26549;

XX 08-JAN-1993 (first entry)

Control probe #4 for caucosoid RING11 gene.

XX immunosuppressants; immunoenhancers; treatment; diagnosis; screening;
 KW immune disorders; transporter peptides; proteasome complex;
 KW MHC class I molecules; HLA; antigen processing;
 KW antigen presentation; autoimmune disease; ankylosing spondylitis;
 XX prenatal diagnosis; polymerase chain reaction; ss.

OS Synthetic.

XX WO9211289-A.

XX 09-JUL-1992.

XX 19-DEC-1991; 91WO-GB02278.

XX 19-DEC-1990; 90GB-0027520.

XX 16-SEP-1991; 91GB-0019711.

XX (IMCR) IMPERIAL CANCER RES TECHNOLOGY.

XX Glynne R, Kelly AP, Powis SH, Trowsdale J;

XX WFI; 1992-250030/30.

PT DNA encoding RING4, RING10, RING11 AND RING12 proteins - for
PT treatment and diagnosis of immune disorders and screening of new
PT immunosuppressants and immuno-enhancers
XX
XX Example 2; Page 40; 101pp; English.
XX
XX This probe was used together with AAQ26546-51 to analyse caucosoid
CC controls by oligonucleotide typing, whilst investigating RING 11
CC polymorphisms - see AAQ26544,5.
XX
SQ Sequence 18 BP; 3 A; 6 C; 6 G; 3 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 625 GACACGCTCCAGGAG 639
Db 16 GCCCAGCTCCAGGAG 2
RESULT 359
AAQ52841/c
ID AAQ52841 standard; RNA; 18 BP.
XX
XX AC AAQ52841;
XX
DT 25-MAR-2003 (updated)
DT 26-MAY-1994 (first entry)
XX
XX Cytomegalovirus target sequence 18.
XX
XX RNA; enzyme; enzymatic RNA molecule; ERM; cleave; RNA; mRNA; HnRNA;
KW picornavirus; HIV; immunodeficiency virus; hepatitis B virus; HBV;
KW papilloma virus; HPV; Epstein-Barr virus; EBV; TCLV;
KW T-cell leukaemia virus; hepatitis C virus; HCV; cytomegalovirus;
KW influenza virus; HSV; herpes simplex virus; vector; immune response;
KW antibody; ribozyme; viral RNA; treatment; ss.
XX
XX Synthetic.
XX
XX WO9323569-A1.
XX
XX 25-NOV-1993.
XX
XX 29-APR-1993; 93WO-US04020.
XX
XX 11-MAY-1992; 92US-0882689.
XX 14-MAY-1992; 92US-0882712.
XX 14-MAY-1992; 92US-0882713.
XX 14-MAY-1992; 92US-0882714.
XX 14-MAY-1992; 92US-0882823.
XX 14-MAY-1992; 92US-0882824.
XX 14-MAY-1992; 92US-0882886.
XX 14-MAY-1992; 92US-0882888.
XX 14-MAY-1992; 92US-0882889.
XX 14-MAY-1992; 92US-0882921.
XX 14-MAY-1992; 92US-0882922.
XX 14-MAY-1992; 92US-0883823.
XX 14-MAY-1992; 92US-0883849.
XX 14-MAY-1992; 92US-0884073.
XX 14-MAY-1992; 92US-0884074.
XX 14-MAY-1992; 92US-0884333.
XX 14-MAY-1992; 92US-0884422.
XX 14-MAY-1992; 92US-0884431.
XX 14-MAY-1992; 92US-0884436.
XX 31-JUL-1992; 92US-0884521.
XX 26-AUG-1992; 92US-0923738.
XX 26-AUG-1992; 92US-0935854.
XX 18-SEP-1992; 92US-0936086.
XX 15-OCT-1992; 92US-0948359.
XX 07-DEC-1992; 92US-0963322.
XX 07-DEC-1992; 92US-0987129.

PR 07-DEC-1992; 92US-0987130.
PR 07-DEC-1992; 92US-0987133.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Draper KG, Dudycz LW, Mcswiggen JA, Macejak DG, Holecsek JJ;
XX Mamone JA;
XX WPI; 1993-386599/48.
XX
XX Enzymatic RNA molecules - used to inhibit viral replication,
PT infection and gene expression
XX
XX Claim 5; Fig 13; 287pp; English.
XX
XX The sequences (AAQ52824-Q52890) are pref. Cytomegalovirus target
CC sequences for enzymatic RNA molecules. The RNA molecules are
CC complementary to a substrate binding region in the specified gene
CC target. They also have enzymatic activity, in that they specifically
CC cleave RNA in the target. The ERMs interfere with viral replication and
CC therefore have anti-viral properties. They can be used to attenuate
CC viruses to be used in vaccines.
CC (Updated on 25-MAR-2003 to correct PN field.)
CC (Updated on 25-MAR-2003 to correct PI field.)
CC (Updated on 25-MAR-2003 to correct PI field.)
XX
XX Sequence 18 BP; 8 A; 4 C; 4 G; 2 U; 0 other;
SQ
Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 703 CTCCTTGATTCGTG 717
Db 15 CTCCTTGATTCGTG 1
RESULT 360
AAQ67098
ID AAX67098 standard; RNA; 18 BP.
XX
XX AAX67098;
XX
XX 20-JUL-1999 (first entry)
XX
XX Human B7-2 hairpin ribozyme target SEQ ID NO:3730.
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW streptolysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX
XX Homo sapiens.
XX
XX WO9618736-A2.
XX
XX 20-JUN-1996.
XX
XX 22-NOV-1995; 95WO-US15516.
XX
XX 05-OCT-1995; 95US-0541365.
XX 13-DEC-1994; 94US-0354920.
XX 23-DEC-1994; 94US-0363253.
XX 23-DEC-1994; 94US-0363254.
XX 17-FEB-1995; 95US-0390850.
XX 20-APR-1995; 95US-0426124.
XX 02-MAY-1995; 95US-0432874.
XX 04-MAY-1995; 95US-0434509.
XX 07-JUL-1995; 95US-0000951.
XX 07-JUL-1995; 95US-0000974.
XX 07-AUG-1995; 95US-0512861.
XX

PA (RIBO-) RIBOZYME PHARM INC.
 XX Draper K, Gustofson J, McSwiggen J, Pavco P, Stinchcomb DT;
 PI Beigelman L, Karpeisky A, Modak A, Usman N, Burgin A;
 PI Matulic-Adamic J, Jarvis T, Thompson JD, Wincott F;
 XX WPI; 1996-300653/30.
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used
 PT for the treatment of arthritis, induction of graft tolerance or
 PT treatment of auto-immune diseases
 XX Claim 10; Page 216; 307pp; English.
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose
 CC residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
 CC at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
 CC The ENA's can inhibit collagenase and stromelysin production in the
 CC synovial membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention.
 XX Sequence 18 BP; 3 A; 3 C; 2 G; 10 U; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 33.3%; Pred. No. 2.3e+02;
 Matches 5; Conservative 9; Mismatches 1; Indels 0; Gaps 0;
 QY 1111 GTTTTCTGTTTAATT 1125
 Db 1 GUUUUCUGUUAUU 15
 RESULT 361
 AAV54171
 ID AAV54171 standard; cDNA; 18 BP.
 AC AAV54171;
 AC AAV54171;
 DT 21-DEC-1998 (first entry)
 XX Nucleotide sequence PCR primer 8.
 DE PCR; primer; amplification; apoptosis; antibody; inhibition; ss;
 XX immunohistological staining.
 KW Synthetic.
 XX WO9839437-A1.
 XX 11-SEP-1998.
 PD 05-MAR-1998; 98WO-JP00905.
 PF 05-MAR-1997; 97JP-0050302.
 PR (KYOW) KYOWA HAKKO KOGYO KK.
 PA Sakaki Y;
 PI WPI; 1998-495844/42.
 DR
 XX

PT Novel apoptosis-related DNAs and proteins - for diagnosis,
 PT preventing or treating diseases associated with apoptosis
 XX Example 1; Page 49; 70pp; Japanese.
 XX This is the nucleotide sequence of a PCR primer used in the method
 CC of the invention, involving the use of novel apoptosis-related DNAs
 CC and proteins. The inventions can be used as diagnostic reagents for
 CC apoptosis e.g. (monoclonal) antibodies for the protein, as a reagent
 CC in immunohistological staining, as apoptosis inhibitors. It can also
 CC be used for treatment of apoptosis-related diseases.
 XX Sequence 18 BP; 0 A; 0 C; 3 G; 15 T; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1144 TTTTCTCTTTTGG 1158
 Db 4 TTTTCTTTTGG 18
 RESULT 362
 AAA48761/C
 ID AAA48761 standard; DNA; 18 BP.
 XX AAA48761;
 AC AAA48761;
 XX 08-SEP-2000 (first entry)
 DT Human G-alpha-16 antisense oligonucleotide ISIS# 20818.
 DE Human G-alpha-16 protein; cytostatic; hyperproliferative disorder;
 KW cancer; inflammation; infection; antisense inhibition; ss.
 XX Homo sapiens.
 OS WO200032817-A1.
 XX 08-JUN-2000.
 PD 25-AUG-1999; 99WO-US19613.
 PF 03-DEC-1998; 98US-0205143.
 PR (ISIS-) ISIS PHARM INC.
 XX Cowser LM;
 PI WPI; 2000-412354/35.
 DR A new antisense compound for inhibiting the expression of human
 PT G-alpha-16 and treating, preventing or delaying infections,
 PT inflammation or hyperproliferative disorders such as cancer -
 XX Example 15; Page 72; 100pp; English.
 XX The present sequence is an antisense oligonucleotide used to
 CC modulate expression of G-alpha-16. G-alpha-16 is a human G protein which
 CC interacts differentially with several receptor types including members
 CC of the opioid and chemokine receptor families. A series of antisense
 CC oligonucleotides have been designed to target different regions of the
 CC human G-alpha-16 RNA. They may be used to inhibit the expression of
 CC G-alpha-16 in human cells and tissues and thus to treat diseases
 CC associated with G-alpha-16, such as hyperproliferative disorders,
 CC especially cancer. Infections, inflammation or tumour formation can
 CC be prevented or delayed. The compounds can be used in research and
 CC diagnostics in sandwich and other assays.
 CC Note: The sequence has a phosphorothioate backbone and may be
 CC either an oligodeoxynucleotide or a chimeric oligonucleotide
 CC containing 2'-methoxyethyl (2'-MOE) wings and a deoxy gap. The ISIS
 CC number given above corresponds to the oligodeoxynucleotide sequence.

XX SQ Sequence 18 BP; 4 A; 8 C; 2 G; 4 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1336 GGTTCAGGCGAGG 1350
 Db 16 GTGTTTCAGGCAAG 2

RESULT 363
 AAA10983
 ID AAA10983 standard; DNA; 18 BP.
 AC AAA10983;
 XX
 DT 20-JUL-2000 (first entry)
 XX
 DE DNA sequence #4 used in target nucleic acid detection method.
 XX
 XX Detect; target analyte; electrode array; environmental pollutant;
 KW pesticide; insecticide; toxin; chemical; virus; spore; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 18 /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = T(CH2)16SH"
 XX
 PN WO200016089-A2.
 XX
 PD 23-MAR-2000.
 XX
 PF 17-SEP-1999; 99WO-US21683.
 XX
 PR 17-SEP-1998; 98US-0100730.
 XX
 PA (CLIN-) CLINICAL MICRO SENSORS INC.
 XX
 PI O'Connor SD;
 XX
 DR WPI; 2000-271554/23.
 XX
 PT Signal processing method useful for achieving higher signal to noise ratios and to increase detection limits of target analytes -
 XX
 PS Example 2; Page 122; 145pp; English.
 XX
 CC This sequence represents an oligonucleotide used as a detection probe in an array for the detection of target analytes. The invention relates to the detection of target analytes in a sample using an electrode array. At least one electrode forms an assay complex consisting of a capture binding ligand covalently attached to the electrode, a target analyte, and an electron transfer moiety. An input signal is applied to the electrode, a target analyte, and the resulting output signal is processed to detect the presence of the target analytes. Preferred analytes include proteins and nucleic acids. However, the analyte may also be an environmental pollutant (pesticides, insecticides or toxins), a chemical (solvent or organic material), biomolecules (hormones, cytokines, proteins, lipids, carbohydrates, cellular membrane antigens and receptors), whole cells (prokaryotic and eukaryotic cells), viruses, and spores. The method achieves higher signal to noise ratios to increase the detection limits of the target analytes.

XX SQ Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 7 GCAGTTGAGGTGGAT 21
 Db 4 GCAGTTGAGGTGGAT 18

RESULT 364
 AAA10986/c
 ID AAA10986 standard; DNA; 18 BP.
 AC AAA10986;
 XX
 DT 20-JUL-2000 (first entry)
 XX
 DE Partial signalling probe sequence used in analyte detection method.
 XX
 XX Detect; target analyte; electrode array; environmental pollutant; ss;
 KW pesticide; insecticide; toxin; chemical; virus; spore; signalling probe.
 XX
 OS Synthetic.
 XX
 PN WO200016089-A2.
 XX
 PD 23-MAR-2000.
 XX
 PF 17-SEP-1999; 99WO-US21683.
 XX
 PR 17-SEP-1998; 98US-0100730.
 XX
 PA (CLIN-) CLINICAL MICRO SENSORS INC.
 XX
 PI O'Connor SD;
 XX
 DR WPI; 2000-271554/23.
 XX
 PT Signal processing method useful for achieving higher signal to noise ratios and to increase detection limits of target analytes -
 XX
 PS Example 2; Page 122; 145pp; English.
 XX
 CC This sequence represents a signalling probe used in an example of the method of the invention. The invention relates to the detection of target analytes in a sample using an electrode array. At least one electrode forms an assay complex consisting of a capture binding ligand covalently attached to the electrode, a target analyte, and an electron transfer moiety. An input signal is applied to the assay complex, and the resulting output signal is processed to detect the presence of the target analytes. Preferred analytes include proteins and nucleic acids. However, the analyte may also be an environmental pollutant (pesticides, insecticides or toxins), a chemical (solvent or organic material), biomolecules (hormones, cytokines, proteins, lipids, carbohydrates, cellular membrane antigens and receptors), whole cells (prokaryotic and eukaryotic cells), viruses, and spores. The method achieves higher signal to noise ratios to increase the detection limits of the target analytes.

XX SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 7 GCAGTTGAGGTGGAT 21
 Db 15 GCAGTTGAGGTGGAT 1

RESULT 365
 AAZ90641
 ID AAZ90641 standard; DNA; 18 BP.
 AC AAZ90641;
 XX
 DT 13-JUN-2000 (first entry)

```

XX DE Human adipose tissue gene amplifying primer #2.
XX KW Adipose tissue; obesity; diabetes; hyperlipemia; hypertension; human;
XX KW arteriosclerosis; hyperuricemia; sleep apnea syndrome; PCR primer; ss.
XX OS Homo sapiens.
XX PN JF2000037190-A.
XX PD 08-FEB-2000.
XX PF 23-JUL-1998; 98JP-0225228.
XX PR 23-JUL-1998; 98JP-0225228.
XX PA (NISB ) JAPAN TOBACCO INC.
XX DR WPI; 2000-306578/27.
XX PT A physiologically active protein specifically derived from mammal
XX PT tissue -
XX PS Example 2; Page 18; 50pp; Japanese.
XX CC The invention relates to identification of genes and proteins of adipose
XX CC tissue relating to obesity, particularly complications of visceral
XX CC obesity including diabetes, hyperlipemia, hypertension,
XX CC arteriosclerosis, hyperuricemia and sleep apnea syndrome. The genes
XX CC (AAZ90631-633) and the proteins (AAV67598-Y67600) are used in the genetic
XX CC diagnosis, prevention and treatment of adipose tissue related diseases.
XX CC Sequences AAZ90640-51 represent PCR primers amplifying the human adipose
XX CC tissue genes.
XX SQ Sequence 18 BP; 0 A; 0 C; 3 G; 15 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTTTGG 1158
Db 4 TTTTTCCTTTTGG 18

RESULT 366
AAZ97002
ID AAZ97002 standard; DNA; 18 BP.
XX AC AAZ97002;
XX DT 14-APR-2000 (first entry)
XX DE Nucleotide sequence of DNA4.
XX KW Target analyte; nucleic acid detection; capture ligand; pesticide;
XX KW electron transfer moiety; pollutant; therapeutic drug; cancer;
XX KW Alzheimer's disease; cystic fibrosis; blood screening; water testing;
XX KW forensic fingerprinting; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 18
XX FT /*tag= a
XX FT /note= "T(CH2)16SH"
XX PN WO9967425-A2.
XX XX
XX PD 29-DEC-1999.
XX PF 23-JUN-1999; 99WO-US14191.
XX PR 23-JUN-1998; 98US-0090389.
XX PR 14-AUG-1998; 98US-0134058.
XX PA (CLIN-) CLINICAL MICRO SENSORS INC.
XX XX

23-JUN-1998; 98US-0090389.
14-AUG-1998; 98US-0134058.
(CLIN-) CLINICAL MICRO SENSORS INC.
Kayyem JF, Blackburn G, O'Connor SD;
WPI; 2000-136990/12.
Complex-forming assay for analyte, particularly nucleic acid, used e.g.
in detecting genetic disease, with accelerated complex formation by
electrophoretic concentration of analyte -
Example 2; Page 113; 140pp; English.
The invention relates to a method of detecting a target analyte that
comprises concentrating the analyte in a detection chamber comprising a
detection electrode with a covalently attached capture ligand to form an
assay complex comprising the analyte, ligand and at least 1 electron
transfer moiety (ETM), and detecting the ETM with the the detection
electrode. The method is particularly used for assaying nucleic acids or
proteins, but more generally the target analyte is any compound for which
a binding partner is available, e.g. pesticide or other pollutants;
therapeutic or illicit drugs; whole cells; viruses etc. Particularly the
method is used in array formats, optionally with many thousands of
different capture ligands. Particular applications are detecting genes
associated with cancer, Alzheimer's disease, cystic fibrosis etc.;
detecting bacteria and viruses (e.g. for blood screening or testing water
or foods); for forensic fingerprinting; for sequencing and for detecting
successful gene amplification. The rate of complex formation is
increased, resulting in more sensitive detection, particularly down to
CC 100 molecules. The present sequence represents a DNA fragment used in the
CC course of the invention for detection of target sequences.
XX SQ Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 GCAGTTGAGGTGGAT 21
Db 4 GCAGTTGAGGTGGAT 18

RESULT 367
AAZ97005/C
ID AAZ97005 standard; DNA; 18 BP.
XX AC AAZ97005;
XX DT 14-APR-2000 (first entry)
XX DE Nucleotide sequence of a 30nm signalling probe D-1055.
XX KW Target analyte; nucleic acid detection; capture ligand; pesticide;
XX KW electron transfer moiety; pollutant; therapeutic drug; cancer;
XX KW Alzheimer's disease; cystic fibrosis; blood screening; water testing;
XX KW forensic fingerprinting; ss.
XX OS Synthetic.
XX PN WO9967425-A2.
XX XX
XX PD 29-DEC-1999.
XX PF 23-JUN-1999; 99WO-US14191.
XX PR 23-JUN-1998; 98US-0090389.
XX PR 14-AUG-1998; 98US-0134058.
XX PA (CLIN-) CLINICAL MICRO SENSORS INC.
XX XX

```

PI Kayyem JF, Blackburn G, O'Connor SD;
 XX WPI; 2000-136990/12.
 XX
 XX Complex-forming assay for analyte, particularly nucleic acid, used e.g.
 PT in detecting genetic disease, with accelerated complex formation by
 PT electrophoretic concentration of analyte -
 XX
 XX Example 2; Page 113; 140pp; English.
 PS
 XX The invention relates to a method of detecting a target analyte that
 CC comprises concentrating the analyte in a detection chamber comprising a
 CC detection electrode with a covalently attached capture ligand to form an
 CC assay complex comprising the analyte, ligand and at least 1 electron
 CC transfer moiety (ETM), and detecting the ETM with the the detection
 CC electrode. The method is particularly used for assaying nucleic acids or
 CC proteins, but more generally the target analyte is any compound for which
 CC a binding partner is available, e.g. pesticide or other pollutants;
 CC therapeutic or illicit drugs; whole cells; viruses etc. Particularly the
 CC method is used in array formats, optionally with many thousands of
 CC different capture ligands. Particular applications are detecting genes
 CC associated with cancer, Alzheimer's disease, cystic fibrosis etc.;
 CC detecting bacteria and viruses (e.g. for blood screening or testing water
 CC or foods); for forensic fingerprinting; for sequencing and for detecting
 CC successful gene amplification. The rate of complex formation is
 CC increased, resulting in more sensitive detection, particularly down to
 CC 100 molecules. The present sequence represents a signalling probe used in
 CC the course of the invention for detection of target sequences.
 CC
 XX Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 other;
 SQ

 Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 QY 7 GCAGTTGAGTGGAT 21
 DB 15 GCAGTTGAGTGGAT 1

 RESULT 368
 AAZ44140/C
 ID AAZ44140 standard; DNA; 18 BP.
 XX
 XX AAZ44140;
 AC
 XX
 DT 24-MAR-2000 (first entry)
 XX
 DE Human EGR-1 DNA antisense primer #24162.
 XX
 KW EGR-1; early growth response 1; antisense; inhibition; human; primer;
 KW anti-inflammatory; cytostatic; antiviral; detection; diagnosis;
 KW viral infection; inflammation; tumor; ss.
 XX
 OS Homo sapiens.
 XX
 XX US6008048-A.
 PN
 XX 28-DEC-1999.
 PD
 XX
 PF 04-DEC-1998; 98US-0205921.
 XX
 PR 04-DEC-1998; 98US-0205921.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Menia BP, Cowser LM;
 PI
 XX WPI; 2000-096375/08.
 DR
 XX
 XX Antisense oligonucleotides that inhibit expression of human early
 PT growth response-1, useful for diagnosis, treatment and prevention of
 PT tumors, inflammation and infection -

 Claim 1; Column 37-38; 31pp; English.
 XX
 PS This invention describes novel antisense oligonucleotides (I) capable of
 XX inhibiting expression of human EGR-1 (early growth response-1). The
 CC products of the invention have anti-inflammatory, cytostatic and
 CC antiviral activity. (I) was tested for its effects on EGR-1 mRNA levels
 CC by real-time polymerase chain reaction (PCR), results indicated that 60%
 CC inhibition was achieved. When (I) was modified by 2'-O-methoxyethyl
 CC substitution of the first 4 and last 4 residues, and by replacing any C
 CC in these flanking regions with 5-methyl-C, the degree of inhibition was
 CC increased to 71%. (I) is used to inhibit expression of EGR-1 in cells
 CC and tissues in vitro, for research or diagnosis, e.g. detecting EGR-1
 CC encoding nucleic acid. (I) may also be used to treat or prevent
 CC EGR-1-associated diseases, particularly viral infections, inflammation
 CC and tumors. AAZ44124-244169 represent antisense primers used to inhibit
 CC the human EGR-1 protein.
 XX
 SQ Sequence 18 BP; 4 A; 8 C; 3 G; 3 T; 0 other;

 Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 QY 348 CAGTGGCCGAGTGAG 362
 DB 15 CAGTGGCCGAGTGAG 1

 RESULT 369
 AAZ35905/C
 ID AAZ35905 standard; DNA; 18 BP.
 XX
 XX AAZ35905;
 AC
 XX
 DT 03-FEB-2000 (first entry)
 XX
 DE Human sentrin phosphorothioate antisense oligonucleotide SEQ ID NO:47.
 XX
 KW Human; sentrin; antisense oligonucleotide; phosphorothioate;
 KW inhibition; modulation; expression; diagnosis; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..18 /tag= a
 FT /note= "phosphorothioate linkages"
 FT
 XX
 XX US5985664-A.
 PN
 XX 16-NOV-1999.
 PD
 XX
 PF 17-DEC-1998; 98US-0213768.
 XX
 PR 17-DEC-1998; 98US-0213768.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Baker BF, Cowser LM;
 PI
 XX WPI; 2000-022284/02.
 DR
 XX
 XX Antisense compound which modulates human sentrin expression, useful for
 PT treating diseases associated with sentrin expression -
 XX
 XX Example 15; Column 38; 29pp; English.
 PS
 XX
 XX The present invention describes an antisense compound (I) 8-30
 CC nucleotides long targeted to a nucleic acid molecule encoding human
 CC sentrin. The antisense compound comprises a phosphorothioate antisense
 CC oligonucleotide which inhibits expression of human sentrin. (I) is

CC useful for inhibiting expression of sentrin in human cells or tissues
 CC in vitro, for treating humans or other animals suspected of having or
 CC being prone to a disease associated with sentrin expression. (1) can
 CC also be used for research or diagnostic purposes. The present
 CC sequence represents a human sentrin phosphorothioate antisense
 CC oligonucleotide from the present invention.
 XX
 SQ Sequence 18 BP; 4 A; 5 C; 3 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 440 GAAAGTTCCTGAAGT 454
 Db 18 GAAAGTTACTGAAGT 4
 RESULT 370
 AAH75239
 ID AAH75239 standard; DNA; 18 BP.
 AC AAH75239;
 DT 02-OCT-2001 (first entry)
 DE Human inducible NOS antisense oligonucleotide SEQ ID NO 83.
 XX Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
 KW modulate expression; immunomodulator; antidiabetic; cardiovascular;
 KW cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;
 KW 2'-O-methoxyethyl; phosphorothioate; human; ss.
 XX Homo sapiens.
 OS
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone, 5' and 3' four
 FT nucleotide 2'-MOE (2'-O-methoxyethyl) wings, all
 FT cytidine residues are 5-methylcytidines and a
 FT deoxy gap"
 XX
 PN WO200152902-A1.
 XX
 DD 26-JUL-2001.
 XX
 PF 15-JAN-2001; 2001WO-US01381.
 XX
 PR 24-JAN-2000; 2000US-0490208.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Dean NM, Cowseert LM;
 XX
 DR WPI; 2001-465340/50.
 XX
 PT New antisense oligonucleotides for modulating the expression of
 PT inducible nitric oxide synthase in cells or tissues, particularly
 PT useful for treating e.g. immunological, cardiovascular or neurological
 PT disorders, or ischaemia -
 XX
 PS Claim 3; Page 84; 144pp; English.
 XX
 CC The invention relates to antisense compounds, especially
 CC oligonucleotides, which are targeted to a nucleic acid encoding inducible
 CC nitric oxide synthase and which specifically hybridise to and modulate
 CC expression of inducible nitric oxide synthase. The antisense compounds
 CC have immunomodulator, antidiabetic, cardiovascular, cardiant,
 CC neuroprotective, disorder and vasotropic activity. The antisense
 CC oligonucleotides are useful for inhibiting the expression of inducible
 CC nitric oxide synthase in cells or tissues. In particular, the antisense

CC oligonucleotides are useful for treating diseases or disorders associated
 CC with inducible nitric oxide synthase, e.g. diabetes, immunological
 CC disorder, cardiovascular disorder, neurological disorder or
 CC ischaemia/reperfusion injury. The antisense oligonucleotides are also
 CC useful for research and diagnostics. The present sequence is that of an
 CC antisense 2'-O-methoxyethyl gapmer oligonucleotide with a
 CC phosphorothioate backbone, a central "gap" region of ten nucleotides
 CC flanked by four nucleotide 2'-MOE (2'-methoxyethyl) wings and
 CC 5-methylcytidine residues throughout the oligonucleotide. The antisense
 CC oligonucleotide is targeted to human inducible nitric oxide synthase (NOS)
 CC mRNA (AAH47973).
 XX
 SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 552 GGCAGGCATGCACAC 566
 Db 4 GGCAGGCACGCACAC 18
 RESULT 371
 AAH55881
 ID AAH55881 standard; DNA; 18 BP.
 XX
 AC AAH55881;
 DT 04-SEP-2001 (first entry)
 XX
 DE Human SCN1A PCR-SSCP PCR primer SEQ ID NO.125.
 XX
 KW Human; epilepsy; chromosome 2; SCN1A; SCN2A; SCN3A; identification;
 KW diagnosis; mutation; chromosome 2q23-q31; neurological disorder;
 KW anticonvulsant; neuroprotective; PCR primer; ss.
 XX Homo sapiens.
 OS
 XX Synthetic.
 XX
 PN WO200138564-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 24-NOV-2000; 2000WO-CA01404.
 XX
 PR 26-NOV-1999; 99US-0167623.
 XX
 PA (UYWC-) UNIV MCGILL.
 XX
 PI Rouleau GA, LaFreniere RG, Rochefort D, Cossette P, Ragsdale D;
 XX
 DR WPI; 2001-355945/37.
 XX
 PT Determining a predisposition to epilepsy and/or development of epilepsy
 PT comprises determining the genotype of SCN1A, SCN2A and/or SCN3A, or a
 PT DNA variant, equivalent, or mutation which shows a linkage
 PT disequilibrium -
 XX
 PS Example 3; Fig 2; 268pp; English.
 XX
 CC The present invention describes a method (M1) of determining an
 CC individual's predisposition to epilepsy and/or development of epilepsy,
 CC as well as predicting the individual's response to medication. The
 CC method comprises determining the genotype of at least one gene selected
 CC from SCN1A, SCN2A or SCN3A, or a DNA variant, equivalent, or mutation
 CC which shows a linkage disequilibrium. SCN1A, SCN2A and SCN3A are all
 CC sodium channel genes located on chromosome 2. The idiopathic generalised
 CC epilepsy (IGE) gene is more specifically localised on chromosome
 CC 2q23-q31. Compounds identified as modulators of the biological activity
 CC of SCN1A, SCN2A or SCN3A proteins or genes, are useful for treating
 CC epilepsy or other neurological disorders. They have anticonvulsant and
 CC neuroprotective activities. AAH55763 to AAH56164 and AAH99674 to

Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GCAGTTGAGGTGGAT 21
Db 4 GCAGTTGAGGTGGAT 18

RESULT 374

AAF62366/c
ID AAF62366 standard; DNA; 18 BP.

XX AC AAF62366;

DT 06-JUN-2001 (first entry)

XX Zinc finger coding sequence related oligo SEQ ID NO: 91.

XX Leptin; human; LSR; lipolysis stimulated receptor; obesity;
KW hypertension; anorexia; cachexia; stroke; atherosclerosis; ds.

XX Synthetic.

XX WO200121647-A2.

XX 29-MAR-2001.

XX 22-SEP-2000; 2000WO-1B01470.

XX 22-SEP-1999; 99US-0155506.

XX (GEST) GENSET.

PI Yen F, Erickson MR, Fruebis J, Bihain B;

DR WPI; 2001-218642/22.

XX New leptin polypeptide fragment and related polynucleotides, useful for
PT the prevention and treatment of obesity and obesity-related diseases
PT such as hypertension and diabetes -

PS Example 12; Page 244; 247pp; English.

XX The present invention provides the protein and coding sequences of leptin
CC fragments which modulate the activity of lipolysis stimulated factor
CC (LSR). These sequences are useful in the treatment of obesity related
CC diseases, including obesity, anorexia, cachexia, cardiac and coronary
CC insufficiency, stroke, hypertension, atherosclerotic disease,
CC atherosclerosis, non-insulin dependent diabetes, hyperlipidaemia,
XX hyperuricaemia and syndrome X.

SQ Sequence 18 BP; 2 A; 2 C; 12 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;

Best Local Similarity 93.3%; Pred. No. 2.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 186 CCCCGCCGCCACCC 200

Db 18 CCCCGCCGCTACCC 4

RESULT 375

AAF58213
ID AAF58213 standard; DNA; 18 BP.

XX AAF58213;

XX 06-DEC-2001 (updated)

DT 24-APR-2001 (first entry)

DE Sequence determination using electronic detection probe #4.

XX

KW Electron-transfer group; ETM; mismatch; genotyping;
KW gene expression; probe; ss.

XX Synthetic.

XX OS Location/Qualifiers
FH modified_base 18

FT /*tag= a

FT /mod_base= OTHER

FT /note= "modified by (CH2)16SH"

XX WO200107665-A2.

XX 01-FEB-2001.

XX 26-JUL-2000; 2000WO-US20476.

XX 26-JUL-1999; 99US-0145695.

XX 17-MAR-2000; 2000US-0190259.

XX (CLIN-) CLINICAL MICRO SENSORS INC.

XX Umek RM;

XX WPI; 2001-159728/16.

XX Nucleic acids containing electron-transfer group, useful as labels in
PT hybridization assays, e.g. for genotyping, allowing repeat analyses on
PT a single surface -

XX Example 2; Page 111; 159pp; English.

XX The present invention relates to a composition comprising two nucleic
CC acids each containing an electron-transfer group (ETM) having
CC different redox potentials. The invention is used for electronic
CC detection of nucleic acids, especially of substitutions (mismatches)
CC and single-nucleotide polymorphisms, e.g. for genotyping and
CC monitoring gene expression. The present sequence is a probe used in the
CC exemplification of the invention.

CC (NOTE: Revised record submitted with a corrected sequence)

XX SQ Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;

Best Local Similarity 93.3%; Pred. No. 2.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GCAGTTGAGGTGGAT 21

Db 4 GCAGTTGAGGTGGAT 18

RESULT 376

AAF58216/c

ID AAF58216 standard; DNA; 18 BP.

XX AAF58216;

XX 06-DEC-2001 (updated)

DT 24-APR-2001 (first entry)

DE Sequence determination using electronic detection signalling probe #1.

KW Electron-transfer group; ETM; mismatch; genotyping;

KW gene expression; probe; ss.

XX Synthetic.

XX OS Location/Qualifiers
FH modified_base 1

FT /*tag= a

FT /mod_base= OTHER

FT /note= "(C23)4-N87-N87-adenosine, where each N87

FT group has (C23)4 appended, where N87 is a branch point
 PT comprising a ring structure and C23 is shown in Fig 1F of
 FT PCTUS99/01705"

XX WO200107665-A2.

XX 01-FEB-2001.

XX 26-JUL-2000; 2000WO-US20476.

XX 26-JUL-1999; 99US-0145695.

XX 17-MAR-2000; 2000US-0190259.

XX (CLIN-) CLINICAL MICRO SENSORS INC.

XX Umek RM;

XX WPI; 2001-159728/16.

XX Nucleic acids containing electron-transfer group, useful as labels in
 PT hybridization assays, e.g. for genotyping, allowing repeat analyses on
 PT a single surface -

XX Example 2; Page 111; 159pp; English.

XX The present invention relates to a composition comprising two nucleic
 CC acids each containing an electron-transfer group (ETM) having
 CC different redox potentials. The invention is used for electronic
 CC detection of nucleic acids, especially of substitutions (mismatches)
 CC and single-nucleotide polymorphisms, e.g. for genotyping and
 CC monitoring gene expression. The present sequence is a probe used in the
 CC exemplification of the invention.

XX (NOTE: Revised record submitted with a corrected sequence)

XX Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 other;

XX Query Match 1.0%; Score 13.4; DB 1; Length 18;

XX Best Local Similarity 93.3%; Pred. No. 2.3e+02;

XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GCAGTTGAGTGAT 21

DB 15 GCAGTTGAGTGAT 1

RESULT 377

ABZ10842/c

ID ABZ10842 standard; DNA; 18 BP.

XX AC ABZ10842;

XX 16-JAN-2003 (first entry)

XX Haematopoietic cell proliferation disorder related oligonucleotide #982.

XX Human; haematopoietic cell proliferation disorder; cytostatic;
 KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
 KW cytosine methylation state; probe; primer; ss.

XX Homo sapiens.

XX Synthetic.

XX WO200277272-A2.

XX 03-OCT-2002.

XX 26-MAR-2002; 2002WO-EP03401.

XX 26-MAR-2001; 2001US-278333P.

XX (EPIG-) EPIGENOMICS AG.

XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;

PI Olek A, Piepenbrock C, Adorian P, Grabs G, Lesche R, Leu E;
 PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
 PI Pelet C, Schwöpe I, Ziebarth H;
 XX WPI; 2003-018942/01.

XX Detecting and differentiating between hematopoietic cell proliferative
 PT disorders, comprises contacting a target nucleic acid with a reagent
 PT that distinguishes between methylated and non-methylated CpG
 PT dinucleotides -

XX Claim 15; Page 65; 117pp; English.

XX The present invention describes a method for detecting and
 CC differentiating between haematopoietic cell proliferative disorders
 CC associated with at least 1 gene and/or their regulatory regions in a
 CC subject. The method comprises contacting a target nucleic acid in a
 CC biological sample obtained from the subject with at least 1 reagent,
 CC which distinguishes between methylated and non-methylated CpG
 CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
 CC represent specifically claimed nucleotide sequences from the present
 CC invention. Oligonucleotides from the present invention can be used: for
 CC differentiating between healthy haematopoietic cells and proliferative
 CC disorder haematopoietic cells; for differentiating between acute
 CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
 CC determining the cytosine methylation state and/or single nucleotide
 CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
 CC related sequences and their complements; and as primers for the
 CC amplification of haematopoietic cell proliferation disorder related
 CC DNA sequences. The nucleotide sequences from the present invention can
 CC also be used for detecting a predisposition to, differentiation between
 CC subclases, diagnosis, prognosis, treatment and/or monitoring of
 CC haematopoietic cell proliferative disorders. The present method enables
 CC a highly specific classification of haematopoietic cell proliferative
 CC disorders allowing for improved and informed treatment of patients.

XX Sequence 18 BP; 6 A; 0 C; 7 G; 5 T; 0 other;

XX Query Match 1.0%; Score 13.4; DB 1; Length 18;

XX Best Local Similarity 93.3%; Pred. No. 2.3e+02;

XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 54 TACTCTCAATTACC 68

DB 17 TACTCTCAATTAC 3

RESULT 378

AAQ75547

ID AAQ75547 standard; DNA; 19 BP.

XX AC AAQ75547;

XX 04-AUG-1995 (first entry)

XX Reverse transcription primer used in cDNA analysis technique.

XX Analysis; gene expression; reverse transcription; primer; cDNA;
 KW aggregate; restriction enzyme; ss.

XX Synthetic.

XX JP06303997-A.

XX 01-NOV-1994.

XX 16-APR-1993; 93JP-0112515.

XX 16-APR-1993; 93JP-0112515.

XX (NITE) NIPPON TELEGRAPH & TELEPHONE CORP.

XX WPI; 1995-018287/03.

XX Analysis of cDNA and gene expression - by amplification of mRNA
PT followed by digestion with restriction enzymes
XX
XX Disclosure; Page 5; 11pp; Japanese.
XX
XX A method for the analysis of cDNA comprises (a) preparing an
CC aggregate of double-stranded cDNAs by using an aggregate of mRNAs
CC and a plural type of labelled reverse transcription primers
CC (GENSEQ files AAQ75547-Q75798) and using the aggregate of mRNAs as the
CC template for each reverse transcription primer; (b) digesting each of
CC the prepared aggregates of the double-stranded cDNAs with restriction
CC enzyme and; (c) electrophoresing the digested cDNAs with restriction
CC separate lanes. The method can be used to analyse gene expression
CC rapidly and easily.
XX
SQ Sequence 19 BP; 0 A; 0 C; 2 G; 17 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1144 TTTTTCCTTTTGG 1158
DB 5 TTTTTCCTTTTGG 19
RESULT 379
AA06004
ID AAX06004 standard; DNA; 19 BP.
XX
AC AAX06004;
XX
DT 10-MAY-1999 (first entry)
XX
DE Oligo used in construction of plasmid pGP2.
XX
XX Human; Immunoglobulin transgene; Ig; VH gene; D gene; JH gene; mu gene;
KW switch sequence; gamma gene; IgM; IgG; ss.
XX
XX Synthetic.
XX
XX US5874299-A.
XX
XX 23-FEB-1999.
XX
XX 14-FEB-1997; 97US-0800353.
XX
XX 05-FEB-1992; 92US-0834539.
XX
XX 29-AUG-1990; 90US-0574748.
XX
XX 31-AUG-1990; 90US-0575962.
XX
XX 28-AUG-1991; 91WO-US06185.
XX
XX 14-FEB-1997; 97US-0800353.
XX
XX (GENP-) GENPHARM INT INC.
XX
XX Kay RM, Lonberg N;
XX
XX WPI; 1999-179989/15.
XX
XX Human immunoglobulin transgene - with mu and gamma isotype switching
PT segments
XX
XX Example 5; Column 33; 88pp; English.
XX
XX The invention relates to a heavy chain (human) immunoglobulin (Ig)
CC transgene. The transgene comprises: (i) human VH gene segments; (ii)
CC human D gene segments; (iii) human JH gene segments; and either (iv) a
CC mu constant region comprising a mu switch sequence upstream from a mu
CC coding segment; (v) a gamma constant region comprising a gamma switch
CC sequence upstream from a human gamma coding segment; where (vi) the mu
CC and gamma constant regions are closer than in wild type human Ig heavy
CC chain loci; or (vii) a heavy chain enhancer; (viii) a mu constant region

CC comprising a mu switch sequence upstream from a mu coding segment; (ix) a
CC gamma constant region comprising a gamma switch sequence upstream from a
CC human gamma coding segment; and (x) at least one discontinuity of at
CC least 2 kb between the mu and gamma gene segments as compared to a human
CC germ-line heavy chain locus; or (xi) a human mu CH gene and at least two
CC non-mu human CH genes and their associated isotype switching sequences;
CC where (xii) the human mu and human gamma switch sequences are closer than
CC in wild type human Ig heavy chain loci. The transgenes allow non-human
CC animals to produce heterologous (human) Ig's with varying specificities.
CC The presence of mu and gamma switch segments allows isotype switching of
CC the human heavy chain mini-locus from IgM (for maturation) to IgG.
XX
SQ Sequence 19 BP; 3 A; 7 C; 7 G; 2 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 391 GTGGCAGCAATGCC 405
DB 4 GTGGCAGCAATGCC 18
RESULT 380
AA945588
ID AAS45588 standard; DNA; 19 BP.
XX
AC AAS45588;
XX
DT 18-DEC-2001 (first entry)
XX
DE Human PAPP-2 RT-PCR reverse primer.
XX
XX Human; ss; PAPP; Poly (ADP-ribose) polymerase; antisense oligonucleotide;
KW cytostatic; neurotropic; neuroprotective; antiinflammatory; antidiabetic;
KW immunosuppressant; hyperproliferative disorder; cancer; cellular injury;
KW oxidative stress; neurological disorder; parkinsonism; apoptosis;
KW meningitis-associated intracranial complication; ischaemia; PCR primer;
KW inflammatory disorder; autoimmune disorder; arthritis; diabetes.
XX
XX Homo sapiens.
XX
XX WO200164955-A1.
XX
XX 07-SEP-2001.
XX
XX 01-MAR-2001; 2001WO-US06572.
XX
XX 02-MAR-2000; 2000US-0517467.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Popoff I, Cowser LM;
XX
XX WPI; 2001-602570/68.
XX
XX Antisense compound useful for treating hyperproliferative,
PT neurological, inflammatory and autoimmune disorders and diabetes
PT inhibits human PAPP -
XX
XX Example 13; Page 80; 168pp; English.
XX
XX The invention relates to antisense oligonucleotides targeted to human
CC PAPP nucleic acid and inhibiting expression of human PAPP. PAPP
CC (Poly (ADP-ribose) polymerase plays an important role in chromatin
CC decondensation, DNA replication, DNA repair, gene expression, malignant
CC transformation, cellular differentiation and apoptosis. The antisense
CC oligonucleotide inhibitors are useful for inhibiting the expression of
CC PAPP in human cells or tissues. They are also useful for treating a
CC human with a disease associated with PAPP especially hyperproliferative
CC disorders (e.g. cancer), cellular injury resulting from oxidative stress,
CC neurological (e.g parkinsonism, meningitis-associated intracranial
CC complications and ischaemia) , inflammatory and autoimmune disorders (e.g

CC arthritis) and diabetes. The present sequence is an RT-PCR (reverse
 CC transcriptase PCR) primer used to quantitate PARP mRNA levels.
 CC
 SQ Sequence 19 BP; 4 A; 9 C; 3 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 19;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 229 CAGCCTCAGGCATCT 243
 ||||| |||||
 Db 5 CAGCCACAGGCATCT 19

RESULT 381
 ABL88875/c
 ID ABL88875 standard; DNA; 19 BP.
 AC ABL88875;
 XX
 DT 22-MAY-2002 (first entry)
 XX
 DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:97.
 XX
 KW Binding molecule; HIV-1; human immunodeficiency virus type 1;
 KW reverse transcriptase; binding group; ss.
 XX
 OS Human immunodeficiency virus type 1.
 OS Synthetic.
 XX
 XX EP1174518-A1.
 PN
 XX 23-JAN-2002.
 XX
 XX 20-JUL-2000; 2000EP-0202611.
 XX
 XX 20-JUL-2000; 2000EP-0202611.
 PR
 XX (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
 PA
 XX Loukachov VV, Van Gemen B, Goudsmit J;
 PI
 XX WPI; 2002-156696/21.
 DR
 XX
 CC Collection of binding groups for determining or typing samples,
 CC especially clinical samples, has groups capable to identify essentially
 PT all members of the family of nucleic acids of relatively high
 PT significance -
 XX
 PS Disclosure; Page 30; 166pp; English.

CC The present invention describes a collection of binding groups for a
 CC family of nucleic acids comprising members of relative high and relative
 CC low significance, where the binding groups are selected to be capable to
 CC identify, alone or in combination, essentially all members of the family
 CC of nucleic acids of relatively high significance. The collection of
 CC binding groups is useful for typing of nucleic acid in a clinical sample,
 CC by contacting the nucleic acid with the collection and determining
 CC whether one or more binding groups bound to the nucleic acid of the
 CC sample. This method is useful for determining whether the sample
 CC comprises at least a part of a member of relatively high significance of
 CC a family of nucleic acids. The collection of binding groups is useful for
 CC diagnosing the severity of a disease caused by a pathogen containing a
 CC member of a family of nucleic acids. ABL88779 to ABL89321 represent
 CC oligonucleotide sequences used in the exemplification of the present
 CC invention.
 XX
 SQ Sequence 19 BP; 13 A; 3 C; 2 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 19;
 Best Local Similarity 93.3%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGG 1158
 ||||| |||||
 Db 15 TTTTTCCTTTATGG 1

RESULT 382
 AAN92661
 ID AAN92661 standard; DNA; 18 BP.
 XX
 AC AAN92661;
 XX
 DT 25-MAY-2003 (updated)
 DT 16-MAY-1990 (first entry)
 XX
 DE Probe to polymorphic site of the second exon of DPbeta allele of HLA DP
 DE gene.
 XX
 KW HLA; autoimmune diseases; probe; DP gene; DPbeta allele.
 XX
 OS Homo sapiens.
 OS
 PN WO89111547-A.
 XX
 PD 30-NOV-1989.
 XX
 PF 18-MAY-1989; 89WO-US02169.
 XX
 PR 20-MAY-1988; 88US-0196660.
 PR 14-OCT-1988; 88US-0258212.
 PR 04-MAY-1989; 89US-0347506.
 XX
 XX (CETU) CETUS CORP.
 XX
 XX Erlich H, Horn GT, Bugawan TL;
 PI
 XX WPI; 1989-370738/50.
 DR
 XX
 PT HLA DP genotyping by amplifying target DNA then hybridisation -
 PT with panel of sequence specific oligonucleotide(s), esp. for
 PT assessing risk of autoimmune disease.
 XX
 PS Claim 8; Page 48; 54pp; English.
 CC
 CC Target region for probe is amplified by polymerase chain reaction, and
 CC probe binds to complementary regions in very stringent conditions,
 CC identifying variations in the hypervariable DP gene.
 CC (Updated on 25-MAR-2003 to correct PI field.)
 XX
 SQ Sequence 18 BP; 5 A; 5 C; 6 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 521 ACCTCCCGAGGAGCAGC 538
 ||||| |||||
 Db 1 ACCTCTGGAGGAGAGC 18

RESULT 383
 AAQ54537
 ID AAQ54537 standard; DNA; 18 BP.
 XX
 AC AAQ54537;
 XX
 DT 25-MAR-2003 (updated)
 DT 29-JUN-1994 (first entry)
 XX
 DE HLA-DP genotype determination probe #26.
 XX
 KW Polymerase chain reaction; PCR; amplify; primer; probe; HLA-DP;
 KW genotype; sequence specific; polymorphic region; variable segment;
 KW panel; autoimmune disease; insulin-dependant diabetes mellitus;

KW coeliac disease; CD; allele; DPB1; DPB3; DPB4.2; juvenile;
 KW rheumatoid arthritis; DPB2.1; forensic evidence; ss.
 OS Synthetic.
 XX
 XX
 XX BP575845-A2.
 XX
 XX
 PD 29-DEC-1993.
 XX
 XX
 PF 14-JUN-1993; 93EP-0109447.
 XX
 XX 23-JUN-1992; 92US-0903028.
 XX
 XX (HOFF) HOFFMANN LA ROCHE & CO AG F.
 XX
 XX Begovich AB, Bugawan TL, Erlich HA;
 XX
 XX WPI; 1994-001049/01.
 XX
 XX Method for HLA - DP typing - comprises amplification of target nucleic
 PT acid region and hybridisation with oligo-nucleotide probes
 PT
 XX
 PS Claim 2; Page 81; 85pp; English.
 XX
 XX The sequences given in AAQ54509-614 are primers and probes which were
 CC used in the method of the invention for determining the HLA-DP
 CC genotype of an individual. The method comprises amplifying a target
 CC region of the nucleic acid in the sample in question, under
 CC conditions suitable for carrying out PCR with a sequence specific
 CC primer. The target region contains a polymorphic region (variable
 CC segment) of an HLA DP gene. The amplified sequences are mixed with
 CC a panel of probes, where each probe is complementary to a variant
 CC sequence of a variable segment of an HLA DP gene, under stringent
 CC binding conditions. The method is useful for determining an
 CC individuals susceptibility to an autoimmune disease including
 CC insulin-dependent diabetes mellitus and coeliac disease (CD) by
 CC determining the HLA-DP genotype. CD is linked to the alleles DPB13,
 CC DPB1, DPB3 or DPB4.2. Susceptibility to particular juvenile rheumatoid
 CC arthritis is indicated by the DPB2.1 allele. The process can also be
 CC used to provide forensic evidence.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 18 BP; 5 A; 5 C; 6 G; 2 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 521 ACCTGCGGAGGAGCAGC 538
 Db 1 ACCTCTGGAGGAGAGC 18
 RESULT 384
 AAQ89247/c
 ID AAQ89247 standard; DNA; 18 BP.
 XX
 XX
 AC AAQ89247;
 XX
 XX 09-MAY-1995 (first entry)
 DT
 XX
 XX Hepatitis C virus 8003-9388 fragment PCR primer.
 DE
 XX
 XX Non-A non-B hepatitis virus antigens; NANBH; hepatitis C virus; ss.
 KW
 XX
 OS Synthetic.
 XX
 XX JP06225770-A.
 XX
 XX 16-AUG-1994.
 PD
 XX
 XX 08-JUL-1993; 93JP-0193104.
 XX

XX 10-JUL-1992; 92JP-0207391.
 XX
 XX (KOKU-) KOKUSAI SHIYAKU KK.
 PA (SANW) SANWA KAGAKU KENKYUSHO CO.
 PA (TOFU) TONEN CORP.
 PA (TOKR-) ZH TOKYOTO RINSHO IGAKU SOGO KENKYUSHO.
 XX
 XX WPI; 1994-298800/37.
 DR
 XX
 XX A nucleic acid fragment coding Non-A Non-B Hepatitis virus
 PT antigens - for diagnosis of NANBH and detection of HCV
 PT
 XX
 PS Example 1; Page 7; 22pp; Japanese.
 XX
 XX AAQ89234-Q89253 are PCR primers for fragments of hepatitis C virus (HCV)
 CC or non-A non-B hepatitis virus (NANBH) cDNA. These cDNAs code for amino
 CC acid sequences, which are antigens to structural and non-structural
 CC regions of the HCV virus. These antigens can be used in the diagnosis
 CC of NANBH patients and the detection of HCV carriers.
 XX
 XX Sequence 18 BP; 12 A; 2 C; 2 G; 2 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1139 ATGCCCTTTTCTTTT 1156
 Db 18 AGGCCATTTTCTTTT 1
 RESULT 385
 AAX75643
 ID AAX75643 standard; RNA; 18 BP.
 XX
 AC AAX75643;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 XX Mouse flt-1 VEGF receptor hairpin ribozyme substrate #102.
 DE
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammethead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 XX WO9715662-A2.
 PN
 XX
 XX 01-MAY-1997.
 PD
 XX
 XX 25-OCT-1996; 96WO-US17480.
 PF
 XX
 XX 11-JAN-1996; 96US-0584040.
 PR
 XX 26-OCT-1995; 95US-0005974.
 XX
 XX (CHIR) CHIRON CORP.
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
 PI
 XX
 XX WPI; 1997-259017/23.
 DR
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient
 XX
 XX Claim 4; Page 189; 218pp; English.
 PS
 XX
 XX The present invention describes nucleic acid molecules which modulate

CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 3 A; 7 C; 4 G; 4 U; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 61.1%; Pred. No. 2.5e+02;
 Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1053 CAGCCCTGGCTTCCCAT 1070
 Db 1 CAGGCCGACCCUCCAU 18

RESULT 386

AAAX71704
 ID AAX71704 standard; RNA; 18 BP.
 XX
 AC AAX71704;

DT 28-JUL-1999 (first entry)

DE Human KDR VEGF receptor hairpin ribozyme substrate #2.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

OS Homo sapiens.

XX WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

XX 11-JAN-1996; 96US-0584040.

XX 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

XX (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 118; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 0 A; 7 C; 7 G; 4 U; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 61.1%; Pred. No. 2.5e+02;
 Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1239 GCTGGACGTGGCCCATGTG 1256
 Db 1 GCUGGCCGUCGCCUGUG 18

RESULT 387

AAAX70233

ID AAX70233 standard; RNA; 18 BP.

XX

AC AAX70233;

XX 28-JUL-1999 (first entry)

XX Human flt1 VEGF receptor hairpin ribozyme substrate #1.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

OS Homo sapiens.

XX WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

XX 11-JAN-1996; 96US-0584040.

XX 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

XX (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 91; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 0 A; 11 C; 3 G; 4 U; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 72.2%; Pred. No. 2.5e+02;
 Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 142 CCGCTCGGCTCCGCTCCG 159

Db 1 CCUCUCGUCUCCUCCUG 18

RESULT 388

```
AAT84310
ID AAT84310 standard; DNA; 18 BP.
AC AAT84310;
XX
XX
DT 10-NOV-1997 (first entry)
XX
XX Human VEGF-C gene intron 4-exon 5 junction.
XX
XX VEGF-C; Flt4; receptor tyrosine kinase; VEGFR-3; human;
KW vascular endothelial growth factor receptor-3; ligand;
KW angiogenesis; wound healing; lymph vessel; lymphangioma; cancer;
KW metastasis; therapy; diagnosis; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH intron 1..11
FT /tag= a
FT /note= "3' end of intron 4"
FT 12..18
FT /tag= b
FT /note= "5' end of exon 5, encodes amino acids
FT 231-233 of VEGF-C"
XX
XX WO9705250-A2.
XX
XX 13-FEB-1997.
XX
XX 01-AUG-1996; 96WO-FI00427.
XX
XX 28-JUN-1996; 96US-0671573.
XX
XX 01-AUG-1995; 95US-0510133.
XX
XX 12-JAN-1996; 96US-0585895.
XX
XX 14-FEB-1996; 96US-0601132.
XX
XX (UYHE-) UNIV HELSINKI LICENSING LTD OY.
XX
XX Alitalo K, Joukov V;
XX
XX WPI; 1997-145688/13.
XX
XX Flt4 receptor tyrosine kinase ligand and related nucleic acid - used
PT to modulate growth of endothelial cells and for diagnosis of
PT endothelial cell diseases
XX
XX Example 31; Page 130; 183pp; English.
XX
XX This DNA sequence comprises the junction region between intron 4
CC (over 10 kb) and exon 5 of the human VEGF-C gene (see also AAT84276).
CC Exon-intron junctions were determined (see AAT84303-14) for the
CC entire VEGF-C gene, which comprises 7 exons and 6 exons. The
CC VEGF-C gene on chromosome 4q23 codes for a novel ligand (AAW00932)
CC of Flt4 receptor tyrosine kinase that can be used in a claimed
CC method to modulate growth of endothelial cells.
XX
XX Sequence 18 BP; 4 A; 4 C; 4 G; 6 T; 0 other;
SQ
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 380 TTCCTCCAGGTGGCAG 397
DB 1 TTCTTCCAAAGGTGTGAC 18
RESULT 389
AAT80260/c
ID AAT80260 standard; DNA; 18 BP.
XX
XX AAT80260;
XX
```

```
DT 15-OCT-1997 (first entry)
XX
XX Oligo HCV91, targetted to HCV region -1 to -6.
XX
XX Complementary; 5' untranslated region; UTR; hepatitis C virus; HCV;
KW inhibition; replication; expression; detection; chronic hepatitis;
KW acute hepatitis; hepatocarcinoma; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 7..18
FT /tag= a
FT /note= "2' OMe modified"
FT 1..6
FT /tag= b
FT /note= "Phosphorothioate linkages"
XX
XX WO9639500-A2.
XX
XX 12-DEC-1996.
XX
XX 04-JUN-1996; 96WO-EP02427.
XX
XX 06-JUN-1995; 95US-0471968.
XX
XX (HOFF) HOFFMANN LA ROCHE & CO AG F.
XX (HYBR-) HYBRIDON INC.
XX
XX Frank BL, Goodchild J, Hamlin HA, Kilkuskie RE;
XX Roberts NA, Roberts PC, Walther DM, Wolfe JL;
XX WPI; 1997-043122/04.
XX
XX Oligo:nucleotide(s) complementary to HCV 5' untranslated region -
PT used in the treatment and detection of HCV infection, esp. hepatitis
PT and hepato-carcinoma
XX
XX Claim 19; Page 31; 100pp; English.
XX
XX The sequences given in AAT80211-382 represent synthetic oligonucleotides
CC which are complementary to a portion of the 5' untranslated region (UTR)
CC of hepatitis C virus (HCV). These sequences may be used in a
CC pharmaceutical composition for the control or prevention of HCV
CC infection. They may be used to inhibit replication or expression of
CC HCV or for detecting the presence of HCV in a sample. They may be used
CC to inhibit HCV replication in a cell and are therefore useful in the
CC treatment of HCV infections such as chronic and acute hepatitis and
CC hepatocarcinoma. This oligo was used in a luciferase assay to determine
CC whether it binds successfully to its target.
XX
XX Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 other;
SQ
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 631 CTCGAGGAGCTCTGCATC 648
DB 18 CTCGAGGAGCTCTGCATC 1
RESULT 390
AAQ67556
ID AAQ67556 standard; cDNA to mRNA; 18 BP.
XX
XX AAQ67556;
XX
XX 20-AUG-1997 (first entry)
XX
XX Anti-metallothionein phosphorothioate oligodeoxyribonucleotide.
DE PS-ODN; phosphorothioate oligodeoxyribonucleotide; chelate; ss;
KW
```


KW heavy metal poisoning; cadmium; mercury; lead; metallothionein.

OS Synthetic.

PN US5618796-A.

XX 08-APR-1997.

XX 12-SEP-1991; 91US-0759841.

XX 12-SEP-1991; 91US-0759841.

XX (UYNE-) UNIV NEBRASKA.

XX Iversen PL;

XX WPI; 1997-234701/21.

XX Treatment for heavy metal poisoning - by chelating heavy metal ions

PT with phosphorothioate oligonucleotide to cause excretion in urine

XX Example 3; Column 10; 10pp; English.

XX The invention relates to a new method of treating an animal suffering
CC from heavy metal poisoning, comprising administering a phosphorothioate
CC oligonucleotide to the animal in an amount sufficient to chelate heavy
CC metals to cause their excretion in the urine of the animal.

CC The method can be used to treat poisoning caused by cadmium, lead
CC and/or mercury. The present sequence is one of two complementary
CC phosphorothioate oligonucleotides (PS-ODNs) which were synthesised and
CC tested for use in the method. Each PS-ODN is 18 bases in length
CC and is associated with bases 7-24 downstream from the ATG translational
CC start site of human metallothionein-II mRNA. The present sequence is
CC the anti-WT antisense sequence, while the complementary sequence is
CC shown in AAQ67557.

XX Sequence 18 BP; 3 A; 3 C; 10 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 525 GCCGAGGAGCAGCTGGG 542

DB 1 GCCGAGGAGCAGCTGGG 18

RESULT 391

AAQ67557/C

ID AAQ67557 standard; cDNA to mRNA; 18 BP.

XX AAQ67557;

XX 20-AUG-1997 (first entry)

XX Anti-metlothionein phosphorothioate oligodeoxyribonucleotide.

DE PS-ODN; phosphorothioate oligodeoxyribonucleotide; chelate; ss;

KW heavy metal poisoning; cadmium; mercury; lead; metallothionein.

XX Synthetic.

XX US5618796-A.

XX 08-APR-1997.

XX 12-SEP-1991; 91US-0759841.

XX 12-SEP-1991; 91US-0759841.

XX (UYNE-) UNIV NEBRASKA.

XX Iversen PL;

XX

XX WPI; 1997-234701/21.

XX Treatment for heavy metal poisoning - by chelating heavy metal ions

PT with phosphorothioate oligonucleotide to cause excretion in urine

XX Example 3; Column 10; 10pp; English.

XX The invention relates to a new method of treating an animal suffering
CC from heavy metal poisoning, comprising administering a phosphorothioate
CC oligonucleotide to the animal in an amount sufficient to chelate heavy
CC metals to cause their excretion in the urine of the animal.

CC The method can be used to treat poisoning caused by cadmium, lead
CC and/or mercury. The present sequence is one of two complementary
CC phosphorothioate oligonucleotides (PS-ODNs) which were synthesised and
CC tested for use in the method. Each PS-ODN is 18 bases in length
CC and is associated with bases 7-24 downstream from the ATG translational
CC start site of human metallothionein-II mRNA. The anti-WT antisense
CC sequence is shown in AAQ67556, and the present sequence is its
CC complementary sequence.

XX Sequence 18 BP; 2 A; 10 C; 3 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 525 GCCGAGGAGCAGCTGGG 542

DB 18 GCCGAGGAGCAGCTGGG 1

RESULT 392

AAV16730

ID AAV16730 standard; DNA; 18 BP.

XX AAV16730;

XX 18-JUN-1998 (first entry)

XX Oligonucleotide of the specification.

DE Thrombopoietic receptor; therapeutic drug; treatment; prevention;

KW disease; abnormality; haematogenic process; megakaryocyte; ss.

XX Synthetic.

XX JPI0072492-A.

XX 17-MAR-1998.

XX 02-SEP-1996; 96JP-0231807.

XX 02-SEP-1996; 96JP-0231807.

XX (HOKR) HOKURIKU PHARM CO LTD.

XX WPI; 1998-234763/21.

XX New recombinant therapeutic peptide - useful for, e.g. treating
PT diseases caused by abnormality in megakaryocyte haematogenic process

XX Disclosure; Page 6; 11pp; Japanese.

XX The present sequence represents an oligonucleotide of the specification.
CC The specification describes a peptide which has affinity for
CC thrombopoietic receptor. The peptide, which can be cyclic, can be used
CC in the preparation of therapeutics useful for treating and preventing
CC diseases caused by abnormality in haematogenic process of megakaryocytes.

XX Sequence 18 BP; 1 A; 10 C; 5 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;

```
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 686 TTGGGAGCCAGCGGCC 703
Db 1 TTGGGCCCCAGCGGCC 18

RESULT 393

AAZ01197	
ID	AAZ01197 standard; DNA, 18 BP.
XX	
AC	AAZ01197;
XX	
DT	27-SEP-1999 (first entry)
XX	
DE	PCR primer for PGI biallelic markers 4-58-289 and 4-58-318.
XX	
KW	PGI gene; biallelic marker; PCR primer; PGI-related biallelic marker;
KW	cancer; prostate cancer; diagnosis; therapy; prostate specific antigen;
KW	PSA; human; ss.

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels

RESULT 394

RESUL 394
AAX77049/C

AAX77049 standard; DNA; 18 BP.

AAX77049;

DT 10-AUG-1999 (first entry)

PCR primer for the pericentrin gene.

KW PCR primer; proto-oncogene; oncogene; nucleic acid synthesis; ultrasound;
 KW stress protein; repair protein; phenylketonuria; p53 tumour suppressor;
 KW phenylalanine hydroxylase; IL-2 production; cancer; AIDS; haemophilia;
 KW autoimmune disease; chronic viral infection; cystic fibrosis; therapy;
 KW ss.

This sequence represents a PCR primer for a proto-oncogene/oncogene, and was used to test the method of the invention. The method is for increasing synthesis of nucleic acid (I) in a cell by exposing it to ultrasound, where (I) is: (a) an endogenous sequence (Ia) encoding a stress or repair protein; or (b) an introduced exogenous sequence (Ib). The method is specifically used therapeutically: (i) to treat phenylketonuria (following introduction of Ib) for phenylalanine hydroxylase; (ii) to increase expression of the p53 tumour suppressor; (iii) to increase production of IL-2, particularly associated with natural killer cells; and (iv) for treating cancer by administering a sequence antisense to initiation factor 3 and/or RNA synthase. More generally, (Ib) may include one or more genes or fragments, or even complete chromosomes, for delivering *in vivo*, *in vitro* or *ex vivo* to animal or plant cells for treating a very wide range of conditions, e.g. acquired immune deficiency syndrome, autoimmune diseases, chronic viral infections, haemophilia, cystic fibrosis, and cancer. Ultrasound treatment increases expression of (I) and increases uptake of (Ib), particularly of 4-6 kb.

Sequence 18 BP; 5 A; 4 C; 7 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. NO. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3 Indels

506 WILLISIA

RESULT 395
AAX57940/C

AXS 7940/C
ID AAX57940 standard: DNA: 18 BP.

AX57940:

DT 15-JUL-1999 (first entry)

DE PCR primer for G. oxydans D-sorbitol dehydrogenase coding sequence.
 XX
 KW D-sorbitol dehydrogenase; L-sorbose; 2-keto-L-gulononic acid; precursor;
 KW L-ascorbic acid production; PCR primer; ss.
 XX
 OS Synthetic.
 OS Gluconobacter oxydans.
 XX
 PN WO9920763-A1.
 XX
 PD 29-APR-1999.
 XX
 PF 13-OCT-1998; 98WO-JP04612.
 XX
 PR 17-OCT-1997; 97JP-0285280.
 XX
 PA (FUJI) FUJISAWA PHARM CO LTD.
 XX
 PI Ishii Y, Noguchi Y, Saito Y, Soeda S, Yoshikawa K;
 XX
 XX WPI; 1999-302741/25.
 XX
 XX Gene group for D-sorbitol dehydrogenase, useful for simple
 PT large-scale production of L-sorbose or 2-keto-L-gulononic acid as
 PT precursor for L-ascorbic acid
 XX
 XX Example 5; Page 26; 83pp; Japanese.
 XX
 CC This sequence represents a PCR primer for DNA encoding the D-sorbitol
 CC dehydrogenase of the invention. Cells transformed with a vector
 CC containing DNA encoding the dehydrogenase can be used to produce
 CC L-sorbose or 2-keto-L-gulononic acid as precursor for simple large-scale
 CC L-ascorbic acid production.
 XX
 SQ Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 other;
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 474 GGGGAGGACTGCCGAGA 491
 DB |||||
 18 GGGTGAGGAATGCCGAGA 1
 RESULT 396
 AAX03321/c
 ID AAX03321 standard; DNA; 18 BP.
 AC AAX03321;
 XX
 DT 23-MAR-1999 (first entry)
 DE
 DE PCR primer PCR53 used for amplification of isolated RNA.
 XX
 KW Topoisomerase; 5' tagging; RNA transcript; isolating;
 KW gene sequence; PCR primer; ss.
 XX
 OS Synthetic.
 OS
 PN WO9856943-A1.
 XX
 PD 17-DEC-1998.
 XX
 PF 12-JUN-1998; 98WO-US12372.
 XX
 PR 12-JUN-1997; 97US-0049405.
 XX
 XX (INVI-) INVITROGEN CORP.
 PA (SLOK) SLOAN KETTERING INST CANCER RES.
 PA
 XX Comisky J, Fernandez J, Hoeffler J, Marcil R, Sekiguchi J;
 PI Shuman S;

XX WPI; 1999-080916/07.
 DR Use of topoisomerase enzymes - for covalently joining a DNA strand
 XX to an RNA strand, used particularly for isolating and cloning
 PT full-length gene sequences
 PT
 XX
 PS Disclosure; Page 63; 93pp; English.
 XX
 CC PCR primers AAX03320-21 were used to amplify reverse-transcribed RNA
 CC isolated using the method of the invention. The specification describes
 CC a method for covalently joining a DNA strand to an RNA strand. The
 CC method comprises forming a topoisomerase-DNA intermediate by incubating a
 CC DNA cleavage substrate comprising a topoisomerase cleavage site with a
 CC topoisomerase specific for that site, where the topoisomerase-DNA
 CC intermediate has one or more 5' single-stranded tails, and adding to the
 CC topoisomerase-DNA intermediate an acceptor RNA strand complementary to
 CC the 5' single-strand tail to permit a ligation of the covalently bound
 CC DNA strand to the RNA acceptor strand and dissociation of the
 CC topoisomerase, thereby covalently joining the DNA strand to the RNA
 CC strand. The products and methods can be used for the 5' tagging of RNA
 CC transcripts. They are used particularly for isolating and cloning
 CC full-length gene sequences.
 XX
 SQ Sequence 18 BP; 4 A; 7 C; 3 G; 4 T; 0 other;
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 677 GCGTGGTATTGGGAGCC 694
 DB |||||
 18 GAGTCGTATATGGGAGCC 1
 RESULT 397
 AAZ71683/c
 ID AAZ71683 standard; DNA; 18 BP.
 XX
 AC AAZ71683;
 XX
 DT 10-SEP-2001 (first entry)
 DE
 DE Human biallelic marker upstream amplification primer SEQ ID NO:6039.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 21-APR-1999; 99WO-IB00822.
 XX
 PR 21-APR-1998; 98US-0082614.
 PR 23-NOV-1998; 98US-0109732.
 XX
 XX (GEST) GENSET.
 XX
 XX Cohen D, Blumenfeld M, Chumakov I;
 PI WPI; 2000-013267/01.
 XX
 DR Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome
 XX
 XX Claim 8; Page 1518; 2745pp; English.
 PS
 XX

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 471 GCAGGGGAGGACTGCG 488
 |||||
 Db 1 GCCGGGCGAGGACTGCTG 18

RESULT 400
 AAA27086
 ID AAA27086 standard; DNA; 18 BP.
 XX AC
 XX AAA27086;
 DT 21-AUG-2000 (first entry)

XX Human NF-kappa-B p65 subunit antisense oligodeoxynucleotide ISIS# 23738.
 DE Human; anti-inflammatory; cytostatic; antimicrobial; infection;
 XX antisense inhibition; inflammation; transcription factor;
 KW apoptosis; cancer; ss.
 XX OS Homo sapiens.

XX Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /note= "all or some internucleoside bonds are
 FT phosphorothioate and optionally some sugars may
 FT be 2' methoxyethyl"
 XX

PN US6069008-A.
 XX
 XX 30-MAY-2000.
 XX
 XX 25-NOV-1998; 98US-0199859.
 XX 25-NOV-1998; 98US-0199859.
 XX (ISIS-) ISIS PHARM INC.

PI Bennett CF, Cowser LM, Monia BP;
 XX
 XX WPI; 2000-410858/35.

XX Antisense compounds which inhibit the expression of the human
 XX NF-kappa-B p65 subunit (p65) useful for treating diseases associated
 XX with p65 expression and as prophylaxis to prevent of delay infection,
 XX inflammation or tumor formation -

XX Example 15; Column 40; 33pp; English.

XX The present sequence is one of a number of oligonucleotides designed to
 XX target different regions of the human NF-kappa-B p65 subunit, which is a
 XX member of the Rel/NF-kappa-B family of transcription factors.
 XX Rel/NF-kappa-B proteins are involved in a diverse set of signaling
 XX pathways involving stress, apoptosis, cancer, growth, infection and
 XX inflammation. Antisense oligonucleotides are able to inhibit expression
 XX of the p65 subunit and may therefore be used in the treatment of
 XX disorders associated with NF-kappa-B p65 subunit expression. They may be
 XX used as a prophylaxis to prevent or delay infection, inflammation or
 XX tumor formation. Antisense compounds may also be used for research and
 XX diagnostics because they hybridize to nucleic acids encoding
 XX NF-kappa-B p65 subunit. The effect of antisense oligonucleotides on
 XX NF-kappa-B p65 subunit mRNA levels was measured using real-time
 XX quantitative PCR and Northern blot analysis. Antisense
 XX oligonucleotides were synthesised on an automated DNA synthesiser.

SQ Sequence 18 BP; 2 A; 6 C; 5 G; 5 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1300 CCTGCCCCCATGTAGCCA 1317
 |||||
 Db 1 CCTGGTCTCTGTAGCCA 18

RESULT 401
 AAA39029/C
 ID AAA39029 standard; DNA; 18 BP.

XX AC
 XX AAA39029;
 DT 25-AUG-2000 (first entry)

XX Unknown bacterial 16S rRNA gene primer 0531R SEQ ID NO:7.

XX Bacterial; 16S rRNA; identification; polymorphism; microorganism;
 KW classification; primer; human medicine; veterinary medicine;
 KW agriculture; food science; industrial microbiology; infectious disease;
 KW food safety; ss.

XX Unidentified.

XX US6054278-A.

XX 25-APR-2000.

XX 05-MAY-1998; 98US-0073465.

XX 05-MAY-1997; 97US-0045603.

XX (PEKE) PERKIN-ELMER CORP.

XX Smith DH, Dodge DE;

XX WPI; 2000-338488/29.

XX Identifying an unknown microorganism by generating a composite sequence
 of its ribosomal RNA gene region and comparing with composite ribosomal
 RNA region sequences of distinct microorganisms in a database -

XX Example; Column 10; 11pp; English.

XX The present invention describes a method for identifying a microorganism
 by comparing a composite sequence (I) of a ribosomal RNA gene region
 with RNA region sequences of unknown microorganisms in a database and
 identifying the region in the database that matches with (I). (I) is
 generated by simultaneously obtaining nucleotide base sequence data from
 every copy of the rRNA gene region in the genome of the unknown
 microorganism. Also described is a method for identifying the species of
 microorganism by generating (I) and entering it into a first data
 register of a programmable computer, comparing the first data register
 with reference data registers that encode a unique composite rRNA
 sequence corresponding to (I) and correlated with unique microorganism
 species name, and displaying the unique microorganism name correlated
 with the best matching first data register. The method is useful for
 identifying microorganisms which are useful in a variety of fields
 including human medicine, veterinary medicine, agriculture, food science
 and industrial microbiology. The microorganisms found in patients
 suffering from an infectious disease can also be identified.
 Microorganism identification is also useful for monitoring food safety
 by testing for pathogens. Plants harbouring phytopathogenic bacteria are
 also identified. The method is convenient and efficient as there is no
 need to isolate one or more individual 16S rRNA genes. AAA39023 to
 AAA39039 represent primers for the 16S rRNA gene, which are used in the
 exemplification of the present invention.

SQ Sequence 18 BP; 2 A; 7 C; 6 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 2.5e+02;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 882 GTTCAGGAGCTGGGTA 899
 |||||
 Db 18 GTGCCAGCAGCGGGTA 1

RESULT 402

AAA15532/C
 ID AAA15532 standard; DNA; 18 BP.

XX AC AAA15532;
 XX 28-JUL-2000 (first entry)
 DT Human G-alpha-i3 antisense oligonucleotide ISIS#25951.
 DE Human; G-alpha-i3; G protein; Gi protein; adenylyl cyclase;
 XX dopamine; thyrotropin-releasing hormone; somatostatin;
 KW signal transduction pathway; antisense oligonucleotide; ss.
 XX OS Homo sapiens.

XX Key Location/Qualifiers
 FH modified_base 1..18
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Optionally phosphorothioate
 FT deoxynucleotides"
 FT 1..4
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "Optionally 2'-methoxyethyl nucleotides
 FT providing bases 15..18 are also 2'-methoxyethyl
 FT nucleotides. All cytidine residues within this region are
 FT then 5-methylcytidine"
 FT 15..18
 FT modified_base
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "Optionally 2'-methoxyethyl nucleotides
 FT providing bases 1..4 are also 2'-methoxyethyl
 FT nucleotides. All cytidine residues within this region are
 FT then 5-methylcytidine"

US6063626-A.

16-MAY-2000.

24-JUN-1999; 99US-0339775.

24-JUN-1999; 99US-0339775.

(ISIS-) ISIS PHARM INC.

Cowsert LM;

WPI; 2000-375497/32.

XX New antisense compounds targeting nucleic acids encoding human
 FT G-alpha-i3 useful for treating diseases associated with G-alpha-i3
 FT expression and as prophylaxis to prevent or delay infection,
 FT inflammation or tumor formation -

Claim 3; Column 39; 30pp; English.

XX The present sequence is an antisense oligonucleotide for the human
 CC G-alpha-i3 gene. The protein produced from this gene is a member of the
 CC G protein family, and more specifically of the Gi family. The Gi proteins
 CC are involved in hormonal inhibition of adenylyl cyclase and the
 CC regulation of plasma membrane enzymes. In addition, G-alpha-i3 has been
 CC shown to have a role in the dopamine, thyrotropin-releasing hormone and
 CC somatostatin signal transduction pathways. The oligonucleotide may
 CC be used to modulate expression of the G-alpha-i3 gene and can be used

CC to prevent infection, inflammation and tumours.

XX SQ Sequence 18 BP; 5 A; 2 C; 8 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 973 CTCACCTTGACAGTCCCA 990
 |||||
 Db 18 CTCACCTTGACCTGTGCA 1

RESULT 403

AAA09715/C
 ID AAA09715 standard; DNA; 18 BP.

XX AC AAA09715;
 XX 23-JUN-2000 (first entry)
 DT G-alpha-i2 antisense inhibitor oligonucleotide #15 (ISIS #25823).
 DE G-alpha-i2; antisense inhibitor; infection; inflammation; prevent;
 KW tumor formation; treatment; inhibit; ss.
 XX OS Homo sapiens.

XX US6040179-A.

21-MAR-2000.

25-JUN-1999; 99US-0339993.

25-JUN-1999; 99US-0339993.

(ISIS-) ISIS PHARM INC.

Cowsert LM;

WPI; 2000-270140/23.

XX Novel antisense oligonucleotide containing compounds, useful for
 FT inhibiting the expression of G-alpha-i2 in human cells and tissues and
 FT treating infection, inflammation and cancer -

Claim 1; Column 40; 3lpp; English.

XX This sequence represents an antisense oligonucleotide sequence targeted
 CC to a nucleotide sequence encoding human G-alpha-i2. G-alpha-i2 is a
 CC member of the Gi subfamily of G proteins, which is involved in hormonal
 CC inhibition of adenylyl cyclase and in the regulation of plasma membrane
 CC enzymes. The expression of G-alpha-i2 has been shown to be altered in
 CC some tumours. Mice lacking the G-alpha-i2 gene display growth retardation
 CC and develop adenocarcinoma of the colon and a form of lethal diffuse
 CC colitis similar to ulcerative colitis in humans. The antisense molecules
 CC are useful for inhibiting the expression of G-alpha-i2 in human cells or
 CC tissues, and for treating and preventing various disorders such as
 CC infection, inflammation and tumor formation. The antisense
 CC oligonucleotides are also useful for research and diagnostic purposes.

XX SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 860 GCTTTGAGTCCCAACAG 877

Db 18 GCTTTGAGGCGGTACAG 1

RESULT 404

```

AAZ91440
ID AAZ91440 standard; DNA; 18 BP.
XX
AC AAZ91440;
XX
DT 22-MAY-2000 (first entry)
XX
DE Human Ship-2 phosphorothioate antisense oligonucleotide #30722.
XX
KW Human; Ship-2; antisense oligonucleotide; phosphorothioate; detection;
KW inhibition; SH2-containing phosphatidylinositol phosphatase-2; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..18
FT /*tag= a
FT /*note= "phosphorothioate linkages"
XX
PN US6025198-A.
XX
PD 15-FEB-2000.
XX
PF 25-JUN-1999; 99US-0339964.
XX
PR 25-JUN-1999; 99US-0339964.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowser LM;
XX
DR WPI; 2000-181819/16.
XX
PT Antisense oligonucleotides, useful for inhibiting human Ship-2
PT expression and for detecting nucleic acids encoding Ship-2 -
XX
PS Example 15; Column 39; 34pp; English.
XX
CC The present invention describes phosphorothioate antisense
CC oligonucleotides that specifically hybridize with, and inhibit the
CC expression of, nucleic acids encoding human Ship-2 (also called
CC SH2-containing phosphatidylinositol phosphatase-2). Also described
CC is a method of inhibiting the expression of Ship-2 in human cells
CC or tissues in vitro comprising contacting the cells with the
CC phosphorothioate antisense oligonucleotides. The phosphorothioate
CC antisense oligonucleotides can be used to treat animals (especially
CC humans) suspected of having or being prone to a disease or condition
CC associated with Ship-2 expression. The present sequence represents
CC a phosphorothioate antisense oligonucleotide for human Ship-2, from
CC the present invention.
XX
SQ Sequence 18 BP; 2 A; 11 C; 1 G; 4 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 869 TCCCCACAGCCAGTCC 886
Db 1 TCCCCACTGCCACTTCC 18

RESULT 405
AAZ65527
ID AAZ65527 standard; DNA; 18 BP.
XX
AC AAZ65527;
XX
DT 30-MAR-2000 (first entry)
XX
DE Immunosuppressant inhibitor oligonucleotide TGF-beta1-98-15.
XX
KW Immunosuppressant inhibitor; transforming growth factor beta; TGF beta;

```

```

KW vascular endothelial growth factor; VEGF; interleukin-10; IL-10; cancer;
KW prostaglandin E2; PGE2; immune response; tumour; asthma; Crohn's disease;
KW monocyte chemotactic protein-1; MCP-1; ulcerative colitis; diabetes;
KW glomerulonephritis; acute respiratory distress syndrome; ss;
KW atherosclerosis.
XX
OS Unidentified.
XX
PN WO9963975-A2.
XX
PD 16-DEC-1999.
XX
PF 10-JUN-1999; 99WO-EP04013.
XX
PR 10-JUN-1999; 98EP-0110709.
PR 25-JUL-1999; 98EP-0113974.
XX
PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI Schlingensiepen K, Schlingensiepen R, Brysch W;
XX
DR WPI; 2000-097470/08.
XX
PT Composition containing immune stimulant and inhibitor of agent that
PT adversely affects the immune response, for treating cancers and
PT infections -
XX
PS Claim 10; Figure 1; 30pp; English.
XX
CC This sequence is an immunosuppressant inhibitor oligonucleotide, which
CC is used in the invention. The invention relates to a composition which
CC contains at least one inhibitor (less than 100 kD) of a substance (e.g.
CC transforming growth factor TGF-beta, vascular endothelial growth factor
CC VEGF, interleukin-10 IL-10, prostaglandin E2 PGE2, or their receptors)
CC that adversely affects the immune response. The composition also includes
CC at least one stimulant that positively affects the immune response. This
CC oligonucleotide is an example of an inhibitor that is used in the
CC composition. The composition is used as an immunostimulant for the
CC treatment of neoplasms and infections, particularly hyperproliferation;
CC leukaemia; (non-Hodgkin's lymphoma; carcinoma (of oesophagus, bronchi,
CC colon-rectum, stomach, intestine, gall bladder or duct, pancreas, anus,
CC breast, ovary, cervix, endometrium, prostate or bladder), liver tumours,
CC malignant melanoma, brain tumours and sarcomas. The oligonucleotides,
CC most of which are directed against TGFbeta or VEGF, are inhibitors of
CC monocyte chemotactic protein-1 (MCP-1) and are useful as
CC anti-inflammatories for treating e.g. asthma, Crohn's disease, ulcerative
CC colitis, diabetes, glomerulonephritis, acute respiratory distress
CC syndrome and the formation of atherosclerotic plaque.
XX
SQ Sequence 18 BP; 1 A; 9 C; 7 G; 1 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 191 CCGCCACCCGCGCGCG 208
Db 1 CCGCCACCCGCGCGCG 18

RESULT 405
AAI66785/c
ID AAI66785 standard; DNA; 18 BP.
XX
AC AAI66785;
XX
DT 07-JAN-2002 (first entry)
XX
DE PPAR-gamma mRNA amplifying RT-PCR primer R.
XX
KW Adipocyte; hedgehog polypeptide; desert hedgehog; indian hedgehog; Dhh;
KW Ihh; sonic hedgehog; Shh; therapeutic; cytostatic; primer; RT-PCR; ss.
XX

```

```

OS Synthetic.
XX WO200164238-A2.
XX
XX
XX PD 07-SEP-2001.
XX
XX PT 28-FEB-2001; 2001WO-US06450.
XX PF
XX PR 29-FEB-2000; 2000US-186058P.
XX
XX PA (CURI-) CURIS INC.
XX
XX PI Zehentner B, Leser-Reiff U, Burtscher H;
XX
XX WPI; 2001-607352/69.
XX
XX PT Method for regulating formation and/or maintenance of adipocyte tissue
XX by contacting pre-adipocyte or adipocyte cells with a hedgehog
XX peptide or ptc therapeutic -
XX
XX PS Example; Page 76; 132pp; English.
XX
XX CC The invention provides a method for regulating formation and/or
XX maintenance of adipocyte tissue that comprises contacting pre adipocyte
XX or adipocyte cells with a hedgehog polypeptide or ptc therapeutic. The
XX method is used for regulating the growth state of an adipocyte stem/
XX progenitor cell, and treating or preventing disorders of, or surgical or
XX cosmetic repair of, adipocyte tissues, e.g. for treating or preventing
XX hyperplastic or neoplastic conditions affecting adipocyte tissue, such
XX as soft tissue tumors, especially adipose cell tumors, e.g. lipomas,
XX fibrolipomas, lipoblastomas, lipomatosis, hibernomas, hemangiomas and/or
XX liposarcomas. Hedgehog polypeptides can be used in combination with other
XX therapeutic agents. Sequences AA166784-793 represent primers used in
XX quantitative RT-PCR of PPARGgamma, ap2, gli, ptc and actin mRNAs, during
XX the course of the invention.
XX
XX SQ Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 304 GTGGGGGCTGCAACTCCA 321
Db 18 GTGGAGCTGCATCTCCA 1

RESULT 407
AAF89283
ID AAF89283 standard; DNA; 18 BP.
AC AAF89283;
XX
XX DT 10-DEC-2001 (first entry)
XX
XX DE Sample member clustering method related human DNA PCR primer #20.
XX
XX KW Cluster; hierarchical clustering algorithm; population based study;
XX clinical trial; DNA fingerprint; genetic profile analysis; PCR primer;
XX SNP; single nucleotide polymorphism; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200129257-A2.
XX
XX PD 26-APR-2001.
XX
XX PF 20-OCT-2000; 2000WO-IB01632.
XX
XX PR 22-OCT-1999; 95US-0161231.
XX
XX PR 07-JUL-2000; 2000US-0216897.
XX
XX FA (GBST ) GENSET.

```

```

XX PI Schork N, Skierczynski B;
XX
XX DR WPI; 2001-316248/33.
XX
XX PT Genetic clustering by distributing members into optimal numbers of
XX clusters determined by a hierarchical clustering algorithm or by
XX paired-pair analysis of homozygous pairs in clusters got from
XX non-hierarchical clustering -
XX
XX PS Claim 61; Page 78; 100pp; English.
XX
XX CC The present invention describes methods of clustering members of a
XX sample, involving applying a hierarchical clustering algorithm to the
XX sample members, determining the optimal number of clusters based on this
XX and distributing the sample members into clusters using non-hierarchical
XX clustering. The methods are useful in population based studies such as
XX clinical trials, DNA fingerprinting and genetic profile analyses. The
XX present sequence was used to demonstrate the method of the invention.
XX
XX SQ Sequence 18 BP; 5 A; 8 C; 3 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 869 TCCCCACAGCCAAAGTTC 886
Db 1 TCCCCACAGCTAAGAGCC 18

RESULT 408
AAH75784
ID AAH75784 standard; DNA; 18 BP.
AC AAH75784;
XX
XX DT 15-OCT-2001 (first entry)
XX
XX DE Human NOV 12 reverse PCR primer.
XX
XX KW NOV; olfactory; cytostatic; immunomodulator; vulnery; anti-HIV;
XX antiasthmatic; antiinflammatory; gastrointestinal; neuroprotective;
XX osteopathic; gene therapy; odorant receptor; olfactory receptor;
XX G-protein coupled receptor; GPCR; neuro-olfactory; trauma; PCR primer;
XX neoplastic disorder; cancer; adenocarcinoma; lymphoma; prostate cancer;
XX uterus cancer; immune response; AIDS; asthma; Crohn's disease;
XX multiple sclerosis; Albright hereditary osteodystrophy; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200155179-A2.
XX
XX PD 02-AUG-2001.
XX
XX PF 29-JAN-2001; 2001WO-US02849.
XX
XX PR 27-JAN-2000; 2000US-0178370.
XX
XX PR 27-JAN-2000; 2000US-0178371.
XX
XX PR 27-JAN-2000; 2000US-0178406.
XX
XX PR 27-JAN-2000; 2000US-0178408.
XX
XX PR 27-JAN-2000; 2000US-0178409.
XX
XX PR 27-JAN-2000; 2000US-0178413.
XX
XX PR 27-JAN-2000; 2000US-0178414.
XX
XX PR 07-FEB-2000; 2000US-0180634.
XX
XX PR 24-JUL-2000; 2000US-0220516.
XX
XX PR 28-JUL-2000; 2000US-0221408.
XX
XX PR 31-JUL-2000; 2000US-0221943.
XX
XX PR 21-DEC-2000; 2000US-0257599.
XX
XX PR 08-JAN-2001; 2001US-0260290.
XX
XX FA (CURA-) CURAGEN CORP.
XX
XX

```


PI Prayaga SK, Padigar M, Spytek KA, Li L, Tchernev VT, Vernet CM;
PI Peyman JA, Macdougall J;
XX WPI; 2001-514556/56.
XX New NOVX polypeptides and polynucleotides, useful for treating or
PT preventing a syndrome associated with a human disease (e.g. disorders
PT of the neuro-olfactory system), as well as in gene therapy -
XX
XX Example 2; Page 229; 242pp; English.
XX The present invention relates to novel human NOVX proteins and coding
CC sequences, where x is any number from 1 to 18 (see AAH5716-AAH5733, and
CC AAG6400 and AAG66322-AAG66338). NOVX are members of the
CC odorant/olfactory receptor (OR) family, which are G-protein coupled
CC receptors (GPCRs). The NOVX proteins and coding sequences are useful as
CC therapeutics, particularly in the manufacture of a medicament for
CC treating a syndrome associated with a human disease/disorders of the
CC neuro-olfactory system, e.g. those induced by trauma, surgery and/or
CC neoplastic disorders. Furthermore, the coding sequences and proteins are
CC useful in treating cancer e.g. adenocarcinoma, lymphoma, prostate cancer,
CC uterus cancer, inappropriate immune response, AIDS, asthma, Crohn's
CC disease, multiple sclerosis or Albright hereditary osteodystrophy. The
CC coding sequences are also useful in gene therapy for treating the above
CC conditions. The present PCR primer was used in an example from the
XX present invention.
XX Sequence 18 BP; 5 A; 5 C; 7 G; 1 T; 0 other;
SQ
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 905 GGCCCTGGTCTTAAGGA 923
Db 1 GGCCCGAGGACCTGAAGA 18
RESULT 409
AAH51027
ID AAH51027 standard; DNA; 18 BP.
XX
AC AAH51027;
XX
XX 28-AUG-2001 (first entry)
DT
XX Human nGPCR3 PCR primer #2.
XX G protein-coupled receptor; nGPCR; seven transmembrane receptor;
KW signal transduction; schizophrenia; thyroid disorder; renal failure;
KW rheumatoid arthritis; CNS disorder; infection; metabolic disease;
KW cardiovascular disease; proliferative disorder; hormonal disorder;
KW neurological disorder; neuronal disorder; Alzheimer's disease; cancer;
KW attention deficit-hyperactivity disorder/attention deficit disorder;
KW Parkinson's disease; migraine; senile dementia; inflammatory disease;
KW rheumatoid arthritis; autoimmune disorder; respiratory ailment;
KW neuroprotective; PCR primer; ss.
XX
OS Homo sapiens.
XX
XX WO200136473-A2.
XX
XX 25-MAY-2001.
XX
XX 16-NOV-2000; 2000WO-US31581.
XX
XX 16-NOV-1999; 99US-0165838.
PR 17-NOV-1999; 99US-0166071.
PR 19-NOV-1999; 99US-0166678.
PR 28-DEC-1999; 99US-0173396.
PR 22-FEB-2000; 2000US-0184129.
PR 28-FEB-2000; 2000US-0185421.
PR 28-FEB-2000; 2000US-0185554.

PR 02-MAR-2000; 2000US-0186530.
PR 03-MAR-2000; 2000US-0188811.
PR 09-MAR-2000; 2000US-0188114.
PR 17-MAR-2000; 2000US-0190310.
PR 21-MAR-2000; 2000US-0190800.
PR 20-APR-2000; 2000US-0198568.
PR 02-MAY-2000; 2000US-0201190.
PR 08-MAY-2000; 2000US-0203111.
PR 25-MAY-2000; 2000US-0207094.
XX
XX (PHAA) PHARMACIA & UPJOHN CO.
XX
XX Vogeli G, Wood LS, Parodi LA, Hiesch RR, Lind P, Slightom J;
PI Schellin KA, Kayes PS, Bannigan CM, Ruff V, Sejlitz T, Ruff RM;
XX WPI; 2001-389826/41.
XX
XX New G protein-coupled receptor (nGPCR-x) and its encoding
PT polynucleotide useful for diagnosing and treating e.g. schizophrenia -
XX
XX Example 4; Page 116; 261pp; English.
XX The present invention relates to novel G protein-coupled receptors
CC (nGPCRx; where x is 1, 3, 4, 5, 9, 11, 12, 14-18, 20, 21, 22, 24, 27,
CC 28, 31-38, 40, 41, 53-60) and their coding sequences (see
CC AAH50969-AAH51015 and AAH51105 and AAG80929-AAG80975 and AAG80977). The
CC present sequence is a PCR primer, which was used in an example from the
CC present invention. GPCRs are also known as seven transmembrane receptors
CC and function in signal transduction. The nGPCRx coding sequences are
CC useful for screening a human to diagnose a disorder affecting the brain
CC or a genetic predisposition, specifically schizophrenia. nGPCRx are
CC useful for identifying compounds useful for treating schizophrenia.
CC Detection of nGPCRx in a sample is useful as a diagnostic tool for
CC diseases or disorders e.g. thyroid disorders, renal failure, rheumatoid
CC arthritis, CNS disorders, infections such as HIV-1, metabolic and
CC cardiovascular diseases, proliferative disorders and hormonal disorders.
CC Modulators of nGPCRx activity have the utility for treating neurological
CC disorders, including schizophrenia, ADHD/ADD (attention deficit-
CC hyperactivity disorder/attention deficit disorder), and neuronal
CC disorders such as Alzheimer's disease, Parkinson's disease, migraine and
CC senile dementia. Additional disorders include inflammatory conditions
CC (e.g. Crohn's disease), rheumatoid arthritis, autoimmune disorders,
CC cancers, respiratory ailments such as asthma, and inflammatory diseases
CC e.g. inflammatory bowel disease.
XX
XX Sequence 18 BP; 1 A; 5 C; 8 G; 4 T; 0 other;
SQ
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 524 TGCCGAGGAGGAGCTGG 541
Db 1 TGCCCTGGAGCGCTGG 18
RESULT 410
AA26667
ID AA26667 standard; DNA; 18 BP.
XX
XX AAF26667;
XX
XX 02-APR-2001 (first entry)
DT
XX Human Smad7 phosphorothioate antisense oligonucleotide SEQ ID NO:10.
XX Human; Smad7; antisense oligonucleotide; phosphorothioate; inhibition;
KW antiinflammatory; cytostatic; infection; inflammation; tumour formation;
KW ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
XX

```

FT modified_base 1..18
FT /*tag= a
FT /note= "phosphorothioate linkages"
FN US6159697-A.
PD 12-DEC-2000.
XX
XX 09-JAN-2000; 2000US-0487444.
XX
XX 09-JAN-2000; 2000US-0487444.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowsert LM;
XX
XX WPI; 2001-070108/08.
XX
XX Antisense compound capable of inhibiting the expression of human Smad7,
XX useful for preventing or delaying infection, inflammation or tumor
XX formation -
XX
XX Claim 1; Column 40; 33pp; English.
XX
XX The present invention describes an antisense compound (I) of up to 30
XX nucleobases in length capable of inhibiting the expression of human
XX Smad7. (I) has antiinflammatory and cytostatic, and is a modulator of
XX Smad7 expression. (I) can be useful for inhibiting the expression of
XX human Smad7 in human cells or tissues, in vitro. (I) is commonly used
XX as a research reagent and in diagnostics for example, to elucidate the
XX function of particular genes. (I) is also useful for distinguishing
XX between functions of various members of a biological pathway and for
XX research use. (I) is also utilised for diagnostics, therapeutics,
XX prophylaxis and in kits. (I) is also useful prophylactically, e.g. to
XX prevent or delay infection, inflammation or tumour formation. AAF26667
XX to AAF26706 represent human Smad7 antisense oligonucleotides from the
XX present invention.
XX
XX Sequence 18 BP; 1 A; 12 C; 3 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 583 CTCGCTGCGCCGCCACC 600
Db 1 CTCGGCTGCGCCGCCACC 18

RESULT 411
ABQ82729
ID ABQ82729 standard; DNA; 18 BP.
XX
XX AC ABQ82729;
XX
XX 09-JAN-2003 (first entry)
XX
XX VEGFR-3 binding peptide library related primer SEQ ID NO:75.
XX
XX Vascular endothelial growth factor receptor 3 inhibitor; VEGFR-3;
XX angiogenesis; lymphangiogenesis; vascular endothelial growth factor;
XX cytostatic; hepatotropic; antiinflammatory; hypotensive; antidiabetic;
XX vulnary; cell surface receptor; cancer; neovascularisation;
XX liver disease; hypertension; post-trauma; chronic hepatitis; primer;
XX haemangioma; diabetes; PDGF; platelet derived growth factor; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200257299-A2.
XX
XX 25-JUL-2002.
XX

16-JAN-2002; 2002WO-IB00099.
17-JAN-2001; 2001US-262476P.
(LUDW-) LUDWIG INST CANCER RES.
(LICN ) LICENTIA LTD.
Alitalo K, Koivunen E, Kubo H;
WPI; 2002-691521/74.
New isolated peptide that inhibits VEGF-C and VEGF-D, useful for
diagnosing, evaluating, treating disorders mediated by VEGFR-3
activity, such as cancer and diseases of neovascularization -
Example; Page 74; 149pp; English.
The present invention describes an isolated peptide (I) that binds to
and inhibits vascular endothelial growth factor receptor 3 (VEGFR-3).
(I) have cytostatic, hepatotropic, antiinflammatory, hypotensive,
antidiabetic and vulnary activities, and can be used in gene therapy.
Compositions and methods from the present invention are useful for
diagnosing, evaluating and treating disorders mediated by the activity
of the cell surface receptor VEGFR-3 such as cancer, e.g. brain, lung,
liver, spleen, kidney, lymph node, small intestine, blood cells,
pancreas, colon, stomach, breast, endometrium, prostate, testicle,
ovary, skin, head and neck, oesophagus, bone, marrow or blood, and
diseases of neovascularisation, e.g. liver diseases, hypertension,
post-trauma, chronic hepatitis, haemangiomas and diabetes. The present
sequence represents a primer used in the construction of a VEGFR-3
binding peptide library, which is used in an example from the present
invention.
Sequence 18 BP; 1 A; 10 C; 5 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 686 TTGGGAGCCAGCGGCCCC 703
Db 1 TTGGGAGCCAGCGGCCCC 18

RESULT 412
ABS70260
ID ABS70260 standard; DNA; 18 BP.
XX
XX AC ABS70260;
XX
XX 26-NOV-2002 (first entry)
XX
XX PCR primer, #6, used to detect expression of nGPCR-9.
XX
XX Human; PCR; ss; G protein-coupled receptor; GPCR; nGPCR; beGPCR; primer;
XX nG protein coupled receptor; communication; serpentine structure;
XX seven transmembrane receptor; 7TM; mental disorder; diagnosis;
XX genetic predisposition; brain; immune response; gene therapy;
XX anxiety disorder; depression; bipolar disorder; schizophrenia;
XX Huntington's disease; dyskinesia; manic depression; stroke;
XX Parkinson's disease; Alzheimer's disease; diabetes; inflammation; wound;
XX tranquiliser.
XX
XX Homo sapiens.
XX
XX WO200264789-A1.
XX
XX 22-AUG-2002.
XX
XX 14-FEB-2001; 2001WO-US04641.
XX
XX 14-FEB-2001; 2001WO-US04641.
XX

```

PA (PHAA) PHARMACIA & UPJOHN CO.
XX Lind P, Parodi LA, Vogeli G, Wood LS;
XX WPI; 2002-674879/72.
XX
XX New nucleic acids and polypeptides of the ng protein-coupled receptor,
PT useful for treating or diagnosing a mental disorder or a disorder
PT affecting the brain, e.g. anxiety disorders, schizophrenia, stroke or
PT Parkinson's disease
XX
XX Example 4; Page 110; 244pp; English.
PS
XX The invention discloses an isolated human polypeptide, and encoding
CC nucleic acid, for a G protein-coupled receptor (GPCR), particularly the
CC ng protein coupled receptor-14 (ngPCR-14). GPCRs are vital in the
CC communication between cells and their environment and are characterised
CC by a serpentine structure that passes through the cell membrane seven
CC times, hence the reason such receptors are sometimes called seven
CC transmembrane receptors (7TM). The polynucleotides and polypeptides are
CC useful for identifying an ngPCR allelic variant that correlates with a
CC mental disorder, for isolating an antibody that binds to an epitope of
CC the polypeptide, for identifying a compound that binds to the polypeptide
CC or polynucleotide and/or modulates its biological activity, for
CC screening a human subject to diagnose a disorder, or a genetic
CC predisposition to a disorder, affecting the brain or a genetic
CC disposition to the disorder, for identifying compounds useful for the
CC treatment of a mental disorder and for identifying a compound useful as a
CC modulator of binding between ngPCR-14 and a binding partner of ngPCR-14.
CC The polypeptide is also useful for inducing an immune response in a
CC mammal. The nucleic acid or polypeptide is particularly useful, using
CC gene therapy, for treating e.g. anxiety disorders, depression, bipolar
CC disorder, schizophrenia, Huntington's disease, dyskinesias, manic
CC depression, stroke, Parkinson's disease or Alzheimer's disease. The
CC nucleic acid and polypeptide may also be used for treating diabetes,
CC inflammation or wounds. The sequences presented in ABS70249-ABS70352,
CC ABS70355-ABS70382, ABS70305-ABS70337 and ABS70339-ABS70242 are the PCR
CC primers which were used to amplify, and detect, the DNA encoding the
CC ngPCRs (also referred to as beGPCRs).
XX
XX Sequence 18 BP; 1 A; 5 C; 8 G; 4 T; 0 other;
SQ Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 524 TCCCGAGGAGCAGCTGG 541
DB 1 TGCCTGTGGAGCCGCTGG 18
XX
XX RESULT 413
XX ABS65844/C
ID ABS65844 standard; DNA; 18 BP.
XX
XX ABS65844;
AC
XX
XX 15-NOV-2002 (first entry)
DT
XX
XX Inhibitory oligonucleotide specific for hepatitis C virus #50.
DE
XX Hepatitis C virus; HCV; hepatocyte infection; non-A hepatitis;
XX non-B hepatitis; acute hepatitis; chronic hepatitis;
XX hepatocellular carcinoma; virucide; cytostatic; antisense therapy;
KW gene therapy; ss; DNA-RNA hybrid.
XX
XX Synthetic.
OS
XX
XX US2002081577-A1.
FN
XX
XX 27-JUN-2002.
PD
XX
XX 02-JUL-1997; 97US-0887505.
PF

XX
PR 02-JUL-1996; 96US-021104P.
PR 06-JUN-1995; 95US-0471968.
XX
XX (KILK/) KILKUSKIE R L.
PA (FRAN/) FRANK B L.
PA (GOOD/) GOODCHILD J.
PA (WOLF/) WOLFE J L.
PA (ROBE/) ROBERTS P C.
PA (HAML/) HAMLIN H A.
PA (ROBE/) ROBERTS N A.
PA (WALT/) WALTHER D M.
XX
XX Kilkuskie RL, Frank BL, Goodchild J, Wolfe JL, Roberts PC;
PI Hamlin HA, Roberts NA, Walther DM;
XX WPI; 2002-537132/57.
DR
XX Synthetic oligonucleotides complementary to a portion of the 5'
PT untranslated region of hepatitis C virus (HCV), useful for diagnosing
PT and treating HCV infections and hepatocellular carcinoma -
XX Claim 22; Page 11; 74pp; English.
PS
XX The invention describes synthetic oligonucleotides complementary to a
CC portion of the 5' untranslated region of hepatitis C virus. The
CC oligonucleotides may be used in methods for controlling, preventing, and
CC treating hepatitis C virus infection, in antisense technology and gene
CC therapy, and of detecting the presence of hepatitis C virus in a sample.
CC Hepatitis C virus (HCV) is an enveloped, positive sense, single-stranded
CC RNA virus which infects hepatocytes. HCV is the major cause of non-A,
CC non-B, acute and chronic hepatitis, and has been associated with
CC hepatocellular carcinoma. The invention describes methods and kits for
CC inhibiting replication of HCV, inhibiting the expression of HCV nucleic
CC acid and protein, and for treating HCV infections. This sequence
CC represents a synthetic DNA-RNA hybrid oligonucleotide used for inhibiting
CC HCV replication and expression of HCV.
XX
XX Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 other;
SQ Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 631 CTCGAGGAGCTCTGCATC 648
DB 18 CTCGAGGAGCCCTGCACC 1
XX
XX RESULT 414
XX ABT06049/C
ID ABT06049 standard; DNA; 18 BP.
XX
XX ABT06049;
AC
XX
XX 28-OCT-2002 (first entry)
DT
XX
XX Human IgM heavy chain gene related PCR primer SEQ ID No 63.
DE
XX
XX Single Primer Amplification; nested oligonucleotide extension reaction;
KW hairpin; SPA; library; PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX WO200248401-A2.
FN
XX
XX 20-JUN-2002.
PD
XX
XX 10-DEC-2001; 2001WO-US47727.
PF
XX
XX 11-DEC-2000; 2000US-254669P.
PR
XX 19-SEP-2001; 2001US-323400P.
XX

PA (ALEX-) ALEXION PHARM INC.
 XX Bowdish KS, Barbas-frederickson S, Lin Y, Mcwhirter J, Maruyama T;
 PI WPI; 2002-500537/53.
 XX
 XX Amplifying nucleic acid by synthesizing template nucleic acid
 PT containing a predetermined sequence and hairpin structure and using the
 PT template for target amplification by Single Primer Amplification -
 XX
 XX Example 3; Page 22; 54pp; English.
 XX
 CC The invention relates to a method for amplifying a nucleic acid using
 CC Single Primer Amplification (SPA). The method comprises synthesising a
 CC template nucleic acid containing a predetermined sequence and hairpin
 CC structure with the nested oligonucleotide extension reaction. The method
 CC is useful for amplifying a nucleic acid, preferably for amplifying a
 CC family of related nucleic acid sequences to build a complex library of
 CC polypeptides encoded by the sequences. The engineered nucleic acid strand
 CC is useful for amplifying a nucleic acid strand by providing a nucleic
 CC acid with a predetermined sequence engineered onto its first end, a
 CC sequence complementary to the predetermined sequence and a hairpin
 CC structure between them and contacting the engineered nucleic acid strand
 CC with a primer containing at least a portion of the predetermined
 CC sequence. This process is done in the presence of a polymerase and
 CC nucleotides under conditions suitable for polymerisation to produce a
 CC complementary nucleic acid strand. The method of the invention is useful
 CC for producing large amounts of a target nucleic acid sequence and for
 CC amplifying simultaneously more than one different target nucleic acid
 CC sequence located on the same or different nucleic acid molecules. This
 CC polynucleotide sequence represents a PCR primer of the invention.
 XX
 XX Sequence 18 BP; 1 A; 2 C; 7 G; 8 T; 0 other;
 SQ

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 28 AAACCCAGCTACGCCAAA 45
 Db 18 AAACCCAGCTACGCCAAA 1

RESULT 415
 ABK47739/c
 ID ABK47739 standard; DNA; 18 BP.
 XX
 AC ABK47739;
 XX
 DT 18-JUN-2002 (first entry)
 XX
 DE Beta-actin reverse PCR primer used in invention relating to TMOs.
 XX
 KW Primer-dependent polymerase-mediated DNA synthesis; TMO;
 KW template-mimic oligonucleotide; nucleic acid amplification;
 KW multiplex RT-PCR; reverse transcriptase-PCR; Competimer method;
 KW PCR; primer; beta-actin; ss.
 XX
 OS Unidentified.
 XX
 XX WO200218616-A1.
 PN
 XX
 XX 07-MAR-2002.
 PD
 XX
 PF 30-AUG-2001; 2001WO-US27287.
 XX
 XX 01-SEP-2000; 2000US-230184P.
 PR
 XX (HITB) HITACHI CHEM CO LTD.
 PA (HITB) HITACHI CHEM RES CENT INC.
 XX
 XX Ke S;
 PI
 XX

DR WPI; 2002-315546/35.
 XX
 PT Modulating amplification efficiency of a target sequence in
 PT primer-dependent polymerase-mediated DNA synthesis, useful for
 PT adjusting the efficiency nucleic acid amplification comprises adding a
 PT template mimic-oligonucleotide -
 XX
 XX Example; Page 12; 39pp; English.
 PS
 XX
 CC The present invention relates to a method of modulating amplification
 CC efficiency of a target sequence in primer-dependent polymerase-mediated
 CC DNA synthesis. The method comprises adding a template-mimic
 CC oligonucleotide (TMO) to a primer-dependent polymerase-mediated DNA
 CC synthesis reaction mixture containing primers, to block a primer for
 CC amplifying a target sequence in the mixture from hybridising to the
 CC target sequence. The method is useful for adjusting the efficiency of
 CC target template nucleic acid amplification by controlling the ratio of
 CC template-like oligonucleotides to amplification primers. The new method
 CC provides a convenient and efficient method for simultaneous detection
 CC of high and low-abundant genes in multiplex RT-PCR, and is more potent
 CC and easier to control than the Competimer method. The present sequence
 CC represents a PCR primer used in a real-time PCR assay in the example
 CC of the present invention.
 XX
 XX Sequence 18 BP; 2 A; 7 C; 3 G; 6 T; 0 other;
 SQ

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 935 TGGAGAAAGAGGTGTGAGC 952
 Db 18 TGGAGAAAGAGCTACGAGC 1

RESULT 416
 ABK24039/c
 ID ABK24039 standard; DNA; 18 BP.
 XX
 AC ABK24039;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE B7-related protein, BSL2, PCR primer #5.
 XX
 KW Human; immunosuppressive; antirheumatic; antiarthritic; antiulcer;
 KW antianaemic; antipsoriatic; B7-related polypeptide; BSL1; BSL2; BSL3;
 KW autoimmune disease; rheumatoid arthritis; multiple sclerosis;
 KW Hashimoto's thyroiditis; Graves' disease; Crohn's disease; psoriasis;
 KW ulcerative colitis; pernicious anaemia; bone marrow transplantation;
 KW graft versus host disease; organ transplantation; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200194413-A2.
 PN
 XX
 PD 13-DEC-2001.
 XX
 XX 06-JUN-2001; 2001WO-US18257.
 PF
 XX
 XX 06-JUN-2000; 2000US-209811P.
 PR
 XX 28-FEB-2001; 2001US-272107P.
 XX
 XX (BRIM) BRISTOL-MYERS SQUIBB CO.
 PA
 XX Mikesell GE, Chang H, Finger JN, Yang G, Lu P, Zhou X, Peach R;
 PI WPI; 2002-090141/12.
 XX
 XX Nucleic acids encoding B7-related polypeptides, i.e. BSL1, BSL2, or
 PT BSL3 polypeptides, useful for treating autoimmune diseases (e.g.
 PT rheumatoid arthritis, multiple sclerosis, and psoriasis), and graft
 PT versus host disease -
 XX


```

Db      18 GGTGAGCAGGTGGGGC 1
RESULT 419
ABT15904/c
ID      ABT15904 standard; DNA; 18 BP.
XX
XX      ABT15904;
AC
XX
XX
DT      28-MAR-2003 (first entry)
XX
XX      B7-related PCR primer - SEQ ID No 21.
DE
XX
XX      PCR; ss; gene therapy; B7-related fusion protein; BSL2; viral infection;
KW      immune response modulation; inflammatory response modulation; cancer;
KW      transplantation rejection; graft versus host disease; asthma; herpes;
KW      chronic obstructive pulmonary disease; HIV; encephalitis; psoriasis;
KW      autoimmune disease; rheumatoid arthritis; multiple sclerosis; primer.
XX
XX      Unidentified.
OS
XX
XX      WO200299119-A2.
PN
XX
XX      12-DEC-2002.
PD
XX
XX      06-JUN-2002; 2002WO-US18049.
PF
XX
XX      06-JUN-2001; 2001US-0875338.
PR
XX      15-FEB-2002; 2002US-0077023.
PR
XX      (BRIM ) BRISTOL-MYERS SQUIBB CO.
PA
XX
XX      Mikesell GE, Shen H;
PI
XX
XX      WPI; 2003-140629/13.
DR
XX
XX      New isolated B7-related nucleic acid fusion molecules and fusion
PT      polypeptides, useful for diagnostic applications, modulating the
PT      activation of immune or inflammatory response cells, preventing or
PT      treating cancer or psoriasis -
XX
XX      Example 1; Page 129; 180pp; English.
PS
XX
XX      The invention comprises the amino acid and coding sequence of B7-related
CC      (BSL2) fusion proteins. The B7-related fusion proteins of the invention
CC      are useful for modulating the activation of immune or inflammatory
CC      response cells (e.g. T cells). The B7-related fusion proteins are useful
CC      for treating or preventing: transplantation rejection; graft versus host
CC      disease; asthma; chronic obstructive pulmonary disease; cancers; viral
CC      infections (e.g. HIV, herpes or encephalitis); and autoimmune disease
CC      (e.g. rheumatoid arthritis, multiple sclerosis or psoriasis). The present
CC      DNA sequence represents a PCR primer that was used in an example of the
CC      invention.
XX
XX      Sequence 18 BP; 4 A; 7 C; 3 G; 4 T; 0 other;
SQ
Query Match      1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1014 CCTGAGATGGTGCAAG 1031
      |||||
Db      16 CCTGTGATGGTGACAG 1

RESULT 420
ABV77248
ID      ABV77248 standard; DNA; 18 BP.
XX
XX      ABV77248;
AC
XX
XX      28-MAR-2003 (first entry)
DT
XX

```

```

DE      PCR primer for human early mitotic inhibitor 1 (Emil) cDNA.
XX
KW      Early mitotic inhibitor 1; Emil; anaphase-promoting complex; APC;
KW      mitosis; cell cycling; hyperproliferative condition; oocyte activation;
KW      gene therapy; PCR; primer; ss.
XX
OS      Homo sapiens.
XX
XX      WO200294198-A2.
PN
XX
XX      28-NOV-2002.
PD
XX
XX      23-MAY-2002; 2002WO-US16346.
PF
XX      24-MAY-2001; 2001US-293921P.
PR
XX
XX      (STRD ) UNIV LELAND STANFORD JUNIOR.
PA
XX
XX      Jackson PK, Reimann JDR;
PI
XX
XX      WPI; 2003-129363/12.
DR
XX
XX      Inhibiting the anaphase-promoting complex in a proliferating cell,
PT      useful for treating hyperproliferative conditions, comprises providing
PT      an early mitotic inhibitor 1 polypeptide to a cell undergoing mitosis
PT
XX
XX      Example 2; Page 42; 82pp; English.
PS
XX
XX      PCR primers ABV77248-49 were used to amplify cDNA encoding human early
CC      mitotic inhibitor 1 (Emil) polypeptide. Emil polypeptides are used in
CC      the method of the invention to inhibit the anaphase-promoting complex
CC      (APC) in a proliferating cell. To this end, the Emil polypeptide is
CC      provided to a cell undergoing mitosis. The method is used to inhibit APC
CC      agents that modulate Emil function or that mimic Emil activity, and the
CC      agents are used for enhancing APC in a proliferating cell. The Emil is
CC      useful for modulating the cycling of cells, e.g. for treating
CC      hyperproliferative conditions, in diseases involving oocyte activation.
CC      Emil proteins may also be used in screening and research methods for
CC      determining specific analogues, agonists, antagonists and mimetics.
CC      Nucleic acid compositions are useful in identifying homologous or related
CC      genes, in producing the encoded protein, in producing compositions that
CC      modulate the expression or function of its encoded protein, for gene
CC      therapy, mapping functional regions of the protein, and in studying
CC      associated physiological pathways.
XX
XX      Sequence 18 BP; 5 A; 1 C; 10 G; 2 T; 0 other;
SQ
Query Match      1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      928 GCAGATCTGGAGAGAGG 945
      |||||
Db      1 GTAGATCGGAGGAGAGG 18

RESULT 421
ABQ84276/c
ID      ABQ84276 standard; DNA; 18 BP.
XX
XX      ABQ84276;
AC
XX
XX      20-FEB-2003 (first entry)
DT
XX
XX      Beta-actin reverse PCR primer.
DE
XX
XX      DPP10; dipeptidyl peptidase; prololigopeptidase; enzyme; asthma;
KW      antiinflammatory; antiasthmatic; antipsoriatic; antiarthritis;
KW      antirheumatic; vaccine; gene therapy; inflammatory disease;
KW      inflammatory bowel disease; atopy; rheumatoid arthritis; psoriasis;
KW

```

KW chromosome 2q14; PCR primer; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX
 XX W0200286113-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 24-APR-2002; 2002WO-GB01887.
 XX
 XX 24-APR-2001; 2001GB-0010044.
 PR
 XX 24-APR-2001; 2001GB-0010045.
 PR
 XX 12-OCT-2001; 2001GB-0024575.
 PR
 XX 12-OCT-2001; 2001GB-0024594.
 XX
 XX (ISIS-) ISIS INNOVATIONS LTD.
 PA
 XX Cookson WOCM, Moffat MF, Allen M, Lench N;
 XX
 XX WPI; 2003-093132/08.
 DR
 XX New nucleic acid sequence comprising DPP10 mRNA, useful for the
 PT manufacture of a medicament for regulating DPP10 protein expression or
 PT for preventing or treating inflammatory disease e.g., inflammatory
 PT bowel disease -
 XX
 XX Example 2; Page 70; 321pp; English.
 PS
 XX The present invention describes a new isolated nucleic acid sequence (I)
 XX comprising a DPP10 mRNA sequence. DPP10 is a dipeptidyl peptidase (also
 CC known as prololigopeptidase). (I) has anti-inflammatory, antiasthmatic,
 CC antiproliferative, antitumor and antirheumatic activities, and can be
 CC used in vaccines and gene therapy. A composition comprising (I) can be
 CC used for the manufacture of a medicament for regulating DPP10 expression
 CC or for preventing or treating inflammatory disease e.g., inflammatory
 CC bowel disease, asthma, atopy, rheumatoid arthritis or psoriasis. (I) can
 CC also be used in an assay for detecting or measuring DPP10 in a sample.
 CC A host cell comprising (I) can be used for producing recombinant DPP10
 CC gene products, or in drug screening systems to identify agents for
 CC diagnosis or treatment of individuals having or susceptible to
 CC inflammatory disease. Human DPP10 is located on chromosome 2, more
 CC specifically chromosome 2q14. ABQ84254 to ABQ84612 and ABP55569 to
 CC ABP55629 represent sequences used in the exemplification of the present
 CC invention.
 XX
 XX Sequence 18 BP; 2 A; 7 C; 3 G; 6 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 935 TGGAGAGAGAGTGTGAGC 952
 Db 18 TGGAGAGAGAGTGTGAGC 1
 |||||
 RESULT 422
 ABZ10445/C
 ID ABZ10445 standard; DNA; 18 BP.
 XX
 XX ABZ10445;
 AC
 XX 16-JAN-2003 (first entry)
 DT
 XX Haematopoietic cell proliferation disorder related oligonucleotide #585.
 DE
 XX Human; haematopoietic cell proliferation disorder; cytostatic;
 KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
 KW cytosine methylation state; probe; primer; ss.
 XX
 XX Homo sapiens.
 OS Synthetic.

XX W0200277272-A2.
 PN
 XX 03-OCT-2002.
 PD
 XX
 XX 26-MAR-2002; 2002WO-EP03401.
 XX
 XX 26-MAR-2001; 2001US-278333P.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
 PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Iesche R, Leu E;
 PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
 PI Pelet C, Schwöpe I, Ziebarth H;
 XX
 XX WPI; 2003-018942/01.
 DR
 XX Detecting and differentiating between hematopoietic cell proliferative
 XX disorders, comprises contacting a target nucleic acid with a reagent
 PT that distinguishes between methylated and non-methylated CpG
 PT dinucleotides -
 PT
 XX Claim 15; SEQ ID 585; 117pp; English.
 PS
 XX The present invention describes a method for detecting and
 XX differentiating between haematopoietic cell proliferative disorders
 CC associated with at least 1 gene and/or their regulatory regions in a
 CC subject. The method comprises contacting a target nucleic acid in a
 CC biological sample obtained from the subject with at least 1 reagent,
 CC which distinguishes between methylated and non-methylated CpG
 CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
 CC represent specifically claimed nucleotide sequences from the present
 CC invention. Oligonucleotides from the present invention can be used for
 CC differentiating between healthy haematopoietic cells and proliferative
 CC disorder haematopoietic cells; for differentiating between acute
 CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
 CC determining the cytosine methylation state and/or single nucleotide
 CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
 CC related sequences and their complements; and as primers for the
 CC amplification of haematopoietic cell proliferation disorder related
 CC DNA sequences. The nucleotide sequences from the present invention can
 CC also be used for detecting a predisposition to, differentiation between
 CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
 CC haematopoietic cell proliferative disorders. The present method enables
 CC a highly specific classification of haematopoietic cell proliferative
 CC disorders allowing for improved and informed treatment of patients.
 XX
 XX Sequence 18 BP; 1 A; 1 C; 8 G; 8 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 24 AACCAAAACCCAGCTACGC 41
 Db 18 AACCAAAACCCAGCTACAC 1
 |||||
 RESULT 423
 ABZ10446/C
 ID ABZ10446 standard; DNA; 18 BP.
 XX
 XX ABZ10446;
 AC
 XX 16-JAN-2003 (first entry)
 DT
 XX Haematopoietic cell proliferation disorder related oligonucleotide #586.
 DE
 XX Human; haematopoietic cell proliferation disorder; cytostatic;
 KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
 KW cytosine methylation state; probe; primer; ss.
 XX
 XX Homo sapiens.
 OS Synthetic.

```

OS Homo sapiens.
OS Synthetic.
FN WO200277272-A2.
XX
XX 03-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-EP03401.
XX
XX 26-MAR-2001; 2001US-278333P.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
XX Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
XX Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
XX Pellet C, Schwöpe I, Ziebarth H;
XX WPI; 2003-018942/01.
XX
XX Detecting and differentiating between hematopoietic cell proliferative
XX disorders, comprises contacting a target nucleic acid with a reagent
XX that distinguishes between methylated and non-methylated CpG
XX dinucleotides -
XX
XX Claim 15; SEQ ID 586; 117pp; English.
XX
XX The present invention describes a method for detecting and
XX differentiating between hematopoietic cell proliferative disorders
XX associated with at least 1 gene and/or their regulatory regions in a
XX subject. The method comprises contacting a target nucleic acid in a
XX biological sample obtained from the subject with at least 1 reagent,
XX which distinguishes between methylated and non-methylated CpG
XX dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
XX represent specifically claimed nucleotide sequences from the present
XX invention. Oligonucleotides from the present invention can be used: for
XX differentiating between healthy hematopoietic cells and proliferative
XX disorder hematopoietic cells; for differentiating between acute
XX lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
XX determining the cytosine methylation state and/or single nucleotide
XX polymorphisms (SNPs) of hematopoietic cell proliferation disorder
XX related sequences and their complements; and as primers for the
XX amplification of hematopoietic cell proliferation disorder related
XX DNA sequences. The nucleotide sequences from the present invention can
XX also be used for detecting a predisposition to, differentiation between
XX subclasses, diagnosis, prognosis, treatment and/or monitoring of
XX hematopoietic cell proliferative disorders. The present method enables
XX a highly specific classification of hematopoietic cell proliferative
XX disorders allowing for improved and informed treatment of patients.
XX
XX Sequence 18 BP; 1 A; 0 C; 8 G; 9 T; 0 other;
XX
XX Query Match 1.0%; Score 13.2; DB 1; Length 18;
XX Best Local Similarity 83.3%; Pred. No. 2.5e+02;
XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 24 AACCAAAACCCAGCTACGC 41
XX |||||
XX 18 AACCAAAACCCAGCTACAC 1
XX
XX RESULT 424
XX ABZ11019/c
XX ID ABZ11019 standard; DNA; 18 BP.
XX
XX AC ABZ11019;
XX
XX 16-JAN-2003 (first entry)
XX
XX Haematopoietic cell proliferation disorder related oligonucleotide #1159.
XX
XX Human; haematopoietic cell proliferation disorder; cytostatic;
XX gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW

```

```

KW cytosine methylation state; probe; primer; ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX WO200277272-A2.
XX
XX 03-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-EP03401.
XX
XX 26-MAR-2001; 2001US-278333P.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
XX Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
XX Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
XX Pellet C, Schwöpe I, Ziebarth H;
XX WPI; 2003-018942/01.
XX
XX Detecting and differentiating between hematopoietic cell proliferative
XX disorders, comprises contacting a target nucleic acid with a reagent
XX that distinguishes between methylated and non-methylated CpG
XX dinucleotides -
XX
XX Claim 15; Page 44; 117pp; English.
XX
XX The present invention describes a method for detecting and
XX differentiating between hematopoietic cell proliferative disorders
XX associated with at least 1 gene and/or their regulatory regions in a
XX subject. The method comprises contacting a target nucleic acid in a
XX biological sample obtained from the subject with at least 1 reagent,
XX which distinguishes between methylated and non-methylated CpG
XX dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
XX represent specifically claimed nucleotide sequences from the present
XX invention. Oligonucleotides from the present invention can be used: for
XX differentiating between healthy hematopoietic cells and proliferative
XX disorder hematopoietic cells; for differentiating between acute
XX lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
XX determining the cytosine methylation state and/or single nucleotide
XX polymorphisms (SNPs) of hematopoietic cell proliferation disorder
XX related sequences and their complements; and as primers for the
XX amplification of hematopoietic cell proliferation disorder related
XX DNA sequences. The nucleotide sequences from the present invention can
XX also be used for detecting a predisposition to, differentiation between
XX subclasses, diagnosis, prognosis, treatment and/or monitoring of
XX hematopoietic cell proliferative disorders. The present method enables
XX a highly specific classification of hematopoietic cell proliferative
XX disorders allowing for improved and informed treatment of patients.
XX
XX Sequence 18 BP; 1 A; 1 C; 8 G; 8 T; 0 other;
XX
XX Query Match 1.0%; Score 13.2; DB 1; Length 18;
XX Best Local Similarity 83.3%; Pred. No. 2.5e+02;
XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 24 AACCAAAACCCAGCTACGC 41
XX |||||
XX 18 AACCAAAACCCAGCTACAC 1
XX
XX RESULT 425
XX ABZ11020/c
XX ID ABZ11020 standard; DNA; 18 BP.
XX
XX AC ABZ11020;
XX
XX 16-JAN-2003 (first entry)
XX
XX Haematopoietic cell proliferation disorder related oligonucleotide #1160.
XX

```


KW Human; haematopoietic cell proliferation disorder; cytostatic;
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW cytosine methylation state; probe; primer; ss.

OS Homo sapiens.
OS Synthetic.

PN WO200277272-A2.

XX 03-OCT-2002.

XX 26-MAR-2002; 2002WO-EP03401.

XX 26-MAR-2001; 2001US-278333P.

XX (EPIG-) EPIGENOMICS AG.

XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
PI Pelet C, Schwöpe I, Ziebarth H;

XX WPI; 2003-018942/01.

XX Detecting and differentiating between haematopoietic cell proliferative
XX disorders, comprises contacting a target nucleic acid with a reagent
XX that distinguishes between methylated and non-methylated CpG
XX dinucleotides -

XX Claim 15; Page 44; 117pp; English.

XX The present invention describes a method for detecting and
XX differentiating between haematopoietic cell proliferative disorders
XX associated with at least 1 gene and/or their regulatory regions in a
XX subject. The method comprises contacting a target nucleic acid in a
XX biological sample obtained from the subject with at least 1 reagent,
XX which distinguishes between methylated and non-methylated CpG
XX dinucleotides within the target nucleic acid. AB209861 to AB211118
XX represent specifically claimed nucleotide sequences from the present
XX invention. Oligonucleotides from the present invention can be used: for
XX differentiating between healthy haematopoietic cells and proliferative
XX disorder haematopoietic cells; for differentiating between acute
XX lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
XX determining the cytosine methylation state and/or single nucleotide
XX polymorphisms (SNPs) of haematopoietic cell proliferation disorder
XX related sequences and their complements; and as primers for the
XX amplification of haematopoietic cell proliferation disorder related
XX DNA sequences. The nucleotide sequences from the present invention can
XX also be used for detecting a predisposition to, differentiation between
XX subclasses, diagnosis, prognosis, treatment and/or monitoring of
XX haematopoietic cell proliferative disorders. The present method enables
XX a highly specific classification of haematopoietic cell proliferative
XX disorders allowing for improved and informed treatment of patients.

XX Sequence 18 BP; 1 A; 0 C; 8 G; 9 T; 0 other;

XX Query Match 1.0%; Score 13.2; DB 1; Length 18;
XX Best Local Similarity 83.3%; Pred. No. 2.5e+02;
XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 24 AACCAAAACCCAGCTACGC 41

Db 18 AACCAAAACCCAGCTACAC 1

RESULT 426

AB211021

ID AB211021 standard; DNA; 18 BP.

XX AC AB211021;

XX DT 16-JAN-2003 (first entry)

XX

DE Haematopoietic cell proliferation disorder related oligonucleotide #1161.
XX Human; haematopoietic cell proliferation disorder; cytostatic;
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW cytosine methylation state; probe; primer; ss.

OS Homo sapiens.

OS Synthetic.

PN WO200277272-A2.

XX 03-OCT-2002.

XX 26-MAR-2002; 2002WO-EP03401.

XX 26-MAR-2001; 2001US-278333P.

XX (EPIG-) EPIGENOMICS AG.

XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
PI Pelet C, Schwöpe I, Ziebarth H;

XX WPI; 2003-018942/01.

XX Detecting and differentiating between haematopoietic cell proliferative
XX disorders, comprises contacting a target nucleic acid with a reagent
XX that distinguishes between methylated and non-methylated CpG
XX dinucleotides -

XX Claim 15; Page 76; 117pp; English.

XX The present invention describes a method for detecting and
XX differentiating between haematopoietic cell proliferative disorders
XX associated with at least 1 gene and/or their regulatory regions in a
XX subject. The method comprises contacting a target nucleic acid in a
XX biological sample obtained from the subject with at least 1 reagent,
XX which distinguishes between methylated and non-methylated CpG
XX dinucleotides within the target nucleic acid. AB209861 to AB211118
XX represent specifically claimed nucleotide sequences from the present
XX invention. Oligonucleotides from the present invention can be used: for
XX differentiating between healthy haematopoietic cells and proliferative
XX disorder haematopoietic cells; for differentiating between acute
XX lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
XX determining the cytosine methylation state and/or single nucleotide
XX polymorphisms (SNPs) of haematopoietic cell proliferation disorder
XX related sequences and their complements; and as primers for the
XX amplification of haematopoietic cell proliferation disorder related
XX DNA sequences. The nucleotide sequences from the present invention can
XX also be used for detecting a predisposition to, differentiation between
XX subclasses, diagnosis, prognosis, treatment and/or monitoring of
XX haematopoietic cell proliferative disorders. The present method enables
XX a highly specific classification of haematopoietic cell proliferative
XX disorders allowing for improved and informed treatment of patients.

XX Sequence 18 BP; 8 A; 8 C; 1 G; 1 T; 0 other;

XX Query Match 1.0%; Score 13.2; DB 1; Length 18;
XX Best Local Similarity 83.3%; Pred. No. 2.5e+02;
XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 24 AACCAAAACCCAGCTACGC 41

Db 1 AACCAAAACCCAGCTACAC 18

RESULT 427

AB211022

ID AB211022 standard; DNA; 18 BP.

XX AC AB211022;

XX

```

DT 16-JAN-2003 (first entry)
DE Haematopoietic cell proliferation disorder related oligonucleotide #1162.
DE Human; haematopoietic cell proliferation disorder; cytostatic;
DE gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
DE cytosine methylation state; probe; primer; ss.
DE Homo sapiens.
DE OS Synthetic.
DE XX WO200277272-A2.
DE XX 03-OCT-2002.
DE XX 26-MAR-2002; 2002WO-EP03401.
DE XX 26-MAR-2001; 2001US-278333P.
DE XX (EPIG-) EPIGENOMICS AG.
DE Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
DE Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
DE Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
DE Pelet C, Schwobe I, Ziebarth H;
DE WPI; 2003-018942/01.
DE Detecting and differentiating between hematopoietic cell proliferative
DE disorders, comprises contacting a target nucleic acid with a reagent
DE PT that distinguishes between methylated and non-methylated CpG
DE PT dinucleotides -
DE XX Claim 15; Page 76; 117pp; English.
DE The present invention describes a method for detecting and
DE differentiating between haematopoietic cell proliferative disorders
DE associated with at least 1 gene and/or their regulatory regions in a
DE subject. The method comprises contacting a target nucleic acid in a
DE biological sample obtained from the subject with at least 1 reagent,
DE which distinguishes between methylated and non-methylated CpG
DE dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
DE represent specifically claimed nucleotide sequences from the present
DE invention. Oligonucleotides from the present invention can be used: for
DE differentiating between healthy haematopoietic cells and proliferative
DE disorder haematopoietic cells; for differentiating between acute
DE lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
DE determining the cytosine methylation state and/or single nucleotide
DE polymorphisms (SNPs) of haematopoietic cell proliferation disorder
DE related sequences and their complements; and as primers for the
DE amplification of haematopoietic cell proliferation disorder related
DE DNA sequences. The nucleotide sequences from the present invention can
DE also be used for detecting a predisposition to, differentiation between
DE subclasses, diagnosis, prognosis, treatment and/or monitoring of
DE haematopoietic cell proliferative disorders. The present method enables
DE a highly specific classification of haematopoietic cell proliferative
DE disorders allowing for improved and informed treatment of patients.
DE XX Sequence 18 BP; 9 A; 8 C; 0 G; 1 T; 0 other;
DE
DE Query Match 1.0%; Score 13.2; DB 1; Length 18;
DE Best Local Similarity 83.3%; Pred. No. 2.5e+02;
DE Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
DE
DE QY 24 AACCAACCAGCTACGC 41
DE Db 1 AACCAACCAGCTACAC 18
DE
DE RESULT 428
DE ABC89050/c
DE ID ABC89050 standard; DNA; 13 BP.
DE XX

```

```

AC ABC89050;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 89067 for detecting SNP TSC0022361.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX WO200177384-A2.
XX XX 18-OCT-2001.
XX XX 06-APR-2001; 2001WO-IB00713.
XX XX 07-APR-2000; 2000DE-1019173.
XX XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status -
XX PS Claim 1; SEQ ID 89067; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation.
XX ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX ABJ00010-ABJ99989 represent the oligomers described in the invention.
XX NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 13 BP; 12 A; 0 C; 1 G; 0 U; 0 other;
DE
DE Query Match 1.0%; Score 13; DB 1; Length 13;
DE Best Local Similarity 100.0%; Pred. No. 1.8e+02;
DE Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DE
DE QY 1144 TTTTCTCTTTT 1156
DE Db 13 TTTTCTCTTTT 1
DE
DE RESULT 429
DE ABC89051
DE ID ABC89051 standard; DNA; 13 BP.
DE XX
DE XX ABC89051;
DE XX 21-FEB-2002 (first entry)
DE XX
DE XX Oligonucleotide SEQ ID NO 89069 for detecting SNP TSC0022361.
DE XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
DE XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
DE XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
DE XX OS Homo sapiens.
DE XX XX WO200177384-A2.

```

```

XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status -
XX PS Claim 1; SEQ ID 89068; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.
XX CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX CC ABT00010-ABT82073 represent the oligomers described in the invention.
XX CC NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 13 BP; 0 A; 1 C; 0 G; 12 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTT 1156
Db 1 TTTTTCCTTTT 13

RESULT 430
ABC99986/c
ID ABC99986 standard; DNA; 13 BP.
XX AC ABC99986;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 100003 for detecting SNP TSC0024859.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX OS Homo sapiens.
XX DR WO200177384-A2.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single nucleotide polymorphisms and cytosine
methylation status -
Claim 1; SEQ ID 100003; 29pp + Sequence Listing; German.
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation.
ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
ABT00010-ABT82073 represent the oligomers described in the invention.
NOTE: The sequence data for this patent did not form part of the printed
specification, but was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences.

Query Match 1.0%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 187 CCCGCCGCCACC 199
Db 13 CCCGCCGCCACC 1

RESULT 431
ABC99987
ID ABC99987 standard; DNA; 13 BP.
XX AC ABC99987;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 100004 for detecting SNP TSC0024859.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX OS Homo sapiens.
XX DR WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single nucleotide polymorphisms and cytosine
methylation status -
Claim 1; SEQ ID 100004; 29pp + Sequence Listing; German.
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligomers are also used for detecting cell type differentiation.

```

```
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 1 A; 10 C; 2 G; 0 U; 0 other;

  Query Match      1.0%; Score 13; DB 1; Length 13;
  Best Local Similarity 100.0%; Pred. No. 1.8e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 187 CCGCGCGCCACC 199
Db 1 CCGCGCGCCACC 13

RESULT 432
ABF16196
ID ABF16196 standard; DNA; 13 BP.
XX
AC ABF16196;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 116193 for detecting SNP TSC0029109.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single nucleotide polymorphisms and cytosine
methylation status -
XX
Claim 1; SEQ ID 116193; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 other;

  Query Match      1.0%; Score 13; DB 1; Length 13;
  Best Local Similarity 100.0%; Pred. No. 1.8e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1186 TAGGTGAGTGTTG 1198
Db 1186 TAGGTGAGTGTTG 1198

RESULT 434
ABH17590/c
ID ABH17590 standard; DNA; 13 BP.
XX
AC ABH17590;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 217567 for detecting SNP TSC0052918.
```

```
Db 1 TAGGTGAGTGTTG 13

RESULT 433
ABF16197/c
ID ABF16197 standard; DNA; 13 BP.
XX
AC ABF16197;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 116194 for detecting SNP TSC0029109.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single nucleotide polymorphisms and cytosine
methylation status -
XX
Claim 1; SEQ ID 116194; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 other;

  Query Match      1.0%; Score 13; DB 1; Length 13;
  Best Local Similarity 100.0%; Pred. No. 1.8e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1186 TAGGTGAGTGTTG 1198
Db 13 TAGGTGAGTGTTG 1

RESULT 434
ABH17590/c
ID ABH17590 standard; DNA; 13 BP.
XX
AC ABH17590;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 217567 for detecting SNP TSC0052918.
```

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB00713.
 PF 07-APR-2000; 2000DE-1019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single nucleotide polymorphisms and cytosine
 XX methylation status -
 PT Claim 1; SEQ ID 217567; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABH00010-ABH82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;
 CC Query Match 1.0%; Score 13; DB 1; Length 13;
 CC Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 CC Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 314 CAACTCCATACCT 326
 DB 13 CAACTCCATACCT 1
 RESULT 435
 ABH17591
 ID ABH17591 standard; DNA; 13 BP.
 XX AC ABH17591;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 217568 for detecting SNP TSC0052918.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB00713.
 PF 07-APR-2000; 2000DE-1019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single nucleotide polymorphisms and cytosine
 XX methylation status -
 PT Claim 1; SEQ ID 218073; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABH00010-ABH82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;
 CC Query Match 1.0%; Score 13; DB 1; Length 13;
 CC Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 CC Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 314 CAACTCCATACCT 326
 DB 13 CAACTCCATACCT 1
 RESULT 435
 ABH17591
 ID ABH17591 standard; DNA; 13 BP.
 XX AC ABH17591;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 217568 for detecting SNP TSC0052918.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB00713.
 PF 07-APR-2000; 2000DE-1019173.
 PR (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single nucleotide polymorphisms and cytosine
 XX methylation status -
 PT Claim 1; SEQ ID 218073; 29pp + Sequence Listing; German.

PR 07-APR-2000; 2000DE-1019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single nucleotide polymorphisms and cytosine
 XX methylation status -
 PT Claim 1; SEQ ID 217568; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABH00010-ABH82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 other;
 CC Query Match 1.0%; Score 13; DB 1; Length 13;
 CC Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 CC Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 314 CAACTCCATACCT 326
 DB 1 CAACTCCATACCT 13
 RESULT 436
 ABH18096
 ID ABH18096 standard; DNA; 13 BP.
 XX AC ABH18096;
 XX 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 218073 for detecting SNP TSC0053025.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB00713.
 PR 07-APR-2000; 2000DE-1019173.
 PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single nucleotide polymorphisms and cytosine
 XX methylation status -
 PT Claim 1; SEQ ID 218073; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABT00010-ABT82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;
 SQ Query Match 1.0%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1184 TATAGTGCAGTGT 1196
 Db 1 TATAGTGCAGTGT 13

RESULT 437
 ABH18097/c
 ID ABH18097 standard; DNA; 13 BP.

XX AC ABH18097;
 XX 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 218074 for detecting SNP TSC0053025.
 XX SNp, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal, respiratory; immune; metabolic.
 XX Homo sapiens.

XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB00713.
 XX 07-APR-2000; 2000DE-1019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status

XX Claim 1; SEQ ID 218074; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABT00010-ABT82073 represent the oligomers described in the invention.

XX NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1184 TATAGTGCAGTGT 1196
 Db 13 TATAGTGCAGTGT 1

RESULT 438
 AAV92063
 ID AAV92063 standard; RNA; 14 BP.

XX AC AAV92063;
 XX 18-FEB-1999 (first entry)
 XX DE Human C-raf target sequence nucleotide position 2567.
 XX Human; C-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KW target; substrate; catalyst; modulation; expression; Raf gene;
 KW delivery; screening; identification; synthesis; deprotection;
 KW purification; cancer; inflammation; psoriasis; non-hepatic ascites;
 KW infection; genetic drift; restenosis; rheumatoid arthritis; ss.

XX OS Homo sapiens.
 XX WO9850530-A2.
 XX 12-NOV-1998.

XX 05-MAY-1998; 98WO-US09249.
 XX 19-DEC-1997; 97US-0068212.
 XX 09-MAY-1997; 97US-0046059.
 XX 09-JUN-1997; 97US-0049002.
 XX 03-JUL-1997; 97US-0051718.
 XX 22-AUG-1997; 97US-0056808.
 XX 02-OCT-1997; 97US-0061321.
 XX 02-OCT-1997; 97US-0061324.
 XX 05-NOV-1997; 97US-0064866.
 XX (RIBO-) RIBOZYME PHARM INC.

XX Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T;
 PI Karpeisky A, Kisich K, Matulic-Adamic J, McSwiggen JA;
 PI Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;
 XX WPI; 1999-009494/01.

XX Identifying new catalytic nucleic acid that modulates selected
 PT processes - especially ribozymes that cleave Raf RNA for treating
 PT cancer, restenosis, and also new ribozymes and modified nucleoside
 PT triphosphates used as antiviral agents and synthons

XX Claim 179; Page 156; 259pp; English.

XX A method has been developed for the identification of a nucleic acid
 CC capable of modulating a process in a biological system. The method
 CC comprises: (a) introducing into the system a random library of nucleic
 CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 CC in systems where modulation has occurred and/or determining the sequence
 CC of at least part of the SBDs in such systems. Nucleic acid molecules
 CC with endonuclease activity and catalytic activity, from the present
 CC invention, are used to modulate gene expression in plant and mammalian
 CC cells and to cleave target nucleic acid, particularly for treating
 CC systemic diseases caused by specific RNA, e.g. cancer, inflammation,
 CC psoriasis, non-hepatic ascites and infection. They may also be used to
 CC detect genetic drift and mutations in diseased cells and to determine

CC c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
 CC expression of the Raf gene. are used to treat cancer, restenosis,
 CC psoriasis or rheumatoid arthritis, or generally any condition associated
 CC with the level of c-raf. introduction of sugar/phosphate modifications
 CC increases stability against nuclease and activity. AAV90922 to AAV93877
 CC represent NACs that can be used in the method, specifically for
 CC modulating the expression of a Raf gene.

XX Sequence 14 BP; 3 A; 4 C; 5 G; 2 U; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 2e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 480 GGACTGCCGAGAC 492

Db 1 GGACUGCCGAGAC 13

RESULT 439

AAT55016

ID AAT55016 standard; RNA; 15 BP.

XX AAT55016;

XX 25-MAR-2003 (updated)

DT 18-APR-1997 (first entry)

XX Human relA hammerhead ribozyme target sequence (nt. position 585).
 DE Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW translocation; chronic myelogenous leukaemia; CML; cancer;
 KW Philadelphia chromosome; inflammation; autoimmune disease;
 KW atherosclerosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome;
 KW AIDS; ss.

OS Homo sapiens.

XX WO9523225-A2.

XX 31-AUG-1995.

XX 23-FEB-1995; 95WO-IB00156.

XX 30-JAN-1995; 95US-0380734.

XX 23-FEB-1994; 94US-0201109.

XX 29-MAR-1994; 94US-0218934.

XX 04-APR-1994; 94US-0222795.

XX 07-APR-1994; 94US-0224483.

XX 15-APR-1994; 94US-0227958.

XX 15-APR-1994; 94US-0228041.

XX 18-MAY-1994; 94US-0245736.

XX 06-JUL-1994; 94US-0271280.

XX 15-AUG-1994; 94US-0291932.

XX 16-AUG-1994; 94US-0291433.

XX 17-AUG-1994; 94US-0293620.

XX 19-AUG-1994; 94US-0293520.

XX 02-SEP-1994; 94US-0300000.

XX 23-SEP-1994; 94US-0311749.

XX 28-SEP-1994; 94US-0314397.

XX 03-OCT-1994; 94US-0316771.

XX 07-OCT-1994; 94US-0319492.

XX 11-OCT-1994; 94US-0321993.

XX 04-NOV-1994; 94US-0334847.

XX 10-NOV-1994; 94US-0337608.

PR 28-NOV-1994; 94US-0345516.
 PR 16-DEC-1994; 94US-0357577.
 PR 23-DEC-1994; 94US-0363233.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
 PI Grimm S, Karpeisky A, Kisich K, Matulic-adamic J, Mcswiggen JA;
 PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D;
 PI Thompson JD, Tracz D, Usman N, Wincott FE, Woolf T;
 XX WPI; 1995-351090/45.
 DR Ribozymes having modified bases and methods for producing them -
 PT for use in inhibiting disease related genes
 XX Claim 2; Page 228; 407pp; English.

XX The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves rela
 CC mRNA at the nucleotide base position indicated in the DE line.
 CC The rela gene product is a subunit of the transcriptional
 CC regulator NF-kappaB and is implicated specifically in the induction
 CC of inflammatory responses. Regions of the mRNA that do not form
 CC secondary folding structures and that contain potential hammerhead
 CC analysis. Ribozymes directed against these mRNA sequences were
 CC designed and synthesised with modifications that improve their
 CC nuclease resistance. The ribozymes are designed to cleave the
 CC target sequences and thereby inhibit rela expression, making them
 CC potentially useful for treating rheumatoid arthritis, restenosis
 CC and asthma as well as for increasing tolerance to transplanted
 CC tissues. The potential immunosuppressive properties of a ribozyme
 CC that cleaves rela mRNA means that uses are limited to local
 CC delivery, acute indications or ex vivo treatment.
 CC (Updated on 25-MAR-2003 to correct PI field.)

XX Sequence 15 BP; 4 A; 5 C; 5 G; 1 U; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.1e+02;

Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1066 CCCATCAGGCAGG 1078

Db 3 CCCAUCAGGCAGG 15

RESULT 440

AAC73458/C

ID AAC73458 standard; DNA; 15 BP.

XX AAC73458;

XX 02-FEB-2001 (first entry)

XX Reverse primer #97 used in multiplexing PCR/SBE assay.

XX Oligonucleotide array; genotyping; single base extension reaction; SBE;

XX PCR primer; polymorphic locus; single nucleotide polymorphism; ss.

XX Unidentified.

XX WO200058516-A2.

XX 05-OCT-2000.

XX 27-MAR-2000; 2000WO-US08069.

XX 26-MAR-1999; 99US-0126473.

XX 23-JUN-1999; 99US-0140359.

XX (WHED) WHITEHEAD INST BIOMEDICAL RES.

CC	sclerotic disease, kidney disease, hyperproliferation of the inside of
CC	blood vessels or any other hyperplasia.
XX	
SQ	Sequence 15 BP; 4 A; 2 C; 6 G; 3 T; 0 other;
Query Match 1.0%; Score 13; DB 1; Length 15;	
Best Local Similarity 100.0%; Pred. No. 2.1e+02;	
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	160 CGCTGATCCTCAA 172
Db	15 CGCTGATCCTCAA 3
RESULT 443	
AAF51702/c	
ID	AAF51702 standard; DNA; 15 BP.
XX	
AC	AAF51702;
XX	
DT	30-MAR-2001 (first entry)
XX	
DE	IGF-I oligonucleotide #2662.
XX	
KW	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW	cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW	skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW	IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW	growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW	keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW	hyperneovascular condition; hyperplasia; kidney disease;
KW	neovascular condition of the retina; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200078341-A1.
XX	
PD	28-DEC-2000.
XX	
PF	21-JUN-2000; 2000WO-AU00693.
XX	
PR	21-JUN-1999; 99US-0140345.
XX	
FA	(MURD-) MURDOCH CHILDRENS RES INST.
XX	
PI	Wright CJ, Werther GA, Edmondson SR;
XX	
DR	WPI; 2001-041421/05.
XX	
PT	Ameliorating the effects of a disorder, e.g. psoriasis, by
PT	administering UV (ultra-violet) treatment (optional) and an antisense
PT	nucleic acid that inhibits or reduces growth factor mediated cell
PT	proliferation and/or inflammation -
XX	
PS	Example 8; Page 78; 201pp; English.
XX	
CC	The present invention relates to a method for ameliorating the effects
CC	of skin disorders. The method comprises contacting the skin with an
CC	antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC	receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC	inhibiting or reducing growth factor mediated cell proliferation,
CC	inflammation and/or other disorders. The present sequence is an
CC	oligonucleotide which can be used to design the antisense
CC	oligonucleotides of the present invention (see AAF5151 and
CC	AAF5153-F45161). The method is useful for ameliorating the effects of
CC	psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
CC	keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC	skin, a hyperneovascular condition such as a neovascular condition of the
CC	retina, brain or skin, growth factor-mediated malignancies, other
CC	sclerotic disease, kidney disease, hyperproliferation of the inside of
CC	blood vessels or any other hyperplasia.
XX	
SQ	Sequence 15 BP; 4 A; 2 C; 6 G; 3 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 15;	
Best Local Similarity 100.0%; Pred. No. 2.1e+02;	
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	160 CGCTGATCCTCAA 172
Db	14 CGCTGATCCTCAA 2
RESULT 444	
ABK98166	
ID	ABK98166 standard; DNA; 15 BP.
XX	
AC	ABK98166;
XX	
DT	07-OCT-2002 (first entry)
XX	
DE	Triple helix forming associated oligonucleotide #36.
XX	
KW	Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW	gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW	pathogenic bacteria; virus; replication; virulence; cancer;
KW	oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX	
OS	Synthetic.
XX	
PN	US6403302-B1.
XX	
PD	11-JUN-2002.
XX	
PF	16-DEC-1993; 93US-0168920.
XX	
PR	17-SEP-1992; 92US-0946976.
XX	
FA	(CALY) CALIFORNIA INST OF TECHNOLOGY.
XX	
PI	Dervan PB, Beal PA;
XX	
DR	WPI; 2002-536030/57.
XX	
PT	A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT	oligonucleotide which binds in parallel and antiparallel orientation,
PT	respectively, for targeting sequences on alternate strands of DHNA to
PT	control gene expression -
XX	
PS	Example 6; Fig 20A; 108pp; English.
XX	
CC	The present invention relates to methods and oligonucleotides for
CC	forming a triple-helix comprising a double helical nucleic acid
CC	comprising first and second substantially complementary strands, and
CC	an oligonucleotide bound to a purine-rich target sequence within the
CC	double helical nucleic acid, where the oligonucleotide binds in a
CC	parallel and antiparallel orientation, respectively, to target
CC	sequences on alternate strands of the double helical nucleic acid.
CC	The method has therapeutic applications, where gene expression is
CC	controlled by selective triple-helix formation within expression
CC	regulatory sequences of a target gene. The oligonucleotides can be
CC	used to form triple-helices, and are useful to detect the presence or
CC	absence of specific sequences within genomic DNA for diagnostic and
CC	therapeutic purposes. The oligonucleotides can be selected to
CC	specifically bind to pathogenic double-stranded DNA including specific
CC	sequences required by pathogenic bacteria or viruses for replication or
CC	virulence, reducing their pathogenicity. Alternatively, the
CC	oligonucleotide can be chosen to target a unique sequence of the
CC	pathogen which is not found in the genome of pathogen's host. The
CC	oligonucleotides can be used in cancer treatment by way of triple-helix
CC	suppression of specific oncogenes including those of endogenous or
CC	viral origin. Such therapeutic oligonucleotides are capable of forming
CC	triple-helices with such sequences in cancerous cells containing the
CC	activated oncogene, so preferentially killing or repressing the cancer
CC	causing cell. The present sequence represents an oligonucleotide
CC	used in the methods of the present invention.

XX SQ Sequence 15 BP; 0 A; 1 C; 0 G; 14 T; 0 other;
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1144 TTTTTCCTTTT 1156
 |||||
 Db 1 TTTTTCCTTTT 13

RESULT 445
 ABK98185
 ID ABK98185 standard; DNA; 15 BP.
 XX AC ABK98185;
 DT 07-OCT-2002 (first entry)
 XX Triple helix forming associated oligonucleotide #49.
 DE Triple-helix formation; purine-rich target sequence; double-helix DNA;
 XX gene expression; regulatory sequence; pathogenic double-stranded DNA;
 KW pathogenic bacteria; virus; replication; virulence; cancer;
 KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
 XX OS Synthetic.
 XX US6403302-B1.
 FN 11-JUN-2002.
 XX 16-DEC-1993; 93US-0169920.
 XX 17-SEP-1992; 92US-0946976.
 PR (CALY) CALIFORNIA INST OF TECHNOLOGY.
 PA Dervan PB, Beal PA;
 PI WPI; 2002-536030/57.
 DR A triple-helix comprising a double helical nucleic acid (DHNA) and an
 XX oligonucleotide which binds in parallel and antiparallel orientation,
 PT respectively, for targeting sequences on alternate strands of DNA to
 PT control gene expression -
 XX Example 7; Fig 24A; 108pp; English.

XX The present invention relates to methods and oligonucleotides for
 CC forming a triple-helix comprising a double helical nucleic acid
 CC comprising first and second substantially complementary strands, and
 CC an oligonucleotide bound to a purine-rich target sequence within the
 CC double helical nucleic acid, where the oligonucleotide binds in a
 CC parallel and antiparallel orientation, respectively, to target
 CC sequences on alternate strands of the double helical nucleic acid.
 CC The method has therapeutic applications, where gene expression is
 CC controlled by selective triple-helix formation within expression
 CC regulatory sequences of a target gene. The oligonucleotides can be
 CC used to form triple-helices, and are useful to detect the presence or
 CC absence of specific sequences within genomic DNA for diagnostic and
 CC therapeutic purposes. The oligonucleotides can be selected to
 CC specifically bind to pathogenic double-stranded DNA including specific
 CC sequences required by pathogenic bacteria or viruses for replication or
 CC virulence, reducing their pathogenicity. Alternatively, the
 CC oligonucleotide can be chosen to target a unique sequence of the
 CC pathogen which is not found in the genome of pathogen's host. The
 CC oligonucleotides can be used in cancer treatment by way of triple-helix
 CC suppression of specific oncogenes including those of endogenous or
 CC viral origin. Such therapeutic oligonucleotides are capable of forming
 CC triple-helices with such sequences in cancerous cells containing the
 CC activated oncogene, so preferentially killing or repressing the cancer

CC causing cell. The present sequence represents an oligonucleotide
 CC used in the methods of the present invention.
 XX SQ Sequence 15 BP; 0 A; 1 C; 0 G; 14 T; 0 other;
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1144 TTTTTCCTTTT 1156
 |||||
 Db 1 TTTTTCCTTTT 13

RESULT 446
 ABK95944/C
 ID ABK95944 standard; DNA; 15 BP.
 XX AC ABK95944;
 DT 24-SEP-2002 (first entry)
 XX Human LIPE gene polymorphism detection ASO probe #6.
 DE Human; lipase; hormone sensitive; LIPE; isogene; obesity; ss;
 KW male sterility; polymorphism; allele-specific oligonucleotide; ASO.
 XX OS Homo sapiens.
 XX WO200240502-A2.
 FN 23-MAY-2002.
 XX 16-NOV-2001; 2001WO-US43518.
 XX 16-NOV-2000; 2000US-249302P.
 PR (GENA-) GENAISSANCE PHARM INC.
 PA Anastasio AE, Bentivegna SC, Chew A, Koshy B, Rounds E;
 PI WPI; 2002-519369/55.
 DR Novel genetic variants of Lipase, Hormone-Sensitive isogenes, useful
 XX for improving efficiency and reliability in drug development for
 PT treating diseases associated with LIPE activity, e.g. obesity and male
 PT sterility -
 XX Claim 15; Page 14; 142pp; English.

XX The present invention relates to a new polynucleotide comprising a
 CC nucleotide sequence which comprises lipase, hormone sensitive (LIPE)
 CC isogenes. The invention is useful in screening for drugs targeting LIPE
 CC isogenes that are useful for treating obesity and male sterility. The
 CC methods of the invention are useful for improving the efficiency and
 CC reliability of several steps in the discovery and development of drugs
 CC for treating diseases associated with LIPE activity. The polynucleotide
 CC is useful in studying the expression and function of LIPE, and in
 CC expressing LIPE protein for use in screening for candidate drugs to treat
 CC diseases related to LIPE activity. It is also useful in studying the
 CC effect of the variation on the biological activity of LIPE as well as on
 CC the binding affinity of candidate drugs targeting LIPE for the treatment
 CC of obesity and male sterility. The invention is useful for studying the
 CC expression of LIPE isogenes in vivo, for in vivo screening and testing of
 CC drugs targeted against LIPE protein, and for testing the efficacy of
 CC therapeutic agents and compounds for treating obesity and male sterility
 CC in a biological system. The present nucleic acid sequence represents one
 CC of a collection (ABK95939-ABK95967) of allele-specific oligonucleotide
 CC (ASO) probes that were used in the invention to detect polymorphisms in
 CC the human LIPE gene.
 XX Sequence 15 BP; 5 A; 4 C; 1 G; 4 T; 1 other;

Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 440 GAAAGTTGCTGAAGT 454
Db 15 GATAGTTCGAGT 1

RESULT 447

ABK81414
ID ABR81414 standard; DNA; 15 BP.
AC ABR81414;
DT 13-AUG-2002 (first entry)
XX
XX SCYA20 allele specific oligonucleotide probe #3.

XX Small inducible cytokine subfamily A (Cys-Cys) member 20; SCYA20;
XX polymorphism; haplotype; psoriasis; gene expression; ASO;
XX allele specific oligonucleotide; probe; ss.

XX Homo sapiens.
XX WO200232927-A2.
XX
XX

PD 25-APR-2002.

XX 19-OCT-2001; 2001WO-US46093.

XX 19-OCT-2000; 2000US-241725P.

XX (GENA-) GENAISSANCE PHARM INC.

XX Bieglecki KM, Chew A, Russo DP, Sausker EA;

XX WPI; 2002-435525/46.

XX New genetic variants comprising haplotypes of the small inducible
XX cytokine subfamily A, member 20 (SCYA20) gene, useful in improving the
XX efficiency drug screening protocols for compounds (e.g. antipsoriatic
XX drug) targeting SCYA20 -

XX Claim 14; Page 13; 62pp; English.

XX The invention describes an isolated polynucleotide, which comprises genes
XX and haplotypes of the small inducible cytokine subfamily A (Cys-Cys),
XX member 20 (SCYA20) gene. The polynucleotide comprises polymorphic sites
XX referred to as P81-9 to designate the order in which they are located in
XX the gene. The polymorphisms and haplotypes of SCYA20 gene are useful for
XX validating whether SCYA20 is a suitable target for drugs to treat
XX psoriasis and disorders associated with its abnormal expression or
XX function, screening for such drugs and reducing bias in clinical trials
XX of such drugs. Haplotype information would be useful in improving the
XX efficiency and output of several steps in the drug discovery and
XX development process, including target validation, identifying lead
XX compounds, early phase clinical trials. The methods are useful in
XX screening for compounds targeting SCYA20 to treat a specific condition
XX or disease predicted to be associated with SCYA20 activity, e.g.
XX psoriasis. This sequence represents an allele specific oligonucleotide
XX (ASO) probe used to identify polymorphisms in the SCYA20 gene.

SQ Sequence 15 BP; 2 A; 7 C; 1 G; 4 T; 1 other;

Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1199 GACCTTCACACCTCC 1213
Db 1 GACCTTCACACCTTC 15

RESULT 448

ABL52099
ID ABL52099 standard; DNA; 15 BP.

XX ABL52099;

XX 12-JUL-2002 (first entry)

XX Human PER1 allele specific oligonucleotide probe SEQ ID NO:24.

XX Human; period (Drosophila) homologue 1; PER1; polymorphic variant;
XX polymorphic site; genotyping; haplotyping; circadian rhythm regulation;
XX single nucleotide polymorphism; SNP; gene; probe; ss.

XX Homo sapiens.

XX Key Location/Qualifiers
XX misc_feature 8

XX /*tag= a
XX /note= "polymorphic site indicated by an ambiguity base"

XX WO200222650-A2.

XX 21-MAR-2002.

XX 13-SEP-2001; 2001WO-US28780.

XX 13-SEP-2000; 2000US-232468P.

XX (GENA-) GENAISSANCE PHARM INC.

XX Duda A, Kliem SE, Koshy B;

XX WPI; 2002-393941/42.

XX Novel isolated human period Drosophila homolog 1 polynucleotide, useful
XX for therapeutic purposes, for studying the expression and function of
XX the polynucleotide, and for expressing the homolog -

XX Claim 17; Page 14; 162pp; English.

XX The present invention describes an isolated human period (Drosophila)
XX homologue 1, (PER1) polynucleotide (I) comprising a sequence which is a
XX polymorphic variant for a reference sequence (ABL52077) for the PER1 gene
XX or its fragment, or a polymorphic variant of a reference sequence
XX (ABL52078) for a PER1 cDNA or its fragment. The present invention also
XX describes methods for genotyping and haplotyping the PER1 gene of an
XX individual. (I) is useful in studying the expression and function of
XX PER1, and in expressing PER1 protein for use in screening for candidate
XX drugs to treat diseases related to PER1 activity. (I) is useful for
XX therapeutic purposes. A recombinant non-human organism transformed or
XX transduced with (I) can be used for studying expression of the PER1
XX isogenes in vivo, for in vivo screening and testing of drugs targeted
XX against PER1 protein, and for testing the efficacy of therapeutic agents
XX and compounds for disorders associated with circadian rhythm regulation.
XX The present sequence represents an allele specific oligonucleotide probe
XX for human PER1, which is used in the exemplification of the present
XX invention.

SQ Sequence 15 BP; 2 A; 5 C; 4 G; 3 T; 1 other;

Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 287 CAGCAGCAATCTCTG 301
Db 1 CAGCAGCCTCTCTG 15

RESULT 449

ABK67885/c

ID ABK67885 standard; DNA; 15 BP.
 AC ABK67885;
 XX
 XX
 DT 02-JUL-2002 (first entry)
 XX
 XX
 DE Human ADH7 gene allele-specific oligonucleotide probe #12.
 XX
 XX
 KW Human; alcohol dehydrogenase 7 class IV; ADH7; probe; ss; haplotype pair;
 KW haplotyping; cytostatic; antiparkinsonian; sigma polypeptide; cancer;
 KW single nucleotide polymorphism; genotyping; gene therapy; drug screening;
 KW mu polypeptide; Parkinson's disease; chromosome 4q23-q24.
 XX
 OS Homo sapiens.
 XX
 XX WO200224958-A1.
 PN
 XX
 PD 28-MAR-2002.
 XX
 XX
 PF 19-SEP-2001; 2001WO-US29508.
 XX
 XX
 PR 19-SEP-2000; 2000US-233520P.
 XX
 XX (GENA-) GENAISANCE PHARM INC.
 PA
 XX Bieglecki KM, Finkel K, Kazemi A, Koshy B, Parks KE, Sausker EA;
 PI
 XX WPI; 2002-352009/38.
 DR
 XX
 XX
 PT New genetic variants of the alcohol dehydrogenase 7 (class IV) mu or
 PT sigma polypeptide (ADH7) gene having polymorphisms, useful for treating
 PT disorders affected by ADH7 isogene expression or function, e.g. cancer
 PT or Parkinson's disease
 XX
 PS Claim 16; Page 13; 113pp; English.
 XX
 CC The invention relates to single nucleotide polymorphisms in the gene
 CC encoding human alcohol dehydrogenase 7 (class IV), mu or sigma
 CC polypeptide (ADH7). A method for haplotyping the ADH7 gene in an
 CC individual comprises identifying the nucleotide at one or more
 CC polymorphic sites and determining whether one of the copies of the gene
 CC is defined by one of the ADH7 haplotypes given in the specification or
 CC whether both copies are defined by a haplotype pair. This method is
 CC useful in genotyping, whereby all possible haplotype pairs can be
 CC assigned to specific genotypes. An association between a trait and a
 CC haplotype or haplotype pair of the ADH7 gene can be identified by
 CC comparing the frequency of the ADH7 gene in a population exhibiting
 CC the trait with the frequency of the haplotype pair in a
 CC population exhibiting the trait with the frequency of the haplotype or
 CC haplotype pair in a reference population, where a higher haplotype
 CC frequency in the trait population indicates the trait is associated with
 CC the haplotype or haplotype pair. ADH7 and its corresponding DNA are used
 CC for studying the expression and function of ADH7, and in screening for
 CC candidate drugs to treat diseases related to ADH7 activity, such as
 CC cancer and Parkinson's disease. Sequences ABK67874-ABK67888 represent
 CC allele-specific oligonucleotide probes used for detecting ADH7 gene
 CC polymorphisms.
 XX
 SQ Sequence 15 BP; 2 A; 3 C; 6 G; 3 T; 1 other;
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 2.1e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1052 ACAGCCCTGGCCTTC 1066
 ||||| : |||||
 Db 15 ACAGCCAYGGCTTC 1
 RESULT 450
 ABA97405
 ID ABA97405 standard; DNA; 15 BP.
 XX
 XX ABA97405;
 AC

XX
 DT 18-JUN-2002 (first entry)
 XX
 XX Nucleotide sequence of oligomer # 12 used to compare mismatches.
 DE
 XX
 KW Protein nucleic acid molecule; PNA; ds.
 XX
 XX Synthetic.
 OS
 XX WO200168673-A1.
 PN
 XX 20-SEP-2001.
 PD
 XX
 PF 13-MAR-2001; 2001WO-US08111.
 XX
 XX 14-MAR-2000; 2000US-189190P.
 PR
 XX 30-NOV-2000; 2000US-250334P.
 XX
 XX (ACTI-) ACTIVE MOTIF.
 PA
 XX Efimov V, Fernandez J, Archdeacon D, Archdeacon J;
 PI Chakhmakheau O, Buryakova A, Choob M, Hondorp K;
 PI
 XX WPI; 2002-041177/05.
 DR
 XX
 XX Oligonucleotides analogues useful in detection, separation and
 PT purification of nucleic acid molecules, comprise monomers, dimers and
 PT oligomers -
 XX
 XX Example 20; Page 123; 197pp; English.
 PS
 CC This invention relates to oligonucleotide analogues comprising a protein
 CC nucleic acid molecule (PNA) monomer. They are used in the detection and
 CC separation of nucleic acid molecules and as probes, primers, linkers,
 CC adaptors and antisense agents on solid supports. Modifications enhance
 CC their use as capture and detection probes e.g. by the incorporation of
 CC biotin, digoxigenin, radioisotopes, fluorescent labels such as
 CC fluorescein and reporter molecules such as alkaline phosphatase.
 CC They are also used for enhancing or inhibiting the activity of an enzyme
 CC or cellular activity. The compounds are stable to nucleases and
 CC proteases, have high affinity, binding specificity and solubility. The
 CC polyamide backbone of PNAs is resistant to both nucleases and proteases.
 CC PNAs bind nucleic acid molecules with greater affinity than DNA or RNA
 CC concentration. The compounds are relatively simple to synthesize and
 CC are used in a wide variety of applications. This sequence
 CC represents a DNA oligomer which is used to represent the effect of
 CC single base mismatches on oligonucleotides.
 XX
 SQ Sequence 15 BP; 0 A; 1 C; 0 G; 14 T; 0 other;
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1144 TTTTTCCTTTT 1156
 ||||| : |||||
 Db 1 TTTTTCCTTTT 13
 RESULT 451
 ABK64023
 ID ABK64023 standard; DNA; 15 BP.
 XX
 XX AC ABK64023;
 AC
 XX 18-JUN-2002 (first entry)
 DT
 XX
 XX Human BF gene allele-specific oligonucleotide sequencing primer #30.
 DE
 XX Human; B-factor; properdin; BF; primer; ss; gene therapy; drug screening;
 KW antidiabetic; dermatological; diabetes; immunosuppressive;
 KW antiinflammatory; systemic lupus erythematosus.
 XX

```
OS Homo sapiens.
PN WO200218414-A2.
XX
XX 07-MAR-2002.
ED
XX 29-AUG-2001; 2001WO-US27098.
XX PF
XX 29-AUG-2000; 2000US-228940P.
XX PR
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
XX Anastasio AE, Finkel K, Kazemi A, Koshy B;
XX WPI; 2002-304244/34.
XX
XX New genetic variants having polymorphisms in the B-Factor, Properdin
XX (BF) gene, useful for studying the function of BF, and for treating
XX disorders affected by expression or function of the BF isogene -
XX
XX Claim 17; Page 16; 151pp; English.
XX
XX The invention relates to single nucleotide polymorphisms in the gene
XX encoding the human B-factor properdin protein (BF). A method for
XX haplotyping the BF gene in an individual comprises identifying the
XX nucleotide at one or more polymorphic sites and determining whether one
XX of the copies of the gene is defined by one of the BF haplotypes given in
XX the specification or whether both copies are defined by a haplotype pair.
XX This method is useful in genotyping, whereby all possible haplotype pairs
XX can be assigned to specific genotypes. An association between a trait and
XX a haplotype or haplotype pair of the BF gene can be identified by
XX comparing the frequency of the haplotype or haplotype pair in a
XX population exhibiting the trait with the frequency of the haplotype or
XX haplotype pair in a reference population, where a higher haplotype
XX frequency in the trait population indicates the trait is associated with
XX the haplotype or haplotype pair. BF and its corresponding DNA are used
XX for studying the expression and function of BF, for use in screening for
XX candidate drugs to treat diseases related to BF activity, such as
XX diabetes and systemic lupus erythematosus. Sequences ABK63994-ABK64049
XX represent allele-specific sequencing primers used to detect human BF gene
XX polymorphisms.
XX
XX Sequence 15 BP; 3 A; 3 C; 8 G; 0 U; 1 other;
SQ Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Oy 129 GGGACAGGGAGCGCC 143
Db 1 GGGACAGGGAGGCYC 15
RESULT 452
AAS19628
ID AAS19628 standard; DNA; 15 BP.
XX
XX AAS19628;
AC
XX
XX 26-MAR-2002 (first entry)
DT
XX
XX ASO primer #7 to detect human GHRHR gene polymorphisms.
DE
XX
XX Human; single nucleotide polymorphism; SNP; GHRHR; chromosome 7p14;
XX growth hormone releasing hormone receptor; haplotyping; genotyping;
XX isolated growth hormone deficiency; IGHD; pituitary adenoma; ASO;
XX allele-specific oligonucleotide; primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200179239-A2.
PN
XX
XX 25-OCT-2001.
PD
```

```
XX
XX 17-APR-2001; 2001WO-US12453.
XX PF
XX 17-APR-2000; 2000US-197978P.
XX PR
XX (GENA-) GENAISSANCE PHARM INC.
XX PA
XX
XX Chew A, Choi JY, Denton RR, Nandabalan K, Sausker EA;
XX WPI; 2002-066342/09.
XX
XX Genotyping human Growth hormone releasing hormone receptor gene of
XX individual for determining haplotype of individual by determining
XX identity of nucleotide pair at specific polymorphic sites for two
XX copies of gene -
XX
XX Claim 16; Page 14; 90pp; English.
XX
XX The present invention relates to novel single nucleotide polymorphisms
XX (SNPs) in the human growth hormone releasing hormone receptor (GHRHR)
XX gene located on chromosome 7p14, and methods for haplotyping and/or
XX genotyping the GHRHR gene. The methods of the invention make use of
XX allele-specific oligonucleotides (ASOs) as probes and primers and/or
XX primer-extensions oligonucleotides for detecting the GHRHR gene
XX polymorphisms. The polynucleotides and screened compounds are useful
XX for the treatment of diseases associated with GHRHR activity, such as
XX isolated growth hormone deficiency (IGHD) and pituitary adenomas.
XX AAS19622-AAS19647 represent ASO primers for detecting human GHRHR
XX gene polymorphisms.
XX
XX Sequence 15 BP; 7 A; 2 C; 5 G; 0 U; 1 other;
SQ Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Oy 1158 GAAGTAAAGCAGCTA 1172
Db 1 GAAGTAAAGCAGCTA 15
RESULT 453
AAS98667/C
ID AAS98667 standard; DNA; 15 BP.
XX
XX AAS98667;
AC
XX
XX 26-MAR-2002 (first entry)
DT
XX
XX Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #33.
XX
XX Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;
XX cytostatic; gene therapy; malignant histiocytosis; isogene;
XX myeloid malignancy; inflammatory disorder; transgenic animal;
XX haplotype; genotype; human; allele specific oligonucleotide; ASO;
XX probe; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200179225-A2.
PN
XX
XX 25-OCT-2001.
PD
XX
XX 12-APR-2001; 2001WO-US12044.
XX PF
XX 12-APR-2000; 2000US-196411P.
XX PR
XX (GENA-) GENAISSANCE PHARM INC.
XX PA
XX
XX Chew A, Choi JY, Koshy B;
XX WPI; 2002-075058/10.
XX
XX
```


XX Predicting nucleic acid hybridization thermodynamics based on
 PT hybridization information, thermodynamic parameter, correction data and
 PT first set of data which represents hybridization conditions -
 XX
 PS Disclosure; Fig 8; 100pp; English.
 XX
 CC The present invention describes a method for predicting nucleic acid
 CC hybridisation thermodynamics (HT) comprising providing a database of
 CC thermodynamic parameters (TP), receiving hybridisation information which
 CC represents a sequence, receiving correction data, and a first set of
 CC data which represents hybridisation conditions, and calculating HT
 CC including net HT based on the hybridisation information, TP, the
 CC correction data and the first set of data. Also described are: (1) a
 CC computer-readable storage medium having stored in it, a database of TP
 CC and a computer program which executes the above method; and (2) a system
 CC for predicting nucleic acid HT, comprising a database of TP, units for
 CC receiving hybridisation information which represents at least one
 CC sequence and for receiving correction data, receiving a first set of
 CC data which represents hybridisation conditions and unit for calculating
 CC HT. The method and system are useful to optimise and predict probe-target
 CC hybridisation. The method and system takes into account of single strand
 CC folding thermodynamics to calculate effective hybridisation
 CC thermodynamics not taken into account by prior art methods. ABL42498 to
 CC ABL42626 represent oligonucleotide sequences which are used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 15 BP; 0 A; 1 C; 4 G; 10 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1146 TTTTTCCTTTTGG 1158
 |||||
 Db 3 TTTTTCCTTTTGG 15

RESULT 456
 AAQ20008
 ID AAQ20008 standard; DNA; 16 BP.
 XX
 AC AAQ20008;
 XX
 DT 01-APR-1992 (first entry)
 XX
 DE Oligonucleotide #4 able to covalently cross-link to target DNA.
 XX
 KW deoxyribonucleic acid; major groove; ethanoamino group;
 KW aziridinylcytosine; cross-linking group; ss.
 XX
 OS Synthetic.

Key	Location/Qualifiers
modified_base	8
	/*tag= a
	/mod_base= OTHER
	/note= "N4N4-ethanocytosine"
modified_base	14
	/*tag= b
	/mod_base= m5c

WO9118997-A.
 12-DEC-1991.
 24-MAY-1991; 91WO-1003680.
 14-JAN-1991; 91US-0640654.
 25-MAY-1990; 90US-0529346.
 (GILE-) GILEAD SCIE INC.

PI Matteucci MD, Krawczyk S;
 XX
 DR WPI; 1992-007480/01.
 XX
 PT New sequence-specific non-photo-activated crosslinking agents -
 PT bind to the major groove of duplex DNA and are esp. useful for
 PT treating latent infections e.g. HIV
 XX
 PS Example 2; Page 21; 42pp; English.
 XX
 CC The 3' end of this oligonucleotide carries 1,3-propanediol. The
 CC oligo is one of four oligonucleotides which were designed to
 CC specifically bind and cross-link to the duplex target sequence
 CC AAQ20004. Oligo #4 with its internal cross-linking group was less
 CC effective than the other oligonucleotides with terminal
 CC cross-linking groups. See also AAQ20005-7.
 XX
 SQ Sequence 16 BP; 0 A; 2 C; 0 G; 14 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTTT 1156
 |||||
 Db 1 TTTTTCCTTTT 13

RESULT 457
 AAQ20006
 ID AAQ20006 standard; DNA; 17 BP.
 XX
 AC AAQ20006;
 XX
 DT 01-APR-1992 (first entry)
 XX
 DE Oligonucleotide #2 able to covalently cross-link to target DNA.
 XX
 KW deoxyribonucleic acid; major groove; ethanoamino group;
 KW aziridinylcytosine; cross-linking group; ss.
 XX
 OS Synthetic.

Key	Location/Qualifiers
modified_base	17
	/*tag= a
	/mod_base= OTHER
	/note= "N4N4-ethanocytosine"
modified_base	8
	/*tag= b
	/mod_base= m5c
modified_base	14
	/*tag= c
	/mod_base= m5c

WO9118997-A.
 12-DEC-1991.
 24-MAY-1991; 91WO-1003680.
 14-JAN-1991; 91US-0640654.
 25-MAY-1990; 90US-0529346.
 (GILE-) GILEAD SCIE INC.
 Matteucci MD, Krawczyk S;
 WPI; 1992-007480/01.

New sequence-specific non-photo-activated crosslinking agents -
 bind to the major groove of duplex DNA and are esp. useful for
 treating latent infections e.g. HIV

XX Example 2; Page 20; 42pp; English.

XX The 3' end of this oligonucleotide carries 1,3-propanediol. The

CC oligo is one of four oligonucleotides which were designed to

CC specifically bind and cross-link to the duplex target sequence

CC AAQ20004. Oligo #2 has the covalent cross-linking group, i.e.

CC N4N4-ethanocytosine, at its 3' end. An assay for crosslinked triple

CC helix showed considerable reaction with Oligo #2 and with Oligo #1

CC (see AAQ20005) which has the crosslinking group at the 5' end.

CC The most complete reaction was seen with Oligo #3 (see AAQ20007) having

CC N4N4-ethanocytosine at both the 5' and 3' termini. A control oligo

CC with no cross-linking group showed no reaction. The half-life of the

CC cross-linking reaction for Oligo #2 was ca. 1 hr (1 microm);

CC Oligo #1 showed a rate four times slower. See also AAQ20008.

XX Sequence 17 BP; 0 A; 3 C; 0 G; 14 T; 0 other;

SQ

Query Match 1.0%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTTT 1156

Db 1 TTTTTCCTTTT 13

RESULT 458

AAQ33416

ID AAQ33416 standard; cDNA; 17 BP.

XX AC AAQ33416;

XX 25-MAR-2003 (updated)

DT 06-MAY-1993 (first entry)

XX Polymorphic site recognition probe, Arg-506.

DE

XX Acid sphingomyelinase; ASM; type; 1; 2; PCR; primer; amplify; cryptic;

KW polymerase chain reaction; mutation; R496L; deltaR608; L302; NPD;

KW Niemann-Pick disease; Jewish community; ss.

XX Synthetic.

OS

XX EP520843-A2.

PN

XX 30-DEC-1992.

PD

XX 30-APR-1992; 92EP-0401241.

PF

XX 03-MAY-1991; 91US-0695472.

PR

XX (MOUN) MOUNT SINAI MEDICAL CENT.

PA

XX Desnick RJ, Schuchman EH;

PI

XX WPI; 1993-001632/01.

DR

XX Pure and recombinant acid sphingomyelinase and its nucleic acid -

PT for treatment and diagnosis of Niemann-Pick disease

PT

XX Disclosure; Page 12; 50pp; English.

PS

XX The sequences given in AAQ33414-17 are probes which were used to

CC recognise polymorphic sites within the full length acid sphingo-

CC myelinase (ASM) gene. This was done to determine the population

CC frequency of the different alleles. The template DNA was genomic DNA

CC from normal Caucasian individuals. Certain mutations in the ASM gene

CC ie. R496L, deltaR608 and L302 have been found to correlate with

CC Niemann-Pick disease (NPD). See also AAQ33390-423.

CC (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 other;

SQ

Query Match 1.0%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 631 CTCACGAGGCTCT 643

Db 5 CTCACGAGGCTCT 17

RESULT 459

AAQ92208

ID AAQ92208 standard; DNA; 17 BP.

XX AC AAQ92208;

XX 12-JAN-1996 (first entry)

DT

XX p53 detection probe, (codon 178 ins 1 C).

DE

XX Primer; polymerase chain reaction; amplify; mutant; K-ras; PCR;

KW flanking region; amplification; probe; detection; sputum; diagnosis;

KW benign; malignant; neoplasm; lung; lung cancer; head; neck; ss.

XX Synthetic.

OS

XX WO9513397-A1.

PN

XX 18-MAY-1995.

PD

XX 10-NOV-1994; 94WO-US12947.

PF

XX 12-NOV-1993; 93US-0152313.

PR

XX (UYJO) UNIV JOHNS HOPKINS SCHOOL MED.

PA

XX Sidransky D;

PI

XX WPI; 1995-194114/25.

DR

XX Detecting target nucleic acid in mammalian sputum - particularly for

PT diagnosis of lung neoplasia involving mutation(s) in the K-ras

PT oncogene or p53 tumour suppressor

PT

XX Example 1; Page 36; 122pp; English.

PS

XX The sequences given in AAQ92112-211 are probes which were used in the

CC detection of a mutant p53 gene sequence. The DNA to be detected is

CC amplified using PCR and then these probes which are pref. labeled using

CC 32-P gamma-ATP are used to detect the mutant sequences. The primers and

CC probes given in AAQ92098-219 are used in the method of the invention for

CC detecting mammalian target DNA in sputum samples. Analysis of the

CC target DNA is used to diagnose benign or malignant neoplasms of the

CC lung. It is also useful for screening people at high risk or for

CC monitoring progress of treatment of lung neoplasms. The method is

CC based on the discovery that mutant target DNA associated with lung

CC cancer is present at detectable levels in sputum. Cells shed into

CC sputum from head and neck cancers may also be detected.

XX Sequence 17 BP; 3 A; 9 C; 3 G; 2 T; 0 other;

SQ

Query Match 1.0%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 589 CTCGCCCCCACCACCA 601

Db 2 CTCGCCCCCACCACCA 14

RESULT 460

AAT95093

ID AAT95093 standard; DNA; 17 BP.

XX AC AAT95093;
 XX DT 17-FEB-1998 (first entry)
 XX DE Probe for acid sphingomyelinase genomic DNA codon 506 mutation.
 XX DE Prenatal diagnosis; Type A; Type B; Niemann-Pick disease;
 XX KW identification; potential genetic transmitter; detection;
 XX KW recessive mutation; acid sphingomyelinase; Ashkenazi Jew;
 XX KW human; treatment; codon 506 mutation; probe; ss.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN US5686240-A.
 XX PD 11-NOV-1997.
 XX PF 27-MAY-1994; 94US-0250740.
 XX PR 27-MAY-1994; 94US-0250740.
 XX PR 03-MAY-1991; 91US-0695572.
 XX PA (MOUNT) MOUNT SINAI SCHOOL MEDICINE.
 XX PI Desnick RJ, Schuchman EH;
 XX PF WPI; 1997-558133/51.
 XX DT Diagnosing Type A or B Niemann-Pick disease - by detecting recessive
 XX PT mutation in acid sphingomyelinase gene
 XX PS Example; Columns 51-52; 58pp; English.
 XX CC The present sequence is a probe for a human acid sphingomyelinase
 XX CC (ASM) genomic DNA codon 506 mutation.
 XX CC Diagnosing Type A or B Niemann-Pick disease (NPD), or identifying a
 XX CC person as having the potential to genetically transmit Type A or B
 XX CC NPD, comprises detecting a recessive mutation in the ASM gene,
 XX CC which results in an alteration of at least 1 amino acid in the ASM
 XX CC amino acid sequence. The method is especially useful for prenatal
 XX CC diagnosis in Ashkenazi Jewish populations. The mutation is
 XX CC Arg496Leu, deltaArg608, Leu302Pro or fsp330, where fsp330 is a
 XX CC frame shift mutation comprising a cytosine deletion in ASM codon
 XX CC 330. The mutations are detected by selectively amplifying mutation
 XX CC containing portions of the ASM gene by PCR using primers
 XX CC complementary and identical to a portion of the ASM cDNA sequence,
 XX CC and sequencing the amplified DNA or subjecting it to a
 XX CC hybridisation assay using mutation specific probes. The ASM type 1
 XX CC sequence, or the cDNA sequence encoding it can also be used in the
 XX CC treatment of NPD.
 XX SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 other;
 Query Match 1.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 631 CTCGAGGAGCTCT 643
 Db 5 CTCGAGGAGCTCT 17
 RESULT 461
 AAV97224/c
 ID AAV97224 standard; RNA; 17 BP.
 XX AC AAV97224;
 XX DT 17-MAR-1999 (first entry)
 XX DE Human EGF-R target sequence nucleotide position 73.
 Query Match 1.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 631 CTCGAGGAGCTCT 643
 Db 5 CTCGAGGAGCTCT 17
 RESULT 461
 AAV97224/c
 ID AAV97224 standard; RNA; 17 BP.
 XX AC AAV97224;
 XX DT 17-MAR-1999 (first entry)
 XX DE Human EGF-R target sequence nucleotide position 73.

XX KW Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
 KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
 KW cancer; genetic drift; detection; mutation; ss.
 XX OS Homo sapiens.
 XX PN WO9833893-A2.
 XX PD 06-AUG-1998.
 XX PF 14-JAN-1998; 98WO-US00730.
 XX PR 04-DEC-1997; 97US-0985162.
 XX PR 31-JAN-1997; 97US-0036476.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (UYAS-) UNIV ASTON.
 XX PI Akhtar S, Fell P, McSwiggen JA;
 XX PF WPI; 1998-437449/37.
 XX DT Enzymatic nucleic acids - which cleave RNA derived from an epidermal
 XX PT growth factor receptor, useful for inhibiting cell proliferation and
 XX PT for treating cancers
 XX PS Claim 5; Page 68; 109pp; English.
 XX CC The present invention describes enzymatic nucleic acid molecules (NAMs)
 XX CC which specifically cleave RNA derived from an epidermal growth factor
 XX CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
 XX CC represent specifically claimed target sequence from human EGF-R. AAV98044
 XX CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
 XX CC hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
 XX CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
 XX CC expression levels e.g. to inhibit cell proliferation in the prevention or
 XX CC treatment of cancers. The NAMs can also be used as diagnostic tools to
 XX CC examine genetic drift and mutations within diseased cells or to detect
 XX CC the presence of EGF-R RNA in a cell.
 XX SQ Sequence 17 BP; 1 A; 8 C; 5 G; 3 U; 0 other;
 Query Match 1.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 200 CGGACGCCGACGA 212
 Db 17 CGGACGCCGACGA 5
 RESULT 462
 AAV79135
 ID AAV79135 standard; DNA; 17 BP.
 XX AC AAV79135;
 XX DT 03-JAN-2003 (first entry)
 XX DE Human HTPL scanning oligonucleotide SEQ ID 381.
 XX KW Human; gene therapy; tumour suppressor; HTP; chromosome 10p12.1;
 KW human testis expressed patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX OS Homo sapiens.
 XX PN EP1229046-A2.
 XX PD 07-AUG-2002.
 XX DE

```

PF 28-JAN-2002; 2002EP-0001167.
XX
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 23-MAY-2001; 2001US-0864761.
PR 09-OCT-2001; 2001US-0327898.
XX
PA (AEOM-) AEOMICA INC.
XX
FI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL),
PT useful for identifying agonist and antagonist and specific binding
PT partners, and for treating subjects having defects in HTPL -
XX
FS Example 2; Page 113; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention.
XX
SQ Sequence 17 BP; 3 A; 7 C; 6 G; 1 T; 0 other;
    Query Match      1.0%; Score 13; DB 1; Length 17;
    Best Local Similarity 100.0%; Pred. No. 2.5e+02;
    Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 522 CCTGCCGGAGGAG 534
Db 5 CCTGCCGGAGGAG 17

RESULT 463
ID ABV79136
XX ABV79136 standard; DNA; 17 BP.
AC ABV79136;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 382.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EF1229046-A2.
XX

```

```

PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-0001167.
XX
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 23-MAY-2001; 2001US-0864761.
PR 09-OCT-2001; 2001US-0327898.
XX
PA (AEOM-) AEOMICA INC.
XX
FI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL),
PT useful for identifying agonist and antagonist and specific binding
PT partners, and for treating subjects having defects in HTPL -
XX
FS Example 2; Page 113; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention.
XX
SQ Sequence 17 BP; 3 A; 6 C; 7 G; 1 T; 0 other;
    Query Match      1.0%; Score 13; DB 1; Length 17;
    Best Local Similarity 100.0%; Pred. No. 2.5e+02;
    Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 522 CCTGCCGGAGGAG 534
Db 4 CCTGCCGGAGGAG 16

RESULT 464
AAD33183
ID AAD33183 standard; DNA; 17 BP.
XX
AC AAD33183;
XX
DT 01-JUL-2002 (first entry)
XX
DE LDLR cDNA amplifying RT-PCR primer, LDLR/pl.
XX
KW Phytanic acid; non-insulin dependent diabetes mellitus; NIDDM; obesity;
KW glucose tolerance; food supplement; feed supplement; hyperinsulinaemia;
KW hyperlipidaemia; hypertension; insulin therapy; hypercholesterolaemia;
KW hypertriglyceridaemia; primer; RT-PCR; LDLR; reverse transcription PCR;
KW low-density lipoprotein receptor; ss.
XX
OS Unidentified.
XX

```

```

XX PN EP117789-A2.
XX XX
XX PD 06-FEB-2002.
XX XX
XX PF 30-JUL-2001; 2001EP-0118230.
XX XX
XX PR 04-AUG-2000; 2000EP-0116948.
XX XX
XX PA (ROCH-) ROCHE VITAMINS AG.
XX XX
XX PI Fluehmann B, Heim M, Hunziker W, Weber P;
XX XX
XX DR WPI; 2002-270864/32.
XX XX
XX PT New composition comprising phytanic acid or its derivatives, useful for
XX PT treating or preventing non-insulin dependent diabetes mellitus,
XX PT impaired glucose tolerance and related obesity -
XX XX
XX PS Example 3; Page 9; 29pp; English.
XX XX
XX CC The invention relates to the use of phytanic acid or its derivatives
XX CC for the treatment or prevention of diabetes mellitus. The invention
XX CC also relates to a method for treating or preventing non-insulin
XX CC dependent diabetes mellitus (NIDDM) or other conditions associated
XX CC with impaired glucose tolerance such as obesity using phytanic acid
XX CC or its derivatives. The phytanic acid, their derivatives or their
XX CC precursors are useful as pharmaceutical compounds or supplements to
XX CC foods or feeds for the treatment or prevention of type II or NIDDM,
XX CC hyperlipidaemia, hypercholesterolaemia, hyperinsulinaemia, syndrome X,
XX CC hypertension, hypertriglyceridaemia, impaired glucose tolerance and
XX CC related obesity. They are also useful in insulin therapy in combination
XX CC with known active compounds. The present sequence is low-density
XX CC lipoprotein receptor (LDLR) cDNA amplifying reverse transcription PCR
XX CC (RT-PCR) primer used in the exemplification of the invention.
XX XX
XX SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 457 GTGTCAGCAGCC 469
Db 2 GTGTCAGCAGCC 14

RESULT 465
AAT05895/c
ID AAT05895 standard; DNA; 18 BP.
XX XX
XX AC AAT05895;
XX XX
XX DT 22-AUG-1996 (first entry)
XX XX
XX DE Human IL-2 exon 3-specific probe.
XX XX
XX KW Interleukin-2; IL-2; interleukin-4; IL-4; splice variant;
XX KW probe; ss.
XX OS Synthetic.
XX PN WO9527052-A1.
XX XX
XX PD 12-OCT-1995.
XX XX
XX PF 30-MAR-1995; 95WO-US04094.
XX XX
XX PR 06-APR-1994; 94US-0224010.
XX PR 30-MAR-1994; 94US-0219831.
XX XX
XX FA (UTMA-) UNIV MARYLAND BALTIMORE.
XX XX

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 457 GTGTCAGCAGCC 469
Db 2 GTGTCAGCAGCC 14

RESULT 465
AAT05895/c
ID AAT05895 standard; DNA; 18 BP.
XX XX
XX AC AAT05895;
XX XX
XX DT 22-AUG-1996 (first entry)
XX XX
XX DE Human IL-2 exon 3-specific probe.
XX XX
XX KW Interleukin-2; IL-2; interleukin-4; IL-4; splice variant;
XX KW probe; ss.
XX OS Synthetic.
XX PN WO9527052-A1.
XX XX
XX PD 12-OCT-1995.
XX XX
XX PF 30-MAR-1995; 95WO-US04094.
XX XX
XX PR 06-APR-1994; 94US-0224010.
XX PR 30-MAR-1994; 94US-0219831.
XX XX
XX FA (UTMA-) UNIV MARYLAND BALTIMORE.
XX XX

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 379 CTTCTCCAGAGG 391
Db 13 CTTCTCCAGAGG 1

RESULT 466
AAZ31808
ID AAZ31808 standard; DNA; 18 BP.
XX XX
XX AC AAZ31808;
XX XX
XX DT 24-JAN-2000 (first entry)
XX XX
XX DE Human G-alpha-13 antisense inhibitor ISIS# 20763.
XX XX
XX KW G-alpha-13; human; inhibitor; cancer; antisense compound; therapy; ss.
XX XX
XX OS Synthetic.
XX OS Homo sapiens.
XX PN US5981732-A.
XX XX
XX PD 09-NOV-1999.
XX XX
XX PF 04-DEC-1998; 98US-0205860.
XX XX
XX PR 04-DEC-1998; 98US-0205860.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX XX
XX PI Cowser LM;
XX XX
XX DR WPI; 1999-633376/54.
XX XX
XX PT Antisense compound inhibiting expression of human G-alpha-13 -
XX PS Claim 11; Column 39; 38pp; English.
XX XX
XX CC This sequence represents an antisense inhibitor of the invention, and
XX CC inhibits the expression of the human G-alpha-13 protein. The antisense
XX CC compounds of the invention are of 8 to 30 nucleobases in length, that
XX CC inhibits the expression of the human G-alpha-13. The antisense compound
XX CC is useful for treating an animal, particularly humans, having or being
XX CC prone to a disease or condition associated with the expression of
XX CC G-alpha-13, such as cancer.
XX XX
XX SQ Sequence 18 BP; 4 A; 7 C; 6 G; 1 T; 0 other;

```

```

PI Alms W, White B;
XX WPI; 1995-358629/46.
XX XX
XX PT New human interleukin alternative splice variants - expressed by
XX PT exon(s) 1, 3 and 4 of IL-4 or IL-2, used for regulating the activity
XX PT of corresp. interleukin(s)
XX XX
XX PS Example 6; Page 29; 58pp; English.
XX XX
XX CC Cytokine-specific probes were used to screen products obtd. by
XX CC RT-PCR amplification (see AAT05878-93) of cellular RNA from human
XX CC peripheral blood mononuclear cells stimulated with an anti-CD3 Mab.
XX CC Probes were human IL-2 exon 2-specific (AAT05894), human IL-2 exon
XX CC 3-specific (AAT05895), human IL-3 exon 1/exon 3 junction-specific
XX CC (AAT05896), human IL-5 exon 1/exon 3 junction-specific (AAT05897) and
XX CC human GM-CSF exon 1/exon 3 junction-specific (AAT05898). Novel splice
XX CC variants of IL-4 (AAT05899) and IL-2 (AAT05900) lacking exon 2 were
XX CC identified.
XX XX
XX SQ Sequence 18 BP; 4 A; 4 C; 6 G; 4 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 379 CTTCTCCAGAGG 391
Db 13 CTTCTCCAGAGG 1

RESULT 466
AAZ31808
ID AAZ31808 standard; DNA; 18 BP.
XX XX
XX AC AAZ31808;
XX XX
XX DT 24-JAN-2000 (first entry)
XX XX
XX DE Human G-alpha-13 antisense inhibitor ISIS# 20763.
XX XX
XX KW G-alpha-13; human; inhibitor; cancer; antisense compound; therapy; ss.
XX XX
XX OS Synthetic.
XX OS Homo sapiens.
XX PN US5981732-A.
XX XX
XX PD 09-NOV-1999.
XX XX
XX PF 04-DEC-1998; 98US-0205860.
XX XX
XX PR 04-DEC-1998; 98US-0205860.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX XX
XX PI Cowser LM;
XX XX
XX DR WPI; 1999-633376/54.
XX XX
XX PT Antisense compound inhibiting expression of human G-alpha-13 -
XX PS Claim 11; Column 39; 38pp; English.
XX XX
XX CC This sequence represents an antisense inhibitor of the invention, and
XX CC inhibits the expression of the human G-alpha-13 protein. The antisense
XX CC compounds of the invention are of 8 to 30 nucleobases in length, that
XX CC inhibits the expression of the human G-alpha-13. The antisense compound
XX CC is useful for treating an animal, particularly humans, having or being
XX CC prone to a disease or condition associated with the expression of
XX CC G-alpha-13, such as cancer.
XX XX
XX SQ Sequence 18 BP; 4 A; 7 C; 6 G; 1 T; 0 other;

```

Query Match 1.0%; Score 13; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 718 GCCACGACGAGG 730
 |||||
 DB 4 GCCACGACGAGG 16

RESULT 467
 AAZ74428/c
 ID AAZ74428 standard; DNA; 18 BP.
 XX
 AC AAZ74428;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Human biallelic marker downstream amplification primer SEQ ID NO:8784.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO9954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 21-APR-1999; 99WO-IB00822.
 XX
 PR 21-APR-1998; 98US-0082614.
 PR 23-NOV-1998; 98US-0109732.
 XX
 PA (GEST) GENSET.
 XX
 PI Cohen D, Blumenfeld M, Chumakov I;
 XX
 DR WPI; 2000-013267/01.
 XX
 PT Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome
 XX
 PS Claim 8; Page 2103; 2745pp; English.
 XX
 CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the
 CC invention have a variety of uses: they can be used for high density
 CC mapping of the human genome, and in complex association studies and
 CC haplotyping studies which are useful in determining the genetic basis
 CC for disease states. Compositions and methods of the invention can also
 CC be useful for the identification of the targets for the development of
 CC pharmaceutical agents and diagnostic methods, as well as the
 CC characterisation of the differential efficacious responses to and side
 CC effects from pharmaceutical agents acting on a disease as well as other
 CC treatment.
 CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
 CC and 3367, are not actually given a sequence in the Sequence Listing
 CC from the present invention.
 XX
 SQ Sequence 18 BP; 10 A; 2 C; 6 G; 0 U; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1140 TGCCTTTTCT 1152
 |||||

DB 17 TGCCTTTTCT 5

RESULT 468
 AAZ26911/c
 ID AAZ26911 standard; DNA; 18 BP.
 XX
 AC AAZ26911;
 XX
 DT 21-DEC-2001 (first entry)
 XX
 DE Fluorescent oligonucleotide target for electronic hybridisation.
 XX
 KW Capture probe; hybridisation; electronics; photonics;
 KW nanotechnology; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= "OTHER"
 FT /note= "fluorescent dye with 493 nm absorption and
 FT 503 nm emission"
 XX
 FN WO200153799-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 12-JAN-2001; 2001WO-US00926.
 XX
 PR 24-JAN-2000; 2000US-0498855.
 XX
 PA (NANO-) NANOGEN INC.
 XX
 PI Edman CF, Heller MJ, Gurtner C, Formosa R;
 XX
 DR WPI; 2001-607116/69.
 XX
 CC Device for photoelectric transport of charged materials in liquid
 CC environment for micro- and opto- electronic devices, has a substrate
 CC generating light induced current, conductor, permeation layer and light
 CC source to illuminate substrate
 PS Disclosure; Page 60; 119pp; English.
 XX
 CC The present sequence is that of fluorescent target oligonucleotide
 CC T2, which was used to demonstrate an electron hybridisation method
 CC of the invention. Mn2O3 stabilised n-type silicon photoelectrodes
 CC coated with a streptavidin-agarose permeation layer were shown to
 CC constitute a simple platform for rapid manipulation of DNA
 CC oligonucleotides by electron hybridisation. In this process, a
 CC set of unlabelled oligonucleotides (capture strands) are first
 CC targeted to specific locations and anchored. A second set of
 CC fluorescent labeled oligonucleotides (target strands) is then
 CC targeted to the same locations and actively hybridised to the
 CC capture strands. In the example provided, 2 sets of biotinylated
 CC capture probes, C1 (see AAZ26908) and C2 (see AAZ26909), were
 CC successively transported and anchored to 4 different locations on a
 CC streptavidin-agarose and Mn2O3 coated amorphous silicon substrate.
 CC 2 Fluorescence labeled target sequences, T1 (see AAZ26910) and
 CC T2 (present sequence), were then transported to a location with
 CC complementary capture probes and a location with non-complementary
 CC capture probes. This step produced 2 clearly detectable
 CC fluorescence signals at the 2 locations with matching sequences.
 CC The ratio between signal and non-specific background was better
 CC than 4. The method allows for detection of DNA oligonucleotides in
 CC an extremely short time. The invention generally provides systems
 CC and devices for photoelectrophoretic transport and hybridisation of
 CC oligonucleotides; the techniques of the invention have wide use in
 CC manufacture of micro electronic and opto electronic devices.
 CC Self-assembly fabrication techniques based on DNA polymers enables
 CC micron, sub-micron or nanoscale devices to be fabricated.

```

XX SQ Sequence 18 BP; 5 A; 6 C; 3 G; 4 T; 0 other;
Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 84 ATACGAGTTCTAC 96
Db 17 ATACGAGTTCTAC 5

RESULT 469
AADI5912/c
ID AAD15912 standard; RNA; 18 BP.
XX AC AAD15912;
XX DT 15-NOV-2001 (first entry)
XX DE Y strand RNA oligonucleotide #6.
XX KW Nucleic acid activity modulator; targeting portion; reactive portion;
XX KW ss.
XX OS Unidentified.
XX FH Key Location/Qualifiers
FT misc_feature 9 /*tag= a
FT FT /note= "Optionally absent"
PN US626241-B1.
XX PD 17-JUL-2001.
XX PF 03-FEB-1995; 95US-0383666.
XX PR 01-JUL-1992; 92US-0854634.
XX PR 13-AUG-1990; 90US-0566977.
XX PR 11-JAN-1991; 91US-0463358.
XX PR 11-JAN-1991; 91WO-US00243.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Cook PD, Ecker DJ, Guinasso CJ, Acevedo OL, Kawasaki A;
XX PI Ramasamy K;
XX DR WPI; 2001-528597/58.
XX PT New heterocycle derivatives, useful for modulating the activity of RNA
XX PT and DNA -
XX PS Example 136; Column 66; 54pp; English.
XX CC The present invention relates to compositions and methods for modulating
XX CC the activity of RNA and DNA. The compositions comprise a targeting
XX CC portion specifically hybridisable with a preselected nucleotide sequence
XX CC of RNA. The composition further provides a reactive portion capable of
XX CC catalysing, alkylating, or otherwise effecting the cleavage of RNA,
XX CC especially of its phosphodiester bonds. The compositions are useful for
XX CC modulating the activity of RNA and DNA. The present sequence is
XX CC Y strand RNA oligonucleotide used in the exemplification of the
XX CC invention.
XX SQ Sequence 18 BP; 5 A; 3 C; 8 G; 1 U; 1 other;
Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1057 CCTGGCCTTCCAT 1070
Db 1057 CCTGGCCTTCCAT 1070

```

```

Db 18 CCTGGCCTTNCAT 5

RESULT 470
ABK41151/c
ID ABK41151 standard; DNA; 18 BP.
XX AC ABK41151;
XX DT 21-MAY-2002 (first entry)
XX DE Human obesity-associated biallelic marker downstream PCR primer #57.
XX KW Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;
XX KW drug response; hyperuricaemia; digestive pathology; hypertension; cancer;
XX KW hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;
XX KW insulin disorder; atheromatous disease; cardiac insufficiency; primer.
XX OS Homo sapiens.
XX PN WO200206525-A2.
XX PD 24-JAN-2002.
XX PF 28-JUN-2001; 2001WO-IB01477.
XX PR 18-JUL-2000; 2000US-219704P.
XX PA (GEST ) GENSET.
XX PI Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;
XX DR WPI; 2002-155043/20.
XX PT Set of novel map-related biallelic markers, preferably located on
XX PT obesity disorder-associated chromosomal regions on chromosomes 3, 10
XX PT and 19, useful, for e.g. detecting statistical correlations between
XX PT marker allele and a phenotype -
XX PS Example 2; Page 274; 31pp; English.
XX CC The invention relates to a set of novel map-related biallelic markers,
XX CC preferably located on obesity disorder-associated chromosomal regions on
XX CC chromosomes 3, 10 and 19. The markers are useful for genotyping or
XX CC estimating the frequency of an allele in a population, for detecting an
XX CC association between a genotype or haplotype and a phenotype, e.g. a
XX CC disease involving drug responses, obesity or disorders related to
XX CC obesity, such as hyperuricaemia, digestive pathology, hyperlipidaemia,
XX CC disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,
XX CC insulin disorders, atheromatous disease and cardiac insufficiency. The
XX CC markers are useful for detecting a statistical correlation between a
XX CC biallelic marker allele and a phenotype. This sequence represents a PCR primer used to
XX CC amplify a human obesity-associated biallelic marker.
XX SQ Sequence 18 BP; 6 A; 3 C; 5 G; 4 T; 0 other;
Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 325 CTGCATCATCTCG 337
Db 18 CTGCATCATCTCG 6

RESULT 471
AAQ68252/c
ID AAQ68252 standard; DNA; 16 BP.
XX AC AAQ68252;
XX DT 25-MAR-2003 (updated)

```

DT 16-FEB-1995 (first entry)
XX Triple helix forming methylphosphonate oligomer 2104.
XX Methylphosphonate; MP; triple helix; translation;
XX oligonucleoside; ss.
XX Synthetic.
XX OS
XX WO9413326-A1.
XX 23-JUN-1994.
XX 08-DEC-1993; 93WO-US11986.
XX 08-DEC-1992; 92US-0987746.
XX (GENT-) GENTA INC.
XX Arnold LJ, Reynolds MA;
XX WPI; 1994-217542/26.
XX Detection, recognition, inhibition and alteration of single and
XX double stranded target nucleic acid sequences - by formation of a
XX triple helix structure using 2 oligomers which block translation
XX
XX Example 11; Page 50; 67pp; English.
XX Triple helix formation with 2:1 MP:RNA oligomers was demonstrated
XX with thermal denaturation methods. Exemplary triple helix
XX forming MP-oligomers are given in AAQ8242-52.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 16 BP; 8 A; 2 C; 6 G; 0 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1216 TTCCCTGTACATTGT 1231
Db 16 TTCCCTGTCCCTTTGT 1
RESULT 472
AAQ80862/c
ID AAQ80862 standard; DNA; 16 BP.
XX
XX AAQ80862;
XX
DT 25-MAR-2003 (updated)
DT 16-FEB-1995 (first entry)
XX
XX Purine-rich methylphosphonate oligonucleoside G2104.
XX
XX Purine; methylphosphonate; MP; triple helix; translation;
XX oligonucleoside; ss.
XX Synthetic.
XX OS
XX WO9413326-A1.
XX 23-JUN-1994.
XX
XX 08-DEC-1993; 93WO-US11986.
XX
XX 08-DEC-1992; 92US-0987746.
XX (GENT-) GENTA INC.
XX Arnold LJ, Reynolds MA;
XX

DR WPI; 1994-217542/26.
XX Detection, recognition, inhibition and alteration of single and
XX double stranded target nucleic acid sequences - by formation of a
XX triple helix structure using 2 oligomers which block translation
XX
XX Example 4; Page 39; 67pp; English.
XX Five sets of purine-rich methylphosphonate oligonucleosides ("MP
XX oligomers") and complementary ribooligonucleosides ("RNA oligomers")
XX were examined for their ability to form triple helix complexes.
XX (Set 1:G2100 and R39; Set 2:G2101 and R289; Set 3:G2102 and R291;
XX Set 4:G2104 and R293; Set 5:G2106 and R84 - see AAQ68223-34 and
XX AAQ80860-63).
XX It was shown that replacing two adenines with two thymidines
XX is somewhat destabilising, and that replacing two guanines with
XX two cytidines is more destabilising w.r.t. triple helix formation.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 16 BP; 8 A; 2 C; 6 G; 0 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1216 TTCCCTGTACATTGT 1231
Db 16 TTCCCTGTCCCTTTGT 1
RESULT 473
AAQ95859/c
ID AAQ95859 standard; DNA; 16 BP.
XX
XX AAQ95859;
XX
DT 21-FEB-1996 (first entry)
XX
DE Primer A (Group 11, set B) for marker D5S425, chromosome 5.
XX
XX Primer; polymerase chain reaction; PCR; linkage study; locus;
XX microsatellite marker sequence; automated genotyping; allele;
XX polymorphism; detection; Homo sapiens; ss.
XX Synthetic.
XX OS
XX WO9515400-A1.
XX
XX 08-JUN-1995.
XX
XX 05-DEC-1994; 94WO-US13945.
XX
XX 03-DEC-1993; 93US-0160837.
XX
XX (UYJO) UNIV JOHNS HOPKINS.
XX
XX Levitt RC;
XX
XX WPI; 1995-215278/28.
XX
XX Kit for automated genotyping contg. pairs of PCR primers - designed
XX to amplify polymorphic nucleotide repeat sequences, arranged in sets
XX each with a characteristic fluorescence label, useful e.g. in
XX detection of disease related genetic rearrangement
XX
XX Disclosure; Fig 7K-2; 104pp; English.
XX The method aims to provide a collection of highly reproducible
XX microsatellite marker sequences (MMS) at approx. 10-50 cm intervals
XX throughout the human genome which can be detectably labelled. The
XX MMS are polymorphic, simple sequence repeats and can be used in
XX automated genotyping. esp. fluorescence-based. The primers correspond
XX to the unique DNA sequence surrounding each marker, and PCR is used to

CC detect each polymorphism. When the MMS show considerable polymorphism
 CC (ie. a difference in the number of repeats) between individuals, the
 CC markers can be particularly informative. The MMS can be ideal for
 CC linkage studies. Kits comprise at least 4 groups, of at least 3 sets,
 CC each comprising labelled primers for PCR amplification of the DNA.
 CC Group 11 primer pairs are shown in AAQ95841-82. The published size range
 CC of the D5S425 allele is 224-248 bp, and the degree of heterozygosity
 CC in the population is about 77%.

XX SQ Sequence 16 BP; 2 A; 8 C; 3 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 459 GGTGAGCAGCTGCAG 474

Db 16 GGTGAGCAGCTGCAG 1

RESULT 474

AAAT43025

ID AAT43025 standard; DNA; 16 BP.

XX AC AAT43025;

XX 19-JUN-1997 (first entry)

XX Juvenile glaucoma marker afm350yh1 upstream amplification primer.

XX Microsatellite; genetic marker; screening; detection; PCR primer;

XX polymerase chain reaction; juvenile glaucoma; predisposition; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1

FT /*tag= a

FT /note= "linked to JOE fluorochrome label"

XX W09633287-A1.

XX 24-OCT-1996.

XX 18-APR-1996; 96WO-FR00592.

XX 18-APR-1995; 95FR-0004590.

XX (INRM) INSERM INST NAT SANTE & RECH MEDICALE.

XX Bach JF, Garchon HJ;

XX WPI; 1996-485791/48.

XX Detecting pre-disposition to juvenile glaucoma - from presence of

XX specific microsatellite markers on chromosome 1q21q31, also DNA

XX from the region defined by these markers.

XX Example; Page 7; 25pp; French.

XX Predisposition to juvenile glaucoma is detected by characterising

XX the following microsatellite markers on chromosome 1q21q31 associated

XX with occurrence of juvenile glaucoma: afm350yh1; afm122xa3; ngal;

XX afm21; afm248wg5; afm278ye5; afm212xb10; afm157xe7 and NGA5. An

XX oligonucleotide primer of the present sequence was used with a

XX primer having the sequence given in AAT43026 to amplify the afm350yh1

XX marker. Apart from detecting predisposition to disease, the

XX microsatellites should allow localisation, and thus isolation, of

XX the gene involved in juvenile glaucoma.

XX SQ Sequence 16 BP; 2 A; 9 C; 1 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1042 TCTTCCACGACAGCC 1057

Db 1 TCTTCCACGACAGCC 16

RESULT 475

AAAX18366

ID AAX18366 standard; DNA; 16 BP.

XX AC AAX18366;

XX 11-MAY-1999 (first entry)

XX RT-PCR primer of the invention SEQ ID 7.

XX RT-PCR primer; DNA sequence determination; gene sequence analysis; ss.

XX Synthetic.

XX JF11032765-A.

XX 09-FEB-1999.

XX 18-JUL-1997; 97JP-0208312.

XX 18-JUL-1997; 97JP-0208312.

XX (TAKI) TAKARA SHUZO CO LTD.

XX WPI; 1999-183822/16.

XX Peptides having at least two new nucleotides - useful as primers in
 XX RT-PCR

XX Disclosure; Page 10; 19pp; Japanese.

XX This sequence represents a primer of the invention. The invention relates
 XX to sequences of at least two nucleotides of formula:
 XX (X)m5'-(alpha)n-beta-N3'; or (X)m5'-(gamma)k-delta-N3'; where

XX X = a labelled compound and/or a nucleotide with voluntary sequence;

XX m = 0 or 1; alpha = thymine; n = natural number indicating the repetition

XX of alpha; beta, delta = V or N; V = adenine, guanine or cytosine;

XX N = adenine, guanine, cytosine or thymine; gamma = thymine;

XX k = natural number of 3 or over indicating the repetition of gamma, in

XX which thymine expressed by gamma is composed of 1/3 or less of adenine,

XX guanine and/or cytosine. The new nucleotides are useful as primers for

XX RT-PCR and determination of base sequences. The new sequences allow for

XX reproductive and highly efficient analysis of gene sequences.

XX SQ Sequence 16 BP; 1 A; 0 C; 1 G; 14 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTTCGA 1159

Db 1 TTTTTCCTTTTTCGA 16

RESULT 476

AAAC63258/c

ID AAC63258 standard; DNA; 16 BP.

XX AC AAC63258;

XX 06-FEB-2001 (first entry)

XX Oligonucleotide #31 used in a method for primer selection.

KW PCR primer; nucleic acid amplification; melting temperature; T_m; ss.
 XX Homo sapiens.
 OS WO200060123-A2.
 XX 12-OCT-2000.
 PD 05-APR-2000; 2000WO-US08962.
 PF 06-APR-1999; 99US-0127891.
 XX (GENO-) GENOME TECHNOLOGIES LLC.
 PA Senapathy P;
 PI WPI; 2000-656235/63.
 DR Determining T_m range for several degenerate primers with a
 XX fixed-sequence and a degenerate-sequence portion for use in polymerase
 PT chain reaction amplification by identifying a specific sequence in the
 PT nucleic acid template -
 XX Disclosure; Fig 3B; 34pp; English.
 PS The present invention relates to a method for selecting PCR primers for
 CC nucleic acid amplification. The method comprises determining the melting
 CC temperature (T_m) range for degenerate oligonucleotide primers with a
 CC fixed-sequence portion (FS) and a degenerate-sequence portion (DS) by
 CC searching known portion of a nucleic acid template for a sequence
 CC complementary to a desired FS of a primer. Nucleotide base pairs flanking
 CC or interspersed between the sequence complementary to a DS of one of the
 CC primers are detected and T_m is calculated. The method of the present
 CC invention allows primers which produce more efficient DNA amplification
 CC to be produced. The present sequence is a primer used in the method of
 CC the present invention.
 XX SQ Sequence 16 BP; 0 A; 4 C; 11 G; 1 T; 0 other;
 PS Query Match 0.9%; Score 12.8; DB 1; Length 16;
 CC Best Local Similarity 87.5%; Pred. NO. 2.5e+02;
 CC Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 191 CGCCGCCACCGGACGC 206
 DB 16 CGCCGCCACCGGACCC 1
 RESULT 477
 AAC63300
 ID AAC63300 standard; DNA; 16 BP.
 XX AAC63300;
 AC 06-FEB-2001 (first entry)
 DT Oligonucleotide #73 used in a method for primer selection.
 DE PCR primer; nucleic acid amplification; melting temperature; T_m; ss.
 KW Homo sapiens.
 XX WO200060123-A2.
 XX 12-OCT-2000.
 PD 05-APR-2000; 2000WO-US08962.
 PF 06-APR-1999; 99US-0127891.
 XX (GENO-) GENOME TECHNOLOGIES LLC.
 PA Senapathy P;
 PI

XX WPI; 2000-656235/63.
 DR Determining T_m range for several degenerate primers with a
 XX fixed-sequence and a degenerate-sequence portion for use in polymerase
 PT chain reaction amplification by identifying a specific sequence in the
 PT nucleic acid template -
 XX Disclosure; Fig 3B; 34pp; English.
 PS The present invention relates to a method for selecting PCR primers for
 CC nucleic acid amplification. The method comprises determining the melting
 CC temperature (T_m) range for degenerate oligonucleotide primers with a
 CC fixed-sequence portion (FS) and a degenerate-sequence portion (DS) by
 CC searching known portion of a nucleic acid template for a sequence
 CC complementary to a desired FS of a primer. Nucleotide base pairs flanking
 CC or interspersed between the sequence complementary to a DS of one of the
 CC primers are detected and T_m is calculated. The method of the present
 CC invention allows primers which produce more efficient DNA amplification
 CC to be produced. The present sequence is a primer used in the method of
 CC the present invention.
 XX SQ Sequence 16 BP; 1 A; 9 C; 6 G; 0 U; 0 other;
 PS Query Match 0.9%; Score 12.8; DB 1; Length 16;
 CC Best Local Similarity 87.5%; Pred. NO. 2.5e+02;
 CC Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 191 CGCCGCCACCGGACGC 206
 DB 1 CGCCGCCACCGGAGGC 16
 RESULT 478
 AAA46382
 ID AAA46382 standard; DNA; 16 BP.
 XX AAA46382;
 AC 04-SEP-2000 (first entry)
 DT PCR primer used for screening for ESP carrying fragments.
 DE Polymorphism; endonuclease site polymorphism; ESP; genetic marker;
 KW restriction endonuclease; high throughput genetic analysis;
 KW animal breeding; plant breeding; PCR primer; ss.
 XX Zea sp.
 OS WO200028081-A2.
 PN 18-MAY-2000.
 PD 09-NOV-1999; 99WO-IB01958.
 PF 09-NOV-1999; 98US-0107293.
 XX (METH-) METHEXIS NV.
 PA Zabeau M, Stanssens P;
 PI WPI; 2000-376586/32.
 DR Novel method for restricted amplicon analysis of endonuclease site
 XX polymorphisms resulting in loss of restriction sites, useful for
 PT multiplex genotyping -
 PT Example 2; Page 34; 67pp; English.
 PS The specification describes methods for genotyping polymorphisms that
 CC result in the gain or loss of an endonuclease site polymorphisms (ESPs).
 CC The method comprises deriving a set of concomitantly amplifiable target
 CC DNA fragments from sample DNA, treating the target DNA fragments with a

CC probe restriction endonuclease reagent, amplifying the DNA fragments,
 CC and analysing the DNA to determine which target fragments have been, and
 CC have not been, amplified. Target DNA fragments which have been amplified
 CC lack a recognition site for the probe restriction endonuclease reagent,
 CC and target fragments having a recognition site for the probe restriction
 CC endonuclease reagent are not amplified. The method is capable of
 CC diagnosing the immense number of genetic markers that are needed to
 CC unravel complex traits. The method is useful for high throughput genetic
 CC analysis in pharmacogenomics, and in animal and plant breeding to
 CC identify genes involved in quantitative agronomic traits. The methods
 CC are also useful to monitor mutations in specific genes or loci in
 CC addition to scanning the entire genome. The present sequence represents
 CC a PCR primer used in the course of the invention, for genetic analysis
 CC of Corr.

SQ Sequence 16 BP; 3 A; 4 C; 5 G; 4 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 739 CTGCGCATGTGTGCTG 754
 Db 1 CTGACCGATGTGCG 16

RESULT 479
 AAF73460
 ID AAF73460 standard; DNA; 16 BP.
 AC AAF73460;
 XX
 DT 08-MAY-2001 (first entry)
 DE HGF nucleic acid ligand SEQ ID NO: 10.
 XX
 KW Hepatocyte growth factor/ scatter factor; HGF; c-met; integrin; stroke;
 KW cell adhesion; cell migration; nucleic acid ligand; thrombosis; cancer;
 KW hypertension; arteriosclerosis; myocardial infarction; restenosis;
 KW rheumatoid arthritis; macular degeneration; endometriosis; psoriasis;
 KW osteoporosis; DNA-RNA hybrid; ss.

OS Synthetic.
 XX
 XX
 FH Key Location/Qualifiers
 FT misc_RNA 5..16
 FT modified_base 1..16
 FT /*tag= a
 FT /*tag= b
 FT /mod_base= "OTHER"
 FT /note= "all bases are 2'OMe"

XX WO200109159-A1.
 XX
 XX
 PD 08-FEB-2001.
 XX
 XX 24-JUL-2000; 2000WO-US20139.
 XX
 XX 29-JUL-1999; 99US-0364539.
 XX
 XX 29-JUL-1999; 99US-0364543.
 XX
 XX (NEXS-) NEXSTAR PHARM INC.
 XX
 XX Ruckman J, Gold L, Stephens A, Janjic N, Rabin R, Lochrie M;
 XX WPI; 2001-103180/11.

XX Isolation of nucleic acid ligands to hepatocyte growth factor, its
 XX receptor c-met and integrins, useful for treating tumors, deep vein
 XX thrombosis and diabetic retinopathy -
 XX
 XX Example 1; Fig 2; 226pp; English.

CC The present invention provides nucleic acid ligands to hepatocyte growth
 CC factor/scatter factor (HGF), its receptor c-met and integrins. Integrins
 CC are involved in cell adhesion and migration, and HGF is a cytokine
 CC involved in cell proliferation and migration. The ligands of the
 CC invention are useful in the treatment of diseases such as cancer,
 CC thrombosis, hypertension, arteriosclerosis, myocardial infarction,
 CC rheumatoid arthritis, macular degeneration, endometriosis, psoriasis,
 CC stroke, osteoporosis and restenosis. The present sequence is an example
 CC of a ligand of the invention.

SQ Sequence 16 BP; 1 A; 4 C; 7 G; 2 T; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 75.0%; Pred. No. 2.5e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY 297 GTCTGCTGTGGGGCT 312
 Db 1 GTCTGCTGTGGGGCT 16

RESULT 480
 ABL95939
 ID ABL95939 standard; DNA; 16 BP.

AC ABL95939;
 XX
 DT 19-JUN-2002 (first entry)
 DE Probe #23 for assaying nucleic acids.

KW Probe: polymorphism detection; mutation detection;
 KW disease diagnosis; microbial identification; ss.

OS Unidentified.

XX WO200208414-A1.

XX 31-JAN-2002.

XX 27-JUN-2001; 2001WO-IB01147.

XX 27-JUN-2000; 2000JP-0193133.

XX 03-AUG-2000; 2000JP-0236115.

XX 26-SEP-2000; 2000JP-0292483.

XX (NAAD-) NAT INST ADVANCED IND SCI & TECHNOLOGY.

XX (KANK-) KANKYO ENG CO LTD.

XX Kurane R, Kanagawa T, Kamagata Y, Torimura M, Kurata S, Yamada K;
 XX Yokomaku T;

XX WPI; 2002-195876/25.

XX Fluorescently-labeled nucleic acid probes for assaying nucleic acids
 XX and their polymorphism and mutation, particularly useful in science and
 XX medicine for e.g. analytical applications, disease diagnosis and
 XX microbial identification -

XX Example 22; Page 76; 152pp; Japanese.

XX The present invention relates to nucleic acid probes, which are useful
 XX for assaying nucleic acids by hybridising with a target nucleic acid, in
 XX which a single-stranded oligonucleotide is labelled with a fluorescent
 XX substance and a quencher in a manner that the fluorescence intensity of
 XX the hybridisation reaction system is increased after completion of the
 XX hybridisation but no stem loop structure is formed. The probes are useful
 XX for assaying nucleic acids and their polymorphism and mutation,
 XX particularly useful for e.g. analytical applications, disease diagnosis
 XX and microbial identification. The present sequence was used to illustrate
 XX the invention.

XX Sequence 16 BP; 0 A; 6 C; 2 G; 8 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1214 CCTTCCTGCTACATTT 1229
 |||||
 DB 1 CCTTCCTGCTGCTTT 16

RESULT 481
 ABX94194
 ID ABX94194 standard; DNA; 16 BP.
 XX AC
 XX ABX94194;
 XX
 DT 10-JUN-2003 (first entry)
 XX
 DE Human SCCA2 gene, PCR primer #2.
 XX
 KW Bronchial asthma attack; SCCA1; SCCA2; gene expression; risk of attack;
 KW PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2003014395-A1.
 XX
 XX 20-FEB-2003.
 XX
 PF 02-AUG-2002; 2002WO-JP07918.
 XX
 PR 07-AUG-2001; 2001JP-0239857.
 XX
 XX (GENO-) GENOX RES INC.
 XX
 PI Ohtani N, Matsui K, Yoshida N, Sugita Y, Hamasaki Y, Izuha K;
 XX
 DR WPI; 2003-248304/24.
 XX
 PT Method for examining bronchial asthma based on SCCA1 and SCCA2 as
 PT allergy-associated genes, useful in assessing risk of attacks with
 PT their expression levels as indication -
 XX
 PS Example 2; Page 20; 44pp; Japanese.
 XX
 CC The present invention relates to a method of examining attacks of
 CC bronchial asthma by using SCCA1 and/or SCCA2 as the indicator genes.
 CC The method comprises determining the expression levels of the
 CC indicator genes in the biological sample from a patient, and comparing
 CC the expression level with that in the sample of a healthy individual.
 CC The method is useful for examining bronchial asthma, which is useful
 CC in assessing the risk of attacks with SCCA1 and SCCA2 gene expression
 CC levels as indication. The method is cheap and capable of operating in
 CC high throughput, even for bedside diagnosis. The present sequence
 CC represents a PCR primer used in the examples of the present invention.
 XX
 SQ Sequence 16 BP; 3 A; 6 C; 4 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 GCAGCTGAGCTTTCA 843
 |||||
 DB 1 GCAGCTGAGCTTTCA 16

RESULT 482
 ABX94515
 ID ABX94515 standard; DNA; 16 BP.
 XX AC
 XX ABX94515;
 XX

DT 10-JUN-2003 (first entry)
 XX
 DE 23S rDNA helix 54 region probe SEQ ID 33.
 XX
 KW Diagnostic; Gram-positive bacterium; high G+C content; amplification;
 KW mycobacterial infection; PCR; primer; probe; detection; ss.
 XX
 OS Corynebacterium jeikeium.
 XX
 XX WO200297126-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 09-APR-2002; 2002WO-EP03956.
 XX
 PR 03-MAY-2001; 2001DE-1021505.
 XX
 XX (HAIN-) HAIN LIFESCIENCE GMBH.
 PA
 XX Weizenegger M;
 PI
 XX WPI; 2003-140491/13.
 DR
 XX
 XX Detecting and identifying Gram-positive bacteria of high G/C content,
 XX useful particularly for diagnosis of mycobacterial infection, by
 XX specific amplification and hybridization -
 XX
 PS Claim 1b; Figure 2B; 34pp; German.
 XX
 CC This invention describes a novel method for the diagnostic detection
 CC and/or identification of Gram-positive bacteria that have a high G+C
 CC content, especially Mycobacteria. The method comprises subjecting a
 CC sample to nucleic acid amplification using the PCR primers represented in
 CC ABX94483-ABX94492. The amplification mixture, or part of it, is then
 CC tested for hybridisation to at least one of the probes represented in
 CC ABX94493-ABX94524 which can be immobilised on a solid phase or used in
 CC kit form. The specified primers/probes provide highly specific detection
 CC of particular Gram positive bacteria, which are difficult to
 CC differentiate by morphological or biochemical tests and/or those which
 CC take a long time to test because of their slow growth.
 XX
 SQ Sequence 16 BP; 4 A; 6 C; 4 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 598 ACCAGCCTGAGCCTG 613
 |||||
 DB 1 ACCAGCCTGAGCCTG 16

RESULT 483
 AAT53533/c
 ID AAT53533 standard; RNA; 17 BP.
 XX
 XX AC AAT53533;
 XX
 DT 25-MAR-2003 (updated)
 DT 27-MAR-1997 (first entry)
 XX
 XX Rat ICAM hammerhead ribozyme target sequence (nt. position 1006).
 DE
 XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW translocation; chronic myelogenous leukaemia; CML; cancer;
 KW Philadelphia chromosome; inflammation; autoimmune disease;
 KW atherosclerosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome;

KW AIDS; ss.

XX Rattus rattus.

XX PN WO9523225-A2.

XX PD 31-AUG-1995.

XX PF 23-FEB-1995; 95WO-IB00156.

XX PR 30-JAN-1995; 95US-0380734.

XX PR 23-FEB-1994; 94US-0201109.

XX PR 29-MAR-1994; 94US-0218934.

XX PR 04-APR-1994; 94US-0222795.

XX PR 07-APR-1994; 94US-0224483.

XX PR 15-APR-1994; 94US-0227958.

XX PR 15-APR-1994; 94US-0228041.

XX PR 18-MAY-1994; 94US-0245736.

XX PR 06-JUL-1994; 94US-0271280.

XX PR 15-AUG-1994; 94US-0291932.

XX PR 16-AUG-1994; 94US-0291433.

XX PR 17-AUG-1994; 94US-0292620.

XX PR 19-AUG-1994; 94US-0293520.

XX PR 02-SEP-1994; 94US-0300000.

XX PR 08-SEP-1994; 94US-0303039.

XX PR 23-SEP-1994; 94US-0311486.

XX PR 23-SEP-1994; 94US-0311749.

XX PR 28-SEP-1994; 94US-0314397.

XX PR 03-OCT-1994; 94US-0316771.

XX PR 07-OCT-1994; 94US-0319492.

XX PR 11-OCT-1994; 94US-0321993.

XX PR 04-NOV-1994; 94US-0334847.

XX PR 10-NOV-1994; 94US-0337608.

XX PR 28-NOV-1994; 94US-0345516.

XX PR 16-DEC-1994; 94US-0357577.

XX PR 23-DEC-1994; 94US-0363233.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;

XX PI Grimm S, Karpeisky A, Kisich K, Matulic-adamic J, Mcswiggen JA;

XX PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D;

XX PI Thompson JD, Tracz D, Usman N, Wincott FE, Woolf T;

XX WPI; 1995-351090/45.

XX Ribozyms having modified bases and methods for producing them

XX PT for use in inhibiting disease related genes

XX XX

Db

17 CCTGGTGATCTCCCA 2

RESULT 484

AAT53757/c

ID AAT53757 standard; RNA; 17 BP.

XX AC AAT53757;

XX XX

DT 25-MAR-2003 (updated)

DT 03-APR-1997 (first entry)

XX XX

Rat ICAM hammerhead ribozyme target sequence (nt. position 2607).

XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;

XX gene expression; downregulation; interleukin-5; IL-5; ICAM-1;

XX intercellular adhesion molecule; rel A; tumour necrosis factor;

XX TNF-alpha; respiratory syncytial virus; RSV; bor-abl; oncogene;

XX translocation; chronic myelogenous leukaemia; CML; cancer;

XX Philadelphia chromosome; inflammation; autoimmune disease;

XX atherosclerosis; myocardial infarction; stroke; restenosis;

XX transplant rejection; rheumatoid arthritis; psoriasis;

XX myocardial ischaemia; Kawasaki disease; septic shock; HIV;

XX human immunodeficiency virus; acquired immune deficiency syndrome;

XX AIDS; ss.

XX OS Rattus rattus.

XX XX

XX PN WO9523225-A2.

XX PD 31-AUG-1995.

XX XX

PF 23-FEB-1995; 95WO-IB00156.

XX PR 30-JAN-1995; 95US-0380734.

XX PR 23-FEB-1994; 94US-0201109.

XX PR 29-MAR-1994; 94US-0218934.

XX PR 04-APR-1994; 94US-0222795.

XX PR 07-APR-1994; 94US-0224483.

XX PR 15-APR-1994; 94US-0227958.

XX PR 15-APR-1994; 94US-0228041.

XX PR 18-MAY-1994; 94US-0245736.

XX PR 06-JUL-1994; 94US-0271280.

XX PR 15-AUG-1994; 94US-0291932.

XX PR 16-AUG-1994; 94US-0291433.

XX PR 17-AUG-1994; 94US-0292620.

XX PR 19-AUG-1994; 94US-0293520.

XX PR 02-SEP-1994; 94US-0300000.

XX PR 08-SEP-1994; 94US-0303039.

XX PR 23-SEP-1994; 94US-0311486.

XX PR 23-SEP-1994; 94US-0311749.

XX PR 28-SEP-1994; 94US-0314397.

XX PR 03-OCT-1994; 94US-0316771.

XX PR 07-OCT-1994; 94US-0319492.

XX PR 11-OCT-1994; 94US-0321993.

XX PR 10-NOV-1994; 94US-0334847.

XX PR 10-NOV-1994; 94US-0337608.

XX PR 28-NOV-1994; 94US-0345516.

XX PR 16-DEC-1994; 94US-0357577.

XX PR 23-DEC-1994; 94US-0363233.

XX XX

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;

XX PI Grimm S, Karpeisky A, Kisich K, Matulic-adamic J, Mcswiggen JA;

XX PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D;

XX PI Thompson JD, Tracz D, Usman N, Wincott FE, Woolf T;

XX WPI; 1995-351090/45.

XX Ribozyms having modified bases and methods for producing them

XX PT for use in inhibiting disease related genes

XX XX

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

334 CCTGGTGATCTCACA 349

|||||||

The present sequence represents a preferred target sequence for an enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the nucleotide base position indicated in the DE line. Regions of the mRNA that do not form secondary folding structures and that contain potential hammerhead and hairpin ribozyme cleavage sites were identified by computer analysis. Ribozymes directed against these mRNA sequences were designed and synthesised with modifications that improve their nuclease resistance. The ribozymes cleave the ICAM-1 target sequences and thereby inhibit ICAM-1 expression, making them useful for reducing transplant rejection and alleviating symptoms in patients with rheumatoid arthritis, asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to correct PI field.)

Sequence 17 BP; 4 A; 3 C; 7 G; 3 U; 0 other;

PS Claim 2; Page 204; 407pp; English.

XX The present sequence represents a preferred target sequence for

CC an enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1

CC mRNA at the nucleotide base position indicated in the DE line.

CC Regions of the mRNA that do not form secondary folding

CC structures and that contain potential hammerhead and hairpin

CC ribozyme cleavage sites were identified by computer analysis.

CC Ribozymes directed against these mRNA sequences were designed and

CC synthesised with modifications that improve their nuclease

CC resistance. The ribozymes cleave the ICAM-1 target sequences and

CC thereby inhibit ICAM-1 expression, making them useful for reducing

CC transplental rejection and alleviating symptoms in patients with

CC rheumatoid arthritis, asthma and other inflammatory disorders.

CC (Updated on 25-MAR-2003 to correct PI field.)

XX

SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CCTGGTGATAGTCA 349

DB 17 CCTGGTGATAGTCA 2

RESULT 485

AAAT81190

ID AAT81190 standard; RNA; 17 BP.

AC AAT81190;

XX

DT 29-SEP-1997 (first entry)

XX

DE Human c-myb hammerhead ribozyme target sequence (nt. position 1276).

XX

KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;

KW smooth muscle cell; hyperproliferation; restenosis; cancer;

KW c-myb; coronary angioplasty; ss.

XX

OS Homo sapiens.

XX

PN WO9531541-A2.

XX

PD 23-NOV-1995.

XX

PF 18-MAY-1995; 95WO-US06368.

XX

PR 13-JAN-1995; 95US-0373124.

PR 18-MAY-1994; 94US-0245466.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Draper K, Jarvis T, McSwiggen J, Stinchcomb DT;

XX

DR WPI; 1996-010927/01.

XX

PT New enzymatic nucleic acid molecules - which cleave RNA produced by

PT e.g. c-myb, for treating restenosis or cancer

XX

PS Claim 1; Page 68; 128pp; English.

XX

CC The present sequence represents the preferred target sequence for an

CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves

CC the human c-myb sequence at the base position indicated in the

CC descriptor line. The c-myb sequence was screened for optimal ribozyme

CC target sites using a computer folding algorithm, and regions of the mRNA

CC which did not form secondary folding structures and contained potential

CC ribozyme cleavage sites were identified. Ribozymes were synthesised and

CC their activities optimised by either varying the length of the binding

CC arms or by modification to prevent degradation by nucleases.

CC The ribozymes cleave the c-myb sequence and can be used to prevent

CC

CC smooth muscle cell hyperproliferation in restenosis, especially after

CC coronary angioplasty, and in cancers.

XX

SQ Sequence 17 BP; 1 A; 8 C; 3 G; 5 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 62.5%; Pred. No. 2.7e+02;

Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 795 COTGGCTGCTCCCTG 810

DB 2 CCGGCGUCCUACUG 17

RESULT 486

AAAX75174

ID AAX75174 standard; RNA; 17 BP.

XX

AC AAX75174;

XX

DT 28-JUL-1999 (first entry)

XX

DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #702.

XX

KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1;

KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;

KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;

KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;

KW foetal liver kinase 1; ss.

XX

OS Mus sp.

XX

PN WO9715662-A2.

XX

PD 01-MAY-1997.

XX

PF 25-OCT-1996; 96WO-US17480.

XX

PR 11-JAN-1996; 96US-0584040.

PR 26-OCT-1995; 95US-0005974.

XX

PA (CHIR) CHIRON CORP.

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX

DR WPI; 1997-259017/23.

XX

PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or

PT mRNA stability - useful for treating e.g. tumour angiogenesis,

PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX

PS Claim 4; Page 176; 218pp; English.

XX

CC The present invention describes nucleic acid molecules which modulate

CC the synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can

CC be treated by administering the nucleic acid molecule or the expression

CC vector to the patient. AAX75174 to AAX75752 represent specific examples

CC of nucleic acid molecules from the present invention.

XX

SQ Sequence 17 BP; 3 A; 7 C; 2 G; 5 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 56.2%; Pred. No. 2.7e+02;

Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 47 CTTAGCATCTCTCA 62

DB 17 CTTAGCATCTCTCA 62

```

Db      1 CUUUGCAUACUGCUCA 16

RESULT 487
AAX71624/c
ID    AAX71624 standard; RNA; 17 BP.
XX
AC    AAX71624;
XX
XX
DT    28-JUL-1999 (first entry)
XX
DE    Human KDR VEGF receptor hammerhead ribozyme substrate #636.
XX
KW    Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
KW    flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW    tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW    fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW    foetal liver kinase 1; ss.
XX
OS    Homo sapiens.
XX
PN    WO9715662-A2.
XX
XX
PD    01-MAY-1997.
XX
XX
PF    25-OCT-1996; 96WO-US17480.
XX
PR    11-JAN-1996; 96US-0584040.
PR    26-OCT-1995; 95US-0005974.
XX
PA    (CHIR ) CHIRON CORP.
PA    (RIBO-) RIBOZYME PHARM INC.
XX
PI    Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
XX
XX    WPI; 1997-259017/23.
XX
PT    Nucleic acid molecule modulating VEGF receptor(s) gene expression or
PT    mRNA stability - useful for treating e.g. tumour angiogenesis,
PT    psoriasis, rheumatoid arthritis, etc., in a human patient
XX
PS    Claim 4; Page 116; 218pp; English.
XX
CC    The present invention describes nucleic acid molecules which modulate
CC    the synthesis, expression and/or stability of a mRNA encoding 1 or more
CC    receptors of vascular endothelial growth factor (VEGF). A patient
CC    (preferably human) having a condition associated with the level of the
CC    fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC    receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC    angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC    be treated by administering the nucleic acid molecule or the expression
CC    vector to the patient. AAX67275 to AAX75752 represent specific examples
CC    of nucleic acid molecules from the present invention.
XX
SQ    Sequence 17 BP; 2 A; 3 C; 5 G; 7 U; 0 other;

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY    41 CAAAATCTTAGCATAC 56
      |||||
Db    17 CAAAATCTGAGCAGAC 2

RESULT 488
AAX63011
ID    AAX63011 standard; RNA; 17 BP.
XX
AC    AAX63011;
XX
XX
DT    16-JUL-1999 (first entry)
XX
DE    Granule bound starch synthase hammerhead substrate SEQ ID NO:75.
XX
KW    Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
KW    granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
KW    modulation; gene expression; transgenic plant; cleavage; canola plant;
KW    caffeine synthesis; coffee plant; nicotine production; tobacco;
KW    fruit ripening; flower pigmentation; lignin production; ss.
XX
OS    Zea mays.
XX
DE    Delta-9 desaturase hamerhead ribozyme target SEQ ID NO:886.
XX
KW    Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
KW    granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
KW    modulation; gene expression; transgenic plant; cleavage; canola plant;
KW    caffeine synthesis; coffee plant; nicotine production; tobacco;
KW    fruit ripening; flower pigmentation; lignin production; ss.
XX
OS    Zea mays.
XX
PN    WO9710328-A2.
XX
XX
PD    20-MAR-1997.
XX
XX
PF    12-JUL-1996; 96WO-US11689.
XX
PR    13-JUL-1995; 95US-0001135.
XX
PA    (DOWC ) DOWELANCO.
PA    (RIBO-) RIBOZYME PHARM INC.
XX
PI    Edington BE, Folkerts O, Guo L, McSwiggen JA, Merlo DJ;
PI    Merlo PRO, Skokut TA, Young SA, Zwick MG;
XX
XX    WPI; 1997-202224/18.
XX
PT    Ribozyme which modulates plant gene expression - preferably
PT    modulates expression of DELTA-9 desaturase or granule bound starch
PT    synthase in maize or canola
XX
PS    Claim 38; Page 87; 155pp; English.
XX
CC    The present invention describes an enzymatic nucleic acid molecule (I)
CC    with RNA cleaving activity, which modulates the expression of a plant
CC    gene. Also described is a gene comprising a cDNA sequence encoding maize
CC    Delta-9 desaturase. (I) can be used to modulate expression of a gene,
CC    preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
CC    gene, in a plant (preferably a maize or canola plant). (I) can be used
CC    to modulate caffeine synthesis in a coffee plant, nicotine production in
CC    a tobacco plant, fruit ripening processes in an apple, tomato, pear,
CC    plum or peach plant, flower pigmentation in a rose, petunia,
CC    chrysanthemum or marigold plant or lignin production in a tobacco,
CC    aspen, poplar or pine plant.
XX
SQ    Sequence 17 BP; 2 A; 1 C; 2 G; 12 U; 0 other;

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 2.7e+02;
Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY    1103 ATTATGTTAGTTTCTG 1118
      ||:|:|:|:|:|:|
Db    2 AUUUGUAUUUUUCUG 17

RESULT 489
AAX62200
ID    AAX62200 standard; RNA; 17 BP.
XX
XX
AC    AAX62200;
XX
XX
DT    16-JUL-1999 (first entry)
XX
DE    Granule bound starch synthase hammerhead substrate SEQ ID NO:75.
XX
KW    Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
KW    granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
KW    modulation; gene expression; transgenic plant; cleavage; canola plant;
KW    caffeine synthesis; coffee plant; nicotine production; tobacco;
KW    fruit ripening; flower pigmentation; lignin production; ss.
XX
OS    Zea mays.
XX

```


CC from the present invention. The ribozymes can be used for the treatment
 CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis,
 CC allergy and other inflammatory conditions. The ribozymes are also used
 CC to induce tolerance in a recipient to alloantigen from a donor.

XX SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 2.7e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 625 GACCAGTCCAGGAGC 640
 | | | | | : | | | | |
 Db 1 GUCCAGTCCAGGACC 16

RESULT 492

AAV94898

ID AAV94898 standard; RNA; 17 BP.

XX AC AAV94898;

DT 24-FEB-1999 (first entry)

DE Mouse IL-2 receptor g-chain substrate position 248.

XX Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
 KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
 KW autoimmune disease; psoriasis; allergy; inflammatory disease;
 KW graft rejection; ss.

XX Mus sp.

PN WO9824913-A2.

XX 11-JUN-1998.

XX 02-DEC-1997; 97WO-US21748.

XX 03-DEC-1996; 96US-0758306.

XX (RIBO-) RIBOZYME PHARM INC.

XX McSwiggen JA, Stinchcomb DT;

XX WPI; 1998-333332/29.

XX Ribozymes targeted to interleukin 2 - useful for treating e.g.
 PT cancer, autoimmune disease and allergies

XX Claim 4; Page 41; 61pp; English.

XX The present sequence invention describes ribozymes targeted to modulate
 CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded
 CC RNA. AAV93889 to AAV94574 represent specifically claimed ribozymes, and
 CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
 CC from the present invention. The ribozymes can be used for the treatment
 CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis,
 CC allergy and other inflammatory conditions. The ribozymes are also used
 CC to induce tolerance in a recipient to alloantigen from a donor.

XX Sequence 17 BP; 4 A; 7 C; 4 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 2.7e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 227 CTCAGCCTCAGGCATC 242
 | : | | | : | | | | |
 Db 1 CUGAGCCUCAGGCAAC 16

RESULT 493

AAV39410

ID AAV39410 standard; DNA; 17 BP.

XX AC AAV39410;

XX 21-SEP-1998 (first entry)

XX Humanised anti-HM1.24 antibody PCR primer SEQ ID NO:72.

XX Mouse; human; humanised; anti-HM1.24 antibody; myeloma; FR; CDR;
 KW framework region; complementarity determining region; antigenicity;
 KW PCR primer; ss.

XX Synthetic.

XX Mus sp.

XX Homo sapiens.

XX WO9814580-A1.

XX 09-APR-1998.

XX 03-OCT-1997; 97WO-JP03553.

XX 04-OCT-1996; 96JP-0264756.

XX (CHUS) CHUGAI SEIYAKU KK.

XX Koishihara Y, Kosaka M, Ohtomo T, Ono K, Tsuchiya M;

XX Yoshimura Y;

XX WPI; 1998-286421/25.

XX Humanised anti-HM1.24 antibody - for treatment of myeloma

XX Example 9; Page 140; 210pp; Japanese.

XX A humanised anti-HM1.24 antibody has been developed which comprises
 CC human L and H chain C regions, and L and/or H chain V regions
 CC containing material originating in mouse anti-HM1.24 antibody. The V
 CC regions contain framework (FR) regions of human origin and
 CC complementarity determining regions (CDR) of mouse origin, leading to
 CC a reshaped humanised antibody. The C regions are human Ck (L-chain) and
 CC human C gamma (especially C gamma 1) (H-chain). The FR regions of the
 CC L chain V region are derived from human subtype HSG1 (e.g. from human
 CC antibody RE1) and the FR regions of the H chain V region are derived
 CC from human subtype HSG1 (e.g. FR1-3 from human antibody HG3 and FR4
 CC from human antibody JH6). The present sequence represents a PCR primer
 CC used in an example from the present invention. The antibodies are used
 CC for the treatment of myeloma, especially by injection, intravenously,
 CC intramuscularly or subcutaneously. The antibodies are used at 0.01-1000
 CC (especially 5-100) mg/kg body weight. The humanised antibody has low
 CC antigenicity and is therefore effective therapeutically in humans.

XX Sequence 17 BP; 5 A; 7 C; 4 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 870 CCCACAGCCCAAGTTC 885
 | | | | | | | | | | | | | | |
 Db 2 CCCCAAGCCCAAGGTC 17

RESULT 494

AAA20491

ID AAA20491 standard; RNA; 17 BP.

XX AC AAA20491;

XX 19-JUN-2000 (first entry)

XX Integrin alpha 6 subunit substrate sequence SEQ ID NO:3717.

XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Zwick M, Pavco P, McSwiggen J;
XX DR WPI; 2000-647423/62.
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor
PT protein, interferon alpha and erythropoietin -
XX
PS Claim 37; Page 80; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
CC transcription factor gene, IRF-2 and/or the CAAT Displacement
CC Protein (CDP). Inhibition of the repressors removes prevents
CC inhibition (and consequently increases expression of) genes involved in
CC the production of erythropoietin, granulocyte colony stimulating factor
CC protein and interferon alpha.
XX
SQ Sequence 17 BP; 0 A; 9 C; 3 G; 5 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 145 CTCGGCTCCGCTCCGC 160
DB 2 CTCGGCTTCTCTCCGC 17

RESULT 497
AAF02789
ID AAF02789 standard; DNA; 17 BP.
XX
XX AAF02789;
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #1084.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US09721.
XX
PR 12-APR-1999; 99US-0129390.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, McSwiggen J;
XX
DR WPI; 2000-647423/62.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US09721.
XX
PR 12-APR-1999; 99US-0129390.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, McSwiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor
PT protein, interferon alpha and erythropoietin -
XX
PS Claim 37; Page 80; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
CC transcription factor gene, IRF-2 and/or the CAAT Displacement
CC Protein (CDP). Inhibition of the repressors removes prevents

CC inhibition (and consequently increases expression of) genes involved in
CC the production of erythropoietin, granulocyte colony stimulating factor
CC protein and interferon alpha.
XX
SQ Sequence 17 BP; 0 A; 9 C; 4 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 147 CGGCTCCGCTCCGCGC 162
DB 1 CGGCTTCTCTCCGCGC 16

RESULT 498
AAF03345
ID AAF03345 standard; DNA; 17 BP.
XX
XX AAF03345;
AC AAF03345;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #1640.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US09721.
XX
PR 12-APR-1999; 99US-0129390.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, McSwiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor
PT protein, interferon alpha and erythropoietin -
XX
PS Claim 37; Page 93; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
CC transcription factor gene, IRF-2 and/or the CAAT Displacement
CC Protein (CDP). Inhibition of the repressors removes prevents
CC inhibition (and consequently increases expression of) genes involved in
CC the production of erythropoietin, granulocyte colony stimulating factor
CC protein and interferon alpha.
XX
SQ Sequence 17 BP; 2 A; 1 C; 2 G; 12 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGGGA 1159
DB 2 TTTTTCCTTTTGGGA 17

RESULT 499
AAF05405/c
ID AAF05405 standard; DNA; 17 BP.

CC Protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.

XX SQ Sequence 17 BP; 6 A; 1 C; 5 G; 5 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 439 ACAAGTTCCTGAAGT 454
 |||||
 Db 2 AGGAATTGCTGAAGT 17

RESULT 502

AAAF07122
 ID AAF07122 standard; DNA; 17 BP.

XX AC AAF07122;

XX DT 16-FEB-2001 (first entry)

XX DE Hammerhead ribozyme substrate #3379.

XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;

XX KW interferon alpha; ss.

XX OS Homo sapiens.

XX FN WO200061729-A2.

XX PD 19-OCT-2000.

XX PF 11-APR-2000; 2000WO-US09721.

XX PR 12-APR-1999; 99US-0129390.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PL Blatt L, Zwick M, Pavco P, McSwiggen J;

XX DR WPI; 2000-647423/62.

XX PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 useful for producing e.g. granulocyte colony stimulating factor

XX PT protein, interferon alpha and erythropoietin -

XX PS Claim 54; Page 133; 164pp; English.

XX CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, ERX3/COUP-TF-1, the GATA
 CC transcription factor gene, IRF-2 and/or the CAAT Displacement
 CC Protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.

XX SQ Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 394 GCAGCAATGCCCGGC 409
 |||||
 Db 1 GCAGAAATGCCCGGC 16

RESULT 503

AAC70618/c

ID AAC70618 standard; DNA; 17 BP.

XX AC AAC70618;

XX DT 09-FEB-2001 (first entry)

XX DE Single nucleotide polymorphism PCR primer #299.

XX KW Single nucleotide polymorphism; SNP; human; genetic disease;

XX KW disease susceptibility; cardiovascular system; endocrine system;

XX KW neurological system; forensic testing; paternity testing; PCR primer; ss.

XX OS Homo sapiens.

XX FN WO200058519-A2.

XX PD 05-OCT-2000.

XX PF 30-MAR-2000; 2000WO-US08440.

XX PR 31-MAR-1999; 99US-0127248.

XX PA (WHED) WHITEHEAD INST BIOMEDICAL RES.

XX PA (AFFY-) AFFYMETRIX INC.

XX PI Altschuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;

XX PI Lipshutz RJ, Patil N, Sklar P;

XX DR WPI; 2000-611722/58.

XX CC Nucleic acid selected from one of 106 genes comprising single

XX CC nucleotide polymorphisms, allele-specific oligonucleotides to the genes

XX CC are useful for phenotypic correlations, forensics, paternity testing,

XX CC medicine and genetic analysis -

XX PS Claim 8; Fig 5; 214pp; English.

XX CC The present invention is concerned with a number of human single
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human
 CC genes. These SNPs can be used in disease diagnosis and prediction of an
 CC individual's susceptibility to disease, in forensic and paternity testing
 CC and in genetic mapping. In particular, the SNPs of the invention can be
 CC used to diagnose susceptibility to diseases of the cardiovascular,
 CC endocrine and neurological systems, such as coronary artery disease,
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
 CC diseases.

XX SQ Sequence 17 BP; 6 A; 7 C; 3 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;

XX CC Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 CTCCTGGGCTGGCTGA 274

Db 16 CTCCTGGGCTGGGCTGA 1

RESULT 504

AAC70621/c

ID AAC70621 standard; DNA; 17 BP.

XX AC AAC70621;

XX DT 09-FEB-2001 (first entry)

XX DE Single nucleotide polymorphism PCR primer #301.

XX KW Single nucleotide polymorphism; SNP; human; genetic disease;

XX KW disease susceptibility; cardiovascular system; endocrine system;

XX KW neurological system; forensic testing; paternity testing; PCR primer; ss.

XX OS Homo sapiens.

XX PN WO200058519-A2.
XX PD 05-OCT-2000.
XX PF 30-MAR-2000; 2000WO-US08440.
XX PR 31-MAR-1999; 99US-0127248.
XX PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX PA (AFFY-) AFFYMETRIX INC.
XX PI Altshuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
XX PI Lipshutz RJ, Patil N, Sklar P;
XX DR WPI; 2000-611722/58.
XX XX Nucleic acid selected from one of 106 genes comprising single
PT nucleotide polymorphisms, allele-specific oligonucleotides to the genes
PT are useful for phenotypic correlations, forensics, paternity testing,
PT medicine and genetic analysis -
XX XX Claim 8; Fig 5; 214pp; English.
XX CC The present invention is concerned with a number of human single
CC nucleotide polymorphisms (SNPs) which the inventors identified in human
CC genes. These SNPs can be used in disease diagnosis and prediction of an
CC individual's susceptibility to disease, in forensic and paternity testing
CC and in genetic mapping. In particular, the SNPs of the invention can be
CC used to diagnose susceptibility to diseases of the cardiovascular,
CC endocrine and neurological systems, such as coronary artery disease,
CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC diseases.
XX CC
XX SQ Sequence 17 BP; 6 A; 7 C; 3 G; 1 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 259 CTCCTGGGCTGGCTGA 274
DB 16 CTCCTGGGCTGGCTGA 1
RESULT 505
AAA25453
ID AAA25453 standard; DNA; 17 BP.
XX AC AAA25453;
XX DT 19-JUL-2000 (first entry)
XX DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1951.
XX KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX OS Homo sapiens.
XX XX
XX PN WO9954459-A2.
XX PD 28-OCT-1999.
XX PF 19-APR-1999; 99WO-US08547.
XX PR 20-APR-1998; 98US-0082404.
XX PR 23-JUN-1998; 98US-0103636.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Thompson JD, Beigelman L, McSwiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;

PI Thompson JD, Beigelman L, McSwiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
XX PI Matulic-Adamic J;
XX DR WPI; 2000-013248/01.
XX XX New nucleic acids that interact, and optionally cleave, target
PT sequences, used to treat cancer -
XX XX Claim 77; Page 79; 148pp; English.
XX CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodithioate
CC link, having endonuclease activity. (A), and more generally any
CC catalytic nucleic acid (A') that modulates expression of the oestrogen
CC receptor gene, are used to treat cancer (particularly of breast or
CC endometrium), in vivo or by transforming cells ex vivo and implanting
CC treated cells, or for other conditions associated with levels of
CC oestrogen receptor. Because of the high selectivity for targeted RNA, (A)
CC can also be used to correlate inhibition of gene expression with
CC alterations in phenotype, particularly for identification of therapeutic
CC targets, and as research reagents (for RNA, in the same way that
CC restriction endonucleases are used with DNA). The combination of
CC modifications in (A) improves resistance to nucleases, binding affinity
CC and/or activity. AAA23503 to AAA24747 represent oestrogen receptor
CC hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their
CC corresponding target sequences. AAA25993 to AAA26105 represent oestrogen
CC receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent
CC their corresponding target sequences. AAA26219 to AAA26271 represent
CC other ribozyme sequences and antisense oligonucleotides used in the
CC exemplification of the present invention.
XX CC
XX SQ Sequence 17 BP; 1 A; 0 C; 1 G; 15 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1144 TTTTTCCTTTTTCCTTTTTCCTGA 1159
DB 2 TTTTTCCTTTTTCCTTTTTCCTGA 17
RESULT 506
AAA25454
ID AAA25454 standard; DNA; 17 BP.
XX AC AAA25454;
XX DT 19-JUL-2000 (first entry)
XX DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1952.
XX KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX OS Homo sapiens.
XX XX
XX PN WO9954459-A2.
XX PD 28-OCT-1999.
XX PF 19-APR-1999; 99WO-US08547.
XX PR 20-APR-1998; 98US-0082404.
XX PR 23-JUN-1998; 98US-0103636.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Thompson JD, Beigelman L, McSwiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;


```

PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX (UYDE ) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification -
XX
XX Claim 7; Page 252; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention.
XX
XX Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 974 TCACCTTGACCACTCC 989
Db 1 TCATCTGACCACTCC 16

RESULT 509
ABA81248
ID ABA81248 standard; DNA; 17 BP.
XX
XX ABA81248;
XX
XX 24-JAN-2002 (first entry)
XX
XX PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4094.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antileptic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US09761.
XX
XX 27-MAR-2000; 2000US-192176P.
XX

```

```

PR 27-MAR-2000; 2000US-192179P.
PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX (UYDE ) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification -
XX
XX Claim 7; Page 265; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention.
XX
XX Sequence 17 BP; 0 A; 2 C; 9 G; 6 T; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1235 TGGTGTGGACGTGGC 1250
Db 1 TGGTGTGGTGTGGC 16

RESULT 510
ABA81249/c
ID ABA81249 standard; DNA; 17 BP.
XX
XX ABA81249;
XX
XX 24-JAN-2002 (first entry)
XX
XX PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4095.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antileptic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US09761.
XX
XX

```

```

PR 27-MAR-2000; 2000US-192176P.
PR 27-MAR-2000; 2000US-192179P.
PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification -
XX
XX Claim 7; Page 265; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p33, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CTRF, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention.
XX
XX Sequence 17 BP; 6 A; 9 C; 2 G; 0 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1235 TGGTCTGGACGTGGC 1250
DB ||||| ||||| |||||
17 TGGTGTGGTGTGGTGGC 2

RESULT 511
ABK03155/c
ID ABK03155 standard; RNA; 17 BP.
XX
XX AC ABK03155;
XX
XX 12-MAR-2002 (first entry)
XX
XX Human CD20 Inozyme #106.
XX
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
XX muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
XX inflammatory arthropathy; central nervous system injury;
XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX Parkinson's disease; ataxia; Huntington's disease;
XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
XX OS
XX Synthetic.
XX
XX PN WO200159103-A2.
XX

```

```

PD 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US04273.
XX
XX 11-FEB-2000; 2000US-181797P.
XX 28-FEB-2000; 2000US-185516P.
XX 06-MAR-2000; 2000US-187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, McSwiggen J, Chowrira BM;
XX
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
XX and central nervous system injury -
XX
XX Claim 30; Page 147; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO).
XX The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNazyme) an inozyme (an endolytic nucleic acid cleaving a RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
XX motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinczyme
XX (cleaving RNA with a VGY motif). The CD20-targeting nucleic acid is used
XX to cleave RNA of CD20 in the presence of a divalent cation that is
XX preferably Mg2+. Furthermore, it may be contacted with a cell to reduce
XX CD20 activity of the cell and treat a patient having a condition
XX associated with the level of CD20. The treatment may further comprise the
XX use of one or more therapeutics. In particular, the CD20 targeting
XX nucleic acid may be used to treat lymphoma, leukaemia, B-cell
XX lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
XX low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
XX immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
XX immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
XX thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting
XX nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
XX divalent cation that is preferably Mg2+. Furthermore, the nucleic acid
XX may be contacted with a cell to reduce NOGO activity of the cell and
XX treat a patient having a condition associated with the level of NOGO. The
XX treatment may further comprise the use of one or more therapies.
XX In particular, the NOGO-targeting nucleic acid may be used to treat
XX central nervous system (CNS) injury and cerebrovascular accident (CVA,
XX stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX disease, muscular dystrophy, and/or other neurodegenerative disease
XX states which respond to the modulation of NOGO expression. The
XX present sequence is an inozyme of the invention.
XX
XX Sequence 17 BP; 1 A; 4 C; 4 G; 8 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 385 CCAGAGGTGGCAGCAA 400
DB ||||| ||||| |||||
17 CCAGAAATGGCAGCAA 2

RESULT 512
ABK03627/c
ID ABK03627 standard; RNA; 17 BP.
XX
XX AC ABK03627;

```

XX 12-WAR-2002 (first entry)
XX Human CD20 DNazyme #81.
XX Human; ss: antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
XX muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX DNazyme; inozyme; G-cleaver; amberyne; zinzyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytoma; IWC; immune thrombocytopenia; stroke; dementia;
XX inflammatory arthropathy; central nervous system injury;
XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX Parkinson's disease; ataxia; Huntington's disease;
XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
OS Homo sapiens.
OS Synthetic.
XX WO200159103-A2.
XX 16-AUG-2001.
XX 09-FEB-2001; 2001WO-US04273.
XX 11-FEB-2000; 2000US-181797P.
XX 28-FEB-2000; 2000US-185516P.
XX 06-MAR-2000; 2000US-187128P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWIRRA B M.
XX Blatt L, McSwiggen J, Chowirra BM;
XX WPI; 2001-607195/69.
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
XX and central nervous system injury -
XX Claim 30; Page 160; 200pp; English.
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO).
XX The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
XX motif) or an amberyne (cleaving RNA with an NGN triplet), a zinzyme
XX (cleaving RNA with a YGY motif). The CD20-targetting nucleic acid is used
XX to cleave RNA of CD20 in the presence of a divalent cation that is
XX preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
XX CD20 activity of the cell and treat a patient having a condition
XX associated with the level of CD20. The treatment may further comprise the
XX use of one or more therapies. In particular, the CD20 targeting
XX nucleic acid may be used to treat lymphoma, leukaemia, B-cell
XX lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
XX immunodeficiency virus associated NHL, mantle-cell lymphoma (MCL),
XX immunocytoma (IWC), small B-cell lymphocytic lymphoma, immune
XX thrombocytopenia, and inflammatory arthropathy. The NOGO-targetting
XX nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
XX divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
XX may be contacted with a cell to reduce NOGO activity of the cell and
XX treat a patient having a condition associated with the level of NOGO. The
XX treatment may further comprise the use of one or more therapies.
XX In particular, the NOGO-targetting nucleic acid may be used to treat
XX central nervous system (CNS) injury and cerebrovascular accident (CVA),

CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob.
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The
CC present sequence is a DNazyme molecule of the invention.
XX Sequence 17 BP; 4 A; 3 C; 2 G; 8 U; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 437 TCAGAAAGTTCGTGAA 452
DB 17 TAAGAAAGTTCGTCAA 2
RESULT 513
ABV80570/c
ID ABV80570 standard; DNA; 17 BP.
XX AC ABV80570;
XX DT 03-JAN-2003 (first entry)
XX DE Human HTPL scanning oligonucleotide SEQ ID 1816.
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
XX human testis expressed Patched like protein; testis; adrenal; liver;
XX male germ cell development; bone marrow; brain; kidney; lung; placenta;
XX prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX OS Homo sapiens.
XX PN EP1229046-A2.
XX PD 07-AUG-2002.
XX PF 28-JAN-2002; 2002EP-0001167.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 23-MAY-2001; 2001US-0864761.
XX 09-OCT-2001; 2001US-0327898.
XX (AEOM-) AEOMICA INC.
XX Zhan J;
XX WPI; 2002-676582/73.
XX Novel isolated human testis expressed Patched like protein (HTPL),
XX useful for identifying agonist and antagonist and specific binding
XX partners, and for treating subjects having defects in HTPL -
XX Example 2; Page 301; 718pp; English.
XX The present invention relates to human testis expressed Patched like
XX protein (HTPL), see ABV78759 to ABV78762 and AB988519 to AB988520. HTPL
XX has two isoforms, with a few single base pair differences between the
XX two. One of the single base pair changes introduces a premature stop
XX codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX shares an overall structure organisation with the Patched protein. The
XX shared structural features strongly imply that HTPL plays a role similar
XX to that of Patched, and is a potential tumour suppressor. HTPL is
XX important in regulating male germ cell development, and the HTPL gene was
XX mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX useful for diagnosing a disorder caused by mutation in HTPL, and in

CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.

XX SQ Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 239 CATCTGCATCTGGGAC 254
 ||| |||||
 Db 17 CATGTTTCATCTGGGAC 2

RESULT 514
 ABV80571/c
 ID ABV80571 standard; DNA; 17 BP.
 XX AC ABV80571;
 XX 03-JAN-2003 (first entry)
 XX Human HTPL scanning oligonucleotide SEQ ID 1817.
 DE Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX Homo sapiens.
 XX OS
 XX EP1229046-A2.
 XX 07-AUG-2002.
 XX 28-JAN-2002; 2002EP-0001167.
 XX 30-JAN-2001; 2001WO-US00663.
 XX 30-JAN-2001; 2001WO-US00664.
 XX 30-JAN-2001; 2001WO-US00665.
 XX 30-JAN-2001; 2001WO-US00667.
 XX 30-JAN-2001; 2001WO-US00668.
 XX 23-MAY-2001; 2001WO-US00669.
 XX 09-OCT-2001; 2001US-0864761.
 XX (AEOM-) AEOMICA INC.
 XX Zhan J;
 XX WPI; 2002-676582/73.
 XX Novel isolated human testis expressed Patched like protein (HTPL),
 XX useful for identifying agonist and antagonist and specific binding
 XX partners, and for treating subjects having defects in HTPL -
 XX Example 2; Page 302; 718pp; English.

CC The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was

CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.

XX SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 239 CATCTGCATCTGGGAC 254
 ||| |||||
 Db 16 CATGTTTCATCTGGGAC 1

RESULT 515
 ABV82838
 ID ABV82838 standard; DNA; 17 BP.
 XX AC ABV82838;
 XX 03-JAN-2003 (first entry)
 XX Human HTPL scanning oligonucleotide SEQ ID 4084.
 DE Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX Homo sapiens.
 XX OS
 XX EP1229046-A2.
 XX 07-AUG-2002.
 XX 28-JAN-2002; 2002EP-0001167.
 XX 30-JAN-2001; 2001WO-US00663.
 XX 30-JAN-2001; 2001WO-US00664.
 XX 30-JAN-2001; 2001WO-US00665.
 XX 30-JAN-2001; 2001WO-US00667.
 XX 30-JAN-2001; 2001WO-US00668.
 XX 23-MAY-2001; 2001US-0864761.
 XX 09-OCT-2001; 2001US-0327898.
 XX (AEOM-) AEOMICA INC.
 XX Zhan J;
 XX WPI; 2002-676582/73.
 XX Novel isolated human testis expressed Patched like protein (HTPL),
 XX useful for identifying agonist and antagonist and specific binding
 XX partners, and for treating subjects having defects in HTPL -
 XX Example 2; Page 599; 718pp; English.

CC The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was

CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.

XX Sequence 17 BP; 2 A; 4 C; 2 G; 9 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1137 CTATGCTTTTCT 1152

Db 2 CTATGCTTTTCT 17

RESULT 516

ABV82839

ID ABV82839 standard; DNA; 17 BP.

XX AC ABV82839;

XX DT 03-JAN-2003 (first entry)

XX DE Human HTPL scanning oligonucleotide SEQ ID 4085.

XX KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX OS Homo sapiens.

XX XX

PN EF1229046-A2.

XX XX

PD 07-AUG-2002.

XX XX

XX PF 28-JAN-2002; 2002EP-0001167.

XX PR 30-JAN-2001; 2001WO-US00663.

XX PR 30-JAN-2001; 2001WO-US00664.

XX PR 30-JAN-2001; 2001WO-US00665.

XX PR 30-JAN-2001; 2001WO-US00667.

XX PR 30-JAN-2001; 2001WO-US00668.

XX PR 30-JAN-2001; 2001WO-US00669.

XX PR 23-MAY-2001; 2001US-0864761.

XX PR 09-OCT-2001; 2001US-0327898.

XX XX

PA (AEOM-) AEOMICA INC.

XX XX

PI Zhan J;

XX XX

XX WPI; 2002-676582/73.

XX XX

XX Novel isolated human testis expressed Patched like protein (HTPL),

XX useful for identifying agonist and antagonist and specific binding

XX partners, and for treating subjects having defects in HTPL -

XX XX

XX Example 2; Page 599; 718pp; English.

XX PS

XX The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and ABV8519 to ABV8520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL

CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.

XX Sequence 17 BP; 3 A; 3 C; 2 G; 9 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1137 CTATGCTTTTCT 1152

Db 1 CTATGCTTTTCT 16

RESULT 517

ABV89507

ID ABV89507 standard; DNA; 17 BP.

XX AC ABV89507;

XX DT 23-DEC-2002 (first entry)

XX DE Human POSHL1 scanning oligonucleotide SEQ ID NO 220.

XX KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX OS Homo sapiens.

XX XX

PN EP1239051-A2.

XX XX

PD 11-SEP-2002.

XX XX

XX PF 28-JAN-2002; 2002EP-0001165.

XX PR 30-JAN-2001; 2001WO-US00663.

XX PR 30-JAN-2001; 2001WO-US00664.

XX PR 30-JAN-2001; 2001WO-US00665.

XX PR 30-JAN-2001; 2001WO-US00666.

XX PR 30-JAN-2001; 2001WO-US00667.

XX PR 30-JAN-2001; 2001WO-US00668.

XX PR 30-JAN-2001; 2001WO-US00669.

XX PR 30-JAN-2001; 2001WO-US00670.

XX PR 23-MAY-2001; 2001US-0864761.

XX PR 10-OCT-2001; 2001US-0328205.

XX XX

PA (AEOM-) AEOMICA INC.

XX XX

PI Shannon M;

XX XX

XX WPI; 2002-684061/74.

XX XX

XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,

XX POSHL-1, useful for treating disorders associated with decreased

XX expression or activity of human POSHL1 -

XX XX

XX Example 2; SEQ ID NO 220; 60pp + Sequence Listing; English.

XX PS

XX The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino

CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.
 CC
 CC SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. NO. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 CGCTGATCCTCAAGGT 175
 Db 2 CGCTGCTCTCCAGGT 17
 ||||| ||||| |||||

RESULT 518
 ABV89508
 ID ABV89508 standard; DNA; 17 BP.
 AC ABV89508;
 XX
 XX 23-DEC-2002 (first entry)
 XX
 XX Human POSHL1 scanning oligonucleotide SEQ ID NO 221.
 XX
 KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX
 OS Homo sapiens.
 XX
 XX EP1239051-A2.
 XX
 XX 11-SEP-2002.
 XX
 XX 28-JAN-2002; 2002EP-0001165.
 XX
 XX 30-JAN-2001; 2001WO-US00663.
 XX
 XX 30-JAN-2001; 2001WO-US00664.
 XX
 XX 30-JAN-2001; 2001WO-US00665.
 XX
 XX 30-JAN-2001; 2001WO-US00666.
 XX
 XX 30-JAN-2001; 2001WO-US00667.
 XX
 XX 30-JAN-2001; 2001WO-US00668.
 XX
 XX 30-JAN-2001; 2001WO-US00669.
 XX
 XX 23-MAY-2001; 2001WO-US00670.
 XX
 XX 10-OCT-2001; 2001US-0328205.
 XX
 XX (AEOM-) AEOMICA INC.
 XX
 XX Shannon M;
 XX
 XX WPI; 2002-684061/74.
 XX

Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 PT POSHL-1, useful for treating disorders associated with decreased
 PT expression or activity of human POSHL1 -
 XX

PS Example 2; SEQ ID NO 221; 60pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.
 CC
 CC SQ Sequence 17 BP; 1 A; 7 C; 5 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. NO. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 CGCTGATCCTCAAGGT 175
 Db 1 CGCTGCTCTCCAGGT 16
 ||||| ||||| |||||

RESULT 519
 ABV90534
 ID ABV90534 standard; DNA; 17 BP.
 AC ABV90534;
 XX
 XX 23-DEC-2002 (first entry)
 XX
 XX Human POSHL1 scanning oligonucleotide SEQ ID NO 1247.
 XX
 KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX
 OS Homo sapiens.
 XX
 XX EP1239051-A2.
 XX
 XX 11-SEP-2002.
 XX
 XX 28-JAN-2002; 2002EP-0001165.
 XX
 XX 30-JAN-2001; 2001WO-US00663.
 XX
 XX 30-JAN-2001; 2001WO-US00664.
 XX
 XX 30-JAN-2001; 2001WO-US00665.
 XX
 XX 30-JAN-2001; 2001WO-US00666.
 XX
 XX 30-JAN-2001; 2001WO-US00667.
 XX
 XX 30-JAN-2001; 2001WO-US00668.
 XX
 XX 30-JAN-2001; 2001WO-US00669.
 XX
 XX 23-MAY-2001; 2001WO-US00670.
 XX
 XX 10-OCT-2001; 2001US-0328205.
 XX
 XX (AEOM-) AEOMICA INC.
 XX
 XX Shannon M;
 XX
 XX WPI; 2002-684061/74.
 XX

PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 PT POSHL-1, useful for treating disorders associated with decreased
 PT expression or activity of human POSHL1 -
 XX
 XX Example 2; SEQ ID NO 1247; 60pp + Sequence Listing; English.
 PS
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, AB88399), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.
 XX
 XX Sequence 17 BP; 4 A; 9 C; 2 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 570 GCTCCAGCAGGCCCTC 585
 DB 2 GCTCCAGCAGGCCCTC 17

RESULT 520
 ABV90535
 ID ABV90535 standard; DNA; 17 BP.
 AC ABV90535;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1248.

XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.

XX Homo sapiens.

XX EP1239051-A2.

XX 11-SEP-2002.

XX 28-JAN-2002; 2002EP-0001165.

XX 30-JAN-2001; 2001WO-US00663.

XX 30-JAN-2001; 2001WO-US00664.

XX 30-JAN-2001; 2001WO-US00665.

XX 30-JAN-2001; 2001WO-US00666.

XX 30-JAN-2001; 2001WO-US00667.

XX 30-JAN-2001; 2001WO-US00668.

XX 30-JAN-2001; 2001WO-US00669.

XX 23-MAY-2001; 2001US-0864761.

XX 10-OCT-2001; 2001US-0328205.

XX (ABOM-) AEOMICA INC.

XX

PI Shannon M;
 XX WPI; 2002-684061/74.

PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 PT POSHL-1, useful for treating disorders associated with decreased
 PT expression or activity of human POSHL1 -

XX Example 2; SEQ ID NO 1248; 60pp + Sequence Listing; English.

XX The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, AB88399), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.

CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.

XX Sequence 17 BP; 3 A; 9 C; 2 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 570 GCTCCAGCAGGCCCTC 585
 DB 1 GCTCCAGCAGGCCCTC 16

RESULT 521

ABV90546/c

ID ABV90546 standard; DNA; 17 BP.

XX AC ABV90546;

XX

XX 23-DEC-2002 (first entry)

XX

DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1259.

XX

KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;

KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;

KW gene therapy; transgenic; ss.

XX Homo sapiens.

XX EP1239051-A2.

XX 11-SEP-2002.

XX 28-JAN-2002; 2002EP-0001165.

XX 30-JAN-2001; 2001WO-US00663.

XX 30-JAN-2001; 2001WO-US00664.

XX 30-JAN-2001; 2001WO-US00665.

XX 30-JAN-2001; 2001WO-US00666.

XX 30-JAN-2001; 2001WO-US00667.

XX 30-JAN-2001; 2001WO-US00668.

XX 30-JAN-2001; 2001WO-US00669.

XX 30-JAN-2001; 2001WO-US00670.

XX 23-MAY-2001; 2001US-0864761.

```
PR 10-OCT-2001; 2001US-0328205.
XX (AEOM-) AEOMICA INC.
XX Shannon M;
PI WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 1259; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, AB88399), a sequence having 65% sequence identity to (SI),
CC (SI) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (II) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
XX Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 268 TGGCTGATCACAAGAGG 283
DB 17 TGGGTGATCACAGAGG 2
RESULT 522
ABV90554/C
ID ABV90554 standard; DNA; 17 BP.
XX
XX ABV90554;
AC
XX
XX 23-DEC-2002 (first entry)
DT
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 1267.
DE
XX
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
XX Homo sapiens.
OS
XX
XX EP1239051-A2.
PN
XX
XX 11-SEP-2002.
PD
XX
XX 28-JAN-2002; 2002EP-0001165.
PF
XX
XX 30-JAN-2001; 2001WO-US00663.
PR
XX
XX 30-JAN-2001; 2001WO-US00664.
PR
XX
XX 30-JAN-2001; 2001WO-US00665.
PR
XX
XX 30-JAN-2001; 2001WO-US00666.
PR
XX
XX 30-JAN-2001; 2001WO-US00667.
PR
```

```
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 23-MAY-2001; 2001US-0864761.
PR 10-OCT-2001; 2001US-0328205.
XX
XX (AEOM-) AEOMICA INC.
XX Shannon M;
PI WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 1267; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, AB88399), a sequence having 65% sequence identity to (SI),
CC (SI) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
XX Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 261 CCTGGGCTGGCTGATC 276
DB 16 CATGGGCTGGGTGATC 1
RESULT 523
ABV91053/C
ID ABV91053 standard; DNA; 17 BP.
XX
XX ABV91053;
AC
XX
XX 23-DEC-2002 (first entry)
DT
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 1766.
DE
XX
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
XX Homo sapiens.
OS
XX
XX EP1239051-A2.
PN
XX
XX 11-SEP-2002.
PD
XX
XX 28-JAN-2002; 2002EP-0001165.
PF
XX
XX 30-JAN-2001; 2001WO-US00663.
PR
```

PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 23-MAY-2001; 2001US-0864761.
 PR 10-OCT-2001; 2001US-0328205.
 XX (AEOM-) ABOMICA INC.
 PA Shannon M;
 XX WPI; 2002-684061/74.
 XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 PT POSHL-1, useful for treating disorders associated with decreased
 PT expression or activity of human POSHL1 -
 XX Example 2; SEQ ID NO 1766; 60pp + Sequence Listing; English.
 PS The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, AB983999), a sequence having 55% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC for identifying a specific binding partner. (I) is useful
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they are useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.
 XX SQ Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 906 GGCCCTGGTCTAAAG 921
 Db 17 GACCCCTGGTCTAAAG 2
 RESULT 524
 ABV91054/c
 ID ABV91054 standard; DNA; 17 BP.
 XX AC ABV91054;
 DT 23-DEC-2002 (first entry)
 XX Human POSHL1 scanning oligonucleotide SEQ ID NO 1767.
 DE Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX Homo sapiens.
 OS EP1239051-A2.
 XX 11-SEP-2002.

XX 28-JAN-2002; 2002EP-0001165.
 XX 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 23-MAY-2001; 2001US-0864761.
 PR 10-OCT-2001; 2001US-0328205.
 XX (AEOM-) ABOMICA INC.
 PA Shannon M;
 XX WPI; 2002-684061/74.
 XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 PT POSHL-1, useful for treating disorders associated with decreased
 PT expression or activity of human POSHL1 -
 XX Example 2; SEQ ID NO 1767; 60pp + Sequence Listing; English.
 PS The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, AB983999), a sequence having 55% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC for identifying a specific binding partner. (I) is useful
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they are useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.
 XX SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 906 GGCCCTGGTCTAAAG 921
 Db 16 GACCCCTGGTCTAAAG 1
 RESULT 525
 ABQ63634/c
 ID ABQ63634 standard; DNA; 17 BP.
 XX AC ABQ63634;
 XX 20-AUG-2002 (first entry)
 DT Human KTOM1a portion (ABQ63232) probe # 347.
 DE Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
 KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
 KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
 XX Homo sapiens.

```

XX  WO200224750-A2.
XX  28-MAR-2002.
XX  21-SEP-2001; 2001WO-US29656.
XX  21-SEP-2000; 2000US-234687P.
XX  27-SEP-2000; 2000US-236359P.
XX  04-OCT-2000; 2000GB-0024263.
XX  30-JAN-2001; 2001WO-US00661.
XX  30-JAN-2001; 2001WO-US00662.
XX  30-JAN-2001; 2001WO-US00663.
XX  30-JAN-2001; 2001WO-US00664.
XX  30-JAN-2001; 2001WO-US00665.
XX  30-JAN-2001; 2001WO-US00666.
XX  30-JAN-2001; 2001WO-US00667.
XX  30-JAN-2001; 2001WO-US00668.
XX  30-JAN-2001; 2001WO-US00669.
XX  23-MAY-2001; 2001US-0864761.
XX  28-AUG-2001; 2001US-315676P.
XX  (AEOM-) AEOMICA INC.
XX  Zhang J;
XX  WPI; 2002-479509/51.
XX  New human kidney tumor overexpressed membrane (KTOM1) protein and
XX  nucleic acids encoding the protein, useful for treating subjects having
XX  defects in KTOM1 which can manifest as cancer of the kidney, or as a
XX  disorder of e.g., liver or bone -
XX  Example 2; Page 203; 418pp; English.
XX  The invention relates to a novel isolated nucleic acid encoding human
XX  KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
XX  invention has cytostatic activity. The nucleotide may have a use in gene
XX  therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX  monitor a disease caused by altered expression of human KTOM1.
XX  Compositions comprising the nucleic acids, proteins or antibodies may be
XX  used to treat subjects having defects in KTOM1 which can manifest as
XX  cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX  heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX  function. The sequence represents a probe used in the invention to
XX  scan the nt 1-1001 portion of human KTOM1a (ABQ63232).
XX  Sequence 17 BP; 2 A; 8 C; 5 G; 2 T; 0 other;
XX  Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX  Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX  Qy 1249 GCCATGTGAGCCGAG 1264
XX  Db 17 GCCCTGTGGGCGCAG 2
XX  RESULT 526
XX  ABQ63636/c
XX  ID ABQ63636 standard; DNA; 17 BP.
XX  AC ABQ63636;
XX  XX 20-AUG-2002 (first entry)
XX  DT Human KTOM1a portion (ABQ63232) probe # 349.
XX  DE Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
XX  KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
XX  KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX  XX 21-SEP-2001; 2001WO-US29656.
XX  21-SEP-2000; 2000US-234687P.
XX  27-SEP-2000; 2000US-236359P.
XX  04-OCT-2000; 2000GB-0024263.
XX  30-JAN-2001; 2001WO-US00661.
XX  30-JAN-2001; 2001WO-US00662.
XX  30-JAN-2001; 2001WO-US00663.
XX  30-JAN-2001; 2001WO-US00664.
XX  30-JAN-2001; 2001WO-US00665.
XX  30-JAN-2001; 2001WO-US00666.
XX  30-JAN-2001; 2001WO-US00667.
XX  30-JAN-2001; 2001WO-US00668.
XX  30-JAN-2001; 2001WO-US00669.
XX  23-MAY-2001; 2001US-0864761.
XX  28-AUG-2001; 2001US-315676P.
XX  (AEOM-) AEOMICA INC.
XX  Zhang J;
XX  WPI; 2002-479509/51.
XX  New human kidney tumor overexpressed membrane (KTOM1) protein and
XX  nucleic acids encoding the protein, useful for treating subjects having
XX  defects in KTOM1 which can manifest as cancer of the kidney, or as a
XX  disorder of e.g., liver or bone -
XX  Example 2; Page 203; 418pp; English.
XX  The invention relates to a novel isolated nucleic acid encoding human
XX  KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
XX  invention has cytostatic activity. The nucleotide may have a use in gene
XX  therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX  monitor a disease caused by altered expression of human KTOM1.
XX  Compositions comprising the nucleic acids, proteins or antibodies may be
XX  used to treat subjects having defects in KTOM1 which can manifest as
XX  cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX  heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX  function. The sequence represents a probe used in the invention to
XX  scan the nt 1-1001 portion of human KTOM1a (ABQ63232).
XX  Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 other;
XX  Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX  Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX  Qy 1248 GCCATGTGAGCCGAG 1263
XX  Db 16 GCCCTGTGGGCGCAG 1
XX  RESULT 527
XX  ABK55869
XX  ID ABK55869 standard; RNA; 17 BP.
XX  AC ABK55869;
XX  XX 02-JUL-2002 (first entry)
XX  DT Human CLCA1 gene enzymatic nucleic acid #240.
XX  DE Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
XX  KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
XX  KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;

```

```
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US24970.
XX
PP 09-AUG-2000; 2000US-224383P.
XX
PR (RIBO-) RIBOZYME PHARM INC.
XX (SYNT ) SYNTEX USA LLC.
XX (THOM/) THOMPSON J.
XX
PI Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
DR Enzymatic polynucleotide that down regulates expression of chloride
XX channel calcium activated gene, useful for treating Chronic obstructive
XX pulmonary disease (COPD), chronic bronchitis and asthma
XX
PS Claim 4; Page 57; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention.
XX
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 U; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 4 CAGGCAGTTGAGGTGG 19
Db 1 CAGACAGUUGAGCUGG 16
RESULT 528
ABK56045/c
ID ABK56045 standard; RNA; 17 BP.
XX
AC ABK56045;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #416.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
XX antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
XX oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
```

```
OS Homo sapiens.
XX WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US24970.
XX
PP 09-AUG-2000; 2000US-224383P.
XX
PR (RIBO-) RIBOZYME PHARM INC.
XX (SYNT ) SYNTEX USA LLC.
XX (THOM/) THOMPSON J.
XX
PI Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
DR Enzymatic polynucleotide that down regulates expression of chloride
XX channel calcium activated gene, useful for treating Chronic obstructive
XX pulmonary disease (COPD), chronic bronchitis and asthma
XX
PS Claim 4; Page 60; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention.
XX
SQ Sequence 17 BP; 5 A; 7 C; 3 G; 2 U; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 660 GGTGGGGGACTTGGCC 675
Db 16 GGTGGGTGATTGGCC 1
RESULT 529
ABK56620/c
ID ABK56620 standard; RNA; 17 BP.
XX
AC ABK56620;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #991.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
XX antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
XX oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX WO200211674-A2.
XX
```



```
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX Disclosure; SEQ ID 1782; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 547 CTGCTGGCAGGCTGC 562
DB 17 CTGCTGGCAGGCTGC 2
RESULT 534
ABN01792/c
ID ABN01792 standard; DNA; 17 BP.
XX ABN01792;
XX 29-MAY-2002 (first entry)
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1784.
XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
OS
XX WO200192524-A2.
XX
```

```
PD 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US16981.
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX Disclosure; SEQ ID 1784; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 546 CCTGCTGGCAGGCTGC 561
DB 16 CCTGCTGGCAGGCTGC 1
RESULT 535
ABN01897
ID ABN01897 standard; DNA; 17 BP.
XX ABN01897;
XX
```

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1889.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US16981.

XX PR 26-MAY-2000; 2000US-207456P.

XX PR 21-SEP-2000; 2000US-234687P.

XX PR 27-SEP-2000; 2000US-236359P.

XX PR 04-OCT-2000; 2000GB-0024263.

XX PR 30-JAN-2001; 2001WO-US00661.

XX PR 30-JAN-2001; 2001WO-US00662.

XX PR 30-JAN-2001; 2001WO-US00663.

XX PR 30-JAN-2001; 2001WO-US00664.

XX PR 30-JAN-2001; 2001WO-US00665.

XX PR 30-JAN-2001; 2001WO-US00666.

XX PR 30-JAN-2001; 2001WO-US00667.

XX PR 30-JAN-2001; 2001WO-US00668.

XX PR 30-JAN-2001; 2001WO-US00669.

XX PR 30-JAN-2001; 2001WO-US00670.

XX PR 05-FEB-2001; 2001US-266860P.

XX PA (AEOM-) AEOMICA INC.

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX DR WPI; 2002-179446/23.

XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1

XX PT proteins, or as specific biomolecule capture probes for

XX PT surface-enhanced laser desorption/ionization, comprises human

XX PT myosin-like protein hGDMPLP-1 -

XX PS Disclosure; SEQ ID 1889; 214pp; English.

XX CC The present invention describes a human genome-derived myosin-like

XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of

XX CC hGDMPLP-1 can be used in gene therapy and vaccine production. The

XX CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise

XX CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification

XX CC substrates, to provide initial substrates for the recombinant engineering

XX CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and

XX CC biomolecule capture probes for surface-enhanced laser desorption

XX CC ionisation, as therapeutic supplement in patients having specific

XX CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement

XX CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for

XX CC diagnosing a disorder associated with the expression of hGDMPLP-1, in

XX CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to

XX CC chromosome 22. The present sequence represents an oligomer used in the

XX CC screening of the hGDMPLP-1 sequence in the exemplification of the present

XX CC invention.

XX CC N.B. The sequence data for this patent did not form part of the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequence.

XX SQ Sequence 17 BP; 3 A; 5 C; 7 G; 2 T; 0 other;

XX Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 GGTGGGACTGCTGCC 675

Db 2 GGTGGGACTGCTGCC 17

RESULT 536

ABN01898

ID ABN01898 standard; DNA; 17 BP.

XX AC ABN01898;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1890.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US16981.

XX PR 26-MAY-2000; 2000US-207456P.

XX PR 21-SEP-2000; 2000US-234687P.

XX PR 27-SEP-2000; 2000US-236359P.

XX PR 04-OCT-2000; 2000GB-0024263.

XX PR 30-JAN-2001; 2001WO-US00661.

XX PR 30-JAN-2001; 2001WO-US00662.

XX PR 30-JAN-2001; 2001WO-US00663.

XX PR 30-JAN-2001; 2001WO-US00664.

XX PR 30-JAN-2001; 2001WO-US00665.

XX PR 30-JAN-2001; 2001WO-US00666.

XX PR 30-JAN-2001; 2001WO-US00667.

XX PR 30-JAN-2001; 2001WO-US00668.

XX PR 30-JAN-2001; 2001WO-US00669.

XX PR 30-JAN-2001; 2001WO-US00670.

XX PR 05-FEB-2001; 2001US-266860P.

XX PA (AEOM-) AEOMICA INC.

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX DR WPI; 2002-179446/23.

XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1

XX PT proteins, or as specific biomolecule capture probes for

XX PT surface-enhanced laser desorption/ionization, comprises human

XX PT myosin-like protein hGDMPLP-1 -

XX PS Disclosure; SEQ ID 1890; 214pp; English.

XX CC The present invention describes a human genome-derived myosin-like

XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of

XX CC hGDMPLP-1 can be used in gene therapy and vaccine production. The

XX CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise

XX CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification

XX CC substrates, to provide initial substrates for the recombinant engineering

XX CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and

XX CC biomolecule capture probes for surface-enhanced laser desorption

XX CC ionisation, as therapeutic supplement in patients having specific

XX CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement

XX CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for

XX CC diagnosing a disorder associated with the expression of hGDMPLP-1, in

XX CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to

XX CC chromosome 22. The present sequence represents an oligomer used in the

XX CC screening of the hGDMPLP-1 sequence in the exemplification of the present

XX CC invention.

XX CC N.B. The sequence data for this patent did not form part of the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequence.

CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 GGTGGGGGACCTGGGCC 675

Db 1 GGTGGGGGACCTGGGCC 16

RESULT 537

ABN06164
 ID ABN06164 standard; DNA; 17 BP.

AC ABN06164;

XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6156.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

XX 21-SEP-2000; 2000US-234687P.

XX 27-SEP-2000; 2000US-236359P.

XX 04-OCT-2000; 2000GB-0024263.

XX 30-JAN-2001; 2001WO-US00661.

XX 30-JAN-2001; 2001WO-US00662.

XX 30-JAN-2001; 2001WO-US00663.

XX 30-JAN-2001; 2001WO-US00664.

XX 30-JAN-2001; 2001WO-US00665.

XX 30-JAN-2001; 2001WO-US00666.

XX 30-JAN-2001; 2001WO-US00667.

XX 30-JAN-2001; 2001WO-US00668.

XX 30-JAN-2001; 2001WO-US00669.

XX 30-JAN-2001; 2001WO-US00670.

XX 05-FEB-2001; 2001US-266860P.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -

XX Disclosure; SEQ ID 6156; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 255 CGACCTCTGGGCTGG 270

Db 2 CGACCTCAGGGCTGG 17

RESULT 538

ABN06167

ID ABN06167 standard; DNA; 17 BP.

XX AC ABN06167;

XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6159.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

XX 21-SEP-2000; 2000US-234687P.

XX 27-SEP-2000; 2000US-236359P.

XX 04-OCT-2000; 2000GB-0024263.

XX 30-JAN-2001; 2001WO-US00661.

XX 30-JAN-2001; 2001WO-US00662.

XX 30-JAN-2001; 2001WO-US00663.

XX 30-JAN-2001; 2001WO-US00664.

XX 30-JAN-2001; 2001WO-US00665.

XX 30-JAN-2001; 2001WO-US00666.

XX 30-JAN-2001; 2001WO-US00667.

XX 30-JAN-2001; 2001WO-US00668.

XX 30-JAN-2001; 2001WO-US00669.

XX 30-JAN-2001; 2001WO-US00670.

XX 05-FEB-2001; 2001US-266860P.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMPLP-1 -
XX Disclosure; SEQ ID 6159; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 257 ACCTCTGGGCTGGCT 272
Db 1 ACCTCAGGGCTGGCT 16

RESULT 539
ABN06274
ID ABN06274 standard; DNA; 17 BP.
XX
XX AC ABN06274;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6266.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.

PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMPLP-1 -
XX Disclosure; SEQ ID 6266; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 2 A; 8 C; 5 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 371 GGCCCGAGCTTCCTCC 386
Db 2 GGCCCGAGCTTCCTCC 17

RESULT 540
ABN06275
ID ABN06275 standard; DNA; 17 BP.
XX
XX AC ABN06275;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6267.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.
XX PN WO200192524-A2.
XX XX 06-DEC-2001.
XX PD 25-MAY-2001; 2001WO-US16981.
XX PF 26-MAY-2000; 2000US-207456P.
XX PR 21-SEP-2000; 2000US-234687P.
XX PR 27-SEP-2000; 2000US-236359P.
XX PR 04-OCT-2000; 2000GB-0024263.
XX PR 30-JAN-2001; 2001WO-US00661.
XX PR 30-JAN-2001; 2001WO-US00662.
XX PR 30-JAN-2001; 2001WO-US00663.
XX PR 30-JAN-2001; 2001WO-US00664.
XX PR 30-JAN-2001; 2001WO-US00665.
XX PR 30-JAN-2001; 2001WO-US00666.
XX PR 30-JAN-2001; 2001WO-US00667.
XX PR 30-JAN-2001; 2001WO-US00668.
XX PR 30-JAN-2001; 2001WO-US00669.
XX PR 05-FEB-2001; 2001US-266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
XX XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMLP-1
XX PT proteins, or as specific biomolecule capture probes for
XX PT surface-enhanced laser desorption/ionization, comprises human
XX PT myosin-like protein hGDMLP-1 -
XX PS Disclosure; SEQ ID 6267; 214pp; English.
XX XX The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX CC hGDMLP-1 can be used in gene therapy and vaccine production. The
XX CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX CC substrates, to provide initial substrates for the recombinant engineering
XX CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX CC be used as immunogens to raise antibodies that specifically recognise
XX CC hGDMLP-1 proteins, as standards in assays used to determine the
XX CC concentration and/or amount specifically of hGDMLP proteins, as specific
XX CC biomolecule capture probes for surface-enhanced laser desorption
XX CC ionisation, as therapeutic supplement in patients having specific
XX CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX CC diagnosing a disorder associated with the expression of hGDMLP-1, in
XX CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX CC chromosome 22. The present sequence represents an oligomer used in the
XX CC screening of the hGDMLP-1 sequence in the exemplification of the present
XX CC invention.
XX CC N.B. The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence.
XX SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 371 GGGCCAGCTTCCTCC 386
||||| ||||| |||||
Db 1 GGGCCAGCTTCCTCC 16

RESULT 541
ABN06515
ID ABN06515 standard; DNA; 17 BP.
XX AC ABN06515;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6507.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; Gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US16981.
XX PR 26-MAY-2000; 2000US-207456P.
XX PR 21-SEP-2000; 2000US-234687P.
XX PR 27-SEP-2000; 2000US-236359P.
XX PR 04-OCT-2000; 2000GB-0024263.
XX PR 30-JAN-2001; 2001WO-US00661.
XX PR 30-JAN-2001; 2001WO-US00662.
XX PR 30-JAN-2001; 2001WO-US00663.
XX PR 30-JAN-2001; 2001WO-US00664.
XX PR 30-JAN-2001; 2001WO-US00665.
XX PR 30-JAN-2001; 2001WO-US00666.
XX PR 30-JAN-2001; 2001WO-US00667.
XX PR 30-JAN-2001; 2001WO-US00668.
XX PR 30-JAN-2001; 2001WO-US00669.
XX PR 05-FEB-2001; 2001US-266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
XX XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMLP-1
XX PT proteins, or as specific biomolecule capture probes for
XX PT surface-enhanced laser desorption/ionization, comprises human
XX PT myosin-like protein hGDMLP-1 -
XX PS Disclosure; SEQ ID 6507; 214pp; English.
XX XX The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX CC hGDMLP-1 can be used in gene therapy and vaccine production. The
XX CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX CC substrates, to provide initial substrates for the recombinant engineering
XX CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX CC be used as immunogens to raise antibodies that specifically recognise
XX CC hGDMLP-1 proteins, as standards in assays used to determine the
XX CC concentration and/or amount specifically of hGDMLP proteins, as specific
XX CC biomolecule capture probes for surface-enhanced laser desorption
XX CC ionisation, as therapeutic supplement in patients having specific
XX CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX CC diagnosing a disorder associated with the expression of hGDMLP-1, in
XX CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX CC chromosome 22. The present sequence represents an oligomer used in the
XX CC screening of the hGDMLP-1 sequence in the exemplification of the present
XX CC invention.
XX CC N.B. The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence.

CC at ftp.wipo.int/pub/published_pct_sequence.
 XX
 SQ Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 775 GTAGCAATCTCCACCA 790
 Db 2 GCAGGAATCTCCACCA 17
 RESULT 542
 ABN06516
 ID ABN06516 standard; DNA; 17 BP.
 XX
 AC ABN06516;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6508.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US16981.
 XX
 PR 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236353P.
 PR 04-OCT-2000; 2000GB-0024283.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX
 FA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 XX WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID 6508; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise

CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX
 SQ Sequence 17 BP; 5 A; 7 C; 3 G; 2 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 775 GTAGCAATCTCCACCA 790
 Db 1 GCAGGAATCTCCACCA 16
 RESULT 543
 ABN08389/c
 ID ABN08389 standard; DNA; 17 BP.
 XX
 AC ABN08389;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8381.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US16981.
 XX
 PR 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236353P.
 PR 04-OCT-2000; 2000GB-0024283.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX
 FA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 XX WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID 6508; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise

PT myosin-like protein hGDMPLP-1 -
XX Disclosure; SEQ ID 8381; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1, in
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 7 G; 1 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 566 CACTGCTCCAGCAGC 581
Db 17 CTCTGCTCCAGCTGCG 2
RESULT 544
ABN08392/c
ID ABN08392 standard; DNA; 17 BP.
XX
AC ABN08392;
XX
XX
DT 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8384.
DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
XX
XX 21-SEP-2000; 2000US-234687P.
XX
XX 27-SEP-2000; 2000US-236359P.
XX
XX 04-OCT-2000; 2000GB-0024263.
XX
XX 30-JAN-2001; 2001WO-US00661.
XX
XX 30-JAN-2001; 2001WO-US00662.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX
XX 30-JAN-2001; 2001WO-US00664.
XX
XX 30-JAN-2001; 2001WO-US00665.
XX
XX 30-JAN-2001; 2001WO-US00666.
XX
XX 30-JAN-2001; 2001WO-US00667.
XX
XX 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX
XX (ABOM-) ABOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption ionization, comprises human
XX myosin-like protein hGDMPLP-1 -
XX Disclosure; SEQ ID 8384; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
XX hGDMPLP-1 can be used in gene therapy and vaccine production. The
XX hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMPLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMPLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMPLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMPLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMPLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMPLP-1, in
XX diagnosing a disorder associated with the expression of hGDMPLP-1, in
XX particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMPLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 564 CACACTGCTCCAGCAG 579
Db 16 CACTCTGCTCCAGCTG 1
RESULT 545
ABN09587/c
ID ABN09587 standard; DNA; 17 BP.
XX
XX ABN09587;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9579.
DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX

XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX
 XX Disclosure; SEQ ID 9579; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 1041 CTCCTCCACGACG 1056
 Db 17 CTTTCCCTCGACG 2
 RESULT 546
 ABN09588/c
 ID ABN09588 standard; DNA; 17 BP.
 XX AC ABN09588;
 XX 29-MAY-2002 (first entry)
 DT
 XX

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9580.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 OS Homo sapiens.
 XX W0200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US16981.
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX
 XX Disclosure; SEQ ID 9580; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 1041 CTCCTCCACGACG 1056
 Db 17 CTTTCCCTCGACG 2
 RESULT 546
 ABN09588/c
 ID ABN09588 standard; DNA; 17 BP.
 XX AC ABN09588;
 XX 29-MAY-2002 (first entry)
 DT
 XX

QY 1041 CTCCTCCACGACG 1056
 Db 16 CTTTCCCTCGACG 1

RESULT 547
 ABN10235
 ID ABN10235 standard; DNA; 17 BP.
 XX AC ABN10235;
 XX DT 29-MAY-2002 (first entry)
 XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10227.
 XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX OS Homo sapiens.
 XX PN WO200192524-A2.
 XX PD 06-DEC-2001.
 XX PF 25-MAY-2001; 2001WO-US16981.
 XX PR 26-MAY-2000; 2000US-207456P.
 XX PR 21-SEP-2000; 2000US-234687P.
 XX PR 27-SEP-2000; 2000US-236359P.
 XX PR 04-OCT-2000; 2000GB-0024263.
 XX PR 30-JAN-2001; 2001WO-US00661.
 XX PR 30-JAN-2001; 2001WO-US00662.
 XX PR 30-JAN-2001; 2001WO-US00663.
 XX PR 30-JAN-2001; 2001WO-US00664.
 XX PR 30-JAN-2001; 2001WO-US00665.
 XX PR 30-JAN-2001; 2001WO-US00666.
 XX PR 30-JAN-2001; 2001WO-US00667.
 XX PR 30-JAN-2001; 2001WO-US00668.
 XX PR 30-JAN-2001; 2001WO-US00669.
 XX PR 30-JAN-2001; 2001WO-US00670.
 XX PR 05-FEB-2001; 2001WO-US00670.
 XX PA (AEOM-) AEOMICA INC.
 XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX PS Disclosure; SEQ ID 10227; 214pp; English.
 XX CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to

CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX SQ Sequence 17 BP; 2 A; 8 C; 2 G; 5 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. NO. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 253 ACCGACCTCTGGGCT 268
 Db 2 ACCTACCTCTGGGCT 17
 RESULT 548
 ABN10238
 ID ABN10238 standard; DNA; 17 BP.
 XX AC ABN10238;
 XX DT 29-MAY-2002 (first entry)
 XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10230.
 XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX OS Homo sapiens.
 XX PN WO200192524-A2.
 XX PD 06-DEC-2001.
 XX PF 25-MAY-2001; 2001WO-US16981.
 XX PR 26-MAY-2000; 2000US-207456P.
 XX PR 21-SEP-2000; 2000US-234687P.
 XX PR 27-SEP-2000; 2000US-236359P.
 XX PR 04-OCT-2000; 2000GB-0024263.
 XX PR 30-JAN-2001; 2001WO-US00661.
 XX PR 30-JAN-2001; 2001WO-US00662.
 XX PR 30-JAN-2001; 2001WO-US00663.
 XX PR 30-JAN-2001; 2001WO-US00664.
 XX PR 30-JAN-2001; 2001WO-US00665.
 XX PR 30-JAN-2001; 2001WO-US00666.
 XX PR 30-JAN-2001; 2001WO-US00667.
 XX PR 30-JAN-2001; 2001WO-US00668.
 XX PR 30-JAN-2001; 2001WO-US00669.
 XX PR 30-JAN-2001; 2001WO-US00670.
 XX PR 05-FEB-2001; 2001WO-US00670.
 XX PA (AEOM-) AEOMICA INC.
 XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX PS Disclosure; SEQ ID 10230; 214pp; English.
 XX CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to

CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.

XX Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 255 CGACTCTCTGGCTGG 270

Db 1 CTACTCTCTGGCTGG 16

RESULT 549

ABN10239

ID ABN10239 standard; DNA; 17 BP.

AC ABN10239;

DT 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10231.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

XX 21-SEP-2000; 2000US-234687P.

XX 27-SEP-2000; 2000US-236359P.

XX 04-OCT-2000; 2000GB-0024263.

XX 30-JAN-2001; 2001WO-US00661.

XX 30-JAN-2001; 2001WO-US00662.

XX 30-JAN-2001; 2001WO-US00663.

XX 30-JAN-2001; 2001WO-US00664.

XX 30-JAN-2001; 2001WO-US00665.

XX 30-JAN-2001; 2001WO-US00666.

XX 30-JAN-2001; 2001WO-US00667.

XX 30-JAN-2001; 2001WO-US00668.

XX 30-JAN-2001; 2001WO-US00669.

XX 05-FEB-2001; 2001WO-US00670.

DR WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption ionization, comprises human
 PT myosin-like protein hGDMLP-1 -

XX Disclosure; SEQ ID 10231; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.

CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.

XX Sequence 17 BP; 2 A; 5 C; 4 G; 6 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 257 ACCTCTCTGGCTGGCT 272

Db 2 ACCTCTCTGGCTGGAT 17

RESULT 550

ABN10240

ID ABN10240 standard; DNA; 17 BP.

XX AC ABN10240;

XX 29-MAY-2002 (first entry)

XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10232.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

XX 21-SEP-2000; 2000US-234687P.

XX 27-SEP-2000; 2000US-236359P.

XX 04-OCT-2000; 2000GB-0024263.

XX 30-JAN-2001; 2001WO-US00661.

XX 30-JAN-2001; 2001WO-US00662.

XX 30-JAN-2001; 2001WO-US00663.

PA (AEOM-) AEOMICA INC.

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX

PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX Disclosure; SEQ ID 10232; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 257 ACCTCTGGGCTGGCT 272
 Db |||||
 1 ACCTCTGGCTGGAT 16
 RESULT 551
 ABN10735/C
 XX ABN10735 standard; DNA; 17 BP.
 AC AC ABN10735;
 XX 29-MAY-2002 (first entry)
 DT Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10727.
 XX Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS
 XX

PN WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US16981.
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMLP-1 -
 XX Disclosure; SEQ ID 10727; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 1 A; 5 C; 8 G; 3 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 636 GGAGCTCTGCATCCCC 651
 Db |||||
 17 GGAGCCCCGATCCCC 2
 RESULT 552
 ABN10736/C
 ID ABN10736 standard; DNA; 17 BP.

CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.

SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 368 TGGGGGCCCGAGCTCC 383

Db 17 TGGGAGCCCGAGCATCC 2

RESULT 554

ID ABN10738/c

XX ABN10738 standard; DNA; 17 BP.

AC ABN10738;

XX 29-MAY-2002 (first entry)

DT Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10730.

DE Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;

XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

OS WO200192524-A2.

XX 06-DEC-2001.

PD 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

PR 21-SEP-2000; 2000US-234687P.

PR 27-SEP-2000; 2000US-236359P.

PR 04-OCT-2000; 2000GB-0024263.

PR 30-JAN-2001; 2001WO-US00661.

PR 30-JAN-2001; 2001WO-US00662.

PR 30-JAN-2001; 2001WO-US00663.

PR 30-JAN-2001; 2001WO-US00664.

PR 30-JAN-2001; 2001WO-US00665.

PR 30-JAN-2001; 2001WO-US00666.

PR 30-JAN-2001; 2001WO-US00667.

PR 30-JAN-2001; 2001WO-US00668.

PR 30-JAN-2001; 2001WO-US00669.

PR 05-FEB-2001; 2001US-266860P.

XX (AEOM-) AEOMICA INC.

PA Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

PI WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1

XX proteins, or as specific biomolecule capture probes for

PT surface-enhanced laser desorption/ionization, comprises human

PT myosin-like protein hGDMLP-1 -

XX Disclosure; SEQ ID 10730; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1, protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.

SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 368 TGGGGGCCCGAGCTCC 383

Db 16 TGGGAGCCCGAGCATCC 1

RESULT 555

ABK17830

ID ABK17830 standard; RNA; 17 BP.

XX ABK17830;

AC 09-APR-2002 (first entry)

DT Human ERG hammerhead ribozyme target sequence, Seq ID No 477.

DE Human, hammerhead ribozyme; cytostatic; antitumour; antidiabetic;

XX ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;

KW vulvar; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

KW tumour angiogenesis; diabetic retinopathy; macular degeneration;

KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;

KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;

KW Sturge-Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;

KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;

XX amberyzyme.

OS Homo sapiens.

XX WO200188124-A2.

PN 22-NOV-2001.

PD 16-MAY-2001; 2001WO-US15866.

XX 16-MAY-2000; 2000US-0572021.

PR (RIBO-) RIBOZYME PHARM INC.

PA (GLAX) GLAXO GROUP LTD.

XX Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;

PI WPI; 2002-082995/11.

XX

PT Novel polynucleotide which down regulates expression of Ets-related
PT gene, useful for treating cancer, diabetic retinopathy, macular
PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
PT syndrome
XX
XX Claim 4; Page 67; 149pp; English.
XX
XX The invention relates to a nucleic acid molecule (I) which down regulates
XX expression of an Ets-related gene (ERG). (I) is useful for treating
XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
XX tumour angiogenesis, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
XX vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge
XX Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
XX syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
XX treating a patient having a condition associated with the level of ERG,
XX by contacting cells of the patient with (I) under conditions suitable for
XX the treatment. The method comprises the use of one or more therapies
XX under conditions suitable for the treatment. Leukaemia or tumour
XX angiogenesis is treated by administering (I) to the patient in
XX conjunction with one or more of other therapies such as radiation or
XX chemotherapy treatment. (I) is useful for reducing ERG activity in a
XX cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
XX ERG gene, by contacting (I) with RNA, in the presence of a divalent
XX cation such as Mg2+. (I) is useful for diagnosis of conditions and
XX diseases related to the expression of ERG, and as diagnostic tool to
XX examine genetic drift and mutations within diseased cells or to detect
XX the presence of ERG RNA in a cell. (I) is useful for specifically
XX targeting genes that share homology with ERG gene or ERG fusion genes.
XX ABK17354-ABK22719 represent nucleic acids, including antisense and
XX enzymatic nucleic acid molecules which regulate expression of ERG, and
XX related PCR primers of the invention.
XX
XX Sequence 17 BP; 2 A; 0 C; 5 G; 10 U; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 2.7e+02;
Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
QY 1325 TTGTAGATCTGTGTGT 1340
::: ||: ||: ||: ||: ||:
Db 1 UUGUGGAUUUGUGGU 16
RESULT 556
ABK18357
ID ABK18357 standard; RNA; 17 BP.
XX
XX AC ABK18357;
XX
XX 09-APR-2002 (first entry)
XX
XX Human ERG hammerhead ribozyme target sequence, Seq ID No 1004.
XX
XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
XX ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
XX vulnarary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
XX tumour angiogenesis; diabetic retinopathy; macular degeneration;
XX neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
XX angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;
XX Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
XX Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;
XX amberzyme.
XX
XX Homo sapiens.
XX
XX WO200168124-A2.
XX
XX 22-NOV-2001.
XX
XX 16-MAY-2001; 2001WO-US15866.
XX
XX 16-MAY-2000; 2000US-0572021.
XX

XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
XX Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;
XX WPI; 2002-082995/11.
XX
XX Novel polynucleotide which down regulates expression of Ets-related
XX gene, useful for treating cancer, diabetic retinopathy, macular
XX degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
XX syndrome
XX
XX Claim 4; Page 77; 149pp; English.
XX
XX The invention relates to a nucleic acid molecule (I) which down regulates
XX expression of an Ets-related gene (ERG). (I) is useful for treating
XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
XX tumour angiogenesis, diabetic retinopathy, macular degeneration,
XX neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
XX vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge
XX Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
XX syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
XX treating a patient having a condition associated with the level of ERG,
XX by contacting cells of the patient with (I) under conditions suitable for
XX the treatment. The method comprises the use of one or more therapies
XX under conditions suitable for the treatment. Leukaemia or tumour
XX angiogenesis is treated by administering (I) to the patient in
XX conjunction with one or more of other therapies such as radiation or
XX chemotherapy treatment. (I) is useful for reducing ERG activity in a
XX cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
XX ERG gene, by contacting (I) with RNA, in the presence of a divalent
XX cation such as Mg2+. (I) is useful for diagnosis of conditions and
XX diseases related to the expression of ERG, and as diagnostic tool to
XX examine genetic drift and mutations within diseased cells or to detect
XX the presence of ERG RNA in a cell. (I) is useful for specifically
XX targeting genes that share homology with ERG gene or ERG fusion genes.
XX ABK17354-ABK22719 represent nucleic acids, including antisense and
XX enzymatic nucleic acid molecules which regulate expression of ERG, and
XX related PCR primers of the invention.
XX
XX Sequence 17 BP; 5 A; 6 C; 3 G; 3 U; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.7e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 713 CTGTGGCCCGACGACA 728
::: ||: ||: ||: ||: ||:
Db 2 CUGUGGCCCAACA 17
RESULT 557
ABK18359
ID ABK18359 standard; RNA; 17 BP.
XX
XX AC ABK18359;
XX
XX 09-APR-2002 (first entry)
XX
XX Human ERG hammerhead ribozyme target sequence, Seq ID No 1006.
XX
XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
XX ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
XX vulnarary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
XX tumour angiogenesis; diabetic retinopathy; macular degeneration;
XX neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
XX angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;
XX Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
XX Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;
XX amberzyme.
XX
XX Homo sapiens.
XX

XX PN WO2001188124-A2.
 XX PD 22-NOV-2001.
 XX PF 16-MAY-2001; 2001WO-US15866.
 XX PR 16-MAY-2000; 2000US-0572021.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (GLAXO) GLAXO GROUP LTD.
 XX PI Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;
 XX PI WPI; 2002-082995/11.
 XX PT Novel polynucleotide which down regulates expression of Ets-related
 XX PT gene, useful for treating cancer, diabetic retinopathy, macular
 XX PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 XX PT syndrome -
 XX PS Claim 4; Page 77; 149pp; English.
 XX CC The invention relates to a nucleic acid molecule (I) which down regulates
 XX CC expression of an Ets-related gene (ERG). (I) is useful for treating
 XX CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 XX CC tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca
 XX CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 XX CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 XX CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 XX CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 XX CC treating a patient having a condition associated with the level of ERG,
 XX CC by contacting cells of the patient with (I) under conditions suitable for
 XX CC the treatment. The method comprises the use of one or more therapies
 XX CC under conditions suitable for the treatment. Leukaemia or tumour
 XX CC angiogenesis is treated by administering (I) to the patient in
 XX CC conjunction with one or more of other therapies such as radiation or
 XX CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 XX CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 XX CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 XX CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 XX CC diseases related to the expression of ERG, and as diagnostic tool to
 XX CC examine genetic drift and mutations within diseased cells or to detect
 XX CC the presence of ERG RNA in a cell. (I) is useful for specifically
 XX CC targeting genes that share homology with ERG gene or ERG fusion genes.
 XX CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 XX CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 XX CC related PCR primers of the invention.
 XX SQ Sequence 17 BP; 5 A; 5 C; 4 G; 3 U; 0 other;
 XX CC Query Match 0.9%; Score 12.8; DB 1; Length 17;
 XX CC Best Local Similarity 75.0%; Pred. No. 2.7e+02;
 XX CC Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 714 TGTGGCCGACGACGACG 729
 Db 1 UGUGGCCCAUACACAG 16
 RESULT 558
 ABK18805/C
 ID ABK18805 standard; RNA; 17 BP.
 XX AC ABK18805;
 XX XX 09-APR-2002 (first entry)
 XX DT Human ERG DNase target sequence Seq ID No 1452.
 XX DE Human, hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 XX KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 XX KW vulnary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNase; inozyme;
 KW amberzyme.
 XX OS Homo sapiens.
 XX XX WO2001188124-A2.
 XX PD 22-NOV-2001.
 XX PF 16-MAY-2001; 2001WO-US15866.
 XX PR 16-MAY-2000; 2000US-0572021.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (GLAXO) GLAXO GROUP LTD.
 XX PI Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;
 XX PI WPI; 2002-082995/11.
 XX PT Novel polynucleotide which down regulates expression of Ets-related
 XX PT gene, useful for treating cancer, diabetic retinopathy, macular
 XX PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 XX PT syndrome -
 XX PS Claim 4; Page 92; 149pp; English.
 XX CC The invention relates to a nucleic acid molecule (I) which down regulates
 XX CC expression of an Ets-related gene (ERG). (I) is useful for treating
 XX CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 XX CC tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca
 XX CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 XX CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 XX CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 XX CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 XX CC treating a patient having a condition associated with the level of ERG,
 XX CC by contacting cells of the patient with (I) under conditions suitable for
 XX CC the treatment. The method comprises the use of one or more therapies
 XX CC under conditions suitable for the treatment. Leukaemia or tumour
 XX CC angiogenesis is treated by administering (I) to the patient in
 XX CC conjunction with one or more of other therapies such as radiation or
 XX CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 XX CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 XX CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 XX CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 XX CC diseases related to the expression of ERG, and as diagnostic tool to
 XX CC examine genetic drift and mutations within diseased cells or to detect
 XX CC the presence of ERG RNA in a cell. (I) is useful for specifically
 XX CC targeting genes that share homology with ERG gene or ERG fusion genes.
 XX CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 XX CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 XX CC related PCR primers of the invention.
 XX SQ Sequence 17 BP; 5 A; 7 C; 2 G; 3 U; 0 other;
 XX CC Query Match 0.9%; Score 12.8; DB 1; Length 17;
 XX CC Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 XX CC Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 824 TGATGCGAGCTGAGCT 839
 Db 17 TGATGCGAGCTGAGCTT 2
 RESULT 559
 ABK19286
 ID ABK19286 standard; RNA; 17 BP.
 XX AC ABK19286;

XX DT 09-APR-2002 (first entry)

XX DE Human ERG Amberzyme target sequence Seq ID No 1933.

XX KW Human; hammerhead ribozyme; cytosolic; antitumour; antidiabetic;

XX KW Ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;

XX KW vulvar; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

XX KW tumour angiogenesis; diabetic retinopathy; macular degeneration;

XX KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;

XX KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;

XX KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;

XX KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;

XX KW amberzyme.

XX OS Homo sapiens.

XX PN WO200188124-A2.

XX XX 22-NOV-2001.

XX PF 16-MAY-2001; 2001WO-US15866.

XX PR 16-MAY-2000; 2000US-0572021.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (GLAX) GLAXO GROUP LTD.

XX PI Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;

XX PI WPI; 2002-082995/11.

XX DR Novel polynucleotide which down regulates expression of Ets-related

XX PT gene, useful for treating cancer, diabetic retinopathy, macular

XX PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber

XX PT syndrome

XX XX Claim 4; Page 124; 149pp; English.

XX CC The invention relates to a nucleic acid molecule (I) which down regulates

XX CC expression of an Ets-related gene (ERG). (I) is useful for treating

XX CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,

XX CC tumour angiogenesis, diabetic retinopathy, macular degeneration,

XX CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca

XX CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge

XX CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu

XX CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for

XX CC treating a patient having a condition associated with the level of ERG,

XX CC by contacting cells of the patient with (I) under conditions suitable for

XX CC the treatment. The method comprises the use of one or more therapies

XX CC under conditions suitable for the treatment. Leukaemia or tumour

XX CC angiogenesis is treated by administering (I) to the patient in

XX CC conjunction with one or more of other therapies such as radiation or

XX CC chemotherapy treatment. (I) is useful for reducing ERG activity in a

XX CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of

XX CC ERG gene, by contacting (I) with RNA, in the presence of a divalent

XX CC cation such as Mg2+. (I) is useful for diagnosis of conditions and

XX CC diseases related to the expression of ERG, and as diagnostic tool to

XX CC examine genetic drift and mutations within diseased cells or to detect

XX CC the presence of ERG RNA in a cell. (I) is useful for specifically

XX CC targeting genes that share homology with ERG gene or ERG fusion genes.

XX CC ABK17354-ABK22719 represent nucleic acids, including antisense and

XX CC enzymatic nucleic acid molecules which regulate expression of ERG, and

XX CC related PCR primers of the invention.

XX SQ Sequence 17 BP; 8 A; 5 C; 3 G; 1 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 2.7e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

66 ACCCAGAGGATGAA 81

||||||| | | | | |

Db 2 ACCCAGAGGATGAA 17

RESULT 560

ABK19333/c

ID ID ABK19333 standard; RNA; 17 BP.

XX AC ABK19333;

XX DT 09-APR-2002 (first entry)

XX DE Human ERG Amberzyme target sequence Seq ID No 1980.

XX KW Human; hammerhead ribozyme; cytosolic; antitumour; antidiabetic;

XX KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;

XX KW vulvar; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

XX KW tumour angiogenesis; diabetic retinopathy; macular degeneration;

XX KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;

XX KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;

XX KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;

XX KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;

XX KW amberzyme.

XX OS Homo sapiens.

XX PN WO200188124-A2.

XX XX 22-NOV-2001.

XX PF 16-MAY-2001; 2001WO-US15866.

XX PR 16-MAY-2000; 2000US-0572021.

XX XX (RIBO-) RIBOZYME PHARM INC.

XX PA (GLAX) GLAXO GROUP LTD.

XX PI Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;

XX PI WPI; 2002-082995/11.

XX DR Novel polynucleotide which down regulates expression of Ets-related

XX PT gene, useful for treating cancer, diabetic retinopathy, macular

XX PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber

XX PT syndrome

XX XX Claim 4; Page 126; 149pp; English.

XX CC The invention relates to a nucleic acid molecule (I) which down regulates

XX CC expression of an Ets-related gene (ERG). (I) is useful for treating

XX CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,

XX CC tumour angiogenesis, diabetic retinopathy, macular degeneration,

XX CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca

XX CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge

XX CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu

XX CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for

XX CC treating a patient having a condition associated with the level of ERG,

XX CC by contacting cells of the patient with (I) under conditions suitable for

XX CC the treatment. The method comprises the use of one or more therapies

XX CC under conditions suitable for the treatment. Leukaemia or tumour

XX CC angiogenesis is treated by administering (I) to the patient in

XX CC conjunction with one or more of other therapies such as radiation or

XX CC chemotherapy treatment. (I) is useful for reducing ERG activity in a

XX CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of

XX CC ERG gene, by contacting (I) with RNA, in the presence of a divalent

XX CC cation such as Mg2+. (I) is useful for diagnosis of conditions and

XX CC diseases related to the expression of ERG, and as diagnostic tool to

XX CC examine genetic drift and mutations within diseased cells or to detect

XX CC the presence of ERG RNA in a cell. (I) is useful for specifically

XX CC targeting genes that share homology with ERG gene or ERG fusion genes.

XX CC ABK17354-ABK22719 represent nucleic acids, including antisense and

XX CC enzymatic nucleic acid molecules which regulate expression of ERG, and

XX CC related PCR primers of the invention.

CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyrin herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention.

XX SQ Sequence 17 BP; 4 A; 5 C; 3 G; 5 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 164 GATCCTCAAGTCTCG 179
 ||||| |||||
 Db 1 GATCCTCTAGATCTCG 16

RESULT 563

ABK25527/C
 ID ABK25527 standard; DNA; 17 BP.

AC ABK25527;

DT 09-APR-2002 (first entry)

DE Male-sterile plant producing genome altering oligonucleotide #427.

XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyrin herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW modified fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.

XX Oryza sativa.
 OS Synthetic.

FN WO200192512-A2.

XX PD 06-DEC-2001.

XX PF 01-JUN-2001; 2001WO-US17672.

XX PR 01-JUN-2000; 2000US-208538P.

XX PR 30-OCT-2000; 2000US-244989P.

XX PR 27-WAR-2001; 2001US-0818875.

XX PA (UYDE) UNIV DELAWARE.

XX PI Kmiec EB, Gamber HB, Rice MC, Kim J;

XX DR WPI; 2002-106307/14.

XX

PT New oligonucleotides with modified nuclease-resistant termini, useful
 PT for creating plants with desired phenotypes, e.g. stress tolerance,
 PT improved nutritional value, herbicide or disease resistance, or
 PT modified oil production -

XX Claim 7; Page 94; 220pp; English.

XX The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyrin herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention.

XX SQ Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 164 GATCCTCAAGTCTCG 179
 ||||| |||||
 Db 17 GATCCTCTAGATCTCG 2

RESULT 564

ABK25528
 ID ABK25528 standard; DNA; 17 BP.

XX AC ABK25528;

XX DT 09-APR-2002 (first entry)

XX DE Male-sterile plant producing genome altering oligonucleotide #428.

XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyrin herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW modified fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.

XX Oryza sativa.
 OS Synthetic.

XX PN WO200192512-A2.

XX PD 06-DEC-2001.

XX PF 01-JUN-2001; 2001WO-US17672.

XX

PR 01-JUN-2000; 2000US-208538P.
 PR 30-OCT-2000; 2000US-244989P.
 PR 27-MAR-2001; 2001US-0818875.
 XX (UYDE) UNIV DELAWARE.
 XX Kmiec EB, Gamper HB, Rice MC, Kim J;
 XX WPI; 2002-106307/14.
 XX New oligonucleotides with modified nuclease-resistant termini, useful
 PT for creating plants with desired phenotypes, e.g. stress tolerance,
 PT improved nutritional value, herbicide or disease resistance, or
 PT modified oil production
 XX Claim 7; Page 94; 220pp; English.
 XX The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an DNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyrin herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention.
 XX Sequence 17 BP; 4 A; 5 C; 3 G; 5 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 164 GATCCTCAAGTCTCG 179
 Db 1 GATCCTCTAGATCTCG 16
 RESULT 565
 ABL31073
 ID ABL31073 standard; DNA; 17 BP.
 XX ABL31073;
 XX 21-MAR-2002 (first entry)
 XX Human HLA genotyping oligonucleotide SEQ ID NO 562.
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX Homo sapiens.
 XX WO200192572-A1.
 XX 06-DEC-2001.
 XX 01-JUN-2001; 2001WO-JP04662.
 XX 01-JUN-2000; 2000JP-0164798.
 XX (NISN) NISSHINBO IND INC.
 PA (SYSTEM-) SYSTEM RES INC.
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 of individuals e.g. by determining immunogenetic differences when
 transplanting between them -
 Claim 10; Page 293; 345pp; Japanese.

XX (NISN) NISSHINBO IND INC.
 PA (SYSTEM-) SYSTEM RES INC.
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 of individuals e.g. by determining immunogenetic differences when
 transplanting between them -
 Claim 10; Page 199; 345pp; Japanese.
 XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX Sequence 17 BP; 1 A; 7 C; 6 G; 3 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 803 GCTCCTCGAGCCGAG 818
 Db 1 GCTGCTGCGCCGAG 16
 RESULT 566
 ABL31564
 ID ABL31564 standard; DNA; 17 BP.
 XX ABL31564;
 XX 21-MAR-2002 (first entry)
 XX Human HLA genotyping oligonucleotide SEQ ID NO 1053.
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX Homo sapiens.
 XX WO200192572-A1.
 XX 06-DEC-2001.
 XX 01-JUN-2001; 2001WO-JP04662.
 XX 01-JUN-2000; 2000JP-0164798.
 XX (NISN) NISSHINBO IND INC.
 PA (SYSTEM-) SYSTEM RES INC.
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 of individuals e.g. by determining immunogenetic differences when
 transplanting between them -
 Claim 10; Page 293; 345pp; Japanese.

XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 531 GGAGCAGCTGGGTGCC 546
 Db 1 GGAGCAGCTGAGAGCC 16
 RESULT 567
 ABL31655
 ID ABL31655 standard; DNA; 17 BP.
 AC ABL31655;
 XX
 XX 21-MAR-2002 (first entry)
 DT
 DE Human HLA genotyping oligonucleotide SEQ ID NO 1144.
 XX
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192572-A1.
 XX
 XX 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-JP04662.
 XX
 XX 01-JUN-2000; 2000JP-0164798.
 XX
 XX (N1SN) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 PS Claim 10; Page 310; 345pp; Japanese.
 XX
 CC The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.

XX
 SQ Sequence 17 BP; 5 A; 8 C; 3 G; 1 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 195 CCACCCGACGCGCGAC 210
 Db 2 CCACCCGACGCGCGCTAC 17
 RESULT 568
 ABL31671
 ID ABL31671 standard; DNA; 17 BP.
 XX
 AC ABL31671;
 XX
 XX 21-MAR-2002 (first entry)
 DT
 DE Human HLA genotyping oligonucleotide SEQ ID NO 1160.
 XX
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192572-A1.
 XX
 XX 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-JP04662.
 XX
 XX 01-JUN-2000; 2000JP-0164798.
 XX
 XX (N1SN) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 PS Claim 10; Page 313; 345pp; Japanese.
 XX
 CC The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 531 GGAGCAGCTGGGTGCC 546
 Db 1 GGAGCAGCTGAGAGCC 16
 RESULT 569

```

ABL31720
ID ABL31720 standard; DNA; 17 BP.
XX
XX AC ABL31720;
XX
XX DT 21-MAR-2002 (first entry)
XX
XX DE Human HLA genotyping oligonucleotide SEQ ID NO 1209.
XX
XX KW Human leukocyte antigen; HLA; genotype; polymorphism;
XX immunogenetic; transplantation; genetic disease; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200192572-A1.
XX
XX PD 06-DEC-2001.
XX
XX PF 01-JUN-2001; 2001WO-JP04662.
XX
XX PR 01-JUN-2000; 2000JP-0164798.
XX
XX PA (NISON) NISSHINBO IND INC.
XX (SYST-) SYSTEM RES INC.
XX
XX PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX WPI; 2002-122074/16.
XX
XX PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
XX of individuals e.g. by determining immunogenetic differences when
XX transplanting between them -
XX
XX PS Claim 10; Page 322; 345pp; Japanese.
XX
XX CC The invention relates to a typing kit for judging human leukocyte antigen
XX (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
XX oligonucleotides (ABL30512-ABL31809) originating in the sequences of
XX genes e.g. belonging to HLA class I antigens on human genome and
XX containing gene polymorphisms as alloantigens have been immobilised as
XX primers for amplification of cleaved nucleic acids relating to gene
XX polymorphisms. The method is useful for judging HLA genotypes of
XX individuals by determining immunogenetic differences before transplanting
XX between them, providing genetic information to decide compatibility of
XX organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
XX pancreas, langerhans islet in pancreas and cornea, susceptibility
XX diagnosis of genetic diseases and identifying individuals..
XX
XX SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 346 CACAGTGGCGAGTGA 361
DB 2 CAGACTGGCGAGTGA 17
|||||
|||||

RESULT 570
ABAO1457
ID ABAO1457 standard; DNA; 17 BP.
XX
XX AC ABAO1457;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Streptococcus thermophilus eps operon PCR primer 304.
XX
XX KW Exopolysaccharide; lactic acid bacterium; eps; fermented food product;
XX PCR primer; ss.
XX
XX OS Streptococcus thermophilus.

ABL31720
ID ABL31720 standard; DNA; 17 BP.
XX
XX AC ABL31720;
XX
XX DT 21-MAR-2002 (first entry)
XX
XX DE Human HLA genotyping oligonucleotide SEQ ID NO 1209.
XX
XX KW Human leukocyte antigen; HLA; genotype; polymorphism;
XX immunogenetic; transplantation; genetic disease; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200192572-A1.
XX
XX PD 06-DEC-2001.
XX
XX PF 01-JUN-2001; 2001WO-JP04662.
XX
XX PR 01-JUN-2000; 2000JP-0164798.
XX
XX PA (NISON) NISSHINBO IND INC.
XX (SYST-) SYSTEM RES INC.
XX
XX PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX WPI; 2002-122074/16.
XX
XX PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
XX of individuals e.g. by determining immunogenetic differences when
XX transplanting between them -
XX
XX PS Claim 10; Page 322; 345pp; Japanese.
XX
XX CC The invention relates to a typing kit for judging human leukocyte antigen
XX (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
XX oligonucleotides (ABL30512-ABL31809) originating in the sequences of
XX genes e.g. belonging to HLA class I antigens on human genome and
XX containing gene polymorphisms as alloantigens have been immobilised as
XX primers for amplification of cleaved nucleic acids relating to gene
XX polymorphisms. The method is useful for judging HLA genotypes of
XX individuals by determining immunogenetic differences before transplanting
XX between them, providing genetic information to decide compatibility of
XX organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
XX pancreas, langerhans islet in pancreas and cornea, susceptibility
XX diagnosis of genetic diseases and identifying individuals..
XX
XX SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 346 CACAGTGGCGAGTGA 361
DB 2 CAGACTGGCGAGTGA 17
|||||
|||||

RESULT 570
ABAO1457
ID ABAO1457 standard; DNA; 17 BP.
XX
XX AC ABAO1457;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Streptococcus thermophilus eps operon PCR primer 304.
XX
XX KW Exopolysaccharide; lactic acid bacterium; eps; fermented food product;
XX PCR primer; ss.
XX
XX OS Streptococcus thermophilus.

WO200179500-A2.
XX
XX 25-OCT-2001.
XX
XX 18-APR-2001; 2001WO-FR01199.
XX
XX 18-APR-2000; 2000FR-0004972.
XX
XX (INRG) INRA INST NAT RECH AGRONOMIQUE.
XX (DANO-) CIE DANONE SA GERVAIS.
XX (RHOD) RHODIA CHIM.
XX
XX PI Rallu F, Besancon-Yoshpe I, Fremaux C, Mengaud J, Renault P;
XX WPI; 2002-017616/02.
XX
XX New nucleic acid fragments containing exopolysaccharide operon, useful
XX e.g. for increasing exopolysaccharide synthesis in lactic acid bacteria
XX
XX Example 1; Page 31; 144pp; French.
XX
XX The present invention relates to eps operons from Streptococcus
XX thermophilus (see ABA01433-ABA01448). Proteins encoded by the eps operon
XX function in exopolysaccharide (EPS) synthesis. The operons are useful for
XX producing chimeric eps operons, for optimising production of EPS in
XX lactic acid bacteria. EPS impart texture, mouth feel and rheological
XX properties to fermented food products (e.g. yoghurt). They function as
XX thickeners, to provide free-flowing and creamy texture, and may also have
XX biological activities beneficial to health. The present sequence is a PCR
XX primer, which was used in an example from the present invention.
XX
XX SQ Sequence 17 BP; 3 A; 5 C; 7 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 464 GCAGCCTGCAGGGGA 479
DB 1 GCAGCCTGCAGGGGA 16
|||||
|||||

RESULT 571
ABT35820
ID ABT35820 standard; DNA; 17 BP.
XX
XX AC ABT35820;
XX
XX DT 12-JUN-2003 (first entry)
XX
XX DE Tumour suppression related human fukutin oligo SEQ ID NO 1457.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO2003025175-A2.
XX
XX PD 27-MAR-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB04208.
XX
XX PR 17-SEP-2001; 2001FR-0011978.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX

```

PT WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

XX polypeptides, antibodies and transfected cells -

PS Disclosure; Page 206; 720pp; French.

XX

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,

CC given in the specification, a sequence containing at least 15

CC consecutive nucleotides from the 17 mer sequence, a sequence with, after

CC optimal alignment, at least 80 % identity to the 17 mer sequence, a

CC sequence that hybridizes to them under highly stringent conditions, or

CC the complement of any of them, or the corresponding RNA. The novel

CC isolated nucleic acids of the invention are useful as probes and primers

CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,

CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,

CC and for production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and

CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in

CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and

CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression

CC related human fukutin oligonucleotide of the invention.

XX

XX Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 other;

SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GGCAGTTGAGCTGGAT 21

DB 17 GGCAGTTGAGCTGGAT 2

RESULT 573

ABT36006

ID ABT36006 standard; DNA; 17 BP.

XX

XX ABT36006;

XX

XX 12-JUN-2003 (first entry)

XX

XX Tumour suppression related human fukutin oligo SEQ ID No 1643.

XX

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

XX schizophrenia; protein chip; gene therapy; tumour suppression;

XX human fukutin; ds.

XX

XX Homo sapiens.

XX

XX WO2003025175-A2.

XX

XX 27-MAR-2003.

XX

XX 17-SEP-2002; 2002WO-IB04208.

XX

XX 17-SEP-2001; 2001FR-0011978.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

XX

XX Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-313353/30.

XX

XX New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

DR WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

XX polypeptides, antibodies and transfected cells -

PS Disclosure; Page 203; 720pp; French.

XX

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,

CC given in the specification, a sequence containing at least 15

CC consecutive nucleotides from the 17 mer sequence, a sequence with, after

CC optimal alignment, at least 80 % identity to the 17 mer sequence, a

CC sequence that hybridizes to them under highly stringent conditions, or

CC the complement of any of them, or the corresponding RNA. The novel

CC isolated nucleic acids of the invention are useful as probes and primers

CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,

CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,

CC and for production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and

CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in

CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and

CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression

CC related human fukutin oligonucleotide of the invention.

XX

XX Sequence 17 BP; 2 A; 3 C; 1 G; 11 T; 0 other;

SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1139 ATGCTTTTTCCTTT 1154

DB 2 ATGCTTTTTCCTTT 17

RESULT 572

ABT35849/C

ID ABT35849 standard; DNA; 17 BP.

XX

XX ABT35849;

XX

XX 12-JUN-2003 (first entry)

XX

XX Tumour suppression related human fukutin oligo SEQ ID No 1486.

XX

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

XX schizophrenia; protein chip; gene therapy; tumour suppression;

XX human fukutin; ds.

XX

XX Homo sapiens.

XX

XX WO2003025175-A2.

XX

XX 27-MAR-2003.

XX

XX 17-SEP-2002; 2002WO-IB04208.

XX

XX 17-SEP-2001; 2001FR-0011978.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

XX

XX Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-313353/30.

XX

XX New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

PT polypeptides, antibodies and transfected cells -
XX
PS Disclosure; Page 225; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
SQ Sequence 17 BP; 6 A; 2 C; 5 G; 4 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 429 GAGCAGGTCGAGAAG 444
DB 1 GATCATGTTTCGAGAAG 16
|||||
RESULT 574
ABT37187
ID ABT37187 standard; DNA; 17 BP.
XX
AC ABT37187;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 2824.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB04208.
XX
PR 17-SEP-2001; 2001FR-0011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
XX
XX

PS Disclosure; Page 363; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
SQ Sequence 17 BP; 8 A; 2 C; 5 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 273 GATCAAGAGGAGCA 288
DB 1 GATCCAGAGGAGAA 16
|||||
RESULT 575
ABT37634
ID ABT37634 standard; DNA; 17 BP.
XX
AC ABT37634;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3271.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB04208.
XX
PR 17-SEP-2001; 2001FR-0011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
XX
XX Disclosure; Page 416; 720pp; French.
XX

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 164 GATCCTCAAGGTCTCG 179
 ||||| |||||
 Db 1 GATCCCAAGGTCTCG 16

RESULT 576
 ABT37805/c
 ID ABT37805 standard; DNA; 17 BP.

XX ABT37805;

XX 12-JUN-2003 (first entry)

XX Tumour suppression related human fukutin oligo SEQ ID No 3442.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 XX schizophrenia; protein chip; gene therapy; tumour suppression;
 XX human fukutin; ds.

XX Homo sapiens.

XX WO2003025175-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB04208.

XX 17-SEP-2001; 2001FR-0011978.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases
 XX associated with tumors and cell degeneration, also related
 XX polypeptides, antibodies and transfected cells -

XX Disclosure; Page 436; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15

CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 4 G; 5 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 CAGTCCCATTCAGATC 998

Db 16 CAGTCCCATTAAGATC 1

RESULT 577

ABT38097/c

ID ABT38097 standard; DNA; 17 BP.

XX ABT38097;

XX 12-JUN-2003 (first entry)

XX Tumour suppression related human fukutin oligo SEQ ID No 3734.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 XX schizophrenia; protein chip; gene therapy; tumour suppression;
 XX human fukutin; ds.

XX Homo sapiens.

XX WO2003025175-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB04208.

XX 17-SEP-2001; 2001FR-0011978.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases
 XX associated with tumors and cell degeneration, also related
 XX polypeptides, antibodies and transfected cells -

XX Disclosure; Page 470; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a

CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1066 CCCATCAGGCGGCTC 1081
Db 16 CCCATCAGGAGATC 1

RESULT 578
ABT39257/c
ID ABT39257 standard; DNA; 17 BP.

AC ABT39257;

DT 12-JUN-2003 (first entry)

DE Tumour suppression related human fukutin oligo SEQ ID No 4894.

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.

OS Homo sapiens.

XX WO2003025175-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB04208.

XX 17-SEP-2001; 2001FR-0011978.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases
XX associated with tumors and cell degeneration, also related
XX polypeptides, antibodies and transfected cells -

XX Disclosure; Page 606; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15
XX consecutive nucleotides from the 17 mer sequence, a sequence with, after
XX optimal alignment, at least 80 % identity to the 17 mer sequence, a
XX sequence that hybridizes to them under highly stringent conditions, or
XX the complement of any of them, or the corresponding RNA. The novel

CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 7 A; 3 C; 3 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 855 ATACCGCTTTCAGGTC 870
Db 16 ATACTGCTTTCAGATC 1

RESULT 579
ABT39551
ID ABT39551 standard; DNA; 17 BP.

AC ABT39551;

DT 12-JUN-2003 (first entry)

DE Tumour suppression related human fukutin oligo SEQ ID No 5188.

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.

OS Homo sapiens.

XX WO2003025175-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB04208.

XX 17-SEP-2001; 2001FR-0011978.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases
XX associated with tumors and cell degeneration, also related
XX polypeptides, antibodies and transfected cells -

XX Disclosure; Page 640; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15
XX consecutive nucleotides from the 17 mer sequence, a sequence with, after
XX optimal alignment, at least 80 % identity to the 17 mer sequence, a
XX sequence that hybridizes to them under highly stringent conditions, or
XX the complement of any of them, or the corresponding RNA. The novel
XX isolated nucleic acids of the invention are useful as probes and primers
XX for detecting, identifying, quantifying and/or amplifying a nucleic acid,

CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the nucleic acids, cells containing the
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 2 A; 3 C; 1 G; 11 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1139 ATGCCTTTTCTTT 1154
 || |||||
 Db 2 ATCACTTTTCTTT 17

RESULT 580

ABT39720

ID ABT39720 standard; DNA; 17 BP.

XX AC

XX ABT39720;

XX DT

DE 12-JUN-2003 (first entry)

XX Tumour suppression related human fukutin oligo SEQ ID No 5357.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.

OS Homo sapiens.

XX WO2003025175-A2.

XX 27-MAR-2003.

XX 17-SRP-2002; 2002WO-IB04208.

XX 17-SEP-2001; 2001FR-0011978.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -

XX Disclosure; Page 660; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC and for production of recombinant polypeptides.

CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 4 A; 2 C; 5 G; 6 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 435 GTTCAGAAAGTTGCTG 450
 |||||
 Db 1 GATCAGATAGTTGCTG 16

RESULT 581

ACA06264

ID ACA06264 standard; RNA; 17 BP.

XX AC

XX ACA06264;

XX DT

XX 03-JUN-2003 (first entry)

XX NFKB sub-unit modulating inozyme substrate #83.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberyzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 ss.

XX Homo sapiens.

XX US2002177568-A1.

XX 29-NOV-2002.

XX 23-MAY-2001; 2001US-0864785.

XX 15-AUG-1994; 94US-0291932.

XX 07-DEC-1992; 92US-0987132.

XX 18-MAY-1994; 94US-0245466.

XX 23-DEC-1996; 96US-0777916.

XX (STIN/) STINCHCOMB D T.

XX (MCSW/) MCSWIGGEN J.

XX (DRAP/) DRAPER K G.

XX Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -

```

XX PS Claim 3; Page 28; 72pp; English.
XX
CC The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg2+. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel
CC enzymatic nucleic acid molecule.
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 479 AGGACTCGCGAGACGG 494
Db 1 AGGACUGCGCGAUGG 16
RESULT 582
ACA06326
ID ACA06326 standard; RNA; 17 BP.
AC ACA06326;
XX
DT 03-JUN-2003 (first entry)
XX
DE NFkB sub-unit modulating inozyme substrate #145.
XX
KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection;
KW ss.
XX
OS Homo sapiens.
XX
PN US2002177568-A1.
XX
PD 28-NOV-2002.
XX
PF 23-MAY-2001; 2001US-0864785.
XX
PR 15-AUG-1994; 94US-0291932.

```

```

PR 07-DEC-1992; 92US-0987132.
PR 18-MAY-1994; 94US-0245466.
PR 23-DEC-1996; 96US-0777916.
XX
XX (STIN/) STINCHCOMB D T.
PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
PI Stinchcomb DT, Mcswiggen J, Draper KG;
XX WPI; 2003-340953/32.
DR
XX Novel enzymatic nucleic acid molecules which down regulates expression
XX of a sequence encoding a subunit of nuclear factor kappa B useful for
XX treating cancer, inflammatory disorders and autoimmune diseases -
XX
XX Claim 3; Page 29; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
XX regulates expression of a sequence encoding a subunit of nuclear factor
XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
XX configuration. The enzymatic nucleic acid molecule is adapted to treat
XX cancer and is useful for down-regulating REL-A activity in a cell, for
XX treating a patient having a condition associated with the level of REL-A.
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
XX the presence of a divalent cation, especially Mg2+. The enzymatic and
XX antisense nucleic acid molecules are useful for treating breast, lung,
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
XX multidrug resistant cancer. The method involves use of other drug
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
XX gemcitabine or radiation therapy. The enzymatic and antisense nucleic
XX acid molecules are also useful for treating inflammatory disease such as
XX rheumatoid arthritis, restenosis, lupus, multiple sclerosis, transplant/graft
XX rejection, gene therapy applications, ischaemia/reperfusion injury
XX (central nervous system (CNS) and myocardial), glomerulonephritis,
XX sepsis, allergic airway inflammation, inflammatory bowel disease or
XX infection. This sequence represents the substrate of a novel
XX enzymatic nucleic acid molecule.
XX
SQ Sequence 17 BP; 0 A; 11 C; 3 G; 3 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.7e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Qy 581 CCCTCCGCTGTCGCCCC 596
Db 1 CCCUCCGCGCGCGCC 16
RESULT 583
ACA06585/c
ID ACA06585 standard; RNA; 17 BP.
XX
AC ACA06585;
XX
XX 03-JUN-2003 (first entry)
XX
XX NFkB sub-unit modulating inozyme substrate #404.
XX
XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
XX G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
XX lung cancer; prostate cancer; colorectal cancer; brain cancer;
XX oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
XX cervical cancer; head and neck cancer; ovarian cancer; melanoma;
XX lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
XX chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
XX cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
XX gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
XX

```

KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 KW ss.
 XX Homo sapiens.
 XX OS
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-0864785.
 XX
 XX 15-AUG-1994; 94US-0291932.
 XX 07-DEC-1992; 92US-0987132.
 XX 18-MAY-1994; 94US-0245466.
 XX 23-DEC-1996; 96US-0777916.
 XX
 XX (STIN/) STINCHCOMB D T.
 XX (MCSW/) MCSWIGGEN J.
 XX (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 XX of a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 XX Claim 3; Page 33; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 XX regulates expression of a sequence encoding a subunit of nuclear factor
 XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberyze
 XX configuration. The enzymatic nucleic acid molecule is adapted to treat
 XX cancer and is useful for down-regulating REL-A activity in a cell, for
 XX treating a patient having a condition associated with the level of REL-A.
 XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 XX antisense nucleic acid molecules are useful for treating breast, lung,
 XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 XX multidrug resistant cancer. The method involves use of other drug
 XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 XX chemotherapies including paclitaxel, docetaxel, cisplatin, methotrexate,
 XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 XX gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 XX acid molecules are also useful for treating inflammatory disease such as
 XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 XX rejection, gene therapy applications, ischaemia/reperfusion injury
 XX (central nervous system (CNS) and myocardial), glomerulonephritis,
 XX sepsis, allergic airway inflammation, inflammatory bowel disease or
 XX infection. This sequence represents the substrate of a novel
 XX enzymatic nucleic acid molecule.
 XX
 XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 U; 0 other;
 XX
 XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
 XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 570 GTCACGAGGCGCTC 585
 DB 17 GCTGACGAGGCGCTC 2
 RESULT 584
 ACA06587
 ID ACA06587 standard; RNA; 17 BP.
 XX

AC ACA06587;
 XX 03-JUN-2003 (first entry)
 DT
 DE NFKB sub-unit modulating inozyme substrate #406.
 XX
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberyze; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapies; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 KW ss.
 XX Homo sapiens.
 XX OS
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-0864785.
 XX
 XX 15-AUG-1994; 94US-0291932.
 XX 07-DEC-1992; 92US-0987132.
 XX 18-MAY-1994; 94US-0245466.
 XX 23-DEC-1996; 96US-0777916.
 XX
 XX (STIN/) STINCHCOMB D T.
 XX (MCSW/) MCSWIGGEN J.
 XX (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 XX of a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 XX Claim 3; Page 33; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 XX regulates expression of a sequence encoding a subunit of nuclear factor
 XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberyze
 XX configuration. The enzymatic nucleic acid molecule is adapted to treat
 XX cancer and is useful for down-regulating REL-A activity in a cell, for
 XX treating a patient having a condition associated with the level of REL-A.
 XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 XX antisense nucleic acid molecules are useful for treating breast, lung,
 XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 XX multidrug resistant cancer. The method involves use of other drug
 XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 XX chemotherapies including paclitaxel, docetaxel, cisplatin, methotrexate,
 XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 XX gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 XX acid molecules are also useful for treating inflammatory disease such as
 XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 XX rejection, gene therapy applications, ischaemia/reperfusion injury
 XX (central nervous system (CNS) and myocardial), glomerulonephritis,
 XX sepsis, allergic airway inflammation, inflammatory bowel disease or
 XX infection. This sequence represents the substrate of a novel
 XX enzymatic nucleic acid molecule.

SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 2.7e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 822 CCTGATGCGAGCTGAAG 837
 ||| :|||:|
 Db 1 CCUGGUGGAGGUGCAG 16

RESULT 585
 ACA06653/c
 ID ACA06653 standard; RNA; 17 BP.
 XX
 AC ACA06653;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating inozyme substrate #472.

Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 lung cancer; prostate cancer; colorectal cancer; brain cancer;
 oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 transplant/graft rejection; reperfusion injury; glomerulonephritis;
 allergic airway inflammation; inflammatory bowel disease; infection;
 ss.

OS Homo sapiens.
 XX
 XX US2002177568-A1.
 PN
 XX 28-NOV-2002.
 PD
 XX 23-MAY-2001; 2001US-0864785.
 PF
 XX 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 DR WPI; 2003-340953/32.
 XX

Novel enzymatic nucleic acid molecules which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B useful for treating cancer, inflammatory disorders and autoimmune diseases -

Claim 3; Page 34; 72pp; English.

The invention describes an enzymatic nucleic acid molecule (I) which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme configuration. The enzymatic nucleic acid molecule is adapted to treat cancer and is useful for down-regulating REL-A activity in a cell, for treating a patient having a condition associated with the level of REL-A. (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in the presence of a divalent cation, especially Mg²⁺. The enzymatic and antisense nucleic acid molecules are useful for treating breast, lung, prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,

CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX
 SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 528 GGAGGAGGAGCTGGGT 543
 ||||| :|||:|
 Db 17 GGAGGAGGAGCTGGGT 2

RESULT 586
 ACA06814/c
 ID ACA06814 standard; RNA; 17 BP.
 XX
 AC ACA06814;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating inozyme substrate #633.

Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 lung cancer; prostate cancer; colorectal cancer; brain cancer;
 oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 transplant/graft rejection; reperfusion injury; glomerulonephritis;
 allergic airway inflammation; inflammatory bowel disease; infection;
 ss.

OS Homo sapiens.
 XX
 XX US2002177568-A1.
 PN
 XX 28-NOV-2002.
 PD
 XX 23-MAY-2001; 2001US-0864785.
 PF
 XX 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 DR WPI; 2003-340953/32.
 XX

Novel enzymatic nucleic acid molecules which down regulates expression

cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
gemicitabine; radiation therapy; inflammatory disease; asthma; diabetes;
rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
transplant/graft rejection; reperfusion injury; glomerulonephritis;
allergic airway inflammation; inflammatory bowel disease; infection;
ss.

XX
XX Homo sapiens.
XX
XX US2002177568-A1.
XX
XX 28-NOV-2002.
XX
XX 23-MAY-2001; 2001US-0864785.
XX
XX 15-AUG-1994; 94US-0291932.
XX 07-DEC-1992; 92US-0987132.
XX 18-MAY-1994; 94US-0245466.
XX 23-DEC-1996; 96US-0777916.
XX
XX (STIN/) STINCHCOMB D T.
XX (MCSW/) MCSWIGGEN J.
XX (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
XX WFI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression
XX of a sequence encoding a subunit of nuclear factor kappa B useful for
XX treating cancer, inflammatory disorders and autoimmune diseases -
XX
XX Claim 3; Page 37; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
XX regulates expression of a sequence encoding a subunit of nuclear factor
XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
XX configuration. The enzymatic nucleic acid molecule is adapted to treat
XX cancer and is useful for down-regulating REL-A activity in a cell, for
XX treating a patient having a condition associated with the level of REL-A.
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
XX antisense nucleic acid molecules are useful for treating breast, lung,
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
XX multidrug resistant cancer. The method involves use of other drug
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
XX cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
XX gemicitabine or radiation therapy. The enzymatic and antisense nucleic
XX acid molecules are also useful for treating inflammatory disease such as
XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes, graft
XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
XX rejection, gene therapy applications, ischaemia/reperfusion injury/
XX (central nervous system (CNS) and myocardial), glomerulonephritis,
XX sepsis, allergic airway inflammation, inflammatory bowel disease or
XX infection. This sequence represents the substrate of a novel
XX enzymatic nucleic acid molecule.
XX
XX SQ Sequence 17 BP; 1 A; 9 C; 1 G; 6 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0

QY 937 GAGAGAGGTTGTGAGC 952
|||||
Db 16 GAGNAGAGGGGAGAC 1

RESULT 589
ACA07770/c

CC enzymatic nucleic acid molecule.

XX Sequence 17 BP; 2 A; 6 C; 6 G; 3 U; 0 other;

SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 570 GTCACGACGAGGCTTC 585

DB 16 GCTGCACGAGGCTTC 1

RESULT 590

ACA08920

ID ACA08920 standard; RNA; 17 BP.

XX

AC ACA08920;

XX

DT 03-JUN-2003 (first entry)

XX

DE NFKB sub-unit modulating amberzyme substrate #83.

XX

Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme; G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human; lung cancer; prostate cancer; colorectal cancer; brain cancer; oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer; cervical cancer; head and neck cancer; ovarian cancer; melanoma; lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor; chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate; cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate; gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes; rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia; gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis; transplant/graft rejection; reperfusion injury; glomerulonephritis; allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX

OS Homo sapiens.

XX

US2002177568-A1.

XX

28-NOV-2002.

XX

23-MAY-2001; 2001US-0864785.

XX

15-AUG-1994; 94US-0291932.

PR

07-DEC-1992; 92US-0987132.

PR

18-MAY-1994; 94US-0245466.

PR

23-DEC-1996; 96US-0777916.

XX

(STIN/) STINCHCOMB D T.

PA

(MCSW/) MCSWIGEN J.

PA

(DRAP/) DRAPER K G.

XX

Stinchcomb DT, Mcswiggen J, Draper KG;

PI

WPI; 2003-340953/32.

DR

Novel enzymatic nucleic acid molecules which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B useful for treating cancer, inflammatory disorders and autoimmune diseases -

PT

Claim 3; Page 51; 72pp; English.

XX

The invention describes an enzymatic nucleic acid molecule (I) which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme configuration. The enzymatic nucleic acid molecule is adapted to treat cancer and is useful for down-regulating REL-A activity in a cell, for treating a patient having a condition associated with the level of REL-A. (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in the presence of a divalent cation, especially Mg²⁺. The enzymatic and

CC

antisense nucleic acid molecules are useful for treating breast, lung, prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic, cervical, head and neck, ovarian cancer, melanoma, lymphoma or multidrug resistant cancer. The method involves use of other drug therapies such as monoclonal antibodies, REL-A-specific inhibitors or chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate, cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate, gemcitabine or radiation therapy. The enzymatic and antisense nucleic acid molecules are also useful for treating inflammatory disease such as rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, gene therapy applications, ischaemia/reperfusion injury (central nervous system (CNS) and myocardial), glomerulonephritis, sepsis, allergic airway inflammation, inflammatory bowel disease or infection. This sequence represents the substrate of a novel enzymatic nucleic acid molecule.

XX

SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 2.7e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1069 ATCAGGCGAGGCTTC 1084

DB 1 AUCAGGCGAGGCTTC 16

RESULT 591

ACC44610

ID ACC44610 standard; DNA; 17 BP.

XX

AC ACC44610;

XX

DT 30-MAY-2003 (first entry)

XX

DE Human CBFA1 type II related PCR primer SEQ ID NO:11.

XX

Core-binding factor alpha subunit 1; CBFA1; cancer; metastasis; leukaemia; PCR primer; ss.

KW

OS Homo sapiens.

OS

Synthetic.

OS

WO2003008966-A1.

EN

30-JAN-2003.

PD

16-JUL-2002; 2002WO-JP07204.

PF

17-JUL-2001; 2001JP-0217186.

PR

(TAKE) TAKEDA CHEM IND LTD.

PA

Hikichi Y;

PI

WPI; 2003-239371/23.

DR

Screening compounds inhibiting expression of core binding factor alpha subunit 1 type II for prevention and treatment of cancer and metastasis

PT

Example 2; Page 61; 66pp; Japanese.

PS

The present invention describes a screening method for selecting compounds and their salts inhibiting the expression of core binding factor alpha subunit 1 (CBFA1) type II, by measuring the amount of mRNA encoding CBFA1 type II exon 0 present in cells expressing CBFA1, in the presence and absence of the test compound. CBFA1 has cytostatic activity. The method can be used for the treatment, prevention and diagnosis of cancer (including cancer of the colon, breast, lung, prostate, oesophagus, liver, gall-bladder, spleen, kidney, pancreas, uterus, testis, thyroid, bladder or brain, and leukaemia) and inhibition

CC

CC of cancer proliferation and metastasis. The present sequence represents
CC a PCR primer for human CBFA1 type II, which is used in an example from
CC the present invention.

XX SQ Sequence 17 BP; 4 A; 8 C; 3 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCC 694
DB 16 GTGGTATCTGGGGCC 1

RESULT 592
ABZ60572/c
ID ABZ60572 standard; RNA; 17 BP.
XX AC ABZ60572;
XX DT 21-MAR-2003 (first entry)
XX DE Human K-Ras DNase substrate #684.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.

XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.
XX PF Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX Claim 58; Page 98; 185pp; English.

XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531.
CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
CC sequences for the human ribozymes of the invention.

XX SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1013 ACCTGAGATGGTGCCA 1028

DB 17 AGCTGAGATGGGCCA 2

RESULT 593
ABZ61171
ID ABZ61171 standard; RNA; 17 BP.
XX AC ABZ61171;
XX DT 21-MAR-2003 (first entry)
XX DE Human K-Ras DNase substrate #1283.

XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.

XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.

XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX Claim 58; Page 109; 185pp; English.

XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and
CC anti-rheumatic activity. The nucleic acid molecules are useful for
CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
CC acids are also useful for treating breast, ovarian, colorectal, lung,
CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
CC sequences for the human ribozymes of the invention.

XX SQ Sequence 17 BP; 7 A; 4 C; 5 G; 1 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 279 AGAGGAGCAGCAGCA 294
DB 2 AAGGAGCAGCAGCA 17

RESULT 594
ABZ61760/c
ID ABZ61760 standard; RNA; 17 BP.
XX AC ABZ61760;
XX DT 21-MAR-2003 (first entry)

```
XX DE Human H-Ras DNazyme target #551.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX XX
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX XX
XX DR WPI; 2003-140484/13.
XX XX
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX XX
XX PS Claim 58; Page 121; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytostatic, anti-HIV, and
XX CC anti-rheumatic activity. The nucleic acid molecules are useful for
XX CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX CC acids are also useful for treating breast, ovarian, colorectal, lung,
XX CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
XX CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
XX CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 5 A; 2 C; 8 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 693 CCAGCGCGCCCTCCTT 708
DB 16 CCAGCAGCCCTTCCTT 1

RESULT 595
ABZ61761/c
ID ABZ61761 standard; RNA; 17 BP.
XX AC ABZ61761;
XX XX
XX DT 21-MAR-2003 (first entry)
XX DE Human H-Ras DNazyme target #552.
XX XX
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX XX
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX XX
```

```
PD 05-DEC-2002.
XX XX
XX PF 29-MAY-2002; 2002WO-US16840.
XX XX
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX XX
XX PI Mcswiggen J;
XX XX
XX DR WPI; 2003-140484/13.
XX XX
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX XX
XX PS Claim 58; Page 121; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytostatic, anti-HIV, and
XX CC anti-rheumatic activity. The nucleic acid molecules are useful for
XX CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX CC acids are also useful for treating breast, ovarian, colorectal, lung,
XX CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
XX CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
XX CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 570 GCTCCAGCAGCCCTTC 585
DB 16 GCTCCAGCAGCCCTTC 1

RESULT 596
ABZ64859
ID ABZ64859 standard; RNA; 17 BP.
XX AC ABZ64859;
XX XX
XX DT 21-MAR-2003 (first entry)
XX DE Human HER2 DNazyme substrate #316.
XX XX
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX XX
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX XX
```

XX WPI; 2003-140484/13.
 DR Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
 XX
 PS Claim 4; Page 139; 185pp; English.
 XX The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and
 CC anti-rheumatic activity. The nucleic acid molecules are useful for
 CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
 CC acids are also useful for treating breast, ovarian, colorectal, lung,
 CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
 CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.
 XX
 SQ Sequence 17 BP; 2 A; 10 C; 3 G; 2 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 2.7e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 589 CTGCCCCCACCAGCC 604
 | : | | | | | | | | | |
 Db 2 CUGCCCCGCCACGCC 17
 RESULT 597
 ABZ64966
 ID ABZ64966 standard; RNA; 17 BP.
 XX
 AC ABZ64966;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human HER2 DNzyme substrate #423.
 XX
 XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 XX enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 XX anti-rheumatic; cancer; AIDS; ss.
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 29-MAY-2002; 2002WO-US16840.
 XX
 PR 29-MAY-2001; 2001US-294140P.
 PR 06-JUN-2001; 2001US-296249P.
 PR 10-SEP-2001; 2001US-318471P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Meswigen J;
 XX
 DR WPI; 2003-140484/13.
 XX
 PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
 XX
 PS Claim 4; Page 141; 185pp; English.
 XX The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates

CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and
 CC anti-rheumatic activity. The nucleic acid molecules are useful for
 CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
 CC acids are also useful for treating breast, ovarian, colorectal, lung,
 CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
 CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 8 G; 3 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 2.7e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 475 GGGGAGGAGTGGCGAG 490
 | : | | | | | | | | | |
 Db 1 GUGGAGGGAUGCCGAG 16
 RESULT 598
 AAQ70348
 ID AAQ70348 standard; DNA; 18 BP.
 XX
 AC AAQ70348;
 XX
 DT 25-MAR-2003 (updated)
 DT 15-FEB-1995 (first entry)
 XX
 DE Antisense oligonucleotide for mouse FGF.
 XX
 XX Fibroblast growth factor; hybridisation; laser procedures;
 XX vascular smooth muscle cell; proliferation;
 XX SMC; vascular stenosis; post angioplasty restenosis;
 XX atherosclerosis; cardiac hypertrophy; organ transplant; ss.
 OS Synthetic.
 XX
 PN WO9415945-A1.
 XX
 PD 21-JUL-1994.
 XX
 PF 28-DEC-1993; 93WO-US12600.
 XX
 PR 31-DEC-1992; 92US-0999706.
 XX
 PA (TEXA-) TEXAS BIOTECHNOLOGY CORP.
 XX
 PI Denner LA, Dixon RAF, Rege AA, Dixon RA;
 XX
 DR WPI; 1994-249123/30.
 XX
 PT New anti-sense polynucleotide(s) to fibroblast growth factor
 PT receptor - used for inhibiting vascular smooth muscle cell
 PT proliferation, partic. for treating restenosis
 XX
 PS Claim 3; Page 9; 53pp; English.
 XX
 CC The sequence is an antisense molecule directed against position -9
 CC to +9, relative to the start codon of the gene for
 CC mouse fibroblast growth factor 1. The polynucleotide can be used for
 CC inhibiting vascular smooth muscle cell proliferation and for treating
 CC a disease e.g. vascular stenosis, post angioplasty restenosis,
 CC atherectomy, atherosclerosis, atrial venous shunt failure, cardiac
 CC hypertrophy, vascular surgery and organ transplant.
 CC See also AAQ70333-60.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 18 BP; 3 A; 9 C; 2 G; 4 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 CCCACACCCAGTTC 885
|||||
Db 2 CCCACATCCAGTTC 17

RESULT 599

AAQ86978/c
ID AAQ86978 standard; DNA; 18 BP.

XX AC
XX AAQ86978;

DT 17-JAN-1996 (first entry)

XX Primer 1 to amplify MRSA target DNA.

XX MRSA; methicillin resistant Staphylococcus aureus; probe;
KW hybridisation; meca; MRSE; Staphylococcus epidermis; primer; PCR;
KW polymerase chain reaction; ss.

XX Staphylococcus aureus.

OS DE4338119-Al.

XX 11-MAY-1995.

PD 08-NOV-1993; 93DE-4338119.

XX 08-NOV-1993; 93DE-4338119.

PR (FARB) BAYER AG.

XX Endermann R, Springer W;

XX WPI; 1995-180108/24.

XX Detection of methicillin resistant Staphylococcus - using an

PT oligo:nucleotide derived from the meca gene

XX Claim 3; Page 11; 14pp; German.

XX Primer 1 and 2 (AAQ86978-79) were used to amplify a target nucleotide

CC sequence from methicillin resistant S. aureus (MRSA). The target

CC is detected with a probe specifically derived from the meca gene of

CC S. aureus and S. epidermidis. The meca gene product has no homology

CC with known PBPs (penicillin-binding proteins). The new probes allow

CC for the rapid identification of all MRSE, eradicating need for labour

CC intensive in vitro cultivation and physiological assays.

XX Sequence 18 BP; 7 A; 1 C; 4 G; 6 T; 0 other;

SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 2.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 321 ATACCTGCATCATCCT 336

Db 18 ATACTGTCATCATCTT 3

RESULT 600

AAAT50704/c

ID AAT50704 standard; RNA; 18 BP.

XX AC

XX AAT50704;

DT 07-MAR-1997 (first entry)

XX Rabbit CERP hairpin ribozyme target sequence #191.

DE Hairpin ribozyme; cholesterol ester transfer protein; mRNA cleavage;

XX DT

KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
KW reverse cholesterol transport; high density lipoprotein; therapy; CERP;
KW familial hypercholesterolaemia; dyslipidaemia; hypolipoproteinaemia;
KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW angioplastic restenosis; low density lipoprotein; diabetes; HDL; rabbit;
KW LDL; ss.

XX Oryctolagus cuniculus.

XX W09620279-Al.

XX 04-JUL-1996.

XX 11-DEC-1995; 95WO-US16000.

XX 23-DEC-1994; 94US-0363240.

XX (RIBO-) RIBOZYME PHARM INC.

XX (WARN) WARNER LAMBERT CO.

XX Bisgaier C, Couture L, McSwiggen J, Pape M, Stinchcomb D;

XX WPI; 1996-321852/32.

XX New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA

PT - useful for preventing or treating initial development, progression

PT or regression of vascular diseases, esp. familial

PT hypercholesterolaemia

XX Claim 4; Page 55; 72pp; English.

XX AAT50699-T50754 represent target sequences for the rabbit cholesterol

CC ester transfer protein (CERP) hairpin ribozymes (see AAT50643-T50698).

CC CERP is a 74 kD glycoprotein that facilitates neutral lipid transfer

CC between plasma lipoproteins. The numbering of the targets refers to the

CC position of the cleavage site in full length CERP. The ribozyme then

CC binds to 4-6 nucleotides 5', and a variable number 3' of this site. The

CC ribozymes are able to cleave mRNA from the gene encoding CERP, thereby

CC blocking synthesis and/or expression of the mRNA. By inhibiting CERP,

CC the reverse cholesterol transport (RCT) pathway can be inhibited (or

CC eliminated) thereby preventing the reduction in size density of the high

CC density lipoproteins (HDL), prolonging HDL half life, and therefore

CC increasing HDL levels. The ribozymes can be used to treat conditions

CC associated with abnormal levels of CERP, specifically atherosclerosis,

CC peripheral vascular disease, hyperbetalipoproteinaemia, dyslipidaemia,

CC familial hypercholesterolaemia, hypolipoproteinaemia, vascular

CC complications of diabetes, transplant, atherectomy and angioplastic

CC restenosis. By inhibiting CERP, the levels of HDL and low density

CC lipoproteins (LDL), and the HDL:LDL ratio are favourably altered (a

CC decrease in LDL levels, and a corresponding increase in HDL levels). The

CC ribozymes can also be used diagnostically to study genetic drift and

CC mutations in diseased cells, and to detect CERP mRNA. As the ribozymes

CC target specific regions of the CERP gene, they have low non-specific

CC activity.

XX Sequence 18 BP; 5 A; 9 C; 2 G; 2 U; 0 other;

SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 2.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 924 GATGGCAGATCTGGAG 939

Db 18 GGTGGCTGATCTGGAG 3

RESULT 601

AAT28333/c

ID AAT28333 standard; DNA; 18 BP.

XX AC

XX AAT28333;

XX DT 20-NOV-1996 (first entry)

KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

OS Mus sp.

PN WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

XX 11-JAN-1996; 96US-0584040.

XX 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

PA (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 188; 218pp; English.

CC The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 2 A; 5 C; 6 G; 5 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 56.2%; Pred. No. 2.9e+02;
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGGCTGCTTTT 1326

Db 1 GGAGCCAGCGCUUUU 16

RESULT 604

AAX70294

ID AAX70294 standard; RNA; 18 BP.

XX AAX70294;

XX 28-JUL-1999 (first entry)

XX Human-flt1 VEGF receptor hairpin ribozyme substrate #62.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

XX Homo sapiens.

XX WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

XX

PR 11-JAN-1996; 96US-0584040.
 PR 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

PA (RIBO-) RIBOZYME PHARM INC.

PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 94; 218pp; English.

CC The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 2 A; 4 C; 6 G; 6 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 56.2%; Pred. No. 2.9e+02;
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGGCTGCTTTT 1326

Db 1 GGAGCCAGCGCUUUU 16

RESULT 605

AAX62734/C

ID AAX62734 standard; RNA; 18 BP.

XX AAX62734;

DT 16-JUL-1999 (first entry)

DE Granule bound starch synthase hairpin substrate SEQ ID NO:609.

XX Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
 KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
 KW modulation; gene expression; transgenic plant; cleavage; canola plant;
 KW caffeine synthesis; coffee plant; nicotine production; tobacco;
 KW fruit ripening; flower pigmentation; lignin production; ss.

XX Zea mays.

XX WO9710328-A2.

XX 20-MAR-1997.

XX 12-JUL-1996; 96WO-US11689.

XX 13-JUL-1995; 95US-0001135.

XX (DOWC) DOWELANCO.

PA (RIBO-) RIBOZYME PHARM INC.

XX Edington BE, Folkerts O, Guo L, McSwiggen JA, Merlo DJ;

PI Merlo PAO, Skokut TA, Young SA, Zwick MG;

XX WPI; 1997-202224/18.

PT Ribozyme which modulates plant gene expression - preferably

PT modulates expression of DELTA-9 desaturase or granule bound starch
 PT synthase in maize or canola
 XX Claim 42; Page 84; 155pp; English.
 PS The present invention describes an enzymatic nucleic acid molecule (I)
 CC with RNA cleaving activity, which modulates the expression of a plant
 CC gene. Also described is a gene comprising a cDNA sequence encoding maize
 CC Delta-9 desaturase. (I) can be used to modulate expression of a gene,
 CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
 CC gene, in a plant (preferably a maize or canola plant). (I) can be used
 CC to modulate caffeine synthesis in a coffee plant, nicotine production in
 CC a tobacco plant, fruit ripening processes in an apple, tomato, pear,
 CC plum or peach plant, flower pigmentation in a rose, petunia,
 CC chrysanthemum or marigold plant or lignin production in a tobacco,
 CC aspen, poplar or pine plant.
 XX Sequence 18 BP; 4 A; 6 C; 5 G; 3 U; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 884 TCACGAGCTGCGGTA 899
 Db 16 TCACGAGCTGCGGTA 1
 RESULT 606
 AAX62754
 ID AAX62754 standard; RNA; 18 BP.
 AC AAX62754;
 XX
 DT 16-JUL-1999 (first entry)
 XX
 DE Granule bound starch synthase hairpin substrate SEQ ID NO:629.
 XX
 KW Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
 KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
 KW modulation; gene expression; transgenic plant; cleavage; canola plant;
 KW caffeine synthesis; coffee plant; nicotine production; tobacco;
 KW fruit ripening; flower pigmentation; lignin production; ss.
 XX
 OS Zea mays.
 XX
 FN WO9710328-A2.
 XX
 PD 20-MAR-1997.
 XX
 PF 12-JUL-1996; 96WO-US11689.
 XX
 PR 13-JUL-1995; 95US-0001135.
 XX
 PA (DOWC) DOWELANCO.
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Edington BE, Folkerts O, Guo L, McSwiggen JA, Merlo DJ;
 PI Merlo PAO, Skokut TA, Young SA, Zwick WG;
 XX
 DR WPI; 1997-202224/18.
 XX
 XX Ribozyme which modulates plant gene expression - preferably
 PT modulates expression of DELTA-9 desaturase or granule bound starch
 PT synthase in maize or canola
 XX Claim 42; Page 84; 155pp; English.
 XX The present invention describes an enzymatic nucleic acid molecule (I)
 CC with RNA cleaving activity, which modulates the expression of a plant
 CC gene. Also described is a gene comprising a cDNA sequence encoding maize
 CC Delta-9 desaturase. (I) can be used to modulate expression of a gene,
 CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
 CC gene, in a plant (preferably a maize or canola plant). (I) can be used
 CC to modulate caffeine synthesis in a coffee plant, nicotine production in
 CC a tobacco plant, fruit ripening processes in an apple, tomato, pear,
 CC plum or peach plant, flower pigmentation in a rose, petunia,
 CC chrysanthemum or marigold plant or lignin production in a tobacco,
 CC aspen, poplar or pine plant.

CC gene, in a plant (preferably a maize or canola plant). (I) can be used
 CC to modulate caffeine synthesis in a coffee plant, nicotine production in
 CC a tobacco plant, fruit ripening processes in an apple, tomato, pear,
 CC plum or peach plant, flower pigmentation in a rose, petunia,
 CC chrysanthemum or marigold plant or lignin production in a tobacco,
 CC aspen, poplar or pine plant.
 XX Sequence 18 BP; 2 A; 7 C; 5 G; 4 U; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 68.8%; Pred. No. 2.9e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 OY 220 CGAGCTCTCTCAGCTC 235
 Db 2 CGUGCUGCUCAGCCUC 17
 RESULT 607
 AAT94805
 ID AAT94805 standard; DNA; 18 BP.
 XX
 AC AAT94805;
 XX
 DT 19-FEB-1998 (first entry)
 XX
 DE Human leukocyte antigen class I gene URSTO probe 531-548.
 XX
 KW Human leukocyte antigen; HLA; probe; tissue transplantation;
 KW MHC gene; major histocompatibility complex; paternity test;
 KW forensic medicine; haematological malignancy; inherited disorder;
 KW adoptive immunotherapy; identification; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 FN WO9720197-A2.
 XX
 PD 05-JUN-1997.
 XX
 PF 29-NOV-1996; 96WO-GB02959.
 XX
 PR 29-NOV-1995; 95GB-0024381.
 XX
 PA (NOLA-) NOLAN BONE MARROW TRUST ANTHONY.
 XX
 PI Arguello R, Avakian H, Madrigal A;
 XX
 DR WPI; 1997-310717/28.
 XX
 PT Identifying unknown allele(s) of a polyallelic gene using panel of
 PT probes each recognising a sequence motif present in some allele(s) -
 PT useful for donor matching in tissue transplantation
 XX
 PS Claim 5; Page 19; 64pp; English.
 XX
 CC A novel method has been developed for identifying an unknown allele of a
 CC polyallelic gene. The method involves: (a) contacting the unknown allele
 CC with a panel of probes, each of which recognises a sequence motif that
 CC is present in some alleles of the polyallelic gene but not in others;
 CC (b) observing which probes recognise the unknown allele so as to obtain
 CC a fingerprint of the unknown allele; and (c) comparing the fingerprint
 CC with fingerprints of known alleles. The present sequence represents a
 CC specifically claimed probe for use in the method where the polyallelic
 CC gene is a human leukocyte antigen class I gene. The method can be used
 CC for genes such as mammalian MHC genes, specifically the HLA class I and
 CC II genes, the T cell receptor genes in mammals, TAP, LMP, ras,
 CC nonclassical HLA class I genes, human complement factor genes C4 and C2,
 CC Bf in the HLA complex, and genes located in mitochondrial DNA, bacterial
 CC chromosomes and viral DNA. The method is particularly useful for
 CC matching the alleles of the HLA genes in a prospective donor and a
 CC prospective recipient in tissue or organ transplantations. The method
 CC can also be used in paternity testing, in forensic medicine, as a

CC follow up technique in treatment of haematological malignancies or
 CC inherited disorders, in adoptive immunotherapy, and in identification
 CC of bacteria and viruses. The method can provide for the identification
 CC of alleles of the polyallelic genes using a limited number of selected
 CC recurring motif probes.
 XX
 SQ Sequence 18 BP; 5 A; 4 C; 7 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 531 GGAGCAGCTGGGTGCC 546
 Db 1 GGAGCAGCTGGAGGCC 16

RESULT 608
 AAT76410
 ID AAT76410 standard; DNA; 18 BP.
 XX
 AC AAT76410;
 DT 15-SEP-1997 (first entry)
 XX Human endothelin-1 antisense oligonucleotide.
 DE
 XX Asthma; airway epithelium; adenosine free; cystic fibrosis;
 KW chronic obstructive pulmonary disease; bronchitis; ss.
 KW
 XX Synthetic.
 OS
 XX WO9640162-A1.
 EN
 XX 19-DEC-1996.
 PD
 XX 06-JUN-1996; 96WO-US09306.
 PF
 XX 07-JUN-1995; 95US-0474497.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX Metzger WJ, Nyce JW;
 PI
 XX WPI; 1997-051871/05.
 DR
 XX Treatment of airway diseases such as asthma - by topically applying
 PT adenosine-free antisense oligonucleotide to airway epithelium of
 PT subject
 PT
 XX Claim 5; Page 38; 71pp; English.
 PS
 XX A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine
 CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide
 CC specific for the human endothelin-1. The method can be used to treat
 CC airway diseases such as cystic fibrosis, asthma, chronic obstructive
 CC pulmonary disease, bronchitis and other airway diseases characterised
 CC by an inflammatory response. By eliminating adenosine from the
 CC antisense ON, its liberation upon antisense degradation is prevented,
 CC thereby preventing adenosine-induced bronchoconstriction in patients
 CC with hyper-reactive airways.
 XX
 SQ Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTTGG 1158
 Db 1 CTTCTGTCTTTTGG 16

RESULT 609
 AAX10189
 ID AAX10189 standard; DNA; 18 BP.
 XX
 AC AAX10189;
 DT 24-MAR-1999 (first entry)
 XX Human biallelic polymorphic marker downstream primer #495.
 DE
 XX Polymorphism; biallelic; human; forensic; paternity testing; disease;
 KW detection; phenotypic typing; characteristic; infection; hereditary;
 KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
 KW treatment; marker; primer; ss.
 KW
 XX Synthetic.
 OS
 XX Homo sapiens.
 OS
 XX WO9820165-A2.
 PN
 XX 14-MAY-1998.
 PD
 XX 05-NOV-1997; 97WO-US20313.
 PF
 XX 06-NOV-1996; 96US-0030455.
 PR
 XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
 PA
 XX Hudson T, Lander ES, Wang D;
 PI
 XX WPI; 1998-286974/25.
 DR
 XX New isolated nucleic acid segments from the human genome - used for
 PT determining polymorphic forms for use in e.g. forensics, paternity
 PT testing or phenotypic typing for disease
 PT
 XX Claim 16; Page 212; 310pp; English.
 PS
 XX AAX09121-X10268 are allele-specific oligonucleotide primers used in the
 CC isolation of various biallelic polymorphic markers found in the human
 CC genome (represented in AAX10269-X12937). These primers can be used in a
 CC method for determining polymorphic forms in an individual for use in
 CC e.g. forensics, paternity testing or for phenotypic typing for diseases
 CC such as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome,
 CC muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial
 CC hypercholesterolemia, polycystic kidney disease, hereditary
 CC spherocytosis, von Willebrand's disease, tuberculous sclerosis, hereditary
 CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
 CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
 CC autoimmune diseases, inflammation, cancer, diseases of the nervous
 CC system, infection by pathogenic microorganisms, and characteristics such
 CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
 CC endurance, fertility, and susceptibility or receptivity to particular
 CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
 CC segments can also be used to produce medicaments for the treatment or
 CC prophylaxis of such diseases.
 XX
 SQ Sequence 18 BP; 5 A; 6 C; 4 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1285 CATACAGTGTCTCAGC 1300
 Db 3 CATACATGGCTCAGC 18

RESULT 610
 AAV95056
 ID AAV95056 standard; RNA; 18 BP.

```

XX AC AAV95056;
XX DT 24-FEB-1999 (first entry)
XX DE Mouse IL-2 receptor g-chain substrate position 399.
XX KW Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
XX KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
XX KW autoimmune disease; psoriasis; allergy; inflammatory disease;
XX KW graft rejection; ss.
XX OS Mus sp.
XX FN WO9824913-A2.
XX PD 11-JUN-1998.
XX PF 02-DEC-1997; 97WO-US21748.
XX PR 03-DEC-1996; 96US-0758306.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI McSwiggen JA, Stinchcomb DT;
XX DR WPI; 1998-333332/29.
XX PT Ribozymes targeted to interleukin 2 - useful for treating e.g.
XX PT cancer, autoimmune disease and allergies
XX PS Claim 4; Page 44; 61pp; English.
XX CC The present sequence invention describes ribozymes targeted to modulate
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded
CC RNA. AAV93889 to AAV94574 represent specifically claimed ribozymes, and
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
CC from the present invention. The ribozymes can be used for the treatment
CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis,
CC allergy and other inflammatory conditions. The ribozymes are also used
CC to induce tolerance in a recipient to alloantigen from a donor.
XX SQ Sequence 18 BP; 3 A; 7 C; 4 G; 4 U; 0 other;
XX Query Match 0.9%; Score 12.8; DB 1; Length 18;
XX Best Local Similarity 81.2%; Pred. No. 2.9e+02;
XX Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
OY 625 GACCAGCTCCAGGAC 640
DB 3 GUCCAGCUCCAGGACC 18

RESULT 611
AAV54165
ID AAV54165 standard; cDNA; 18 BP.
XX AC AAV54165;
XX DT 21-DEC-1998 (first entry)
XX DE Nucleotide sequence PCR primer 2.
XX KW PCR; primer; amplification; apoptosis; antibody; inhibition; ss;
XX KW immunohistological staining.
XX OS Synthetic.
XX FN WO9839437-A1.
XX PD 11-SEP-1998.
XX PR 05-MAR-1998; 98WO-JP00905.

```

```

XX 05-MAR-1997; 97JP-0050302.
XX (KYOW ) KYOWA HAKKO KOGYO KK.
XX PI Sakaki Y;
XX DR WPI; 1998-495844/42.
XX PT Novel apoptosis-related DNAs and proteins - for diagnosis,
XX PT preventing or treating diseases associated with apoptosis.
XX PS Example 1; Page 47; 70pp; Japanese.
XX CC This is the nucleotide sequence of a PCR primer used in the method
XX CC of the invention, involving the use of novel apoptosis-related DNAs
XX CC and proteins. The inventions can be used as diagnostic reagents for
XX CC apoptosis e.g. (monoclonal) antibodies for the protein, as a reagent
XX CC in immunohistological staining, as apoptosis inhibitors. It can also
XX CC be used for treatment of apoptosis-related diseases.
XX SQ Sequence 18 BP; 1 A; 0 C; 2 G; 15 T; 0 other;
XX Query Match 0.9%; Score 12.8; DB 1; Length 18;
XX Best Local Similarity 87.5%; Pred. No. 2.9e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1144 TTTTCTCTTTTGA 1159
DB 3 TTTTCTCTTTTGA 18

RESULT 612
AAV35391
ID AAV35391 standard; DNA; 18 BP.
XX AC AAV35391;
XX DT 13-OCT-1998 (first entry)
XX DE HIV-1 gag protein DNA primer #4.
XX KW Hypervariable region; ENV protein; vaccinia virus; gag gene; retrovirus;
XX KW vaccines; infection; protection; primer; ss.
XX OS Synthetic.
XX FN WO9822596-A1.
XX PD 28-MAY-1998.
XX PF 19-NOV-1997; 97WO-JP04216.
XX PR 19-NOV-1996; 96JP-0323412.
XX PA (NINA-) JAPAN NAT INST INFECTIOUS DISEASES.
XX PA (JAPG ) NIPPON ZEON KK.
XX PI Kojima A, Kurata T, Yasuda A;
XX DR WPI; 1998-312481/27.
XX PT Recombinant vaccinia virus containing fusion H1B gag gene - for
XX PT production in host cells of gag protein for use as vaccine
XX PS Example 1; Page 64; 84pp; Japanese.
XX CC AAV35388-V35414 are primers used in a method which results in a
XX CC recombinant vaccinia virus comprising of a gag gene from a retrovirus
XX CC such as HIV-1 or HIV-2, fused to a DNA fragment containing an epitope
XX CC region (30-300 bases in length) of a retroviral gene other than the gag
XX CC gene. The gag gene may be altered so as to produce a gag protein modified
XX CC from the natural sequence by the addition, deletion or substitution of at

```


CC AAZ41220, and AAY52701 to AAY52706, represent sequences used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 18 BP; 1 A; 6 C; 4 G; 7 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 257 ACCTCTGGGCTGGCT 272
 Db 3 ATCTCTGGGCTGTCT 18
 RESULT 615
 AAZ22129
 ID AAZ22129 standard; DNA; 18 BP.
 AC AAZ22129;
 XX
 DT 26-NOV-1999 (first entry)
 XX
 DE Human c-IAP-2 mRNA inhibiting antisense oligo ISIS #23438.
 XX
 KW Cellular Inhibitor of Apoptosis-2; antisense; diagnostic; therapeutic;
 KW c-IAP-2; prophylaxis; infection; inflammation; tumor formation; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US958771-A.
 XX
 PD 28-SEP-1999.
 XX
 PF 03-DEC-1998; 98US-0205144.
 XX
 PR 03-DEC-1998; 98US-0205144.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Cowsett LM, Ackermann EU;
 XX
 DR WPI; 1999-561046/47.
 XX
 PT Antisense compounds complementary to Cellular Inhibitor of Apoptosis-2
 XX useful for e.g. diagnostics, therapeutics, and as research reagents -
 PS Claim 3; Column 39; 33pp; English.
 CC The invention provides antisense compounds of 8-30 nucleotides that
 CC inhibit the expression of human Cellular Inhibitor of Apoptosis-2
 CC (c-IAP-2). The antisense compounds may be used for diagnostics,
 CC therapeutics (for modulating the expression of c-IAP-2), prophylaxis
 CC (e.g. to prevent or delay infection, inflammation, or tumor formation),
 CC as research reagents (e.g. to distinguish between members of a
 CC biological pathway) and in kits. Sequences AAZ22103-142 represent
 CC phosphorothioate oligonucleotides used for antisense inhibition of
 CC cellular inhibitor of apoptosis-2.
 XX
 SQ Sequence 18 BP; 1 A; 6 C; 4 G; 7 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 257 ACCTCTGGGCTGGCT 272
 Db 3 ATCTCTGGGCTGTCT 18
 RESULT 616
 AAZ21232/c
 ID AAZ21232 standard; DNA; 18 BP.

XX AAZ21232;
 AC
 XX 22-NOV-1999 (first entry)
 XX
 DE Human CG1CE PCR primer SEQ ID NO:8.
 XX
 KW CG1CE; Best's macular dystrophy; mutation; diagnosis; detection;
 KW BMD; age-related macular dystrophy; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9943695-A1.
 XX
 PD 02-SEP-1999.
 XX
 PF 22-FEB-1999; 99WO-US03790.
 XX
 PR 25-FEB-1998; 98US-0075941.
 PR 18-DEC-1998; 98US-0112926.
 XX
 PA (MERI) MERCK & CO INC.
 PA (UYUP-) UNIV UPPSALA.
 XX
 PI Petrukhin K, Caskey CT, Metzker M, Wadelius C;
 XX
 DR WPI; 1999-540560/45.
 XX
 PT Human and mouse polynucleotides encoding CG1CE polypeptides -
 XX
 PS Disclosure; Page 17; 67pp; English.
 XX
 CC The present invention describes human and mouse CG1CE polynucleotides
 CC and proteins. When the CG1CE gene is mutated it is responsible for
 CC Best's macular dystrophy (BMD). Polynucleotides encoding CG1CE are
 CC useful for diagnosing whether a patient carries a mutation in the
 CC CG1CE gene. Normal and mutated CG1CE proteins are useful for
 CC identifying activators and/or inhibitors of these proteins, in order
 CC to treat BMD. The CG1CE gene offers a simpler and cheaper method of
 CC diagnosing BMD without the need for the presence of the patient. The
 CC gene may also be useful to discovering the genetic cause of age-related
 CC macular dystrophy. The present sequence represents a PCR primer for
 CC the human CG1CE cDNA sequence.
 XX
 SQ Sequence 18 BP; 1 A; 6 C; 3 G; 8 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 269 GCCTGATCAACAGGA 284
 Db 18 GCCTGATCAACAGGA 3
 RESULT 617
 AAX54203
 ID AAX54203 standard; DNA; 18 BP.
 AC AAX54203;
 XX
 DT 05-JUL-1999 (first entry)
 XX
 DE Human endothelin-1 antisense oligonucleotide fragment.
 XX
 KW Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;

KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX Synthetic.
 OS WO9913886-A1.
 PN 25-MAR-1999.
 PD 17-SEP-1998; 98WO-US19419.
 XX 09-JUN-1998; 98US-0093972.
 PR 17-SEP-1997; 97US-0059160.
 XX (UYEC-) UNIV EAST CAROLINA.
 PA Nyce JW;
 XX WPI; 1999-229400/19.
 DR New antisense oligonucleotides used in treatment of, e.g. pulmonary
 XX vasoconstriction
 PT Disclosure; Page 58; 120pp; English.
 PS The specification describes antisense oligonucleotides (AA52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding
 CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences AA5272-74. These multiple target
 CC oligonucleotides (specifically AA55180-271) can be used for the
 CC antisense treatment of diseases and conditions. Typical diseases and
 CC conditions are those associated with impaired respiration and
 CC inflammation, including lung diseases, pulmonary vasoconstriction,
 CC asthma, allergic rhinitis, acute asthma, allergies, asthma, impaired
 CC respiration, respiratory distress syndrome, pain, cystic fibrosis,
 CC pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic
 CC obstructive pulmonary disease (COPD), and cancers such as leukemias,
 CC lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,
 CC pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,
 CC hepatic metastases, as well as all types of cancers which may metastasize
 CC or have metastasized to the lungs, including breast and prostate cancer.
 XX Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1143 CTTTTCCTTTTGG 1158
 |||||
 Db 1 CTTCTGCTTTTGG 16
 RESULT 618
 AA54193
 ID AA54193 standard; DNA; 18 BP.
 XX AA54193;
 AC 05-JUL-1999 (first entry)
 XX Human endothelin-1 antisense oligonucleotide fragment.
 DE Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impaired respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;

KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX Synthetic.
 OS WO9913886-A1.
 PN 25-MAR-1999.
 PD 17-SEP-1998; 98WO-US19419.
 XX 09-JUN-1998; 98US-0093972.
 PR 17-SEP-1997; 97US-0059160.
 XX (UYEC-) UNIV EAST CAROLINA.
 PA Nyce JW;
 XX WPI; 1999-229400/19.
 DR New antisense oligonucleotides used in treatment of, e.g. pulmonary
 XX vasoconstriction
 PT Disclosure; Page 57; 120pp; English.
 PS The specification describes antisense oligonucleotides (AA52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding
 CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences AA5272-74. These multiple target
 CC oligonucleotides (specifically AA55180-271) can be used for the
 CC antisense treatment of diseases and conditions. Typical diseases and
 CC conditions are those associated with impaired respiration and
 CC inflammation, including lung diseases, pulmonary vasoconstriction,
 CC asthma, allergic rhinitis, acute asthma, allergies, asthma, impaired
 CC respiration, respiratory distress syndrome, pain, cystic fibrosis,
 CC pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic
 CC obstructive pulmonary disease (COPD), and cancers such as leukemias,
 CC lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,
 CC pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,
 CC hepatic metastases, as well as all types of cancers which may metastasize
 CC or have metastasized to the lungs, including breast and prostate cancer.
 XX Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1143 CTTTTCCTTTTGG 1158
 |||||
 Db 1 CTTCTGCTTTTGG 16
 RESULT 619
 AA526160/c
 ID AA526160 standard; DNA; 18 BP.
 XX AA526160;
 AC 21-MAY-1999 (first entry)
 XX Primer for cDNA synthesis.
 DE Replication-competent; Sabin type 1 poliovirus vector; cloning site;
 KW 3C-protease cleavage site; mucosal vaccine; infectious disease; AIDS;
 KW human immunodeficiency virus type 1; HIV-1; small pox; poliomyelitis;

KW Hepatitis C; acquired immunodeficiency syndrome; Mahoney vector; viral;
 KW primer; ss.
 OS Synthetic.
 XX WO9907859-A1.
 FN 18-FEB-1999.
 PD 07-AUG-1998; 98WO-KR00242.
 PF 07-AUG-1997; 97KR-0037812.
 XX (ALTW-) ALTWELL BIOTECH INC.
 PA Bae YS, Jung HR;
 PI WPI; 1999-167434/14.
 XX New replication-competent recombinant Sabin type 1 poliovirus vector
 PT - useful for developing mucosal vaccines against HIV-type 1, small
 PT pox, poliomyelitis and hepatitis C
 XX Disclosure; Page 58; 64pp; English.
 PS The invention relates to a replication-competent recombinant Sabin type 1
 XX poliovirus vector encoding a multiple cloning site and 3C-protease
 CC cleavage site between the two end N-terminal residues. This comprises a
 CC vector containing an exogenous vaccine gene at the multiple cloning site.
 CC A method of production of both vectors is also provided. The recombinant
 CC vectors are useful for developing various mucosal vaccines against a
 CC number of infectious diseases, including human immunodeficiency virus
 CC type 1 (HIV-1) (which causes acquired immunodeficiency syndrome (AIDS)),
 CC small pox, poliomyelitis and Hepatitis C. The poliovirus-mediated mucosal
 CC vaccine vectors overcome the disadvantages exhibited by Mahoney vectors
 CC by being safe to humans, replicable (having equal replication ability to
 CC that of the wild type) vectors, where the introduced vaccine genes are
 CC stably maintained during viral passages.
 XX SQ Sequence 18 BP; 1 A; 10 C; 4 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 302 CTGTGGGGGGCGGCAAC 317
 Db 17 CGGTGGGGGGCGGCAAC 2
 RESULT 620
 ID AAV81061 standard; DNA; 18 BP.
 XX AAV81061;
 AC AAV81061;
 XX 03-MAR-1999 (first entry)
 DT De-immunised 708 Vb constructing flanking primer DIVK7.
 DE Non-immunogenic; epitope, T-cell; immunogenicity; immune system; SK;
 KW immunoglobulin; therapeutic; streptokinase; de-immunised; 708;
 KW primer; ss.
 XX Synthetic.
 OS WO9852976-A1.
 FN 26-NOV-1998.
 PD 21-MAY-1998; 98WO-GB01473.
 PF 14-APR-1998; 98GB-0007751.
 XX

PR 21-MAY-1997; 97GB-0010480.
 PR 31-JUL-1997; 97GB-0016197.
 PR 28-NOV-1997; 97GB-0025270.
 PR 02-DEC-1997; 97US-0067235.
 XX (BIOV-) BIOVATION LTD.
 PA Carr FJ;
 PI WPI; 1999-045301/04.
 XX Reducing immunogenicity of proteins - by modifying the amino acid
 PT sequence of the protein to eliminate potential epitopes for T-cells
 PT of a given species
 XX Example 3; Fig 16; 77pp; English.
 PS The invention relates to a method for the production of non-immunogenic
 XX proteins. The method comprises determining at least part of the amino
 CC acid sequence of the protein; (b) identifying in the amino acid sequence
 CC one or more potential epitopes for T-cells (T-cell epitopes) of the
 CC given species; and (c) modifying the amino acid sequence to eliminate at
 CC least one of the T-cell epitopes identified in step (b) thereby to
 CC eliminate or reduce the immunogenicity of the protein when exposed to the
 CC immune system of the given species. A method of analysing a pre-existing
 CC protein to predict the basis for immunogenic responses is also provided.
 CC The methods can be used particularly for reducing the immunogenicity of
 CC immunoglobulins or therapeutic proteins, e.g. Streptokinase (SK). The
 CC products can be used for diagnosis and therapy. Sequences AAV81047-68
 CC represent oligonucleotides used for the construction of de-immunised 708
 CC Vb and Vc.
 XX SQ Sequence 18 BP; 2 A; 5 C; 4 G; 7 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 991 TTCAGATCCGCTTGG 1006
 Db 2 TTCAGATCCGCTTGG 17
 RESULT 621
 ID AAV73148 standard; DNA; 18 BP.
 XX AAV73148;
 AC AAV73148;
 XX 10-SEP-2001 (first entry)
 DT Human biallelic marker upstream amplification primer SEQ ID NO:7504.
 DE Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX Homo sapiens.
 OS WO9954500-A2.
 PN 28-OCT-1999.
 PD 21-APR-1999; 99WO-IB00822.
 PF 21-APR-1998; 98US-0082614.
 XX 23-NOV-1998; 98US-0109732.
 XX (GEST) GENSET.
 PA Cohen D, Blumenfeld M, Chumakov I;
 PI

```

XX WPI; 2000-013267/01.
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome
XX
XX Claim 9; Page 1830; 2745pp; English.
XX
XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the
XX invention have a variety of uses: they can be used for high density
XX mapping of the human genome, and in complex association studies and
XX haplotyping studies which are useful in determining the genetic basis
XX for disease states. Compositions and methods of the invention can also
XX be useful for the identification of the targets for the development of
XX pharmaceutical agents and diagnostic methods, as well as the
XX characterisation of the differential efficacious responses to and side
XX effects from pharmaceutical agents acting on a disease as well as other
XX treatment.
XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
XX and 3367, are not actually given a sequence in the Sequence Listing
XX from the present invention.
XX
XX Sequence 18 BP; 4 A; 4 C; 4 G; 6 T; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 850 TCAGCATACCGCTTGG 865
Db 3 TCAGCATACCGCTTGG 18
RESULT 622
AAZ76819
ID AAZ76819 standard; DNA; 18 BP.
XX AAZ76819;
XX
XX 10-SEP-2001 (first entry)
XX Human biallelic marker downstream amplification primer SEQ ID NO:11175.
XX Human genome; biallelic marker; high density disequilibrium map;
XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX haplotyping; hybridisation; identification; characterisation;
XX amplification; single nucleotide polymorphism; SNP; PCR primer;
XX diagnosis; ss.
XX Homo sapiens.
XX
XX WO9954500-A2.
XX
XX 28-OCT-1999.
XX
XX 21-APR-1999; 99WO-1B00822.
XX
XX 21-APR-1998; 98US-0082614.
XX 23-NOV-1998; 98US-0109732.
XX
XX (GEST ) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
XX WPI; 2000-013267/01.
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome
XX
XX Claim 9; Page 2613; 2745pp; English.

```

```

XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the
XX invention have a variety of uses: they can be used for high density
XX mapping of the human genome, and in complex association studies and
XX haplotyping studies which are useful in determining the genetic basis
XX for disease states. Compositions and methods of the invention can also
XX be useful for the identification of the targets for the development of
XX pharmaceutical agents and diagnostic methods, as well as the
XX characterisation of the differential efficacious responses to and side
XX effects from pharmaceutical agents acting on a disease as well as other
XX treatment.
XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
XX and 3367, are not actually given a sequence in the Sequence Listing
XX from the present invention.
XX
XX Sequence 18 BP; 8 A; 5 C; 4 G; 1 T; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 955 AGACTGACGAGCTGAC 970
Db 3 ACACAGCAGGACTGAC 18
RESULT 623
AAAF19759
ID AAF19759 standard; DNA; 18 BP.
XX AAF19759;
XX
XX 14-MAR-2001 (first entry)
XX Human endothelin-1 polynucleotide fragment #1326.
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
XX human; airway disorder; bronchoconstriction; lung inflammation;
XX surfactant depletion; respiratory; bronchodilator; anti-inflammatory;
XX immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
XX respiratory obstruction; pulmonary obstruction; impeded respiration;
XX surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
XX respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
XX pulmonary hypertension; emphysema; pulmonary transplantation rejection;
XX chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
XX cancer; ss.
XX Homo sapiens.
XX
XX WO200062736-A2.
XX
XX 26-OCT-2000.
XX
XX 24-MAR-2000; 2000WO-US08020.
XX
XX 06-APR-1999; 99US-0127958.
XX
XX (UYEC-) UNIV EAST CAROLINA.
XX (NYCE/) NYCE J W.
XX
XX Nyce JW;
XX
XX WPI; 2000-679539/66.
XX
XX Low adenosine (A) content antisense oligonucleotides which do not
XX trigger adenosine receptors during metabolism, useful e.g. for treating
XX cancers and respiratory obstructions -
XX Claim 14; Page 241; 1592pp; English.

```


XX 04-DEC-1998; 98US-0110954.
 XX (IMMU-) IMMUSOL INC.
 XX Tritz R, Welch PJ, Barber JR, Robbins JM;
 XX WPI; 2000-412314/35.
 XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
 PT PCNA and Cyclin B1 -
 XX Example 1; Page 19; 109pp; English.
 XX The present invention relates to a hairpin or hammerhead ribozyme,
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
 CC Representative examples of ribozyme recognition sites are given in
 CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
 CC inhibiting restenosis by introduction of the ribozyme into cells.
 CC The ribozyme is resistant to endonuclease activity and hence is
 CC efficient in restenosis treatment.
 XX Sequence 18 BP; 4 A; 3 C; 5 G; 6 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 600 CAGCCTGAAGCCTGAC 615
 |||||
 DB 18 CATCCTGAAGACTGAC 3

RESULT 626
 AAA86619/c
 ID AAA86619 standard; DNA; 18 BP.
 AC AAA86619;
 XX 04-DEC-2000 (first entry)
 XX Cdc 2 kinase hammerhead ribozyme recognitoins site #50.
 XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
 XX restenosis; ss.
 XX Mammalia.
 XX WO200032765-A2.
 XX 08-JUN-2000.
 XX 06-DEC-1999; 99WO-US28772.
 XX 04-DEC-1998; 98US-0110954.
 XX (IMMU-) IMMUSOL INC.
 XX Tritz R, Welch PJ, Barber JR, Robbins JM;
 XX WPI; 2000-412314/35.
 XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
 PT PCNA and Cyclin B1 -
 XX Example 1; Page 19; 109pp; English.
 XX The present invention relates to a hairpin or hammerhead ribozyme,
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.

CC Representative examples of ribozyme recognition sites are given in
 CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
 CC inhibiting restenosis by introduction of the ribozyme into cells.
 CC The ribozyme is resistant to endonuclease activity and hence is
 CC efficient in restenosis treatment.
 XX Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 600 CAGCCTGAAGCCTGAC 615
 |||||
 DB 16 CATCCTGAAGACTGAC 1

RESULT 627
 AAA29110/c
 ID AAA29110 standard; DNA; 18 BP.
 XX AAA29110;
 AC AAA29110;
 XX 12-SEP-2000 (first entry)
 XX Primer 1 for eosinophil peroxidase gene promoter amplification.
 XX Eosinophil; promoter; peroxidase; heterologous protein expression;
 XX major basic protein; granule ribonuclease; transgenic animal model;
 XX tissue-specific; primer; ss.
 XX Mus musculus.
 XX WO200034304-A1.
 XX 15-JUN-2000.
 XX 09-DEC-1999; 99WO-US29162.
 XX 11-DEC-1998; 98US-0210342.
 XX (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
 XX Lee JJ, Lee NA, Macias MP;
 XX WPI; 2000-423368/36.
 XX New nucleotide comprising an eosinophil-specific promoter for
 PT expression of proteins such as cell toxins or eosinophil peroxidase in
 PT eosinophils and for ablating the eosinophil lineage from transgenic
 PT mammals
 XX Disclosure; Page 6; 40pp; English.
 XX AAA29110-11 are primers, which can be used to clone an
 CC eosinophil-specific promoter (e.g. AAA29109) from the 5' flanking
 CC sequences of genomic eosinophil peroxidase gene. The promoter is useful
 CC for manipulating expression of heterologous proteins such as murine or
 CC human major basic proteins, eosinophil peroxidase, human granule
 CC ribonuclease, ribozyme, cell toxin and reporter proteins such as
 CC beta-galactosidase, within eosinophils. Transgenic animals are useful for
 CC producing large quantities of eosinophils and as animal models for
 CC pulmonary pathologies such as asthma, using eosinophil-specific
 CC expression of transgenes. Discovery of the promoter is advantageous
 CC because eosinophil-specific expression of proteins is not toxic to the
 CC eosinophil and absence of eosinophil does not affect survival of the
 CC animal.
 XX Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 CCAGCTCCAGGAGCTC 642
 |||||
 Db 17 CCAGCTCCAGGGATC 2

RESULT 628
 AAA12057
 ID AAA12057 standard; DNA; 18 BP.
 XX
 AC AAA12057;
 XX
 DT 14-AUG-2000 (first entry)
 XX
 DE Murine promoter OBHrel D4 HRE binding site primer.
 XX
 KW HRE; hypoxia response element; hypoxia-inducible factor; HIF; vasotropic;
 KW cardiant; cycostatic; antiaerthritic; gene therapy; ischaemia; arthritis;
 KW cardiovascular disease; peripheral arterial disease; cancer; primer
 KW phosphoglycerate kinase; PGK; murine; promoter; OBHrel; ss.
 XX
 OS Mus sp.
 XX WO200017371-A1.
 XX
 XX 30-MAR-2000.
 XX
 XX 22-SEP-1999; 99WO-GB03181.
 XX
 XX 23-SEP-1998; 98WO-GB02885.
 PR 28-JAN-1999; 99GB-0001906.
 PR 16-FEB-1999; 99GB-0003538.
 XX
 XX (OXFO-) OXFORD BIOMEDICA UK LTD.
 XX
 XX Binley KM, Naylor S;
 XX WPI; 2000-283595/24.
 XX
 XX Novel polynucleotide constructs comprising at least two repeats of a
 PT hypoxia response element useful for driving expression of nucleic acids
 PT of interest in a cell under hypoxic conditions -
 XX
 XX Example 21; Page 109; 155pp; English.
 XX
 XX This invention describes novel polynucleotide comprising at least 2
 CC repeats of a hypoxia response element (HRE), where the hypoxia-inducible
 CC factor (HIF) consensus binding sites within each of the 2 repeats are
 CC separated by a spacer of at least 20 contiguous nucleotides. The products
 CC of the invention have vasotropic, cardiant, cycostatic and antiaerthritic
 CC activity and can be used for gene therapy. The polynucleotides are useful
 CC for delivering nucleic acids of interest to mammalian cells. Lentiviral
 CC vectors are responsive to hypoxic agents and to agents that mimic
 CC hypoxia. This regulation can be harnessed in vitro to enhance the
 CC production of the vector and can be used in vivo to regulate gene
 CC expression in response to a physiological signal. The vectors have
 CC utility in disease, where ischaemia, including hypoxia, is a feature,
 CC e.g. cardiovascular disease, peripheral arterial disease, cancer and
 CC arthritis. The novel regulatory construct is capable of driving very high
 CC levels of transcription under conditions of hypoxia whilst providing only
 CC low basal levels of transcription under normal oxygen conditions. The
 CC polynucleotide construct targets cells within a tumor mass that are under
 CC conditions of hypoxia without affecting normal surrounding tissue. This
 CC sequence represents a murine phosphoglycerate kinase (PGK) promoter
 CC OBHrel HRE binding site primer which is described in the method of the
 CC invention.
 XX
 SQ Sequence 18 BP; 3 A; 4 C; 8 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1235 TGGTGCTGGAGCTGGC 1250
 |||||
 Db 2 TCGTGCAGGAGCTGGC 17

RESULT 629
 AAA33637
 ID AAA33637 standard; DNA; 18 BP.
 XX
 AC AAA33637;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Low adenosine antisense oligonucleotide SEQ ID NO:1326.
 XX
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; anti-inflammatory;
 KW antiallergic; antiaerthritic; cycostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200009525-A2.
 XX
 XX 24-FEB-2000.
 XX
 XX 03-AUG-1999; 99WO-US17712.
 XX
 XX 03-AUG-1998; 98US-0095212.
 XX
 XX (UYEC-) UNIV EAST CAROLINA.
 XX
 XX Nyce JW;
 XX WPI; 2000-205971/18.
 XX
 XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 XX
 XX Claim 18; Page 430; 1343pp; English.
 XX
 XX The present invention describes a new composition comprising an
 CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
 CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiaerthritic, cycostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
 CC asthma, impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of
 CC the ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680
 CC (AAA32323 to AAA33992) are specifically claimed ONs from the present
 CC invention. N.B. Sequences given in the disclosure of the present
 CC invention do not match up with their corresponding SEQ ID NO: sequences
 CC given in the sequence listing.

SQ Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 CTTTCTTTCTTTTGG 1158
 |||||
 Db 1 CTTCTGTCTTTTGG 16

RESULT 630
 AAA33647
 ID AAA33647 standard; DNA; 18 BP.
 XX AC AAA33647;
 XX DT 28-JUL-2000 (first entry)
 XX DE Low adenosine antisense oligonucleotide SEQ ID NO:1336.
 XX KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; anti-inflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX OS Homo sapiens.
 XX PN WO200009525-A2.
 XX PD 24-FEB-2000.
 XX PF 03-AUG-1999; 99WO-US17712.
 XX PR 03-AUG-1998; 98US-0095212.
 XX PA (UYEC-) UNIV EAST CAROLINA.
 XX PI Nyce JW;
 XX WPI; 2000-205971/18.
 XX PT New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 XX PS Claim 18; Page 431; 1343pp; English.
 XX CC The present invention describes a new composition comprising an
 CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
 CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have anti-inflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
 CC asthma, impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of
 CC the ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences

CC differ from the previously named sequences. SEQ ID NO:11 to 1680
 CC (AAA32323 to AAA33992) are specifically claimed ONs from the present
 CC invention. N.B. Sequences given in the disclosure of the present
 CC invention do not match up with their corresponding SEQ ID NO: sequences
 CC given in the sequence listing.

SQ Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 CTTTCTTTCTTTTGG 1158
 |||||
 Db 1 CTTCTGTCTTTTGG 16

RESULT 631
 AAZ90647
 ID AAZ90647 standard; DNA; 18 BP.
 XX AC AAZ90647;
 XX DT 13-JUN-2000 (first entry)
 XX DE Human adipose tissue gene amplifying primer #8.
 XX KW Adipose tissue; obesity; diabetes; hyperlipemia; hypertension; human;
 KW arteriosclerosis; hyperuricemia; sleep apnea syndrome; PCR primer; ss.
 XX OS Homo sapiens.
 XX PN JP2000037190-A.
 XX PD 08-FEB-2000.
 XX PF 23-JUL-1998; 98JP-0225228.
 XX PR 23-JUL-1998; 98JP-0225228.
 XX PA (NISH) JAPAN TOBACCO INC.
 XX DR WPI; 2000-306578/27.
 XX PT A physiologically active protein specifically derived from mammal
 PT tissue -
 XX PS Example 2; Page 18; 50pp; Japanese.
 XX CC The invention relates to identification of genes and proteins of adipose
 CC tissue relating to obesity, particularly complications of visceral
 CC obesity including diabetes, hyperlipemia, hypertension,
 CC arteriosclerosis, hyperuricemia and sleep apnea syndrome. The genes
 CC (AAZ90631-633) and the proteins (AAZ97598-Y67600) are used in the genetic
 CC diagnosis, prevention and treatment of adipose tissue related diseases.
 CC Sequences AAZ90640-51 represent PCR primers amplifying the human adipose
 CC tissue genes.
 XX SQ Sequence 18 BP; 1 A; 0 C; 2 G; 15 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTCTTTCTTTTGG 1159
 |||||
 Db 3 TTTTCTTTCTTTTGA 18

RESULT 632
 AAH47994/C
 ID AAH47994 standard; DNA; 18 BP.
 XX

DB 18 CATCTGAAGACTGAC 3

RESULT 634
AAH61785/C
ID AAH61785 standard; DNA; 18 BP.
XX AC
XX AAH61785;
XX DT 10-SEP-2001 (first entry)
XX DE Cdc 2 kinase hammerhead ribozyme recognition site SEQ ID NO:4209.
XX KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulvar;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX KW Homo sapiens.
OS Synthetic.
OS WO200130362-A2.
XX FN 03-MAY-2001.
XX PD 26-OCT-2000; 2000WO-US295500.
XX PF 26-OCT-1999; 99US-0161532.
XX PR (IMMU-) IMMUSOL INC.
XX PA Robbins JM, Tritz R;
XX PI WPI; 2001-300427/31.
XX DR
XX KW Treating proliferative skin or eye diseases and scarring, using
PT ribozymes that cleave RNA encoding cytokines involved in inflammation,
PT matrix metalloproteinases, growth factors and cell-cycle dependent
PT kinases -
XX PS Disclosure; Page 379; 409pp; English.
XX CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulvar, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative
CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention.
XX SQ Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 600 CAGCCTGAAGCTGAC 615
DB 16 CATCTGAAGACTGAC 1

RESULT 635
AAH61243/C
ID AAH61243 standard; DNA; 18 BP.
XX AC
XX AAH61243;
XX DT 25-MAY-2001 (first entry)
XX DE C. glutamicum ATCC13032 thrE PCR primer thrE-reverse.
XX KW L-threonine; thrE; animal nutrition; human medicine;
KW pharmaceutical industry; PCR primer; ss.
XX OS Corynebacterium glutamicum.
XX DE19941478-A1.
XX FN 08-MAR-2001.
XX PD 01-SEP-1999; 99DE-1041478.
XX PF 01-SEP-1999; 99DE-1041478.
XX PR (DEGS) DEGUSSA-HUELS AG.
XX PA (KERJ) FORSCHUNGSZENTRUM JUELICH GMBH.
XX PI Thierbach G, Ziegler P, Eggeling L, Sahm H;
XX DR WPI; 2001-227606/24.
XX KW New cloned Corynebacterium glutamicum thrE gene useful for producing
PT thrE-overexpressing coryneform bacteria for production of L-threonine
XX -
XX PS Example 2; Page 7; 22pp; German.
XX CC This invention describes a novel Corynebacterium glutamicum thrE gene
CC (I). The invention also describes (1) an amino acid sequence that is
CC derived from the nucleic acid sequence of (I) and is selected from two
CC sequences of 489 amino acids given in the specification; (2) coryneform
CC microorganisms transformed with (I); (3) production of L-threonine by the
CC culturing coryneform bacteria in which nucleotide sequences encoding the
CC thrE gene (sic) are overexpressed; and (4) a process for producing (I).
CC Coryneform bacteria that overexpress (I) are useful for producing (I).
CC L-threonine, which is useful in animal nutrition, human medicine and the
CC pharmaceutical industry.
XX SQ Sequence 18 BP; 0 A; 6 C; 5 G; 7 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 278 AAGAGGAGCAGCAGC 293
DB 18 AAGAGGAGGAGCAGC 3

RESULT 636
AAH79677
ID AAH79677 standard; DNA; 18 BP.
XX AC
XX AAH79677;
XX DT 29-MAY-2001 (first entry)
XX DE Human Akt-3 antisense oligonucleotide, SEQ ID NO: 85.

XX Human; Akt-3; protein kinase; cytostatic; antiinflammatory; infection;
 KW antisense therapy; inflammation; tumour; ss.
 XX Homo sapiens.
 OS US6187586-B1.
 FN 13-FEB-2001.
 PD 29-DEC-1999; 99US-0474922.
 PF 29-DEC-1999; 99US-0474922.
 XX (ISIS-) ISIS PHARM INC.
 PA Monia BP, Cowser LM, Roth RA;
 PI WPI; 2001-264979/27.
 DR New antisense compounds targeting nucleic acids encoding human Akt-3
 PT useful for treating a disease or condition associated with Akt-3
 PT expression, or in preventing or delaying inflammation or tumor
 PT formation
 XX Claim 1; Column 40; 37pp; English.
 PS The present sequence is one of a number of antisense compounds of up to
 CC 30 nucleobases in length targeted to a nucleic acid encoding human Akt-3.
 CC The antisense compounds are useful for inhibiting the expression of human
 CC Akt-3 in human cells or tissues. They are also useful for modulating the
 CC expression of Akt-3, and for treating a human or an animal suspected of
 CC having, or being prone to, a disease or condition associated with Akt-3
 CC expression. The antisense compounds may also be used as research
 CC reagents, in kits and in diagnostics, e.g. to elucidate the function of a
 CC particular gene or to distinguish between functions of various members of
 CC a biological pathway; and as a prophylactic, e.g. to prevent or delay
 CC infection, inflammation or tumour formation.
 XX Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 375 CCAGCTTCTCCAGAG 390
 DB 2 CCAGTTTACTCCAGAG 17
 RESULT 637
 AAF74480/c
 ID AAF74480 standard; DNA; 18 BP.
 XX AAF74480;
 AC AAF74480;
 XX 09-MAY-2001 (first entry)
 DT Clone 21399247.0.1 PRO5 sequencing primer SEQ ID NO:66.
 DE Human; PRO; cytostatic; immunomodulatory; reproduction;
 XX gene therapy; cell proliferation; differentiation disorder; cancer;
 KW immune associated disorder; gestational disease; pre-clampsia;
 KW PCR primer; sequencing primer; ss.
 XX Homo sapiens.
 OS WO200110902-A2.
 FN 15-FEB-2001.
 PD 11-AUG-2000; 2000WO-US21857.
 PF 11-AUG-1999; 99US-0148433.
 PR 10-AUG-2000; 2000US-0148433.
 XX (CURA-) CURAGEN CORP.
 PA Shimkets RA, Fernandes E;
 PI WPI; 2001-147509/15.
 DR

PR 11-AUG-1999; 99US-0148433.
 PR 10-AUG-2000; 2000US-0148433.
 XX (CURA-) CURAGEN CORP.
 PA Shimkets RA, Fernandes E;
 PI WPI; 2001-147509/15.
 DR Nucleic acids encoding secreted polypeptides, designated PROX
 PT polypeptides, useful for treating a syndrome associated with a
 PT PROX-associated disorder, e.g. cancer -
 XX Example 9; Page 125; 166pp; English.
 PS The present invention describes isolated nucleic acids encoding secreted
 CC polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where
 CC X is an integer from 1 to 17). PROX polypeptides have cytosolic,
 CC immunomodulatory and reproduction activities, and can be used in gene
 CC therapy, and as PROX antagonists and PROX agonists. PROX polypeptides,
 CC nucleic acids and antibodies are useful in the manufacture of a
 CC medicament for treating a syndrome associated with a PROX-associated
 CC disorder, e.g. a cell proliferation and/or differentiation disorder
 CC (e.g. cancer or immune associated disorders) and a gestational disease
 CC (e.g. pre-clampsia). They are also used for screening for a modulator of
 CC activity or of latency or predisposition to a PROX-associated disorder.
 CC AAF74432 to AAF74448 encode the specifically claimed human PROX
 CC polypeptides PRO1 to PRO17 given in AAB70531 to AAB70547. The present
 CC sequence represents a primer used in an example from the present
 CC invention.
 XX Sequence 18 BP; 4 A; 5 C; 7 G; 2 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1292 TTGCTCAGCCGTGGCC 1307
 DB 18 TTGCTCAGCCGTGCC 3
 RESULT 638
 AAF74483
 ID AAF74483 standard; DNA; 18 BP.
 XX AAF74483;
 AC AAF74483;
 XX 09-MAY-2001 (first entry)
 DT Clone 21399247.0.1 PRO5 sequencing primer SEQ ID NO:69.
 DE Human; PRO; cytostatic; immunomodulatory; reproduction;
 XX gene therapy; cell proliferation; differentiation disorder; cancer;
 KW immune associated disorder; gestational disease; pre-clampsia;
 KW PCR primer; sequencing primer; ss.
 XX Homo sapiens.
 OS WO200110902-A2.
 FN 15-FEB-2001.
 PD 11-AUG-2000; 2000WO-US21857.
 PF 11-AUG-1999; 99US-0148433.
 PR 10-AUG-2000; 2000US-0148433.
 XX (CURA-) CURAGEN CORP.
 PA Shimkets RA, Fernandes E;
 PI WPI; 2001-147509/15.
 DR

XX Nucleic acids encoding secreted polypeptides, designated PROX
PT polypeptides, useful for treating a syndrome associated with a
PT PROX-associated disorder, e.g. cancer -
XX Example 9; Page 126; 166pp; English.

XX The present invention describes isolated nucleic acids encoding secreted
CC polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where
CC X is an integer from 1 to 17). PROX polypeptides have cytosolic,
CC immunomodulatory and reproduction activities, and can be used in gene
CC therapy, and as PROX antagonists and PROX agonists. PROX polypeptides,
CC nucleic acids and antibodies are useful in the manufacture of a
CC medicament for treating a syndrome associated with a PROX-associated
CC disorder, e.g. a cell proliferation and/or differentiation disorder
CC (e.g. cancer or immune associated disorders) and a gestational disease
CC (e.g. pre-clampsia). They are also used for screening for a modulator of
CC activity or of latency or predisposition to a PROX-associated disorder.
CC AAF74432 to AAF74448 encode the specifically claimed human PROX
CC polypeptides PRO1 to PRO17 given in AAB70531 to AAB70547. The present
CC sequence represents a primer used in an example from the present
XX invention.

XX Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1292 TTGCTCAGCTGGCC 1307
Db 1 TTGCTCAGCTGGCTCC 16

RESULT 639
AAF68906
ID AAF68906 standard; DNA; 18 BP.
XX
AC AAF68906;
XX
XX 12-APR-2001 (first entry)
XX
XX COXII probe #12.
XX Mitochondria; cytochrome C oxidase; COX; Alzheimer's disease;
XX probe; ss.
XX Homo sapiens.
XX US6171859-B1.
XX 09-JAN-2001.
XX
XX 30-MAR-1995; 95US-0413740.
XX
XX 30-MAR-1994; 94US-0219842.
XX
XX (MITO-) MITOKOR.
XX Herrnstadt C, Parker WD;
XX WPI; 2001-136875/14.
XX
XX Targeting conjugate molecule to mitochondria having defective
PT cytochrome C oxidase activity for diagnosing Alzheimer's disease,
PT involves contacting mitochondria with a conjugate of targeting molecule
PT and toxin -
XX Disclosure; Columns 21-22; 88pp; English.

XX The present invention relates to a method for selectively accumulating
CC a mitochondrial disabling or destructive amount of a conjugate molecule
CC in mitochondria having defective cytochrome C oxidase (COX) activity or

CC displaying increased membrane potential. The method involves contacting
CC mitochondria with a conjugate molecule comprising a targeting molecule
CC conjugated to a toxin, where the conjugate or targeting molecule selected
CC accumulates in the mitochondria. The method is useful for diagnosis of
CC Alzheimer's disease (AD), especially sporadic AD. The present sequence
CC is a probe used in the method of the present invention.

XX Sequence 18 BP; 3 A; 9 C; 3 G; 3 T; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 TGCCCCCACCAGCCT 605
Db 1 TGCCCCCACCACCTCT 16

RESULT 640
AAH49174
ID AAH49174 standard; DNA; 18 BP.
XX
AC AAH49174;
XX
XX 26-NOV-2001 (first entry)
XX Human procalcitonin pCT PCR primer 1101.
XX
XX Procalcitonin; pCT; antitumor; antiseptis; antiinflammatory; tumor;
XX sepsis; systemic inflammatory response syndrome; PCR primer; ss.
XX Homo sapiens.
XX EP1111050-A2.
XX
XX 27-JUN-2001.
XX
XX 24-NOV-2000; 2000EP-0125719.
XX
XX 22-DEC-1999; 99DE-1062434.
XX 03-APR-2000; 2000DE-1016278.
XX 08-JUN-2000; 2000DE-1027954.
XX
XX (DADE-) DADE BEHRING MARBURG GMBH.
XX Althaus H, Hauser HP;
XX WPI; 2001-572431/65.
XX
XX New, preferably recombinant, human procalcitonin, useful for diagnosis
PT and treatment of sepsis, tumors and systemic inflammatory response
PT syndrome -
XX Example 1; Page 22; 36pp; German.

XX This invention describes novel isolated, preferably recombinant,
CC polypeptides (I) containing the amino acid sequence for human
CC procalcitonin (hpCT). The products of the invention have antitumor,
CC antiseptis and antiinflammatory activity. (I) (also antibodies (Ab)
CC raised against it) are used: (i) for diagnosis and treatment of tumors,
CC sepsis and systemic inflammatory response syndrome; (ii) to raise Ab;
CC (iii) for quantitative or qualitative detection and analysis, especially
CC of hpCT and antibodies against it; (iv) as controls or standards for
CC assays; and (v) for affinity chromatography. Isolated (I) can be produced
CC inexpensively in large amounts by recombinant expression. Solutions of
CC (I) that contain a polyethoxylated sterol ester have good storage
CC stability. This sequence represents a PCR primer used in the
CC amplification of human procalcitonin pCT.

XX Sequence 18 BP; 3 A; 2 C; 6 G; 7 T; 0 other;
SQ

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 833 TGAGCTTTCAGATGG 848
 |||||
 Db 2 TGAGCTTTTATGTTGG 17

RESULT 641
 ABZ72206/c
 ID ABZ72206 standard; DNA; 18 BP.

AC ABZ72206;
 DT 03-APR-2003 (first entry)

DE Gene 216 SSCP sequencing primer SEQ ID NO 178.
 KW Human; Gene 216; chromosome 20p13-p12; antiasthmatic; anorectic;
 KW antiinflammatory; gastrointestinal; gene therapy; vaccine; asthma;
 KW obesity; inflammatory bowel disease; primer; ss.

OS Synthetic.
 XX WO200178894-A2.
 XX 25-OCT-2001.

PF 13-APR-2001; 2001WO-US12245.
 XX 13-APR-2000; 2000US-0548797.
 XX (GENO-) GENOME THERAPEUTICS CORP.

PI Keith T;
 XX WPI; 2001-639428/73.

Isolated genes (Gene 216) from human chromosome 20p13-p12 and the proteins they encode, useful for the prevention, diagnosis and treatment of asthma, obesity and inflammatory bowel disease -
 Example 10; Page 150; 520pp; English.

The invention relates to isolated genes (Gene 216) from human chromosome 20p13-p12 and the proteins they encode. The nucleic acids and proteins may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate gene 216 expression. For example, the nucleic acids (or vectors) and proteins may be used to treat disorders associated with decreased expression by rectifying mutations or deletions in a patient's genome that affect the activity of gene 216 by expressing inactive proteins or to supplement the patients own production of Gene 216 proteins. Additionally, the nucleic acids may be used to produce the secreted Gene 216 protein, by inserting the nucleic acids into a host cell and culturing the cell to express the protein. The nucleic acids and complementary sequences may also be used as DNA probes in diagnostic assays to detect and quantitate the presence of similar nucleic acid sequences in samples and therefore which patients may be in need of restorative therapy. The Gene 216 protein may also be used as antigens in the production of antibodies against gene 216 and in assays to identify modulators of Gene 216 expression and activity. The anti-Gene 216 antibodies and antagonists may also be used to down regulate expression and activity. The anti-Gene 216 antibodies may also be used as diagnostic agents for detecting the presence of Gene 216 proteins in samples (e.g. by enzyme linked immunosorbant assay or ELISA). Disorders that may be prevented, diagnosed and/or treated by the above methods include, for example asthma, obesity and inflammatory bowel disease. The present invention is that of a Gene 216 related primer used in examples of the invention. The primers are used in the physical mapping of the gene (ABZ72067-ABZ72088), polymorphism identification using single strand conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184), sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362).

Sequence 18 BP; 2 A; 7 C; 3 G; 6 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 725 AGCAGGGGGCTGGCT 740
 |||||
 Db 16 AGCAGAGGGCATGGCT 1

RESULT 642
 ABT11916
 ID ABT11916 standard; DNA; 18 BP.

AC ABT11916;
 DT 19-DEC-2002 (first entry)
 DE Neublabin DNA related PCR primer.

KW Nootropic; neuroprotective; antiparkinsonian; anticonvulsant; analgesic;
 KW tranquiliser; antidiabetic; ophthalmological; neurodegenerative disorder;
 KW neublabin; ischemic neuronal damage; traumatic brain injury; diabetes;
 KW peripheral neuropathy; neuropathic pain; Alzheimer's disease; glaucoma;
 KW Huntington's disease; parkinson's disease; amyotrophic lateral sclerosis;
 KW memory impairment; renal disease; PCR; primer; ss.

OS Unidentified.
 XX WO200272826-A2.
 XX 19-SEP-2002.

PF 12-MAR-2002; 2002WO-EP02691.
 XX 12-MAR-2001; 2001US-0804615.

PA (BIOJ) BIOGEN INC.
 PA (NSGE-) NS GENE AS.
 PI Sah DWY, Johansen TE, Rossomando A;
 XX WPI; 2002-713515/77.

New truncated neublabin polypeptides lacking one or more amino-terminal amino acids of a mature neublabin polypeptide useful for treating neurodegenerative disorders, e.g. peripheral neuropathy, neuropathic pain, brain injury -
 Disclosure; Fig 8; 138pp; English.

The invention relates to a truncated neublabin polypeptide comprising an amino acid terminus that lacks one or more amino-terminal amino acids of a mature neublabin polypeptide. The polypeptides and nucleic acids are useful for treating neurodegenerative disorders such as ischemic neuronal damage, traumatic brain injury, peripheral neuropathy, neuropathic pain, Alzheimer's disease, Huntington's disease, parkinson's disease, anyotrophic lateral sclerosis, memory impairment, diabetes, renal diseases, or glaucoma by moderating metabolism, growth, differentiation or survival of a nerve or neuronal cell. This polynucleotide sequence is a neublabin PCR primer of the invention.

Sequence 18 BP; 1 A; 6 C; 9 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 716 TGGCCCCAGCAGGG 731
 |||||
 Db 3 TGGCCCCGCTGAGGG 18

RESULT 643
ABQ65394
ID ABQ65394 standard; DNA; 18 BP.
XX AC ABQ65394;
XX DT 20-AUG-2002 (first entry)
XX DE Human gene methylation status determination oligo SEQ ID NO: 6.
XX DE Toxicological diagnosis; DNA methylation; methylation status;
KW KW toxic response; human; de.
XX OS Homo sapiens.
XX PN WO200240710-A2.
XX PD 23-MAY-2002.
XX PF 08-NOV-2001; 2001WO-EP12951.
XX PR 14-NOV-2000; 2000DE-1056802.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2002-463571/49.
XX XX Toxicological diagnosis, useful for diagnosis and prognosis of adverse
PT reactions, based on effect of test compounds on methylation status of
PT selected genes, involves determining changes in DNA methylation status
PT the method of the invention.
XX PS Example 3; Page 107; 113pp; German.
XX CC The present invention relates to a method of toxicological diagnosis,
CC involving taking a DNA-containing sample from an organism or cell culture
CC that has been treated with a test compound and determining any changes in
CC the DNA methylation status or pattern caused by said test compound. The
CC method is used for diagnosis and prognosis of adverse toxic responses in
CC individuals. The present sequence is a human sequence used to demonstrate
CC the method of the invention.
XX SQ Sequence 18 BP; 2 A; 1 C; 4 G; 11 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1144 TTTTTCCTTTTTCGA 1159
Db 2 TTTTTCCTTTTTCGA 17
RESULT 644
ABK11324
ID ABK11324 standard; DNA; 18 BP.
XX AC ABK11324;
XX DT 05-JUN-2002 (first entry)
XX DE Arabidopsis Acyl coenzyme A thioesterase 4 PCR primer ACH4-SECOri.
XX ss; PCR: ACH4; Acyl coenzyme A thioesterase; plant; transgenic;
KW lipid oxidation; regulation of Coenzyme A; fatty acid metabolism;
KW primer; ACH4-SECOri.
XX OS Arabidopsis thaliana.
XX PN WO200208433-A2.
RESULT 645
ABL40174/c
ID ABL40174 standard; DNA; 18 BP.
XX AC ABL40174;
XX DT 21-MAY-2002 (first entry)
XX DE Mouse reelin protein CR-50 epitope region PCR primer SEQ ID NO:11.
XX KW Mouse; reelin protein CR-50 epitope region; elucidation; neuron;
KW cerebral disturbance; reelin protein; neuroprotective; PCR primer; ss.
XX OS Mus musculus.
XX PN JP2002017361-A.
XX PD 22-JAN-2002.
XX PF 04-JUL-2000; 2000JP-0202801.
XX PR 04-JUL-2000; 2000JP-0202801.
XX PA (RIKA) RIKAGAKU KENKYUSHO.
XX XX WPI; 2002-221707/28.
XX PT Reelin protein CR-50 epitope region, useful for diagnosis and treatment

PD 31-JAN-2002.
XX 19-JUL-2001; 2001WO-US22907.
XX PR 21-JUL-2000; 2000US-220028P.
XX PR 16-JUL-2001; 2001US-0906408.
XX PA (TILT/) TILTON G B.
XX PA (SHOC/) SHOCKEY J M.
XX PA (BROW/) BROWSE J A.
XX Tilton GB, Shockey JM, Browse JA;
XX WPI; 2002-241573/29.
XX Novel acyl coenzyme A thioesterase gene useful for altering a phenotype
PT of a plant, making a transgenic plant and for producing variants of
PT acyl-CoA thioesterases
XX Example 1; Page 47; 78pp; English.
XX CC The invention relates to an isolated acyl coenzyme A thioesterase (ACH)
CC encoding nucleic acid, encoding one of ACH1, ACH2, ACH4 or ACH5. ACH
CC enzymes have a role in lipid oxidation, regulation of Coenzyme A pools
CC and in fatty acid metabolism. Also include are a host cell
CC transfected with the nucleic acid, a transgenic plant transfected with
CC the nucleic acid (including its seed or oil) and ACH antisense
CC molecules. The ACH nucleic acid is useful for altering a phenotype of a
CC plant and for making a transgenic plant, by transfecting the
CC plant tissue with the ACH nucleic acid under conditions such that a
CC transgenic plant is generated. The ACH nucleic acid is also useful for
CC producing variants of acyl-CoA thioesterases. The present sequence
CC is a PCR primer used to amplify Arabidopsis ACH4 encoding sequences.
XX SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 643 TGCATCCCCCAAGACC 658
Db 2 TGAATTCCTCCCAAGACC 17
RESULT 645
ABL40174/c
ID ABL40174 standard; DNA; 18 BP.
XX AC ABL40174;
XX DT 21-MAY-2002 (first entry)
XX DE Mouse reelin protein CR-50 epitope region PCR primer SEQ ID NO:11.
XX KW Mouse; reelin protein CR-50 epitope region; elucidation; neuron;
KW cerebral disturbance; reelin protein; neuroprotective; PCR primer; ss.
XX OS Mus musculus.
XX PN JP2002017361-A.
XX PD 22-JAN-2002.
XX PF 04-JUL-2000; 2000JP-0202801.
XX PR 04-JUL-2000; 2000JP-0202801.
XX PA (RIKA) RIKAGAKU KENKYUSHO.
XX XX WPI; 2002-221707/28.
XX PT Reelin protein CR-50 epitope region, useful for diagnosis and treatment

PT of cerebral disturbance -
 XX PS Example 2; Page 7; 16pp; Japanese.
 XX
 CC The present invention describes the mouse reelin protein CR-50 epitope
 CC region, which contains the CR-50 antibody recognition site and is free
 CC from F-spondin domains and repetitive sites. Also described are: (1) an
 CC expression vector comprising a polynucleotide encoding a reelin protein
 CC epitope region; (2) host cells with transfected the expression vector;
 CC (3) polypeptides prepared by culture of the host cells; and (4)
 CC polynucleotides comprising the 351 base sequence given in ABL40165 which
 CC encodes the 117 amino acid sequence given in ABB06244; and (5) use of
 CC the polynucleotide for diagnosis and/or treatment of diseases caused by
 CC abnormal positioning of neural cells, and stimulation of association of
 CC reelin protein. The mouse reelin protein CR-50 epitope region has
 CC neuroprotective activity, and can be used in the diagnosis and treatment
 CC of cerebral disturbance due to an abnormal reelin gene and positioning
 CC of neurons. The present sequence represents a PCR primer for the mouse
 CC reelin protein CR-50 epitope region, which is used in an example from
 CC the present invention.
 XX
 SQ Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1019 GATGGTGCCAAAGTGC 1034
 Db |||||
 18 GATGGTGCCCACTGC 3
 RESULT 646
 ABA05859/c
 ID ABA05859 standard; DNA; 18 BP.
 AC ABA05859;
 XX
 XX 15-MAR-2002 (first entry)
 DE Corynebacterium thrE gene vector construction PCR primer #4.
 KW Corynebacterium; L-threonine production; fermentation;
 KW animal nutrition; medicine; pharmaceutical industry; PCR primer; ss.
 XX
 OS Corynebacterium glutamicum.
 XX
 PN DE10102823-A1.
 XX
 XX 29-NOV-2001.
 XX
 XX 23-JAN-2001; 2001DE-1002823.
 XX
 XX 27-MAY-2000; 2000DE-1026494.
 XX (DEGS) DEGUSSA AG.
 XX
 XX Rieping M;
 XX
 XX WPI; 2002-115532/16.
 XX
 XX Fermentative production of L-threonine, useful in animal nutrition,
 XX comprises culturing enterobacterium with increased thrE gene activity
 XX
 XX Example 2; Page 6; 23pp; German.
 XX
 XX The present invention relates to the fermentative production of
 CC L-threonine using an Enterobacterium, particularly one already capable of
 CC producing L-threonine, in which activity of the thrE gene sequence (or
 CC sequences) is increased by overexpression. L-threonine is useful in
 CC animal nutrition, human medicine and the pharmaceutical industry. The
 CC present sequence is a PCR primer used to isolate the Corynebacterium

CC glutamicum thrE gene.
 XX
 SQ Sequence 18 BP; 0 A; 6 C; 5 G; 7 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 278 AAGAGGAGCAGCAGC 293
 Db |||||
 18 AAGAGGAGCAGCAGC 3
 RESULT 647
 ABL30619
 ID ABL30619 standard; DNA; 18 BP.
 XX
 AC ABL30619;
 XX
 XX 21-MAR-2002 (first entry)
 DT
 XX
 XX Human HLA genotyping oligonucleotide SEQ ID NO 108.
 DE Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200192572-A1.
 XX
 XX 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-JP04662.
 XX
 XX 01-JUN-2000; 2000JP-0164798.
 XX
 XX (NISN) NISSHINBO IND INC.
 XX (SYST-) SYSTEM RES INC.
 XX
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 PS Claim 10; Page 113; 345pp; Japanese.
 XX
 XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 SQ Sequence 18 BP; 2 A; 7 C; 6 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 803 GCTCCCTGCAGCCGAG 818
 Db |||||
 1 GCTCCCTGCAGCCGAG 16

PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX Claim 10; Page 203; 345pp; Japanese.
 XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX Sequence 18 BP; 4 A; 5 C; 8 G; 1 T; 0 other;
 XX Query Match 0.9%; Score 12.8; DB 1; Length 18;
 XX Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 143 CGCTCGGCTCCGCTCC 158
 Db 18 CGCTCGGCTCCGCTCC 3
 RESULT 651
 ABL31108
 ID ABL31108 standard; DNA; 18 BP.
 XX ABL31108;
 XX 21-MAR-2002 (first entry)
 XX Human HLA genotyping oligonucleotide SEQ ID NO 597.
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 XX immunogenetic; transplantation; genetic disease; ss.
 XX Homo sapiens.
 XX WO200192572-A1.
 XX 06-DEC-2001.
 XX 01-JUN-2001; 2001WO-JP04662.
 XX 01-JUN-2000; 2000JP-0164798.
 XX (NISHI) NISSHINBO IND INC.
 XX (SYST-) SYSTEM RES INC.
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX Claim 10; Page 206; 345pp; Japanese.
 XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of

CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 other;
 XX Query Match 0.9%; Score 12.8; DB 1; Length 18;
 XX Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1182 TCTATAGGTGAGTGT 1197
 Db 3 TCTACGGGTGAGTGT 18
 RESULT 652
 ABL31109
 ID ABL31109 standard; DNA; 18 BP.
 XX ABL31109;
 XX 21-MAR-2002 (first entry)
 XX Human HLA genotyping oligonucleotide SEQ ID NO 598.
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 XX immunogenetic; transplantation; genetic disease; ss.
 XX Homo sapiens.
 XX WO200192572-A1.
 XX 06-DEC-2001.
 XX 01-JUN-2001; 2001WO-JP04662.
 XX 01-JUN-2000; 2000JP-0164798.
 XX (NISHI) NISSHINBO IND INC.
 XX (SYST-) SYSTEM RES INC.
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX Claim 10; Page 206; 345pp; Japanese.
 XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;
 XX Query Match 0.9%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 2.9e+02; Mismatches 0; Indels 2; Gaps 0; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1182 TCTATAGGTGAGTGT 1197
 DB 3 TCTAGGGGTGAGTGT 18

RESULT 653
 AAS18869/C
 ID AAS18869 standard; DNA; 18 BP.
 XX AAS18869;
 XX
 XX 12-MAR-2002 (first entry)
 XX
 XX Growth hormone 1 gene (GH1), locus control region (LCR) primer LCR25.
 XX
 XX Growth hormone 1; GH1; osteopathic; gene therapy; protein therapy;
 KW diabetes; obesity; infection; acromegaly; gigantism; sodium retention;
 KW water retention; metabolic syndrome; mood disorder; sleep disorder;
 KW Growth hormone dysfunction; familial growth hormone deficiency;
 KW short stature; pituitary storage defect; human; PCR primer; LCR25;
 KW locus control region; LCR; ss.
 XX
 XX Homo sapiens.
 XX WO200185993-A2.
 XX
 XX 15-NOV-2001.
 XX
 XX 14-MAY-2001; 2001WO-GB021126.
 XX
 XX 12-MAY-2000; 2000GB-0011459.
 XX
 XX 14-JUL-2000; 2000EP-0306004.
 XX
 XX (UTWA-) UNIV WALES COLLEGE OF MEDICINE.
 XX
 XX Cooper DN, Procter AM, Gregory J, Millar DS;
 XX WPI; 2002-089798/12.
 XX
 XX Detecting growth hormone variants (GH1), useful in screening patients
 PT for growth hormone irregularities, comprises comparing the nucleotide
 PT sequence of a GH1 gene from a test sample with that of a standard
 PT sequence of the human GH1 -
 XX
 XX Claim 11; Page 77; 95pp; English.

the invention described a method of detecting variation in growth hormone
 1 (GH1), and therefore GH dysfunction in an individual. The method
 comprises comparing the nucleotide sequence of GH1 gene obtained from the
 test sample with a standard human GH1 gene sequence, in order to identify
 variation (GH1 variant). The method is useful in screening patients for
 growth hormone irregularities or producing variant proteins for treating
 irregularities, and for the early detection and appropriate clinical
 management of familial GH deficiency. The GH1 variants are useful in
 therapeutic, diagnostic or detection method, particularly for determining
 binding defects and susceptibility to a disease such as diabetes, obesity
 or infection; for treating acromegaly or gigantism conditions associated
 with lactogenic, diabetogenic, lipolytic and protein anabolic effects,
 conditions associated with sodium and water retention, metabolic
 syndromes, mood and sleep disorders; diagnosing GH dysfunction and
 determining pituitary storage defects. The GH1 variants are especially
 useful in gene therapy or protein therapy. The GH1 or GH variant may also
 be used in the preparation of a medicament, diagnostics composition or
 kit, or detection kit. The method has the advantage of: expanding the
 know spectrum of GH1 gene mutations; evaluating the role of GH1 gene
 mutations in the etiology of short stature; identifying of the mode of
 inheritance of novel lesions; evaluation the effects of GH1 mutations on
 the structure and function of the GH molecule and development of rapid
 diagnostic tests for inherited GH deficiency. This sequence is the GH1
 gene locus control region (LCR) specific primer, LCR25, used to amplify

the LCR during sequence analysis to identify GH1 variants, described in
 the method of the invention.

Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1255 TGAGCCAGGTTGAGG 1270
 DB 16 TGAGGTCAGCTTGAGG 1

RESULT 654
 ABL43144
 ID ABL43144 standard; DNA; 18 BP.
 XX
 XX ABL43144;
 XX
 XX 11-APR-2002 (first entry)
 XX
 XX Human chromosome 1p36-35 PCR primer SEQ ID NO:188.
 XX
 XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis;
 KW genome; PCR primer; ss.
 XX
 XX Homo sapiens.
 XX JP2001321190-A.
 XX
 XX 20-NOV-2001.
 XX
 XX 12-MAR-2001; 2001JP-0068285.
 XX
 XX 10-MAR-2000; 2000JP-0066716.
 XX
 XX (RIKA) RIKAGAKU KENKYUSHO.
 XX (GENO-) GENOTEX YG.
 XX
 XX WPI; 2002-144136/19.
 XX
 XX Arraying genome clones -
 PT
 XX Claim 4; Page 8; 528pp; Japanese.

The present invention describes a method of arraying genome clones. The
 method comprises: (a) clones of the genomic libraries contained in
 multiwell plates numbered for discrimination are mixed in each of the
 multiwell plates; (b) a primer designed based on the chromosome marker
 sequence is added to the mixture to carry out an amplification reaction;
 (c) a signal corresponding to the marker is detected from the resultant
 amplified product to specify the discrimination Nos. of the multiwell
 plates containing the clones having said marker sequence; (d) the order
 of the markers is changed so that the same discrimination Nos. succeed to
 the maximum in the specified discrimination Nos. to array the multiwell
 plates; (e) the clones in the multiwell plates of the specified
 discrimination Nos. are mixed respectively in each wells of longitudinal
 and lateral directions; (f) the mixed clones are cultured and the
 resultant cultures are amplified by using the above primer; (g) signals
 are detected from the amplified products; (h) the clones in the multiwell
 plates are specified from the detected result; and (i) the clones are
 reconstituted as the positions on the chromosome and arrayed. The
 microarray is useful for gene analysis. ABL42957 to ABL45322 represent
 PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
 represent PCR primers for human chromosome 21q22.1, which are
 specifically claimed for use in the present invention.

Sequence 18 BP; 4 A; 1 C; 11 G; 2 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Thu Jan 8 16:51:54 2004

us09904568-3.rng

QY 936 GGAGAGAGAGTGTGAG 951
 Db 2 GGAGCAGGGTGTGAG 17

RESULT 655
 ABL44827
 ID ABL44827 standard; DNA; 18 BP.
 XX AC ABL44827;
 XX AC
 XX DT 11-APR-2002 (first entry)
 XX DE
 XX DE Human chromosome 1p36-35 PCR primer SEQ ID NO:1871.
 XX DE
 XX KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis;
 XX KW genome; PCR primer; ss.
 XX KW
 XX OS Homo sapiens.
 XX OS
 XX EN JP2001321190-A.
 XX PD 20-NOV-2001.
 XX PF 12-MAR-2001; 2001JP-0068285.
 XX PF 10-MAR-2000; 2000JP-0066716.
 XX PF (RIKA) RIKAGAKU KENKYUSHO.
 XX FA (GENO-) GENOTEX YG.
 XX FA
 XX DR WPI; 2002-144136/19.
 XX DR
 XX PT Arraying genome clones -
 XX PS Claim 4; Page 41; 528pp; Japanese.
 XX PS
 XX CC The present invention describes a method of arraying genome clones. The
 XX CC method comprises: (a) clones of the genomic libraries contained in
 XX CC multiwell plates numbered for discrimination are mixed in each of the
 XX CC multiwell plates; (b) a primer designed based on the chromosome marker
 XX CC sequence is added to the mixture to carry out an amplification reaction;
 XX CC (c) a signal corresponding to the marker is detected from the resultant
 XX CC amplified product to specify the discrimination Nos. of the multiwell
 XX CC plates containing the clones having said marker sequence; (d) the order
 XX CC of the markers is changed so that the same discrimination Nos. succeed to
 XX CC the maximum in the specified discrimination Nos. to array the multiwell
 XX CC plates; (e) the clones in the multiwell plates of the specified
 XX CC discrimination Nos. are mixed respectively in each well of longitudinal
 XX CC and lateral directions; (f) the mixed clones are cultured and the
 XX CC resultant cultures are amplified by using the above primer; (g) signals
 XX CC are detected from the amplified products; (h) the clones in the multiwell
 XX CC plates are specified from the detected result; and (i) the clones are
 XX CC reconstituted as the positions on the chromosome and arrayed. The
 XX CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
 XX CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
 XX CC represent PCR primers for human chromosome 21q22.1, which are
 XX CC specifically claimed for use in the present invention.
 XX CC
 XX SX Sequence 18 BP; 6 A; 7 C; 3 G; 2 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 554 CAGGATGCACACT 569
 Db 2 CAGGATGCACCACT 17

RESULT 656
 ACA60576

ID ACA60576 standard; DNA; 18 BP.
 XX ACA60576;
 XX DT 11-JUN-2003 (first entry)
 XX DE
 XX DE Antisense inhibition of human cyclin D2 related oligonucleotide #13.
 XX KW Human; cyclin D2; diagnostic; therapeutic; prophylaxis;
 XX KW cyclin 2 inhibition; ss.
 XX OS Homo sapiens.
 XX OS
 XX EN US6492173-B1.
 XX PD 10-DEC-2002.
 XX PF 01-AUG-2001; 2001US-0920760.
 XX PF 01-AUG-2001; 2001US-0920760.
 XX PF (ISIS-) ISIS PHARM INC.
 XX PF Cowser LM;
 XX PF WPI; 2003-361492/34.
 XX DR Novel antisense compound useful for treating diseases associated with
 XX DR Cyclin D2 expression, comprises an oligonucleotide comprising up to 50
 XX DR nucleobases in length, which inhibits expression of Cyclin D2 in cells
 XX DR or tissues in vitro -
 XX PS Example 15; Column 45-46; 40pp; English.
 XX PS
 XX CC The invention describes a compound (I) of up to 50 nucleobases in
 XX CC length, which inhibits the expression of Cyclin D2. (I) is useful for
 XX CC inhibiting the expression of Cyclin D2 in cells or tissues in vitro.
 XX CC (I) is thus useful for treating diseases associated with Cyclin D2
 XX CC expression. (I) is useful for diagnostics, therapeutics, prophylaxis
 XX CC and as research reagents and kits. This sequence represents human
 XX CC cyclin D2 inhibition associated oligonucleotide.
 XX SX Sequence 18 BP; 2 A; 0 C; 4 G; 12 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTCTTTTGGAA 1160
 Db 3 TTTTCTTTTGGAA 18

RESULT 657
 ABX75059/c
 ID ABX75059 standard; DNA; 18 BP.
 XX ABX75059;
 XX AC
 XX DT 25-MAR-2003 (first entry)
 XX DT
 XX DE Human gene 216 polymorphism detection PCR primer #116.
 XX DE
 XX KW Human; mouse; ss; primer; gene 216; antiasthmatic; antiinflammatory;
 XX KW anorectic; chromosome 20p13-p12; single nucleotide polymorphism;
 XX KW SNP; gene therapy; respiratory disease; asthma; obesity; PCR;
 XX KW bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
 XX KW adult respiratory distress syndrome; inflammatory bowel syndrome.
 XX OS Homo sapiens.
 XX OS
 XX EN WO200293077-A2.
 XX PN
 XX XX

PD 24-OCT-2002.
 XX
 XX PF 15-APR-2002; 2002WO-US12063.
 XX
 XX PR 13-APR-2001; 2001US-0834597.
 PR 13-APR-2001; 2001WO-US12245.
 XX
 PA (SCHE) SCHERING CORP.
 PA (GENO-) GENOME THERAPEUTICS CORP.
 XX
 XX PI Keith T, Little RD, Van Berdewegh P, Dupuis J, Del Mastro RG;
 PI Simon J, Allen K, Pandit S;
 XX
 XX WPI; 2003-092960/08.
 DR
 XX
 XX New isolated gene 216 nucleic acids, useful for diagnosing, preventing
 PT or treating a disorder, such as asthma, bronchial hyper-responsiveness,
 PT chronic obstructive pulmonary disease, obesity or inflammatory bowel
 PT syndrome -
 XX
 XX Example 10; Page 156; 650pp; English.
 PS
 XX This invention relates to a novel isolated nucleic acid, gene 216,
 CC identified from human chromosome 20p13-p12. The invention also discloses
 CC regions of the 216 gene that contain single nucleotide polymorphisms
 CC (SNP's) which may be used as markers for disease susceptibility or
 CC severity. The nucleotides of the invention may have anti-infective,
 CC anti-inflammatory or anorectic activities and may be used in gene
 CC therapy. The nucleic acids, antibodies or its fragments are useful for
 CC diagnosing, preventing or treating a disorder, such as respiratory
 CC diseases (e.g. asthma, bronchial hyper-responsiveness, chronic
 CC obstructive pulmonary disease or adult respiratory distress syndrome),
 CC obesity, or inflammatory bowel syndrome. The nucleic acids are also
 CC useful for identifying increased susceptibility of a subject to the
 CC disorders mentioned. The nucleic acids can also be used as primers and
 CC templates for the recombinant production of disorder-associated
 CC peptides or polypeptides, for chromosome and gene mapping, or for
 CC tissue distribution studies. The present sequence represents a gene
 CC 216 specific PCR primer used in the scope of the invention.
 XX
 XX Sequence 18 BP; 2 A; 7 C; 3 G; 6 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 725 AGCAGGGGGCTGGCT 740
 DB ||||| ||||| |||||
 16 AGCAGAGGGCATGGCT 1
 RESULT 658
 AAD50969
 ID AAD50969 standard; DNA; 18 BP.
 XX
 XX AC AAD50969;
 XX
 XX DT 02-APR-2003 (first entry)
 XX
 DE DM20 primer, to detect the presence of pTUBZ011-2 in Schizochytrium sp.
 XX
 XX Acetolactate synthase; ALS; alpha-tubulin; polyketide synthase; PKS;
 KW fatty acid desaturase; primer; ss.
 XX
 XX OS Schizochytrium sp.
 XX
 XX PN WO200283869-A2.
 XX
 XX PD 24-OCT-2002.
 XX
 PF 16-APR-2002; 2002WO-US12040.
 XX
 XX PR 16-APR-2001; 2001US-284116P.

XX (OMEG-) OMEGATECH INC.
 XX
 XX Roessler PG, Matthews TD, Ramseier TM, Metz JG;
 XX
 XX WPI; 2003-075541/07.
 XX
 XX New nucleic acid molecule, useful for transforming Thraustochytriales
 PT microorganisms or the foreign nucleic acids in a Thraustochytriales -
 PT
 XX Example 4; Page 106; 112pp; English.
 PS
 XX The present invention relates to novel nucleic acids and proteins for
 CC acetolactate synthase, acetolactate synthase (ALS) regulatory regions,
 CC alpha-tubulin promoter, polyketide synthase (PKS) promoter and fatty acid
 CC desaturase promoter from Thraustochytriales microorganisms. The nucleic
 CC acids of the invention are useful for transforming Thraustochytriales
 CC microorganisms or the foreign nucleic acids in a Thraustochytriales.
 CC The present sequence is a primer which is used to detect the presence
 CC of pTUBZ011-2 sequences in Schizochytrium species. This sequence is
 CC used in the exemplification of the invention.
 XX
 XX Sequence 18 BP; 2 A; 6 C; 5 G; 5 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 978 TTGACCACTGCCATTC 993
 DB ||||| ||||| |||||
 2 TTGACCACTGCCGTC 17
 RESULT 659
 ABZ56925/c
 ID ABZ56925 standard; DNA; 18 BP.
 XX
 XX AC ABZ56925;
 XX
 XX DT 04-APR-2003 (first entry)
 XX
 DE Vallinoid receptor (VR1) related PCR primer 1 # SEQ ID 4.
 XX
 KW Dermatological; analgesic; anti-inflammatory; epithelial cell;
 KW skin; vallinoid receptor; VR1; PCR; primer; ss.
 XX
 OS Rattus sp.
 XX
 XX PN WO2002103351-A1.
 XX
 XX PD 27-DEC-2002.
 XX
 XX PF 10-JUN-2002; 2002WO-JP05736.
 XX
 XX PR 14-JUN-2001; 2001JP-0180366.
 XX
 XX PA (SHIS) SHISEIDO CO LTD.
 XX
 XX PI Inoue K, Fujiwara S, Denda M, Denda S;
 XX
 XX WPI; 2003-140773/13.
 DR
 XX Receptor-based method for detecting skin stimulation effect useful in
 PT screening analgesics, anti-inflammatory agents and inhibitors on
 PT epidermal abnormality, comprising measuring changes in calcium ion
 PT concentration -
 XX
 XX Examples; Page 8; 22pp; Japanese.
 PS
 XX The invention relates to a method for detecting a skin stimulation effect
 CC by using a test substance. The method comprises contacting a test
 CC substance with epithelial cells, and detecting the increase or decrease
 CC of calcium ion concentration in the cells. The method is useful as a

CC dermatological agent in the screening of analgesics, antiinflammatory
CC agents and inhibitors on epidermal abnormality. The current sequence
CC represents a rat vallinoid receptor (VR1) related PCR primer sequence
CC used in an example from the invention.
XX
XX Sequence 18 BP; 5 A; 7 C; 5 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 546 CCTGCTGCAGGCGATG 561
Db 18 CCTGCTGGTGGCATG 3

RESULT 560
ABQ83705
ID ABQ83705 standard; DNA; 18 BP.
XX
XX AC ABQ83705;
XX
XX DT 28-JAN-2003 (first entry)
XX
XX DE EPO B-A oligonucleotide.
XX
XX KW Gene regulation; expression; nucleic acid binding protein; cytostatic;
XX KW nephrotropic; gene therapy; kidney failure; cancer; ss.
XX OS Synthetic.
XX
XX FN WO200274996-A1.
XX
XX PD 26-SEP-2002.
XX
XX PF 19-MAR-2002; 2002WO-US08554.
XX
XX PR 19-MAR-2001; 2001GB-0006786.
XX
XX PA (SANG-) SANGAMO BIOSCIENCES INC.
XX
XX PI Girdlestone J, England N, Demaison C;
XX
XX DR WPI; 2003-058340/05.

Regulating expression of a nucleic acid sequence in a primary cell for
treating or preventing a disease e.g., cancer, comprises contacting the
nucleic acid binding polypeptide with the nucleic acid sequence -
XX
XX Disclosure; Page 3; 81pp; English.
XX
XX The present invention describes a method (M1) for regulating expression
of a nucleic acid sequence in a primary cell comprising providing a
nucleic acid binding polypeptide capable of binding to the nucleic acid
sequence and contacting the nucleic acid binding polypeptide with the
nucleic acid sequence in the primary cell. Also described: (1) a nucleic
acid binding polypeptide (I) capable of binding to, and regulating the
expression of, a nucleic acid sequence in a primary cell; (2) a primary
cell (II) comprising an exogenous nucleic acid binding polypeptide;
CC (3) a pharmaceutical composition (III) comprising the polypeptide or the
primary cell and a carrier or diluent; (4) treating (M2) or preventing a
disease; or (5) expressing (M3) an exogenous nucleic acid binding
polypeptide in a primary cell. (I) has cytostatic and nephrotropic
activities, and can be used in gene therapy. The method is useful for
treating or preventing a disease e.g., kidney failure or cancer. The
present sequence represents an oligonucleotide which is used in the
exemplification of the present invention.

Sequence 18 BP; 0 A; 2 C; 12 G; 4 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 298 TCTGCTGTGGGGGCTG 313
Db 1 TCTGGGGTGGGGGCTG 16

RESULT 661
ABF87744/c
ID ABF87744 standard; DNA; 13 BP.

XX
XX AC ABF87744;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 187741 for detecting SNP TSC0046249.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX
XX FN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB00713.
XX
XX PR 07-APR-2000; 2000DE-1019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single nucleotide polymorphisms and cytosine
methylation status -
XX
XX Claim 1; SEQ ID 187741; 29pp + Sequence Listing; German.
XX

This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
specification, but was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences.

Sequence 13 BP; 3 A; 0 C; 8 G; 1 T; 1 other;
Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1206 ACACCTCCCTTC 1218
Db 13 RCACCTCCCTTC 1

RESULT 662
ABF87745
ID ABF87745 standard; DNA; 13 BP.

XX
XX AC ABF87745;
XX
XX DT 22-FEB-2002 (first entry)

XX PS Claim 1; SEQ ID 193456; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.
XX CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX CC ABI00010-ABI82073 represent the oligomers described in the invention.
XX CC NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1104 TTATGTAGTTTC 1116
Db 13 TTATGTAGTTT 1

RESULT 665
ABH10200
ID ABH10200 standard; DNA; 13 BP.
XX AC ABH10200;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 210177 for detecting SNP TSC0051320.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX FA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status
XX PS Claim 1; SEQ ID 210177; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.
XX CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX CC ABI00010-ABI82073 represent the oligomers described in the invention.
XX CC NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1104 TTATGTAGTTTC 1116
Db 13 TTATGTAGTTT 1

RESULT 665
ABH10200
ID ABH10200 standard; DNA; 13 BP.
XX AC ABH10200;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 210177 for detecting SNP TSC0051320.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX FA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status
XX PS Claim 1; SEQ ID 210177; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.
XX CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX CC ABI00010-ABI82073 represent the oligomers described in the invention.
XX CC NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1104 TTATGTAGTTTC 1116
Db 13 TTATGTAGTTT 1

RESULT 666
ABH10201/C
ID ABH10201 standard; DNA; 13 BP.
XX AC ABH10201;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 210178 for detecting SNP TSC0051320.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX FA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status
XX PS Claim 1; SEQ ID 210178; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.
XX CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX CC ABI00010-ABI82073 represent the oligomers described in the invention.
XX CC NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 13 BP; 5 A; 3 C; 0 G; 4 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GTAATTATGTAGT 1112
Db 13 GTAATTATGTAGY 1

CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 13 BP; 4 A; 0 C; 3 G; 5 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GTAATTATGTAGT 1112
Db 1 GTAATTATGTAGY 13

RESULT 666
ABH10201/C
ID ABH10201 standard; DNA; 13 BP.

XX AC ABH10201;
XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 210178 for detecting SNP TSC0051320.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB00713.

XX PR 07-APR-2000; 2000DE-1019173.

XX FA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status

XX PS Claim 1; SEQ ID 210178; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.
XX CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX CC ABI00010-ABI82073 represent the oligomers described in the invention.

XX CC NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 13 BP; 5 A; 3 C; 0 G; 4 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GTAATTATGTAGT 1112
Db 13 GTAATTATGTAGY 1

```

RESULT 667
AAL44238
ID AAL44238 standard; DNA; 15 BP.
XX AC
XX AAL44238;
XX AC
XX 08-NOV-2002 (first entry)
XX DT
XX DE Human interleukin 12A (IL-12A) allele specific oligonucleotide primer 6.
XX DE
XX KW Human; primer; interleukin 12A; IL-12A; drug screening; AIDS; malaria;
XX KW tuberculosis; cancer; haplotyping; genotyping; transgenic animal; ss.
XX OS
XX OS Homo sapiens.
XX XX
XX PN WO200229115-A1.
XX PD
XX PD 11-APR-2002.
XX XX
XX PF 05-OCT-2001; 2001WO-US31656.
XX XX
XX PR 06-OCT-2000; 2000US-238693P.
XX XX
XX PA (GENA-) GENAISSANCE PHARM INC.
XX XX
XX PI Armstrong B, Cappola G, Choi JY, Gilson CR, Kliem SE, Koshy B;
XX PI Parks KE;
XX PI
XX DR WPI; 2002-315865/35.
XX XX
XX PT New interleukin 12A (IL-12A) gene polymorphic variants, for studying
XX PT the expression and function of IL-12A and screening candidate drugs for
XX PT treating AIDS and cancer -
XX XX
XX PS Claim 15; Page 13; 72pp; English.
XX XX
CC CC The invention comprises the amino acid and coding sequence of the human
CC CC interleukin 12A (IL-12A) protein. Specifically the invention relates to
CC CC the identification of polymorphisms within the human (IL-12A) gene
CC CC sequence. The polymorphisms identified in the human IL-12A gene sequence
CC CC are useful in studying the expression and function of IL-12A, and in
CC CC screening drugs for the treatment of disorders such as AIDS, malaria,
CC CC tuberculosis and cancer. The IL-12A polymorphisms may be used to
CC CC haplotype and genotype the IL-12A gene of an individual. The IL-12A DNA
CC CC sequences of the invention can be used to create transgenic animals for
CC CC studying expression of the IL-12A isogenes in vivo. The present DNA
CC CC sequence represents a human interleukin 12A (IL-12A) gene allele specific
CC CC oligonucleotide primer.
XX XX
SQ Sequence 15 BP; 3 A; 2 C; 5 G; 4 T; 1 other;
Query Match 0.9%; Score 12.6; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 744 GCATGTTGCTGAC 756
DB 2 GCATGTTGCTGAY 14
|||||||
|||||||

RESULT 668
ABL36325
ID ABL36325 standard; DNA; 15 BP.
XX AC
XX ABL36325;
XX AC
XX 22-APR-2002 (first entry)
XX DT
XX DE Human lysosomal acid phosphatase 2 (ACP2) allele-specific PCR primer 5.
XX DE
XX KW Human; ss; lysosomal acid phosphatase 2; ACP2; gene; chromosome 11;
XX KW lysosome-specific enzyme; orthophosphoric monoester hydrolysis;
Hodgkin's disease; HD; acid phosphatase deficiency;
novel polymorphic site; ACP2 haplotype; ACP2 genotype; polymorphism;
transgenic animal; primer; probe; primer-extension oligonucleotide;
SNP; single nucleotide polymorphism.
XX OS
XX OS Homo sapiens.
XX XX
XX PN WO200194362-A2.
XX PD
XX PD 13-DEC-2001.
XX XX
XX PF 07-JUN-2001; 2001WO-US18457.
XX XX
XX PR 07-JUN-2000; 2000US-210047P.
XX XX
XX PA (GENA-) GENAISSANCE PHARM INC.
XX XX
XX PI Kliem SE, Messer C, Tanguay DA;
XX PI
XX DR WPI; 2002-154563/20.
XX XX
XX PT Novel genetic variants of acid phosphatase 2, lysosomal polypeptide
XX PT gene useful in studying expression and function of the protein, and for
XX PT screening drugs to treat diseases e.g. Hodgkin's disease -
XX XX
XX PS Claim 17; Page 14; 109pp; English.
XX XX
CC CC The invention comprises the human lysosomal acid phosphatase 2 (ACP2)
CC CC nucleic acid and protein sequences. Specifically, the invention relates
CC CC to the discovery of 22 novel polymorphic sites within the ACP2 gene. The
CC CC invention also comprises methods for haplotyping and genotyping the ACP2
CC CC gene in an individual. The ACP2 gene (located on chromosome 11) encodes a
CC CC lysosomal-specific enzyme that catalyses the hydrolysis of
CC CC orthophosphoric monoesters to alcohol and phosphate. The ACP2 gene and
CC CC protein are pharmaceutically important in the treatment of Hodgkin's
CC CC disease (HD) and acid phosphatase deficiency. The novel ACP2 gene
CC CC polymorphisms of the invention are useful in haplotyping the ACP2 gene.
CC CC ACP2 haplotyping is useful in validating ACP2 as a target (and designing
CC CC drugs) for treating an ACP2-related disease or condition (e.g. Hodgkin's
CC CC disease and acid phosphatase deficiency). The ACP2 gene polymorphisms are
CC CC useful for ACP2 genotyping, which can also be used to develop diagnostic
CC CC tests and therapeutic treatments. The ACP2 protein and nucleic acids of
CC CC the invention are useful in the production of a transgenic animal which
CC CC expresses ACP2 protein. The ACP2 nucleic acids of the invention are
CC CC useful in the production of allele-specific oligonucleotides designed to
CC CC genotype each of the ACP2 polymorphisms. Nucleic acids ABL36299-ABL36320
CC CC represent claimed ACP2 allele-specific probes. Nucleic acids ABL36321-
CC CC ABL36364 represent claimed ACP2 allele-specific PCR primers. Nucleic
CC CC acids ABL36365-ABL36408 represent claimed ACP2 primer-extension
CC CC oligonucleotides.
XX XX
SQ Sequence 15 BP; 2 A; 8 C; 3 G; 1 T; 1 other;
Query Match 0.9%; Score 12.6; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 190 GCGGCCACCCGG 202
DB 3 GCGGCCACCCRG 15
|||||||
|||||||

RESULT 669
AAD44145
ID AAD44145 standard; DNA; 16 BP.
XX AC
XX AAD44145;
XX AC
XX 13-DEC-2002 (first entry)
XX DT
XX DE Oligo-dT PCR primer #5 used to illustrate the method of the invention.
XX DE Sequential consensus region-directed amplification; gene expression;
KW

```

KW disease diagnosis; gene analysis; human; matrix metalloproteinase;
 XX PCR; primer; ss.
 XX Unidentified.
 XX OS
 XX PN US6277571-B1.
 XX PD 21-AUG-2001.
 XX XX
 XX PF 30-SEP-1998; 98US-0163485.
 XX XX
 XX PR 03-OCT-1997; 97US-108152P.
 XX XX
 XX PA (UYVI-) UNIV VIRGINIA COMMONWEALTH INTELLECTUAL.
 XX XX
 XX PI Fillmore H, Broadus W, Gillies G;
 XX XX
 XX DR WPI; 2002-412824/44.
 XX XX
 XX PT Sequential consensus region-directed amplification for sorting mixture
 XX of DNAs into 2 or more subsets or distinguishing gene expression
 XX PT patterns in 2 samples, useful for disease diagnosis and gene analysis -
 XX XX
 XX PS Example; Fig 1C; 19pp; English.
 XX XX
 XX CC The invention relates to a method of sequential consensus region-directed
 CC amplification for sorting a mixture of DNAs into 2 or more subsets or
 CC distinguishing gene expression patterns in 2 samples. The methods, kits
 CC and oligonucleotides are useful for sorting a mixture of DNAs into 2 or
 CC more subsets or distinguishing gene expression patterns in 2 samples
 CC e.g. for disease diagnosis and gene analysis. The present sequence is
 CC oligo dT PCR primer used to illustrate the method of the invention.
 XX XX
 XX SQ Sequence 16 BP; 0 A; 1 C; 0 G; 14 T; 1 other;
 XX
 Query Match 0.9%; Score 12.6; DB 1; Length 16;
 Best Local Similarity 86.7%; Pred. No. 2.8e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1142 CCTTTTTCCTTTT 1156
 Db 1 CTTTTTTTTTTT 15
 RESULT 670
 AAX87332
 ID AAX87332 standard; DNA; 18 BP.
 AC AAX87332;
 XX AC
 XX DT 27-SEP-1999 (first entry)
 XX DE Reverse transcription primer P1.
 XX XX
 XX KW SAG gene; sensitive to apoptosis; mouse; cancer; tumour;
 KW neurodegenerative disease; muscular dystrophy; wound healing;
 KW vulnery; therapy; PCR; primer; ss.
 XX XX
 XX OS Synthetic.
 XX XX
 XX PN WO9932514-A2.
 XX XX
 XX PD 01-JUL-1999.
 XX XX
 XX PF 15-DEC-1998; 98WO-US26705.
 XX XX
 XX PR 11-SEP-1998; 98US-009840.
 XX PR 19-DEC-1997; 97US-0068179.
 XX XX
 XX PA (WARN) WARNER LAMBERT CO.
 XX XX
 XX PI Sun Y;
 XX CC

DR WPI; 1999-430152/36.
 XX
 XX SAG: Sensitive to Apoptosis Gene and related proteins, useful for
 PT promoting cell growth and protecting cells against apoptosis
 XX
 XX PS Example 1; Page 14; 84pp; English.
 XX XX
 XX CC This primer was used for reverse transcription of RNA isolated
 CC from mouse tumour lines L-R101 (epidermal tumour cell line) and
 CC H-Tx (spontaneously transformed liver line). It was also used as
 CC the reverse primer in PCR amplification of the resulting cDNA.
 CC Primers P1 and P2 (see AAX87333) reproducibly detected differential
 CC expression of a gene between L10-phenanthroline (OP)-treated and
 CC OP-nontreated L-R101 and H-Tx cells. An OP-inducible clone was
 CC used as a probe to isolate a full-length clone (see AAX87313)
 CC corresponding to the mouse sensitive to apoptosis gene (SAG). SAG
 CC is a redox-sensitive, haem-binding protein domain that promotes
 CC cell growth, protects cells from apoptosis, scavenges oxygen
 CC radicals and can be used for the reversion of a tumour phenotype.
 XX
 XX SQ Sequence 18 BP; 2 A; 1 C; 1 G; 13 T; 1 other;
 XX
 Query Match 0.9%; Score 12.6; DB 1; Length 18;
 Best Local Similarity 86.7%; Pred. No. 3.2e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1143 CTTTTTTCCTTTT 1157
 Db 4 CTTTTTTTTTTT 18
 RESULT 671
 ABT11916/C
 ID ABT11916 standard; DNA; 18 BP.
 XX
 XX AC ABT11916;
 XX XX
 XX DT 19-DEC-2002 (first entry)
 XX XX
 XX DE Neublabin DNA related PCR primer.
 XX XX
 XX KW Nootropic; neuroprotective; antiparkinsonian; anticonvulsant; analgesic;
 KW tranquiliser; antidiabetic; ophthalmological; neurodegenerative disorder;
 KW neublabin; ischemic neuronal damage; traumatic brain injury; diabetes;
 KW peripheral neuropathy; neuropathic pain; Alzheimer's disease; glaucoma;
 KW Huntington's disease; Parkinson's disease; amyotrophic lateral sclerosis;
 KW memory impairment; renal disease; PCR; primer; ss.
 XX
 XX OS Unidentified.
 XX XX
 XX PN WO200272826-A2.
 XX XX
 XX PD 19-SEP-2002.
 XX XX
 XX PF 12-MAR-2002; 2002WO-EP02691.
 XX XX
 XX PR 12-MAR-2001; 2001US-0804615.
 XX XX
 XX PA (BIOJ) BIOGEN INC.
 XX PA (NSGE-) NS GENE AS.
 XX XX
 XX PI Sah DWY, Johansen TE, Rossomando A;
 XX XX
 XX DR WPI; 2002-713515/77.
 XX XX
 XX PT New truncated neublabin polypeptides lacking one or more
 PT amino-terminal amino acids of a mature neublabin polypeptide useful
 PT for treating neurodegenerative disorders, e.g. peripheral neuropathy,
 PT neuropathic pain, brain injury -
 XX
 XX PS Disclosure; Fig 8; 138pp; English.
 XX XX
 XX CC The invention relates to a truncated neublabin polypeptide comprising an

CC amino acid terminus that lacks one or more amino-terminal amino acids of
 CC a mature neublastin polypeptide. The polypeptides and nucleic acids are
 CC useful for treating neurodegenerative disorders such as ischemic neuronal
 CC damage, traumatic brain injury, peripheral neuropathy, neuroathic pain,
 CC Alzheimer's disease, Huntington's disease, Parkinson's disease,
 CC amyotrophic lateral sclerosis, memory impairment, diabetes, renal
 CC diseases, or glaucoma by moderating metabolism, growth, differentiation
 CC or survival of a nerve or neuronal cell. This polynucleotide sequence is
 CC a neublastin PCR primer of the invention.

XX Sequence 18 BP; 1 A; 6 C; 9 G; 2 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 18;
 Best Local Similarity 92.9%; Pred. No. 3.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 806 CCTGCGAGCGGAGC 819
 |||||
 Db 18 CCTGCGAGCGGAGC 5

RESULT 672
 ABK94277/c
 ID ABK94277 standard; DNA; 21 BP.

AC ABK94277;

XX 27-AUG-2002 (first entry)

DE Endothelin converting enzyme 1 (ECE-1) SNP detection primer #65.

XX Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
 KW EDNR; signaling system; cardiovascular disease; coronary heart disease;
 KW hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
 KW diabetes; familial hypercholesterolaemia; forensic marker;
 KW transgenic animal; solid support; cardiovascular regulator; SNP;
 KW single nucleotide polymorphism; PCR; primer; ss.

XX Synthetic.

XX WO200224747-A2.

XX 28-MAR-2002.

XX 31-AUG-2001; 2001WO-EF10087.

XX 19-SEP-2000; 2000EP-0120123.

PR (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

XX Brinkmann U, Hoffmeyer S;

XX WPI; 2002-435060/46.

XX Novel polynucleotide of the endothelin/endothelin converting
 PT enzyme/receptors of endothelin and endothelin converting enzyme
 PT signaling system associated with cardiovascular disease, useful for
 PT treating the disease -

PS Claim 1; Page 63; 190pp; English.

XX The invention describes a polynucleotide (I) of the endothelin
 CC (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
 CC signaling system which is associated with a cardiovascular disease. (I),
 CC the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I),
 CC or (II) is useful for producing cells capable of expressing a molecular
 CC variant polypeptide which is associated with a cardiovascular disease.
 CC (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing
 CC a molecular variant gene comprising (I) is useful for identifying and
 CC obtaining a pro-drug or drug capable of modulating the activity of a
 CC molecular variant of the EDN/EDNR/ECE signaling system
 CC or its gene product, or for identifying and obtaining an inhibitor of
 CC the activity of a molecular variant of the EDN/EDNR/ECE

CC signaling system or its gene product. The isolated proteins and
 CC polynucleotides encoding them are useful for preparation of a
 CC pharmaceutical composition for treating a cardiovascular disease such as
 CC coronary heart disease, hypertension, atherosclerosis, or related to
 CC abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial
 CC hypercholesterolaemia. The gene or a polynucleotide fragment of the
 CC EDN/ECE/EDNR signaling system are useful as forensic markers, for
 CC creating a transgenic animal and in creation of a solid support
 CC comprising polynucleotides, genes, vectors, polypeptides, antibodies or
 CC host cells of the invention. This sequence represents a PCR primer used
 CC to identify single nucleotide polymorphisms in DNA encoding
 CC cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.

XX Sequence 21 BP; 6 A; 3 C; 11 G; 1 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 21;
 Best Local Similarity 92.9%; Pred. No. 4.1e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 802 CCTCTCTCGAGCC 815
 |||||
 Db 18 CTCTCTCTCGAGCC 5

RESULT 673

ABK94278
 ID ABK94278 standard; DNA; 21 BP.

AC ABK94278;

XX 27-AUG-2002 (first entry)

DE Endothelin converting enzyme 1 (ECE-1) SNP detection primer #66.

XX Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
 KW EDNR; signaling system; cardiovascular disease; coronary heart disease;
 KW hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
 KW diabetes; familial hypercholesterolaemia; forensic marker;
 KW transgenic animal; solid support; cardiovascular regulator; SNP;
 KW single nucleotide polymorphism; PCR; primer; ss.

XX Synthetic.

XX WO200224747-A2.

XX 28-MAR-2002.

XX 31-AUG-2001; 2001WO-EF10087.

XX 19-SEP-2000; 2000EP-0120123.

PR (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

XX Brinkmann U, Hoffmeyer S;

XX WPI; 2002-435060/46.

XX Novel polynucleotide of the endothelin/endothelin converting
 PT enzyme/receptors of endothelin and endothelin converting enzyme
 PT signaling system associated with cardiovascular disease, useful for
 PT treating the disease -

PS Claim 1; Page 63; 190pp; English.

XX The invention describes a polynucleotide (I) of the endothelin
 CC (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
 CC signaling system which is associated with a cardiovascular disease. (I),
 CC the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I),
 CC or (II) is useful for producing cells capable of expressing a molecular
 CC variant polypeptide which is associated with a cardiovascular disease.
 CC (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing
 CC a molecular variant gene comprising (I) is useful for identifying and
 CC obtaining a pro-drug or drug capable of modulating the activity of a

CC molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system
CC or its gene product, or for identifying and obtaining an inhibitor of
CC the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE
CC signaling system or its gene product. The isolated proteins and
CC polynucleotides encoding them are useful for preparation of a
CC pharmaceutical composition for treating a cardiovascular disease such as
CC coronary heart disease, hypertension, atherosclerosis, or related to
CC abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial
CC hypercholesterolaemia. The gene or a polynucleotide fragment of the
CC EDN/ECE/EDNR signaling system are useful as forensic markers, for
CC creating a transgenic animal and in creation of a solid support
CC comprising polynucleotides, genes, vectors, polypeptides, antibodies or
CC host cells of the invention. This sequence represents a PCR primer used
CC to identify single nucleotide polymorphisms in DNA encoding
CC cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.

XX Sequence 21 BP; 1 A; 11 C; 3 G; 6 T; 0 other;
SQ Query Match 0.9%; Score 12.4; DB 1; Length 21;
Best Local Similarity 92.9%; Pred. No. 4.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 802 CCTCCTCGACCC 815
DB 4 CTCCTCCTCGACCC 17

RESULT 674

AAH570294/C
ID AAX70294 standard; RNA; 18 BP.

XX AC AAX70294;

XX DT 28-JUL-1999 (first entry)

XX DE Human flt1 VEGF receptor hairpin ribozyme substrate #62.

XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
XX flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX foetal liver kinase 1; ss.

XX OS Homo sapiens.

XX PN WO9715662-A2.

XX PD 01-MAY-1997.

XX PF 25-OCT-1996; 96WO-US17480.

XX PR 11-JAN-1996; 96US-0584040.

XX PR 26-OCT-1995; 95US-0005974.

XX PA (CHIR) CHIRON CORP.

XX PI (RIBO-) RIBOZYME PHARM INC.

XX PS Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX DR WPI; 1997-259017/23.

XX PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or
XX mRNA stability - useful for treating e.g. tumour angiogenesis,
XX psoriasis, rheumatoid arthritis, etc., in a human patient

XX PS Claim 4; Page 94; 218pp; English.

XX CC The present invention describes nucleic acid molecules which modulate
XX the synthesis, expression and/or stability of a mRNA encoding 1 or more
XX receptors of vascular endothelial growth factor (VEGF). A patient
XX (preferably human) having a condition associated with the level of the
XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
CC be treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX57525 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention.

XX SQ Sequence 18 BP; 2 A; 4 C; 6 G; 6 U; 0 other;

XX Query Match 0.9%; Score 12.2; DB 1; Length 18;
XX Best Local Similarity 82.4%; Pred. No. 3.8e+02;
XX Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1027 CAAGTCGAGCTGACTC 1043

DB 18 CAAAGCAGCTGGCTC 2

RESULT 675

AAH57086

ID AAH57086 standard; DNA; 20 BP.

XX AC AAH57086;

XX DT 10-SEP-2001 (first entry)

XX DE Human oestrogen receptor alpha probe oligonucleotide 31.

XX KW Ligand dependent transcriptional factor; oestrogen receptor; ER;
XX glucocorticoid receptor protein; GR; mineralocorticoid receptor protein;
XX MR; peroxisome proliferator-activated receptor protein; PPAR;
XX progesterone receptor protein; PR; pregnane X receptor protein; PXR;
XX thyroid hormone receptor protein; TR; vitamin D receptor protein; VDR;
XX transactivation; ERalpha; breast cancer; PCR primer; probe; ss.

XX OS Homo sapiens.

XX PN WO200142307-A1.

XX PD 14-JUN-2001.

XX PF 01-DEC-2000; 2000WO-JP08553.

XX PR 07-DEC-1999; 99JP-0348022.

XX PR 27-DEC-1999; 99JP-0370667.

XX PR 07-JUL-2000; 2000JP-0207011.

XX PR 21-JUL-2000; 2000JP-0220508.

XX PR 02-AUG-2000; 2000JP-0234053.

XX PR 03-AUG-2000; 2000JP-0235460.

XX PR 03-AUG-2000; 2000JP-0235461.

XX PR 03-AUG-2000; 2000JP-0235463.

XX PA (SUMO) SUMITOMO CHEM CO LTD.

XX PI Saito K, Ohe N, Satoh H;

XX WPI; 2001-367866/38.

XX PT Ligand dependent transcriptional factors, nucleic acids encoding them
XX and cells comprising them and a specified reporter gene, useful for
XX screening agents for the treatment of breast cancer -

XX PS Disclosure; Page 243; 276pp; English.

XX CC The present invention relates to ligand dependent transcriptional factors
XX including oestrogen receptor (ER) alpha and beta protein, glucocorticoid
XX receptor protein (GR), mineralocorticoid receptor protein (MR),
XX peroxisome proliferator-activated receptor protein (PPAR), progesterone
XX receptor protein (PR), pregnane X receptor protein (PXR), thyroid hormone
XX receptor protein (TR) and vitamin D receptor protein (VDR), the nucleic
XX acids encoding them and cells comprising them and a specified reporter
XX gene for the ligand dependent transcriptional factor. These proteins are
XX useful in the modulation of ligand dependent transcriptional factor
XX activity. The cells, mutant ERalpha and the polynucleotide encoding it
XX may be used in assays for qualitatively analysing an activity for

CC transactivation of a reporter gene by a test ERalpha, for screening
CC mutant ligand dependent transcriptional factors, for evaluating an
CC activity for transactivation of a reporter gene by a test ERalpha and/or
CC for screening a compound useful for treating a disorder of a mutant
CC ERalpha, especially breast cancer.
XX
SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 other;

Query Match 0.9%; Score 12.2; DB 1; Length 20;
Best Local Similarity 82.4%; Pred. No. 4.2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 960 GCAGGACTGACCCCTCA 976
||||| ||||| ||||| ||||| |||||
Db 3 GCAGGCTGACCCCTGCA 19

RESULT 676
AAA11329/c
ID AAA11329 standard; DNA; 20 BP.
XX
AC AAA11329;
XX
DT 08-NOV-2000 (first entry)
XX
DE Human TRPC7 gene exon 23/intron 23 junction.
XX
KW Transmembrane protein; TRPC7; brain; transient receptor potential; TRP;
KW calcium channel function; human; Gene therapy; periodic psychosis;
KW mutation; ss.
XX
OS Homo sapiens.

XX Key Location/Qualifiers
FH exon 1..10
FT /tag= a
FT /number= 23
FT intron 11..20
FT /tag= b
FT /number= 23
XX
PN WO200029571-A1.

XX 25-MAY-2000.
XX
XX 11-NOV-1999; 99WO-JP06289.
XX
XX 12-NOV-1998; 98JP-0321200.
XX
XX (EIKE) EIKEN KAGAKU KK.
XX
XX Shimizu N, Nagamine K;
XX WPI; 2000-387784/33.
XX
XX Nucleic acids encoding transmembrane protein TRPC7 expressed in brain
FT and homologous to transient receptor potential protein useful in the
PT treatment of associated diseases such as periodic psychosis
XX
XX Example 7; Page 39; 77pp; Japanese.

XX The invention relates to the isolation of a nucleic acid (AAA11284)
CC coding for a transmembrane protein TRPC7 (AA92944) which is expressed in
CC brain and is homologous to transient receptor potential (TRP) protein.
CC This suggests that the TRPC7 protein may have a calcium channel
CC function. The genomic sequence has been shown to contain 31 introns. This
CC sequence represents an exon/intron junction from the genomic TRPC7
CC sequence. The DNA and protein can be used in the diagnosis and treatment
CC of disorders associated with TRPC7, especially the screening, monitoring
CC and treatment (by gene therapy) of periodic psychosis, which appears to
CC be associated with mutations in the TRPC7 gene.
XX

SQ Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 other;

Query Match 0.9%; Score 12; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 4.5e+02;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 687 TG3GAGCCAGCGCCCTCC 706
||||| ||||| ||||| ||||| |||||
Db 20 TCGACCCACCTGCTCCTCC 1

RESULT 677
AAD37217
ID AAD37217 standard; DNA; 20 BP.
XX
AC AAD37217;
XX
DT 21-AUG-2002 (first entry)
XX
DE Human MEK4 antisense oligonucleotide, ISIS #123152.

XX Human; MEK4 modulation; mitogen-activated protein kinase 4; MTK1;
KW MAP3K4; MAP three kinase 1; MAP/ERK kinase 4; MAPKKK4; cytostatic;
KW prophylaxis; immunological; hyperproliferative disorder; cancer; therapy;
KW antisense; inflammatory; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
OS Synthetic.

XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 5
FT /tag= d
FT /mod_base= m5c
FT modified_base 12
FT /tag= e
FT /mod_base= m5c
FT modified_base 16
FT /tag= f
FT /mod_base= m5c
FT modified_base 20
FT /tag= g
FT /mod_base= m5c
XX

PN WO200227033-A1.

XX
XX 04-APR-2002.
XX
XX 28-SEP-2001; 2001WO-US30549.
XX
XX 29-SEP-2000; 2000US-0676436.
XX
XX (ISIS-) ISIS PHARM INC.

XX Ward DT, Gaarde WA, Monia BP, Wyatt JR;
XX WPI; 2002-416486/44.
XX

XX New antisense compound targeted to nucleic acid encoding
PT mitogen-activated protein kinase 4, useful for treating immunologic
PT disorder, inflammatory disorder or cancer
XX
PS Claim 3; Page 93; 132pp; English.

XX The present invention relates to antisense compounds, compositions and
 CC methods for modulating the expression of MEK4 (also referred as mitogen-
 CC activated protein kinase kinase 4; MAP3K4; MAP three kinase 1; MAP/ERK
 CC kinase kinase 4; MAPKKK4; MTK1). The antisense oligos are useful for
 CC inhibiting the expression of MEK4 in cells or tissues. They are also
 CC useful for treating an animal having a disease or condition associated
 CC with MEK4 such as immunological, inflammatory, hyperproliferative
 CC disorder or cancer. Sequences of the invention are also useful for
 CC diagnostics, therapeutics, prophylaxis and as research reagents and kits.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human MEK4 DNA. This sequence
 CC is used in the exemplification of the invention.
 XX Sequence 20 BP; 2 A; 4 C; 10 G; 4 T; 0 other;
 SQ

Query Match 0.9%; Score 12; DB 1; Length 20;
 Best Local Similarity 75.0%; Pred. No. 4.5e+02;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 659 TGGTCGGGACWTGGCCAGC 678
 Db 1 TGGTCGAGGAGCTGGCTGC 20

RESULT 678
 AAL47730/c
 ID AAL47730 standard; DNA; 21 BP.
 XX
 AC AAL47730;
 XX
 DT 18-SEP-2002 (first entry)
 XX
 DE Ras gene PCR primer SEQ ID NO: 26.
 XX
 KW K-ras; N-ras; H-ras; ras; oncogene; mutation detection; PCR; primer;
 KW probe; restriction mediated selection PCR; cancer; ss.
 XX Unidentified.
 OS
 PN WO200229005-A2.
 XX
 PD 11-APR-2002.
 XX
 PF 02-OCT-2001; 2001WO-US42422.
 XX
 PR 02-OCT-2000; 2000US-237416P.
 XX
 PA (ORTH) ORTHO CLINICAL DIAGNOSTICS INC.
 XX
 PI Belly RT, Todd AV, Fuary CJ;
 XX
 DR WPI; 2002-479599/51.
 XX
 PT Amplifying and determining mutant sequences in DNA sample using
 PT thermostable restriction enzyme so that during thermocycling mutant
 PT sequences are enriched while wild-type sequences and/or primer induced
 PT sites are cleaved
 XX
 PS Claim 1; Page 74; 116pp; English.
 XX
 CC The present invention relates to a method of amplifying and determining
 CC target mutant Ras sequences in a DNA sample, involving the use of a
 CC thermostable restriction enzyme and primers shown in AAL47705-AAL47771.
 CC The method used is designated restriction mediated selection polymerase
 CC chain reaction (REMS-PCR). The method can be used to detect H-ras, K-ras
 CC and N-ras mutations, which may lead to cancer. The present sequence is a
 CC PCR primer useful in the method of the invention.
 XX
 SQ Sequence 21 BP; 3 A; 9 C; 6 G; 3 T; 0 other;
 SQ

Query Match 0.9%; Score 12; DB 1; Length 21;
 Best Local Similarity 75.0%; Pred. No. 4.7e+02;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 529 GAGGAGCAGCTGGGTCCT 548
 Db 20 GAGGGGCGCTGGGTGCAT 1

RESULT 679
 ABS52111
 ID ABS52111 standard; DNA; 18 BP.
 XX
 AC ABS52111;
 XX
 DT 05-NOV-2002 (first entry)
 XX
 DE Human adipocyte Clq Tumour Necrosis Factor-like PCR primer 1.
 XX
 KW Human; NOVX; NOVX-associated disorder; cardiomyopathy; atherosclerosis;
 KW cell signal processing; metabolic pathway modulation; metabolic disorder;
 KW obesity; diabetes; infectious disease; neurodegenerative disorder; cancer;
 KW Alzheimer's disease; Parkinson's disease; immune disorder; cancer;
 KW haematopoietic disorder; cirrhosis; pancreatitis; learning defect;
 KW memory defect; infertility; congenital heart defect; hair growth;
 KW pigmentation disorder; endocrine disorder; respiratory disease; health;
 KW gastro-intestinal disease; reproductive; neurological disease;
 KW bone marrow transplantation; endocrine disease; allergy; inflammation;
 KW neurological disorder; urinary system disorder; age-related disorder;
 KW neuropsychiatric disorder; EGF-related protein; SCUBE1; TEN-M4;
 KW adipocyte complement-related Clq tumour necrosis factor; out at first;
 KW beta adrenergic receptor kinase; EphA6/ebk-2; glucose transporter;
 KW type 1a membrane sushi-containing domain; butyrophillin;
 KW type 1a membrane sushi domain containing; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200257453-A2.
 XX
 PD 25-JUL-2002.
 XX
 PF 19-DEC-2001; 2001WO-US50331.
 XX
 PR 19-DEC-2000; 2000US-265704P.
 PR 20-DEC-2000; 2000US-257314P.
 PR 02-MAY-2001; 2001US-288153P.
 PR 29-MAY-2001; 2001US-294075P.
 PR 24-JUL-2001; 2001US-307506P.
 PR 10-AUG-2001; 2001US-311590P.
 PR 10-AUG-2001; 2001US-311613P.
 PR 29-AUG-2001; 2001US-315617P.
 PR 14-SEP-2001; 2001US-322358P.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Gangolli EA, Patturajan M, Vernet CAM, Malyankar UM, Kekuda R;
 PI Stone DJ, Anderson S, Shimkets RA, Burgess CE, Zethusen BD, Liu X;
 PI Spytek KA, Casman SJ, Boldog FL, Smithson G, Li L, Ji W;
 XX
 DR WPI; 2002-590744/63.
 XX
 PT Novel isolated NOVX polypeptide useful for treating cardiomyopathy,
 PT atherosclerosis, metabolic disorders, diabetes, obesity, infectious
 PT disease, anorexia, neurodegenerative disorders, Alzheimer's disease or
 PT cancer
 XX
 PS Example 1; Page 198; 318pp; English.
 XX
 CC The present invention relates to new NOVX polypeptides. The invention is
 CC useful for treating or preventing a NOVX-associated disorder such as
 CC cardiomyopathy or atherosclerosis, where the disorder is related to cell
 CC signal processing and metabolic pathway modulation in a subject,
 CC preferably human. The invention is also useful for treating metabolic
 CC disorders (e.g. obesity), diabetes, infectious disease, neurodegenerative
 CC disorders (e.g. Alzheimer's disease, Parkinson's disease), immune

CC disorders, haematopoietic disorders and various cancers. The molecules of
 CC the invention are also useful for treating or preventing cirrhosis,
 CC pancreatitis, learning and memory defects, infertility, congenital heart
 CC defects, acne, hair growth, pigmentation disorders, endocrine disorders,
 CC respiratory disease, gastro-intestinal diseases, reproductive, health,
 CC neurological diseases, bone marrow transplantation, endocrine diseases,
 CC allergy and inflammation, nephrological disorders, urinary system
 CC disorders, neuropsychiatric disorders and age-related disorders.
 CC The present nucleic acid sequence represents a PCR primer that was used
 CC in the methods of the invention.

SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 other;

Query Match 0.9%; Score 11.8; DB 1; Length 18;
 Best Local Similarity 86.7%; Pred. No. 4.4e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1297 CAGCCTGGCCCATG 1311
 ||||| ||||| |||||
 Db 2 CAGCAGGCGCCATG 16

RESULT 680

ABK85826
 ID ABK85826 standard; DNA; 18 BP.

XX AC ABK85826;

DT 24-SEP-2002 (first entry)

XX Myotonic dystrophy protein kinase (DMPK) isoform, primer 57.

XX Myotonic dystrophy; DM; protein kinase; DMPK; myocardial infarction;
 KW muscle damage; dysfunction; reverse transcriptase PCR; RT-PCR;
 KW primer; ss.

XX Homo sapiens.

XX US2002061571-A1.

XX 23-MAY-2002.

XX 20-MAR-2001; 2001US-0813289.

XX 20-MAR-2000; 2000US-190590P.

XX (MAHA/) MAHADEVAN M S.

XX (TISC/) TISCORNIA G.

XX Mahadevan MS, Tiscornia G;

XX WPI; 2002-507644/54.

XX A new isoform of myotonic dystrophy protein kinase includes a sequence
 PT encoded by exon 16 of the gene and is useful to detect presence or risk
 PT of myotonic dystrophy, myocardial infarction or a condition associated
 PT with muscle damage

PS Example; Page 7; 26pp; English.

XX The invention describes an isolated and purified polypeptide, comprising
 CC an amino acid sequence encoded by exon 16 of the myotonic dystrophy
 CC protein kinase (DMPK) gene. The invention is used to detect presence or
 CC risk of myotonic dystrophy, myocardial infarction or a condition
 CC associated with muscle damage or dysfunction. This sequence represents a
 CC reverse transcriptase PCR primer used to isolate cDNA encoding exon 16 of
 CC the novel Myotonic dystrophy protein kinase DMPK isoform studied in the
 CC invention.

SQ Sequence 18 BP; 3 A; 3 C; 9 G; 3 T; 0 other;

Query Match 0.9%; Score 11.6; DB 1; Length 18;
 Best Local Similarity 77.8%; Pred. No. 4.8e+02;

Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1258 GGCCAGGTGAGGCCCTT 1275
 ||||| ||||| |||||
 Db 1 GGGCAGATGGAGGCCCTT 18

RESULT 681

AAT87896
 ID AAT87896 standard; DNA; 18 BP.

XX AC AAT87896;

DT 12-JAN-1998 (first entry)

XX Lower primer for exon 1 of human interleukin 9 gene.

XX Human; interleukin 9; asthma associated factor 1; IL-9; primer;
 KW atopic allergy; asthma; bronchial hyperresponsiveness; BHR; eczema;
 KW rhinitis; urticaria; allergic inflammation; bowel; amplification;
 KW polymorphism; polymerase chain reaction; PCR; exon 1; ss.

XX Synthetic.

XX WO9708321-A1.

XX 06-MAR-1997.

XX 23-AUG-1996; 96WO-US12757.

XX 06-AUG-1996; 96US-0023800.

XX 24-AUG-1995; 95US-0002765.

XX (MAGA-) MAGAININ PHARM INC.

XX Lee MW, Levitt RC, Nicholas N, Prasad KU;

XX WPI; 1997-179278/16.

XX Human interleukin-9 variant with Met at position 117 - useful for
 PT treating atopic allergy, esp. asthma

XX Disclosure; Page 42; 142pp; English.

XX The present sequence is a primer for the PCR amplification of
 CC exon 1 from the human interleukin 9 (hIL-9), also known as asthma
 CC associated factor 1, gene. hIL-9 plays a role in atopic allergy,
 CC asthma and related disorders, e.g. bronchial hyperresponsiveness,
 CC (BHR), rhinitis, urticaria, allergic inflammatory disorders of the
 CC bowel and various forms of eczema. A naturally occurring
 CC polymorphism has been identified at position 117 of hIL-9,
 CC individuals homozygous for Met at position 117 demonstrate, e.g. a
 CC lack of asthma and low serum immunoglobulin E (IgE) levels, while
 CC Thr/Thr homozygotes and Thr/Met heterozygotes are susceptible to
 CC asthma.

SQ Sequence 18 BP; 2 A; 11 C; 2 G; 3 T; 0 other;

Query Match 0.9%; Score 11.6; DB 1; Length 18;
 Best Local Similarity 77.8%; Pred. No. 4.8e+02;

Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCCGAGC 819
 ||||| ||||| |||||
 Db 1 CTCCTCCCTGCAGCCCTACC 18

RESULT 682

AAV41332
 ID AAV41332 standard; DNA; 18 BP.

XX AC AAV41332;

XX

DT 06-OCT-1998 (first entry)

XX Interleukin-9 (IL-9) gene exon 1 specific lower primer.

DE Interleukin; IL-9; AAF1; asthma associated factor; human; IBD;

XX inflammatory bowel disease; Th2 mediated immune response; lupus;

KW Crohn's disease; chronic non-specific ulcerative colitis; diabetes;

KW multiple sclerosis; arthritis; autoimmune disease; PCR primer; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9827997-A1.

PN 02-JUL-1998.

XX 22-DEC-1997; 97WO-US23527.

XX 19-DEC-1997; 97US-0994986.

XX 20-DEC-1996; 96US-0034331.

XX (MAGA-) MAGAININ PHARM INC.

PA Levitt RC, Nicolaides NC;

XX WPI; 1998-377404/32.

XX Treating inflammatory bowel diseases, e.g. Crohn's disease - and

PT chronic non-specific ulcerative colitis by administering compounds

PT up-regulating function of interleukin-9 or its receptor

XX Disclosure; Page 23; 61pp; English.

XX Sequences shown in AAV41331 to AAV41340 represent exon specific primers

CC for human interleukin (IL-9) gene. The invention provides a method

CC for the treatment of inflammatory bowel disease (IBD) or related

CC disorders that comprises administering a compound that up-regulates the

CC function of IL-9 or the IL-9 receptor. A method for monitoring humans

CC undergoing IBD treatment with polypeptides with human IL-9 sequence

CC (or fragments), by evaluating IL-9 levels in samples taken at different

CC times, and a method for screening for cells expressing the IL-9 receptor

CC by detecting binding of a specific ligand are also provided. Compounds

CC up-regulating the function of IL-9 or the IL-9 receptor can be used

CC therapeutically (in pharmaceutical compositions, optionally with

CC acceptable carriers) to treat IBD and other related inflammatory

CC disorders. IBDs (which include Crohn's diseases and chronic non-specific

CC ulcerative colitis) are diseases characterised by an inappropriate

CC inflammatory response to environmental stimuli. Immune responses to

CC antigens are classified as Th1 or Th2 responses, and evidence suggests

CC that IBDs are dominated by a Th1 mediated, antigen induced, inflammatory

CC response. Other related Th1 mediated diseases include multiple

CC sclerosis, diabetes, arthritis, lupus and autoimmune diseases. The method

CC is based on the observation that the Th2 response is up-regulated by

IL-9.

XX SQ Sequence 18 BP; 2 A; 11 C; 2 G; 3 T; 0 other;

Query Match 0.9%; Score 11.6; DB 1; Length 18;

Best Local Similarity 77.8%; Pred. No. 4.8e+02;

Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCGAGCGGAC 819

Db 1 CTCCCCCTGAGCTTACC 18

RESULT 683

AAAX75628/c

ID AAX75628 standard; RNA; 18 BP.

XX AAX75628;

AC AAX75628;

XX 28-JUL-1999 (first entry)

DT

XX Mouse flt-1 VEGF receptor hairpin ribozyme substrate #87.

DE flk-1; KDR; hamsterhead ribozyme; hairpin ribozyme; cleavage;

XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;

KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;

KW foetal liver kinase 1; ss.

XX Mus sp.

OS WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

XX 11-JAN-1996; 96US-0584040.

XX 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

PA (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or

PT mRNA stability - useful for treating e.g. tumour angiogenesis,

PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 188; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate

CC the synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can

CC be treated by administering the nucleic acid molecule or the expression

CC vector to the patient. AAX67275 to AAX75752 represent specific examples

CC of nucleic acid molecules from the present invention.

XX SQ Sequence 18 BP; 2 A; 5 C; 6 G; 5 U; 0 other;

Query Match 0.9%; Score 11.6; DB 1; Length 18;

Best Local Similarity 77.8%; Pred. No. 4.8e+02;

Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 210 CGAAGCCGAGCGGCTCC 227

Db 18 CGAAGCCGAGCGGCTCC 1

RESULT 684

AAAX32336

ID AAX32336 standard; DNA; 19 BP.

XX AAX32336;

AC AAX32336;

XX 25-JUN-1999 (first entry)

DT Wheat viviparous 1 (taVp1) primer #3.

DE Wheat; oat; viviparous 1; Vp1; afVp1; taVp1; maize; detection; PHS;

XX pre-harvest sprouting; dormant; germination; crop plant; primer; ss.

XX Synthetic.

OS Triticum aestivum.

XX WO9915667-A1.

XX

PR 30-JAN-2001; 2001WO-US006070.
 PR 23-MAY-2001; 2001US-0864761.
 PR 10-OCT-2001; 2001US-0328205.
 XX (AEOM-) AEOMICA INC.
 XX Shannon M;
 XX WPI; 2002-684061/74.
 XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 PT POSHL-1, useful for treating disorders associated with decreased
 PT expression or activity of human POSHL1 -
 XX
 XX Example 2; SEQ ID NO 221; 60pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (II) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 5 G; 4 T; 0 other;
 Query Match 0.8%; Score 11.4; DB 1; Length 17;
 Best Local Similarity 92.3%; Pred. No. 4.9e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 526 CCGGAGGAGCAGC 538
 DB 14 CTGGAGGAGCAGC 2
 RESULT 687
 AAT80260
 ID AAT80260 standard; DNA; 18 BP.
 AC AAT80260;
 XX
 XX 15-OCT-1997 (first entry)
 DT
 DE Oligo HCV91, targetted to HCV region -1 to -6.
 XX
 XX Complementary; 5' untranslated region; UTR; hepatitis C virus; HCV;
 KW inhibition; replication; expression; detection; chronic hepatitis;
 KW acute hepatitis; hepatocarcinoma; ss.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 PH modified_base 7..18
 FT /tag= a
 FT /note= "2' Ome modified"
 FT modified_base 1..6
 FT /tag= b
 FT /note= "Phosphorothioate linkages"
 XX
 XX W09639500-A2.
 FN

XX 12-DEC-1996.
 PD
 XX 04-JUN-1996; 96WO-EP02427.
 PF
 XX 06-JUN-1995; 95US-0471968.
 PR
 XX (HOFF) HOFFMANN LA ROCHE & CO AG F.
 PA (HYER-) HYERIDON INC.
 XX
 PI Frank BL, Goodchild J, Hamlin HA, Kilkuskie RE;
 PI Roberts NA, Roberts PC, Walther DM, Wolfe JL;
 XX WPI; 1997-043122/04.
 DR
 XX Oligonucleotide(s) complementary to HCV 5' untranslated region -
 PT used in the treatment and detection of HCV infection, esp. hepatitis
 PT and hepato-carcinoma
 PS Claim 19; Page 31; 100pp; English.
 XX
 CC The sequences given in AAT80211-382 represent synthetic oligonucleotides
 CC which are complementary to a portion of the 5' untranslated region (UTR)
 CC of hepatitis C virus (HCV). These sequences may be used in a
 CC pharmaceutical composition for the control or prevention of HCV
 CC infection. They may be used to inhibit replication or expression of
 CC HCV or for detecting the presence of HCV in a sample. They may be used
 CC to inhibit HCV replication in a cell and are therefore useful in the
 CC treatment of HCV infections such as chronic and acute hepatitis and
 CC hepatocarcinoma. This oligo was used in a luciferase assay to determine
 CC whether it binds successfully to its target.
 XX
 SQ Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 other;
 Query Match 0.8%; Score 11.4; DB 1; Length 18;
 Best Local Similarity 84.6%; Pred. No. 5.1e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 726 GCAGGGGGCCTGG 738
 DB 4 GCAGGGGGCCTGG 16
 RESULT 688
 ABS65844
 ID ABS65844 standard; DNA; 18 BP.
 XX
 AC ABS65844;
 XX
 XX 15-NOV-2002 (first entry)
 DT
 DE Inhibitory oligonucleotide specific for hepatitis C virus #50.
 XX
 KW Hepatitis C virus; HCV; hepatocyte infection; non-A hepatitis;
 KW non-B hepatitis; acute hepatitis; chronic hepatitis;
 KW hepatocellular carcinoma; virucide; cytostatic; antisense therapy;
 KW gene therapy; ss; DNA-RNA hybrid.
 XX
 OS Synthetic.
 XX
 XX US2002081577-A1.
 FN
 XX 27-JUN-2002.
 PD
 XX 02-JUL-1997; 97US-0887505.
 PF
 XX 02-JUL-1996; 96US-021104P.
 PR
 XX 06-JUN-1995; 95US-0471968.
 PR
 XX (KILK/) KILKUSKIE R L.
 PA (FRAN/) FRANK B L.
 PA (GOOD/) GOODCHILD J.
 PA (WOLF/) WOLFE J L.

PA (ROBE/) ROBERTS P C.
 PA (HAML/) HAMLIN H A.
 PA (ROBE/) ROBERTS N A.
 PA (WALT/) WALTHER D M.
 XX
 XX Kilkuskie RL, Frank BL, Goodchild J, Wolfe JL, Roberts PC;
 PI Hamlin HA, Roberts NA, Walther DM;
 XX WPI; 2002-537132/57.
 DR
 XX
 XX Synthetic oligonucleotides complementary to a portion of the 5'
 PT untranslated region of hepatitis C virus (HCV), useful for diagnosing
 PT and treating HCV infections and hepatocellular carcinoma -
 XX
 XX Claim 22; Page 11; 74pp; English.
 XX
 CC The invention describes synthetic oligonucleotides complementary to a
 CC portion of the 5' untranslated region of hepatitis C virus. The
 CC oligonucleotides may be used in methods for controlling, preventing, and
 CC treating hepatitis C virus infection, in antisense technology and gene
 CC therapy, and of detecting the presence of hepatitis C virus in a sample.
 CC Hepatitis C virus (HCV) is an enveloped, positive sense, single-stranded
 CC RNA virus which infects hepatocytes. HCV is the major cause of non-A,
 CC non-B, acute and chronic hepatitis, and has been associated with
 CC hepatocellular carcinoma. The invention describes methods and kits for
 CC inhibiting replication of HCV, inhibiting the expression of HCV nucleic
 CC acid and protein, and for treating HCV infections. This sequence
 CC represents a synthetic DNA-RNA hybrid oligonucleotide used for inhibiting
 CC HCV replication and expression of HCV.
 XX
 SQ Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 other;
 Query Match 0.8%; Score 11.4; DB 1; Length 18;
 Best Local Similarity 84.8%; Pred. No. 5.1e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 726 GCAGGGGGCTGG 738
 DB 4 GCAGGGGGCTGG 16
 RESULT 689
 AAH89204/c
 ID AAH89204 standard; DNA; 20 BP.
 XX
 AC AAH89204;
 XX
 DT 27-FEB-2002 (first entry)
 XX
 DE Human polymorphic oligonucleotide U85199 fragment #2.
 XX
 KW Human; single nucleotide polymorphic; SNP; forensic science;
 KW paternity testing; phenotypic trait; genetic mapping; animal breeding;
 KW plant breeding; ds.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Variation replace(10,c)
 FT /*tag= a
 FT /standard_name= "single nucleotide polymorphism"
 XX
 XX WO200134840-A2.
 PN
 XX
 XX 17-MAY-2001.
 PD
 XX
 PF 10-NOV-2000; 2000WO-US30766.
 XX
 XX 10-NOV-1999; 99US-0164596.
 XX
 XX (GLAX) GLAXO GROUP LTD.
 PA (AFFY-) AFFIMETRIX INC.
 XX

PI Au X, Chen J, Patil N, Thomas D;
 XX WPI; 2001-335945/35.
 XX
 PT New polymorphic sites derived from the human genome are useful to
 PT determine sites correlating with phenotypic traits, particularly
 PT disease, and also in forensics and paternity testing -
 XX
 XX Claim 95; Page 16; 43pp; English.
 XX
 CC The present invention relates to human oligonucleotides comprising a
 CC single nucleotide polymorphic site (SNP: AAH89219). The present
 CC sequence is one such oligonucleotide. The oligonucleotides can be used in
 CC forensics, paternity testing, correlation of polymorphisms with
 CC phenotypic traits, genetic mapping of phenotypic traits and marker
 CC assisted breeding of animals and crop plants.
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 other;
 Query Match 0.8%; Score 11.4; DB 1; Length 20;
 Best Local Similarity 92.3%; Pred. No. 5.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 226 CCTCAGCCTCAGG 238
 DB 20 CCTCAGCCTCAGG 8
 RESULT 690
 ABK94275/c
 ID ABK94275 standard; DNA; 21 BP.
 XX
 AC ABK94275;
 XX
 DT 27-AUG-2002 (first entry)
 XX
 DE Endothelin converting enzyme 1 (ECE-1) SNP detection primer #63.
 XX
 KW Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
 KW EDNR; signaling system; cardiovascular disease; coronary heart disease;
 KW hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
 KW diabetes; familial hypercholesterolemia; forensic marker;
 KW transgenic animal; solid support; cardiovascular regulator; SNP;
 KW single nucleotide polymorphism; PCR; primer; ss.
 XX
 OS Synthetic.
 XX
 XX WO200224747-A2.
 PN
 XX
 PD 28-MAR-2002.
 XX
 PF 31-AUG-2001; 2001WO-BP10087.
 XX
 PR 19-SEP-2000; 2000EP-0120123.
 XX
 XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
 PA
 XX Brinkmann U, Hoffmeyer S;
 PI
 XX WPI; 2002-435060/46.
 DR
 XX Novel polymorphic site of the endothelin/endothelin converting
 PT enzyme/receptors of endothelin and endothelin converting enzyme
 PT signaling system associated with cardiovascular disease, useful for
 PT treating the disease -
 XX
 XX Example 6; Page 63; 190pp; English.
 XX
 CC The invention describes a polymorphic site (I) of the endothelin
 CC (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
 CC signaling system which is associated with a cardiovascular disease. (I),
 CC the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I)
 CC or (II) is useful for producing cells capable of expressing a molecular

variant polypeptide which is associated with a cardiovascular disease. (I), (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing a molecular variant gene comprising (I) is useful for identifying and obtaining a pro-drug or drug capable of modulating the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system or its gene product, or for identifying and obtaining an inhibitor of the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system or its gene product. The isolated proteins and polynucleotides encoding them are useful for preparation of a pharmaceutical composition for treating a cardiovascular disease such as coronary heart disease, hypertension, atherosclerosis, or related to abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial hypercholesterolaemia. The gene or a polynucleotide fragment of the EDN/ECE/EDNR signaling system are useful as forensic markers, for creating a transgenic animal and in creation of a solid support comprising polynucleotides, genes, vectors, polypeptides, antibodies or host cells of the invention. This sequence represents a PCR primer used to identify single nucleotide polymorphisms in DNA encoding cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.

Sequence 21 BP; 5 A; 3 C; 11 G; 1 T; 1 other;

Query Match 0.8%; Score 11.4; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCC 815
Db 18 CTCCTCCNGCAGCC 5

RESULT 691
ABK94276

ID ABK94276 standard; DNA; 21 BP.

XX
AC ABK94276;

XX 27-AUG-2002 (first entry)

XX Endothelin converting enzyme 1 (ECE-1) SNP detection primer #64.

XX Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
KW EDNR; signaling system; cardiovascular disease; coronary heart disease;
KW hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
KW diabetes; familial hypercholesterolaemia; forensic marker;
KW transgenic animal; solid support; cardiovascular regulator; SNP;
KW single nucleotide polymorphism; PCR; primer; ss.

XX Synthetic.

XX WO200224747-A2.

XX 28-MAR-2002.

XX 31-AUG-2001; 2001WO-BP10087.

XX 19-SEP-2000; 2000EP-0120123.

XX (EPID-) EPIDAUCOS BIOTECHNOLOGIE AG.

XX Brinkmann U, Hoffmeyer S;

XX WPI; 2002-435060/46.

XX Novel polynucleotide of the endothelin/endothelin converting
PT enzyme/receptors of endothelin and endothelin converting enzyme
PT signaling system associated with cardiovascular disease, useful for
PT treating the disease

XX Example 6; Page 63; 190pp; English.

XX The invention describes a polynucleotide (I) of the endothelin
CC (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)

CC signaling system which is associated with a cardiovascular disease. (I),
CC the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I)
CC or (II) is useful for producing cells capable of expressing a molecular
CC variant polypeptide which is associated with a cardiovascular disease.
CC (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing
CC a molecular variant gene comprising (I) is useful for identifying and
CC obtaining a pro-drug or drug capable of modulating the activity of a
CC molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system
CC or its gene product, or for identifying and obtaining an inhibitor of
CC the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE
CC signaling system or its gene product. The isolated proteins and
CC polynucleotides encoding them are useful for preparation of a
CC pharmaceutical composition for treating a cardiovascular disease such as
CC coronary heart disease, hypertension, atherosclerosis, or related to
CC abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial
CC hypercholesterolaemia. The gene or a polynucleotide fragment of the
CC EDN/ECE/EDNR signaling system are useful as forensic markers, for
CC creating a transgenic animal and in creation of a solid support
CC comprising polynucleotides, genes, vectors, polypeptides, antibodies or
CC host cells of the invention. This sequence represents a PCR primer used
CC to identify single nucleotide polymorphisms in DNA encoding
CC cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.

XX Sequence 21 BP; 1 A; 11 C; 3 G; 5 T; 1 other;

Query Match 0.8%; Score 11.4; DB 1; Length 21;

Best Local Similarity 85.7%; Pred. No. 5.8e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCC 815
Db 4 CTCCTCCNGCAGCC 17

RESULT 692

AAF96193/c

ID AAF96193 standard; DNA; 21 BP.

XX
AC AAF96193;

XX 06-JUN-2001 (first entry)

XX Human gene single nucleotide polymorphism #954.

XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.

XX Homo sapiens.

XX Key Location/Qualifiers

XX Variation replace(11,T)

XX /*tag= a

XX /standard_name= "single nucleotide polymorphism"

XX WO200118250-A2.

XX 15-MAR-2001.

XX 07-SEP-2000; 2000WO-US24503.

XX 10-SEP-1999; 99US-0153357.

XX 26-JUL-2000; 2000US-0220947.

XX 16-AUG-2000; 2000US-0225724.

XX (WHEED) WHITEHEAD INST BIOMEDICAL RES.

XX (MILL-) MILLENNIUM PHARM INC.

XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GO, McCarthy JJ;

XX WPI; 2001-226749/23.

XX

PT Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis -
PS Examples; Page 116; 242pp; English.
XX
CC The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism
CC and pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification.
XX
SQ Sequence 21 BP; 5 A; 8 C; 7 G; 1 T; 0 other;
Query Match 0.8%; Score 11.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 892 CTGGGTACAGCGGGCCCTG 912
Db 21 CTGCCCTGCAGTTGGCGCTG 1
RESULT 693
ACA06326/c
ID ACA06326 standard; RNA; 17 BP.
XX
AC ACA06326;
XX
DT 03-JUN-2003 (first entry)
XX
DE NFKB sub-unit modulating inozyme substrate #145.
XX
KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection;
KW ss.
XX
OS Homo sapiens.
XX
XX
PN US2002177568-A1.
XX
XX 28-NOV-2002.
XX
XX 23-MAY-2001; 2001US-0864785.
XX
XX 15-AUG-1994; 94US-0291932.
XX 07-DEC-1992; 92US-0987132.
XX 18-MAY-1994; 94US-0245466.
XX 23-DEC-1996; 96US-0777916.
XX
XX (STIN/) STINCHOMB D T.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression
XX of a sequence encoding a subunit of nuclear factor kappa B useful for
XX treating cancer, inflammatory disorders and autoimmune diseases -
XX
XX Claim 3; Page 29; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
XX regulates expression of a sequence encoding a subunit of nuclear factor
XX kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne
XX configuration. The enzymatic nucleic acid molecule is adapted to treat
XX cancer and is useful for down-regulating REL-A activity in a cell, for
XX treating a patient having a condition associated with the level of REL-A.
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
XX antisenase nucleic acid molecules are useful for treating breast, lung,
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
XX multidrug resistant cancer. The method involves use of other drug
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
XX cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
XX gencitabine or radiation therapy. The enzymatic and antisenase nucleic
XX acid molecules are also useful for treating inflammatory disease such as
XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
XX rejection, gene therapy applications, ischaemia/reperfusion injury
XX (central nervous system (CNS) and myocardial), glomerulonephritis,
XX sepsis, allergic airway inflammation, inflammatory bowel disease or
XX infection. This sequence represents the substrate of a novel
XX enzymatic nucleic acid molecule.
XX
SQ Sequence 17 BP; 0 A; 11 C; 3 G; 3 U; 0 other;
Query Match 0.8%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 5.3e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 466 AGCCTGCAGCGGGGAGG 481
Db 17 AGCGCGCAGCGGGAGG 2
RESULT 694
AAQ26549
ID AAQ26549 standard; DNA; 18 BP.
XX
XX AAQ26549;
XX
XX 08-JAN-1993 (first entry)
XX
XX Control probe #4 for caucosoid RING11 gene.
XX
XX immunosuppressants; immunoenhancers; treatment; diagnosis; screening;
XX immune disorders; transporter peptides; proteasome complex;
XX MHC class I molecules; HLA; antigen processing;
XX antigen presentation; autoimmune disease; ankylosing spondylitis;
XX prenatal diagnosis; polymerase chain reaction; ss.
XX
XX Synthetic.
XX
XX WO9211289-A.
XX
XX 09-JUL-1992.
XX
XX 19-DEC-1991; 91WO-GB02278.
XX
XX 19-DEC-1990; 90GB-0027520.
XX 16-SEP-1991; 91GB-0019711.
XX
XX (IMCR) IMPERIAL CANCER RES TECHNOLOGY.

XX Glynn R, Kelly AP, Powis SH, Trowsdale J;
 XX WPI; 1992-250030/30.
 XX
 PT DNA encoding RING4, RING10, RING11 AND RING12 proteins - for
 PT treatment and diagnosis of immune disorders and screening of new
 PT immunosuppressants and immuno-enhancers
 XX
 PS Example 2; Page 40; 101pp; English.
 XX
 CC This probe was used together with AAQ26546-51 to analyse caucosoid
 CC controls by oligonucleotide typing, whilst investigating RING 11
 CC polymorphisms - see AAQ26544,5.
 XX
 SQ Sequence 18 BP; 3 A; 6 C; 6 G; 3 T; 0 other;
 Query Match 0.8%; Score 11.2; DB 1; Length 18;
 Best Local Similarity 81.2%; Pred. No. 5.5e+02;
 Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 631 CTCGAGGAGCTGCA 646
 Db |||||
 2 CTCCTGGAGCTGGCA 17
 RESULT 695
 ABZ61566
 ID ABZ61566 standard; RNA; 17 BP.
 XX
 AC ABZ61566;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human H-Ras DNazyme target #357.
 XX
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 29-MAY-2002; 2002WO-US16840.
 XX
 PR 29-MAY-2001; 2001US-294140P.
 PR 06-JUN-2001; 2001US-296249P.
 PR 10-SEP-2001; 2001US-318471P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J;
 XX
 WPI; 2003-140484/13.
 XX
 PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
 XX
 PS Claim 58; Page 117; 185pp; English.
 XX
 CC The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytosstatic, anti-HIV, and
 CC anti-rheumatic activity. The nucleic acid molecules are useful for
 CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
 CC acids are also useful for treating breast, ovarian, colorectal, lung,
 CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.

CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ65520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 U; 0 other;
 Query Match 0.8%; Score 11; DB 1; Length 17;
 Best Local Similarity 81.8%; Pred. No. 5.7e+02;
 Matches 9; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 731 GGGCTGCGCTG 741
 Db |||||
 2 GGGCCUGGCGUG 12
 RESULT 696
 AAX33259/C
 ID AAX33259 standard; DNA; 20 BP.
 XX
 AC AAX33259;
 XX
 DT 30-JUN-1999 (first entry)
 XX
 DE PEBP2 alpha A gene expression regulating DNA PCR primer SEQ ID NO:16.
 XX
 KW PEBP2 alpha A gene; expression; regulation; bone disease;
 KW osteoporosis; PCR primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO9911787-A1.
 XX
 PD 11-MAR-1999.
 XX
 PF 02-SEP-1998; 98WO-JF03920.
 XX
 PR 08-APR-1998; 98JP-0114135.
 PR 02-SEP-1997; 97JP-0254250.
 PR 15-OCT-1997; 97JP-0299407.
 XX
 PA (SUMU) SUMITOMO PHARM CO LTD.
 XX
 PI Fujiwara M, Harada H, Katsumata T, Nakatsuka M;
 PI Ogawa S, Tagashira S;
 XX
 WPI; 1999-243621/20.
 XX
 DR DNA regulating expression of PEBP2 alphaA gene to produce regulator
 PT protein, useful as promoter for prevention or/and treatment of bone
 PT diseases e.g. osteoporosis
 XX
 PS Example 2; Page 29; 118pp; Japanese.
 XX
 CC The present invention describes DNA which participates in the regulation
 CC of expression of PEBP2 alpha A gene. The DNA produces a regulator
 CC protein with the activity of promoting bone formation and can serve as a
 CC promoter for prevention and treatment of bone diseases including
 CC osteoporosis. The present sequence represents a PCR primer used in an
 CC example from the present invention.
 XX
 SQ Sequence 20 BP; 3 A; 11 C; 4 G; 2 T; 0 other;
 Query Match 0.8%; Score 11; DB 1; Length 20;
 Best Local Similarity 73.7%; Pred. No. 6.4e+02;
 Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 460 GTCAGCAGCTGCGAGGG 478
 Db |||||
 20 GCTGCGAGCTGCTGGAGG 2
 RESULT 697
 ABS74296/C

ID ABS74296 standard; DNA; 20 BP.
 AC ABS74296;
 XX
 DT 09-DEC-2002 (first entry)
 XX
 DE Human calcium channel alpha2delta SSCP PCR primer #20.
 XX
 KW Human; ss; primer; calcium channel alpha2delta; splice isoform; CACNA2D2;
 KW gene therapy; Lambert-Eaton myasthenic syndrome; LEMS; PCR;
 KW autoimmune disease; epilepsy; migraine; episodic ataxia; cancer; stroke;
 KW brain trauma; Alzheimer's disease; multiinfarct dementia; convulsion;
 KW Korsakoff's disease; amyotrophic lateral sclerosis; seizure;
 KW Huntington's disease; amnesia; cardiac arrhythmia; angina pectoris;
 KW hypoxia; ischaemia; myocardial infarction; congestive heart failure;
 KW muscular dystrophy; hypertension; chromosome 3p21.3; lung cancer;
 KW breast cancer; preneoplastic lesion; hyperplasia; dysplasia; carcinoma;
 KW SSCP; single strand change polymorphism.
 XX
 OS Homo sapiens.
 XX
 PN US6441156-B1.
 XX
 PD 27-AUG-2002.
 XX
 PF 22-DEC-1999; 99US-0470443.
 XX
 PR 30-DEC-1998; 98US-114359P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Lerman MI, Latif F, Wei M, Duh F, Minna JD, Sekido Y, Gao B;
 XX WPI; 2002-730574/79.
 DR
 XX Novel purified nucleic acid sequence encoding human calcium channel
 PT alpha2delta subunit protein, useful for detecting, preventing and
 PT treating cancer, stroke, brain trauma, Huntington's disease, myocardial
 PT infarction -
 XX
 PS Example 7; Column 46; 77pp; English.
 XX
 CC The invention relates to a purified nucleic acid sequence (referred as
 CC CACNA2D2 gene which encodes human calcium channel alpha2delta-2 subunit
 CC protein) comprising a fully defined alpha2delta splice isoform 1, 2 or 3
 CC nucleic acid sequence, or its complement and the encoded proteins.
 CC Also include are: (1) a method of producing a calcium channel protein
 CC which involves introducing a recombinant expression vector comprising the
 CC CACNA2D2 nucleic acids and encoding the calcium channel protein, into
 CC a cultured host cell under conditions such that the host cell expresses
 CC the amino acid sequences; and (2) a method for co-expressing calcium
 CC channel proteins, comprising carrying out the method of (1), but with one
 CC or more than one expression vector comprising one or more nucleic acid
 CC sequences encoding the splice variants. CACNA2D2 nucleic acid is useful
 CC for producing a calcium channel protein. The recombinantly expressed
 CC polypeptide is useful for treating patients with Lambert-Eaton myasthenic
 CC syndrome (LEMS) (an autoimmune disease) and for identifying compounds
 CC useful for treating other diseases associated with abnormal calcium
 CC channel protein activity (e.g. epilepsy, migraine, episodic ataxia,
 CC cancer, stroke, brain trauma, Alzheimer's disease, multiinfarct dementia,
 CC Korsakoff's disease, amyotrophic lateral sclerosis, convulsions,
 CC seizures, Huntington's disease, amnesia, cardiac arrhythmia, angina
 CC pectoris, hypoxic damage to the cardiovascular system, ischaemic damage
 CC to the cardiovascular system, myocardial infarction, congestive heart
 CC failure, muscular dystrophy and hypertension) CACNA2D2 nucleic acid is
 CC useful as primers and probes for detecting presence of nucleic acid
 CC sequence encoding at least a portion of calcium channel protein, in
 CC detection, identification and isolation of alpha2delta sequences
 CC diagnosing and typing of preneoplasias and cancers, since genetic
 CC disruption of 3p21.3 region (in which the alpha 2delta gene is located)
 CC is common in cancer (e.g. lung cancer and breast cancer) and
 CC preneoplastic lesion (e.g. hyperplasia, dysplasia, carcinoma in situ).
 CC The present is an SSCP (single strand change polymorphism) PCR primer

CC used to detect polymorphisms in sequences encoding a human calcium
 CC channel alpha2delta splice isoform protein.
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 other;
 XX
 Query Match 0.8%; Score 11; DB 1; Length 20;
 Best Local Similarity 73.7%; Pred. No. 6.4e+02;
 Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 618 CTTGAGGAGGACCTCCAG 636
 Db 19 CTCCTGTGACCATCACCAG 1
 XX
 RESULT 698
 ABS74306/C
 ID ABS74306 standard; DNA; 20 BP.
 XX
 AC ABS74306;
 XX
 XX 09-DEC-2002 (first entry)
 DT
 XX Human calcium channel alpha2delta SSCP PCR primer #30.
 DE
 XX Human; ss; primer; calcium channel alpha2delta; splice isoform; CACNA2D2;
 KW gene therapy; Lambert-Eaton myasthenic syndrome; LEMS; PCR;
 KW autoimmune disease; epilepsy; migraine; episodic ataxia; cancer; stroke;
 KW brain trauma; Alzheimer's disease; multiinfarct dementia; convulsion;
 KW Korsakoff's disease; amyotrophic lateral sclerosis; seizure;
 KW Huntington's disease; amnesia; cardiac arrhythmia; angina pectoris;
 KW hypoxia; ischaemia; myocardial infarction; congestive heart failure;
 KW muscular dystrophy; hypertension; chromosome 3p21.3; lung cancer;
 KW breast cancer; preneoplastic lesion; hyperplasia; dysplasia; carcinoma;
 KW SSCP; single strand change polymorphism.
 XX
 OS Homo sapiens.
 XX
 PN US6441156-B1.
 XX
 PD 27-AUG-2002.
 XX
 PF 22-DEC-1999; 99US-0470443.
 XX
 PR 30-DEC-1998; 98US-114359P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Lerman MI, Latif F, Wei M, Duh F, Minna JD, Sekido Y, Gao B;
 XX WPI; 2002-730574/79.
 DR
 XX Novel purified nucleic acid sequence encoding human calcium channel
 PT alpha2delta subunit protein, useful for detecting, preventing and
 PT treating cancer, stroke, brain trauma, Huntington's disease, myocardial
 PT infarction -
 XX
 PS Example 7; Column 46; 77pp; English.
 XX
 CC The invention relates to a purified nucleic acid sequence (referred as
 CC CACNA2D2 gene which encodes human calcium channel alpha2delta-2 subunit
 CC protein) comprising a fully defined alpha2delta splice isoform 1, 2 or 3
 CC nucleic acid sequence, or its complement and the encoded proteins.
 CC Also include are: (1) a method of producing a calcium channel protein
 CC which involves introducing a recombinant expression vector comprising the
 CC CACNA2D2 nucleic acids and encoding the calcium channel protein, into
 CC a cultured host cell under conditions such that the host cell expresses
 CC the amino acid sequences; and (2) a method for co-expressing calcium
 CC channel proteins, comprising carrying out the method of (1), but with one
 CC or more than one expression vector comprising one or more nucleic acid
 CC sequences encoding the splice variants. CACNA2D2 nucleic acid is useful
 CC for producing a calcium channel protein. The recombinantly expressed
 CC polypeptide is useful for treating patients with Lambert-Eaton myasthenic
 CC syndrome (LEMS) (an autoimmune disease) and for identifying compounds
 CC useful for treating other diseases associated with abnormal calcium
 CC channel protein activity (e.g. epilepsy, migraine, episodic ataxia,
 CC cancer, stroke, brain trauma, Alzheimer's disease, multiinfarct dementia,
 CC Korsakoff's disease, amyotrophic lateral sclerosis, convulsions,
 CC seizures, Huntington's disease, amnesia, cardiac arrhythmia, angina
 CC pectoris, hypoxic damage to the cardiovascular system, ischaemic damage
 CC to the cardiovascular system, myocardial infarction, congestive heart
 CC failure, muscular dystrophy and hypertension) CACNA2D2 nucleic acid is
 CC useful as primers and probes for detecting presence of nucleic acid
 CC sequence encoding at least a portion of calcium channel protein, in
 CC detection, identification and isolation of alpha2delta sequences
 CC diagnosing and typing of preneoplasias and cancers, since genetic
 CC disruption of 3p21.3 region (in which the alpha 2delta gene is located)
 CC is common in cancer (e.g. lung cancer and breast cancer) and
 CC preneoplastic lesion (e.g. hyperplasia, dysplasia, carcinoma in situ).
 CC The present is an SSCP (single strand change polymorphism) PCR primer

useful for treating other diseases associated with abnormal calcium channel protein activity (e.g. epilepsy, migraine, episodic ataxia, cancer, stroke, brain trauma, Alzheimer's disease, multiinfarct dementia, Korsakoff's disease, amyotrophic lateral sclerosis, convulsions, seizures, Huntington's disease, amnesia, cardiac arrhythmia, angina pectoris, hypoxic damage to the cardiovascular system, ischaemic damage to the cardiovascular system, myocardial infarction, congestive heart failure, muscular dystrophy and hypertension) CACNA2D2 nucleic acid is useful as primers and probes for detecting presence of nucleic acid sequence encoding at least a portion of calcium channel protein, in detection, identification and isolation of alpha2delta sequences diagnosing and typing of preneoplasias and cancers, since genetic disruption of 3p21.3 region (in which the alpha2delta gene is located) is common in cancer (e.g. lung cancer and breast cancer) and preneoplastic lesion (e.g. hyperplasia, dysplasia, carcinoma in situ). The present is an SSCP (single strand change polymorphism) PCR primer used to detect polymorphisms in sequences encoding a human calcium channel alpha2delta splice isoform protein.

Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 other;

Query Match 0.8%; Score 11; DB 1; Length 20;
Best Local Similarity 73.7%; Pred. NO. 6.4e+02;
Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 618 CTTGAGGACCACTCCAG 636
||| ||||| |||||
Db 19 CTCCTGTGACCATCACAG 1

RESULT 699

AAI66616
ID AAI66616 standard; DNA; 20 BP.

AC AAI66616;

DT 07-JAN-2002 (first entry)

DE Rat leukotriene B4 receptor JULF2 DNA amplifying PCR primer.

KW Leukotriene receptor; leukotriene B4; inflammatory disease; rat;
KW JULF2; bronchitis; dermatitis; psoriasis; ulcerative colitis;
KW rheumatoid arthritis; edema; PCR primer; ss.

OS Rattus norvegicus.

XX WO200170815-A1.

XX 27-SEP-2001.

XX 15-MAR-2001; 2001WO-JP02060.

XX 21-MAR-2000; 2000JP-0078992.

XX 22-JUN-2000; 2000JP-0187978.

XX (YAMA) YAMANOUCHI PHARM CO LTD.

XX Kamohara M, Matsumoto M, Takasaki J, Saito T, Ohishi T;

XX WPI; 2001-611487/70.

XX New polypeptide for screening for compounds which treat inflammatory
PT diseases such as bronchitis, dermatitis, psoriasis, ulcerative colitis,
PT rheumatoid arthritis, and edema comprises the leukotriene B4 receptor -
XX Example 10; Page 47; 55pp; Japanese.

XX The invention provides a leukotriene receptor, which binds leukotriene B4
CC and polynucleotides encoding the leukotriene B4 receptor. The receptor
CC can be expressed by standard recombinant methodology. Pharmaceutical
CC compositions containing materials which modify the receptor activity,
CC other than 4-octyloxybenzene carboximidoamide are used for treating and
CC preventing inflammatory disease. The materials detected by screening the

CC receptor (JULF2) are useful for treating diseases such as bronchitis,
CC dermatitis, psoriasis, ulcerative colitis, rheumatoid arthritis, and
CC edema. Sequences AAI66614-19 represent PCR primers for amplifying a
CC rat leukotriene B4 receptor JULF2 DNA.

XX Sequence 20 BP; 5 A; 11 C; 4 G; 0 U; 0 other;

Query Match 0.8%; Score 11; DB 1; Length 20;
Best Local Similarity 73.7%; Pred. NO. 6.4e+02;
Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 585 CCGTCGCGCCGCCACGAGC 603
||| ||||| |||||
Db 2 CAGCCAGACCCGAGCAGC 20

RESULT 700

ABK15887/c
ID ABK15887 standard; DNA; 20 BP.

XX ABK15887;

XX 21-MAY-2002 (first entry)

XX HES-1 (hairy-enhancer of split-1) forward PCR primer DNA sequence.

XX Hairy-enhancer of split-1; HES-1; real-time PCR; primer; ss;
KW multiple sclerosis; rheumatoid arthritis; diabetes; organ transplant;
KW asthma; allergy; autoimmunity; graft rejection; tumour; cytostatic;
KW Notch signal modulator; T-cell mediated disease; infectious disease;
KW human immunodeficiency virus; HIV; virucide; hepatotropic; protozoacide;
KW neuroprotective; cancer.

XX Unidentified.

XX WO200212890-A2.

XX 14-FEB-2002.

XX 03-AUG-2001; 2001WO-GB03503.

XX 04-AUG-2000; 2000GB-0019242.

XX (LORA-) LORANTIS LTD.

XX Lamb JR, Hoyne GF, Dallman MJ, Champion BR;

XX WPI; 2002-217232/27.

XX Monitoring the immune system for prevention and/or treatment of T-cell
PT mediated diseases e.g. allergy, autoimmunity or cancer, involves
PT detecting modulation of Notch signalling

XX Disclosure; Fig 13; 75pp; English.

XX The present invention relates to a new method for monitoring the immune
CC system that involves detecting modulation of Notch signalling. The method
CC of the invention can be used for monitoring the immune system such as
CC detecting or monitoring T-cell activation or inactivation, immunological
CC tolerance or activity, monitoring the efficacy of immunotherapy and for
CC detecting or monitoring the reactivity of a T-cell to an antigen e.g. for
CC detecting increased or decreased reactivity of a T-cell to an antigen and
CC detecting toleration of a T-cell to an antigen, and for detecting
CC whether the antigen is self or foreign antigen. The method is used in the
CC prevention and/or treatment of T-cell mediated diseases such as asthma,
CC allergy, autoimmunity, graft rejection, tumour induced aberrations to the
CC T-cell system, and infectious diseases caused by e.g. Cytomegalovirus,
CC Pseudomonas, Toxoplasma, Microfilariae, Helminths, Mycobacteria, human
CC immunodeficiency virus (HIV), plasmodium species, Echinosoccus,
CC Haemophilus influenza type B, measles, Hepatitis C or Toxocara. The
CC method is also used for the treatment of multiple sclerosis, rheumatoid
CC arthritis, diabetes and for organ transplantation. The present assay
CC method provides a much more objective measure of the effectiveness of

CC therapy than the rather subjective symptoms-based measures which are
 CC often used at present. The ability to detect an immune response could be
 CC used in identifying the cause of an allergic reaction by monitoring the
 CC activity of the immune system in the presence of different potential
 CC allergens. The assay could be used to check for successful immunisation
 CC against a given disease antigen. The present nucleic acid sequence
 CC represents the human HES-1 (hairy-enhancer of split-1) forward PCR primer
 CC that was used in the invention with the HES-1 reverse PCR primer
 CC (ABK15888) and the HES-1 probe (ABK09925) for real-time PCR of the
 CC HES-1 gene.
 XX

SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 other;

Query Match 0.8%; Score 11; DB 1; Length 20;
 Best Local Similarity 73.7%; Pred. No. 6.4e+02;
 Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 435 GTTCAGAAAGTTGCTGAAG 453
 Db 20 GTTCATGCACTCGCTGAAG 2

RESULT 701

AAV47652/C
 ID AAV47652 standard; DNA; 21 BP.

AC AAV47652;

XX 07-DEC-1998 (first entry)

DE Mouse focal adhesion kinase cDNA 3' PCR primer.

XX Protein tyrosine kinase 2; PYK2; mouse; cell adhesion kinase-beta;
 KW related adhesion focal tyrosine kinase; focal adhesion kinase;
 KW platelet; PCR; primer; ss.

XX Synthetic.

OS Mus sp.

XX WO9835016-A1.

XX 13-AUG-1998.

XX 09-FEB-1998; 98WO-US02494.

XX 11-FEB-1997; 97US-0037561.

XX (MERI) MERCK & CO INC.

PI Duong LT, Rodan GA;

XX WPI; 1998-447214/38.

XX New nucleic acid encoding murine protein tyrosine kinase 2 and cells
 PT expressing the recombinant kinase - used to identify specific
 PT modulators, potentially useful for controlling the level of
 PT platelets

XX Example 2; Page 6; 25pp; English.

XX This 3' primer and a 5' primer (see AAV47651) are based on an area
 CC of non-homology between murine protein tyrosine kinase 2 (PYK2)
 CC and focal adhesion kinase (FAK) that is adjacent to the C-terminus
 CC of the kinase domain. They were used in a PCR amplification of
 CC cDNAs of mouse osteoblastic MB1.8. The PCR product (700 bp) was
 CC used as a FAK-specific probe to isolate mouse FAK cDNA. The
 CC invention relates to new nucleic acid (see AAV47653) encoding mouse
 CC PYK2 (see AAW61196), a member of the FAK family. PYK2 can be used in
 CC a claimed method for identifying specific modulators of PYK2
 CC activity.
 XX

SQ Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 other;

Query Match 0.8%; Score 11; DB 1; Length 21;
 Best Local Similarity 73.7%; Pred. No. 6.6e+02;
 Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1019 GATGGTGCCAAAGTCGAGC 1037
 Db 19 GAGGGTGTCAGGCTTCAGC 1

RESULT 702

AAV49607/C
 ID AAV49607 standard; DNA; 21 BP.

AC AAV49607;

XX 24-NOV-1998 (first entry)

XX Focal adhesion kinase 3' PCR primer.

XX Focal adhesion kinase; protein tyrosine kinase 2; PYK2 gene; mouse;
 KW podosome; related adhesion focal tyrosine kinase;
 KW cell adhesion kinase; ligand; monocyte; osteoporosis;
 KW inflammation; therapy; PCR; primer; ss.

XX Synthetic.

OS Mus sp.

XX WO9835056-A1.

XX 13-AUG-1998.

XX 09-FEB-1998; 98WO-US02797.

XX 11-FEB-1997; 97US-0037560.

XX (MERI) MERCK & CO INC.

XX Duong Le T, Rodan GA;

XX WPI; 1998-447250/38.

XX Identifying agents that bind and modulate protein tyrosine kinase 2
 PT - useful for inhibiting migration, adhesion or activity of monocytic
 PT cells, particularly for treatment and prevention of osteoporosis and
 PT inflammation

XX Example 3; Page 20; 56pp; English.

XX This oligonucleotide is based on a non-homologous region, found
 CC adjacent to the C-terminal of the kinase domain, of murine
 CC protein tyrosine kinase 2 (PYK2) and focal adhesion kinase (FAK)
 CC sequences. It was used as a 3' primer, together with a 5' primer
 CC (see AAV49606), in the PCR amplification of mouse osteoblastic MB1.8
 CC cell cDNA. The PCR product was used as a FAK-specific probe to
 CC isolate full-length FAK cDNA. FAK shows homology to murine PYK2
 CC (see AAW64568), another cell adhesion-dependent kinase. Agents that
 CC bind to and modulate PYK2 are isolated using methods of the
 CC invention, and are useful in treating osteoporosis and/or
 CC inflammation.
 XX

SQ Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 other;

Query Match 0.8%; Score 11; DB 1; Length 21;
 Best Local Similarity 73.7%; Pred. No. 6.6e+02;
 Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1019 GATGGTGCCAAAGTCGAGC 1037
 Db 19 GAGGGTGTCAGGCTTCAGC 1

RESULT 703

ABL31720/C

ID ABL31720 standard; DNA; 17 BP.
 AC ABL31720;
 XX
 DT 21-MAR-2002 (first entry)
 XX
 DE Human HLA genotyping oligonucleotide SEQ ID NO 1209.
 XX
 KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192572-A1.
 XX
 PD 06-DEC-2001.
 XX
 PF 01-JUN-2001; 2001WO-JP04662.
 XX
 PR 01-JUN-2000; 2000JP-0164798.
 XX
 PA (NISR) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 DR
 XX
 PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 XX Claim 10; Page 322; 345pp; Japanese.
 PS
 CC The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 other;
 Query Match 0.8%; Score 10.8; DB 1; Length 17;
 Best Local Similarity 85.7%; Pred. No. 6.1e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 974 TCACCTTGACAGTC 987
 DB 17 TCACTCGGCCAGTC 4
 RESULT 704
 ACA07770
 ID ACA07770 standard; RNA; 17 BP.
 AC
 AC ACA07770;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating zinzyme substrate #169.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;

KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel, docetaxel, cisplatin, methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 XX ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-0864785.
 XX
 PR 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 PI (STIN/) STINCHCOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 DR
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 XX Claim 3; Page 40; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 U; 0 other;

Query Match 0.8%; Score 10.8; DB 1; Length 17;
 Best Local Similarity 64.3%; Pred. No. 6.1e+02;
 Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 QY 820 GTCCCTGATCGACT 833
 DB 4 GCCCGCGCGCAGCU 17


```

XX 23-DEC-2002 (first entry)
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 494.
DE
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-0001165.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 23-MAY-2001; 2001US-0864761.
XX 10-OCT-2001; 2001US-0328205.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
XX POSHL-1, useful for treating disorders associated with decreased
XX expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 494; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
XX protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
XX acids (SI, ABB83998), a sequence having 65% sequence identity to (SI),
XX (SI) having 95% deviations, especially conservative substitutions or a
XX fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
XX adaptor protein that interacts with Rho family small GTPases as well as
XX downstream components of the signal transduction pathway. (I) is useful
XX for identifying a specific binding partner. (I) and nucleic acids (II)
XX encoding (I) are useful for diagnosing, monitoring disease and treating
XX caused by altered expression of human POSHL1 including diagnosing and
XX treating cancer, they are useful in the development of vaccines and (II) is
XX useful in gene therapy. (II) is useful for constructing microarrays which
XX are useful for measuring and for surveying gene expression and creating
XX transgenic non-human animals capable of producing the proteins. The
XX present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention.
XX
XX Note: The present sequence did not form part of the printed
XX specification, but is based on sequence information supplied to Derwent
XX by the European Patent Office.
XX
XX Sequence 17 BP; 3 A; 4 C; 9 G; 1 T; 0 other;
XX
XX Query Match 0.8%; Score 10.6; DB 1; Length 17;
XX Best Local Similarity 76.5%; Pred. No. 6.5e+02;
XX Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX 623 GGCACGAGCTCCAGGAG 639
XX |||||
XX 1 GGCAGAGCTCCGGAG 17
XX
XX RESULT 710
XX
XX Human; epilepsy; chromosome 2; SCN1A; SCN2A; SCN3A; identification;
XX diagnosis; mutation; chromosome 2q23-q31; neurological disorder;

```

```

AAZ35905
ID AAZ35905 standard; DNA; 18 BP.
XX
XX AC AAZ35905;
XX
XX 03-FEB-2000 (first entry)
XX
XX Human sentrin phosphorothioate antisense oligonucleotide SEQ ID NO:47.
XX
XX Human; sentrin; antisense oligonucleotide; phosphorothioate;
XX inhibition; modulation; expression; diagnosis; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..18
XX FT /tag= a
XX FT /note= "phosphorothioate linkages"
XX
XX US5985664-A.
XX
XX 16-NOV-1999.
XX
XX 17-DEC-1998; 98US-0213768.
XX
XX 17-DEC-1998; 98US-0213768.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Baker BE, Cowsett LM,
XX
XX WPI; 2000-022284/02.
XX
XX Antisense compound which modulates human sentrin expression, useful for
XX treating diseases associated with sentrin expression -
XX
XX Example 15; Column 38; 29pp; English.
XX
XX The present invention describes an antisense compound (I) 8-30
XX nucleotides long targeted to a nucleic acid molecule encoding human
XX sentrin. The antisense compound comprises a phosphorothioate antisense
XX oligonucleotide which inhibits expression of human sentrin. (I) is
XX useful for inhibiting expression of sentrin in human cells or tissues
XX in vitro, for treating humans or other animals suspected of having or
XX being prone to a disease associated with sentrin expression. (I) can
XX also be used for research or diagnostic purposes. The present
XX sequence represents a human sentrin phosphorothioate antisense
XX oligonucleotide from the present invention.
XX
XX Sequence 18 BP; 4 A; 5 C; 3 G; 6 T; 0 other;
XX
XX Query Match 0.8%; Score 10.6; DB 1; Length 18;
XX Best Local Similarity 76.5%; Pred. No. 6.8e+02;
XX Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX 1077 GGCTCTTCAGTCAGTGT 1093
XX |||||
XX 1 GGCACCTTCAGTAACTTT 17
XX
XX Db
XX
XX RESULT 711
XX
XX AAH55881/C
XX
XX ID AAH55881 standard; DNA; 18 BP.
XX
XX AC AAH55881;
XX
XX 04-SEP-2001 (first entry)
XX
XX Human SCN1A PCR-SSCP PCR primer SEQ ID NO:125.
XX
XX Human; epilepsy; chromosome 2; SCN1A; SCN2A; SCN3A; identification;
XX diagnosis; mutation; chromosome 2q23-q31; neurological disorder;

```


anticonvulsant; neuroprotective; PCR primer; ss.

Homo sapiens.
Synthetic.

WO200138564-A2.

31-MAY-2001.

24-NOV-2000; 2000WO-CA01404.

26-NOV-1999; 99US-0167623.

(UNMC-) UNIV MCGILL.

Rouleau GA, LaFreniere RG, Rochefort D, Cossette P, Ragsdale D;
WPI; 2001-355945/37.

Determining a predisposition to epilepsy and/or development of epilepsy
comprises determining the genotype of SCN1A, SCN2A and/or SCN3A, or a
DNA variant, equivalent, or mutation which shows a linkage
disequilibrium -

Example 3; Fig 2; 268pp; English.

The present invention describes a method (M1) of determining an
individual's predisposition to epilepsy and/or development of epilepsy,
as well as predicting the individual's response to medication. The
method comprises determining the genotype of at least one gene selected
from SCN1A, SCN2A or SCN3A, or a DNA variant, equivalent, or mutation
which shows a linkage disequilibrium. SCN1A, SCN2A and SCN3A are all
sodium channel genes located on chromosome 2. The idiopathic generalised
epilepsy (IGE) gene is more specifically localised on chromosome
2q23-q31. Compounds identified as modulators of the biological activity
of SCN1A, SCN2A or SCN3A proteins or genes, are useful for treating
epilepsy or other neurological disorders. They have anticonvulsant and
neuroprotective activities. AAH55763 to AAH56164 and AAH9674 to
AAH99679 represent SCN1A, SCN2A, and SCN3A cDNAs, gene fragments, PCR
primers, oligonucleotides and proteins given in the exemplification of
the present invention.

Sequence 18 BP; 4 A; 6 C; 6 G; 2 T; 0 other;

Query Match 0.8%; Score 10.6; DB 1; Length 18;

Best Local Similarity 76.5%; Pred. No. 6.8e+02;

Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 729 GGCGGCTGCTGCTGCC 745

Db 17 GAGAGCCTGCTCTGTC 1

RESULT 712

AAV95056/c

ID AAV95056 standard; RNA; 18 BP.

AC AAV95056;

XX

24-FEB-1999 (first entry)

DE Mouse IL-2 receptor g-chain substrate position 399.

XX Human, IL-2 receptor g-chain; interleukin 2 receptor gamma chain;

XX hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;

XX autoimmune disease; psoriasis; allergy; inflammatory disease;

XX graft rejection; ss.

OS Mus sp.

XX WO9824913-A2.

XX 11-JUN-1998.

XX

PF

XX

PR

XX

PA

XX

XX

PI

XX

DR

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

02-DEC-1997; 97WO-US21748.

03-DEC-1996; 96US-0758306.

(RIBO-) RIBOZYME PHARM INC.

McSwiggen JA, Stinchcomb DT;

WPI; 1998-333332/29.

Ribozymes targeted to interleukin 2 - useful for treating e.g.
cancer, autoimmune disease and allergies

Claim 4; Page 44; 61pp; English.

The present sequence invention describes ribozymes targeted to modulate
the synthesis and/or expression of interleukin (IL)-2R gamma encoded
RNA. AAV93899 to AAV94574 represent specifically claimed ribozymes, and
AAV94575 to AAV95260 represent specifically claimed substrate sequences
from the present invention. The ribozymes can be used for the treatment
of, e.g. graft rejection, autoimmune disease, cancer, psoriasis,
allergy and other inflammatory conditions. The ribozymes are also used
to induce tolerance in a recipient to alloantigen from a donor.

Sequence 18 BP; 3 A; 7 C; 4 G; 4 U; 0 other;

Query Match 0.8%; Score 10.6; DB 1; Length 18;

Best Local Similarity 76.5%; Pred. No. 6.8e+02;

Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1236 GGTCGCTGCGCTGGCCA 1252

Db 18 GGTCCTGGAGCTGGACA 2

RESULT 713

AAF91219

ID AAF91219 standard; DNA; 19 BP.

AC AAF91219;

XX 04-MAY-2001 (first entry)

Human multi drug resistance-1 gene related sequence SEQ ID NO: 306.

Human; MDR-1; multi drug resistance-1; drug uptake; disease; cancer;

inflammatory disease; neuronal disease; CNS disease;

cardiovascular disease; PCR primer; ss.

OS Homo sapiens.

XX WO200109183-A2.

XX 08-FEB-2001.

XX 28-JUL-2000; 2000WO-EP07314.

XX 30-JUL-1999; 99EP-0114938.

XX 22-FEB-2000; 2000EP-0103361.

XX (EPID-) EPIDAUS BIOTECHNOLOGIE AG.

XX Brinkmann U, Hoffmeyer S, Eichelbaum M, Roots I;

XX WPI; 2001-159855/16.

New polynucleotide encoding a molecular variant Multi Drug Resistance
(MDR)-1 polypeptide is useful for diagnosing and treating diseases
associated with abnormal MDR-1 expression or function, e.g. cancer -

Disclosure; Page 140; 154pp; English.

XX

CC The present invention provides nucleotides encoding molecular variants of
CC the human multi drug resistance-1 (MDR-1) protein. These can be used to
CC identify compounds capable of treating multidrug resistance and
CC sensitivity interfering resulting from polymorphisms in MDR-1, which can
CC lead to difficulties in treating cancer, cardiovascular, neuronal,
CC inflammatory and CNS diseases.

XX SQ Sequence 19 BP; 2 A; 5 C; 9 G; 3 T; 0 other;

Query Match 0.8%; Score 10.6; DB 1; Length 19;

Best Local Similarity 76.5%; Pred. No. 7.1e+02;

Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 896 GGTACAGCGTGGCCCTG 912

Db 3 GGCAGACGGTGGCCCTG 19

RESULT 714

AAF91221/c

ID AAF91221 standard; DNA; 19 BP.

AC AAF91221;

XX DT 04-MAY-2001 (first entry)

XX Human multi drug resistance-1 gene related sequence SEQ ID NO: 308.

XX Human; MDR-1; multi drug resistance-1; drug uptake; disease; cancer;

XX inflammatory disease; neuronal disease; CNS disease;

XX cardiovascular disease; PCR primer; ss.

XX Homo sapiens.

XX WO200109183-A2.

XX 08-FEB-2001.

XX 28-JUL-2000; 2000WO-EP07314.

XX 30-JUL-1999; 99EP-0114938.

XX 22-FEB-2000; 2000EP-0103361.

XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

XX Brinkmann U, Hoffmeyer S, Eichelbaum M, Roots I;

XX WPI; 2001-159855/16.

XX New polynucleotide encoding a molecular variant Multi Drug Resistance
XX (MDR)-1 polypeptide is useful for diagnosing and treating diseases
XX associated with abnormal MDR-1 expression or function, e.g. cancer -

XX Disclosure; Page 140; 154pp; English.

XX The present invention provides nucleotides encoding molecular variants of
XX the human multi drug resistance-1 (MDR-1) protein. These can be used to
XX identify compounds capable of treating multidrug resistance and
XX sensitivity interfering resulting from polymorphisms in MDR-1, which can
XX lead to difficulties in treating cancer, cardiovascular, neuronal,
XX inflammatory and CNS diseases.

XX SQ Sequence 19 BP; 3 A; 9 C; 5 G; 2 T; 0 other;

Query Match 0.8%; Score 10.6; DB 1; Length 19;

Best Local Similarity 76.5%; Pred. No. 7.1e+02;

Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 896 GGTACAGCGTGGCCCTG 912

Db 17 GGCAGACGGTGGCCCTG 1

RESULT 715

AAF91220

ID AAF91220 standard; DNA; 19 BP.

AC AAF91220;

XX DT 04-MAY-2001 (first entry)

XX Human multi drug resistance-1 gene related sequence SEQ ID NO: 307.

XX Human; MDR-1; multi drug resistance-1; drug uptake; disease; cancer;

XX inflammatory disease; neuronal disease; CNS disease;

XX cardiovascular disease; PCR primer; ss.

XX Homo sapiens.

XX WO200109183-A2.

XX 08-FEB-2001.

XX 28-JUL-2000; 2000WO-EP07314.

XX 30-JUL-1999; 99EP-0114938.

XX 22-FEB-2000; 2000EP-0103361.

XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

XX Brinkmann U, Hoffmeyer S, Eichelbaum M, Roots I;

XX WPI; 2001-159855/16.

XX New polynucleotide encoding a molecular variant Multi Drug Resistance
XX (MDR)-1 polypeptide is useful for diagnosing and treating diseases
XX associated with abnormal MDR-1 expression or function, e.g. cancer -

XX Disclosure; Page 140; 154pp; English.

XX The present invention provides nucleotides encoding molecular variants of
XX the human multi drug resistance-1 (MDR-1) protein. These can be used to
XX identify compounds capable of treating multidrug resistance and
XX sensitivity interfering resulting from polymorphisms in MDR-1, which can
XX lead to difficulties in treating cancer, cardiovascular, neuronal,
XX inflammatory and CNS diseases.

XX SQ Sequence 19 BP; 2 A; 5 C; 8 G; 3 T; 1 other;

Query Match 0.8%; Score 10.6; DB 1; Length 19;

Best Local Similarity 76.5%; Pred. No. 7.1e+02;

Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 896 GGTACAGCGTGGCCCTG 912

Db 3 GGCAGACGGTGGCCCTG 19

RESULT 716

AAF91222/c

ID AAF91222 standard; DNA; 19 BP.

AC AAF91222;

XX DT 04-MAY-2001 (first entry)

XX Human multi drug resistance-1 gene related sequence SEQ ID NO: 309.

XX Human; MDR-1; multi drug resistance-1; drug uptake; disease; cancer;

XX inflammatory disease; neuronal disease; CNS disease;

XX cardiovascular disease; PCR primer; ss.

XX Homo sapiens.

XX WO200109183-A2.

XX

XX PN WO200075317-A2.
 XX PD 14-DEC-2000.
 XX PF 15-MAY-2000; 2000WO-US13358.
 XX PR 09-JUN-1999; 99US-0138385.
 XX PR 20-JUL-1999; 99US-0144790.
 XX PR 03-AUG-1999; 99US-0146843.
 XX PR 10-AUG-1999; 99US-0148188.
 XX PR 17-AUG-1999; 99US-0149320.
 XX PR 17-AUG-1999; 99US-0149327.
 XX PR 17-AUG-1999; 99US-0149396.
 XX PR 20-AUG-1999; 99US-0150114.
 XX PR 31-AUG-1999; 99US-0151700.
 XX PR 31-AUG-1999; 99US-0151734.
 XX PA (GETH) GENENTECH INC.
 XX PI Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WT;
 XX PT WPI; 2001-071075/08.
 XX PS Antibodies against PRO polypeptides, useful for diagnosing and treating
 XX PT tumours are associated with gene amplification, neoplastic cell growth
 XX PT and proliferation in mammals -
 XX PS Example 11; Page 95; 143pp; English.
 XX CC This sequence represents a PCR primer used to isolate DNA encoding
 XX CC human PRO5800 protein of the invention. The PRO proteins are secreted
 XX CC proteins. Antagonists or antibodies of PRO polypeptides are useful for
 XX CC diagnosing and treating tumours are associated with gene amplification,
 XX CC neoplastic cell growth and proliferation in mammals, and those conditions
 XX CC characterised by overexpression and/or activation of the amplified genes.
 XX CC Such conditions include benign or malignant tumours (e.g. renal, liver,
 XX CC kidney, bladder, breast, gastric, ovarian, colorectal, prostate,
 XX CC pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas,
 XX CC glioblastomas and various head and neck tumours); leukaemias and lymphoid
 XX CC malignancies; neuronal, glial, astrocytic, hypothalamic, and other
 XX CC glandular, macrophageal, epithelial, stromal and blastocoeic disorders;
 XX CC and inflammatory, angiogenic and immunologic disorders. These may further
 XX CC be used to qualitatively or quantitatively detect the expression of
 XX CC proteins encoded by the amplified genes, and in tumour diagnostics or
 XX CC prognostics. The PRO polypeptide or its antagonist may be used for the
 XX CC preparation of a medicament in the treatment of a condition, which is
 XX CC responsive to the PRO polypeptide, its antagonist or anti-PRO antibody.
 XX CC
 XX CC Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 other;
 Query Match 0.8%; Score 10.6; DB 1; Length 20;
 Best Local Similarity 76.3%; Pred. No. 7.3e+02;
 Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 828 GCAGCTGAAGCTTTCAG 844
 Dd 18 GAACCTGAAGCTTTCAG 2
 RESULT 722
 AAA59547
 ID AAA59547 standard; DNA; 21 BP.
 AC AAA59547;
 XX 14-NOV-2000 (first entry)
 XX PCR primer used to amplify DNA encoding beta-secretase enzyme.
 DE Beta-secretase; beta-amyloid precursor protein; beta-amyloid peptide;
 KW amyloid plaque component; Alzheimer's disease; amyloidogenic disease;
 KW inhibitor; PCR primer; ss.

XX OS Homo sapiens.
 XX PN WO200047618-A2.
 XX PD 17-AUG-2000.
 XX PF 10-FEB-2000; 2000WO-US03819.
 XX PR 10-FEB-1999; 99US-0119571.
 XX PR 15-JUN-1999; 99US-0139172.
 XX PA (ELAN-) ELAN PHARM INC.
 XX PI Anderson JP, Basi G, Doane MT, Frigon N, John V, Power M;
 XX PI Sinha S, Tatsuno G, Tung J, Wang S, McConlogue L;
 XX PI WPI; 2000-533011/48.
 XX PT Purified beta-secretase protein used in assays to discover inhibitors
 XX PT which can be used for the treatment of amyloidogenic diseases e.g.
 XX PT Alzheimer's disease -
 XX PS Example 3; Page 66; 121pp; English.
 XX CC The specification describes a beta-secretase enzyme. The enzyme cleaves
 XX CC beta-amyloid precursor protein to produce beta-amyloid peptide. This
 XX CC enzyme is therefore implicated in the production of amyloid plaque
 XX CC components which accumulate in the brains of individuals afflicted with
 XX CC Alzheimer's disease. Inhibitors of beta-secretase are administered to
 XX CC a mammalian subject e.g. with Alzheimer's disease or Alzheimer's
 XX CC disease-like pathology to test if they maintain or improve cognitive
 XX CC ability or reduce the plaque burden. The compounds are used for the
 XX CC treatment of amyloidogenic diseases e.g. Alzheimer's disease. PCR
 XX CC primers AAA59530-49 were used to amplify DNA encoding beta-secretase
 XX CC enzyme.
 XX CC Sequence 21 BP; 3 A; 9 C; 7 G; 2 T; 0 other;
 Query Match 0.8%; Score 10.6; DB 1; Length 21;
 Best Local Similarity 76.5%; Pred. No. 7.4e+02;
 Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 575 AGCAGGCCCTCCGCTCG 591
 Dd 3 AGCTGCCCTCCGCGCG 19
 RESULT 723
 AAQ68252
 ID AAQ68252 standard; DNA; 16 BP.
 XX AAQ68252;
 XX 25-MAR-2003 (updated)
 XX 16-FEB-1995 (first entry)
 XX DE Triple helix forming methylphosphonate oligomer 2104.
 XX KW Methylphosphonate; MP; triple helix; translation;
 XX KW oligonucleoside; ss.
 XX OS Synthetic.
 XX WO9413326-A1.
 XX 23-JUN-1994.
 XX 08-DEC-1993; 93WO-US11986.
 XX 08-DEC-1992; 92US-0987746.
 XX (GENT-) GENTA INC.
 XX PA

AC ACA07666;
 XX 03-JUN-2003 (first entry)
 XX NFKB sub-unit modulating zinzyme substrate #85.
 DE Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 XX G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 XX lung cancer; prostate cancer; colorectal cancer; brain cancer;
 XX oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 XX cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 XX lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 XX chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 XX cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 XX gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 XX rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 XX gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 XX transplant/graft rejection; reperfusion injury; glomerulonephritis;
 XX allergic airway inflammation; inflammatory bowel disease; infection;
 XX ss.
 XX Homo sapiens.
 XX OS
 XX US2002177568-A1.
 XX 28-NOV-2002.
 XX 23-MAY-2001; 2001US-0864785.
 XX 15-AUG-1994; 94US-0291932.
 XX 07-DEC-1992; 92US-0987132.
 XX 18-MAY-1994; 94US-0245466.
 XX 23-DEC-1996; 96US-0777916.
 XX (STIN/) STINCHCOMB D T.
 XX (MCSW/) MCSWIGGEN J.
 XX (DRAP/) DRAPER K G.
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 XX of a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases -
 XX Claim 3; Page 38; 72pp; English.
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 XX regulates expression of a sequence encoding a subunit of nuclear factor
 XX kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 XX configuration. The enzymatic nucleic acid molecule is adapted to treat
 XX cancer and is useful for down-regulating REL-A activity in a cell, for
 XX treating a patient having a condition associated with the level of REL-A.
 XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 XX antisense nucleic acid molecules are useful for treating breast, lung,
 XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 XX multidrug resistant cancer. The method involves use of other drug
 XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 XX gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 XX acid molecules are also useful for treating inflammatory disease such as
 XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 XX rejection, gene therapy applications, ischaemia/reperfusion injury
 XX (central nervous system (CNS) and myocardial), glomerulonephritis,
 XX sepsis, allergic airway inflammation, inflammatory bowel disease or
 XX infection. This sequence represents the substrate of a novel
 XX enzymatic nucleic acid molecule.

SQ Sequence 17 BP; 3 A; 9 C; 4 G; 1 U; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 17;
 Best Local Similarity 91.7%; Pred. No. 7e-02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 730 GGGGCTGGCTG 741
 Db 17 GGGGCTGGCTG 6
 RESULT 727
 ACA06320/c
 ID ACA06320 standard; RNA; 17 BP.
 XX ACA06320;
 XX 03-JUN-2003 (first entry)
 XX NFKB sub-unit modulating inozyme substrate #139.
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 XX G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 XX lung cancer; prostate cancer; colorectal cancer; brain cancer;
 XX oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 XX cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 XX lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 XX chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 XX cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 XX gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 XX rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 XX gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 XX transplant/graft rejection; reperfusion injury; glomerulonephritis;
 XX allergic airway inflammation; inflammatory bowel disease; infection;
 XX ss.
 XX Homo sapiens.
 XX OS
 XX US2002177568-A1.
 XX 28-NOV-2002.
 XX 23-MAY-2001; 2001US-0864785.
 XX 15-AUG-1994; 94US-0291932.
 XX 07-DEC-1992; 92US-0987132.
 XX 18-MAY-1994; 94US-0245466.
 XX 23-DEC-1996; 96US-0777916.
 XX (STIN/) STINCHCOMB D T.
 XX (MCSW/) MCSWIGGEN J.
 XX (DRAP/) DRAPER K G.
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 XX of a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases -
 XX Claim 3; Page 29; 72pp; English.
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 XX regulates expression of a sequence encoding a subunit of nuclear factor
 XX kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 XX configuration. The enzymatic nucleic acid molecule is adapted to treat
 XX cancer and is useful for down-regulating REL-A activity in a cell, for
 XX treating a patient having a condition associated with the level of REL-A.
 XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 XX antisense nucleic acid molecules are useful for treating breast, lung,
 XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,

CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies. REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC enzymatic nucleic acid molecule.
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 U; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 17;
 Best Local Similarity 91.7%; Pred. No. 7e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 730 GGGGCTGGCTG 741
 |||||
 Db 15 GGGGCTGGCTG 4
 RESULT 728
 ACA06587/c
 ID ACA06587 standard; RNA; 17 BP.
 AC
 AC ACA06587;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating inozyme substrate #406.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-0864785.
 XX
 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX
 XX WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression

PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 PS Claim 3; Page 33; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 U; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 17;
 Best Local Similarity 91.7%; Pred. No. 7e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 827 TGCAGCTGAGC 838
 |||||
 Db 15 TGCAGCTGAGC 4
 RESULT 729
 ACA08920/c
 ID ACA08920 standard; RNA; 17 BP.
 AC
 AC ACA08920;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating amberzyme substrate #83.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-0864785.
 XX

XX PR 15-AUG-1994; 94US-0291932.
 XX PR 07-DEC-1992; 92US-0987132.
 XX PR 18-MAY-1994; 94US-0245466.
 XX PR 23-DEC-1996; 96US-0777916.
 XX (STIN/) STINCHOMB D T.
 XX PA (MCSW/) MCSWIGGEN J.
 XX PA (DRAP/) DRAPER K G.
 XX PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX DR WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 XX PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 XX PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX PS Claim 3; Page 51; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 XX CC regulates expression of a sequence encoding a subunit of nuclear factor
 XX CC kappa B (NFkB), where (I) is an inozyme, zynzyme, G-cleaver or amberzyme
 XX CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 XX CC cancer and is useful for down-regulating REL-A activity in a cell, for
 XX CC treating a patient having a condition associated with the level of REL-A.
 XX CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 XX CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 XX CC antisense nucleic acid molecules are useful for treating breast, lung,
 XX CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 XX CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 XX CC multidrug resistant cancer. The method involves use of other drug
 XX CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 XX CC chemotherapies including paclitaxel, docetaxel, cisplatin, methotrexate,
 XX CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 XX CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 XX CC acid molecules are also useful for treating inflammatory disease such as
 XX CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 XX CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 XX CC rejection, gene therapy applications, ischaemia/reperfusion injury
 XX CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 XX CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 XX CC infection. This sequence represents the substrate of a novel
 XX CC enzymatic nucleic acid molecule.
 XX SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 U; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 17;
 Best Local Similarity 91.7%; Pred. No. 7e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 730 GGGGCTGGCTG 741
 |||||
 Db 14 GGGGCTGGCTG 3
 RESULT 730
 AAS45551
 ID AAS45551 standard; DNA; 20 BP.
 XX AC AAS45551;
 XX
 XX 18-DEC-2001 (first entry)
 XX
 XX Tumour-specific IgV region H chain, PCR primer gamma.
 XX
 XX Human; B cell lymphoma; cytostatic; immunostimulator; self-antigen;
 XX tumour-specific vaccine; tumour; polyclonal immune response;
 XX idiotype-specific anti-lymphoma immune response; PCR primer; ss.
 XX OS Homo sapiens.
 XX
 XX WO200168682-A1.

XX PD 20-SEP-2001.
 XX PF 13-OCT-2000; 2000WO-US28362.
 XX PR 10-MAR-2000; 2000US-0522900.
 XX (LARG-) LARGE SCALE BIOLOGY CORP.
 XX PA (MCCO/) MCCORMICK A A.
 XX PA (TUSE/) TUSE D.
 XX PI Reindl SJ, Turpen TH;
 XX DR WPI; 2001-596903/67.
 XX
 XX Novel polypeptide vaccine produced in plants, useful for inducing an
 XX PT immune response to a self-antigen on the surface of certain tumour cells
 XX PT -
 XX PS Disclosure; Page 30; 89pp; English.
 XX
 XX The invention relates to a novel polypeptide self-antigen (I) useful as a
 XX CC tumour-specific vaccine in a subject with a tumour or at risk of
 XX CC developing a tumour. (I) includes an epitope or epitopes unique to,
 XX CC or over expressed by, cells of the tumour, thereby distinguishing the
 XX CC tumour from all other tumours of the same or different histological type,
 XX CC or in the subject or in another member of the subject's species. (I) is
 XX CC epitopes in their native form. (I) is capable of inducing an immune
 XX CC response in a mammal, when used as an individual-specific immunogenic
 XX CC product comprising (I); and as a vaccine composition useful for inducing
 XX CC a tumour-specific immune response, idiotype-specific anti-lymphoma immune
 XX CC response, a polyclonal immune response to at least one idiotype of a
 XX CC surface immunoglobulin or a polyclonal immune response to an idiotype.
 XX CC The vaccine composition is useful for inducing a tumour-specific immune
 XX CC antibody response in a tumour-bearing subject or a subject who had a
 XX CC tumour e.g. B-cell lymphoma, and was treated so that no tumour is
 XX CC clinically or radiographically evident. (I) is useful for inducing a
 XX CC protective antitumour immune response. (I) can be produced at high
 XX CC levels, is easy to purify and can be appropriately folded to mimic the
 XX CC conformation of the native epitopes displayed at the tumour cell surface.
 XX CC AAS45529-AAS45579 represent B cell lymphoma self antigen vaccine
 XX CC linker sequences and PCR primers of the invention.
 XX SQ Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 20;
 Best Local Similarity 70.0%; Pred. No. 7.7e+02;
 Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 1043 CTTCCACGACAGCCCTGCG 1062
 |||||
 Db 1 CTTGACCGAGGCCAGGC 20
 RESULT 731
 ABZ76936
 ID ABZ76936 standard; DNA; 20 BP.
 XX AC ABZ76936;
 XX
 XX 07-MAY-2003 (first entry)
 XX
 XX Bovine DGAT BAC-DNA sequencing primer #9.
 XX
 XX Acyl CoA:diacylglycerol transferase; DGAT; enzyme; chromosome 14;
 XX bovine; milk; meat marbling; low fat; polymorphic; SNP;
 XX single nucleotide polymorphism; PCR primer; ss.
 XX OS Bos taurus.
 XX OS Synthetic.
 XX
 XX WO2003004630-A2.

PD 16-JAN-2003.
 XX 05-JUL-2002; 2002WO-EP07520.
 XX 06-JUL-2001; 2001EP-0116412.
 PR 13-MAY-2002; 2002US-379412P.
 XX (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
 PA Fries H, Winter A;
 XX WPI; 2003-239205/23.
 DR New nucleic acid molecule comprising a sequence of an allele of a
 PT polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
 PT testing a mammal for its predisposition for fat content of milk and for
 PT meat marbling -
 XX Example 1; Page 35; 91pp; English.
 XX The present invention describes a nucleic acid molecule (NA) (I) encoding
 CC a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
 CC indicative for low fat content of milk and to low meat marbling
 CC (intramuscular fat content). Human DGAT is located to chromosome 8, and
 CC bovine DGAT is located to chromosome 14. (I) is useful for testing a
 CC mammal for its predisposition for fat content of milk and/or its
 CC predisposition for meat marbling. The method comprises analysing the
 CC gene encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
 CC polymorphisms (SNPs)) which are connected with the predisposition. The
 CC nucleotide polymorphisms are located in the coding region of the DGAT
 CC gene and result in substitution, deletion and/or addition of an amino
 CC acid sequence of the polypeptide which is encoded by the gene. The
 CC nucleic acid molecule has at the position 10433 and 10434 of the DGAT
 CC gene a guanine and a cytosine residue, at position 3343 a cytosine or
 CC thymine, which correlate with a predisposition for low fat content of
 CC milk and low meat marbling. The nucleic acid molecule has at the position
 CC corresponding to position 10433 and 10434 of the DGAT gene two adenine
 CC residues which correlate with a predisposition for high content of milk
 CC and high meat marbling. The nucleotide polymorphisms are located in a
 CC region which is responsible for the regulation of the expression of the
 CC product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
 CC ABP96046 represent sequences used in the exemplification of the present
 CC invention.
 XX Sequence 20 BP; 7 A; 7 C; 5 G; 1 T; 0 other;
 SQ Query Match 0.8%; Score 10.4; DB 1; Length 20;
 Best Local Similarity 91.7%; Pred. No. 7.7e+02;
 Matches 1; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 866 AGGTCTCCACAG 877
 ||| |||||
 Db 1 AGGCCCCACAG 12
 RESULT 732
 ABZ77002
 ID ABZ77002 standard; DNA; 20 BP.
 XX AC ABZ77002;
 XX 07-MAY-2003 (first entry)
 XX Bovine DGAT PCR primer #38.
 DE Acyl CoA-diacylglycerol transferase; DGAT; enzyme; chromosome 14;
 KW bovine; milk; meat marbling; low fat; polymorphic; SNP;
 KW single nucleotide polymorphism; PCR primer; ss.
 XX Bos taurus.
 OS Synthetic.
 XX

PN W02003004630-A2.
 XX 16-JAN-2003.
 XX 05-JUL-2002; 2002WO-EP07520.
 XX 06-JUL-2001; 2001EP-0116412.
 PR 13-MAY-2002; 2002US-379412P.
 XX (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
 PA Fries H, Winter A;
 XX WPI; 2003-239205/23.
 DR New nucleic acid molecule comprising a sequence of an allele of a
 PT polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
 PT testing a mammal for its predisposition for fat content of milk and for
 PT meat marbling -
 XX Example 1; Page 36; 91pp; English.
 XX The present invention describes a nucleic acid molecule (NA) (I) encoding
 CC a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
 CC indicative for low fat content of milk and to low meat marbling
 CC (intramuscular fat content). Human DGAT is located to chromosome 8, and
 CC bovine DGAT is located to chromosome 14. (I) is useful for testing a
 CC mammal for its predisposition for fat content of milk and/or its
 CC predisposition for meat marbling. The method comprises analysing the
 CC gene encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
 CC polymorphisms (SNPs)) which are connected with the predisposition. The
 CC nucleotide polymorphisms are located in the coding region of the DGAT
 CC gene and result in substitution, deletion and/or addition of an amino
 CC acid sequence of the polypeptide which is encoded by the gene. The
 CC nucleic acid molecule has at the position 10433 and 10434 of the DGAT
 CC gene a guanine and a cytosine residue, at position 3343 a cytosine or
 CC thymine, which correlate with a predisposition for low fat content of
 CC milk and low meat marbling. The nucleic acid molecule has at the position
 CC corresponding to position 10433 and 10434 of the DGAT gene two adenine
 CC residues which correlate with a predisposition for high content of milk
 CC and high meat marbling. The nucleotide polymorphisms are located in a
 CC region which is responsible for the regulation of the expression of the
 CC product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
 CC ABP96046 represent sequences used in the exemplification of the present
 CC invention.
 XX Sequence 20 BP; 7 A; 7 C; 5 G; 1 T; 0 other;
 SQ Query Match 0.8%; Score 10.4; DB 1; Length 20;
 Best Local Similarity 91.7%; Pred. No. 7.7e+02;
 Matches 1; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 866 AGGTCTCCACAG 877
 ||| |||||
 Db 1 AGGCCCCACAG 12
 RESULT 733
 AAZ71860
 ID AAZ71860 standard; DNA; 20 BP.
 XX AC AAZ71860;
 XX 10-SEP-2001 (first entry)
 XX Human biallelic marker upstream amplification primer SEQ ID NO:6216.
 DE Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.

```

XX OS Homo sapiens.
XX XX
XX EN WO9954500-A2.
XX XX
XX FD 28-OCT-1999.
XX XX
XX PF 21-APR-1999; 99WO-1B00822.
XX XX
XX PR 21-APR-1998; 98US-0082614.
XX PR 23-NOV-1998; 98US-0109732.
XX XX
XX PA (GEST ) GENSET.
XX XX
XX PI Cohen D, Blumenfeld M, Chumakov I;
XX PI WPI; 2000-013267/01.
XX DR
XX XX
XX PT Novel biallelic markers used to construct a high density disequilibrium
XX PT map of the human genome -
XX PS
XX PS Claim 9; Page 1556; 2745pp; English.
XX XX
XX CC AAZ55654 to AAZ69578 represent human biallelic markers from the present
XX CC invention, which contain a polymorphic base at position 24 of their
XX CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX CC primers for the biallelic markers. The biallelic markers of the
XX CC invention have a variety of uses: they can be used for high density
XX CC mapping of the human genome, and in complex association studies and
XX CC haplotyping studies which are useful in determining the genetic basis
XX CC for disease states. Compositions and methods of the invention can also
XX CC be useful for the identification of the targets for the development of
XX CC pharmaceutical agents and diagnostic methods, as well as the
XX CC characterisation of the differential efficacious responses to and side
XX CC effects from pharmaceutical agents acting on a disease as well as other
XX CC treatment.
XX CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
XX CC and 3367, are not actually given a sequence in the Sequence Listing
XX CC from the present invention.
XX SQ Sequence 20 BP; 5 A; 2 C; 9 G; 4 T; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 20;
Best Local Similarity 91.7%; Pred. NO. 7.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 6 GGCAGTTGAGGT 17
DB 5 GGAAGTTGAGGT 16

RESULT 734
AAC93165
ID AAC93165 standard; DNA; 20 BP.
XX AC AAC93165;
XX XX
XX DT 15-FEB-2001 (first entry)
XX DE
XX DE Human STAT3 phosphorothioate antisense oligonucleotide SEQ ID NO:16.
XX KW Human; mouse; STAT3; phosphorothioate; antisense oligonucleotide;
XX KW modulation; signal transducer and activator of transcription;
XX KW DNA-binding protein; signal transduction; inhibition; apoptosis;
XX KW inflammatory disease; cancer; antiinflammatory; antirheumatic;
XX KW cytostatic; immunostimulatory; rheumatoid arthritis; leukaemia;
XX KW myeloma; melanoma; lymphoma; diagnosis; ss.
XX OS Homo sapiens.
XX XX
XX PN WO200061602-A1.
XX XX
XX FD 19-OCT-2000.

```

```

XX XX
XX PF 06-APR-2000; 2000WO-US09054.
XX PR
XX PR 08-APR-1999; 99US-0288461.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX XX
XX PI Karras JG;
XX XX
XX DR WPI; 2000-619223/59.
XX XX
XX PT New antisense compound for inhibiting the expression of signal
XX PT transducer and activator of transcription 3 (STAT3) in cells or tissues
XX PT and treating diseases or condition associated with STAT3, such as
XX PT rheumatoid arthritis and cancer -
XX XX
XX XX Example 2; Page 46; 104pp; English.
XX XX
XX CC The present invention describes an antisense compound (I), 8 to 30
XX CC nucleobases in length, that is targeted to a nucleic acid molecule
XX CC encoding STAT3 (Signal Transducer and Activator of Transcription) and
XX CC which inhibits the expression of it. (I) has antiinflammatory,
XX CC antirheumatic, cytostatic and immunostimulatory activities. (I) is used
XX CC for inhibiting the expression of STAT3 in cells or tissues, treating
XX CC an animal having a disease or condition associated with STAT3 or a
XX CC human having a disease or condition characterised by a reduction in
XX CC apoptosis, and inducing apoptosis in a cell. Diseases or conditions
XX CC that are treated are rheumatoid arthritis, cancer of the breast,
XX CC prostate, brain, head and/or neck, leukaemia, myeloma, melanoma or
XX CC lymphoma. (I) can also be used for diagnostic methods in detecting and
XX CC determining the role of STAT3 in various cell functions, physiological
XX CC processes and conditions and for diagnosing the conditions associated
XX CC with expression of STAT3. (I) can be used alone or with other drugs as
XX CC an immunostimulator. (I) is used in sandwich and colourimetric assays,
XX CC involving enzyme conjugation and radiolabeling and is used in
XX CC diagnostic kits. AAC93150 encodes human STAT3 and AAC93231 encodes mouse
XX CC STAT3 as given in the exemplification of the present invention. AAC93151
XX CC to AAC93230 and AAC93232 to AAC93299 represent STAT3 phosphorothioate
XX CC antisense oligonucleotides, and AAC93300 represents a mismatch control
XX CC oligonucleotide which are used in example from the present invention.
XX SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 20;
Best Local Similarity 91.7%; Pred. NO. 7.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 823 CTGATGCAGCTG 834
DB 9 CTGATGCAGCTG 20

RESULT 735
AAS96782
ID AAS96782 standard; DNA; 20 BP.
XX AC AAS96782;
XX XX
XX DT 26-FEB-2002 (first entry)
XX DE
XX DE Human STAT3 antisense phosphorothioate oligodeoxynucleotide #15.
XX KW STAT3; human; signal transducer and activator of transcription; ss; STAT;
XX KW antisense gene therapy; Fas-mediated apoptosis; inflammatory disease;
XX KW autoimmune disease; rheumatoid arthritis; cancer; breast; prostate; head;
XX KW neck; brain; leukaemia; myeloma; melanoma; lymphoma; apoptosis;
XX KW antiinflammatory; immunosuppressive; antirheumatic; antiarthritic;
XX KW cytostatic.
XX OS Homo sapiens.
XX OS Synthetic.
XX XX
XX PN US2001029250-A1.

```

```

XX PD 11-OCT-2001.
XX PF 11-JAN-2001; 2001US-0758881.
XX PR 08-APR-1999; 99US-0288461.
XX PR 06-APR-2000; 2000MO-US09054.
XX PA (KARR/) KARRAS J G.
XX PI Karas JG;
XX DR WPI; 2002-009991/01.
XX CC Novel antisense compound useful for treating and diagnosing
XX PT inflammatory diseases and cancers, is targeted to a nucleic acid
XX PT molecule encoding signal transducer and activator of transcription
XX PT proteins -
XX CC
XX PS Example 2; Page 13; 21pp; English.
XX CC The invention relates to antisense compounds targeted to a nucleic acid
XX CC molecule encoding a signal transducer and activator of transcription
XX CC (STAT) protein, specifically STAT3, where the antisense compounds inhibit
XX CC the expression of STAT3. The antisense sequences are useful for
XX CC inhibiting the expression of STAT3 in cells or tissues, inducing
XX CC Fas-mediated apoptosis in cells, and sensitizing cells to apoptosis. They
XX CC are also useful for treating an animal having a disease or condition
XX CC associated with STAT3. These disorders include inflammatory or autoimmune
XX CC disease, particularly rheumatoid arthritis, cancers, such as those of the
XX CC breast, prostate, brain and head and neck and leukaemias, myelomas,
XX CC melanomas and lymphomas. Also treatable are human diseases or conditions
XX CC characterised by a reduction in apoptosis or an insensitivity to
XX CC apoptotic signals. The sequences of the invention can be used in clinical
XX CC research, for detecting and determining the role of STAT3 in various cell
XX CC functions and physiological processes and for diagnosing conditions
XX CC associated with the expression of STAT3. The sequences represent cDNA
XX CC encoding human STAT3 and human STAT3 oligonucleotides.
XX CC
XX PS Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 other;
XX CC
Query Match 0.8%; Score 10.4; DB 1; Length 20;
Best Local Similarity 91.7%; Pred. No. 7.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 823 CTGATGCAGCTG 834
XX DB ||||| |||||
XX 9 CTGATGCAGCTG 20
XX
RESULT 736
AAT84695
XX ID AAT84695 standard; DNA; 21 BP.
XX AC AAT84695;
XX XX
XX DT 02-JAN-1998 (first entry)
XX DE KSHV DNA polymerase antisense oligonucleotide HVLOB.
XX KW KSHV; gamma herpes virus; glycoprotein B; vaccine; infection;
XX KW human Kaposi's sarcoma-associated herpes virus; probe; primer;
XX KW DNA polymerase; ss.
XX OS Synthetic.
XX PN WO9712042-A2.
XX PD 03-APR-1997.
XX PF 26-SEP-1996; 96WO-US15702.
XX PR 26-SEP-1995; 95US-0004297.

```

```

XX PA (UNIW ) UNIV WASHINGTON.
XX PI Bosch ML, Rose TM, Strand K;
XX PR WPI; 1997-212901/19.
XX CC DNA encoding glycoprotein B of retroperitoneal fibromatosis and
XX PT Kaposi's sarcoma associated herpes viruses - useful in vaccines for
XX PT treatment of herpes infection or for detection of viral DNA
XX CC
XX PS Claim 37; Page 76; 138pp; English.
XX CC Claimed type 3 oligonucleotides (AAT84694-96) are specific
XX CC non-degenerate oligonucleotides for the human Kaposi's sarcoma-
XX CC associated herpes virus (KSHV) DNA polymerase (GB). They can
XX CC be used for detecting, amplifying or characterising KSHV
XX CC polynucleotides encoding DNA polymerase (see AAT84697).
XX CC
XX PS Sequence 21 BP; 3 A; 4 C; 11 G; 3 T; 0 other;
XX CC
Query Match 0.8%; Score 10.4; DB 1; Length 21;
Best Local Similarity 91.7%; Pred. No. 7.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 522 CCTGCCGAGGA 533
XX DB ||||| |||||
XX 6 CCTGCCGAGGA 17
XX
RESULT 737
AAT51587
XX ID AAT51587 standard; DNA; 21 BP.
XX AC AAT51587;
XX XX
XX DT 06-NOV-1997 (first entry)
XX DE KSHV DNA polymerase specific oligonucleotide HVLOB.
XX KW Retroperitoneal fibromatosis herpes virus; detection; infection;
XX KW Kaposi's sarcoma herpes virus; viral DNA; viral RNA; vaccine;
XX KW antigen; antibody; ss.
XX OS Synthetic.
XX PN WO9704105-A1.
XX PD 06-FEB-1997.
XX PF 12-JUL-1996; 96WO-US11688.
XX PR 11-JUL-1996; 96US-0001148.
XX PR 14-JUL-1995; 95US-0001148.
XX PA (UNIW ) UNIV WASHINGTON.
XX PI Bosch ML, Rose TM, Strand K, Todaro GJ;
XX PR WPI; 1997-132644/12.
XX CC Herpes virus DNA polymerase and corresponding nucleotide sequence -
XX PT used in the detection and treatment of herpes virus infection
XX CC
XX PS Claim 26; Page 92; 132pp; English.
XX CC The present sequence represents oligonucleotide HVLOB which is
XX CC specific for polynucleotides encoding DNA polymerases from Kaposi's
XX CC sarcoma herpes virus (KSHV). The oligonucleotide may be used for
XX CC detecting viral DNA or RNA in a sample of primate origin, especially
XX CC in the diagnosis of herpes viral infection. Herpes virus DNA
XX CC polymerases of this invention, may be used in vaccines for the
XX CC protection against infection by a herpes virus of the RPHV/KSHV

```

CC family. They may also be used in the design and screening of
 CC anti-viral drugs. Antibodies raised against the polymerase or
 CC fragments of it, may be used in the detection of herpes virus
 CC infection and for drug targeting for the therapy of herpes virus
 CC infection.

XX Sequence 21 BP; 3 A; 4 C; 11 G; 3 T; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 21;
 Best Local Similarity 91.7%; Pred. No. 7.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 522 CCTGCGGAGGA 533
 Db 6 CTTGCTGGAGGA 17
 ||||| |||||

RESULT 738

AAQ64857
 ID AAQ64857 standard; DNA; 23 BP.

XX AC AAQ64857;

XX 25-MAR-2003 (updated)
 DT 18-OCT-1994 (first entry)

XX IG gamma chain probe gamma-CH1.

XX SpA domain D; Ig binding region; gamma chain; B-cell superantigen; sAg;
 KW superantigen; heavy chain variable region; VH3 restricted antibody;
 KW VH; protein-A; Vh26C; combinatorial library; B-lymphocyte;
 KW vaccine; DNA probe; hybridization; ss.

XX Synthetic.

XX WO9409818-Al.

XX 11-MAY-1994.

XX 29-OCT-1993; 93WO-US10555.

XX 30-OCT-1992; 92US-0969936.

XX (REGC) UNIV CALIFORNIA.

XX Silverman GJ;

XX WPI; 1994-167127/20.

XX Stimulating prodn. of variable region gene family restricted
 PT antibodies - through B-cell super-antigen vaccination

XX Disclosure; Page 24; 130pp; English.

XX A B-cell superantigen (sAg) is a fragment of SpA D domain that
 CC specifically binds the Fab portion of variable region restricted
 CC antibodies. The sAg is used to enhance production of VH, especially
 CC VH3, restricted Abs. To detect Ig gamma chain expression, the
 CC antisense sequence given in AAQ64857 was used as probe. Detection of
 CC VH families used the sense oligonucleotides given in AAQ64859-60.
 CC (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 23 BP; 4 A; 8 C; 8 G; 3 T; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 23;
 Best Local Similarity 70.0%; Pred. No. 8e+02;
 Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 704 TCCTTGATTCCTGCGCCAG 723
 ||||| |||||

Db 2 TCCTTGACCGCAGCCAG 21

RESULT 739

AAF45161/c
 ID AAF45161 standard; RNA; 15 BP.

XX AC AAF45161;

XX 30-MAR-2001 (first entry)

XX Antisense oligonucleotide #10.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX Homo sapiens.

XX WO200078341-Al.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU00693.

XX 21-JUN-1999; 99US-0140345.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -

XX Claim 15; Page 115; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is one such
 CC antisense oligonucleotide. The method is useful for ameliorating the
 CC effects of psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea,
 CC keloids, keratosis, neoplasias, sclerodermas, warts, benign growths,
 CC cancers of the skin, a hyperneovascular condition such as a neovascular
 CC condition of the retina, brain or skin, growth factor-mediated
 CC malignancies, other sclerotic disease, kidney disease, hyperproliferation
 CC of the inside of blood vessels or any other hyperplasia.

XX Sequence 15 BP; 4 A; 5 C; 6 G; 0 U; 0 other;

Query Match 0.8%; Score 10.2; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 6.8e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 729 GGGGGCTGGCTGCC 743
 ||||| |||||

Db 15 GTGTGCTGCTGCC 1

RESULT 740

AAF49864
 ID AAF49864 standard; DNA; 15 BP.

XX AC AAF49864;

XX

DT 30-MAR-2001 (first entry)
 XX IGF-I oligonucleotide #824.
 DE Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS
 XX WO200078341-A1.
 PN
 XX 28-DEC-2000.
 PD
 XX 21-JUN-2000; 2000WO-AU00693.
 PF
 XX 21-JUN-1999; 99US-0140345.
 PR
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX Wright CJ, Werther GA, Edmondson SR;
 PI
 XX WPI; 2001-041421/05.
 DR
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by
 XX administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -
 XX
 XX Example 8; Page 66; 201pp; English.
 PS
 XX The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-F45161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.
 XX
 XX Sequence 15 BP; 0 A; 6 C; 5 G; 4 T; 0 other;
 SQ
 Query Match 0.8%; Score 10.2; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 6.8e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 729 GGGGGCTGGCTGCC 743
 Db 1 GTGTGCTGGCTGCC 15
 RESULT 741
 ACA06585
 ID ACA06585 standard; RNA; 17 BP.
 XX
 XX ACA06585;
 AC
 XX
 XX 03-JUN-2003 (first entry)
 DT
 XX NFKB sub-unit modulating inozyme substrate #404.
 DE
 XX

KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberyze; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX US2002177568-A1.
 PN
 XX 28-NOV-2002.
 PD
 XX 23-MAY-2001; 2001US-0864785.
 PF
 XX 15-AUG-1994; 94US-0291932.
 PR
 XX 07-DEC-1992; 92US-0987132.
 PR
 XX 18-MAY-1994; 94US-0245466.
 PR
 XX 23-DEC-1996; 96US-0777916.
 XX
 XX (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 PT
 XX WPI; 2003-340953/32.
 DR
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 XX Claim 3; Page 33; 72pp; English.
 PS
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyze
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX
 XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 U; 0 other;
 SQ
 Query Match 0.8%; Score 10.2; DB 1; Length 17;
 Best Local Similarity 80.0%; Pred. No. 7.5e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 715 GTGCCACGACGAG 729
 Db 2 GAGGCCGCGCAG 16

RESULT 742
 AAX67028
 ID AAX67028 standard, RNA; 18 BP.
 XX
 AC AAX67028;
 XX
 DT 20-JUL-1999 (first entry)
 XX
 DE Mouse B7 hairpin ribozyme target SEQ ID NO:3660.
 XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Mus sp.
 XX
 FN WO9618736-A2.
 XX
 PD 20-JUN-1996.
 XX
 PF 22-NOV-1995; 95WO-US15516.
 XX
 PR 05-OCT-1995; 95US-0541365.
 PR 13-DEC-1994; 94US-0354920.
 PR 23-DEC-1994; 94US-0363253.
 PR 23-DEC-1994; 94US-0363254.
 PR 17-FEB-1995; 95US-0390850.
 PR 20-APR-1995; 95US-0426124.
 PR 02-MAY-1995; 95US-0432874.
 PR 04-MAY-1995; 95US-0434509.
 PR 07-JUL-1995; 95US-0000951.
 PR 07-JUL-1995; 95US-0000974.
 PR 07-AUG-1995; 95US-0512861.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Draper K, Gustofson J, McSwiggen J, Pavco P, Stinchcomb DT;
 PI Beigelman L, Karpeisky A, Modak A, Usman N, Burgin A;
 PI Matulich-Adamic J, Jarvis T, Thompson JD, Wincott F;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used
 PT for the treatment of arthritis, induction of graft tolerance or
 PT treatment of auto-immune diseases
 XX
 PS Claim 10; Page 215; 307pp; English.
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose
 CC residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
 CC at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
 CC The ENA's can inhibit collagenase and stromelysin production in the
 CC synovial membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention.

XX Sequence 18 BP; 1 A; 4 C; 4 G; 9 U; 0 other;
 SQ Query Match 0.8%; Score 10.2; DB 1; Length 18;
 Best Local Similarity 53.3%; Pred. No. 7.7e+02;
 Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1032 TGCAGCTGACTCTTC 1046
 Db 1 GCGCGCGAUGGUC 15

RESULT 743
 AAV57794/c
 ID AAV57794 standard; DNA; 18 BP.
 XX
 AC AAV57794;
 XX
 DT 18-NOV-1998 (first entry)
 XX
 DE Human chromosome 18 PCR mapping primer clone 47r.
 XX
 KW Manic-depressive illness; susceptibility; genotype; diagnosis;
 KW chromosomal marker; polymorphic marker; chromosome 18; human;
 KW myo-inositol monophosphatase protein; IMP-18p; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9818963-A1.
 XX
 PD 07-MAY-1998.
 XX
 PF 28-OCT-1997; 97WO-US19381.
 XX
 PR 28-OCT-1996; 96US-0029278.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Badner JA, Barrettini WH, Detera-Wadleigh SD, Esterling LE;
 PI Gershon ES, Goldin LR, Sanders AR, Yoshikawa T;
 XX
 DR WPI; 1998-272247/24.
 XX
 PT New isolated IMP.18p myo-inositol monophosphatase - used to develop
 PT products for determining susceptibility to manic depressive illness
 PT and as targets for preventive and therapeutic treatments
 XX
 PS Example 5; Page 71; 118pp; English.
 XX
 CC A method has been developed for determining a genotype associated with
 CC increased susceptibility to manic-depressive (MD) illness. The method
 CC comprises determining the genotype of an affected individual with at
 CC least one polymorphic marker localised within the chromosomal region
 CC defined by and including markers D18S843 and D18S869 and determining the
 CC genotype associated with increased susceptibility to MD disorder. The
 CC method can be used for determining susceptibility to MD illness
 CC including bipolar disorder; genetic counselling of individuals from
 CC families affected with MD illness, and aid in the differential diagnosis
 CC of MD illness from other psychiatric pathologies. Products from the
 CC present invention can also be used to obtain modulators of IMP.18p myo-
 CC inositol monophosphatase protein activity and as targets for preventive
 CC and therapeutic treatments. The present sequence represents a PCR primer
 CC used in the mapping of human chromosome 18 for determining the genotype
 CC of MD illness susceptibility, used in an example from the present
 CC invention.
 XX
 SQ Sequence 18 BP; 2 A; 4 C; 4 G; 8 T; 0 other;
 Query Match 0.8%; Score 10.2; DB 1; Length 18;
 Best Local Similarity 80.0%; Pred. No. 7.7e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY	629	AGCTCAGGAGCTCT 643	
Db	15	AGCTCAGGAGCACT 1	
RESULT 744			
AA227086/c			
ID	AAA27086	standard; DNA; 18 BP.	
XX	AC	AA227086;	
XX	DT	21-AUG-2000 (first entry)	
XX	DE	Human NF-kappa-B p65 subunit antisense oligodeoxynucleotide ISIS# 23738.	
XX	KW	Human; anti-inflammatory; cytostatic; antimicrobial; infection;	
XX	KW	antisense inhibition; inflammation; transcription factor;	
XX	KW	apoptosis; cancer; ss.	
OS	OS	Homo sapiens.	
XX	FN	Key	Location/Qualifiers
FT	FT	modified_base	1..18
FT	FT		/*tag= a
FT	FT		/note= "all or some internucleoside bonds are
FT	FT		phosphorothioate and optionally some sugars may
FT	FT		be 2' methoxyethyl"
XX	XX	US6069008-A.	
XX	XX	30-MAY-2000.	
XX	XX	25-NOV-1998;	98US-0199859.
XX	XX	25-NOV-1998;	98US-0199859.
XX	XX	(ISIS-) ISIS PHARM INC.	
XX	XX	Bennett CF, Cowser LM, Monia BP;	
XX	XX	WPI; 2000-410858/35.	
XX	XX	Antisense compounds which inhibit the expression of the human	
XX	XX	NF-kappa-B p65 subunit (p65) useful for treating diseases associated	
XX	XX	with p65 expression and as prophylaxis to prevent of delay infection,	
XX	XX	inflammation or tumor formation -	
XX	XX	Example 15; Column 40; 33pp; English.	
XX	XX	The present sequence is one of a number of oligonucleotides designed to	
XX	XX	target different regions of the human NF-kappa-B p65 subunit, which is a	
XX	XX	member of the Rel/NF-kappa-B family of transcription factors.	
XX	XX	Rel/NF-kappa-B proteins are involved in a diverse set of signaling	
XX	XX	pathways involving stress, apoptosis, cancer, growth, infection and	
XX	XX	inflammation. Antisense oligonucleotides are able to inhibit expression	
XX	XX	of the p65 subunit and may therefore be used in the treatment of	
XX	XX	disorders associated with NF-kappa-B p65 subunit expression. They may be	
XX	XX	used as a prophylaxis to prevent or delay infection, inflammation or	
XX	XX	tumour formation. Antisense compounds may also be used for research and	
XX	XX	diagnostics because they hybridise to nucleic acids encoding	
XX	XX	NF-kappa-B p65 subunit. The effect of antisense oligonucleotides on	
XX	XX	NF-kappa-B p65 subunit mRNA levels was measured using real-time	
XX	XX	quantitative PCR and Northern blot analysis. Antisense	
XX	XX	oligonucleotides were synthesised on an automated DNA synthesiser.	
XX	XX	Sequence 18 BP; 2 A; 6 C; 5 G; 5 T; 0 other;	
Query Match		0.8%; Score 10.2; DB 1; Length 18;	
Best Local Similarity		80.0%; Pred. No. 7.7e+02;	
Matches	12;	Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
QY	421	CTAGACAGGAGCACG 435	

PN W09852976-A1.
XX
PD 26-NOV-1998.
XX
XX
PF 21-MAY-1998; 98WO-GB01473.
XX
XX 14-APR-1998; 98GB-0007751.
PR 21-MAY-1997; 97GB-0010480.
PR 31-JUL-1997; 97GB-0016197.
PR 28-NOV-1997; 97GB-0025270.
PR 02-DEC-1997; 97US-0067235.
XX
XX (BIOV-) BIOVATION LTD.
XX
XX Carr RJ;
XX WPI; 1999-045301/04.
XX
XX Reducing immunogenicity of proteins - by modifying the amino acid
PT sequence of the protein to eliminate potential epitopes for T-cells
PT of a given species
XX
XX Example 3; Fig 16; 77pp; English.
XX
XX The invention relates to a method for the production of non-immunogenic
CC proteins. The method comprises determining at least part of the amino
CC acid sequence of the protein; (b) identifying in the amino acid sequence
CC one or more potential epitopes for T-cells (T-cell epitopes) of the
CC given species; and (c) modifying the amino acid sequence to eliminate at
CC least one of the T-cell epitopes identified in step (b) thereby to
CC eliminate or reduce the immunogenicity of the protein when exposed to the
CC immune system of the given species. A method of analysing a pre-existing
CC protein to predict the basis for immunogenic responses is also provided.
CC The methods can be used particularly for reducing the immunogenicity of
CC immunoglobulins or therapeutic proteins, e.g. Streptokinase (SK). The
CC products can be used for diagnosis and therapy. Sequences AAV81047-68
CC represent oligonucleotides used for the construction of de-immunised 708
CC Vh and Vk.
XX
XX SQ Sequence 18 BP; 2 A; 5 C; 4 G; 7 T; 0 other;
Query Match 0.8%; Score 10.2; DB 1; Length 18;
Best Local Similarity 80.0%; Pred. No. 7.7e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1026 CCAAGTGCAGCTGA 1040
DB 17 CCAAGCTGGAGCTGA 3
RESULT 747
AAV51978/c
ID AAV51978 standard; DNA; 19 BP.
XX
AC AAV51978;
XX
XX 02-FEB-1999 (first entry)
XX
XX Zea mays genome reverse PCR primer #274.
DE
XX Polymorphic marker; allele-specific; probe; amplification; PCR primer;
KW hybridisation; plant; hybrid certification; genetic contribution;
KW progeny; back-cross; hybrid; ancestry; corn; ss.
XX
XX Synthetic.
OS
XX Zea mays.
XX
XX W09824796-A1.
XX
XX 11-JUN-1998.
XX
XX 01-DEC-1997; 97WO-US21782.
XX
XX Zea mays genome reverse PCR primer #274.
DE
XX Polymorphic marker; allele-specific; probe; amplification; PCR primer;
KW hybridisation; plant; hybrid certification; genetic contribution;
KW progeny; back-cross; hybrid; ancestry; corn; ss.
XX
XX Synthetic.
OS
XX Zea mays.
XX
XX W09824796-A1.
XX
XX 11-JUN-1998.
XX
XX 01-DEC-1997; 97WO-US21782.
XX
XX

PR 07-MAR-1997; 97US-0813507.
PR 02-DEC-1996; 96US-0032069.
XX
XX (AFFY-) AFFYMETRIX INC.
XX
XX Landry BS, Lemieux B, Murigneux A, Sapolsky RJ;
XX
XX WPI; 1998-333252/29.
XX
XX Brassica species allele-specific oligonucleotide probes and primers
PT - useful for plant breeding
XX
XX Example 1; Page Page 54; 65pp; English.
XX
XX AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
CC Zea mays genome in order to detect polymorphic markers. Such markers can
CC be used in the construction of allele-specific primers and probes for
CC amplification or hybridisation, e.g. to determine common or disparate
CC ancestry between 2 or more plants, to monitor the genetic contribution
CC of an ancestral plant, to trace the progeny of proprietary plants, in
CC certification of a hybrid plant or to identify the progeny of a
CC back-crossed plant with an ancestral plant.
XX
XX SQ Sequence 19 BP; 5 A; 6 C; 7 G; 1 T; 0 other;
Query Match 0.8%; Score 10.2; DB 1; Length 19;
Best Local Similarity 80.0%; Pred. No. 9e+02; 3; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 729 GGGGGCTGGCTGCC 743
DB 15 GCGTGGCTGGCTGCC 1
RESULT 748
AAV51979/c
ID AAV51979 standard; DNA; 19 BP.
XX
XX AAV51979;
XX
XX 02-FEB-1999 (first entry)
XX
XX Zea mays genome reverse PCR primer #275.
DE
XX Polymorphic marker; allele-specific; probe; amplification; PCR primer;
KW hybridisation; plant; hybrid certification; genetic contribution;
KW progeny; back-cross; hybrid; ancestry; corn; ss.
XX
XX Synthetic.
OS
XX Zea mays.
XX
XX W09824796-A1.
XX
XX 11-JUN-1998.
XX
XX 01-DEC-1997; 97WO-US21782.
XX
XX 07-MAR-1997; 97US-0813507.
PR 02-DEC-1996; 96US-0032069.
XX
XX (AFFY-) AFFYMETRIX INC.
XX
XX Landry BS, Lemieux B, Murigneux A, Sapolsky RJ;
XX
XX WPI; 1998-333252/29.
XX
XX Brassica species allele-specific oligonucleotide probes and primers
PT - useful for plant breeding
XX
XX Example 1; Page Page 54; 65pp; English.
XX
XX AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
CC Zea mays genome in order to detect polymorphic markers. Such markers can

CC be used in the construction of allele-specific primers and probes for
 CC amplification or hybridisation, e.g. to determine common or disparate
 CC ancestry between 2 or more plants, to monitor the genetic contribution
 CC of an ancestral plant, to trace the progeny of proprietary plants, in
 CC certification of a hybrid plant or to identify the progeny of a
 CC back-crossed plant with an ancestral plant.
 XX
 SQ Sequence 19 BP; 5 A; 6 C; 7 G; 1 T; 0 other;

Query Match 0.8%; Score 10.2; DB 1; Length 19;
 Best Local Similarity 80.0%; Pred. No. 8e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 729 GGGGGCTGGTGGC 743
 Db 15 GCGTGCCTGCGCTGCC 1

RESULT 749

AAT39478
 ID AAT39478 standard; DNA; 20 BP.

XX AAT39478;

XX 21-MAY-1997 (first entry)

XX Steroidogenesis acute regulatory protein antisense PCR primer 2.

XX Human; steroidogenesis; acute regulatory protein; hSTAR; analysis;
 KW mutation; detection; prenatal; genetic defect; congenital; protein;
 KW lipid adrenal hyperplasia; treatment; prevention; gene;
 KW replacement therapy; hypercholesterolaemia; primer; PCR;
 KW polymerase chain reaction; ss.

XX Synthetic.

XX WO9629338-A1.

XX 26-SEP-1996.

XX 22-MAR-1996; 96WO-US03896.

XX 23-MAR-1995; 95US-0410540.

XX (REGC) UNIV CALIFORNIA.

XX (UTPE-) UNIV PENNSYLVANIA.

XX Lin D, Miller WL, Strauss JF;

XX WPI; 1996-443130/44.

XX Isolated human steroidogenesis acute regulatory protein gene - used
 PT for detection of mutation(s) of this gene that cause congenital
 PT lipid adrenal hyperplasia

XX Example 7; Page 4; 89pp; English.

XX The present sequence is a PCR primer (nt 717-738) for the human
 CC steroidogenesis acute regulatory protein (hSTAR) cDNA. The hSTAR
 CC gene can be analysed for mutations to detect (e.g. prenatally)
 CC genetic defects associated with congenital lipid adrenal
 CC hyperplasia (CAH), or its transmission to children. CAH can be
 CC treated by protein or gene replacement therapy, which can also be
 CC used to prevent or treat hypercholesterolaemia.
 CC A human adrenal cortex cDNA library was screened with a mouse STAR
 CC probe to isolate a 1.6 kb insert, including an ORF for a 285
 CC residue protein. When it was cloned into pSPORT and expressed in
 CC COS-1 cells cotransfected with pP450scd and pADX, it increased the
 CC level of pregnenolone synthesis from cholesterol or
 CC 20-alpha-hydroxycholesterol.

XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 other;

Query Match 0.8%; Score 10.2; DB 1; Length 20;
 Best Local Similarity 80.0%; Pred. No. 8.1e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1246 GTGCCCATTGTGAGGC 1260
 Db 2 GTGCCCATTGCCAGCC 16

RESULT 750

AAT99084

ID AAT99084 standard; DNA; 20 BP.

XX AAT99084;

XX 24-MAR-1998 (first entry)

XX Primer alphaEN-S2 for alphaENAC coding sequence.

XX Alpha epithelial sodium channel; alphaENACa; alphaENACb; binding assay;
 KW amiloride-sensitive salt channel alpha subunit; membrane-transport;
 KW salt substitute; salty taste blocker; PCR primer; amplify; ss.

XX Synthetic.

XX Rattus rattus.

XX US5693756-A.

XX 02-DEC-1997.

XX 23-JAN-1995; 95US-0376362.

XX 23-JAN-1995; 95US-0376362.

XX 28-FEB-1994; 94US-0202654.

XX (UVJO) UNIV JOHNS HOPKINS.

XX Blackshaw S, Li X, Snyder SH;

XX WPI; 1998-031814/03.

XX Alternatively spliced epithelial sodium channel alpha subunit
 PT proteins - useful in screening assays for salty taste enhancers or
 PT blockers

XX Disclosure; Column 9; 33pp; English.

XX This sequence represents a primer for the coding sequence for the alpha
 CC epithelial sodium channel a (alphaENACa). AlphaENACa (see AAM34529) and
 CC alphaENACb (see AAM34530) represent the sequences of the invention. The
 CC two sodium channels are alternatively spliced forms of the
 CC amiloride-sensitive salt channel alpha subunit and can be used in
 CC membrane-transport or binding assays to identify substances that enhance
 CC or block perception of a salty taste. Enhancers could be used as salt
 CC substitutes and blockers could be used to mask salty tastes in foods and
 CC pharmaceuticals.

XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 other;

Query Match 0.8%; Score 10.2; DB 1; Length 20;
 Best Local Similarity 80.0%; Pred. No. 8.1e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 629 AGCTCCAGGAGCTCT 643
 Db 4 AGCTCCTGGGCTAT 18

Search completed: January 8, 2004, 16:40:18
 Job time : 26 secs

Result No.	Score	Query		DB	ID	Description
		Match	Length			
1	22	1.6	21	1	US-09-302-681-65	Sequence 65, Appl
C 2	17.8	1.3	22	1	US-09-667-135-7	Sequence 7, Appl
C 3	17.6	1.3	24	1	US-08-249-037C-16	Sequence 16, Appl
C 4	17.6	1.3	24	1	US-08-788-622B-16	Sequence 16, Appl
C 5	17.6	1.3	24	1	US-08-788-622B-16	Sequence 16, Appl
6	16.8	1.2	21	1	US-08-052-997-22	Sequence 22, Appl
7	16.8	1.2	21	1	US-08-684-673-22	Sequence 22, Appl
8	16.4	1.2	18	1	US-09-244-794A-29	Sequence 29, Appl
9	16.4	1.2	18	1	US-09-007-005-29	Sequence 29, Appl
10	16.4	1.2	18	1	US-09-247-190-29	Sequence 29, Appl
11	16.4	1.2	18	1	US-09-244-796-29	Sequence 29, Appl
12	16.4	1.2	18	1	US-09-238-710-29	Sequence 29, Appl
C 13	16.2	1.2	21	1	US-09-302-681-76	Sequence 29, Appl
C 14	16.2	1.2	23	1	US-08-709-731A-5	Sequence 76, Appl
C 15	15.8	1.2	20	1	US-09-136-959A-6	Sequence 5, Appl
C 16	15.8	1.2	20	1	US-09-556-031-2	Sequence 5, Appl
C 17	15.8	1.2	20	1	US-09-702-246-25	Sequence 2, Appl
C 18	15.8	1.2	20	1	US-09-322-624-19	Sequence 25, Appl
C 19	15.8	1.2	21	1	US-09-422-978-10530	Sequence 19, Appl
C 20	15.4	1.1	20	1	US-09-422-978-11451	Sequence 10530, A
C 21	15.4	1.1	21	1	US-08-680-326-140	Sequence 1451, A
C 22	15.4	1.1	21	1	US-08-804-439A-89	Sequence 140, App
C 23	15.4	1.1	21	1	US-08-720-228-89	Sequence 89, Appl
C 24	15.2	1.1	20	1	US-07-977-284A-89	Sequence 89, Appl
C 25	15.2	1.1	20	1	US-08-410-540-8	Sequence 89, Appl
C 26	15.2	1.1	20	1	US-08-256-426B-89	Sequence 8, Appl
27	15.2	1.1	20	1	US-09-661-753-55	Sequence 89, Appl
28	15.2	1.1	20	1	US-09-470-443-33	Sequence 55, Appl
29	15.2	1.1	20	1	US-09-470-443-43	Sequence 33, Appl
30	15.2	1.1	20	1	US-09-659-845A-168	Sequence 43, Appl
C 31	15.2	1.1	20	1	US-09-198-452A-1582	Sequence 168, App
C 32	15.2	1.1	20	1	US-09-198-452A-3952	Sequence 1582, Ap
C 33	15.2	1.1	21	1	US-08-276-852-49	Sequence 3952, Ap
						Sequence 49, Appl

C 253	12.6	0.9	15	1	US-08-882-649A-7	Sequence 7, Appl	326	12.2	0.9	17	1	US-08-444-733-104	Sequence 104, App
C 254	12.6	0.9	20	1	US-09-661-753-55	Sequence 55, Appl	C 327	12.2	0.9	17	1	US-08-710-134-49	Sequence 49, Appl
C 255	12.4	0.9	14	1	US-08-832-021-15	Sequence 15, Appl	C 328	12.2	0.9	17	1	US-08-292-620A-1644	Sequence 1644, Ap
C 256	12.4	0.9	14	1	US-08-985-162-1842	Sequence 1842, Ap	C 329	12.2	0.9	17	1	US-08-292-620A-1697	Sequence 1697, Ap
C 257	12.4	0.9	14	1	US-08-724-466B-12	Sequence 12, Appl	C 330	12.2	0.9	17	1	US-08-292-620A-1700	Sequence 1700, Ap
C 258	12.4	0.9	14	1	US-08-882-164D-12	Sequence 12, Appl	C 331	12.2	0.9	17	1	US-08-292-620A-1707	Sequence 1707, Ap
C 259	12.4	0.9	15	1	US-08-319-492B-23	Sequence 23, Appl	C 332	12.2	0.9	17	1	US-08-292-620A-1743	Sequence 1743, Ap
C 260	12.4	0.9	15	1	US-08-863-639A-7	Sequence 7, Appl	C 333	12.2	0.9	17	1	US-08-292-620A-1796	Sequence 1796, Ap
C 261	12.4	0.9	15	1	US-08-832-021-50	Sequence 50, Appl	C 334	12.2	0.9	17	1	US-08-292-620A-1873	Sequence 1873, Ap
C 262	12.4	0.9	15	1	US-08-832-021-51	Sequence 51, Appl	C 335	12.2	0.9	17	1	US-08-292-620A-1873	Sequence 1873, Ap
C 263	12.4	0.9	15	1	US-08-832-021-52	Sequence 52, Appl	C 336	12.2	0.9	17	1	US-08-485-885-49	Sequence 49, Appl
C 264	12.4	0.9	15	1	US-08-275-951-31	Sequence 31, Appl	C 337	12.2	0.9	17	1	US-08-464-134-104	Sequence 104, App
C 265	12.4	0.9	16	1	US-08-087-387-6	Sequence 6, Appl	C 338	12.2	0.9	17	1	US-08-461-361-104	Sequence 104, App
C 266	12.4	0.9	16	1	US-08-061-697-23	Sequence 23, Appl	C 339	12.2	0.9	17	1	US-08-485-910-104	Sequence 104, App
C 267	12.4	0.9	16	1	US-08-131-365B-23	Sequence 23, Appl	C 340	12.2	0.9	17	1	US-08-478-450A-62	Sequence 62, Appl
C 268	12.4	0.9	16	1	US-08-455-627-6	Sequence 6, Appl	C 341	12.2	0.9	17	1	US-08-798-738-10	Sequence 10, Appl
C 269	12.4	0.9	16	1	US-08-484-484A-4	Sequence 4, Appl	C 342	12.2	0.9	17	1	US-08-484-661A-17	Sequence 17, Appl
C 270	12.4	0.9	16	1	US-08-461-271-6	Sequence 6, Appl	C 343	12.2	0.9	17	1	US-08-181-664-64	Sequence 64, Appl
C 271	12.4	0.9	16	1	US-08-713-685A-6	Sequence 6, Appl	C 344	12.2	0.9	17	1	US-08-985-162-85	Sequence 85, Appl
C 272	12.4	0.9	16	1	US-08-689-856-6	Sequence 6, Appl	C 345	12.2	0.9	17	1	US-08-985-162-104	Sequence 104, App
C 273	12.4	0.9	16	1	US-08-668-123-23	Sequence 23, Appl	C 346	12.2	0.9	17	1	US-08-985-162-237	Sequence 237, App
C 274	12.4	0.9	16	1	US-09-070-477-6	Sequence 6, Appl	C 347	12.2	0.9	17	1	US-08-985-162-293	Sequence 293, App
C 275	12.4	0.9	16	1	5256545-4	Sequence 6, Appl	C 348	12.2	0.9	17	1	US-08-656-664-17	Sequence 17, Appl
C 276	12.4	0.9	16	1	5256545-33	Patent No. 5256545	C 349	12.2	0.9	17	1	US-08-998-099-82	Sequence 82, Appl
C 277	12.4	0.9	16	1	US-08-373-124A-338	Sequence 338, App	C 350	12.2	0.9	17	1	US-09-071-845-1644	Sequence 1644, Ap
C 278	12.4	0.9	17	1	US-08-373-124A-2047	Sequence 2047, Ap	C 351	12.2	0.9	17	1	US-09-071-845-1597	Sequence 1597, Ap
C 279	12.4	0.9	17	1	US-08-373-124A-2049	Sequence 2049, Ap	C 352	12.2	0.9	17	1	US-09-071-845-1700	Sequence 1700, Ap
C 280	12.4	0.9	17	1	US-08-261-822A-30	Sequence 30, Appl	C 353	12.2	0.9	17	1	US-09-071-845-1707	Sequence 1707, Ap
C 281	12.4	0.9	17	1	US-08-435-628-338	Sequence 338, App	C 354	12.2	0.9	17	1	US-09-071-845-1743	Sequence 1743, Ap
C 282	12.4	0.9	17	1	US-08-435-628-2047	Sequence 2047, Ap	C 355	12.2	0.9	17	1	US-09-071-845-1796	Sequence 1796, Ap
C 283	12.4	0.9	17	1	US-08-435-628-2049	Sequence 2049, Ap	C 356	12.2	0.9	17	1	US-09-071-845-1873	Sequence 1873, Ap
C 284	12.4	0.9	17	1	US-08-485-611A-9	Sequence 9, Appl	C 357	12.2	0.9	17	1	US-09-071-845-1934	Sequence 1934, Ap
C 285	12.4	0.9	17	1	US-08-985-162-118	Sequence 118, App	C 358	12.2	0.9	17	1	US-08-961-810-104	Sequence 104, App
C 286	12.4	0.9	17	1	US-08-985-162-119	Sequence 119, App	C 359	12.2	0.9	17	1	US-08-352-902D-104	Sequence 104, App
C 287	12.4	0.9	17	1	US-08-998-099-95	Sequence 95, Appl	C 360	12.2	0.9	17	1	US-08-983-466-93	Sequence 93, Appl
C 288	12.4	0.9	17	1	US-09-017-974-79	Sequence 79, Appl	C 361	12.2	0.9	17	1	US-09-021-701-53	Sequence 53, Appl
C 289	12.4	0.9	17	1	US-08-682-255A-79	Sequence 79, Appl	C 362	12.2	0.9	17	1	US-09-021-701-111	Sequence 111, App
C 290	12.4	0.9	17	1	US-08-584-040-2256	Sequence 2256, Ap	C 363	12.2	0.9	17	1	US-09-338-907-84	Sequence 84, Appl
C 291	12.4	0.9	17	1	US-08-584-040-2547	Sequence 2547, Ap	C 364	12.2	0.9	17	1	US-08-584-040-1909	Sequence 1909, Ap
C 292	12.4	0.9	17	1	US-08-584-040-2548	Sequence 2548, Ap	C 365	12.2	0.9	17	1	US-08-584-040-1922	Sequence 1922, Ap
C 293	12.4	0.9	17	1	US-08-584-040-2549	Sequence 2549, Ap	C 366	12.2	0.9	17	1	US-08-584-040-2028	Sequence 2028, Ap
C 294	12.4	0.9	17	1	US-08-584-040-2550	Sequence 2550, Ap	C 367	12.2	0.9	17	1	US-08-584-040-2224	Sequence 2224, Ap
C 295	12.4	0.9	17	1	US-08-584-040-6008	Sequence 6008, Ap	C 368	12.2	0.9	17	1	US-08-584-040-2554	Sequence 2554, Ap
C 296	12.4	0.9	17	1	US-08-584-040-6009	Sequence 6009, Ap	C 369	12.2	0.9	17	1	US-08-584-040-3739	Sequence 3739, Ap
C 297	12.4	0.9	17	1	US-08-679-645-139	Sequence 139, App	C 370	12.2	0.9	17	1	US-08-584-040-3840	Sequence 3840, Ap
C 298	12.4	0.9	17	1	US-09-429-130-79	Sequence 79, Appl	C 371	12.2	0.9	17	1	US-08-584-040-3911	Sequence 3911, Ap
C 299	12.4	0.9	17	1	US-09-788-338-3	Sequence 3, Appl	C 372	12.2	0.9	17	1	US-08-584-040-3912	Sequence 3912, Ap
C 300	12.4	0.9	17	1	US-09-300-958A-64	Sequence 64, Appl	C 373	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 301	12.4	0.9	17	1	US-09-474-432B-409	Sequence 409, App	C 374	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 302	12.4	0.9	17	1	US-09-474-432B-421	Sequence 421, App	C 375	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 303	12.4	0.9	17	1	US-09-474-432B-557	Sequence 557, App	C 376	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 304	12.4	0.9	17	1	US-09-474-432B-815	Sequence 815, App	C 377	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 305	12.4	0.9	17	1	US-09-371-772B-801	Sequence 801, App	C 378	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 306	12.4	0.9	17	1	US-09-371-772B-1071	Sequence 1071, Ap	C 379	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 307	12.4	0.9	17	1	US-09-371-772B-1072	Sequence 1072, Ap	C 380	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 308	12.4	0.9	17	1	US-09-371-772B-1073	Sequence 1073, Ap	C 381	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 309	12.4	0.9	17	1	US-09-371-772B-1074	Sequence 1074, Ap	C 382	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 310	12.4	0.9	17	1	US-09-371-772B-1075	Sequence 1075, Ap	C 383	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 311	12.4	0.9	17	1	US-09-371-772B-2845	Sequence 2845, Ap	C 384	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 312	12.4	0.9	17	1	US-09-371-772B-2846	Sequence 2846, Ap	C 385	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 313	12.4	0.9	17	1	US-09-371-772B-5053	Sequence 5053, Ap	C 386	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 314	12.4	0.9	17	1	US-09-371-772B-5054	Sequence 5054, Ap	C 387	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 315	12.4	0.9	17	1	US-09-371-772B-5055	Sequence 5055, Ap	C 388	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 316	12.4	0.9	17	1	US-09-371-772B-6554	Sequence 6554, Ap	C 389	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 317	12.4	0.9	17	1	PCT-US95-07744A-30	Sequence 30, Appl	C 390	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 318	12.2	0.9	17	1	US-09-371-772B-5055	Sequence 5055, Ap	C 391	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 319	12.2	0.9	17	1	US-08-281-940-49	Sequence 49, Appl	C 392	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 320	12.2	0.9	17	1	US-08-390-850-589	Sequence 589, App	C 393	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 321	12.2	0.9	17	1	US-08-390-850-590	Sequence 590, App	C 394	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 322	12.2	0.9	17	1	US-08-390-850-592	Sequence 592, App	C 395	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 323	12.2	0.9	17	1	US-08-435-634-589	Sequence 589, App	C 396	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 324	12.2	0.9	17	1	US-08-435-634-590	Sequence 590, App	C 397	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 325	12.2	0.9	17	1	US-08-435-634-592	Sequence 592, App	C 398	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
					Sequence 104, App								

399	12.2	0.9	17	1	US-09-371-772B-1607	Sequence 1607, Ap	C 472	11.8	0.9	15	1	US-08-471-033-34	Sequence 34, Appl
400	12.2	0.9	17	1	US-09-371-772B-1678	Sequence 1678, Ap	C 473	11.8	0.9	15	1	US-08-292-620A-74	Sequence 74, Appl
401	12.2	0.9	17	1	US-09-371-772B-1679	Sequence 1679, Ap	C 474	11.8	0.9	15	1	US-08-292-620A-105	Sequence 105, App
C 402	12.2	0.9	17	1	US-09-371-772B-2697	Sequence 2697, Ap	C 475	11.8	0.9	15	1	US-08-292-620A-393	Sequence 393, App
C 403	12.2	0.9	17	1	US-09-371-772B-2764	Sequence 2764, Ap	C 476	11.8	0.9	15	1	US-08-292-620A-656	Sequence 656, App
C 404	12.2	0.9	17	1	US-09-371-772B-3069	Sequence 3069, Ap	C 477	11.8	0.9	15	1	US-08-471-044-34	Sequence 34, Appl
C 405	12.2	0.9	17	1	US-09-371-772B-3213	Sequence 3213, Ap	C 478	11.8	0.9	15	1	US-08-463-483A-34	Sequence 34, Appl
406	12.2	0.9	17	1	US-09-371-772B-3387	Sequence 3387, Ap	C 479	11.8	0.9	15	1	US-08-173-489C-61	Sequence 61, Appl
407	12.2	0.9	17	1	US-09-371-772B-3660	Sequence 3660, Ap	C 480	11.8	0.9	15	1	US-08-173-489C-87	Sequence 87, Appl
408	12.2	0.9	17	1	US-09-371-772B-4161	Sequence 4161, Ap	C 481	11.8	0.9	15	1	US-08-471-046A-34	Sequence 34, Appl
C 409	12.2	0.9	17	1	US-09-371-772B-4457	Sequence 4457, Ap	C 482	11.8	0.9	15	1	US-08-774-306A-201	Sequence 201, App
C 410	12.2	0.9	17	1	US-09-371-772B-4643	Sequence 4643, Ap	C 483	11.8	0.9	15	1	US-08-470-568B-34	Sequence 34, Appl
C 411	12.2	0.9	17	1	US-09-371-772B-4722	Sequence 4722, Ap	C 484	11.8	0.9	15	1	US-08-585-684B-775	Sequence 775, App
C 412	12.2	0.9	17	1	US-09-371-772B-5116	Sequence 5116, Ap	C 485	11.8	0.9	15	1	US-08-585-684B-776	Sequence 776, App
C 413	12.2	0.9	17	1	US-09-371-772B-5579	Sequence 5579, Ap	C 486	11.8	0.9	15	1	US-08-585-684B-1365	Sequence 1365, Ap
414	12.2	0.9	17	1	US-09-371-772B-6296	Sequence 6296, Ap	C 487	11.8	0.9	15	1	US-08-585-684B-1376	Sequence 1376, Ap
C 415	12.2	0.9	17	1	US-09-371-772B-6439	Sequence 6439, Ap	C 488	11.8	0.9	15	1	US-08-585-684B-2270	Sequence 2270, Ap
C 416	12.2	0.9	17	1	US-09-371-772B-6624	Sequence 6624, Ap	C 489	11.8	0.9	15	1	US-08-854-041-4	Sequence 4, Appl
C 417	12.2	0.9	17	1	US-09-371-772B-6701	Sequence 6701, Ap	C 490	11.8	0.9	15	1	US-08-485-133-7	Sequence 7, Appl
418	12.2	0.9	17	1	PCT-US95-06266-87	Sequence 87, Appl	C 491	11.8	0.9	15	1	US-08-469-334-34	Sequence 34, Appl
419	12.2	0.9	17	1	PCT-US96-09641-17	Sequence 17, Appl	C 492	11.8	0.9	15	1	US-08-343-998-24	Sequence 24, Appl
C 420	12.2	0.9	18	1	US-08-584-040-3044	Sequence 3044, Ap	C 493	11.8	0.9	15	1	US-08-832-021-25	Sequence 25, Appl
C 421	12.2	0.9	18	1	US-09-371-772B-1472	Sequence 1472, Ap	C 494	11.8	0.9	15	1	US-08-832-021-37	Sequence 37, Appl
C 422	12.2	0.9	18	1	US-08-214-603-11	Sequence 11, Appl	C 495	11.8	0.9	15	1	US-08-832-021-41	Sequence 41, Appl
C 423	12.2	0.9	13	1	US-08-242-664-14	Sequence 14, Appl	C 496	11.8	0.9	15	1	US-08-832-021-43	Sequence 43, Appl
C 424	12.2	0.9	13	1	US-08-484-138-14	Sequence 14, Appl	C 497	11.8	0.9	15	1	US-08-832-021-45	Sequence 45, Appl
C 425	12.2	0.9	13	1	PCT-US95-06379-14	Sequence 14, Appl	C 498	11.8	0.9	15	1	US-08-832-021-47	Sequence 47, Appl
426	12.2	0.9	14	1	US-08-146-010A-8	Sequence 8, Appl	C 499	11.8	0.9	15	1	US-08-832-021-61	Sequence 61, Appl
C 427	12.2	0.9	14	1	US-08-683-839B-15	Sequence 15, Appl	C 500	11.8	0.9	15	1	US-09-300-529-34	Sequence 34, Appl
428	12.2	0.9	14	1	US-08-674-168-10	Sequence 10, Appl	C 501	11.8	0.9	15	1	US-09-064-156A-201	Sequence 201, App
429	12.2	0.9	14	1	US-08-846-021A-14	Sequence 14, Appl	C 502	11.8	0.9	15	1	US-09-071-845-74	Sequence 74, Appl
430	12.2	0.9	15	1	US-08-365-189-10	Sequence 10, Appl	C 503	11.8	0.9	15	1	US-09-071-845-105	Sequence 105, App
C 431	12.2	0.9	15	1	US-08-208-886C-29	Sequence 29, Appl	C 504	11.8	0.9	15	1	US-09-071-845-393	Sequence 393, App
C 432	12.2	0.9	15	1	US-08-704-744-29	Sequence 29, Appl	C 505	11.8	0.9	15	1	US-09-071-845-656	Sequence 656, App
C 433	12.2	0.9	15	1	US-08-469-557-29	Sequence 29, Appl	C 506	11.8	0.9	15	1	US-09-038-073-775	Sequence 775, App
C 434	12.2	0.9	15	1	US-08-290-793B-29	Sequence 29, Appl	C 507	11.8	0.9	15	1	US-09-038-073-776	Sequence 776, App
435	12.2	0.9	15	1	US-08-606-505B-62	Sequence 62, Appl	C 508	11.8	0.9	15	1	US-09-038-073-1365	Sequence 1365, Ap
436	12.2	0.9	15	1	US-09-115-446-3	Sequence 3, Appl	C 509	11.8	0.9	15	1	US-09-038-073-1376	Sequence 1376, Ap
C 437	12.2	0.9	15	1	US-09-177-359-26	Sequence 26, Appl	C 510	11.8	0.9	15	1	US-09-038-073-2270	Sequence 2270, Ap
438	12.2	0.9	15	1	US-09-616-990-62	Sequence 62, Appl	C 511	11.8	0.9	15	1	US-09-275-850-19	Sequence 19, Appl
C 439	12.2	0.9	15	1	US-08-812-951B-1	Sequence 1, Appl	C 512	11.8	0.9	15	1	US-09-344-888A-9	Sequence 9, Appl
C 440	12.2	0.9	15	1	US-08-812-951B-2	Sequence 2, Appl	C 513	11.8	0.9	15	1	US-09-081-646-513	Sequence 513, App
C 441	12.2	0.9	15	1	US-08-784-747-2	Sequence 2, Appl	C 514	11.8	0.9	15	1	US-09-081-646-616	Sequence 616, App
442	12.2	0.9	15	1	US-08-784-747-3	Sequence 3, Appl	C 515	11.8	0.9	15	1	US-09-011-336-23	Sequence 23, Appl
443	12.2	0.9	15	1	US-09-409-778-9	Sequence 9, Appl	C 516	11.8	0.9	15	1	PCT-US94-06331A-9	Sequence 9, Appl
C 444	12.2	0.9	15	1	US-09-409-778-10	Sequence 10, Appl	C 517	11.8	0.9	15	1	5182195-24	Patent No. 5182195
C 445	12.2	0.9	16	1	US-08-232-087A-5	Sequence 5, Appl	C 518	11.8	0.9	16	1	US-07-988-194A-16	Sequence 16, Appl
446	12.2	0.9	16	1	US-08-882-649A-8	Sequence 8, Appl	C 519	11.8	0.9	16	1	US-08-233-030-52	Sequence 52, Appl
447	12.2	0.9	17	1	US-08-758-306-649	Sequence 649, App	C 520	11.8	0.9	16	1	US-08-291-932A-780	Sequence 780, App
448	12.2	0.9	17	1	US-09-328-501-14	Sequence 14, Appl	C 521	11.8	0.9	16	1	US-08-291-932A-814	Sequence 814, App
449	12.2	0.9	17	1	US-08-984-709A-45	Sequence 45, Appl	C 522	11.8	0.9	16	1	US-08-258-152-18	Sequence 18, Appl
C 450	12.2	0.9	17	1	US-08-584-040-1844	Sequence 1844, Ap	C 523	11.8	0.9	16	1	US-08-241-465B-17	Sequence 17, Appl
C 451	12.2	0.9	17	1	US-08-584-040-7538	Sequence 7538, Ap	C 524	11.8	0.9	16	1	US-08-465-485A-16	Sequence 16, Appl
C 452	12.2	0.9	17	1	US-09-537-720B-15	Sequence 15, Appl	C 525	11.8	0.9	16	1	US-08-076-299A-18	Sequence 18, Appl
C 453	12.2	0.9	17	1	US-08-937-067-17	Sequence 17, Appl	C 526	11.8	0.9	16	1	US-08-527-060-2	Sequence 2, Appl
454	12.2	0.9	17	1	US-09-777-710A-14	Sequence 14, Appl	C 527	11.8	0.9	16	1	US-08-527-060-12	Sequence 12, Appl
C 455	12.2	0.9	17	1	US-09-371-772B-389	Sequence 389, App	C 528	11.8	0.9	16	1	US-08-292-620A-1628	Sequence 1628, Ap
C 456	12.2	0.9	17	1	US-09-371-772B-4638	Sequence 4638, Ap	C 529	11.8	0.9	16	1	US-08-438-582-18	Sequence 18, Appl
457	12.2	0.9	17	1	PCT-US91-03680-7	Sequence 7, Appl	C 530	11.8	0.9	16	1	US-08-137-024-2	Sequence 2, Appl
458	11.8	0.9	15	1	US-08-041-599-2	Sequence 2, Appl	C 531	11.8	0.9	16	1	US-08-137-024-2	Sequence 2, Appl
459	11.8	0.9	15	1	US-08-127-954-50	Sequence 50, Appl	C 532	11.8	0.9	16	1	US-08-817-145-8	Sequence 8, Appl
460	11.8	0.9	15	1	US-08-337-025-2	Sequence 2, Appl	C 533	11.8	0.9	16	1	US-09-071-845-16	Sequence 16, Appl
461	11.8	0.9	15	1	US-08-276-099A-8	Sequence 8, Appl	C 534	11.8	0.9	16	1	US-09-080-285-16	Sequence 16, Appl
C 462	11.8	0.9	15	1	US-08-182-968A-201	Sequence 201, App	C 535	11.8	0.9	16	1	US-09-266-596-18	Sequence 18, Appl
C 463	11.8	0.9	15	1	US-08-291-932A-33	Sequence 33, Appl	C 536	11.8	0.9	16	1	US-08-479-737-16	Sequence 16, Appl
C 464	11.8	0.9	15	1	US-08-291-932A-378	Sequence 378, App	C 537	11.8	0.9	16	1	US-08-679-645-523	Sequence 523, App
465	11.8	0.9	15	1	US-08-334-847-570	Sequence 570, App	C 538	11.8	0.9	16	1	US-08-475-442A-16	Sequence 16, Appl
466	11.8	0.9	15	1	US-08-334-847-606	Sequence 606, App	C 539	11.8	0.9	16	1	US-09-724-426-16	Sequence 16, Appl
467	11.8	0.9	15	1	US-08-334-847-631	Sequence 631, App	C 540	11.8	0.9	16	1	US-08-535-249-97	Sequence 97, Appl
468	11.8	0.9	15	1	US-08-363-240A-142	Sequence 142, App	C 541	11.8	0.9	16	1	US-09-916-228-4	Sequence 14, Appl
C 469	11.8	0.9	15	1	US-08-363-240A-541	Sequence 541, App	C 542	11.8	0.9	16	1	US-09-944-411-18	Sequence 18, Appl
C 470	11.8	0.9	15	1	US-08-363-240A-658	Sequence 658, App	C 543	11.8	0.9	16	1	US-08-754-477A-38	Sequence 38, Appl
471	11.8	0.9	15	1	US-08-781-890-8	Sequence 8, Appl	C 544	11.8	0.9	16	1	US-09-060-299-420	Sequence 420, App

545 11.8 0.9 16 1 US-09-402-923A-420 Sequence 420, App
546 11.8 0.9 16 1 US-09-371-772B-5660 Sequence 5660, Ap
547 11.8 0.9 16 1 US-09-371-772B-5661 Sequence 5661, Ap
c 548 11.8 0.9 16 1 PCT-US96-00331-19 Sequence 19, Appl
549 11.6 0.9 18 1 US-08-702-105A-33 Sequence 33, Appl
550 11.6 0.9 18 1 US-08-702-110A-33 Sequence 33, Appl

ALIGNMENTS

RESULT 1

US-09-302-681-65
; Sequence 65, Application US/09302681
; Patent No. 6441149
; GENERAL INFORMATION:
; APPLICANT: HerrinStadt, Corrina
; APPLICANT: Ghosh, Soumitra S.
; APPLICANT: Clevenger, William
; APPLICANT: Fahy, Eoin F.
; APPLICANT: Davis, Robert E.
; TITLE OF INVENTION: DIAGNOSTIC METHOD BASED ON
; TITLE OF INVENTION: QUANTIFICATION OF EXTRAMITOCHONDRIAL DNA
; FILE REFERENCE: 660088.416C1
; CURRENT APPLICATION NUMBER: US/09/302,681
; CURRENT FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 65
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer corresponding to NADH
; OTHER INFORMATION: dehydrogenase encoding mitochondrial DNA
US-09-302-681-65

Query Match 1.6%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.5;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 34 AGCTACGCAAAATCTTAGCATA 55
|||||
Db 1 AGCTACGCAAAATCTTAGCATA 22

RESULT 2

US-09-667-135-7/c
; Sequence 7, Application US/09667135
; Patent No. 6521749
; GENERAL INFORMATION:
; APPLICANT: Vincent Ling
; APPLICANT: Kyriaki Dunussi-Joannopoulos
; TITLE OF INVENTION: NOVEL GL50 MOLECULES AND USES THEREFOR
; FILE REFERENCE: GNN-007
; CURRENT APPLICATION NUMBER: US/09/667,135
; CURRENT FILING DATE: 2000-09-21
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-667-135-7

Query Match 1.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 21;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 944 GGTGTGAGCGCAGACTGCAGG 964
|||||

Db 21 GGTGCGAGCGCAGACTGCGGG 1

RESULT 3

US-08-249-037C-16/c
; Sequence 16, Application US/08249037C
; Patent No. 5929317
; GENERAL INFORMATION:
; APPLICANT: Kilburn, Douglas G.
; APPLICANT: Miller, Robert C.
; APPLICANT: Warren, Richard A.J.
; APPLICANT: Gilkes, Neil R.
; TITLE OF INVENTION: Polysaccharide binding fusion proteins
; TITLE OF INVENTION: and conjugates
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rae-Venter Law Group, P.C.
; STREET: P.O.Box 60039
; CITY: Palo Alto
; STATE: CA
; COUNTRY: U.S.
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/249,037C
; FILING DATE: 24-MAY-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/865,095
; FILING DATE: 08-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/603,987
; FILING DATE: 25-OCT-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/216,794
; FILING DATE: 08-JUL-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Kung, Viola T.
; REGISTRATION NUMBER: 41,131
; REFERENCE/DOCKET NUMBER: CBDT.002.04US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650)328-4400
; TELEFAX: (650)328-4477
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-249-037C-16

Query Match 1.3%; Score 17.6; DB 1; Length 24;
Best Local Similarity 83.3%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 188 CCGCGCGCCCGCGCGCGCGG 211
|||||

Db 24 CCGACCCCGCCCGCGCGCGG 1

RESULT 4

US-08-788-622B-16/c
; Sequence 16, Application US/08788622B
; Patent No. 5962289
; GENERAL INFORMATION:
; APPLICANT: Kilburn, Douglas G.
; APPLICANT: Miller, Robert C.
; APPLICANT: Warren, Richard A.J.

APPLICANT: Gilkes, Neil R.
TITLE OF INVENTION: Polysaccharide binding fusion proteins
TITLE OF INVENTION: and conjugates
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Rae-Venter Law Group, P.C.
STREET: P.O.Box 60039
CITY: Palo Alto
STATE: CA
COUNTRY: U.S.
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/788,622B
FILING DATE: January 23, 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/249,037
FILING DATE: 24-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/865,095
FILING DATE: 08-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/603,987
FILING DATE: 25-OCT-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/216,794
FILING DATE: 08-JUL-1988
ATTORNEY/AGENT INFORMATION:
NAME: Kung, Viola T.
REGISTRATION NUMBER: 41,131
REFERENCE/DOCKET NUMBER: CBDT.002.06US
TELEPHONE: (650)328-4400
TELEFAX: (650)328-4477
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-788-622B-16

Query Match 1.3%; Score 17.6; DB 1; Length 24;
Best Local Similarity 83.3%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 188 CCGCGCCGCCACCGGAGCGGAGC 211
Db 24 CCGACCCCGCCACCGGAGCGGAGC 1

RESULT 5
US-08-788-621B-16/c
Sequence 16, Application US/08788621B
Patent No. 6124117
GENERAL INFORMATION:
APPLICANT: Kilburn, Douglas G.
APPLICANT: Miller, Robert C.
APPLICANT: Warren, Richard A.J.
APPLICANT: Gilkes, Neil R.
TITLE OF INVENTION: Polysaccharide binding fusion proteins
TITLE OF INVENTION: and conjugates
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Rae-Venter Law Group, P.C.
STREET: P.O.Box 60039
CITY: Palo Alto
STATE: CA

COUNTRY: U.S.
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/788,621B
FILING DATE: January 23, 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/249,037
FILING DATE: 24-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/865,095
FILING DATE: 08-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/603,987
FILING DATE: 25-OCT-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/216,794
FILING DATE: 08-JUL-1988
ATTORNEY/AGENT INFORMATION:
NAME: Kung, Viola T.
REGISTRATION NUMBER: 41,131
REFERENCE/DOCKET NUMBER: CBDT.002.05US
TELEPHONE: (650)328-4400
TELEFAX: (650)328-4477
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-788-621B-16

Query Match 1.3%; Score 17.6; DB 1; Length 24;
Best Local Similarity 83.3%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 188 CCGCGCCGCCACCGGAGCGGAGC 211
Db 24 CCGACCCCGCCACCGGAGCGGAGC 1

RESULT 6
US-08-052-997-22
Sequence 22, Application US/08052997
Patent No. 5556786
GENERAL INFORMATION:
APPLICANT: Kere, Juha
APPLICANT: Schlessinger, David
APPLICANT: de la Chapelle, Albert
TITLE OF INVENTION: ANHIDROTIC ECTODERMAL DYSPLASIA GENE
TITLE OF INVENTION: AND METHOD OF DETECTING SAME
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: POPHAM HAIK SCHNOBRICH & KAUFMAN, LTD.
STREET: 1225 Eye Street N.W., Suite 1000
CITY: Washington, D.C.
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/052,997
FILING DATE: 27-APR-1993
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: O'Shaughnessy, Brian P.
REGISTRATION NUMBER: 32,747
REFERENCE/DOCKET NUMBER: 9594/81-2189
TELEPHONE: (202) 289-1200
TELEFAX: (202) 289-6674
TELEPHONE: (202) 289-1200
TELEFAX: (202) 289-6674
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
IMMEDIATE SOURCE:
CLONE: Yeast artificial chromosome
US-08-052-997-22

Query Match 1.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 35;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 78 TGAATAATAGCAGTTCTACC 97
|||||
DB 2 TGAATAATAGCAGTTCTGCC 21

RESULT 7

US-08-684-672-22
Sequence 22, Application US/08684672
Patent No. 5700926
GENERAL INFORMATION:

APPLICANT: KERE, Juha
APPLICANT: SCHLESSINGER, David
APPLICANT: de la CHAPELLE, Albert
APPLICANT: SRIVASTAVA, Anand Kumar
TITLE OF INVENTION: MOLECULAR CLONING OF THE ANHIDROTIC
TITLE OF INVENTION: ECTODERMAL DYSPLASIA GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/684,672
FILING DATE: 22-JUL-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/052,997
FILING DATE: 27-APR-1993

ATTORNEY/AGENT INFORMATION:
NAME: O'Shaughnessy, Brian P.
REGISTRATION NUMBER: 32,747
REFERENCE/DOCKET NUMBER: 030956-002
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-684-672-22

Query Match 1.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 35;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 78 TGAATAATAGCAGTTCTACC 97
|||||
DB 2 TGAATAATAGCAGTTCTGCC 21

RESULT 8

US-09-244-794A-29
Sequence 29, Application US/09244794A
Patent No. 6214553
GENERAL INFORMATION:

APPLICANT: Szostak, Jack W.
APPLICANT: Roberts, Richard W.
APPLICANT: Liu, Rihe
TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
TITLE OF INVENTION: FUSIONS
FILE REFERENCE: 00786/350006
CURRENT APPLICATION NUMBER: US/09/244,794A
CURRENT FILING DATE: 1999-02-05
PRIOR APPLICATION NUMBER: 60/035,963
PRIOR FILING DATE: 1997-01-27
PRIOR APPLICATION NUMBER: 60/064,491
PRIOR FILING DATE: 1997-11-06
PRIOR APPLICATION NUMBER: 09/007,005
PRIOR FILING DATE: 1998-01-14
NUMBER OF SEQ ID NOS: 33
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 29
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-09-244-794A-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGTGGAGCCAG 696
|||||
DB 1 GTGGTATTGTGGAGCCAG 18

RESULT 9

US-09-007-005-29
Sequence 29, Application US/09007005B
Patent No. 6258558
GENERAL INFORMATION:

APPLICANT: Szostak, Jack W.
APPLICANT: Roberts, Richard W.
APPLICANT: Liu, Rihe
TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
TITLE OF INVENTION: FUSIONS
FILE REFERENCE: 00786/350003
CURRENT APPLICATION NUMBER: US/09/007,005B
CURRENT FILING DATE: 1998-01-14
EARLIER APPLICATION NUMBER: 60/035,963
EARLIER FILING DATE: 1997-01-27
EARLIER APPLICATION NUMBER: 60/064,491
EARLIER FILING DATE: 1997-11-06
NUMBER OF SEQ ID NOS: 33
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 29
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens

US-09-007-005-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCCAG 696
|||||
Db 1 GTGGTATTGGAGCCAG 18

RESULT 10

US-09-247-190-29
; Sequence 29, Application US/09247190
; Patent No. 6261804
; GENERAL INFORMATION:
; APPLICANT: Szostak, Jack W.
; APPLICANT: Roberts, Richard W.
; APPLICANT: Liu, Rihe
; TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
; TITLE OF INVENTION: FUSIONS
; FILE REFERENCE: 00786/350005
; CURRENT APPLICATION NUMBER: US/09/247,190
; CURRENT FILING DATE: 1999-02-09
; EARLIER APPLICATION NUMBER: 60/035,963
; EARLIER FILING DATE: 1997-01-21
; EARLIER APPLICATION NUMBER: 60/064,491
; EARLIER FILING DATE: 1997-11-06
; EARLIER APPLICATION NUMBER: 09/007,005
; EARLIER FILING DATE: 1998-01-14
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-247-190-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCCAG 696
|||||
Db 1 GTGGTATTGGAGCCAG 18

RESULT 11

US-09-244-796-29
; Sequence 29, Application US/09244796
; Patent No. 6281344
; GENERAL INFORMATION:
; APPLICANT: Szostak, Jack W.
; APPLICANT: Roberts, Richard W.
; APPLICANT: Liu, Rihe
; TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
; TITLE OF INVENTION: FUSIONS
; FILE REFERENCE: 00786/350007
; CURRENT APPLICATION NUMBER: US/09/244,796
; CURRENT FILING DATE: 1999-02-05
; EARLIER APPLICATION NUMBER: 60/035,963
; EARLIER FILING DATE: 1997-01-27
; EARLIER APPLICATION NUMBER: 60/064,491
; EARLIER FILING DATE: 1997-11-06
; EARLIER APPLICATION NUMBER: 09/007,005
; EARLIER FILING DATE: 1998-01-14
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-244-796-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCCAG 696
|||||
Db 1 GTGGTATTGGAGCCAG 18

RESULT 12

US-09-238-710-29
; Sequence 29, Application US/09238710A
; Patent No. 6518018
; GENERAL INFORMATION:
; APPLICANT: Szostak, Jack W.
; APPLICANT: Roberts, Richard W.
; APPLICANT: Liu, Rihe
; TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
; TITLE OF INVENTION: FUSIONS
; FILE REFERENCE: 00786/350004
; CURRENT APPLICATION NUMBER: US/09/238,710A
; CURRENT FILING DATE: 1999-01-28
; EARLIER APPLICATION NUMBER: 60/035,963
; EARLIER FILING DATE: 1997-01-27
; EARLIER APPLICATION NUMBER: 60/064,491
; EARLIER FILING DATE: 1997-11-06
; EARLIER APPLICATION NUMBER: 09/007,005
; EARLIER FILING DATE: 1998-01-14
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-238-710-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCCAG 696
|||||
Db 1 GTGGTATTGGAGCCAG 18

RESULT 13

US-09-302-681-76/c
; Sequence 76, Application US/09302681
; Patent No. 6441149
; GENERAL INFORMATION:
; APPLICANT: HerinStadt, Corrina
; APPLICANT: Ghosh, Soumitra S.
; APPLICANT: Clevenger, William
; APPLICANT: Fahy, Eoin P.
; APPLICANT: Davis, Robert E.
; TITLE OF INVENTION: DIAGNOSTIC METHOD BASED ON
; TITLE OF INVENTION: QUANTIFICATION OF EXTRAMITOCHONDRIAL DNA
; FILE REFERENCE: 660088.416C1
; CURRENT APPLICATION NUMBER: US/09/302,681
; CURRENT FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 76
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer corresponding to NADH
; OTHER INFORMATION: dehydrogenase encoding mitochondrial DNA
US-09-302-681-76

Query Match 1.2%; Score 16.2; DB 1; Length 21;

```
Best Local Similarity 85.7%; Pred. No. 48;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 51 GCATCTCTCTCAATACCCAC 71
    ||||| ||||| ||||| |||||
Db 21 GCATCTCTCTCAATACCCAC 1

RESULT 14
US-08-709-731A-5/c
; Sequence 5, Application US/08709731A
; Patent No. 6322780
; GENERAL INFORMATION:
; APPLICANT: Lee, Lucy F
; APPLICANT: Nazerian, Keyvan
; APPLICANT: Witter, Richard L
; APPLICANT: Wu, Ping
; APPLICANT: Yanagida, No. 6322780oru
; TITLE OF INVENTION: Marek's Disease Virus Genes and Their
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch and Birch, LLP
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: VA
; COUNTRY: US
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/709,731A
; FILING DATE: 05-JUL-1996
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: U.S. 08/499,474
; FILING DATE: 07-JULY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 1644-110PPC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)-205-8000
; TELEFAX: (703) 205-8050
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-709-731A-5

Query Match 1.2%; Score 15.2; DB 1; Length 23;
Best Local Similarity 85.7%; Pred. No. 60;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 519 CAACCTGCCGGAGGAGCAGCT 539
    ||||| ||||| ||||| |||||
Db 21 CAACCTGCCGGGGGGGAGCT 1

RESULT 15
US-09-136-959A-6
; Sequence 6, Application US/09136959A
; Patent No. 6248522
; GENERAL INFORMATION:
; APPLICANT: HABERHAUSEN, Gerd
```

```
; APPLICANT: JOGER, Stephan
; APPLICANT: SOBEK, Harald
; TITLE OF INVENTION: REDUCTION OF CROSS-CONTAMINATIONS IN NUCLEIC ACID
; FILE REFERENCE: 1614-8065
; CURRENT APPLICATION NUMBER: US/09/136,959A
; CURRENT FILING DATE: 1998-08-20
; PRIOR APPLICATION NUMBER: DE 197 36 062.9
; PRIOR FILING DATE: 1997-08-20
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Primer
US-09-136-959A-6

Query Match 1.2%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 274 ATCAAGAGGAAGCAGCAG 292
    ||||| ||||| ||||| |||||
Db 1 ATCAATGAGGAGCTGCAG 19

RESULT 16
US-09-556-031-2/c
; Sequence 2, Application US/09556031
; Patent No. 6350868
; GENERAL INFORMATION:
; APPLICANT: Weston, Brent W.
; APPLICANT: Hiller, Kara B.
; TITLE OF INVENTION: Antisense Fucosyltransferase Sequences and Methods of
; FILE REFERENCE: Weston and Hiller
; CURRENT APPLICATION NUMBER: US/09/556,031
; CURRENT FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: 60/131,068
; PRIOR FILING DATE: 1999-04-26
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:antisense
; OTHER INFORMATION: oligonucleotide
US-09-556-031-2

Query Match 1.2%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1322 CTTTGTAGATCTTGTCTT 1340
    ||||| ||||| ||||| |||||
Db 19 CTTTGTAGATCTTCACTT 1

RESULT 17
US-09-702-246-25/c
; Sequence 25, Application US/09702246
; Patent No. 6383809
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF CYTOKINESIN-1 EXPRESSION
; FILE REFERENCE: RTS-0195
; CURRENT APPLICATION NUMBER: US/09/702,246
; CURRENT FILING DATE: 2000-10-30
```


COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/680,326
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Schiff, J. Michael
REGISTRATION NUMBER: 40,253
REFERENCE/DOCKET NUMBER: 29938-20001.00
TELEPHONE: (415) 813-5600
TELEFAX: (415) 494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 140:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-680-326-140

Query Match 1.1%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 72;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TGCTCCAGCAGGCCCTC 585
DB 17 TCCTCCAGCAGGCCCTC 1

RESULT 22
US-08-804-439A-89/c
Sequence 89, Application US/08804439A
Patent No. 6015565
GENERAL INFORMATION:
APPLICANT: Rose, Timothy M.
APPLICANT: Bosch, Marnix L.
APPLICANT: Strand, Kurt
TITLE OF INVENTION: GLYCOPROTEIN B OF THE RFHV/KSHV
TITLE OF INVENTION: SUBFAMILY OF HERPES VIRUSES
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 4225 Executive Square, Ste 1400
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/804,439A
FILING DATE: February 21, 1997
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Haile, Lisa A.
REGISTRATION NUMBER: 38,347
REFERENCE/DOCKET NUMBER: 09176/004001
TELEPHONE: (619) 678-5070
TELEFAX: (619) 678-5099
TELEX:
INFORMATION FOR SEQ ID NO: 89:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-804-439A-89

Query Match 1.1%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 72;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TGCTCCAGCAGGCCCTC 585
DB 17 TCCTCCAGCAGGCCCTC 1

RESULT 23
US-08-720-229-89/c
Sequence 89, Application US/08720229
Patent No. 6022542
GENERAL INFORMATION:
APPLICANT: Rose, Timothy M.
APPLICANT: Bosch, Marnix L.
APPLICANT: Strand, Kurt
TITLE OF INVENTION: GLYCOPROTEIN B OF THE RFHV/KSHV
TITLE OF INVENTION: SUBFAMILY OF HERPES VIRUSES
NUMBER OF SEQUENCES: 100
CORRESPONDENCE ADDRESS:
ADDRESSEE: Morrison & Foerster
STREET: 755 Page Mill Road
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304-1018
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/720,229
FILING DATE: 26-SEP-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Schiff, J. Michael
REGISTRATION NUMBER: 40,253
REFERENCE/DOCKET NUMBER: 29938-20002.00
TELEPHONE: (415) 813-5600
TELEFAX: (415) 494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 89:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-720-229-89

Query Match 1.1%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 72;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TGCTCCAGCAGGCCCTC 585
DB 17 TCCTCCAGCAGGCCCTC 1

RESULT 24
US-07-977-284A-89/c
Sequence 89, Application US/07977284A
Patent No. 5558988
GENERAL INFORMATION:
APPLICANT: Prockop, Darwin J.
APPLICANT: Ala-Kokko, Leena
APPLICANT: Williams, Charlene J.
APPLICANT: Ritvaniemi, Pertti
APPLICANT: Baldwin, Clinton

APPLICANT: Hopkinson, Ian
APPLICANT: Ahmad, Nilofer Nina
TITLE OF INVENTION: METHODS OF DETECTING A GENETIC
TITLE OF INVENTION: PREDISPOSITION FOR OSTEOARTHRITIS
NUMBER OF SEQUENCES: 261
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5558988ris
STREET: One Liberty Place, 46th floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/977,284A
FILING DATE: 13-NOV-1992
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Deluca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: TJU-0697
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 89:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: NUCLEIC ACID
STRANDEDNESS: SINGLE
TOPOLOGY: LINEAR
ANTI-SENSE: NO
US-07-977-284A-89

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 282 GGAAGCAGCAGCAATGCTG 301
Db 20 GGAAGCAGCAGCAGTGACAG 1

RESULT 25
US-08-410-540-8/c
Sequence 8, Application US/08410540
Patent No. 5807678
GENERAL INFORMATION:
APPLICANT: Miller, Walter L.
APPLICANT: Lin, Dong
APPLICANT: Strauss III, Jerome F.
TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS
TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooley Godward Castro Huddleson & Tatum
STREET: 5 Palo Alto Square
CITY: Palo Alto
STATE: CA
COUNTRY: US
ZIP: 94306-2155
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/410,540
FILING DATE: 23-MAR-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Neeley, Richard L.
REGISTRATION NUMBER: 30,092
REFERENCE/DOCKET NUMBER: UCAL-238/00US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415 853 5070
TELEFAX: 415 857 0663
TELEX: 380816COOLEYPA
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
HYPOTHEICAL: NO
ANTI-SENSE: NO
US-08-410-540-8

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 548 TGCTGGCAGGCATGCACACA 567
Db 20 TGCTGGCAGGCATGCACACA 1

RESULT 26
US-08-256-426B-89/c
Sequence 89, Application US/08256426B
Patent No. 5948611
GENERAL INFORMATION:
APPLICANT: Prockop, Darwin J.
APPLICANT: Ala-Kokko, Leena
APPLICANT: Williams, Charlene J.
APPLICANT: Ritvaniemi, Pertti
APPLICANT: Baldwin, Clinton
APPLICANT: Hopkinson, Ian
APPLICANT: Ahmad, Nilofer Nina
TITLE OF INVENTION: Methods of Detecting A Genetic
NUMBER OF SEQUENCES: 293
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5948611ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 3.1
SOFTWARE: WORDPERFECT 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/256,426B
FILING DATE: 03-FEB-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/10964
FILING DATE: 12-NOV-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/977,284
FILING DATE: 13-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: Mark Deluca
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: TJU-1082
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100

```
;
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 89:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: NUCLEIC ACID
; STRANDEDNESS: SINGLE
; TOPOLOGY: LINEAR
; ANTI-SENSE: NO
US-08-256-426B-89

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 282 GGAAGCAGCAGCATGCTG 301
Db 20 GGAAGCAGCAGCATGAG 1

RESULT 27
US-09-661-753-55
; Sequence 55, Application US/09661753
; Patent No. 6436909
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA
; FILE REFERENCE: ISPH-0498
; CURRENT APPLICATION NUMBER: US/09/661,753
; CURRENT FILING DATE: 2000-09-14
; EARLIER APPLICATION NUMBER: 60/154,546
; EARLIER FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 68
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-661-753-55

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 621 CAGGACAGCTCCAGGAGC 640
Db 1 CCGGACAGCATGAGGAGC 20

RESULT 28
US-09-470-443-33
; Sequence 33, Application US/09470443
; Patent No. 6441156
; GENERAL INFORMATION:
; APPLICANT: Lerman, Michael I.
; APPLICANT: Minna, John D.
; APPLICANT: Latif, Farida
; APPLICANT: Wei, Ming-Hui
; APPLICANT: Sekido, Yoshitaka
; APPLICANT: Gao, Boning
; APPLICANT: Duh, Fuh-Mei
; TITLE OF INVENTION: Calcium Channel Compositions and Methods of Use Thereof
; FILE REFERENCE: NIH-05043
; CURRENT APPLICATION NUMBER: US/09/470,443
; CURRENT FILING DATE: 1999-12-22
; EARLIER APPLICATION NUMBER: 60/114,359
; EARLIER FILING DATE: 1998-12-30
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-470-443-33

;
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-470-443-33

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 335 CTGGTGATGTCACAGTGGC 354
Db 1 CTGGTGATGTCACAGGAGC 20

RESULT 29
US-09-470-443-43
; Sequence 43, Application US/09470443
; Patent No. 6441156
; GENERAL INFORMATION:
; APPLICANT: Lerman, Michael I.
; APPLICANT: Minna, John D.
; APPLICANT: Latif, Farida
; APPLICANT: Wei, Ming-Hui
; APPLICANT: Sekido, Yoshitaka
; APPLICANT: Gao, Boning
; APPLICANT: Duh, Fuh-Mei
; TITLE OF INVENTION: Calcium Channel Compositions and Methods of Use Thereof
; FILE REFERENCE: NIH-05043
; CURRENT APPLICATION NUMBER: US/09/470,443
; CURRENT FILING DATE: 1999-12-22
; EARLIER APPLICATION NUMBER: 60/114,359
; EARLIER FILING DATE: 1998-12-30
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-470-443-43

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 335 CTGGTGATGTCACAGTGGC 354
Db 1 CTGGTGATGTCACAGGAGC 20

RESULT 30
US-09-659-845A-168
; Sequence 168, Application US/09659845A
; Patent No. 6492170
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 9 EXPRESSION
; FILE REFERENCE: RTS-0183
; CURRENT APPLICATION NUMBER: US/09/659,845A
; CURRENT FILING DATE: 2001-07-23
; NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-845A-168

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
```

```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 567 ACTGCTCCAGCAGGCGCTCC 586
Db 1 ACTGCTCCAGATGCCATCC 20
RESULT 31
US-09-198-452A-1582/c
; Sequence 1582, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 1582
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-1582
Query Match
Best Local Similarity 1.1%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 274 ATCAAAGAGGAGCAGCAGC 293
Db 20 ATCAAATGCGAAGCAGCAGC 1
RESULT 32
US-09-198-452A-3952/c
; Sequence 3952, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3952
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-3952
Query Match
Best Local Similarity 1.1%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 17 TGGATTAAACCAACCCAGC 36
Db 20 TGGATTATACCAACCCAGC 1
RESULT 33
US-08-276-852-49/c
; Sequence 49, Application US/08276852
; Patent No. 5652138
; GENERAL INFORMATION:
; APPLICANT: Burton, Dennis R.
; APPLICANT: Barbas, Carlos F.
; APPLICANT: Lerner, Richard A.
; TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS
```

```
; NUMBER OF SEQUENCES: 170
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute, Office of
; ADDRESSEE: Patent Counsel
; STREET: 10666 No. 5652138th Torrey Pines Road, Suite 220,
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/276,852
; FILING DATE: 18-JUL-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/178,302
; FILING DATE: 30-SEP-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/954,148
; FILING DATE: 30-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Fitting, Thomas
; REGISTRATION NUMBER: 34,163
; REFERENCE/DOCKET NUMBER: SCR1452P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-554-2937
; TELEFAX: 619-554-6312
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLSCULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-276-852-49
Query Match
Best Local Similarity 1.1%; Score 15.2; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 262 CTGGGCTGGCTGATCAAGA 281
Db 21 CTGGGCTGGCTGATCAAGA 2
RESULT 34
US-08-162-102C-30/c
; Sequence 30, Application US/08162102C
; Patent No. 5762905
; GENERAL INFORMATION:
; APPLICANT: Burton, Dennis R.
; APPLICANT: Barbas, III, Carlos F.
; APPLICANT: Chanock, Robert M.
; APPLICANT: Murphy, Brian R.
; APPLICANT: Crowe, Jr., James E.
; TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 49
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: California
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
```

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/162,102C
FILING DATE: 10-DEC-1993
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Haile, Ph.D., Lisa A.
REGISTRATION NUMBER: 36,347
REFERENCE/DOCKET NUMBER: 07300/007001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 678-5070
TELEFAX: (619) 678-5099
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
IMMEDIATE SOURCE:
CLONE: Gb
FEATURE:
NAME/KEY: CDS
LOCATION: 1..21
US-08-162-102C-30

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 262 CTGGGCTGGCTGATCAAGA 281
Db 21 CTGGGCTGGCTGATCAAGA 2

RESULT 35
US-08-899-575-49/c
Sequence 49, Application US/08899575
Patent No. 5770440
GENERAL INFORMATION:
APPLICANT: Burton, Dennis R
APPLICANT: Barbas, Carlos F
APPLICANT: Lerner, Richard A
TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES
TITLE OF INVENTION: TO HUMAN IMMUNODEFICIENCY VIRUS
NUMBER OF SEQUENCES: 170
CORRESPONDENCE ADDRESS:
ADDRESSEE: The Scripps Research Institute, Office of
ADDRESSEE: Patent Counsel
STREET: 10666 No. 5770440th Torrey Pines Road, Suite 220,
STREET: Mail Drop TPC8
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/899,575
FILING DATE: 24-JUL-1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/276,852
FILING DATE: 18-JUL-1994
APPLICATION NUMBER: US 08/178,302
FILING DATE: 30-SEP-1993
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/954,148
FILING DATE: 30-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Fitting, Thomas
REGISTRATION NUMBER: 34,163
REFERENCE/DOCKET NUMBER: SCRI452P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-554-2937
TELEFAX: 619-554-6312
INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-899-575-49

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 262 CTGGGCTGGCTGATCAAGA 281
Db 21 CTGGGCTGGCTGATCAAGA 2

RESULT 36
US-08-899-575-49/c
Sequence 49, Application US/08899575
Patent No. 5804440
GENERAL INFORMATION:
APPLICANT: Burton, Dennis R
APPLICANT: Barbas, Carlos F
APPLICANT: Lerner, Richard A
TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES
TITLE OF INVENTION: TO HUMAN IMMUNODEFICIENCY VIRUS
NUMBER OF SEQUENCES: 170
CORRESPONDENCE ADDRESS:
ADDRESSEE: The Scripps Research Institute, Office of
ADDRESSEE: Patent Counsel
STREET: 10666 No. 5804440th Torrey Pines Road, Suite 220,
STREET: Mail Drop TPC8
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/899,575
FILING DATE: 24-JUL-1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/276,852
FILING DATE: 18-JUL-1994
APPLICATION NUMBER: US 08/178,302
FILING DATE: 30-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/954,148
FILING DATE: 30-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Fitting, Thomas
REGISTRATION NUMBER: 34,163
REFERENCE/DOCKET NUMBER: SCRI452P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-554-2937
TELEFAX: 619-554-6312

INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-899-575-49

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 262 CTGGGCTGGCTGATCAAGA 281
Db 21 CTGGGCTGGCTGATCAAGA 2

RESULT 37

US-07-974-409C-137/c
Sequence 137, Application US/07974409C
Patent No. 6300058
GENERAL INFORMATION:
APPLICANT: Akitaya, Tatsuo
APPLICANT: Mitsuhashi, Masato
TITLE OF INVENTION: METHOD AND REAGENT
FOR MEASURING MESSENGER RNA
NUMBER OF SEQUENCES: 457
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson, and Bear
STREET: 620 Newport Center Dr. Sixteenth Floor
CITY: Newport Beach
STATE: CA
COUNTRY: USA
ZIP: 92660

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/974,409C
FILING DATE: 12-NOV-1992
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: Altman, Daniel E.
REGISTRATION NUMBER: 34,115
REFERENCE/DOCKET NUMBER: HITACHI.006CP2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 714-760-0404
TELEFAX: 714-760-9502
INFORMATION FOR SEQ ID NO: 137:

SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA to mRNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-07-974-409C-137

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 492 CGGTGTCGACGCTCTTGGG 511
Db 21 CGGTGTCGACGCTCTTGGG 2

RESULT 38

US-08-635-109-21/c
Sequence 21, Application US/08635109
Patent No. 6538114
GENERAL INFORMATION:
APPLICANT: Persson, Mats A. A.
APPLICANT: Allander, Tobias E.
TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR
HEPATITIS C VIRUS (HCV) E2 ANTIGEN
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: REED & ROBINS
STREET: 285 Hamilton Avenue, Suite 200
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94301

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/635,109
FILING DATE: 19-APR-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McCracken, Thomas P
REGISTRATION NUMBER: 38,548
REFERENCE/DOCKET NUMBER: 2300-6146
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 327-3400
TELEFAX: (415) 327-3231
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-635-109-21

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 262 CTGGGCTGGCTGATCAAGA 281
Db 21 CTGGGCTGGCTGATCAAGA 2

RESULT 39

PCT-US93-00977-137/c
Sequence 137, Application PC/TUS9300977
GENERAL INFORMATION:
TITLE OF INVENTION: METHOD AND REAGENT FOR MEASURING MESSENGER RNA
NUMBER OF SEQUENCES: 711
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson, and Bear
STREET: 620 Newport Center Dr. Sixteenth Floor
CITY: Newport Beach
STATE: CA
COUNTRY: USA
ZIP: 92660

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/00977
FILING DATE: 19930129

CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Altman, Daniel E.
REGISTRATION NUMBER: 34,115
REFERENCE/DOCKET NUMBER: HITACHI.006H
TELECOMMUNICATION INFORMATION:
TELEPHONE: 714-760-0404
TELEFAX: 714-760-9502
INFORMATION FOR SEQ ID NO: 137:
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: NUCLEIC ACID
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA to mRNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
PCT-US93-00977-137

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 492 CGGTGTGACGCTCTTGGGG 511
||||| ||||| ||||| |||||
Db 21 CGGTGTGACGCTCTTGGGG 2

RESULT 40
PCT-US95-08743-49/c
Sequence 49, Application PC/TUS9508743
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES
TITLE OF INVENTION: TO HUMAN IMMUNODEFICIENCY VIRUS
NUMBER OF SEQUENCES: 170
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/08743
FILING DATE: 11-JUL-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/276,852
FILING DATE: 18-JUL-1994
INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
PCT-US95-08743-49

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 262 CTGGGCTGGCTGATCAAGA 281
||||| ||||| ||||| |||||
Db 21 CTGGGCTGGCTGATCAAGA 2

RESULT 41
US-09-081-646-727
Sequence 727, Application US/09081646
Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth

APPLICANT: Vogelstein, Bert
APPLICANT: Zhang, Lin
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
REFERENCE/DOCKET NUMBER: HITACHI.006H
TELECOMMUNICATION INFORMATION:
TELEPHONE: 01107.74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
EARLIER FILING DATE: 1997-05-21
NUMBER OF SEQ ID NOS: 871
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 727
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-727

Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 38;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 745 CATGTTGCTGACTTT 759
||||| ||||| ||||| |||||
Db 1 CATGTTGCTGACTTT 15

RESULT 42
US-08-585-684B-2539/c
Sequence 2539, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2539:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-585-684B-2539

Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 67;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 277 AAAGAGGAGCAGCAGCA 294
Db 18 AAAGAGCAGCAGCAGCA 1

RESULT 43

US-09-038-073-2539/c
; Sequence 2539, Application US/09038073
; Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
CITY: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 2539:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-2539

Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 67;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 277 AAAGAGGAGCAGCAGCA 294
Db 18 AAAGAGCAGCAGCAGCA 1

RESULT 44

US-08-630-592-14
; Sequence 14, Application US/08630592
; Patent No. 5770432
; GENERAL INFORMATION:

APPLICANT: Nishina, Patsy
APPLICANT: No. 5770432enTrauth, Konrad
APPLICANT: Naggert, Juergen
APPLICANT: No. 5770432th, Michael
TITLE OF INVENTION: Obesity Associated Genes
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
STREET: 3400 Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-4187

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PCDOS/MSDOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/630,592
FILING DATE:
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: Sherwood, Pamela J.
REGISTRATION NUMBER: 36,677
REFERENCE/DOCKET NUMBER: A59504/BJR/PJS
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 7811989
TELEFAX: (415) 3983249
TELEX: 910 277299

INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-08-630-592-14

Query Match 1.1%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 76;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 822 CCTGATCAGCTGAAGCT 839
Db 2 CCTGAGCAGCAGCAAGCT 19

RESULT 45

US-08-714-991-14
; Sequence 14, Application US/08714991
; Patent No. 5776762
GENERAL INFORMATION:
APPLICANT: NISHINA, Patsy
APPLICANT: NORTH, Michael
APPLICANT: No. 5776762en-Trauth, Konrad
APPLICANT: NAGGERT, Juergen
TITLE OF INVENTION: OBESITY ASSOCIATED GENES
NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESS:
ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
STREET: 4 Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-4187

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:

```
/ APPLICATION NUMBER: US/08/714,991
/ FILING DATE:
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: SHERWOOD, Pamela J.
/ REGISTRATION NUMBER: 36,677
/ REFERENCE/DOCKET NUMBER: A-59504-1/PJS
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-494-8700
/ TELEFAX: 415-494-8771
/ TELEX: 910 277299
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ DESCRIPTION: /desc = "primer"
US-08-714-991-14

Query Match 1.1%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 76;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 822 CCTGATGCAGCTGAAGCT 839
Db 2 CCTGAGGCAGCAGAGCT 19

RESULT 46
US-09-032-365A-26
/ Sequence 26, Application US/09032365A
/ Patent No. 6114502
/ GENERAL INFORMATION:
/ APPLICANT: No. 6114502th, Michael
/ APPLICANT: Nishina, Patsy
/ APPLICANT: Naggart, Juergen
/ APPLICANT: No. 6114502en-Trauth, Konrad
/ TITLE OF INVENTION: GENE FAMILY ASSOCIATED WITH
/ NUMBER OF SEQUENCES: 67
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Bozicevic & Reed, LLP
/ STREET: 285 Hamilton Avenue, Suite 200
/ CITY: Palo Alto
/ STATE: CA
/ COUNTRY: USA
/ ZIP: 94301
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: FastSeq for Windows Version 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/032,365A
/ FILING DATE:
/ CLASSIFICATION: 536
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Sherwood, Pamela J
/ REGISTRATION NUMBER: 36,677
/ REFERENCE/DOCKET NUMBER: SEQ-2CIP2
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 650-327-3400
/ TELEFAX: 650 327-3231
/ TELEX:
/ INFORMATION FOR SEQ ID NO: 26:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
```

```
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: cDNA
US-09-032-365A-26

Query Match 1.1%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 76;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 822 CCTGATGCAGCTGAAGCT 839
Db 2 CCTGAGGCAGCAGAGCT 19

RESULT 47
US-08-623-891-3/c
/ Sequence 3, Application US/08623891
/ Patent No. 5795778
/ GENERAL INFORMATION:
/ APPLICANT: Kenneth G. Draper
/ TITLE OF INVENTION: METHOD AND REAGENT FOR
/ TITLE OF INVENTION: INHIBITING HERPES SIMPLEX
/ TITLE OF INVENTION: VIRUS REPLICATION
/ NUMBER OF SEQUENCES: 115
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 611 West Sixth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: USA
/ ZIP: 90017
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
/ SOFTWARE: WordPerfect (Version 5.1)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/623,891
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/238,200
/ FILING DATE:
/ APPLICATION NUMBER: US/07/987,133
/ FILING DATE:
/ APPLICATION NUMBER: 07/882,921
/ FILING DATE: May 14, 1992
/ APPLICATION NUMBER: 07/948,359
/ FILING DATE: September 18, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 200/209
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 3:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-623-891-3

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 130 GGACAGGGAGCGCCGCTC 147
Db 19 GGACAGGGAGCGCCGATC 2
```

```
RESULT 48
US-09-286-904-42/c
; Sequence 42, Application US/09286904A
; Patent No. 6140124
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; APPLICANT: Gaarde, William A.
; APPLICANT: Nero, Pamela S.
; APPLICANT: McKay, Robert
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of p38 Mitogen
; FILE REFERENCE: ISPH-0347
; CURRENT APPLICATION NUMBER: US/09/286,904A
; CURRENT FILING DATE: 1999-04-06
; NUMBER OF SEQ ID NOS: 95
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-09-286-904-42

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1287 TAGAGTGTCTCAGCCTGG 1304
||| ||||| |||||
Db 19 TAGAGTGTCTCAGCCTGG 2

RESULT 49
US-09-742-703-11
; Sequence 11, Application US/09742703
; Patent No. 6423543
; GENERAL INFORMATION:
; APPLICANT: Patrick Allen Marcotte
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF HEPSEN EXPRESSION
; FILE REFERENCE: RTS-0090
; CURRENT APPLICATION NUMBER: US/09/742,703
; CURRENT FILING DATE: 2000-12-20
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-742-703-11

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 CAGCAGCGGGCGGCTGG 738
||| ||||| |||||
Db 2 CAGCAGCGGGCGGCTGG 19

RESULT 50
US-09-340-861-3/c
; Sequence 3, Application US/09340861
; Patent No. 6432704
; GENERAL INFORMATION:
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HERPES SIMPLEX
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 115
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/340,861
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/987,133
; FILING DATE:
; APPLICATION NUMBER: 07/882,921
; FILING DATE: May 14, 1992
; APPLICATION NUMBER: 07/948,359
; FILING DATE: September 18, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 200/209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-340-861-3

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 130 GGACAGGGACGCCGCTC 147
||| ||||| |||||
Db 19 GGACAGGGACGCCGCTC 2

RESULT 51
US-09-634-262-3/c
; Sequence 3, Application US/09634262
; Patent No. 6440719
; GENERAL INFORMATION:
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HERPES SIMPLEX
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 115
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/634,262
; FILING DATE:
```

```

; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/987,133
; FILING DATE:
; APPLICATION NUMBER: 07/882,921
; FILING DATE: May 14, 1992
; APPLICATION NUMBER: 07/948,359
; FILING DATE: September 18, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 200/209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-634-262-3
```

```

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 130 GGACGGGACGCCGCTC 147
Db 19 GGACGGGACGCCGATC 2
```

RESULT 52

```

US-09-640-101-42/c
; Sequence 42, Application US/09640101
; Patent No. 6448079
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; APPLICANT: Gaarde, William A.
; APPLICANT: Nero, Pamela S.
; APPLICANT: McKay, Robert
; TITLE OF INVENTION: Antisense Modulation of p38 Mitogen
; FILE REFERENCE: ISPH-0488
; CURRENT APPLICATION NUMBER: US/09/640,101
; CURRENT FILING DATE: 2000-08-15
; PRIOR APPLICATION NUMBER: 09/286,904
; PRIOR FILING DATE: 1999-04-06
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
;
US-09-640-101-42
```

```

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 1287 TAGAGTGTCTCAGCTGG 1304
Db 19 TAGAGTGTCTCAGCTGG 2
```

RESULT 53

```

US-09-099-053-19
; Sequence 19, Application US/09099053
; Patent No. 6388063
; GENERAL INFORMATION:
```

```

; APPLICANT: Greg Plowman
; APPLICANT: Susan Orrust
; APPLICANT: David Markby
; APPLICANT: Sara Courtneidge
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/099,053
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/049,914
; FILING DATE: June 18, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 235/121
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-099-053-19
```

```

Query Match 1.1%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 374 CCCAGCTTCTCCAGAGG 391
Db 4 CCCAGCTTCTCCCAAGG 21
```

RESULT 54

```

US-09-359-921-27/c
; Sequence 27, Application US/09359921
; Patent No. 6545162
; GENERAL INFORMATION:
; APPLICANT: DERVAN, PETER B.
; APPLICANT: BAIRD, ELDON E.
; TITLE OF INVENTION: METHOD FOR THE SYNTHESIS OF PYRROLE AND IMIDAZOLE
; FILE REFERENCE: 025098-1602
; CURRENT APPLICATION NUMBER: US/09/359,921
; CURRENT FILING DATE: 1999-07-22
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
```

; OTHER INFORMATION: oligonucleotide
US-09-359-921-27

Query Match 1.1%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1142 CCTTTTCTTTTGG 1157
|||
Db 17 CCTTTTGTCTTTG 2

RESULT 55

US-09-178-115-113/c
; Sequence 113, Application US/09178115
; Patent No. 6297041
; GENERAL INFORMATION:
; APPLICANT: Zavada, Jan
; APPLICANT: Pastorekova, Silvia
; TITLE OF INVENTION: MN Gene and Protein
; FILE REFERENCE: D-0021.5A
; CURRENT APPLICATION NUMBER: US/09/178,115
; CURRENT FILING DATE: 1998-10-23
; EARLIER APPLICATION NUMBER: 09/177,776
; EARLIER FILING DATE: 1998-10-23
; EARLIER APPLICATION NUMBER: 08/787,739
; EARLIER FILING DATE: 1997-01-24
; EARLIER APPLICATION NUMBER: 08/485,049
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/486,756
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/477,504
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/481,658
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/485,862
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/485,863
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/487,077
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/260,190
; EARLIER FILING DATE: 1994-06-15
; EARLIER APPLICATION NUMBER: 08/177,093
; EARLIER FILING DATE: 1993-12-30
; EARLIER APPLICATION NUMBER: 07/964,589
; EARLIER FILING DATE: 1992-10-21
; EARLIER APPLICATION NUMBER: PV-709-92
; EARLIER FILING DATE: 1992-03-11
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 113
; LENGTH: 18
; TYPE: DNA
; ORGANISM: HUMAN
US-09-178-115-113

Query Match 1.1%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 82;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1017 GAGATGGTGCCAAAGT 1032
|||
Db 18 GAGATGGAGCCAAAGT 3

RESULT 56

US-09-177-776-113/c
; Sequence 113, Application US/0917776A
; Patent No. 6297051
; GENERAL INFORMATION:
; APPLICANT: Zavada, Jan

; APPLICANT: Pastorekova, Silvia
; APPLICANT: Pastorek, Jaromir
; TITLE OF INVENTION: MN Gene and Protein
; FILE REFERENCE: D-0021.5A
; CURRENT APPLICATION NUMBER: US/09/177,776A
; CURRENT FILING DATE: 1998-10-23
; EARLIER APPLICATION NUMBER: 08/787,739
; EARLIER FILING DATE: 1997-01-24
; EARLIER APPLICATION NUMBER: 08/485,049
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/486,756
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/477,504
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/481,658
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/485,862
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/485,863
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/487,077
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/260,190
; EARLIER FILING DATE: 1994-06-15
; EARLIER APPLICATION NUMBER: 08/177,093
; EARLIER FILING DATE: 1993-12-30
; EARLIER APPLICATION NUMBER: 07/964,589
; EARLIER FILING DATE: 1992-10-21
; EARLIER APPLICATION NUMBER: PV-709-92
; EARLIER FILING DATE: 1992-03-11
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 113
; LENGTH: 18
; TYPE: DNA
; ORGANISM: HUMAN
US-09-177-776-113

Query Match 1.1%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 82;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1017 GAGATGGTGCCAAAGT 1032
|||
Db 18 GAGATGGAGCCAAAGT 3

RESULT 57

US-08-376-362A-8/c
; Sequence 8, Application US/08376362A
; Patent No. 5693756
; GENERAL INFORMATION:
; APPLICANT: Li, Xiao-Jiang
; APPLICANT: Blackshaw, Seth
; APPLICANT: Snyder, Solomon H.
; TITLE OF INVENTION: AMILORIDE-SENSITIVE SODIUM CHANNEL AND
; TITLE OF INVENTION: METHOD OF IDENTIFYING SUBSTANCES WHICH STIMULATE OR BLOCK
; TITLE OF INVENTION: SALTY TASTE PERCEPTION
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Allegretti, LTD
; STREET: 1001 G Street, N.W., Eleventh Floor
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20001-4597
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/376,362A

```

; FILING DATE: 23-JAN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan A., Sarah
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 01107.48125
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202 508-9100
; TELEFAX: 202 508-9299
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-376-362A-8

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 629 AGCTCCAGGAGCTCTG 644
Db 16 AGCCCCAGGAGCTCTG 1

RESULT 58
US-08-634-331-3
; Sequence 3, Application US/08634331
; Patent No. 5707809
; GENERAL INFORMATION:
; APPLICANT: HALVERSON, Joy L.
; TITLE OF INVENTION: AVIAN SEX IDENTIFICATION PROBES
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOBRACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/634,331
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: SHERWOOD, Pamela J.
; REGISTRATION NUMBER: 36,677
; REFERENCE/DOCKET NUMBER: A-55362-3/BIR/PJS
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 494-8700
; TELEFAX: (415) 494-8771
; TELEX: 910 2777299PHT UR
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Primer"
US-08-634-331-3

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 670 TTGGCCAGCGTGGTAT 685
Db 3 TAGGCCAGCGTGGTAT 18

RESULT 59
US-08-450-905B-134
; Sequence 134, Application US/08450905B
; Patent No. 5856301
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
; NUMBER OF SEQUENCES: 178
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/450,905B
; FILING DATE: 26-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/982,759
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9127319.3
; FILING DATE: 23-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9221587.0
; FILING DATE: 14-OCT-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, HOLLIE L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102.378.120DV-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-526-6110
; TELEFAX: 617-526-5000
; INFORMATION FOR SEQ ID NO: 134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..20
; OTHER INFORMATION: /product= "BB9513 oligomer"
US-08-450-905B-134

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 TTCAGATGGGTACGCA 855
Db 4 TTCAGATGGGTACGCA 19

RESULT 60
US-07-982-759F-134
; Sequence 134, Application US/07982759F
; Patent No. 6057123
; GENERAL INFORMATION:
; APPLICANT: CRAIG, Stewart
; APPLICANT: GEORGE, Michael
```



```
;; APPLICANT: EDWARDS, Richard Mark
;; APPLICANT: CZAPLEWSKI, Lloyd George
;; APPLICANT: GILBERT, Richard
;; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
;; NUMBER OF SEQUENCES: 178
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: HALE and DORR LLP
;; STREET: 60 State Street
;; CITY: Boston
;; STATE: MA
;; ZIP: 02109
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/07/982,759F
;; FILING DATE: 08-MAR-1993
;; PRIOR APPLICATION DATA: GB 9127319.3
;; FILING DATE: 23-DEC-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: GB 9221587.0
;; FILING DATE: 14-OCT-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: BAKER, HOLLIE L.
;; REGISTRATION NUMBER: 31,321
;; REFERENCE/DOCKET NUMBER: 102378.120
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 617-526-6000
;; TELEFAX: 617-526-5000
;; INFORMATION FOR SEQ ID NO: 134:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: 1..20
;; OTHER INFORMATION: /product= "BB9513 oligomer"
US-07-982-759F-134

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 TTCAGATGGGTCCAGCA 855
Db 4 TTCAGATGGGTCCAGCA 19

RESULT 61
US-09-280-805-48/c
; Sequence 48, Application US/09280805
; Patent No. 6184212
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
```

```
;; COMPUTER: IBM PC
;; OPERATING SYSTEM: WINDOWS 95
;; SOFTWARE: WORDPERFECT 6.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/280,805
;; FILING DATE: herewith
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 09/048,810
;; FILING DATE: March 26, 1998
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Licata, Jane Massey
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0346
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 609-810-1515
;; TELEFAX: 609-810-1454
;; INFORMATION FOR SEQ ID NO: 48:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-280-805-48

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 788 CCAGTGCCTGGCTCG 803
Db 20 CCAGTGCCTGGCCCG 5

RESULT 62
US-09-150-460B-2
; Sequence 2, Application US/09150460B
; Patent No. 6190882
; GENERAL INFORMATION:
; APPLICANT: Lee, Cheng-Chi
; APPLICANT: Albrecht, Urs
; APPLICANT: Bichele, Gregor
; APPLICANT: Sun, Zhong Sheng
; TITLE OF INVENTION: Mammalian Circadian Rhythm-Like Gene
; FILE REFERENCE: D6039
; CURRENT APPLICATION NUMBER: US/09/150,460B
; CURRENT FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: US 60/058,256
; PRIOR FILING DATE: 1997-09-09
; NUMBER OF SEQ ID NOS: 21
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: Primer used for the STS-PCR mapping of RIGUI
US-09-150-460B-2

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 624 GGACCAGCTCCAGGAG 639
Db 1 GGACCATCTCCAGGAG 16

RESULT 63
US-09-228-942-7/c
; Sequence 7, Application US/09228942
; Patent No. 6203988
; GENERAL INFORMATION:
```

```

; APPLICANT: Kambara, Hideki
; APPLICANT: Uematsu, Chihiro
; TITLE OF INVENTION: DNA FRAGMENT ANALYSIS METHOD AND REAGENT KIT
; FILE REFERENCE: ASA-757
; CURRENT APPLICATION NUMBER: US/09/228,942
; CURRENT FILING DATE: 1999-01-12
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide ligated to 3' end of DNA fragment
US-09-228-942-7

Query Match          1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGA 1159
Db 18 TTTTTCCTTTTGA 3

RESULT 64
US-09-517-467B-240
; Sequence 240, Application US/09517467B
; Patent No. 6451602
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PAMP EXPRESSION
; FILE REFERENCE: RTS-0150
; CURRENT APPLICATION NUMBER: US/09/517,467B
; CURRENT FILING DATE: 2001-03-02
; PRIOR APPLICATION NUMBER: 09/517,467
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 345
; SEQ ID NO 240
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-467B-240

Query Match          1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1289 CAGTTCCTCAGCTGG 1304
Db 2 CAGTTCCTCAGCTGG 17

RESULT 65
US-08-246-489-7
; Sequence 7, Application US/08246489
; Patent No. 6225049
; GENERAL INFORMATION:
; APPLICANT: Ian, Michael S.
; APPLICANT: No. 6225049Kins, Abner L.
; TITLE OF INVENTION: NOVEL HUMAN INSULINOMA-ASSOCIATED CDNA
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive
; CITY: Newport Beach
; STATE: California
; COUNTRY: USA
; ZIP: 92660

; APPLICANT: Kambara, Hideki
; APPLICANT: Uematsu, Chihiro
; TITLE OF INVENTION: DNA FRAGMENT ANALYSIS METHOD AND REAGENT KIT
; FILE REFERENCE: ASA-757
; CURRENT APPLICATION NUMBER: US/09/228,942
; CURRENT FILING DATE: 1999-01-12
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide ligated to 3' end of DNA fragment
US-09-228-942-7

Query Match          1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGA 1159
Db 18 TTTTTCCTTTTGA 3

RESULT 64
US-09-517-467B-240
; Sequence 240, Application US/09517467B
; Patent No. 6451602
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PAMP EXPRESSION
; FILE REFERENCE: RTS-0150
; CURRENT APPLICATION NUMBER: US/09/517,467B
; CURRENT FILING DATE: 2001-03-02
; PRIOR APPLICATION NUMBER: 09/517,467
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 345
; SEQ ID NO 240
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-467B-240

Query Match          1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1289 CAGTTCCTCAGCTGG 1304
Db 2 CAGTTCCTCAGCTGG 17

RESULT 65
US-08-246-489-7
; Sequence 7, Application US/08246489
; Patent No. 6225049
; GENERAL INFORMATION:
; APPLICANT: Ian, Michael S.
; APPLICANT: No. 6225049Kins, Abner L.
; TITLE OF INVENTION: NOVEL HUMAN INSULINOMA-ASSOCIATED CDNA
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive
; CITY: Newport Beach
; STATE: California
; COUNTRY: USA
; ZIP: 92660

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/246,489
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/901,715
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Israel, Ned A.
; REGISTRATION NUMBER: 29,655
; REFERENCE/DOCKET NUMBER: NIH012.012A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 235-8550
; TELEFAX: (619) 235-0176
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-246-489-7

Query Match          1.0%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 521 ACCTGCCGAGGAGCAGCT 539
Db 1 ACCTGCCGAGGAGCAGCT 19

RESULT 66
US-08-033-081B-18
; Sequence 18, Application US/08033081B
; Patent No. 5498521
; GENERAL INFORMATION:
; APPLICANT: Dryja, Thaddeus P.
; APPLICANT: Berson, Elliot L.
; TITLE OF INVENTION: DIAGNOSIS OF HEREDITARY RETINAL
; TITLE OF INVENTION: DEGENERATIVE DISEASES
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/033,081B
; FILING DATE: March 11, 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/825,296
; FILING DATE: January 23, 1992
; APPLICATION NUMBER: 07/469,215
; FILING DATE: January 24, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
```

REFERENCE/DOCKET NUMBER: 00246/069005

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 542-5070

TELEFAX: (617) 542-8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 18:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-033-081B-18

Query Match 1.0%; Score 14.2; DB 1; Length 20;

Best Local Similarity 84.2%; Pred. No. 1.2e+02;

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 324 CCTGCATCATCCTGGTGAT 342

Db 2 CCTGCACACCTGGTGAT 20

RESULT 67

US-08-117-952-417

Sequence 417, Application US/08117952

Patent No. 5851760

GENERAL INFORMATION:

APPLICANT: Evans, Glen A.

APPLICANT: Smith, Michael W.

TITLE OF INVENTION: METHOD FOR GENERATION OF SEQUENCE

TITLE OF INVENTION: SAMPLED MAPS OF COMPLEX GENOMES

NUMBER OF SEQUENCES: 797

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark

STREET: 444 South Flower Street, Suite 2000

CITY: Los Angeles

STATE: CA

COUNTRY: USA

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/117,952

FILING DATE: 07-SEP-1993

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/078,471

FILING DATE: 15-JUN-1993

ATTORNEY/AGENT INFORMATION:

NAME: Reiter, Stephen E.

REGISTRATION NUMBER: 31,192

REFERENCE/DOCKET NUMBER: P41 9423

TELEPHONE: 619-546-4737

TELEFAX: 619-546-9392

INFORMATION FOR SEQ ID NO: 417:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Oligonucleotide

HYPOTHETICAL: NO

ANTI-SENSE: NO

US-08-117-952-417

Query Match

Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1159 AGTAAAGCAGCTAAACA 1177

Db 1 AAGTAAAGCGCAAAAGCA 19

RESULT 68

US-09-048-880-11/c

Sequence 11, Application US/09048880

Patent No. 5952202

GENERAL INFORMATION:

APPLICANT: Aoyagi et al.

TITLE OF INVENTION: METHODS FOR EXOGENOUS, INTERNAL CONTROLS

TITLE OF INVENTION: DURING NUCLEIC ACID AMPLIFICATION

NUMBER OF SEQUENCES: 16

CORRESPONDENCE ADDRESS:

ADDRESSEE: The Perkin-Elmer Corporation

STREET: 850 Lincoln Centre Drive

CITY: Foster City,

STATE: California

COUNTRY: USA

ZIP: 94044

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/048,880

FILING DATE: 26-MAR-1998

PRIOR APPLICATION DATA:

APPLICATION NUMBER: To Be Assigned

FILING DATE: March 26, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Scott R. Bortner

REGISTRATION NUMBER: 34,298

REFERENCE/DOCKET NUMBER: 4382

TELECOMMUNICATION INFORMATION:

TELEPHONE: (650) 638-6245

TELEFAX: (650) 638-6071

INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-048-880-11

Query Match

Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 620 TCAGGACAGCTCCAGGA 638

Db 20 TCAGGACCTGGTCCAGGA 2

RESULT 69

US-08-991-300-4/c

Sequence 4, Application US/08991300

Patent No. 5973225

GENERAL INFORMATION:

APPLICANT: D'OVIDIO, RENATO

APPLICANT: PORCEDDU, ENRICO

APPLICANT: MERCHITELLI, CINZIA

APPLICANT: CARDELLI, LUISA ERCOLI

TITLE OF INVENTION: ISOLATION AND CHARACTERIZATION OF A GENE

TITLE OF INVENTION: ENCODING A LOW MOLECULAR WEIGHT GLUTENIN

NUMBER OF SEQUENCES: 6

CORRESPONDENCE ADDRESS:

ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,

ADDRESSEE: P.C.

STREET: 1755 S. JEFFERSON DAVIS HIGHWAY

CITY: ARLINGTON

STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/991,300
FILING DATE: 16-DEC-1997
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: IT MI 96/A 002663
FILING DATE: 19-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 2264-0201-0X
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "PRIMER"
US-08-991-300-4
Query Match
Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1011 GCACCTGAGATGTCGCA 1029
Db 20 GCACCGAGTGTGTCCTA 2
RESULT 70
US-08-715-461-4
Sequence 4, Application US/08715461
Patent No. 5985556
GENERAL INFORMATION:
APPLICANT: KAMBARA, Hideki
APPLICANT: OKANO, Kazunori
TITLE OF INVENTION: DNA SEQUENCING METHOD AND DNA SAMPLE
TITLE OF INVENTION: PREPARATION METHOD
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: ANTONELLI, TERRY STOUT & KRAUS
STREET: 1300 No. 598556th Seventeenth Street, Suite 1800
CITY: Arlington
STATE: VA
COUNTRY: USA
ZIP: 22209
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/715,461
FILING DATE: 18-SEP-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: TERRY, David T.
REGISTRATION NUMBER: 20,178
REFERENCE/DOCKET NUMBER: 500.34872X00
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-312-6600

TELEFAX: 703-312-6666
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-715-461-4
Query Match
Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1144 TTTTCTCTTTTGAAGT 1162
Db 2 TTTTCTCTTTTGAAGT 20
RESULT 71
US-08-755-587-59/c
Sequence 59, Application US/08755587
Patent No. 6045997
GENERAL INFORMATION:
APPLICANT: Futreal, Phillip A
APPLICANT: Wooster, Richard F
APPLICANT: Ashworth, Alan
APPLICANT: Stratton, Michael R
TITLE OF INVENTION: Materials and methods relating to the
TITLE OF INVENTION: Identification and sequencing of the BRCA2 cancer
TITLE OF INVENTION: susceptibility gene and uses thereof.
NUMBER OF SEQUENCES: 222
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bell Seltzer Park & Gibson
STREET: 310 UCB Plaza, 3605 Glenwood Avenue, PO Drawer 31107
CITY: Raleigh
STATE: NC
COUNTRY: USA
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/755,587
FILING DATE: 25-NOV-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9523959.6
FILING DATE: 23-NOV-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9525555.0
FILING DATE: 14-DEC-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9617961.9
FILING DATE: 28-AUG-1996
ATTORNEY/AGENT INFORMATION:
NAME: Kenneth D Sibley
REGISTRATION NUMBER: 31,665
REFERENCE/DOCKET NUMBER: 5405-135
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-755-587-59
Query Match
Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;


```

/ CURRENT APPLICATION NUMBER: US/09/130,616C
/
/ CURRENT FILING DATE: 1998-08-07
/
/ EARLIER APPLICATION NUMBER: 08/910,629
/
/ EARLIER FILING DATE: 1997-08-03
/
/ NUMBER OF SEQ ID NOS: 178
/
/ SEQ ID NO 123
/
/ LENGTH: 20
/
/ TYPE: DNA
/
/ ORGANISM: Artificial Sequence
/
/ FEATURE:
/
/ - OTHER INFORMATION: Synthetic sequence
/
/ US-09-130-616-123

```

Query Match	1.0%	Score 14.2;	DB 1;	Length 20;
Best Local Similarity	84.2%;	Pred. No. 1.2e+02;		
Matches 16;	Conservative	0;	Mismatches 3;	Indels 0;
				Gaps 0;

QY
910 CTGGTCCTAAAGGAGATGG 928

Db
2. CTGCACCTAAAGGAGACGG 20

```

RESULT 77
US-09-270-542-155/c
; Sequence 155, Application US/09270542
; Patent No. 6322976
; GENERAL INFORMATION:
; APPLICANT: Altman, Timothy
; APPLICANT: Scott, James
; APPLICANT: Stanton, Lawrence
; TITLE OF INVENTION: Compositions and Methods of Disease Diagnosis and
; TITL OF INVENTION: Therapy
; FILE REFERENCE: 4198/78179
; CURRENT APPLICATION NUMBER: US/09/270,542
; CURRENT FILING DATE: 1999-03-17
; EARLIER APPLICATION NUMBER: 09/221,222
; EARLIER FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 207
; SOFTWARE: PatentIn Ver. 2.0
; SEQ. ID NO 155
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-09-270-542-155

```

Query Match	1.0%	Score 14.2;	DB 1;	Length 20;
Best Local Similarity	84.2%;	Pred. No. 1.2e+02;		
Matches	16;	Conservative	0;	Mismatches 3;
				Indels 0;
				Gaps 0;

Qy 622 AGGACCAGCTCCAGGAGC 640
Db 19 AAGGACCAGATCCAGGGGC 1

```

RESULT 78
US-09-851-062-47/c
; Sequence 47, Application US/09851062
; Patent No. 6448081
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTIGENSE MODULATION OF INTERLEUKIN 12 P40 SUBUNIT EXPRESSION
; FILE REFERENCE: RTS-0247
; CURRENT APPLICATION NUMBER: US/09/851,062
; CURRENT FILING DATE: 2001-05-07
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-851-062-47

```

Query Match	1.0%;	Score 14.2;	DB 1;	Length 20;
Best Local Similarity	84.3%;	Pred. NO. 1.2e+02;		
Matches 16;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
QY	227	CTCAGCCTCAGGCATCTGC	245	
Db	20	CTCAGCCAGGTCATCTGC	2	

Qy	227	CTCAGCCTCAGGCATCTGC	245
Db	20	CTCAGCCACGGTCATCTGC	2

RESULT 79
 US-09-920-672-52/c
 ; Sequence 52, Application US/09920672
 ; Patent No. 6455308
 ; GENERAL INFORMATION:
 ; APPLICANT: Mark J. Graham
 ; APPLICANT: Susan M. Freier
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF SERUM AMYLOID A4 EXPRESSION
 ; FILE REFERENCE: RTS-0251
 ; CURRENT APPLICATION NUMBER: US/09/920,672
 ; CURRENT FILING DATE: 2001-08-01
 ; NUMBER OF SEQ ID NOS: 89
 ; SEQ. ID. NO 52
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-920-672-52

Query Match	1.0%;	Score 14.2;	DB 1;	Length 20;
Best Local Similarity	84.2%;	Pred. No. 1.2e+02;		
Matches 16;	Conservative	0;	Mismatches 3;	Indels 0;
				Caps 0;

Qy 282 GGAAGCAGCAGCAATGTCT 300
| | | | | | | | | |
Db 20 GGAACAGCAGCAGCTGTAT 2

RESULT 80
US-09-527-073-4/c
; Sequence 4, Application US/09527073
; Patent No. 6534313
; GENERAL INFORMATION:
; APPLICANT: Michael M. Neff
; APPLICANT: Joanne Chory
; TITLE OF INVENTION: GENETICALLY MODIFIED PLANTS HAVING
; TITLE OF INVENTION: MODULATED BRASSINOSTEROID SIGNALING
; FILE REFERENCE: SALKINS 024A
; CURRENT APPLICATION NUMBER: US/09/527,073
; CURRENT FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: US 60/124570
; PRIOR FILING DATE: 1999-03-16
; PRIOR APPLICATION NUMBER: US 60/170,931
; PRIOR FILING DATE: 1999-12-14
; PRIOR APPLICATION NUMBER: US 60/172,832
; PRIOR FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
; US-09-527-073-4

```

Query Match      1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1037 CTGACTCTTCCGACAG 1055
      |||||

```

QY 1037 CTGACTCTTCCCACGACAG 1055

Db 19 CTCACACTTCACGACAG 1

RESULT 81
US-09-422-978-6216/c
; Sequence 6216, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6216
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-10151 for SEQ 2282,
US-09-422-978-6216

Query Match 1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1205 CACACCTCCCTCCCTGT 1223
Db 19 CAGACCTCACTCCCTGT 1

RESULT 82
US-09-422-978-11618/c
; Sequence 11618, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11618
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-11303 for SEQ 3753, in complete
US-09-422-978-11618

Query Match 1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1232 CTTGGTGTGACGTGGC 1250
Db 20 CTTGGTGTGGAAGGGC 2

RESULT 83
US-09-230-652-103/c
; Sequence 103, Application US/09230652A
; Patent No. 6537775
; GENERAL INFORMATION:
; APPLICANT: Tournier-Lasserre, Elisabeth
; APPLICANT: Joutel, Anne
; APPLICANT: Bousser, Marie-Germaine
; APPLICANT: Bach, Jean-Francois
; TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
; FILE REFERENCE: 03715.0048-00000
; CURRENT APPLICATION NUMBER: US/09/230,652A
; CURRENT FILING DATE: 1999-05-17
; EARLIER APPLICATION NUMBER: FR 96 09733
; EARLIER FILING DATE: 1996-08-01
; EARLIER APPLICATION NUMBER: FR 97 04680
; EARLIER FILING DATE: 1997-04-16
; EARLIER APPLICATION NUMBER: PCT/FR97/01433
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-230-652-103

Query Match 1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1208 ACCTCCCTTCCCTGTACA 1226
Db 20 ACCTCACCCTCCCTGTGCA 2

RESULT 84
US-09-843-376-62
; Sequence 62, Application US/09843376
; Patent No. 6566132
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTERFERON GAMMA RECEPTOR 1 EXPRESSION
; FILE REFERENCE: RTS-0234
; CURRENT APPLICATION NUMBER: US/09/843,376
; CURRENT FILING DATE: 2001-04-26
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-843-376-62

Query Match 1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1158 GAGTAAAGCAGCTAAAC 1176
Db 1 GTAGTAAAGCAGCAAC 19

```
RESULT 85
US-08-679-529-6
; Sequence 6, Application US/08679529
; Patent No. 6171779
; GENERAL INFORMATION:
; APPLICANT: Chada, Kirin K.
; APPLICANT: Ashar, Hena
; APPLICANT: Tkachenko, Alex
; APPLICANT: Zhou, Xianjin
; TITLE OF INVENTION: HMGI Proteins in Cancer and Obesity
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard R. Muccino
; STREET: 758 Springfield Avenue
; CITY: Summit
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07901
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,529
; FILING DATE: 12-JUL-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Muccino, Richard R.
; REGISTRATION NUMBER: 32,538
; REFERENCE/DOCKET NUMBER: UMD1-037
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908) 273-4988
; TELEFAX: (908) 273-4679
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
US-08-679-529-6

Query Match 1.0%; Score 14; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 282 GGAAGCAGCAGCAA 295
DB 1 GGAAGCAGCAGCAA 14

RESULT 86
PCT-US91-03680-3
; Sequence 3, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy
```

```
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/03680
FILING DATE: 19910524
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Murashige, Kate H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 4610-0011.40
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-327-7250
TELEFAX: 415-327-2951
TELEX: 706141
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: modified_base
LOCATION: 1
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 9
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 15
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 18
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 19
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "1,3-propanediol"
PCT-US91-03680-3

Query Match 1.0%; Score 14; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTTCTTTT 1156
DB 1 CTTTTCCTTTTCTTTT 14

RESULT 87
US-08-921-426-14
; Sequence 14, Application US/08921426
; Patent No. 5837847
; GENERAL INFORMATION:
; APPLICANT: Royer, John C
; APPLICANT: Moyer, Donna L
; APPLICANT: Yoder, Wendy T
; APPLICANT: Shuster, Jeffrey R
; TITLE OF INVENTION: NON-TOXIC, NON-PATHOGENIC
; TITLE OF INVENTION: FUSARIUM EXPRESSION SYSTEM
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5837847o No. 5837847disk of No. 5837847th America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
```



```
; STATE: New York
; COUNTRY: USA
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 29-AUG-1997
; APPLICATION NUMBER: US/08/921,426
; CLASSIFICATION: 435
; PRIORITY INFORMATION:
; APPLICATION NUMBER: US 08/456,433
; FILING DATE: 01-JUN-1995
; APPLICATION NUMBER: US 08/404,678
; FILING DATE: 15-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis Dr., Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 4216.010-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0123
; INFORMATION FOR SEQ ID NO: 14:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-921-426-14

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCAA 400
Db 5 AGAGGTGGCAGCAA 18

RESULT 88
US-08-816-915-14
; Sequence 14, Application US/08816915
; Patent No. 6060305
; GENERAL INFORMATION:
; APPLICANT: Royer, John C.
; APPLICANT: Moyer, Donna L.
; APPLICANT: Yoder, Wendy T.
; APPLICANT: Shuster, Jeffrey R.
; TITLE OF INVENTION: NON-TOXIC, NON-TOXIGENIC, NON-PATHOGENIC
; TITLE OF INVENTION: FUSARIUM EXPRESSION SYSTEM
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESS: No. 6060305 No. 6060305disk of No. 6060305th America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/816,915
; FILING DATE: 13-MAR-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis Dr., Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 4216.240-US
```

```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-878-9655
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-816-915-14

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCAA 400
Db 5 AGAGGTGGCAGCAA 18

RESULT 89
US-08-816-239-2
; Sequence 2, Application US/08816239
; Patent No. 6066493
; GENERAL INFORMATION:
; APPLICANT: Shuster, Jeffrey R.
; APPLICANT: Royer, John C.
; TITLE OF INVENTION: Morphological Mutants of Filamentous
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESS: No. 6066493 No. 6066493disk of No. 6066493th America, Inc.
; STREET: 405 Lexington Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10174
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/816,239
; FILING DATE: 13-MAR-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Starnes, Robert L.
; REGISTRATION NUMBER: 41,324
; REFERENCE/DOCKET NUMBER: 4592.210-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-878-9655
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-816-239-2

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCAA 400
Db 5 AGAGGTGGCAGCAA 18

RESULT 90
US-09-405-564-2
; Sequence 2, Application US/09405564
```

Patent No. 6184026
GENERAL INFORMATION:
APPLICANT: Shuster, Jeffrey R.
APPLICANT: Royer, John C.
TITLE OF INVENTION: Morphological Mutants of Filamentous
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 6184026 of No. 6184026disk of No. 6184026th America, Inc.
STREET: 405 Lexington Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10174
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/405,564
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/816,239
Filing Date: 13-MAR-1997
ATTORNEY/AGENT INFORMATION:
NAME: Starnes, Robert L.
REGISTRATION NUMBER: 41,324
REFERENCE/DOCKET NUMBER: 4592.210-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-878-9655
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-405-564-2

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCAA 400
|||||
Db 5 AGAGGTGGCAGCAA 18

RESULT 91
US-09-309-317-7/c
Sequence 7, Application US/09309317
Patent No. 627970
GENERAL INFORMATION:
APPLICANT: Prusiner, Stanley
APPLICANT: Tremblay, Patrick
APPLICANT: Moore, Richard
APPLICANT: Westaway, David
APPLICANT: Hood, Leroy E.
APPLICANT: Lee, Inyoul
TITLE OF INVENTION: PrP-like Gene
FILE REFERENCE: 6510-130US1
CURRENT APPLICATION NUMBER: US/09/309,317
CURRENT FILING DATE: 1999-05-11
NUMBER OF SEQ ID NOS: 21
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 7
LENGTH: 20
TYPE: DNA
ORGANISM: homosapien
US-09-309-317-7

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 269 GGCTGATCAAGAG 282
|||||
Db 20 GGCTGATCAAGAG 7

RESULT 92

US-09-422-978-7294/c
Sequence 7294, Application US/09422978
Patent No. 6537751
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
FILE REFERENCE: GENSET.020CPI
CURRENT APPLICATION NUMBER: US/09/422,978
CURRENT FILING DATE: 1999-10-20
EARLIER APPLICATION NUMBER: US 09/298,850
EARLIER FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,732
EARLIER FILING DATE: 1998-11-23
EARLIER APPLICATION NUMBER: US 60/082,614
EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 7294
LENGTH: 20
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..20
OTHER INFORMATION: upstream amplification primer 99-3483 for SEQ 3360,
US-09-422-978-7294

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 971 CCTCAGCTTGACCA 984
|||||
Db 14 CCTCAGCTTGACCA 1

RESULT 93
US-09-705-390-2
Sequence 2, Application US/09705390
Patent No. 6544774
GENERAL INFORMATION:
APPLICANT: Shuster, Jeffrey R.
APPLICANT: Royer, John C.
TITLE OF INVENTION: Morphological Mutants of Filamentous
FILE REFERENCE: 4592.230-US
CURRENT APPLICATION NUMBER: US/09/705,390
CURRENT FILING DATE: 2000-11-02
PRIOR APPLICATION NUMBER: 60/010238
PRIOR FILING DATE: 1996-01-19
PRIOR APPLICATION NUMBER: 08/726114
PRIOR FILING DATE: 1996-10-04
PRIOR APPLICATION NUMBER: 08/816239
PRIOR FILING DATE: 1997-03-13
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Fusarium oxysporum
US-09-705-390-2

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCA 400
DB 5 AGAGGTGGCAGCA 18

RESULT 94

PCT-US95-07743-14
; Sequence 14, Application PC/TUS9507743
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: NON-TOXIC, NON-TOXIGENIC, NON-PATHOGENIC
; FUSARIUM EXPRESSION SYSTEM AND PROMOTERS FOR U
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Novo Nordisk of North America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/07743
; FILING DATE: 15-June-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/269,449
; FILING DATE: 30-June-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/404,678
; FILING DATE: 15-March-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis Dr., Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 4216.204-WO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-878-9655
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
PCT-US95-07743-14

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCA 400
DB 5 AGAGGTGGCAGCA 18

RESULT 95

US-08-531-747-4/c
; Sequence 4, Application US/08531747
; Patent No. 5631147
; GENERAL INFORMATION:
; APPLICANT: Lohman, Kenton L.
; APPLICANT: Ostrerova, Natalie V.
; APPLICANT: Van Cleve, Mark
; APPLICANT: Reid, Robert A.
; TITLE OF INVENTION: DETECTION OF NUCLEIC ACIDS IN CELLS BY

; TITLE OF INVENTION: THERMOPHILIC STRAND DISPLACEMENT AMPLIFICATION
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
; ADDRESSEE: Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: NJ
; COUNTRY: US
; ZIP: 07417
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/531,747
; FILING DATE:

; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Fugit, Donna R.
; REGISTRATION NUMBER: 32,135
; REFERENCE/DOCKET NUMBER: P-3462
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-531-747-4

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 274 ATCAAAGAGGAGCAGC 290
DB 17 ATCAATGAGGAGCTGC 1

RESULT 96

US-08-373-124A-2029
; Sequence 2029, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TREATMENT OF RESTENOSIS AND
; CANCELS USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466

```

; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2029:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-2029

Query Match      1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 97;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY      1094 TTGACGCTAATTATGTA 1110
DB      1  UUGAAAGUUAUUGUA 17

RESULT 97
US-08-531-749-4/c
; Sequence 4, Application US/08531749
; Patent No. 5733752
; GENERAL INFORMATION:
; APPLICANT: Lohman, Kenton L.
; APPLICANT: Ostrova, Natalie V.
; APPLICANT: Van Cleve, Mark
; APPLICANT: Reid, Robert A.
; TITLE OF INVENTION: DETECTION OF NUCLEIC ACIDS IN CELLS BY
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
; ADDRESSER: Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: NJ
; COUNTRY: US
; ZIP: 07417
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/531,749
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/531,747
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Fugit, Donna R.
; REGISTRATION NUMBER: 32,135
; REFERENCE/DOCKET NUMBER: P-3462
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-531-749-4

Query Match      1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 97;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY      1094 TTGACGCTAATTATGTA 1110
DB      1  UUGAAAGUUAUUGUA 17

RESULT 97
US-08-531-749-4/c
; Sequence 4, Application US/08531749
; Patent No. 5733752
; GENERAL INFORMATION:
; APPLICANT: Lohman, Kenton L.
; APPLICANT: Ostrova, Natalie V.
; APPLICANT: Van Cleve, Mark
; APPLICANT: Reid, Robert A.
; TITLE OF INVENTION: DETECTION OF NUCLEIC ACIDS IN CELLS BY
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
; ADDRESSER: Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: NJ
; COUNTRY: US
; ZIP: 07417
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/531,749
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/531,747
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Fugit, Donna R.
; REGISTRATION NUMBER: 32,135
; REFERENCE/DOCKET NUMBER: P-3462
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-531-749-4
```

```

Query Match      1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      274 ATCAAAGAGGAGCAGC 290
DB      17 ATCAATGAGGAGCTGC 1

RESULT 98
US-08-781-432-4/c
; Sequence 4, Application US/08781432
; Patent No. 5756702
; GENERAL INFORMATION:
; APPLICANT: Lohman, Kenton L.
; APPLICANT: Ostrova, Natalie V.
; APPLICANT: Van Cleve, Mark
; APPLICANT: Reid, Robert A.
; TITLE OF INVENTION: DETECTION OF NUCLEIC ACIDS IN CELLS BY
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
; ADDRESSER: Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: NJ
; COUNTRY: US
; ZIP: 07417
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/781,432
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/531,747
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Fugit, Donna R.
; REGISTRATION NUMBER: 32,135
; REFERENCE/DOCKET NUMBER: P-3462
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-781-432-4

Query Match      1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      274 ATCAAAGAGGAGCAGC 290
DB      17 ATCAATGAGGAGCTGC 1

RESULT 99
US-08-435-628-2029
; Sequence 2029, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
```

;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
;; TITLE OF INVENTION: CANCER USING RIBOZYMES
;; NUMBER OF SEQUENCES: 2627
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/435,628
;; FILING DATE: 05-MAY-1995
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/373,124
;; FILING DATE: January 13, 1995
;; APPLICATION NUMBER: 08/245,466
;; FILING DATE: May 18, 1994
;; APPLICATION NUMBER: 08/192,943
;; FILING DATE: February 7, 1994
;; APPLICATION NUMBER: 07/987,132
;; FILING DATE: December 7, 1992
;; APPLICATION NUMBER: 07/936,422
;; FILING DATE: August 26, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/035
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 2029:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-435-628--2029

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 97;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1094 TTGAACGTAAATATGTA 1110
:|||||:|:|:|:|:
Db 1 UUGAAGUAUAUGUA 17

RESULT 100
US-08-985-162-17/c
; Sequence 17, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon

;; STREET: 633 West Fifth Street
;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: FastSeq for Windows 2.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/985,162
;; FILING DATE: 04 December 1997
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/036,476
;; FILING DATE: 31 January 1997
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 230/107
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 17:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-985-162-17

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 629 AGCTCCAGGAGCTCTGC 645
|||||
Db 17 AGGCCAGGAGGCTGC 1

RESULT 101
US-08-985-162-645/c
; Sequence 645, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162

FILING DATE: 04 December 1997
 CLASSIFICATION: 514
 PRIOR APPLICATION NUMBER: 60/036,476
 FILING DATE: 31 January 1997
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard J.
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 230/107
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 645:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-985-162-645

Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 97;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 916 CTAAAGGAGATGGCAGA 932
 DB 17 CTAAAGGAGATTTCAGA 1

RESULT 102
 US-08-964-020-2/c
 Sequence 2, Application US/08964020
 Patent No. 6077669
 GENERAL INFORMATION:

APPLICANT: Vonk, Glenn P.
 TITLE OF INVENTION: Kit and Method for Fluorescence Based
 NUMBER OF SEQUENCES: 20
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Richard J. Rodrick - Becton, Dickinson and
 ADDRESS: Company
 STREET: 1 Becton Drive
 CITY: Franklin Lakes
 STATE: NJ
 COUNTRY: USA
 ZIP: 07417

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/964,020
 FILING DATE:

CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Hightet, David W.
 REGISTRATION NUMBER: 30,265
 REFERENCE/DOCKET NUMBER: p-4025
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (201) 847-5317
 TELEFAX: (201) 848-9228
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-964-020-2

Query Match 1.0%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 97;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 274 ATCAAAGAGGAAGCAGC 290
 DB 17 ATCAATGAGGAAGCTGC 1

RESULT 103
 US-09-474-432B-684
 Sequence 684, Application US/09474432B
 Patent No. 6528640
 GENERAL INFORMATION:

APPLICANT: Ribozyne Pharmaceuticals, Inc.
 APPLICANT: Beigelman, Leo
 APPLICANT: Burgin, Alex
 APPLICANT: Beaudry, Amber
 APPLICANT: Karpeisky, Alex
 APPLICANT: Adamic, Jasenka
 APPLICANT: Svedler, David
 APPLICANT: Zinnen, Shawn
 TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleo
 FILE REFERENCE: MBHB00-831-B (247/276)
 CURRENT APPLICATION NUMBER: US/09/474,432B
 CURRENT FILING DATE: 1999-12-19
 PRIOR APPLICATION NUMBER: US 60/064,866
 PRIOR FILING DATE: 1997-11-05
 PRIOR APPLICATION NUMBER: US 60/084,727
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: US 09/186,675
 PRIOR FILING DATE: 1998-11-04
 PRIOR APPLICATION NUMBER: US 09/301,511
 PRIOR FILING DATE: 1999-04-28
 NUMBER OF SEQ ID NOS: 1526
 SOFTWARE: Patent in version 3.0
 SEQ ID NO 684
 LENGTH: 17
 TYPE: RNA
 ORGANISM: Homo sapiens
 US-09-474-432B-684

Query Match 1.0%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 97;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 517 GCCAACCTGCCGAGGA 533
 DB 1 GCCAACCGCCAGAGGA 17

RESULT 104
 US-08-585-684B-2548/c
 Sequence 2548, Application US/08585684B
 Patent No. 5877021
 GENERAL INFORMATION:

APPLICANT: Stinchcomb, Daniel T.
 APPLICANT: Jarvis, Thale
 APPLICANT: McSwiggen, James
 TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
 TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
 NUMBER OF SEQUENCES: 2751
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2548:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2548

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 GGAAGTAAAGCAGCTAA 1173
|||||
DB 18 GGAAGCAAGCAGCTAA 2

RESULT 105

US-08-702-105A-33/c
Sequence 33, Application US/08702105A
Patent No. 5908839
GENERAL INFORMATION:
APPLICANT: Levitt, Roy C.
APPLICANT: Maloy, W. Lee
APPLICANT: Kari, U. Prasad
APPLICANT: Nicolaides, Nicholas C.
TITLE OF INVENTION: Asthma Associated Factors As Targets For
TITLE OF INVENTION: Treating Atopic Allergies Including Asthma And Related
TITLE OF INVENTION: Disorders
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
ADDRESSEE: Dunner L.L.P.
STREET: 1300 I Street N.W., Suite 700
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/702,105A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/874,503
FILING DATE: 13-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Fordis, Jean B.
REGISTRATION NUMBER: 32984
REFERENCE/DOCKET NUMBER: 05387.0056-01000
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 408-4000

TELEFAX: (202) 408-4400
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-702-105A-33

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 464 GCAGCCTGCAGGGGAG 480
|||||
DB 17 GTAGGCTGCAGGGGAG 1

RESULT 106

US-08-702-110A-33/c
Sequence 33, Application US/08702110A
Patent No. 6037149
GENERAL INFORMATION:
APPLICANT: Levitt, Roy C.
APPLICANT: Maloy, W. Lee
APPLICANT: Kari, U. Prasad
APPLICANT: Nicolaides, Nicholas C.
TITLE OF INVENTION: Asthma Associated Factors As Targets For
TITLE OF INVENTION: Treating Atopic Allergies Including Asthma And Related
TITLE OF INVENTION: Disorders
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
ADDRESSEE: Dunner L.L.P.
STREET: 1300 I Street N.W., Suite 700
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/702,110A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/874,503
FILING DATE: 13-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Fordis, Jean B.
REGISTRATION NUMBER: 32984
REFERENCE/DOCKET NUMBER: 05387.0056-01000
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 408-4000
TELEFAX: (202) 408-4400
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-702-110A-33

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 464 GCAGCCTGCAGGGGAG 480

RESULT 110

US-08-679-645-583
; Sequence 583, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 583:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-583

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 1.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 890 AGCTGCGGTACAGCGTG 906

Db 1 AGCUGCGGUACGCCUG 17

RESULT 111

US-08-535-249-98
; Sequence 98, Application US/08535249
; Patent No. 6455689
; GENERAL INFORMATION:

; APPLICANT: Schlingensiepen, Georg-Ferdinand
; APPLICANT: Brysch, Wolfgang
; APPLICANT: Schlingensiepen, Karl-Hermann
; APPLICANT: Schlingensiepen, Reimar
; APPLICANT: Bogdahn, Ulrich
; TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
; immunosuppressive effect of transforming-growth-factor beta
; NUMBER OF SEQUENCES: 137
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/535,249
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 089.0
; FILING DATE: 30-APR-1993
; PRIOR APPLICATION DATA: EP 93 107 849.7
; FILING DATE: 13-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
US-08-535-249-98

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1018 AGATGGTGCCAAAGTGC 1034

Db 2 AGATGGTACAAAAGTGC 18

RESULT 112

US-09-091-952A-193
; Sequence 193, Application US/09091952A
; Patent No. 6458532
; GENERAL INFORMATION:
; APPLICANT: Detera-Wadleigh, Sevilla D.
; APPLICANT: Gershon, Elliot S.
; APPLICANT: Badner, Judith A.
; APPLICANT: Goldin, Lynn R.
; APPLICANT: Berrettini, Wade H.
; APPLICANT: Yoshikawa, Takeo
; APPLICANT: Sanders, Alan R.
; APPLICANT: Esterling, Lisa E.

TITLE OF INVENTION: Chromosomal Markers and Diagnostic
Tests for Manic-Depressive Illness
NUMBER OF SEQUENCES: 197
CORRESPONDENCE ADDRESS:

```
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/091,952A
; FILING DATE: 19-Apr-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/029,278
; FILING DATE: 28-OCT-1996
; APPLICATION NUMBER: PCT/US97/19381
; FILING DATE: 28-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, Timothy L.
; REGISTRATION NUMBER: 35,367
; REFERENCE/DOCKET NUMBER: 015280-297100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 193:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: -
; LOCATION: 1...18
; OTHER INFORMATION: Clone 47 reverse primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 193:
US-09-091-952A-193
```

```
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1319 GTGCTTTCTAGACTCTT 1335
Db 2 GTGCTTCTGAGCTCTT 18
```

```
RESULT 113
US-09-422-978-4727
; Sequence 4727, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4727
; LENGTH: 18
; TYPE: DNA
```

```
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-17363 for SEQ 793,
US-09-422-978-4727
```

```
Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 935 TGGAGAGAGGTTGTGAG 951
Db 2 TGGAGAGAGGTTGTG 18
```

```
RESULT 114
US-07-741-940-49/c
; Sequence 49, Application US/07741940
; Patent No. 5352775
; GENERAL INFORMATION:
; APPLICANT: ALBERTSEN, HANS
; APPLICANT: ANAND, RAKESH
; APPLICANT: CARLSON, MARY
; APPLICANT: GRODEN, JOANNA
; APPLICANT: HEDGE, PHILIP J.
; APPLICANT: JOSLYN, GROFF
; APPLICANT: KINZLER, KENNETH
; APPLICANT: MARKHAM, ALEXANDER F.
; APPLICANT: NAKAMURA, YUSUKE
; APPLICANT: THLIVERIS, ANDREW
; TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
; TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
; NUMBER OF SEQUENCES: 94
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Banner, Birch, McKie & Beckett
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20001-4598
```

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/741,940
; FILING DATE: 19920109
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
```

```
; NAME: Kagan, Sarah A.
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 1107.035574
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
```

```
; TELEFAX: 202-508-9299
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-07-741-940-49
```

```
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 100 ACAACCCCGAGCGCA 116
```



```

;
; NUMBER OF SEQUENCES: 102
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Ltd.
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20001-4598
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,655B
; FILING DATE: 25-MAY-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/289,548
; FILING DATE: 12-AUG-1994
; PRIOR APPLICATION DATA: US 07/741,940
; APPLICATION NUMBER: US 08/289,548
; FILING DATE: 08-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A.
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 1107.49964
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
;
; US-08-452-655B-49
;
; Query Match 1.0%; Score 13.8; DB 1; Length 19;
; Best Local Similarity 88.2%; Pred. No. 1.3e+02;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 100 ACAACCCGAGCGCA 116
Db 17 ACAACCCGAGCGCA 1
;
; RESULT 118
; US-08-468-037A-33/c
; Sequence 33, Application US/08468037A
; Patent No. 5859221
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: A. Kawasaki
; TITLE OF INVENTION: 2'-Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5859221ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,973A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 835,932
; FILING DATE: 05-MAR-1992
; NAME: Joseph Lucci
; ATTORNEY/AGENT INFORMATION:
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-471-973A-33
;
; Query Match 1.0%; Score 13.8; DB 1; Length 19;

```

```

;
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 835,932
; FILING DATE: 05-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-468-037A-33
;
; Query Match 1.0%; Score 13.8; DB 1; Length 19;
; Best Local Similarity 88.2%; Pred. No. 1.3e+02;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 1141 GCGTTTTTCTTTTG 1157
Db 19 GCGTTTTTCTTTTG 3
;
; RESULT 119
; US-08-471-973A-33/c
; Sequence 33, Application US/08471973A
; Patent No. 5872232
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: Andrew Kawasaki
; TITLE OF INVENTION: Sugar Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5872232ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,973A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 835,932
; FILING DATE: 05-MAR-1992
; NAME: Joseph Lucci
; ATTORNEY/AGENT INFORMATION:
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-471-973A-33
;
; Query Match 1.0%; Score 13.8; DB 1; Length 19;

```

Best Local Similarity 88.2%; Pred. No. 1.3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 1141 GCCTTTTTCCTTTTG 1157
Db 19 GCGTTTTTTCCTTTTG 3

RESULT 120

US-08-465-880-28/c
; Sequence 28, Application US/08465880
; Patent No. 5955589
; GENERAL INFORMATION:
; APPLICANT: Philip Dan Cook
; TITLE OF INVENTION: Gapped 2' Modified Oligonucleotides
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5955589ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,880
; FILING DATE: Herewith
; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 244,993
; FILING DATE: 21-JUN-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2002

TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-465-880-28

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTTCCTTTTG 1157
Db 19 GCGTTTTTTCCTTTTG 3

RESULT 121

US-09-035-357-33/c
; Sequence 33, Application US/09035357
; Patent No. 6005087
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: A. Kawasaki
; TITLE OF INVENTION: 2'-Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6005087ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA

COUNTRY: U.S.A.
; ZIP: 19103
COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/035,357
; FILING DATE:

CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/468,037
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-035-357-33

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTTCCTTTTG 1157
Db 19 GCGTTTTTTCCTTTTG 3

RESULT 122

US-08-450-582-49/c
; Sequence 49, Application US/08450582
; Patent No. 6114124
; GENERAL INFORMATION:
; APPLICANT: ALBERTSEN HANS
; APPLICANT: ANAND, RAKESH
; APPLICANT: CARLSON, MARY
; APPLICANT: GRODEN, JOANNA
; APPLICANT: HEDGE, PHILIP J.
; APPLICANT: JOSLYN, GEOFF
; APPLICANT: KINZLER, KENNETH
; APPLICANT: MARKHAM, ALEXANDER F.
; APPLICANT: NAKAMURA, YUSUKE
; APPLICANT: THLIVERIS, ANDREW
; TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
; NUMBER OF SEQUENCES: 102
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Ltd.
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20001-4598

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/08/450,582
; APPLICATION NUMBER: US/08/450,582
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: US 08/452,655
; FILING DATE: 25-MAY-1995
; APPLICATION NUMBER: US 08/289,548
; FILING DATE: 12-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/741,940
; FILING DATE: 08-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A.
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 1107.49964
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-08-450-582-49

Query Match          1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCCGAGCGCA 116
Db 17 ACAACCCCGAGCGCA 1

RESULT 123
US-09-016-520-4/c
; Sequence 4, Application US/09016520A
; Patent No. 6127533
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/016,520A
; CURRENT FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; PRIOR FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Sequence
US-09-016-520-4

Query Match          1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTTCCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 124
US-09-144-611-12/c
; Sequence 12, Application US/09144611A
; Patent No. 6146829
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/477,902
```

```
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Monia, Brett P
; TITLE OF INVENTION: Gapped 2' Modified Oligonucleotides
; FILE REFERENCE: ISIS3153
; CURRENT APPLICATION NUMBER: US/09/144,611A
; CURRENT FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: 08/861,306
; PRIOR FILING DATE: 1997-04-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6146829e1
; OTHER INFORMATION: Sequence
US-09-144-611-12

Query Match          1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTTCCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 125
US-09-130-973-4/c
; Sequence 4, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Prakash, Thazha P
; APPLICANT: Kawasaki, Andrew M
; TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides And Methods For
; TITLE OF INVENTION: Making Same
; FILE REFERENCE: ISIS2955
; CURRENT APPLICATION NUMBER: US/09/130,973
; CURRENT FILING DATE: 1998-08-07
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6172209e1
; OTHER INFORMATION: Sequence
US-09-130-973-4

Query Match          1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTTCCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 126
US-09-477-902-4/c
; Sequence 4, Application US/09477902
; Patent No. 6194598
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Kawasaki, Andrew
; TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides
; FILE REFERENCE: ISIS2824
; CURRENT APPLICATION NUMBER: US/09/477,902
```

```
; CURRENT FILING DATE: 2000-01-05
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 60/037,143
; PRIOR FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Sequence
; OTHER INFORMATION: Sequence
US-09-477-902-4

Query Match          1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1141 GCCTTTTTCCTTTTG 1157
Db      19 GCGTTTTTTTTTTTG 3

RESULT 127
US-09-315-886C-32/c
; Sequence 32, Application US/09315886C
; Patent No. 6225063
; GENERAL INFORMATION:
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Varus, Michael
; TITLE OF INVENTION: RNA Channels in Biological Membranes
; FILE REFERENCE: UTC-03444
; CURRENT APPLICATION NUMBER: US/09/315,886C
; CURRENT FILING DATE: 1999-05-20
; PRIOR APPLICATION NUMBER: 60/086,492
; PRIOR FILING DATE: 1998-05-22
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 32
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-315-886C-32

Query Match          1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      196 CACCGGACCGCGACGA 212
Db      17 CACCGGACCGCGCTAGGA 1

RESULT 128
US-09-453-514A-12/c
; Sequence 12, Application US/09453514A
; Patent No. 6326199
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: Gapped 2-Modified Oligonucleotides
; FILE REFERENCE: ISIS-4291
; CURRENT APPLICATION NUMBER: US/09/453,514A
; CURRENT FILING DATE: 1999-12-01
; PRIOR APPLICATION NUMBER: 09/144,611
; PRIOR FILING DATE: 1998-08-31
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
```

```
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: No. 6326199el Sequence
US-09-453-514A-12

Query Match          1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1141 GCCTTTTTCCTTTTG 1157
Db      19 GCGTTTTTTTTTTTG 3

RESULT 129
US-09-135-202-33/c
; Sequence 33, Application US/09135202
; Patent No. 6399754
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: Andrew Kawasaki
; TITLE OF INVENTION: Sugar Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6399754ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/135,202
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/471,973
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-135-202-33

Query Match          1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1141 GCCTTTTTCCTTTTG 1157
Db      19 GCGTTTTTTTTTTTG 3

RESULT 130
US-08-449-731-49/c
; Sequence 49, Application US/08449731
; Patent No. 6413727
```

GENERAL INFORMATION:
APPLICANT: ALBERTSEN, HANS
ANAND, RAKESH
CARLSON, MARY
GRODEN, JOANNA
HEDGE, PHILIP J.
JOSLYN, GEOFF
KINZLER, KENNETH
MARKHAM, ALEXANDER F.
NAKAMURA, YUSUKE
THLIVERTIS, ANDREW

TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
GENE IN COLORECTAL CANCER IN HUMANS

NUMBER OF SEQUENCES: 102
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Allegretti, LTD
STREET: 1001 G Street, NW
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20001-4598

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/449,731
FILING DATE: 25-May-1995
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/289,548
FILING DATE: 12-AUG-1994

ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A.
REGISTRATION NUMBER: 32,141
REFERENCE/DOCKET NUMBER: 1107.46943

TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-508-9100
TELEFAX: 202-508-9299

INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: Homo sapiens

SEQUENCE DESCRIPTION: SEQ ID NO: 49:
US-08-449-731-49

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCGAGGCCA 116
DB 17 ACAACCCGAGGCCA 1

RESULT 131
US-08-802-331-29/c
Sequence 29, Application US/08802331
Patent No. 6451991

GENERAL INFORMATION:
APPLICANT: Cook, Phillip D.
APPLICANT: Monia, Brett
APPLICANT: Martin, Pierre
APPLICANT: Altman, Karl-Heinz

TITLE OF INVENTION: Sugar-Modified Gapped Oligonucleotides
FILE REFERENCE: ISN00083
CURRENT APPLICATION NUMBER: US/08/802,331

CURRENT FILING DATE: 1997-02-11
NUMBER OF SEQ ID NOS: 32
SOFTWARE: Patent in version 3.1
SEQ ID NO 29
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: No. 6451991el Sequence
US-08-802-331-29

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTTTTGTG 1157
DB 19 GCGTTTTTTTTTTTG 3

RESULT 132
US-09-375-318-29/c
Sequence 29, Application US/09375318
Patent No. 6468791

GENERAL INFORMATION:
APPLICANT: Tanzi, Rudolph E.
Schellenberg, Gerard D.
Masco, Wilma
Levy-Lahad, Ephrat
Bird, Thomas D.
Galas, David J.

TITLE OF INVENTION: CHROMOSOME 1 GENE AND GENE PRODUCTS RELATED TO
NUMBER OF SEQUENCES: 89
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BEERY LLP
STREET: 701 Fifth Ave, Suite 6300
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/375,318
FILING DATE: 16-Aug-1999
CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:
NAME: Verna, James M.
REGISTRATION NUMBER: 33,287
REFERENCE/DOCKET NUMBER: 920010.571C1

TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 29:
US-09-375-318-29

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 581 CCTCCGTCGCCCCC 597
DB 17 CTCCTCGTCGCCAC 1


```
RESULT 133
US-09-375-318-43/c
; Sequence 43, Application US/09375318
; Patent No. 6468791
; GENERAL INFORMATION:
; APPLICANT: Tanzi, Rudolph E.
; Schellenberg, Gerard D.
; Wasco, Wilma
; Levy-Lahad, Ephrat
; Bird, Thomas D.
; Galas, David J.
; TITLE OF INVENTION: CHROMOSOME 1 GENE AND GENE PRODUCTS RELATED TO
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SRED AND BEERY LLP
; STREET: 701 Fifth Ave, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patenlin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/375,318
; FILING DATE: 16-Aug-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Verna, James M.
; REGISTRATION NUMBER: 33,287
; REFERENCE/DOCKET NUMBER: 920010.571C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4300
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 43:
US-09-375-318-43
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 581 CCCTCCGCTGCGCCCC 597
Db 17 CTCCTCCGCTGCGCCAC 1

RESULT 134
US-09-389-283-33/c
; Sequence 33, Application US/09389283
; Patent No. 6531584
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: A. Kawasaki
; TITLE OF INVENTION: 2'-Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6531584ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
```

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/389,283
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: 09/035,357
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-389-283-33
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 135
US-09-302-681-76
; Sequence 76, Application US/09302681
; Patent No. 6441149
; GENERAL INFORMATION:
; APPLICANT: HerinStadt, Corrina
; APPLICANT: Ghosh, Soumitra S.
; APPLICANT: Clevenger, William
; APPLICANT: Fahy, Eoin E.
; APPLICANT: Davis, Robert E.
; TITLE OF INVENTION: DIAGNOSTIC METHOD BASED ON
; FILE REFERENCE: 660088.416C1
; CURRENT APPLICATION NUMBER: US/09/302,681
; CURRENT FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 76
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer corresponding to NADH
; OTHER INFORMATION: dehydrogenase encoding mitochondrial DNA
US-09-302-681-76
Query Match 1.0%; Score 13.6; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 268 TGGCTGATCAAGAGGAAGC 287
Db 2 TGGCTGATTCAGAGATATGC 21

RESULT 136
US-08-832-021-49
```

; Sequence 49, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:

; APPLICANT: Combates, N.
; APPLICANT: Pardini, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.

; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

; FILE REFERENCE: JBP-382

; CURRENT APPLICATION NUMBER: US/08/832,021

; CURRENT FILING DATE: 1997-04-02

; NUMBER OF SEQ ID NOS: 64

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 49

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-49

Query Match

Best Local Similarity 1.0%; Score 13.4; DB 1; Length 15;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTCTCTTTTGA 1159

DB 1 TTTTCTCTTTTGA 15

RESULT 137

US-08-445-515-37

; Sequence 37, Application US/08445515

; Patent No. 6043088

; GENERAL INFORMATION:

; APPLICANT: Bookstein, Robert

; APPLICANT: Isaacs, William B.

; TITLE OF INVENTION: A No. 6043088el Prostate/Colon Tumor Suppressor

; TITLE OF INVENTION: Gene Located on Human Chromosome 8

; NUMBER OF SEQUENCES: 59

; CORRESPONDENCE ADDRESS:

; ADDRESS: Campbell and Flores

; STREET: 4370 La Jolla Village Drive, Suite 700

; CITY: San Diego

; STATE: California

; COUNTRY: USA

; ZIP: 92122

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/445,515

; FILING DATE:

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Campbell, Cathryn A.

; REGISTRATION NUMBER: 31,815

; REFERENCE/DOCKET NUMBER: P-CJ 1607

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (619) 535-9001

; TELEFAX: (619) 535-8949

; INFORMATION FOR SEQ ID NO: 37:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-445-515-37

Query Match

1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 1.2e-02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 237 GGCACTGTCATCTGG 251

DB 3 GGCACTGTCATCTGG 17

RESULT 138

US-09-996-243-493

; Sequence 493, Application US/09996243

; Patent No. 6478825

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Kijavir, Ivar J.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K.

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: P2730P13

; CURRENT APPLICATION NUMBER: US/09/996,243

; CURRENT FILING DATE: 2001-11-14

; PRIOR APPLICATION NUMBER: 60/049787

; PRIOR FILING DATE: 1997-06-16

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/065186

; PRIOR FILING DATE: 1997-11-12

; PRIOR APPLICATION NUMBER: 60/065311

; PRIOR FILING DATE: 1997-11-13

; PRIOR APPLICATION NUMBER: 60/066770

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/075945

; PRIOR FILING DATE: 1998-02-25

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/083322

; PRIOR FILING DATE: 1998-04-28

; PRIOR APPLICATION NUMBER: 60/084600

; PRIOR FILING DATE: 1998-05-07

; PRIOR APPLICATION NUMBER: 60/087106

; PRIOR FILING DATE: 1998-05-28

; PRIOR APPLICATION NUMBER: 60/087607

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087609

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087759

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087827

; PRIOR FILING DATE: 1998-06-03

; PRIOR APPLICATION NUMBER: 60/088021

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088025

; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred.No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 494 GTGTGACGCTCTTG 508

Db 1 GTGGCAGCGCTCTTG 15

RESULT 139
US-09-371-772B-5187 ; Sequence 5187, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Referred to as Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: NEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 5187
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5187

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1154 TTGTGAAGTAAGCA 1168
:::|||||:|||||
Db 1 UUUUGAACUAAGCA 15

RESULT 140
US-08-585-684B-2595
; Sequence 2595, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; City: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078


```
/ NAME: Smith, William M.
/ REGISTRATION NUMBER: 30,223
/ REFERENCE/DOCKET NUMBER: 14643-5
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-543-9600
/ TELEFAX: 415-543-5043
/ INFORMATION FOR SEQ ID NO: 8:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-07-834-539A-8

Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 19;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18

RESULT 147
US-08-053-131-16
/ Sequence 16, Application US/08053131
/ Patent No. 5661016
/ GENERAL INFORMATION:
/ APPLICANT: Lonberg, Nils
/ APPLICANT: Kay, Robert M.
/ TITLE OF INVENTION: Transgenic No. 5661016-Human Animals for
/ TITLE OF INVENTION: Producing Heterologous Antibodies
/ NUMBER OF SEQUENCES: 197
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Townsend and Townsend Kourie and Crew
/ STREET: One Market Plaza, Steuart Tower, Suite 200
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94105
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/053,131
/ FILING DATE: 26-APR-1993
/ CLASSIFICATION: 800
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/990,860
/ FILING DATE: 16-DEC-1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/810,279
/ FILING DATE: 17-DEC-1991
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/853,408
/ FILING DATE: 18-MAR-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Smith, William M.
/ REGISTRATION NUMBER: 30,223
/ REFERENCE/DOCKET NUMBER: 14643-9-3
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-326-2400
/ TELEFAX: 415-326-2422
/ INFORMATION FOR SEQ ID NO: 16:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (primer)

US-07-853-408B-16
/ Sequence 16, Application US/07853408B
/ Patent No. 5789650
/ GENERAL INFORMATION:
/ APPLICANT: Lonberg, Nils
/ APPLICANT: Kay, Robert M.
/ TITLE OF INVENTION: Transgenic No. 5789650-Human Animals for
```

```
US-08-053-131-16
Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 19;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18

RESULT 148
US-08-645-641-16
/ Sequence 16, Application US/08645641
/ Patent No. 5719032
/ GENERAL INFORMATION:
/ APPLICANT: Lonberg, Nils
/ APPLICANT: Kay, Robert M.
/ TITLE OF INVENTION: Transgenic No. 5719032-Human Animals for
/ TITLE OF INVENTION: Producing Heterologous Antibodies
/ NUMBER OF SEQUENCES: 150
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: William M. Smith
/ STREET: Two Embarcadero Center, 8th Floor
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94111-3834
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/645,641
/ FILING DATE: 20-MAY-1996
/ CLASSIFICATION: 800
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/904,068
/ FILING DATE: 23-JUN-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Smith, William M.
/ REGISTRATION NUMBER: 30,223
/ REFERENCE/DOCKET NUMBER: 14643-000913
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-326-2400
/ TELEFAX: 415-326-2422
/ INFORMATION FOR SEQ ID NO: 16:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (primer)
US-08-645-641-16

Query Match
Best Local Similarity 1.0%; Score 13.4; DB 1; Length 19;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18

RESULT 149
US-07-853-408B-16
/ Sequence 16, Application US/07853408B
/ Patent No. 5789650
/ GENERAL INFORMATION:
/ APPLICANT: Lonberg, Nils
/ APPLICANT: Kay, Robert M.
/ TITLE OF INVENTION: Transgenic No. 5789650-Human Animals for
```

```

; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 150
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/853,408B
; FILING DATE: 19920318
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14643-9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; US-07-853-408B-16

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCCGCAATGGCC 18

RESULT 150
US-08-096-762-16
; Sequence 16, Application US/08096762
; Patent No. 5614318
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; APPLICANT: Kay, Robert M.
; TITLE OF INVENTION: Transgenic No. 5814318-Human Animals for
; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 210
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 200
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/096,762
; FILING DATE: 22-JUL-1993
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/053,131
; FILING DATE: 26-APR-1993
; PRIOR APPLICATION DATA:

```

```

; APPLICATION NUMBER: US 07/990,860
; FILING DATE: 16-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/904,068
; FILING DATE: 23-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/853,408
; FILING DATE: 18-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/810,279
; FILING DATE: 17-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14643-9-4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
; US-08-096-762-16

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCCGCAATGGCC 18

RESULT 151
US-08-800-353-8
; Sequence 8, Application US/08800353
; Patent No. 5874299
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; APPLICANT: Kay, Robert M.
; TITLE OF INVENTION: Transgenic No. 5874299-Human Animals Capable of
; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/800,353
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/834,539
; FILING DATE: 1992-02-05
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14643-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-543-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 8:

```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-800-353-8
Query Match          1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 391 GTGGCAGCAATGCC 405
Db 4 GTGGCGCAATGCC 18

RESULT 152
US-08-308-865-16
; Sequence 16, Application US/08308865
; Patent No. 5877397
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; TITLE OF INVENTION: Transgenic No. 5877397-Human Animals for
; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 150
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 23-JUN-1992
; CLASSIFICATION: 800
; PRIOR APPLICATION NUMBER: US 07/904,068
; FILING DATE: 17-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/853,408
; FILING DATE: 18-MAR-1992
; PRIOR APPLICATION NUMBER: US 07/904,068
; FILING DATE: 23-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/990,860
; FILING DATE: 16-DEC-1992
; PRIOR APPLICATION NUMBER: US 08/053,131
; FILING DATE: 26-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/096,762
; FILING DATE: 22-JUL-1993
; PRIOR APPLICATION NUMBER: US 08/155,301
; FILING DATE: 18-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/161,739
; FILING DATE: 03-DEC-1993
; PRIOR APPLICATION NUMBER: US 08/165,699
; FILING DATE: 10-DEC-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/209,741
; FILING DATE: 09-MAR-1994
; PRIOR APPLICATION NUMBER: US 08/352,322
; FILING DATE: 07-DEC-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/544,404
; FILING DATE: 10-OCT-1995
; PRIOR APPLICATION NUMBER: US 08/728,463
; FILING DATE: 10-OCT-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/US96/16433
; FILING DATE: 10-OCT-1996
; PRIOR APPLICATION NUMBER: US 08/758,417
; FILING DATE: 02-DEC-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/US97/21803
```



```
; FILING DATE: 01-DEC-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 014643-009040US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 184:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-09-042-353-184

Query Match          1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      391 GTGGCAGCAATGGCC 405
Db      4 GTGGCCGCAATGGCC 18

RESULT 154
US-08-758-417A-32
; Sequence 32, Application US/08758417A
; Patent No. 6300129
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; Kay, Robert M.
; TITLE OF INVENTION: Transgenic No. 6300129-Human Animals for
; Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 417
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,417A
; FILING DATE: 02-Dec-1996
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/728,463
; FILING DATE: 10-OCT-1996
; APPLICATION NUMBER: US 08/544,404
; FILING DATE: 10-OCT-1995
; APPLICATION NUMBER: US 08/352,322
; FILING DATE: 07-DEC-1994
; APPLICATION NUMBER: US 08/209,741
; FILING DATE: 09-MAR-1994
; APPLICATION NUMBER: US 08/165,699
; FILING DATE: 10-DEC-1993
; APPLICATION NUMBER: US 08/161,739
; FILING DATE: 03-DEC-1993
; APPLICATION NUMBER: US 08/155,301
; FILING DATE: 18-NOV-1993
; APPLICATION NUMBER: US 08/096,762
; FILING DATE: 22-JUL-1993
; APPLICATION NUMBER: US 08/053,131
; FILING DATE: 26-APR-1993
; APPLICATION NUMBER: US 07/990,860
; FILING DATE: 16-DEC-1992
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Serafini, Andrew T.
; REGISTRATION NUMBER: 41,303
; REFERENCE/DOCKET NUMBER: 014643-009030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-08-758-417A-32

Query Match          1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      391 GTGGCAGCAATGGCC 405
Db      4 GTGGCCGCAATGGCC 18

RESULT 155
US-09-517-467B-9
; Sequence 9, Application US/09517467B
; Patent No. 6451602
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF PARP EXPRESSION
; FILE REFERENCE: RTS-0150
; CURRENT APPLICATION NUMBER: US/09/517,467B
; CURRENT FILING DATE: 2001-03-02
; PRIOR APPLICATION NUMBER: 09/517,467
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 345
; SEQ ID NO 9
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
; US-09-517-467B-9

Query Match          1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      229 CAGCCTCAGGCATCT 243
Db      5 CAGCCACAGGCATCT 19

RESULT 156
PCT-US92-06185-8
; Sequence 8, Application PC/TUS9206185
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; APPLICANT: Kay, Robert M.
; TITLE OF INVENTION: Transgenic Non-Human Animals Capable of
; Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 75
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
```

```

;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/06185
; FILING DATE: 19910828
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 87654
; REFERENCE/DOCKET NUMBER: 14643-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-543-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; PCT-US92-06185-8
;
; Query Match 1.0%; Score 13.4; DB 1; Length 19;
; Best Local Similarity 93.3%; Pred. No. 1.5e+02;
; Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
QY 391 GTGGCGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18
;
; RESULT 157
; PCT-US92-10983-16
; Sequence 16, Application PC/TUS9210983
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; APPLICANT: Kay, Robert M.
; TITLE OF INVENTION: Transgenic Non-Human Animals for
; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 152
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/10983
; FILING DATE: 19921217
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14643-9-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
;
; Query Match 1.0%; Score 13.4; DB 1; Length 18;
; Best Local Similarity 83.3%; Pred. No. 1.5e+02;
; Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
;
PCT-US92-10983-16
;
; Query Match 1.0%; Score 13.4; DB 1; Length 19;
; Best Local Similarity 93.3%; Pred. No. 1.5e+02;
; Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
QY 391 GTGGCGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18
;
; RESULT 158
; US-07-759-841C-2
; Sequence 2, Application US/07759841C
; Patent No. 5618796
; GENERAL INFORMATION:
; APPLICANT: Iversen, Patrick L.
; TITLE OF INVENTION: No. 5618796el Metal Binding Agents, and
; TITLE OF INVENTION: Methods and Compositions for Their
; TITLE OF INVENTION: Use to Treat Metal Toxicity
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: John P. Floyd, Esq.
; STREET: P.O. Box 3609
; CITY: Williamsburg
; STATE: Virginia
; COUNTRY: USA
; ZIP: 23187-3609
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 Kb storage
; COMPUTER: IBM-compatible 486/33
; OPERATING SYSTEM: MS-DOS 5.0
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/759,841C
; FILING DATE: 12 September 1991
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA: none
; ATTORNEY/AGENT INFORMATION:
; NAME: Floyd, John P.
; REGISTRATION NUMBER: 19,528
; REFERENCE/DOCKET NUMBER: 63031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (804) 220-0930
; TELEFAX: (804) 220-0930
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotide bases
; TYPE: nucleic acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to a mRNA
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: 16q21-q22.1.
; MAP POSITION: 844 through 861
; UNITS:
; PUBLICATION INFORMATION:
; AUTHORS: Karin, M., and Richards, R. I.
; TITLE: Human metallothionein genes-primary
; TITLE: structure of the Metallothionein-II gene and
; TITLE: a related processed gene
; JOURNAL: Nature
; VOLUME: 299
; ISSUE: 43
; PAGES: 797
; DATE: 1982
; US-07-759-841C-2
;
; Query Match 1.0%; Score 13.2; DB 1; Length 18;
; Best Local Similarity 83.3%; Pred. No. 1.5e+02;
; Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
;
```

Qy 525 GCCGGAGGAGCAGCTGG 542
Db 1 GGCGCAGGAGCAGTTGG 18

RESULT 159
 US-07-759-841C-3/c
 ; Sequence 3, Application US/07759841C
 ; Patent No. 5618796
 ; GENERAL INFORMATION:
 ; APPLICANT: Iversen, Patrick L.
 ; TITLE OF INVENTION: No. 5618796el Metal Binding Agents, and
 ; TITLE OF INVENTION: Methods and Compositions for Their
 ; TITLE OF INVENTION: Use to Treat Metal Toxicity
 ; NUMBER OF SEQUENCES: 3
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: John P. Floyd, Esq.
 ; STREET: P. O. Box 3609
 ; CITY: Williamsburg
 ; STATE: Virginia
 ; COUNTRY: USA
 ; ZIP: 23187-3609
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette, 5.25 inch, 360 Kb storage
 ; COMPUTER: IBM-compatible 486/33
 ; OPERATING SYSTEM: MS-DOS 5.0
 ; SOFTWARE: WordPerfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/07759,841C
 ; FILING DATE: 12 September 1991
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA: none
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Floyd, John P.
 ; REGISTRATION NUMBER: 19,528
 ; REFERENCE/DOCKET NUMBER: 63031
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (804) 220-0930
 ; TELEFAX: (804) 220-0930
 ; INFORMATION FOR SEQ ID NO: 3:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18 nucleotide bases
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: cDNA to a mRNA
 ; HYPOTHETICAL: no
 ; ANTI-SENSE: yes
 ; POSITION IN GENOME:
 ; CHROMOSOME/SEGMENT: 16q21-q22.1.
 ; MAP POSITION: 844 through 861.
 ; UNITS:
 ; PUBLICATION INFORMATION:
 ; AUTHORS: Karin, M., and Richards, R. I.
 ; TITLE: Human metallothionein genes-primary
 ; TITLE: structure of the Metallothionein-II gene and
 ; TITLE: a related processed gene
 ; JOURNAL: Nature
 ; VOLUME: 299
 ; ISSUE: 43
 ; PAGES: 797
 ; DATE: 1982
 ; US-07-759-841C-3

```

RESULT 160
US-09-339-964-33
; Sequence 33, Application US/09339964
; Patent NO. 6025198
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SHIP-2 EXPRESSION
; FILE REFERENCE: RTS-0065
; CURRENT APPLICATION NUMBER: US/09/339,964
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 33
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-339-964-33

```

```

RESULT 161
US-09-339-993-23/c
; Sequence 23, Application US/09339993A
; Patent NO. 6040179
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-I2 EXPRESSION
; FILE REFERENCE: RTS-0064
; CURRENT APPLICATION NUMBER: US/09/339,993A
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-339-993-23

```

```

RESULT 162
US-09-073-465-7/c
; Sequence 7, Application US/09073465
; Patent No. 6054278
; GENERAL INFORMATION:
; APPLICANT: DODGE, Deborah E
; APPLICANT: SMITH, Doug
; TITLE OF INVENTION: RIBOSOMAL RNA GENE POLYMORPHISM BASED MICROORGANISM
; TITLE OF INVENTION: IDENTIFICATION
; FILE REFERENCE: 4343 US
; CURRENT APPLICATION NUMBER: US/09/073,465
; CURRENT FILING DATE: 1998-05-05
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7

```

```
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Bacterial
US-09-073-465-7

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      882 GTTCAGAGCTGGGTA 899
Db      18 GTGCAGAGCGCGGTA 1

RESULT 163
US-09-339-775-31/C
; Sequence 31, Application US/09339775
; Patent No. 6063626
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowert
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-I3 EXPRESSION
; FILE REFERENCE: RGS-0069
; CURRENT APPLICATION NUMBER: US/09/339,775
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 31
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-339-775-31

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      973 CTCACCTGACCGCCCA 990
Db      18 CTCACCTGACCTGCGCA 1

RESULT 164
US-09-199-859-14
; Sequence 14, Application US/09199859
; Patent No. 6063008
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowert
; TITLE OF INVENTION: ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION
; FILE REFERENCE: RGS-0025
; CURRENT APPLICATION NUMBER: US/09/199,859
; CURRENT FILING DATE: 1998-11-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 14
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-199-859-14

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1300 CCTGGCCCCATGTAGCCA 1317
Db      1 CCTGGTCTCTGTAGCCA 18
```

```
RESULT 165
US-08-795-430-31
; Sequence 31, Application US/08795430
; Patent No. 6130071
; GENERAL INFORMATION:
; APPLICANT: Alitalo, Kari
; APPLICANT: Joukov, Vladimir
; TITLE OF INVENTION: Vascular Endothelial Growth Factor C (VEGF-C)
; TITLE OF INVENTION: Protein and Gene, Mutants Thereof, and Uses Thereof
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/795,430
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/00427
; FILING DATE: 01-AUG-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/671,573
; FILING DATE: 28-JUN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/601,132
; FILING DATE: 14-FEB-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,895
; FILING DATE: 12-JAN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/510,133
; FILING DATE: 01-AUG-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/340,011
; FILING DATE: 14-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Gass, David A.
; REGISTRATION NUMBER: 38,153
; REFERENCE/DOCKET NUMBER: 28967/33691
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-795-430-31

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      380 TTCCTCCAGAGTGGCAG 397
Db      1 TTCTCCAAAGGTGTGAG 18

RESULT 166
US-09-487-444-10
```

```
; Sequence 10, Application US/09487444
; Patent No. 6159697
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; TITLE OF INVENTION: Bougueleret, Lydie
; FILE REFERENCE: GENSET.018CP1
; CURRENT APPLICATION NUMBER: US/09/218,207
; CURRENT FILING DATE: 1998-12-22
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-444-10

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred.No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 583 CTCGGTGTGCCCCCACC 600
Db 1 CTCGGTGTGCCCCCACC 18

RESULT 167
US-09-338-907-354
; Sequence 354, Application US/09338907
; Patent No. 6265546
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; TITLE OF INVENTION: Bougueleret, Lydie
; FILE REFERENCE: GENSET.18CP1CP
; CURRENT APPLICATION NUMBER: US/09/338,907
; CURRENT FILING DATE: 1999-06-23
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; EARLIER APPLICATION NUMBER: 09/218,207
; EARLIER FILING DATE: 1998-12-22
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 354
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer for SEQ 218, SEQ 295, SEQ 219, SEQ
US-09-338-907-354

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred.No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 869 TCCCCACAGCCCAAGTTC 886
Db 1 TCCCCACAGCTAAGAGCC 18

RESULT 168
US-09-218-207-354
; Sequence 354, Application US/09218207
; Patent No. 6346381
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; TITLE OF INVENTION: Bougueleret, Lydie
; FILE REFERENCE: GENSET.018CP1
; CURRENT APPLICATION NUMBER: US/09/218,207
; CURRENT FILING DATE: 1998-12-22
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 354
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer for SEQ 218, SEQ 295, SEQ 219, SEQ
US-09-338-907-354

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred.No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 869 TCCCCACAGCCCAAGTTC 886
Db 1 TCCCCACAGCTAAGAGCC 18

RESULT 169
US-08-584-040-2983
; Sequence 2983, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
```

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 29
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-2983

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 3; Indels

Qy 142 CCGCTCGGCTCCGCTCCG 159
|||:|||||
pb 1 CCUCUCGGUCUCCUCCG 18

RESULT 170
US-08-584-040-4454
; Sequence 4454, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:

Query Match
1.0%; Score 13.2; DB 1; Length 18;

```
Best Local Similarity   61.1%;    Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;
```

```

RESULT 171
US-08-584-040-8393
; Sequence 8393, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggan, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:

```

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 11: Conservative 4; Mismatches 3; Indels

Qy 1053 CAGCCCTGGCCTTCCCAT 1070
||| ||| ||| :
Db 1 CAGGCCUGACCUUGCAU 18

RESULT 172
US-09-355-700-31
; Sequence 31, Application US/09355700
; Patent No. 6361946

Query Match

```

; GENERAL INFORMATION:
; APPLICANT: Ludwig Institute for Cancer Research
; Helinski University Licensing
; Aitaio, Kari (U.S. only)
; Joukov, Vladimir (U.S. only)
; TITLE OF INVENTION: Vascular Endothelial Growth Factor C (VEGF-C)
; Protein and Gene, Mutants Thereof, and Uses Thereof
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/355,700
; FILING DATE: 05-NOV-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/795,430
; FILING DATE: 05-FEB-1997
; APPLICATION NUMBER: PCT/FI96/00427
; FILING DATE: 01-AUG-1996
; APPLICATION NUMBER: 08/671,573
; FILING DATE: 28-JUN-1996
; APPLICATION NUMBER: 08/601,132
; FILING DATE: 14-FEB-1996
; APPLICATION NUMBER: 08/585,895
; FILING DATE: 12-JAN-1996
; APPLICATION NUMBER: 08/510,133
; FILING DATE: 01-AUG-1995
; APPLICATION NUMBER: 08/340,011
; FILING DATE: 14-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Gass, David A.
; REGISTRATION NUMBER: 38,153
; REFERENCE/DOCKET NUMBER: 28967/34140
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-09-355-700-31

```

```

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 380 TTCTCCAGAGGTGGCAG 397
Db 1 TTCTCCAAAGGTGTCTAG 18

```

```

RESULT 173
US-09-167-109-8
; Sequence 8, Application US/09167109
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F.
; APPLICANT: Cowser, Lex M.

```

```

; APPLICANT: Monia, Brett P.
; APPLICANT: Xu, Xiaoxing S.
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRAF EXPRESSION
; FILE REFERENCE: ISPH-0321
; CURRENT APPLICATION NUMBER: US/09/167,109
; CURRENT FILING DATE: 1998-10-06
; NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-09-167-109-8

```

```

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 471 GCAGGGGAGGACTGCCG 488
Db 1 GCCGGCGGAGGACTGCTG 18

```

```

RESULT 174
US-08-275-951-33
; Sequence 33, Application US/08275951
; Patent No. 6451368
; GENERAL INFORMATION:
; APPLICANT: Egholm, Michael
; APPLICANT: Kiely, John
; APPLICANT: Griffin, Michael
; APPLICANT: Coull, James M.
; APPLICANT: Neilsen, Peter
; APPLICANT: Buchardt, Ole
; APPLICANT: Dueholm, Kim L.
; APPLICANT: Christensen, Leif
; TITLE OF INVENTION: Linked Peptide Nucleic Acids
; FILE REFERENCE: ISIS1577
; CURRENT APPLICATION NUMBER: US/08/275,951
; CURRENT FILING DATE: 1994-07-15
; PRIOR APPLICATION NUMBER: 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: 08/088,658
; PRIOR FILING DATE: 1993-07-02
; PRIOR APPLICATION NUMBER: 08/088,661
; PRIOR FILING DATE: 1993-07-02
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: 986/91
; PRIOR FILING DATE: 1991-05-22
; PRIOR APPLICATION NUMBER: 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: 510/92
; PRIOR FILING DATE: 1991-04-15
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6451968el Sequence
; NAME/KEY: misc_feature
; LOCATION: (9)..(10)
; OTHER INFORMATION: Lysine, Amino Hexanoic Acid, Lysine, Amino
; OTHER INFORMATION: Hexanoic Acid, Lysine Linkage
US-08-275-951-33

```

```

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY 1138 TATGCTCTTTTCTTTT 1155
DB 1 TTTCTTTTCTTTTCTTTT 18

RESULT 175

US-09-422-978-6039/c
; Sequence 6039, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; FILE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6039
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-8571 for SEQ 2105,
US-09-422-978-6039

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 56 CTCCTCAATTACCACAT 73
DB 18 CTCCTCTTATCCACAT 1

RESULT 176

US-09-371-772B-1411
; Sequence 1411, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1411
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1411

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 142 CCGCTCGGCTCGCTCCG 159
DB 1 CCUCUGGCGUCUCCCG 18

RESULT 177

US-09-371-772B-2167
; Sequence 2167, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2167
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2167

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1239 GCTGGACGTGGCCATGTG 1256
DB 1 GCUGGCCGUGCCCGUG 18

RESULT 178

US-09-371-772B-4049
; Sequence 4049, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4049
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-4049

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1053 CAGCCCTGGCTTCCCAT 1070
Db 1 CAGGCCUGACCUUCGCAU 18

RESULT 179

US-08-450-905B-134/c
; Sequence 134, Application US/08450905B
; Patent No. 5856301
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
; NUMBER OF SEQUENCES: 178
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/450,905B
; FILING DATE: 26-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/982,759
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9127319.3
; FILING DATE: 23-DEC-1991
; APPLICATION DATA:
; FILING DATE: 14-OCT-1992
; TELEPHONE: 617-526-6110
; TELEFAX: 617-526-5000
; INFORMATION FOR SEQ ID NO: 134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..20
; OTHER INFORMATION: /product= "BB9513 oligomer"
US-08-450-905B-134

Query Match 1.0%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 820 GTCTGTGATGCAGCTGAAG 837
Db 20 GTGCTGACGCATCTGAAG 3

RESULT 180

US-07-982-759F-134/c
; Sequence 134, Application US/07982759F
; Patent No. 6057123
; GENERAL INFORMATION:
; APPLICANT: CRAIG, Stewart
; APPLICANT: GEORGE, Michael
; APPLICANT: EDWARDS, Richard Mark

; APPLICANT: CZAPLEWSKI, Lloyd George
; APPLICANT: GILBERT, Richard
; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
; NUMBER OF SEQUENCES: 178
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR LLP
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/982,759F
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9127319.3
; FILING DATE: 23-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9221587.0
; FILING DATE: 14-OCT-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, HOLLIE L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102378.120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-526-6000
; TELEFAX: 617-526-5000
; INFORMATION FOR SEQ ID NO: 134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..20
; OTHER INFORMATION: /product= "BB9513 oligomer"
US-07-982-759F-134

Query Match 1.0%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 820 GTCTGTGATGCAGCTGAAG 837
Db 20 GTGCTGACGCATCTGAAG 3

RESULT 181

US-08-291-932A-311
; Sequence 311, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

```
;
;
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291.932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1500
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 311:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-291-932A-311

Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1066 CCATCAGGCGAGG 1078
Db 3 CCACAGGCGAGG 15

RESULT 182
US-08-152-313-111
; Sequence 111, Application US/08152313
; Patent No. 5561041
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
; TITLE OF INVENTION: ANALYSIS OF SPUTUM
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Spensley Horn Juba & Lubitz
; STREET: 1880 Century Park East, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/152,313
; FILING DATE: 12-NOV-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Wetherell, Jr., Ph.D., John R.,
; REGISTRATION NUMBER: 31,678
; REFERENCE/DOCKET NUMBER: FD-2912
; TELECOMMUNICATION INFORMATION:
```

Two

```
;
;
; TELEPHONE: (619) 455-5100
; TELEFAX: (619) 455-5110
; INFORMATION FOR SEQ ID NO: 111:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..17
; US-08-152-313-111

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 589 CTGCCCCACCA 601
Db 2 CTGCCCCACCA 14

RESULT 183
US-08-250-740-23
; Sequence 23, Application US/08250740
; Patent No. 5686240
; GENERAL INFORMATION:
; APPLICANT: Schuchman, Edward H.
; APPLICANT: Desnick, Robert J.
; TITLE OF INVENTION: Acid Sphingomyelinase Gene and Diagnosis
; TITLE OF INVENTION: of Niemann-Pick Disease
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/250,740
; FILING DATE: 27-MAY-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A.
; REGISTRATION NUMBER: 30742
; REFERENCE/DOCKET NUMBER: 6923-038
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-250-740-23

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 CTCGAGGCTCT 643
Db 5 CTCGAGGCTCT 17
```

RESULT 185
US-07-695-472B-29
; Sequence 29, Application US/07695472B
; Patent No. 5773278
; GENERAL INFORMATION:
; APPLICANT: Schuchman, Edward H.
; APPLICANT: Desnick, Robert J.
; TITLE OF INVENTION: The Acid Splicingmyelinase Gene and
; TITLE OF INVENTION: Diagnosis of Niemann-Pick Disease
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESS: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 230/107
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear

Query Match 1.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 200 CGGACGCCGACGA 212
 DB 17 CGGACGCCGACGA 5

RESULT 187

US-09-106-375-29
 Sequence 29, Application US/09106375
 Patent No. 6541218
 GENERAL INFORMATION:
 APPLICANT: Schuchman, Edward H.
 APPLICANT: Desnick, Robert J.
 TITLE OF INVENTION: The Acid Sphingomyelinase Gene and
 TITLE OF INVENTION: Diagnosis of Niemann-Pick Disease
 NUMBER OF SEQUENCES: 36
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Pennie & Edmonds
 STREET: 1155 Avenue of the Americas
 CITY: New York
 STATE: New York
 COUNTRY: U.S.A.
 ZIP: 10036
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/106,375
 FILING DATE:

CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/695,472
 FILING DATE: 03-MAY-1991
 ATTORNEY/AGENT INFORMATION:
 NAME: Mirock, S. Leslie
 REGISTRATION NUMBER: 18,872
 REFERENCE/DOCKET NUMBER: 6923-014
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 790-9090
 TELEFAX: 66141 PENNIE
 INFORMATION FOR SEQ ID NO: 29:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: unknown
 MOLECULE TYPE: DNA

US-09-106-375-29
 Query Match 1.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 CTCGAGGAGCTCT 643
 DB 5 CTCGAGGAGCTCT 17

RESULT 188

PCT-US94-12947A-111
 Sequence 111, Application PC/TUS9412947A
 GENERAL INFORMATION:
 APPLICANT: The Johns Hopkins University School of Medicine
 TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
 TITLE OF INVENTION: ANALYSIS OF SPUTUM
 NUMBER OF SEQUENCES: 128
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Spensley Horn Jubas & Lubitz
 STREET: 1880 Century Park East, Suite 500
 CITY: Los Angeles
 STATE: California
 COUNTRY: USA
 ZIP: 90067
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US94/12947A
 FILING DATE: 10-NOV-1994
 CLASSIFICATION:
 ATTORNEY/AGENT INFORMATION:
 NAME: Haile, Ph.D., Lisa A.
 REGISTRATION NUMBER: P-38,347
 REFERENCE/DOCKET NUMBER: PD-2912
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 455-5100
 TELEFAX: (619) 455-5110
 INFORMATION FOR SEQ ID NO: 111:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 FEATURE:
 NAME/KEY: CDS
 LOCATION: 1..17
 PCT-US94-12947A-111

Query Match 1.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 589 CTGCCCCCACCACCA 601
 DB 2 CTGCCCCCACCACCA 14

RESULT 189

US-08-469-802B-13/c
 Sequence 13, Application US/08469802B
 Patent No. 5741645
 GENERAL INFORMATION:
 APPLICANT: Orr, Harry T.
 APPLICANT: Rannu, Laura P.W.
 APPLICANT: Chung, Ming-Yi
 APPLICANT: Zoghbi, Huda Y.
 TITLE OF INVENTION: Gene Sequence for Spinocerebellar Ataxia
 Patent No. 5741645
 TITLE OF INVENTION: Type 1 and Method for Diagnosis
 NUMBER OF SEQUENCES: 47
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Mueiting, Raasch, Gebhardt & Schwappach, P.A.
 STREET: 119 No. 5741645th Fourth Street, Suite 203

CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55401
MEDIUM READABLE FORM: disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/469,802B
FILING DATE: 06-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Mueiting, Ann M.
REGISTRATION NUMBER: 33,977
REFERENCE/DOCKET NUMBER: 110.00030101
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-305-1217
TELEFAX: 612-305-1225
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-469-802B-13

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 592 CCCCCCACCAGCC 604
DB 18 CCCCCCACCAGCC 6

RESULT 190
US-08-267-803B-31/c
Sequence 31, Application US/08267803B
Patent No. 5834183
GENERAL INFORMATION:
APPLICANT: Orr, Harry T.
APPLICANT: Ranum, Laura P.W.
APPLICANT: Chung, Ming-yi
APPLICANT: Zoghbi, Huda Y.
TITLE OF INVENTION: Gene Sequence for Spinocerebellar Ataxia
Patent No. 5834183
TITLE OF INVENTION: Type 1 and Method for Diagnosis
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Mueiting, Raasch, Gebhardt & Schwappach, P.A.
STREET: P.O. Box 581415
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55458-1415
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/267,803B
FILING DATE: 28-JUN-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McCormack, Myra H.
REGISTRATION NUMBER: 36,602
REFERENCE/DOCKET NUMBER: 110.00030120
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-305-1217

TELEFAX: 612-305-1228
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-267-803B-31

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 592 CCCCCCACCAGCC 604
DB 18 CCCCCCACCAGCC 6

RESULT 191
US-08-450-905B-135/c
Sequence 135, Application US/08450905B
Patent No. 5856301
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Stem Cell Inhibiting Proteins
NUMBER OF SEQUENCES: 178
CORRESPONDENCE ADDRESS:
ADDRESSEE: HALE and DORR
STREET: 60 State Street
CITY: Boston
STATE: MA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/450,905B
FILING DATE: 26-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/982,759
FILING DATE: 08-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9127319.3
FILING DATE: 23-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9221587.0
FILING DATE: 14-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: BAKER, HOLLIE L.
REGISTRATION NUMBER: 31,321
REFERENCE/DOCKET NUMBER: 102.378.120DV-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-526-6110
TELEFAX: 617-526-5000
INFORMATION FOR SEQ ID NO: 135:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..18
OTHER INFORMATION: /product= "BB9516 oligomer"

US-08-450-905B-135

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 746 ATGTTGCTGACTT 758
Db 14 ATGTTGCTGACTT 2

RESULT 192
US-09-205-860-29
; Sequence 29, Application US/09205860
; Patent No. 5981732
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowert
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION
; FILE REFERENCE: RTS-0031
; CURRENT APPLICATION NUMBER: US/09/205,860
; CURRENT FILING DATE: 1998-12-04
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-860-29

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 718 GCCCAGCAGCAGG 730
Db 4 GCCCAGCAGCAGG 16

RESULT 193
US-07-982-759F-135/c
; Sequence 135, Application US/07982759F
; Patent No. 6057123
; GENERAL INFORMATION:
; APPLICANT: CRAIG, Stewart
; APPLICANT: GEORGE, Michael
; APPLICANT: EDWARDS, Richard Mark
; APPLICANT: CZAPLEWSKI, Lloyd George
; APPLICANT: GILBERT, Richard
; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
; NUMBER OF SEQUENCES: 178
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR LLP
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/982,759F
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9127319.3
; FILING DATE: 23-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9221587.0
; FILING DATE: 14-OCT-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, HOLLIE L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102378.120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-526-6000
; TELEFAX: 617-526-5000
```

```
; INFORMATION FOR SEQ ID NO: 135:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..18
; OTHER INFORMATION: /product= "BB9516 oligomer"
US-07-982-759F-135

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 ATGTTGCTGACTT 758
Db 14 ATGTTGCTGACTT 2

RESULT 194
US-09-422-978-8784/c
; Sequence 8784, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilva
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8784
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-18221 for SEQ 919, in comple
US-09-422-978-8784

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1140 TGCCTTTTCTTCT 1152
Db 17 TGCCTTTTCTTCT 5

RESULT 195
PCT-US91-03680-4
; Sequence 4, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
```

```

; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03680
; FILING DATE: 19910524
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4610-0011.40
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; TELEFAX: 415-327-2951
; TELEX: 706141
;
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 1
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "N4,N4-ethanocytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 9
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 15
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 18
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "1,3-propanediol"
;
PCT-US91-03680-4

```

```

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTT 1156
Db 2 TTTTTCCTTTT 14

```

```

RESULT 196
PCT-US91-03680-5
; Sequence 5, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California

```

```

; COUNTRY: USA
; ZIP: 94025
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03680
; FILING DATE: 19910524
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4610-0011.40
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; TELEFAX: 415-327-2951
; TELEX: 706141
;
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 8
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 14
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 17
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "N4,N4-ethanocytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 18
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "1,3-propanediol"
;
PCT-US91-03680-5

```

```

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTT 1156
Db 1 TTTTTCCTTTT 13

```

```

RESULT 197
PCT-US91-04094-19/c
; Sequence 19, Application PC/TUS9504094
; GENERAL INFORMATION:
; APPLICANT: ALMS, William
; APPLICANT: WHITE, Barbara
; TITLE OF INVENTION: HUMAN INTERLEUKIN VARIANTS GENERATED BY
; TITLE OF INVENTION: ALTERNATIVE SPLICING
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Burns, Doane, Swecker & Mathis
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
;
; COMPUTER READABLE FORM:

```

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/04094
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/224,010
FILING DATE: 06-APR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Crane-Feury, Sharon E
REGISTRATION NUMBER: 36,113
REFERENCE/DOCKET NUMBER: 028754-001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US95-04094-19

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 379 CTTCTCCACAGG 391

Db 13 CTTCTCCACAGG 1

RESULT 198

US-09-364-539-10
Sequence 10, Application US/09364539B
Patent No. 6344321
GENERAL INFORMATION:
APPLICANT: Rabin, Ross
APPLICANT: Lochrie, Michael
APPLICANT: Janjic, Nebojsa
APPLICANT: Gold, Larry
TITLE OF INVENTION: Nucleic Acid Ligands Which Bind to Hepatocyte Growth
TITLE OF INVENTION: Factor/Scatter Factor (HGF/SF) or its Receptor C-Met
FILE REFERENCE: NEX83
CURRENT APPLICATION NUMBER: US/09/364,539B
CURRENT FILING DATE: 1999-07-29
NUMBER OF SEQ ID NOS: 192
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 10
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Sequence
FEATURE:
NAME/KEY: modified base
LOCATION: (1)...(16)
OTHER INFORMATION: Purines and pyrimidines are 2'OMe; purines and
OTHER INFORMATION: pyrimidines at positions 1-4 are DNA; purines and
OTHER INFORMATION: pyrimidines at positions 5-16 are RNA.
US-09-364-539-10

Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 297 GTCTGCTGGGGCT 312

|||||:|:|:|:|:

Db 1 GTCTGCGAGCGGCU 16

RESULT 199

US-09-371-772B-5925
Sequence 5925, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MEH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5925
LENGTH: 16
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-5925

Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGGTGCTTT 1326

Db 1 GGAGCCAGCGCUUUU 16

RESULT 200

US-08-373-124A-420
Sequence 420, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943

;; FILING DATE: February 7, 1994
;; APPLICATION NUMBER: 07/987,132
;; FILING DATE: December 7, 1992
;; APPLICATION NUMBER: 07/936,422
;; FILING DATE: August 26, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/035
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 420:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-373-124A-420

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.6e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 795 CTTGCTCGTCCCTG 810
Db 2 CCUGGCUCCUACCG 17

RESULT 201
US-08-373-124A-2031
; Sequence 2031, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035

;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 2031:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-373-124A-2031

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.6e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1095 TGAACGTAATTATGTA 1110
Db 1 UGAAAGUUAUUGA 16

RESULT 202
US-08-758-306-655
; Sequence 655, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 655:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-758-306-655
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.6e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 227 CTCAGCTCAGGCATC 242
|:|||||
Db 1 CUGAGCCUCCAGGCAAC 16

RESULT 203
US-08-758-306-721
; Sequence 721, Application US/08758306
; Patent No. 5807743

; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 721:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-758-306-721
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.6e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 625 GACGAGCTCCAGGAGC 640
|:|||||
Db 1 GUCCAGCUCAGGACC 16

RESULT 204
US-08-435-628-420
; Sequence 420, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth

; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 420:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-435-628-420

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.6e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 795 CCTGGCTCGCTCCCTG 810
|:|||||
Db 2 CCUGGCUCCUACUG 17

RESULT 205
US-08-435-628-2031
; Sequence 2031, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2031:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-2031

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.6e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1095 TGAACGTAATATCTA 1110
DB 1 UGAAGUUUUAUGUA 16

RESULT 206
US-08-292-620A-1727/c
Sequence 1727, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```

```

STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: including application
described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1727:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1727

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CCTGGTGATAGTCACA 349
DB 17 CCTGGTGATAGTCACCA 2

RESULT 207
US-08-292-620A-1937/c
Sequence 1937, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```

;/ MEDIUM TYPE: storage
;/ COMPUTER: IBM Compatible
;/ OPERATING SYSTEM: IBM P.C. DOS 5.0
;/ SOFTWARE: Word Perfect 5.1
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/08/292,620A
;/ FILING DATE: August 17, 1994
;/ CLASSIFICATION: 435
;/ PRIOR APPLICATION DATA:
;/ PRIOR APPLICATION DATA: including application
;/ PRIOR APPLICATION DATA: described below:
;/ APPLICATION NUMBER: 08/008,895
;/ FILING DATE: January 19, 1993
;/ APPLICATION NUMBER: 07/989,849
;/ FILING DATE: December 7, 1992
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Warburg, Richard J.
;/ REGISTRATION NUMBER: 32,327
;/ REFERENCE/DOCKET NUMBER: 208/149
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (213) 489-1600
;/ TELEX: 67-3510
;/ INFORMATION FOR SEQ ID NO: 1937:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 17 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ US-08-292-620A-1937

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CCTGGTGATAGTCACA 349
Db 17 CCTGGTGATCTCCCA 2

RESULT 208
US-08-765-783A-79
; Sequence 79, Application US/08/765783A
; Patent No. 5994524
; GENERAL INFORMATION:
; APPLICANT: Matsushima, Kouji
; APPLICANT: Matsumoto, Yoshihiro
; APPLICANT: Yamada, Yoshiki
; APPLICANT: Sato, Koh
; APPLICANT: Tsuchiya, Masayuki
; APPLICANT: Yamazaki, Tatsumi
; TITLE OF INVENTION: Reshaped Human Antibody to
; TITLE OF INVENTION: Interleukin-8
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESS: MORRISON & FORSTER
; STREET: 2000 Pennsylvania Avenue, NW, suite 5500
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20006-1888
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/765,783A
; FILING DATE: 07-MAR-1997
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:

two

;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Murashige, Kate H
;/ REGISTRATION NUMBER: 29,959
;/ REFERENCE/DOCKET NUMBER: 35029-20001.20
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: 202-887-1500
;/ TELEX: 202-822-0168
;/ INFORMATION FOR SEQ ID NO: 79:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 17 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ FEATURE:
;/ NAME/KEY: Other
;/ LOCATION: 1...17
;/ OTHER INFORMATION: HIP sequence
;/ US-08-765-783A-79

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 CCCACAGCCAGTTC 885
Db 2 CCCAAAGCCAGGTC 17

RESULT 209
US-08-985-162-452
; Sequence 452, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESS: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 452:
; SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-452

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 574 CAGCAGGCGCTCCGTC 589
DB 1 CAGCAGGCGCTCCCAUC 16

RESULT 210

US-09-071-845-1727/c
Sequence 1727, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1727:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1727

Query Match

0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CCTGGTGATAGTCACA 349
DB 17 CCTGGTGATAGTCACA 2

RESULT 211

US-09-071-845-1937/c
Sequence 1937, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1937:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1937

Query Match

0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CCTGGTGATAGTCACA 349
DB 17 CCTGGTGATAGTCACA 2

RESULT 212

US-09-416-557-79
 ; Sequence 79, Application US/09416557
 ; Patent No. 6245894
 ; GENERAL INFORMATION:
 ; APPLICANT: Matsushima, Kouji
 ; APPLICANT: Matsumoto, Yoshihiro
 ; APPLICANT: Yamada, Yoshiki
 ; APPLICANT: Sato, Koh
 ; APPLICANT: Tsuchiya, Masayuki
 ; APPLICANT: Yamazaki, Tatsumi
 ; TITLE OF INVENTION: Reshaped Human Antibody to
 ; INTERLEUKIN-8
 ; NUMBER OF SEQUENCES: 105
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: MORRISON & FORSTER
 ; STREET: 2000 Pennsylvania Avenue, NW, suite 5500
 ; CITY: Washington
 ; STATE: DC
 ; COUNTRY: USA
 ; ZIP: 20006-1888
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: DOS
 ; SOFTWARE: Fastseq for Windows Version 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/416,557
 ; FILING DATE: 12-October-1999
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/765,783
 ; FILING DATE: 7-March-1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Muraahice, Kate H
 ; REGISTRATION NUMBER: 29,959
 ; REFERENCE/DOCKET NUMBER: 35029-20001.10
 ; TELEPHONE: 202-887-1500
 ; TELEFAX: 202-822-0168
 ; TELEX:
 ; INFORMATION FOR SEQ ID NO: 79:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; FEATURE:
 ; NAME/KEY: Other
 ; LOCATION: 1...17
 ; OTHER INFORMATION: HIP sequence

US-09-416-557-79
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Cy 870 CCCACAGCCCAAGTTC 885
 Db 2 CCCCAAGCCCAAGTTC 17
 RESULT 213
 US-08-584-040-4374/c
 ; Sequence 4374, Application US/08584040
 ; Patent No. 6346398
 ; GENERAL INFORMATION:
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Stinchcomb, Dan T.
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: TREATMENT OF DISEASES OR
 ; CONDITIONS RELATED TO LEVELS
 ; OF VASCULAR ENDOTHELIAL
 ; GROWTH FACTOR
 ; NUMBER OF SEQUENCES: 8502
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; CITY: Suite 4700
 ; STATE: Los Angeles
 ; CITY: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/584,040
 ; FILING DATE: January 11, 1996
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/005,974
 ; FILING DATE: October 26, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/064
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 4374:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-584-040-4374

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.6e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Cy 41 CAAATCTTACATAC 56
 Db 17 CAAATCTGAGCAGAC 2

RESULT 214

US-08-584-040-7924
 ; Sequence 7924, Application US/08584040
 ; Patent No. 6346398
 ; GENERAL INFORMATION:
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Stinchcomb, Dan T.
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TREATMENT OF DISEASES OR
 ; CONDITIONS RELATED TO LEVELS
 ; OF VASCULAR ENDOTHELIAL
 ; GROWTH FACTOR
 ; NUMBER OF SEQUENCES: 8502
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; CITY: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.

ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7924:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7924

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.6e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 47 CTTAGCATCTCTCTCA 62
Db 1 CUUCGCAUACUGCUCA 16

RESULT 215
US-08-679-645-75
Sequence 75, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
APPLICANT: Edington, Brent E.
APPLICANT: McSwiggen, James A.
APPLICANT: Merlo, Patricia Ann Owens
APPLICANT: Guo, Lining
APPLICANT: Skokut, Thomas A.
APPLICANT: Young, Scott A.
APPLICANT: Folkerts, Otto
APPLICANT: Merlo, Donald J.
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645

FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 75:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-679-645-75

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.6e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 891 GCTGCGGTACAGCGTG 906
Db 1 GCUGCGGUACGCCUG 16

RESULT 216
US-08-679-645-886
Sequence 886, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
APPLICANT: Edington, Brent E.
APPLICANT: McSwiggen, James A.
APPLICANT: Merlo, Patricia Ann Owens
APPLICANT: Guo, Lining
APPLICANT: Skokut, Thomas A.
APPLICANT: Young, Scott A.
APPLICANT: Folkerts, Otto
APPLICANT: Merlo, Donald J.
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645
FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 886:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-679-645-886

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 1.6e+02;
Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 1103 ATTATGAGTTTCTG 1118
Db 2 AUUUUGAUUUUCUG 17
||:|:|:|:|:|

RESULT 217

US-09-474-432B-388
Sequence 388, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zimen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MHB00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: Patent in version 3.0
SEQ ID NO 388
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-388

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.6e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 589 CTGCCCCCACCAGCC 604
Db 2 CUGCCCGCUCAGCC 17
|:|:|:|:|:|

RESULT 218

US-09-371-772B-2141/c
Sequence 2141, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
FILE REFERENCE: MHB00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: Patent in version 3.0
SEQ ID NO 2141
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-2141

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 41 CAAATCTTAGCATAC 56
Db 17 CAAAATCTGACGAC 2
|||||

RESULT 219

US-09-371-772B-3707
Sequence 3707, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
FILE REFERENCE: MHB00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: Patent in version 3.0
SEQ ID NO 3707
LENGTH: 17
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-3707

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.6e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 47 CTTAGCATCTCCTCA 62
Db 1 CUUCCGAUCUGCUCA 16
|:|:|:|:|:|

RESULT 220

US-09-371-772B-4175
Sequence 4175, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam

TELEPHONE: (619) 535-9001
 TELEFAX: (619) 535-8949
 INFORMATION FOR SEQ ID NO: 85:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-219-842-85

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 590 TGCCCCCACCACGCT 605
 Db 18 TGCCCGCCACCATCT 3

RESULT 224

US-08-363-240A-1187/c
 ; Sequence 1187, Application US/08363240A
 ; Patent No. 5705388

GENERAL INFORMATION:
 APPLICANT: Couture, Larry
 APPLICANT: McSwiggen, James
 APPLICANT: Bisgaier, Charles
 APPLICANT: Pape, Michael
 TITLE OF INVENTION: METHOD AND REAGENT FOR
 TITLE OF INVENTION: PREVENTION, INHIBITION OF
 TITLE OF INVENTION: PROGRESSION AND REGRESSION
 TITLE OF INVENTION: OF VASCULAR DISEASES
 NUMBER OF SEQUENCES: 1243

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/363,240A
 FILING DATE: December 23, 1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 210/096

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1187:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-363-240A-1187

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 924 GATGGCAGATCTGGAG 939
 Db 18 GGTGGCTGATCTGGAG 3

RESULT 225

US-08-451-096-52
 ; Sequence 52, Application US/08451096
 ; Patent No. 5760205

GENERAL INFORMATION:

APPLICANT: Parker, W. D.

APPLICANT: Herrnstadt, Corinna

TITLE OF INVENTION: Diagnostic and Therapeutic Compositions

TITLE OF INVENTION: for Alzheimer's Disease

NUMBER OF SEQUENCES: 95

CORRESPONDENCE ADDRESS:

ADDRESSEE: Campbell and Flores

STREET: 4370 La Jolla Village Drive, Suite 700

CITY: San Diego

STATE: California

COUNTRY: USA

ZIP: 92122

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/451,096

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/219,842

FILING DATE: 30-MAR-1994

ATTORNEY/AGENT INFORMATION:

NAME: Campbell, Cathryn A.

REGISTRATION NUMBER: 31,815

REFERENCE/DOCKET NUMBER: P-AG 9504

TELECOMMUNICATION INFORMATION:

TELEPHONE: (619) 535-9001

TELEFAX: (619) 535-8949

INFORMATION FOR SEQ ID NO: 52:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-451-096-52

Query Match 0.9%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 1.8e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 590 TGCCCCCACCACGCT 605
 Db 1 TGCCCGCCACCATCT 16

RESULT 226

US-08-451-096-85/c
 ; Sequence 85, Application US/08451096
 ; Patent No. 5760205

GENERAL INFORMATION:

APPLICANT: Parker, W. D.

APPLICANT: Herrnstadt, Corinna

TITLE OF INVENTION: Diagnostic and Therapeutic Compositions

TITLE OF INVENTION: for Alzheimer's Disease

NUMBER OF SEQUENCES: 95

CORRESPONDENCE ADDRESS:

ADDRESSEE: Campbell and Flores

STREET: 4370 La Jolla Village Drive, Suite 700

CITY: San Diego

STATE: California

```

; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/451,096
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/219,842
; FILING DATE: 30-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-AG 9504
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-451-096-85

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 TGCCCCCACCACCT 605
Db 18 TGCCCGCCACCATCT 3

RESULT 227
US-08-800-751-39
; Sequence 39, Application US/08800751
; Patent No. 5807730
; GENERAL INFORMATION:
; APPLICANT: ITO, Kiyoshi
; APPLICANT: YAMAKI, Toshifumi
; APPLICANT: ARII, Teruo
; APPLICANT: TSUKUOKA, Miyuki
; APPLICANT: NAKAMURA, Takeshi
; TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/800,751
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 8-027004
; FILING DATE: 14-FEB-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 028022-007
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-6620
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
; US-08-800-751-40

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
; US-08-800-751-39

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 879 CAAAGTCCAGGAGCTG 894
Db 3 CAGATCCAGGAGCTG 18

RESULT 228
US-08-800-751-40
; Sequence 40, Application US/08800751
; Patent No. 5807730
; GENERAL INFORMATION:
; APPLICANT: ITO, Kiyoshi
; APPLICANT: YAMAKI, Toshifumi
; APPLICANT: ARII, Teruo
; APPLICANT: TSUKUOKA, Miyuki
; APPLICANT: NAKAMURA, Takeshi
; TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/800,751
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 8-027004
; FILING DATE: 14-FEB-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 028022-007
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-6620
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
; US-08-800-751-40

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 879 CAAGTTCAGGAGCTG 894
Db 3 CACGTCACGAGGCTG 18

RESULT 229
US-08-758-306-971
; Sequence 971, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 971:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-758-306-971

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.8e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 625 GACGAGTCACGAGGC 640
Db 3 GUCCAGTCUCCAGGACC 18

RESULT 230
US-08-411-098-35/c
; Sequence 35, Application US/08411098
; Patent No. 5830755
; GENERAL INFORMATION:
; APPLICANT: HWU, PATRICK; NISHIMURA,
; APPLICANT: MICHAEL; ROSENBERG, STEVEN A.
; TITLE OF INVENTION: T-CELL RECEPTORS AND

```

```

; TITLE OF INVENTION: THEIR USE IN THERAPEUTIC AND DIAGNOSTIC
; TITLE OF INVENTION: METHODS
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411,098
; FILING DATE: 27-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: CAROL M. GRUPPEL
; REGISTRATION NUMBER: 37,341
; REFERENCE/DOCKET NUMBER: 2026-4188
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; TELEX: 421792
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: NUCLEOTIDE
; STRANDEDNESS: SINGLE
; TOPOLOGY: UNKNOWN
US-08-411-098-35

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 728 AGGGGCGCTGCTGCC 743
Db 16 AGGGGCTCTGTCTGCC 1

RESULT 231
US-08-880-557-18
; Sequence 18, Application US/08880557
; Patent No. 5876988
; GENERAL INFORMATION:
; APPLICANT: SELTEN, GERARDUS CORNELIUS MAIA
; APPLICANT: SWINKELS, BART WILLEM
; APPLICANT: VAN GORCOM, ROBERTUS
; APPLICANT: FRANCISCUS MARIA
; TITLE OF INVENTION: SELECTION MARKER GENE FREE RECOMBINANT
; TITLE OF INVENTION: STRAINS: A METHOD FOR OBTAINING THEM AND THE USE OF THESE
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Ave. N.W., Suite 5500
; CITY: Washington, D.C.
; COUNTRY: USA
; ZIP: 20006-1888
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/880,557
; FILING DATE: 23-JUN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

```

```

; APPLICATION NUMBER: US 08/279,980
; FILING DATE: 22-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4615-0042.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 887-1500
; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; IMMEDIATE SOURCE:
; CLONE: AB3781
; US-08-880-557-18

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 368 TGGGGGCCAGCTTCC 383
Db 3 TTGGGGCCCGAGCTCC 18

RESULT 232
US-08-990-818-39
; Sequence 39, Application US/08990818
; Patent No. 5910432
; GENERAL INFORMATION:
; APPLICANT: ITO, Kiyoshi
; APPLICANT: YAMAKI, Toshifumi
; APPLICANT: ARII, Teruo
; APPLICANT: TSURUOKA, Miyuki
; APPLICANT: NAKAMURA, Takeshi
; TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/990,818
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/800,751
; FILING DATE:
; APPLICATION NUMBER: JP 8-027004
; FILING DATE: 14-FEB-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 028022-007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
; US-08-990-818-40

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 879 CAACTTCCAGGAGCTG 894
Db 3 CACGATCCAGGAGCTG 18

RESULT 233
US-08-990-818-40
; Sequence 40, Application US/08990818
; Patent No. 5910432
; GENERAL INFORMATION:
; APPLICANT: ITO, Kiyoshi
; APPLICANT: YAMAKI, Toshifumi
; APPLICANT: ARII, Teruo
; APPLICANT: TSURUOKA, Miyuki
; APPLICANT: NAKAMURA, Takeshi
; TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/990,818
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/800,751
; FILING DATE:
; APPLICATION NUMBER: JP 8-027004
; FILING DATE: 14-FEB-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 028022-007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
; US-08-990-818-40

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 879 CAACTTCCAGGAGCTG 894
```

```

; APPLICATION NUMBER: US 08/279,980
; FILING DATE: 22-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4615-0042.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 887-1500
; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; IMMEDIATE SOURCE:
; CLONE: AB3781
; US-08-880-557-18

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 368 TGGGGGCCAGCTTCC 383
Db 3 TTGGGGCCCGAGCTCC 18

RESULT 232
US-08-990-818-39
; Sequence 39, Application US/08990818
; Patent No. 5910432
; GENERAL INFORMATION:
; APPLICANT: ITO, Kiyoshi
; APPLICANT: YAMAKI, Toshifumi
; APPLICANT: ARII, Teruo
; APPLICANT: TSURUOKA, Miyuki
; APPLICANT: NAKAMURA, Takeshi
; TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/990,818
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/800,751
; FILING DATE:
; APPLICATION NUMBER: JP 8-027004
; FILING DATE: 14-FEB-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 028022-007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
; US-08-990-818-40

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 879 CAACTTCCAGGAGCTG 894
```


; HYPOTHETICAL: NO
 ; ANTI-SENSE: NO
 US-08-413-740A-28

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 TGCCCGCCACCCGCT 605
 Db 1 TGCCCGCCACCCATCCT 16

RESULT 237
 US-09-474-922A-85
 ; Sequence 85, Application US/09474922A
 ; Patent No. 6187586
 ; GENERAL INFORMATION:
 ; APPLICANT: Brett P. Monia
 ; APPLICANT: Lex M. Cowsett
 ; APPLICANT: Richard A. Roth
 ; TITLE OF INVENTION: ANTISENSE MODULATION OF Akt-3 EXPRESSION
 ; FILE REFERENCE: RUS-0036
 ; CURRENT APPLICATION NUMBER: US/09/474,922A
 ; CURRENT FILING DATE: 1999-12-29
 ; NUMBER OF SEQ ID NOS: 89
 ; SEQ ID NO 85
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 US-09-474-922A-85

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 375 CCAGCTTCTCCAGAG 390
 Db 2 CCAGTTATCCAGAG 17

RESULT 238
 US-08-584-040-3044
 ; Sequence 3044, Application US/08584040
 ; Patent No. 6346398
 ; GENERAL INFORMATION:
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Stinchcomb, Dan T.
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: TREATMENT OF DISEASES OR
 ; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
 ; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
 ; NUMBER OF SEQUENCES: 8502
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/584,040
 ; FILING DATE: January 11, 1996
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/005,974
 ; FILING DATE: October 26, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/064
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600

; APPLICATION NUMBER: US/08/584,040
 ; FILING DATE: January 11, 1996
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/005,974
 ; FILING DATE: October 26, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/064
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 3044:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 US-08-584-040-3044

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 56.2%; Pred. No. 1.8e+02;
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGGTGCTTTT 1326
 Db 1 GGAGCCAGCGCUUUV 16

RESULT 239
 US-08-584-040-8378
 ; Sequence 8378, Application US/08584040
 ; Patent No. 6346398
 ; GENERAL INFORMATION:
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Stinchcomb, Dan T.
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: TREATMENT OF DISEASES OR
 ; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
 ; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
 ; NUMBER OF SEQUENCES: 8502
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/584,040
 ; FILING DATE: January 11, 1996
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/005,974
 ; FILING DATE: October 26, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/064
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600

```

; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8378:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8378

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGGTGCTTTT 1326
Db 1 GGAGCCAGCUCUUU 16

RESULT 240
US-08-679-645-609/c
; Sequence 609, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 609:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

```

```

; TOPOLOGY: linear
US-08-679-645-609

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 TCCAGGAGCTCGGTA 899
Db 16 TCCATGAGCTCGGGA 1

RESULT 241
US-08-679-645-629
; Sequence 629, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 629:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-629

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```


QY 220 CGAGCTCTCAGCCTC 235
 Db 2 CGUGGUCGACGCCUC 17

RESULT 242

US-08-614-151-51
 ; Sequence 51, Application US/08614151
 ; Patent No. 6436635

GENERAL INFORMATION:

APPLICANT: FU, Dong-Jing
 APPLICANT: KOSTER, Charles R.
 APPLICANT: SMITH, Cassandra L.

TITLE OF INVENTION: SOLID PHASE SEQUENCING OF DOUBLE-STRANDED NUCLEIC ACID

NUMBER OF SEQUENCES: 53

CORRESPONDENCE ADDRESS:

ADDRESSEE: BAKER & BOTS, L.L.P.

STREET: 1299 Pennsylvania Avenue, N.W.

CITY: Washington

STATE: DC

COUNTRY: USA

ZIP: 20004-2400

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: FastSeq Version 1.5
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/614,151
 FILING DATE: 12-MAR-1996

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/420,009
 FILING DATE: 11-APR-1995
 APPLICATION NUMBER: 08/110,691
 FILING DATE: 23-AUG-1993
 APPLICATION NUMBER: 07/972,012
 FILING DATE: 06-NOV-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Remenick, James

REGISTRATION NUMBER: 36,902

REFERENCE/DOCKET NUMBER: 16865-0276

TELECOMMUNICATION INFORMATION:

TELEPHONE: 202-639-7700

TELEFAX: 202-639-7890

TELEX:

INFORMATION FOR SEQ ID NO: 51:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: cDNA

HYPOTHETICAL: NO

ANTI-SENSE: NO

FRAGMENT TYPE:

ORIGINAL SOURCE:

US-08-614-151-51

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 CTACTAGGGGACCTAG 424
 Db 1 CTACTAGGGTCCCTAG 16

RESULT 243

US-09-920-760-14
 ; Sequence 14, Application US/09920760
 ; Patent No. 6492173

GENERAL INFORMATION:
 APPLICANT: Lex M. Cowsett
 TITLE OF INVENTION: ANTISENSE MODULATION OF CYCLIN D2 EXPRESSION
 FILE REFERENCE: RTS-0275
 CURRENT APPLICATION NUMBER: US/09/920,760
 CURRENT FILING DATE: 2001-08-01
 NUMBER OF SEQ ID NOS: 89
 SEQ ID NO 14
 LENGTH: 18
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Antisense Oligonucleotide
 US-09-920-760-14

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGGAA 1160
 Db 3 TTTTGTCTTTTGGAA 18

RESULT 244

US-09-077-619-17
 ; Sequence 17, Application US/09077619
 ; Patent No. 6500614

GENERAL INFORMATION:

APPLICANT: ARGUELLO, Rafael

APPLICANT: AVAKIAN, Hovanes

APPLICANT: MADRIGAL, Alejandro

TITLE OF INVENTION: METHOD FOR IDENTIFYING AN UNKNOWN ALLELE

FILE REFERENCE: 028979/0104

CURRENT APPLICATION NUMBER: US/09/077,619

PRIOR FILING DATE: 2000-03-31

PRIOR APPLICATION NUMBER: PCT/GB96/02959

PRIOR FILING DATE: 1996-11-29

PRIOR APPLICATION NUMBER: GB 9524381.2

PRIOR FILING DATE: 1995-11-29

NUMBER OF SEQ ID NOS: 46

SOFTWARE: PatentIn version 3.0

SEQ ID NO 17

LENGTH: 18

TYPE: DNA

ORGANISM: Homo sapiens

US-09-077-619-17

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 531 GGAGCAGCTGGTGCC 546
 Db 1 GGAGCAGCTGAGAGCC 16

RESULT 245

US-09-422-978-7504
 ; Sequence 7504, Application US/09422978
 ; Patent No. 6537751

GENERAL INFORMATION:

APPLICANT: Cohen, Daniel

APPLICANT: Blumenfeld, Marta

APPLICANT: Chumakov, Ilya

TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

FILE REFERENCE: GENSET.020CPI

CURRENT APPLICATION NUMBER: US/09/422,978

CURRENT FILING DATE: 1999-10-20

EARLIER APPLICATION NUMBER: US 09/298,850

EARLIER FILING DATE: 1999-04-21

EARLIER APPLICATION NUMBER: US 60/109,732

EARLIER FILING DATE: 1998-11-23

```
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7504
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18_bind
; OTHER INFORMATION: upstream amplification primer 99-6071 for SEQ 3570,
US-09-422-978-7504

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 850 TCAGCATACGCTTTG 865
Db 3 TCAGCATACGCTTGG 18

RESULT 246
US-09-422-978-11175
; Sequence 11175, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Iliya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11175
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-3147 for SEQ 3310, in compleme
```

```
US-09-422-978-11175

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 955 ACAGTCAGGACTGAC 970
Db 3 ACAGTCAGGACTGAC 18

RESULT 247
US-09-742-373-6
; Sequence 6, Application US/09742373
; Patent No. 6562946
; GENERAL INFORMATION:
; APPLICANT: Althaus, Harald
; APPLICANT: Hauser, Hans-Peter
; TITLE OF INVENTION: Human Procalcitonin and the Preparation and Use Thereof
; FILE REFERENCE: 05552.1445-00
; CURRENT APPLICATION NUMBER: US/09/742,373
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 19962434.8
; PRIOR FILING DATE: 1999-12-22
```

```
; PRIOR APPLICATION NUMBER: 10016278.9
; PRIOR FILING DATE: 2000-04-03
; PRIOR APPLICATION NUMBER: 10027954.6
; PRIOR FILING DATE: 2000-06-08
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Primer, non
; OTHER INFORMATION: genomic DNA
US-09-742-373-6
```

```
Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 833 TCAGCTTTTCAGATGG 848
Db 2 TCAGCTTTTAGTTGG 17
```

```
RESULT 248
US-09-371-772B-1472
; Sequence 1472, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1472
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1472
```

```
Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGTGTCTTT 1326
Db 1 GGAGCCAGCUCGUUU 16
```

```
RESULT 249
US-09-371-772B-4034
; Sequence 4034, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
```

Qy 870 CCCACAGCCAAGTTC 885

```

;      LENGTH: 18
5182195-70

```

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 473 AGGGGGAGGACTGCCG 488
DB 18 ATGGGGGGGACTGCCG 3

RESULT 253

US-08-882-649A-7/c
; Sequence 7, Application US/08882649A
; Patent No. 6344316
; GENERAL INFORMATION:

APPLICANT: Lockhart, David J.
; Chee, Mark
; Gunderson, Kevin
; Chaogiang, Lai
; Wodicka, Lisa
; Cronin, Maureen T.
; Lee, Danny
; Tran, Hui M.
; Matsuzaki, Hajime
; McCall, Glenn H.

; TITLE OF INVENTION: NUCLEIC ACID ANALYSIS TECHNIQUES

NUMBER OF SEQUENCES: 32

CORRESPONDENCE ADDRESS:

ADDRESS: Joe Liebeschuetz

STREET: Two Embarcadero Center, Eighth Floor

CITY: San Francisco

STATE: CA

COUNTRY: USA

ZIP: 94111-3834

MEDIUM TYPE: Floppy disk

COMPUTER READABLE FORM:

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/882,649A

FILING DATE: 25-Jun-1997

CLASSIFICATION: 435-006.000

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/010,471

FILING DATE: 23-JAN-1996

APPLICATION NUMBER: US 60/035,170

FILING DATE: 09-JAN-1997

APPLICATION NUMBER: PCT/US97/01603

FILING DATE: 22-JAN-1997

ATTORNEY/AGENT INFORMATION:

NAME: Liebeschuetz, Joe

REGISTRATION NUMBER: 37,505

REFERENCE/DOCKET NUMBER: 018547-019410US

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 576-0200

TELEFAX: (415) 576-0300

INFORMATION FOR SEQ ID NO: 7:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

HYPOTHETICAL: YES

SEQUENCE DESCRIPTION: SEQ ID NO: 7:

US-08-882-649A-7

Query Match 0.9%; Score 12.6; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 1.3e+02;

Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGG 1158

DB 1 TTTTTCCTTTTGG 14

RESULT 256

US-08-985-162-1842

; Sequence 1842, Application US/08985162

; Patent No. 6057156

; GENERAL INFORMATION:

Query Match 0.9%; Score 12.4; DB 1; Length 14;

Best Local Similarity 92.9%; Pred. No. 1.2e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158

DB 1 TTTTTCCTTTTGG 14

RESULT 255

US-08-832-021-15

; Sequence 15, Application US/08832021

; Patent No. 6045998

; GENERAL INFORMATION:

APPLICANT: Combates, N.

APPLICANT: Pardinas, J.

APPLICANT: Patimco, S.

APPLICANT: Prouty, S.

APPLICANT: Stenn, K.

TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

FILE REFERENCE: JEP-382

CURRENT APPLICATION NUMBER: US/08/832,021

CURRENT FILING DATE: 1997-04-02

NUMBER OF SEQ ID NOS: 64

SOFTWARE: Patent In Ver. 2.0

SEQ ID NO 15

LENGTH: 14

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-15

Query Match 0.9%; Score 12.4; DB 1; Length 14;

Best Local Similarity 92.9%; Pred. No. 1.2e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158

DB 1 TTTTTCCTTTTGG 14

RESULT 254

US-09-661-753-55/c

; Sequence 55, Application US/09661753

; Patent No. 6436909

; GENERAL INFORMATION:

APPLICANT: Nicholas M. Dean

APPLICANT: Susan F. Murray

TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA

FILE REFERENCE: ISH-0498

CURRENT APPLICATION NUMBER: US/09/661,753

CURRENT FILING DATE: 2000-09-14

EARLIER APPLICATION NUMBER: 60/154,546

EARLIER FILING DATE: 1999-09-17

NUMBER OF SEQ ID NOS: 68

SEQ ID NO 55

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Antisense Oligonucleotide

US-09-661-753-55

Query Match 0.9%; Score 12.6; DB 1; Length 20;

Best Local Similarity 78.9%; Pred. No. 2.5e+02;

Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 238 GCATCTGCATCTGGGACCG 256

DB 20 GCTCTGCATCTGGTCCCG 2

APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1842:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-1842

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1050 CGACAGCCCTGGCC 1063
|||||:|
Db 1 CGACAGCCCTGGCC 14

RESULT 257
US-08-724-466B-12
Sequence 12, Application US/08724466B
Patent No. 6063606
GENERAL INFORMATION:
APPLICANT: Petkovich, P. Martin, White, Jay A.,
APPLICANT: Beckett, Barbara R., Jones, Glenville
TITLE OF INVENTION: Retinoid Metabolizing Protein
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Blake, Cassels & Graydon
STREET: Box 25, Commerce Court West
CITY: Toronto
ZIP: M5L 1A9
COUNTRY: Canada
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
COMPUTER: COMPAQ, IBM PC compatible
OPERATING SYSTEM: MS-DOS 5.1

SOFTWARE: WORD PERFECT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/724,466B
FILING DATE: October 1, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/667,546
FILING DATE: June 21, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Hunt, John C.
REGISTRATION NUMBER: 36,424
REFERENCE/DOCKET NUMBER: 50767/00004
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 863-4344
TELEFAX: (416) 863-2653
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-724-466B-12

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTCTTTTGG 1158
|||||:|
Db 1 TTTTCTTTTGG 14

RESULT 258
US-08-882-164D-12
Sequence 12, Application US/08882164D
Patent No. 6306624
GENERAL INFORMATION:
APPLICANT: Petkovich, P. Martin, White, Jay A.,
APPLICANT: Beckett, Barbara R., Jones, Glenville
TITLE OF INVENTION: Retinoid Metabolizing Protein
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Blake, Cassels & Graydon
STREET: Box 25, Commerce Court West
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5L 1A9
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
COMPUTER: COMPAQ, IBM PC compatible
OPERATING SYSTEM: MS-DOS 5.1
SOFTWARE: WORD PERFECT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/882,164D
FILING DATE: June 25, 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/667,546
FILING DATE: June 21, 1996
APPLICATION NUMBER: 08/724,466
FILING DATE: October 1, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Hunt, John C.
REGISTRATION NUMBER: 36,424
REFERENCE/DOCKET NUMBER: 50767/00010
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 863-4344
TELEFAX: (416) 863-2653
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-882-164D-12

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTG 1158
|||||
Db 1 TTTTTCCTTTTG 14

RESULT 259

US-08-319-492B-23/c
; Sequence 23, Application US/08319492B
; Patent No. 5616488

; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OF IL-5
; TITLE OF INVENTION: OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994

; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-319-492B-23

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 628 CAGCTCCAGAGCT 641
|||||
Db 15 CAGCTCCAGAGCT 2

RESULT 260

US-08-863-639A-7/c
; Sequence 7, Application US/08863639A
; Patent No. 5981185

; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel WordPerfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueh
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; US-08-863-639A-7

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTG 1157
|||||
Db 15 TTTTTCCTTTTG 2

RESULT 261

US-08-832-021-50
; Sequence 50, Application US/08832021
; Patent No. 6045998

; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardini, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
; FILE REFERENCE: JBP-382
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 50
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 628 CAGCTCCAGAGCT 641
|||||
Db 15 CAGCTCCAGAGCT 2

OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-50

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 14

RESULT 262
US-08-832-021-51
Sequence 51, Application US/08832021
Patent No. 6045998
GENERAL INFORMATION:
APPLICANT: Combates, N.
APPLICANT: Pardini, J.
APPLICANT: Parimoo, S.
APPLICANT: Prouty, S.
APPLICANT: Stenn, K.
TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
FILE REFERENCE: JBP-382
CURRENT APPLICATION NUMBER: US/08/832,021
CURRENT FILING DATE: 1997-04-02
NUMBER OF SEQ ID NOS: 64
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 51
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-51

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 14

RESULT 263
US-08-832-021-52
Sequence 52, Application US/08832021
Patent No. 6045998
GENERAL INFORMATION:
APPLICANT: Combates, N.
APPLICANT: Pardini, J.
APPLICANT: Parimoo, S.
APPLICANT: Prouty, S.
APPLICANT: Stenn, K.
TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
FILE REFERENCE: JBP-382
CURRENT APPLICATION NUMBER: US/08/832,021
CURRENT FILING DATE: 1997-04-02
NUMBER OF SEQ ID NOS: 64
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 52
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-52

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 14

RESULT 264
US-08-275-951-31
Sequence 31, Application US/08275951
Patent No. 6451968
GENERAL INFORMATION:
APPLICANT: Egholm, Michael
APPLICANT: Kiely, John
APPLICANT: Griffin, Michael
APPLICANT: Coull, James M.
APPLICANT: Neilsen, Peter
APPLICANT: Buchardt, Ole
APPLICANT: Dueholm, Kim L.
APPLICANT: Christensen, Leif
TITLE OF INVENTION: Linked Peptide Nucleic Acids
FILE REFERENCE: ISIS1577
CURRENT APPLICATION NUMBER: US/08/275,951
CURRENT FILING DATE: 1994-07-15
PRIOR APPLICATION NUMBER: 08/108,591
PRIOR FILING DATE: 1993-11-22
PRIOR APPLICATION NUMBER: 08/088,658
PRIOR FILING DATE: 1993-07-02
PRIOR APPLICATION NUMBER: 08/088,661
PRIOR FILING DATE: 1993-07-02
PRIOR APPLICATION NUMBER: PCT/EP92/01219
PRIOR FILING DATE: 1992-05-22
PRIOR APPLICATION NUMBER: 986/91
PRIOR FILING DATE: 1991-05-22
PRIOR APPLICATION NUMBER: 987/91
PRIOR FILING DATE: 1991-05-24
PRIOR APPLICATION NUMBER: 510/92
PRIOR FILING DATE: 1991-04-15
NUMBER OF SEQ ID NOS: 65
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 31
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: No. 6451968el Sequence
NAME/KEY: misc feature
LOCATION: (6)..(7)
OTHER INFORMATION: Lysine, Amino Hexanoic Acid, Lysine, Amino Hexanoic Acid, Lysine Linkage
OTHER INFORMATION: Hexanoic Acid, Lysine Linkage
US-08-275-951-31

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1142 CCTTTTTCCTTTT 1155
Db 2 CCTTTTTCCTTTT 15

RESULT 265
US-08-087-387-6
Sequence 6, Application US/08087387
Patent No. 5473060
GENERAL INFORMATION:
APPLICANT: Sergei M. Gryaznov
TITLE OF INVENTION: Oligonucleotide clamps having diagnostic and therapeutic app
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Stephen C. Macevitz, Lynx Therapeutics
STREET: 465 Lincoln Centre Drive
CITY: Foster City
STATE: California
COUNTRY: USA

```
;
;
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/087,387
; FILING DATE: 19930702
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stephen C. Macevitz
; REGISTRATION NUMBER: 30,285
; REFERENCE/DOCKET NUMBER: 104
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 358-7855
; TELEFAX: (415) 358-7794
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-087-387-6
```

```
Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred.No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1143 CTTTTCCTTTT 1156
Db 2 CTTTTCCTTTT 15
```

```
RESULT 266
US-08-061-697-23/c
; Sequence 23, Application US/08061697
; Patent No. 5498696
; GENERAL INFORMATION:
; APPLICANT: Brown, Michael S.; Briggs, Michael R.; Wang,
; APPLICANT: Xiaodong; Goldstein, Joseph L.
; TITLE OF INVENTION: Sterol Regulatory Element Binding Proteins
; TITLE OF INVENTION: and Their Use in Screening Assays
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P. O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/061,697
; FILING DATE: Concurrently Herewith
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UTSD:347/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 320-7200
; TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
```

```
;
;
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-061-697-23
```

```
Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred.No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 471 GCAGGGGGAGGACT 484
Db 16 GCAGGGGGAGGACT 3
```

```
RESULT 267
US-08-131-365B-23/c
; Sequence 23, Application US/08131365B
; Patent No. 5527690
; GENERAL INFORMATION:
; APPLICANT: Brown, Michael S.
; APPLICANT: Briggs, Michael R.
; APPLICANT: Wang, Xiaodong
; APPLICANT: Goldstein, Joseph L.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING
; TITLE OF INVENTION: TO STEROL REGULATORY ELEMENT BINDING
; TITLE OF INVENTION: PROTEINS
; NUMBER OF SEQUENCES: 64
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P. O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/131,365B
; FILING DATE: 01-OCT-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UTSD:372/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
; US-08-131-365B-23
```

```
Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred.No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 471 GCAGGGGGAGGACT 484
Db 16 GCAGGGGGAGGACT 3
```

```
RESULT 268
US-08-455-627-6
; Sequence 6, Application US/08455627
```



```
/ Patent No. 5571677
/ GENERAL INFORMATION:
/ APPLICANT: Sergei M. Gryaznov
/ TITLE OF INVENTION: Convergent Synthesis of Branched and Multiply
/ TITLE OF INVENTION: Connected Macromolecular Structures
/ NUMBER OF SEQUENCES: 26
/ CORRESPONDENCE ADDRESS:
/ ADDRESSER: Cooley Godward LLP
/ STREET: Five Palo Alto Square, 3000 El Camino Real
/ CITY: Palo Alto
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94306-2155
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/455,627
/ FILING DATE: 31-MAY-1995
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Nakamura, Jackie N.
/ REGISTRATION NUMBER: 35,966
/ REFERENCE/DOCKET NUMBER: LYNX-003/01 US
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-843-5000
/ TELEFAX: 415-857-0663
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 nucleotides
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
US-08-455-627-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTT 1156
Db 2 CTTTTCCTTTT 15

RESULT 269
US-08-284-484A-4/c
/ Sequence 4, Application US/08284484A
/ Patent No. 5639873
/ GENERAL INFORMATION:
/ APPLICANT: Barascut, et al.
/ TITLE OF INVENTION: Oligothionucleotides
/ NUMBER OF SEQUENCES: 5
/ CORRESPONDENCE ADDRESS:
/ ADDRESSER: Woodcock Washburn Kurtz Mackiewicz and No. 5639873ris
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5 inch disk, 720 Kb
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: WordPerfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/284,484A
/ FILING DATE: 04-AUG-1994
/ CLASSIFICATION: 536
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Paul K. Legaard
```

```
/ REGISTRATION NUMBER: 38,534
/ REFERENCE/DOCKET NUMBER: MSWA-0001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 bases
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-284-484A-4

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158
Db 14 TTTTTCCTTTTGG 1

RESULT 270
US-08-461-271-6
/ Sequence 6, Application US/08461271
/ Patent No. 5741643
/ TELECOMMUNICATION INFORMATION:
/ GENERAL INFORMATION:
/ APPLICANT: Sergei M. Gryaznov
/ TITLE OF INVENTION: Oligonucleotide clamps having diagnostic
/ TITLE OF INVENTION: and therapeutic applications
/ NUMBER OF SEQUENCES: 6
/ CORRESPONDENCE ADDRESS:
/ ADDRESSER: Stephen C. Macevicz, Lynx Therapeutics
/ STREET: 465 Lincoln Centre Drive
/ CITY: Foster City
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94404
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 5.25 inch diskette
/ COMPUTER: IBM compatible
/ OPERATING SYSTEM: Windows 3.1/DOS 5.0
/ SOFTWARE: Microsoft Word for Windows, vers. 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/461,271
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/087,387
/ FILING DATE: 2-Jul-93
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Stephen C. Macevicz
/ REGISTRATION NUMBER: 30,285
/ REFERENCE/DOCKET NUMBER: 104
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (415) 358-7855
/ TELEFAX: (415) 358-7794
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 nucleotides
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-461-271-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTT 1156
Db 2 CTTTTCCTTTT 15
```

RESULT 271
US-08-713-685A-6
; Sequence 6, Application US/08713685A
; Patent No. 5817795
; GENERAL INFORMATION:
; APPLICANT: Sergei M. Gryaznov
; TITLE OF INVENTION: Oligonucleotide clamps having diagnostic
; TITLE OF INVENTION: and therapeutic applications
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stephen C. Macevitz, Lynx Therapeutics
; STREET: 465 Lincoln Centre Drive
; CITY: Foster City
; STATE: California
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/713.685A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/461,271
; FILING DATE:
; APPLICATION NUMBER: 08/087,387
; FILING DATE: 2-Jul-93
; ATTORNEY/AGENT INFORMATION:
; NAME: Stephen C. Macevitz
; REGISTRATION NUMBER: 30,285
; REFERENCE/DOCKET NUMBER: 104
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 358-7855
; TELEFAX: (415) 358-7794
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-713-685A-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1143 CTTTTTTCTTTTT 1156
Db 2 CTTTTTTCTTTTT 15

RESULT 272
US-08-689-856-6
; Sequence 6, Application US/08689856
; Patent No. 5830658
; GENERAL INFORMATION:
; APPLICANT: Sergei M. Gryaznov
; TITLE OF INVENTION: Convergent Synthesis of Branched and Multiply
; TITLE OF INVENTION: Connected Macromolecular Structures
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooley Godward LLP
; STREET: Five Palo Alto Square, 3000 El Camino Real
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/689,856
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/455,627
; FILING DATE: 31-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Nakamura, Jackie N.
; REGISTRATION NUMBER: 35,966
; REFERENCE/DOCKET NUMBER: LYNX-003/01 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-843-5000
; TELEFAX: 415-857-0663
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-689-856-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1143 CTTTTTTCTTTTT 1156
Db 2 CTTTTTTCTTTTT 15

RESULT 273
US-08-668-123-23/c
; Sequence 23, Application US/08668123
; Patent No. 5891631
; GENERAL INFORMATION:
; APPLICANT: Brown, Michael S.
; APPLICANT: Briggs, Michael R.
; APPLICANT: Wang, Xiaodong
; APPLICANT: Goldstein, Joseph L.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING
; TITLE OF INVENTION: TO STEROL REGULATORY ELEMENT BINDING
; NUMBER OF SEQUENCES: 64
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/668,123
; FILING DATE: 14-JUN-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/131,365
; FILING DATE: 01-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UTSD:372/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000

TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-08-668-123-23

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 471 GCAGGGGGAGGACT 484
Db 16 GCAGGGGGAGGAGT 3

RESULT 274
US-09-070-477-6
; Sequence 6, Application US/09070477
; Patent No. 6048974
; GENERAL INFORMATION:
; APPLICANT: Sergei M. Gryaznov
; TITLE OF INVENTION: Oligonucleotide clamps having diagnostic
; TITLE OF INVENTION: and therapeutic applications
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stephen C. Macevicz, Lynx Therapeutics
; STREET: 465 Lincoln Centre Drive
; CITY: Foster City
; STATE: California
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.11/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/070,477
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/713,685
; FILING DATE:
; APPLICATION NUMBER: 08/461,271
; FILING DATE:
; APPLICATION NUMBER: 08/087,387
; FILING DATE: 2-Jul-93
; NAME: Stephen C. Macevicz
; ATTORNEY/AGENT INFORMATION:
; REGISTRATION NUMBER: 30,285
; REFERENCE/DOCKET NUMBER: 104
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 358-7855
; TELEFAX: (415) 358-7794
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-070-477-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTT 1156
TTTTTTTTTTTTTTTT

Db 2 CTTTTTTTTTTTTT 15

RESULT 275
5256545-4/c
; Patent No. 5256545
; APPLICANT: BROWN, MICHAEL S.;GOLDSTEIN, JOSEPH L.;RUSSELL,
; DAVID W.;SUDHOF, THOMAS C.
; TITLE OF INVENTION: STEROL REGULATORY ELEMENTS
; NUMBER OF SEQUENCES: 42
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/425,852
; FILING DATE: 20-OCT-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 33,330
; FILING DATE: 30-MAR-1987
; APPLICATION NUMBER: 33,081
; FILING DATE: 30-MAR-1987
; SEQ ID NO:4:
; LENGTH: 16
5256545-4

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 471 GCAGGGGGAGGACT 484
Db 16 GCAGGGGGAGGAGT 3

RESULT 276
5256545-33
; Patent No. 5256545
; APPLICANT: BROWN, MICHAEL S.;GOLDSTEIN, JOSEPH L.;RUSSELL,
; DAVID W.;SUDHOF, THOMAS C.
; TITLE OF INVENTION: STEROL REGULATORY ELEMENTS
; NUMBER OF SEQUENCES: 42
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/425,852
; FILING DATE: 20-OCT-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 33,330
; FILING DATE: 30-MAR-1987
; APPLICATION NUMBER: 33,081
; FILING DATE: 30-MAR-1987
; SEQ ID NO:33:
; LENGTH: 16
5256545-33

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 471 GCAGGGGGAGGACT 484
Db 1 GCAGGGGGAGGAGT 14

RESULT 277
US-08-373-124A-338/c
; Sequence 338, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 338:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-338

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 GGCAGGCGAGTTGAG 15
Db 15 GGCAGGCGAGTTGAG 2

RESULT 278
US-08-373-124A-2047
Sequence 2047, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 2047:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-2047

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1118 GTTTAATTGAAAAA 1131
Db 4 GUUUUUGAAAAA 17

RESULT 279
US-08-373-124A-2049
Sequence 2049, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466

FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2049:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-2049

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1118 GTTAAATTGAAAAA 1131
DB 2 GUUUUUGAAAAA 15

RESULT 280
US-08-261-822A-30/c
Sequence 30, Application US/08261822A
Patent No. 5650553
GENERAL INFORMATION:
APPLICANT: Ecker, Joseph R. et al.
TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
TITLE OF INVENTION: and Pathogens
NUMBER OF SEQUENCES: 82
CORRESPONDENCE ADDRESS:
ADDRESSER: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5650553ris
STREET: One Liberty Place, 46th floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/261,822A
FILING DATE: 17-JUN-1994
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Beardell, Lori Y.
REGISTRATION NUMBER: 34,293
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: YES
US-08-261-822A-30

FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 338:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-338

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 648 CCCCCAAGACCTGG 661
DB 17 CCACCAAGACCTGG 4

RESULT 281
US-08-435-628-338/c
Sequence 338, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 338:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-338

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 GGCAGGCGATTGAG 15

Db ||||| ||||| ||||| ||||| |||||
15 GCAGGGAGTTGAG 2

RESULT 282
US-08-435-628-2047
; Sequence 2047, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwigen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992

ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2047:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-2047

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1118 GTTTAATTGAAAAA 1131
|:::|:::|:::|:::|:::|:::|
Db 4 GUUUUAUGAAAAA 17

RESULT 283
US-08-435-628-2049

; Sequence 2049, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwigen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992

ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2049:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-2049

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1118 GTTTAATTGAAAAA 1131
|:::|:::|:::|:::|:::|:::|
Db 2 GUUUUAUGAAAAA 15

RESULT 284
US-08-485-611A-9
; Sequence 9, Application US/08485611A
; Patent No. 5849482
; GENERAL INFORMATION:
; APPLICANT: Meyer, Jr., Rich B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Kutayavin, Igor V.

APPLICANT: Gall, Alexander A.
APPLICANT: Petrie, Charles R.
APPLICANT: Tabone, John C.
APPLICANT: Hurst, Gerald D.
TITLE OF INVENTION: CROSSLINKING OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSER: Klein & Szekeres
STREET: 4199 Campus Drive, Suite 700
CITY: Irvine
STATE: CA
COUNTRY: USA
ZIP: 92715
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,611A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/226,949
FILING DATE: 27-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/011,482
FILING DATE: 26-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/334,490
FILING DATE: 04-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/049,807
FILING DATE: 20-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/353,857
FILING DATE: 18-MAY-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/250,474
FILING DATE: 28-SEP-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/178,733
FILING DATE: 07-JAN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/748,138
FILING DATE: 21-AUG-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/353,857
FILING DATE: 18-MAY-1989
ATTORNEY/AGENT INFORMATION:
NAME: Szekeres, Gabor L.
REGISTRATION NUMBER: 28,675
REFERENCE/DOCKET NUMBER: 491-11-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 714-854-5502
TELEFAX: 714-854-4897
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-485-611A-9

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1147 TTTTCTTTTGGAGT 1162
Db 1 TTTTCTTTTGGGGT 16

RESULT 285
US-08-985-162-118
Sequence 118, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 118:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-118

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.9e+02;
Matches 7; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1099 CGTAATTATGTAGT 1112
Db 3 CGUAAUUAUGUGU 16

RESULT 286
US-08-985-162-119
Sequence 119, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 119:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-119

Query Match' 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.9e+02;
Matches 7; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1099 CGTAATATGTAGT 1112
|||:|:|:|:
DB 2 CGAAUAUUGUGGU 15

RESULT 287
US-08-998-099-95
; Sequence 95, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT OF DISEASES
; TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT OF DISEASES
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 95
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-08-998-099-95

Query Match 0.9%; Score 12.4; DB 1; Length 17;

Best Local Similarity 71.4%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 56 CTCCTCAATTACCC 69
|:|:|:|:|:|:
DB 4 CUCCUCAUGACCC 17

RESULT 288
US-09-017-974-79
; Sequence 79, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Taylor, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 79:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-017-974-79

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 762 GTGGCGGGTGGATG 775
|||:|:|:|:|:|:
DB 1 GTGGCGGGTGGGTG 14

RESULT 289
US-08-682-255A-79
; Sequence 79, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.

APPLICANT: Pennewald, Susan
APPLICANT: Zendegei, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommier, Yves
APPLICANT: Mazunder, Abhiit
TITLE OF INVENTION: Anti-viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/682,255A
FILING DATE: 17-JULY-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168
FILING DATE: 23-OCT-95
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/015,714
FILING DATE: 17-APRIL-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 23-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 79:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-682-255A-79

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 762 GTGCGGGTGGATG 775
Db 1 GTGCGGGTGGGTG 14

RESULT 290
US-08-584-040-2256
Sequence 2256, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2256:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-2256

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1155 TTGGAGTAAGCA 1168
Db 1 UUGGAACUAAAGCA 14

RESULT 291
US-08-584-040-2547
Sequence 2547, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

;; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;; TITLE OF INVENTION: TREATMENT OF DISEASES OR
;; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
;; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;; TITLE OF INVENTION: GROWTH FACTOR
;; NUMBER OF SEQUENCES: 8502
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Suite 4700
;; STATE: Los Angeles
;; COUNTRY: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 6009:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-584-040-6009
Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 23 AAACCAACCAGC 36
Db 14 AAACCAACCCTGC 1
RESULT 297
US-08-679-645-139/C
; Sequence 139, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggan, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street

;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/679,645
;; FILING DATE: July 12, 1996
;; CLASSIFICATION: 800
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/001,135
;; FILING DATE: July 13, 1995
;; APPLICATION NUMBER: 08/300,726
;; FILING DATE: September 2, 1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 219/247
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 139:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-679-645-139
Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 884 TCCAGGAGCTGCGG 897
Db 14 TCCATGAGCTGCGG 1
RESULT 298
US-09-429-130-79
; Sequence 79, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Pennewald, Susan
; APPLICANT: Zengdegui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; APPLICANT: 60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)


```
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 409
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-409

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 477 GGAGGACTGCCGAG 490
Db 1 GGAGGAUCCGAG 14

RESULT 302
US-09-474-432B-421
; Sequence 421, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 421
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-421

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1297 CAGCCTGCCGCAT 1310
Db 2 CAGCCUUGCCCAU 15

RESULT 303
US-09-474-432B-557
; Sequence 557, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucle
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 421
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-421

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 GGTCCCCACACGCCA 880
Db 17 GGTCCCCACACGCCA 4

RESULT 305
US-09-371-772B-801
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucle
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-815

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 GGTCCCCACACGCCA 880
Db 17 GGTCCCCACACGCCA 4

RESULT 305
US-09-371-772B-801
```

; Sequence 801, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 801
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-801

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 1155 TTGGAAGTAAAGCA 1168
:||||:|||||
Db 1 UUGGAACUAAGCA 14

RESULT 306
US-09-371-772B-1071
; Sequence 1071, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1071
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1071

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 1.9e+02;
Matches 1; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
QY 1143 CTTTTCCTTTT 1156
|:|||||:|
Db 4 CUUUUUUUUUUU 17

RESULT 307
US-09-371-772B-1072
; Sequence 1072, Application US/09371772B

; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1072
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1072

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.1%; Pred. No. 1.9e+02;
Matches 1; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
QY 1143 CTTTTCCTTTT 1156
|:|||||:|
Db 3 CUUUUUUUUUUU 16

RESULT 308
US-09-371-772B-1073
; Sequence 1073, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1073
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1073

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.1%; Pred. No. 1.9e+02;
Matches 1; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
QY 1143 CTTTTCCTTTT 1156
|:|||||:|
Db 2 CUUUUUUUUUUU 15

RESULT 309
US-09-371-772B-1074
; Sequence 1074, Application US/09371772B
; Patent No. 6566127

```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1074
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1074

```

```

Query Match      0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 7.1%; Pred. No. 1.9e+02;
Matches 1; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1143 CTTTTCCTTTTCTTTT 1156
      |||:|||||:|||||
Db 1 CUUUUUUUUUUU 14

```

```

RESULT 310
US-09-371-772B-2845/c
; Sequence 2845, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2845

```

```

Query Match      0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 23 AAACCAACCCGCGC 36
      |||:|||||:|||||
Db 15 AAACCAACCCCTGC 2

```

```

RESULT 311
US-09-371-772B-2846/c
; Sequence 2846, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:

```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2846

```

```

Query Match      0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 23 AAACCAACCCGCGC 36
      |||:|||||:|||||
Db 14 AAACCAACCCCTGC 1

```

```

RESULT 312
US-09-371-772B-5053
; Sequence 5053, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5053
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5053

```

```

Query Match      0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 687 TGGGAGCCGCGCGC 700
      |||:|||||:|||||
Db 2 UGGGAGCCGCGC 15

```

```

RESULT 313
US-09-371-772B-5054
; Sequence 5054, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```


APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT FILING DATE: 1999-08-10
CURRENT APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: Patentin version 3.0
SEQ ID NO 5054
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-5054

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 687 TGGGAGCCAGCGGC 700
:|||||:|||||
Db 1 UGGGAGCCAGCGUC 14

RESULT 314
US-09-371-772B-5055
Sequence 5055, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT FILING DATE: 1999-08-10
CURRENT APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: Patentin version 3.0
SEQ ID NO 5055
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-5055

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1313 AGCCAGTGCTTTT 1326
:|||||:|||||
Db 2 AGCCAGCUGCUUUU 15

RESULT 315
US-09-371-772B-6554
Sequence 6554, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam

APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT FILING DATE: 1999-08-10
CURRENT APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: Patentin version 3.0
SEQ ID NO 6554
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-6554

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.8%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 550 CTGGCAGGCATGCA 583
:|||||:|||||
Db 4 CUGCCAGGCAUGCA 17

RESULT 316
PCT-US95-07744A-30/c
Sequence 30, Application PC/TUS9507744A
GENERAL INFORMATION:
APPLICANT: Trustees of The University of Pennsylvania
TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
NUMBER OF SEQUENCES: 82
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & Norris
STREET: One Liberty Place, 46th floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/07744A
FILING DATE: 15-JUNE-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/261,822
FILING DATE: June 17, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Beardsell, Lori Y.
REGISTRATION NUMBER: 34,293
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: YES
PCT-US95-07744A-30

```
Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 648 CCCCCAAGACCTGG 661
Db 17 CCACCAAGACCTGG 4

RESULT 317
US-09-371-772B-5055/c
; Sequence 5055, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Bacobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MH000,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5055
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5055

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1027 CAAAGTCAGCTGACTC 1043
Db 17 CAAAAGCAGCTGGCTC 1

RESULT 318
US-08-281-940-49/c
; Sequence 49, Application US/08281940
; Patent No. 5589330
; GENERAL INFORMATION:
; APPLICANT: SHUBER, ANTHONY P.
; TITLE OF INVENTION: METHOD FOR MULTIPLE ALLELE-SPECIFIC
; TITLE OF INVENTION: DISEASE ANALYSIS
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DARBY & DARBY P.C.
; STREET: 805 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/281,940
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: LUDWIG, S. PETER
; REGISTRATION NUMBER: 25351
```

```
REFERENCE/DOCKET NUMBER: 0372/09696
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212/527-7700
TELEFAX: 212/753-6237
TELEX: 236687
INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
ORIGINAL SOURCE:
ORGANISM: Homo sapien
IMMEDIATE SOURCE:
CLONE: 711+1GTN
US-08-281-940-49

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 441 AAAGTTGCTGAAGTTTG 457
Db 17 AAATTGATGAAGTATG 1

RESULT 319
US-08-390-850-589/c
; Sequence 589, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 589:
```

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-390-850-589

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 365 TCCTGGGGCCAGCTT 381
Db 17 TCCTGGGTAACCACTT 1

RESULT 320

US-08-390-850-590/c
Sequence 590, Application US/08390850

Patent No. 5612215

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.

APPLICANT: Pavco, Pamela

APPLICANT: McSwiggen, James

APPLICANT: Gustofson, John

APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

NUMBER OF SEQUENCES: 1151

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/390,850

FILING DATE: February 17, 1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/354,920

FILING DATE: December 13, 1994

APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5612215ember 12, 1993

APPLICATION NUMBER: 07/989,848

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 211/084

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 590:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-390-850-590

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 364 TCCTGGGGCCAGCT 380
Db 17 TCCTGGGTAACCACT 1

RESULT 321

US-08-390-850-592

Sequence 592, Application US/08390850

Patent No. 5612215

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.

APPLICANT: Pavco, Pamela

APPLICANT: McSwiggen, James

APPLICANT: Gustofson, John

APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

NUMBER OF SEQUENCES: 1151

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/390,850

FILING DATE: February 17, 1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/354,920

FILING DATE: December 13, 1994

APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5612215ember 12, 1993

APPLICATION NUMBER: 07/989,848

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 211/084

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 592:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-390-850-592

Query Match

Best Local Similarity 58.8%; Score 12.2; DB 1; Length 17;

Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1056 CCTGGGCTTCCCATCA 1072
Db 1 CCUGGGUUCUUCA 17

RESULT 322

US-08-435-634-589/c

Sequence 589, Application US/08435634

Patent No. 5731295

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.

APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 589:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-589

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 365 TTCTGGGGCCCGCTT 381
DB 17 TCCTGGGTAAACCGCTT 1

RESULT 323
US-08-435-634-590/c
Sequence 590, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 590:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-590

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 364 TTCTGGGGCCCGCTT 380
DB 17 TCCTGGGTAAACCGCTT 1

RESULT 324
US-08-435-634-592
Sequence 592, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435.634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 592:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-592

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1056 CCCTGGCCTTCCCATCA 1072
Db 1 CCCUGGGUUCUUUCA 17
|||||:|:|:|:|:|

RESULT 325
US-08-466-033-104
Sequence 104, Application US/08466033
Patent No. 5766840
GENERAL INFORMATION:
APPLICANT: Kim, Jungshuh P.
APPLICANT: Wages, John
APPLICANT: Young, LaVonne M.
APPLICANT: Fry, Kirk E.
APPLICANT: Linnen, Jeffrey M.
TITLE OF INVENTION: Hepatitis G Virus and Molecular
TITLE OF INVENTION: Cloning Thereof
NUMBER OF SEQUENCES: 277
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Ave., Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,033
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/389,886
FILING DATE: 15-FEB-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/357,509
FILING DATE: 16-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/329,729
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/344,271
FILING DATE: 23-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,558
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,543
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/246,985
FILING DATE: 20-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 104:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Primer PGEX-R
US-08-466-033-104
Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 625 GACCAGCTCCGAGGCT 641
Db 1 GACCGTCTCCGGAGCT 17
|||||:|:|:|:|:|
RESULT 326
US-08-444-733-104
Sequence 104, Application US/08444733
Patent No. 5824507
GENERAL INFORMATION:
APPLICANT: Kim, Jungshuh P.
APPLICANT: Wages, John
APPLICANT: Young, LaVonne M.
APPLICANT: Fry, Kirk E.
APPLICANT: Linnen, Jeffrey M.
TITLE OF INVENTION: Hepatitis G Virus and Molecular
TITLE OF INVENTION: Cloning Thereof
NUMBER OF SEQUENCES: 277
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Ave., Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,033
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:

```
/
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/444,733
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/389,886
/ FILING DATE: 15-FEB-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/357,509
/ FILING DATE: 16-DEC-1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/329,729
/ FILING DATE: 26-OCT-1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/344,271
/ FILING DATE: 23-NOV-1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/285,558
/ FILING DATE: 03-AUG-1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/285,543
/ FILING DATE: 03-AUG-1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/246,985
/ FILING DATE: 20-MAY-1994
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Fabian, Gary R.
/ REGISTRATION NUMBER: 33,875
/ REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (415) 324-0880
/ TELEFAX: (415) 324-0960
/ INFORMATION FOR SEQ ID NO: 104:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: both
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ ORIGINAL SOURCE:
/ INDIVIDUAL ISOLATE: Primer PGEX-R
/
/ US-08-444-733-104
/
/ Query Match 0.9%; Score 12.2; DB 1; Length 17;
/ Best Local Similarity 82.4%; Pred. No. 2.1e+02;
/ Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
/
/ QY 625 GACCAGCTCCAGGAGCT 641
/ Db 1 GACCGTCTCCGGAGCT 17
/
/ RESULT 327
/ US-08-710-134-49/c
/ Sequence 49, Application US/08710134
/ Patent No. 5834181
/ GENERAL INFORMATION:
/ APPLICANT: SHUBER, ANTHONY P.
/ TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
/ SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
/ NUMBER OF SEQUENCES: 65
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Genzyme Corporation
/ STREET: One Mountain Road
/ CITY: Framingham
/ STATE: Massachusetts
/ COUNTRY: USA
/ ZIP: 01701
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/
```

```
/
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/710,134
/ FILING DATE: 13-SEP-1996
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Dugan, Deborah A.
/ REGISTRATION NUMBER: 37,315
/ REFERENCE/DOCKET NUMBER: IG5-8.1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 508-872-8400
/ TELEFAX: 508-872-5415
/ INFORMATION FOR SEQ ID NO: 49:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ DESCRIPTION: /desc = "Oligonucleotides"
/
/ US-08-710-134-49
/
/ Query Match 0.9%; Score 12.2; DB 1; Length 17;
/ Best Local Similarity 82.4%; Pred. No. 2.1e+02;
/ Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
/
/ QY 441 AAAGTTGCTGAAGTTTG 457
/ Db 17 AAATTTGATGAAGTATG 1
/
/ RESULT 328
/ US-08-292-620A-1644/c
/ Sequence 1644, Application US/08292620A
/ Patent No. 5837542
/ GENERAL INFORMATION:
/ APPLICANT: Susan Grimm
/ APPLICANT: Dan T. Stinchcomb
/ APPLICANT: James McSwiggen
/ APPLICANT: Sean Sullivan
/ APPLICANT: Kenneth G. Draper
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF
/ DISEASES OR CONDITIONS
/ TITLE OF INVENTION: RELATED TO LEVELS OF
/ INTRACELLULAR ADHESION
/ TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
/ NUMBER OF SEQUENCES: 2390
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/292,620A
/ FILING DATE: August 17, 1994
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA: including application
/ PRIOR APPLICATION DATA: described below:
/ APPLICATION NUMBER: 08/008,895
/ FILING DATE: January 19, 1993
/ APPLICATION NUMBER: 07/989,849
/
```

;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1644:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-292-620A-1644

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGGACCGAGTCCAGGAG 639
Db 17 GGGACCGAGGACCGAG 1

RESULT 329
US-08-292-620A-1697
; Sequence 1697, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600

two

;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1697:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-292-620A-1697

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 961 CAGGACTGACCCCTCAC 977
Db 1 CAGCAUUAUCCCCUCAC 17

RESULT 330
US-08-292-620A-1700/c
; Sequence 1700, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1700:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

two

```

; TOPOLOGY: linear
US-08-292-620A-1700

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAAGCTCCAGGAG 639
Db 17 GCGACCAAGCTCCAGGAG 1

RESULT 331
US-08-292-620A-1707/c
; Sequence 1707, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1707:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1707

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAAGCTCCAGGAG 639
Db 17 GCGACCAAGCTCCAGGAG 1

RESULT 332
US-08-292-620A-1743/c
; Sequence 1743, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1743:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1743

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAAGCTCCAGGAG 639
Db 17 GCGACCAAGCTCCAGGAG 1

RESULT 333
US-08-292-620A-1796/c

```


; Sequence 1796, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1796:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1796

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGGACCAAGCTCCAGGAG 639
Db 17 GCGACCAAGGACCAAGGAG 1

RESULT 334

US-08-292-620A-1873/c
; Sequence 1873, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1873:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1873

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGGACCAAGCTCCAGGAG 639
Db 17 GCGACCAAGGACCAAGGAG 1

RESULT 335

US-08-292-620A-1934/c
; Sequence 1934, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390

two

two

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620A
;; FILING DATE: August 17, 1994
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1934:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-292-620A-1934

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGGACCAGCTCCAGGAG 639
Db 17 GGGACCAGGACCAGGAG 1

RESULT 336
US-08-485-885-49/c
; Sequence 49, Application US/08485885
; Patent No. 5849483
; GENERAL INFORMATION:
; APPLICANT: SHUBER, ANTHONY P.
; TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genzyme Corporation
; STREET: One Mountain Road
; CITY: Framingham
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 01701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,885

;; FILING DATE: 07-JUN-1995
;; CLASSIFICATION: 435
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Dugan, Deborah A.
;; REGISTRATION NUMBER: 37,315
;; REFERENCE/DOCKET NUMBER: GEN4-12.1
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 508-872-8400
;; TELEFAX: 508-872-5415
;; INFORMATION FOR SEQ ID NO: 49:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: other nucleic acid
;; DESCRIPTION: /desc = "Oligonucleotides"
US-08-485-885-49

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 441 AAAGTTGCTGAAGTTTG 457
Db 17 AAATTTGATGAAGTATG 1

RESULT 337
US-08-464-134-104
; Sequence 104, Application US/08464134
; Patent No. 5849532
; GENERAL INFORMATION:
; APPLICANT: Kim, Jungshuh P.
; APPLICANT: Wages, John
; APPLICANT: Young, LaVonne M.
; APPLICANT: Fry, Kirk E.
; APPLICANT: Linnen, Jeffrey M.
; TITLE OF INVENTION: Hepatitis G Virus and Molecular
; NUMBER OF SEQUENCES: 277
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Ave., Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/464,134
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/389,886
; FILING DATE: 15-FEB-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/357,509
; FILING DATE: 16-DEC-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/329,729
; FILING DATE: 26-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/344,271
; FILING DATE: 23-NOV-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/285,558
; FILING DATE: 03-AUG-1994
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/285,543
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/246,985
FILING DATE: 20-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 104:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Primer PGEX-R
US-08-461-134-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 625 GACCAGCTCCAGGAGCT 641
Db 1 GACCGTCTCCGGAGCT 17

RESULT 338
US-08-461-361-104
Sequence 104, Application US/08461361
Patent No. 5856134
GENERAL INFORMATION:
APPLICANT: Kim, Jungshuh P.
APPLICANT: Wages, John
APPLICANT: Young, LaVonne M.
APPLICANT: Fry, Kirk E.
APPLICANT: Linnen, Jeffrey M.
TITLE OF INVENTION: Hepatitis G Virus and Molecular
Cloning Thereof
NUMBER OF SEQUENCES: 277
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Ave., Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/461,361
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/389,886
FILING DATE: 15-FEB-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/357,509
FILING DATE: 16-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/329,729
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/344,271
FILING DATE: 23-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,558
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,543
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/246,985
FILING DATE: 20-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 104:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Primer PGEX-R
US-08-461-361-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 625 GACCAGCTCCAGGAGCT 641
Db 1 GACCGTCTCCGGAGCT 17

RESULT 339
US-08-485-910-104
Sequence 104, Application US/08485910
Patent No. 5874563
GENERAL INFORMATION:
APPLICANT: Kim, Jungshuh P.
APPLICANT: Wages, John
APPLICANT: Young, LaVonne M.
APPLICANT: Fry, Kirk E.
APPLICANT: Linnen, Jeffrey M.
TITLE OF INVENTION: Hepatitis G Virus and Molecular
Cloning Thereof
NUMBER OF SEQUENCES: 277
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Ave., Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,910
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/389,886
FILING DATE: 15-FEB-1995
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/357,509
FILING DATE: 16-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/329,729
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/344,271
FILING DATE: 23-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,558
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,543
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/246,985
FILING DATE: 20-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 104:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Primer PGEX-R
US-08-485-910-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 625 GACCGCTCCGGAGCT 641
Db 1 GACCGCTCCGGAGCT 17

RESULT 340
US-08-474-450A-62
Sequence 62, Application US/08474450A
Patent No. 5882856
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: UNIVERSAL PRIMER SEQUENCE FOR MULTIPLEX
TITLE OF INVENTION: DNA AMPLIFICATION
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: RAE-VENTER LAW GROUP
STREET: 260 Sheridan Ave., Ste. 440
City: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/474,450A
FILING DATE: 7-JUNE-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Rae-Venter, Barbara

REGISTRATION NUMBER: 32,750
REFERENCE/DOCKET NUMBER: GECO.001.000S
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 328-4400
TELEFAX: (650) 328-4477
INFORMATION FOR SEQ ID NO: 62:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "WT-1 PRIMER SEQUENCE - N"
US-08-474-450A-62

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 386 CACAGGTGGCAGCAATG 402
Db 1 CACAGGTGGCAGCAATG 17

RESULT 341
US-08-798-738-10/c
Sequence 10, Application US/08798738
Patent No. 5885833
GENERAL INFORMATION:
APPLICANT: MUELLER, Rolf
APPLICANT: ZWICKER, Joerk
APPLICANT: SEDLACEK, Hans-Herald
TITLE OF INVENTION: NUCLEIC ACID CONSTRUCTS FOR THE CELL
TITLE OF INVENTION: CYCLE-REGULATED EXPRESSION OF GENES AND THERAPEUTIC
TITLE OF INVENTION: METHODS OF UTILIZING SUCH CONSTRUCTS
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
City: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/798,738
FILING DATE: 13-FEB-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE 19605274.2
FILING DATE: 13-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: GRANADOS, Patricia D.
REGISTRATION NUMBER: 33,683
REFERENCE/DOCKET NUMBER: 18748/318
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-798-738-10

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 598 ACCAGCTGAAGCTGA 614
| | | | | | | | | | | | | | | |
Db 17 ACAGCCTGAGTCTGA 1

RESULT 342

US-08-484-661A-17
; Sequence 17, Application US/08484661A
; Patent No. 6001645
; GENERAL INFORMATION:
; APPLICANT: SLATER, MICHAEL R.
; APPLICANT: HARTNETT, JAMES R.
; APPLICANT: HUANG, FEN
; APPLICANT: BOLCHAKOVA, ELENA
; TITLE OF INVENTION: MODIFIED THERMOPHILIC DNA POLYMERASES
; TITLE OF INVENTION: FROM THERMOTOGA NEAPOLITANA
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL
; STREET: 220 MONTGOMERY STREET, SUITE 2200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/484,661A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: INGOLIA, DIANE E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: PRMG-01175
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-484-661A-17

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1199 GACCTTACACCTGCCC 1215
| | | | | | | | | | | | | | | |
Db 1 GACCTTGACAGTCTC 17

RESULT 343

US-08-181-664-64/C
; Sequence 64, Application US/08181664
; Patent No. 6025127
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION IN
; TITLE OF INVENTION: HISTOLOGIC TISSUE
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Spensley Horn Jubas & Lubitz
; STREET: 1880 Century Park East, Suite 500
; CITY: Los Angeles

; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/181,664
; FILING DATE: JANUARY 14, 1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Wetherell, Jr., Ph.D., John R.
; REGISTRATION NUMBER: 31,678
; REFERENCE/DOCKET NUMBER: PD-3055
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 455-5100
; TELEFAX: (619) 455-5110
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..17
US-08-181-664-64

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1039 GACTCTTCCCGACGACG 1055
| | | | | | | | | | | | | | | |
Db 17 GTCTCTCCCGACGACG 1

RESULT 344

US-08-985-162-85/C
; Sequence 85, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476

```
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-85

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1216 TTCCCTGTACATTGTC 1232
Db      17 TTTCCTGTAATTCTC 1

RESULT 345
US-08-985-162-104/c
; Sequence 104, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-104
```

```
; TOPOLOGY: linear
; US-08-985-162-104

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      629 AGCTCCAGGAGCTCTGC 645
Db      17 AGCGCCCGAGCACTGC 1

RESULT 346
US-08-985-162-237/c
; Sequence 237, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFORMATION FOR SEQ ID NO: 237:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-237

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      645 CATCCCCCAAGACCTGG 661
Db      17 CAGCCTTCAAGACCTGG 1

RESULT 347
US-08-985-162-293
```

```
; Sequence 293, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 293:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-293

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 577 CAGGCCCTCCGCTGACC 593
Db 1 CAUGCCCUUGCGUGCC 17

RESULT 348
US-08-656-664-17
; Sequence 17, Application US/08656664
; Patent No. 6077864
; GENERAL INFORMATION:
; APPLICANT: Slater, Michael R.
; APPLICANT: Huang, Fen
; APPLICANT: Hartnett, James R.
; APPLICANT: Bolchakova, Elena
; APPLICANT: Storts, Douglas R.
; APPLICANT: Otto, Paul
; TITLE OF INVENTION: THERMOPHILIC DNA POLYMERASES FROM
; THERMOTOGA NEAPOLIITANA
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll
```

```
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States Of America
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/656,664
; FILING DATE: 31-MAY-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: PRMG-02185
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-656-664-17

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1199 GACCTTCACACCTCCCC 1215
Db 1 GACCTTCACAGGCTC 17

RESULT 349
US-08-998-099-82
; Sequence 82, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; APPLICANT: STINCHCOMB, DAN T.
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
; OF CONDITIONS RELATED TO LEVELS OF C-POS
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 82
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-08-998-099-82

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1057 CTTGGCCTTCCCATCAG 1073
Db 1 CCUGGGCUUCCAGAG 17
```

RESULT 350
US-09-071-845-1644/c
; Sequence 1644, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1644:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1644

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.le+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGGACGAGCTCCAGGAG 639
Db 17 GCGACGAGGACGAG 1

RESULT 351
US-09-071-845-1697
; Sequence 1697, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:

; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1697:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1697

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.le+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 961 CAGGACTGACCCCTCAC 977
Db 1 CAGCAUUUACCCUCAC 17

RESULT 352
US-09-071-845-1700/c
; Sequence 1700, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:

; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS

;; TITLE OF INVENTION: RELATED TO LEVELS OF
;; TITLE OF INVENTION: INTRACELLULAR ADHESION
;; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
;; NUMBER OF SEQUENCES: 2390
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/071,845
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620
;; FILING DATE: August 17, 1994
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1700:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-071-845-1700

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 353
US-09-071-845-1707/c
;; Sequence 1707, Application US/09071845
;; Patent No. 6132967
;; GENERAL INFORMATION:
;; APPLICANT: Susan Grimm
;; APPLICANT: Dan T. Stinchcomb
;; APPLICANT: James McSwiggen
;; APPLICANT: Sean Sullivan
;; APPLICANT: Kenneth G. Draper
;; TITLE OF INVENTION: RIBOZYME TREATMENT OF
;; TITLE OF INVENTION: DISEASES OR CONDITIONS
;; TITLE OF INVENTION: RELATED TO LEVELS OF
;; TITLE OF INVENTION: INTRACELLULAR ADHESION
;; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
;; NUMBER OF SEQUENCES: 2390
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street

;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/071,845
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620
;; FILING DATE: August 17, 1994
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1707:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-071-845-1707

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 354
US-09-071-845-1743/c
;; Sequence 1743, Application US/09071845
;; Patent No. 6132967
;; GENERAL INFORMATION:
;; APPLICANT: Susan Grimm
;; APPLICANT: Dan T. Stinchcomb
;; APPLICANT: James McSwiggen
;; APPLICANT: Sean Sullivan
;; APPLICANT: Kenneth G. Draper
;; TITLE OF INVENTION: RIBOZYME TREATMENT OF
;; TITLE OF INVENTION: DISEASES OR CONDITIONS
;; TITLE OF INVENTION: RELATED TO LEVELS OF
;; TITLE OF INVENTION: INTRACELLULAR ADHESION
;; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
;; NUMBER OF SEQUENCES: 2390
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1743:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1743

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 355
US-09-071-845-1796/c
; Sequence 1796, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
```

```
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1796:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1796

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 356
US-09-071-845-1873/c
; Sequence 1873, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
```

```
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1873:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1873

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGCACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 357
US-09-071-845-1934/c
; Sequence 1934, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600

; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1934:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1934

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGCACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 358
US-08-961-810-104/c
; Sequence 104, Application US/08961810
; Patent No. 6165713
; GENERAL INFORMATION:
; APPLICANT: Liskay, Robert M.
; APPLICANT: Bronner, C. Eric
; APPLICANT: Baker, Sean M.
; APPLICANT: Bollag, Roni J.
; APPLICANT: Kolodner, Richard D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS RELATING TO DNA
; TITLE OF INVENTION: MISMATCH REPAIR GENES
; NUMBER OF SEQUENCES: 134
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kollisch, Hartwell, Dickinson, McCormack &
; STREET: 520 S.W. Yamhill Street, Suite 200
; CITY: Portland
; STATE: Oregon
; COUNTRY: U.S.A.
; ZIP: 97204
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/961,810
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Rysselberghe, Pierre C.
; REGISTRATION NUMBER: 33,557
; REFERENCE/DOCKET NUMBER: OHSU 306B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (503) 224-6655
; TELEFAX: (503) 295-6679
; TELEX: 360619
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: /note= "primers directed to genomic
; OTHER INFORMATION: intron DNA"
US-08-961-810-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 941 AGAGGTGTGAGCCGAGA 957
Db 17 AGACGTGAGAGCCCGAGA 1

RESULT 359
US-08-352-902D-104/c
; Sequence 104, Application US/08352902D
; Patent No. 6191288
; GENERAL INFORMATION:
; APPLICANT: Liskay, Robert M.
; Bronner, C. Eric
; Baker, Sean M.
; Bollag, Roni J.
; Kolodner, Richard D.
; TITLE OF INVENTION: MISMATCH REPAIR GENES
; NUMBER OF SEQUENCES: 149
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kollisch, Hartwell, Dickinson, McCormack &
; Heuser
; STREET: 520 S.W. Yamhill Street, Suite 200
; CITY: Portland
; STATE: Oregon
; COUNTRY: U.S.A.
; ZIP: 97204
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/352,902D
; FILING DATE: 09-Dec-1994
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Rysselberghe, Pierre C.
; REGISTRATION NUMBER: 33,557
; REFERENCE/DOCKET NUMBER: OHSU 306B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (503) 224-6655
; TELEFAX: (503) 295-6679
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: /note= "primers directed to genomic
; intron DNA"
; SEQUENCE DESCRIPTION: SEQ ID NO: 104:
US-08-352-902D-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 941 AGAGGTGTGAGCCGAGA 957
Db 17 AGACGTGAGAGCCCGAGA 1

RESULT 360
US-08-983-466-93
; Sequence 93, Application US/08983466
; Patent No. 6207372
; GENERAL INFORMATION:
; APPLICANT: SHUBER, ANTHONY P.

; TITLE OF INVENTION: UNIVERSAL PRIMER SEQUENCE FOR MULTIPLEX
; TITLE OF INVENTION: DNA AMPLIFICATION
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: RAE-VENTER LAW GROUP
; STREET: 260 Sheridan Ave., Ste. 440
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/983,466
; FILING DATE: 10-FEB-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/474,450
; FILING DATE: 07-JUNE-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO96/41012
; FILING DATE: 06-JUNE-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Rae-Venter, Barbara
; REGISTRATION NUMBER: 32,750
; REFERENCE/DOCKET NUMBER: GECO.001.01US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 328-4400
; TELEFAX: (650) 328-4477
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "WT-1 PRIMER SEQUENCE - N"
US-08-983-466-93

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 386 CAGAGTGCAGCAATG 402
Db 1 CACAGCTGCCAGCAATG 17

RESULT 361
US-09-091-590A-26
; Sequence 26, Application US/09091590A
; Patent No. 6242574
; GENERAL INFORMATION:
; APPLICANT: Nielsen, Klaus
; APPLICANT: Krull Kristensen, Anne
; APPLICANT: Brunstedt, Janne
; TITLE OF INVENTION: Anti-Microbial Proteins
; FILE REFERENCE: S-137-1101/NA/A/SGS/PCT
; CURRENT APPLICATION NUMBER: US/09/091,590A
; CURRENT FILING DATE: 1999-05-06
; PRIOR APPLICATION NUMBER: PCT/EP96/05765
; PRIOR FILING DATE: 1996-12-20
; PRIOR APPLICATION NUMBER: GB 9526238.2
; PRIOR FILING DATE: 1995-12-21
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: Patent In version 3.0
; SEQ ID NO 26
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial/Unknown

FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(17)
OTHER INFORMATION: primer
NAME/KEY: misc feature
LOCATION: (1)..(17)
OTHER INFORMATION: n = a, t, c, or g
US-09-091-590A-26

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 294 AATGTCGTCTGGGGG 310
Db 1 AAGTGTGTGTCNGG 17

RESULT 362
US-09-021-701-53/c
Sequence 53, Application US/09021701
Patent No. 6251588
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
APPLICANT: Wolber, Paul K.
APPLICANT: Delenstarr, Glenda C.
APPLICANT: Webb, Peter G.
APPLICANT: Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/021,701
FILING DATE: 10-FEB-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-021-701-53

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1249 GCCATGTGAGCCAGGT 1265
Db 17 GCCTGTGGGCAAGT 1

RESULT 363
US-09-021-701-111
Sequence 111, Application US/09021701
Patent No. 6251588
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
APPLICANT: Wolber, Paul K.
APPLICANT: Delenstarr, Glenda C.
APPLICANT: Webb, Peter G.
APPLICANT: Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/021,701
FILING DATE: 10-FEB-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 111:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-021-701-111

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 296 TGTCTGTCTGGGGCT 312
Db 1 TGTCTGTCTGGGGAT 17

RESULT 364
US-09-338-907-84/c
Sequence 84, Application US/09338907
Patent No. 6265546
GENERAL INFORMATION:
APPLICANT: Blumenfeld, Marta
APPLICANT: Ilya, Chumakov
APPLICANT: Bougueret, Lydie
TITLE OF INVENTION: PROSTATE CANCER GENE
FILE REFERENCE: GENSET 18CPLCP
CURRENT APPLICATION NUMBER: US/09/338,907
CURRENT FILING DATE: 1999-06-23
EARLIER APPLICATION NUMBER: 08/996,306
EARLIER FILING DATE: 1997-12-22
EARLIER APPLICATION NUMBER: 60/099,658

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 296 TGTCTGTCTGGGGCT 312
Db 1 TGTCTGTCTGGGGAT 17

RESULT 364
US-09-338-907-84/c
Sequence 84, Application US/09338907
Patent No. 6265546
GENERAL INFORMATION:
APPLICANT: Blumenfeld, Marta
APPLICANT: Ilya, Chumakov
APPLICANT: Bougueret, Lydie
TITLE OF INVENTION: PROSTATE CANCER GENE
FILE REFERENCE: GENSET 18CPLCP
CURRENT APPLICATION NUMBER: US/09/338,907
CURRENT FILING DATE: 1999-06-23
EARLIER APPLICATION NUMBER: 08/996,306
EARLIER FILING DATE: 1997-12-22
EARLIER APPLICATION NUMBER: 60/099,658

```

; EARLIER FILING DATE: 1998-09-09
; EARLIER APPLICATION NUMBER: 09/218,207
; EARLIER FILING DATE: 1998-12-22
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm

```

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels

```

365
US-09-218-207-84/c
; Sequence 84, Application US/09918207
; Patent No. 6346381
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Prostate cancer gene
; FILE REFERENCE: GENSET.018CPI
; CURRENT APPLICATION NUMBER: US/09/218,207
; CURRENT FILING DATE: 1998-12-22
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 84
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Mus Musculus
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..17
; OTHER INFORMATION: sequencing oligonucleotide mopGracesR444
US-09-218-207-84

```

Query Match	0.9%;	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	82.4%;	Pred. No. 2.1e+02;		
Matches 14; Conservative	0;	Mismatches 3;	Indels	

```

RESULT 366
US-08-584-040-1909
; Sequence 1909, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: METHOD OF DISEASES OR

```

/ TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
 / TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
 / TITLE OF INVENTION: GROWTH FACTOR
 / NUMBER OF SEQUENCES: 8502
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: Lyon & Lyon
 / STREET: 633 West Fifth Street
 / CITY: Suite 4700
 / CITY: Los Angeles
 / STATE: California
 / COUNTRY: U.S.A.
 / ZIP: 90071-2066
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 / MEDIUM TYPE: Storage
 / COMPUTER: IBM Compatible
 / OPERATING SYSTEM: IBM P.C. DOS 5.0
 / SOFTWARE: Word Perfect 5.1
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/584,040
 / FILING DATE: January 11, 1996
 / CLASSIFICATION: 514
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: 60/005,974
 / FILING DATE: October 26, 1995
 / ATTORNEY/AGENT INFORMATION:
 / NAME: Warburg, Richard J.
 / REGISTRATION NUMBER: 32,327
 / REFERENCE/DOCKET NUMBER: 218/064
 / TELECOMMUNICATION INFORMATION:
 / TELEPHONE: (213) 489-1600
 / TELEFAX: (213) 955-0440
 / TELEX: 67-3510
 / INFORMATION FOR SEQ ID NO: 1909:
 / SEQUENCE CHARACTERISTICS:
 / LENGTH: 17 base pairs
 / TYPE: nucleic acid
 / STRANDEDNESS: single
 / TOPOLOGY: linear
 / PS-08-584-040-1909

Query Match	0.9%	Score 12.2;	DB 1;	Length 17;
Best Local Similarity	58.8%	Pred. No. 2.1e+02;		
Matches 10;	Conservative	4;	Mismatches 3;	Indels 3;
				Gaps 0;

RESULT 367
US-08-584-040-1922/c
; Sequence 1922, Application US/08594040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McGswiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1922:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1922

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 432 CACGTCAGAAAGTGC 448
Db 17 CACGTCAGATGGTGC 1

RESULT 368
US-08-584-040-2028
Sequence 2028, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2028:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-2028

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 843 AGATGGGTGACATACC 859
Db 1 AGGUGGUCUCCAUACC 17

RESULT 369
US-08-584-040-2224/c
Sequence 2224, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2224:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs

;
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2224

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 480 GGACTCGGAGCGTG 496
Db 17 GGACTCCGAGATGTTG 1

RESULT 370

US-08-584-040-2554
; Sequence 2554, Application US/08584040
; Patent No. 6346398

; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 2554:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2554

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 2.1e+02;
Matches 2; Conservative 12; Mismatches 3; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTTTGAA 1160
Db 1 UUUUUUUUUUUUCAA 17

RESULT 371

US-08-584-040-3739
; Sequence 3739, Application US/08584040
; Patent No. 6346398

; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 3739:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3739

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1240 CTGACGTGCGCCGATG 1256
Db 1 CUGGCGGCGCCGUGUG 17

RESULT 372

US-08-584-040-3840
; Sequence 3840, Application US/08584040
; Patent No. 6346398

; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

;; TITLE OF INVENTION: TREATMENT OF DISEASES OR
;; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
;; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;; TITLE OF INVENTION: GROWTH FACTOR
;; NUMBER OF SEQUENCES: 8502
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Suite 4700
;; STATE: Los Angeles
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 3840:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-584-040-3840

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1073 GGCGAGCTCTTCAGTGA 1089
||| | : : : : ||
Db 1 GGCAUGGUCUUCUGA 17

RESULT 373
US-08-584-040-3911
; Sequence 3911, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.

;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 3911:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-584-040-3911

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 23.5%; Pred. No. 2.1e+02;
Matches 4; Conservative 10; Mismatches 3; Indels 0; Gaps 0;

Qy 1142 CTTTTCCTTTTGG 1158
||: : : : ||
Db 1 CCUUUGUGCUUUGG 17

RESULT 374
US-08-584-040-3912
; Sequence 3912, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:

```

; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3912:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-3912

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 2.1e+02;
Matches 5; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGAAGT 1162
Db 1 UUGUUGUUUGGAAGU 17

RESULT 375
US-08-584-040-5441
; Sequence 5441, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5441:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5441

```

```

; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5441

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1073 GGCAGGCTCTTCAGTGA 1089
Db 1 GGCAUGGUCUUCUGUGA 17

RESULT 376
US-08-584-040-5837/c
; Sequence 5837, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5837:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5837

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 457 GTGTCAGCAGCCTGCA 473

```

Db 17 GTAGTCAGAGCCCGCA 1

RESULT 377
US-08-584-040-5925/c
; Sequence 5925, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5925:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-5925

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 881 AGTTCAGAGCTGGCG 897
Db 17 ATTTCAGAGTTGGGG 1

RESULT 378
US-08-584-040-7260/c
; Sequence 7260, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7260:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7260

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 878 CCAAGTTCAGAGCTG 894
Db 17 CCAAGGTCAGAGTGTG 1

RESULT 379
US-08-584-040-7406/c
; Sequence 7406, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

```

; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7406:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7406

```

```

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 1327 GTAGATCTGTGTTTCA 1343
Db 17 GTAGATCTGAGTTTCA 1

```

```

RESULT 380
US-08-584-040-7591
; Sequence 7591, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514

```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7591:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7591

```

```

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.1e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 234 TCAGGCATCTGCATCTG 250
Db 1 UCAAGCCUCUGCAUUG 17

```

```

RESULT 381
US-08-584-040-7877
; Sequence 7877, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7877:

```

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7877

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 941 AGAGGTGTGAGCGCAGA 957
Db 1 AGAGGUAUCAGACGACA 17

RESULT 382
US-08-679-645-147
; Sequence 147, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 147:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-147

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 221 GAGCTCTTCAGCCTCAG 237
Db 1 GUGCUGCUCAGCCCGG 17
```


; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
 ; FILE REFERENCE: MBH00-831-B (247/276)
 ; CURRENT APPLICATION NUMBER: US/09/474,432B
 ; CURRENT FILING DATE: 1999-12-19
 ; PRIOR APPLICATION NUMBER: US 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; PRIOR APPLICATION NUMBER: US 60/084,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: US 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: US 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; NUMBER OF SEQ ID NOS: 1526
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 355
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-474-432B-355

Query Match 0.9%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 719 CCACGACGACGGGGCC 735

DB 17 CCACGACGCGGGAGCC 1

RESULT 387
 US-09-474-432B-479
 ; Sequence 479, Application US/09474432B
 ; Patent No. 6528640
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Burgin, Alex
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka
 ; APPLICANT: Sweedler, David
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
 ; FILE REFERENCE: MBH00-831-B (247/276)
 ; CURRENT APPLICATION NUMBER: US/09/474,432B
 ; CURRENT FILING DATE: 1999-12-19
 ; PRIOR APPLICATION NUMBER: US 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; PRIOR APPLICATION NUMBER: US 60/084,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: US 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: US 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; NUMBER OF SEQ ID NOS: 1526
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 479
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-474-432B-479

Query Match 0.9%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 2.1e+02;
 Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1240 CTGACGCGGGCCATGTG 1256

DB 1 CUGGACGCGCCAGUGUG 17

RESULT 388

US-09-474-432B-605
 ; Sequence 605, Application US/09474432B
 ; Patent No. 6528640
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Burgin, Alex
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka
 ; APPLICANT: Sweedler, David
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
 ; FILE REFERENCE: MBH00-831-B (247/276)
 ; CURRENT APPLICATION NUMBER: US/09/474,432B
 ; CURRENT FILING DATE: 1999-12-19
 ; PRIOR APPLICATION NUMBER: US 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; PRIOR APPLICATION NUMBER: US 60/084,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: US 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: US 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; NUMBER OF SEQ ID NOS: 1526
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 605
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-474-432B-605

Query Match 0.9%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.1e+02;
 Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 523 CTGCGGAGGAGCAGCT 539

DB 1 CUGGCGGAGCUGCAGCU 17

RESULT 389
 US-09-474-432B-727
 ; Sequence 727, Application US/09474432B
 ; Patent No. 6528640
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Burgin, Alex
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka
 ; APPLICANT: Sweedler, David
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
 ; FILE REFERENCE: MBH00-831-B (247/276)
 ; CURRENT APPLICATION NUMBER: US/09/474,432B
 ; CURRENT FILING DATE: 1999-12-19
 ; PRIOR APPLICATION NUMBER: US 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; PRIOR APPLICATION NUMBER: US 60/084,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: US 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: US 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; NUMBER OF SEQ ID NOS: 1526
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 727
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-474-432B-727

```

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1238 TCGTGGACGTGGCCATG 1254
      :||:||||:||||:|
Db 1 UGCGUGGUGGUGUCUUG 17

RESULT 390
US-09-474-432B-776
; Sequence 776, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 776
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-776

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1018 AGATGGTGCCAAAGTGC 1034
      |||:||||:||||:|
Db 1 AGAUGGGGGCAAGGUGC 17

RESULT 391
US-09-474-432B-831
; Sequence 831, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29

```

```

; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-831

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 894 GCGGTACAGCGTGGCCC 910
      |||:||||:||||:|
Db 1 GCGGACACAGAGGACC 17

RESULT 392
US-09-265-503B-104/c
; Sequence 104, Application US/09265503B
; Patent No. 6538108
; GENERAL INFORMATION:
; APPLICANT: Liskay, Robert M.
; APPLICANT: Bronner, C. Eric
; APPLICANT: Baker, Sean M.
; APPLICANT: Bollag, Roni J.
; APPLICANT: Kolodner, Richard D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS
; TITLE OF INVENTION: RELATING TO DNA MISMATCH REPAIR GENES
; NUMBER OF SEQUENCES: 148
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kolisch, Hartwell, Dickinson, McCormack & Heuser
; STREET: 520 S.W. Yamhill Street, Suite 200
; CITY: Portland
; STATE: Oregon
; COUNTRY: U.S.A.
; ZIP: 97204
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/265,503B
; FILING DATE: March 10, 1999
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Rysselberghe, Pierre C.
; REGISTRATION NUMBER: 33,557
; REFERENCE/DOCKET NUMBER: OHSU 306D
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (503) 224-6655
; TELEFAX: (503) 295-6679
; TELEX: 360619
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: /note= "primers directed to genomic
; OTHER INFORMATION: intron DNA"
; US-09-265-503B-104

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;

```


Qy 480 GGACTGCCGAGACGGTG 496
|||
Db 17 GGACTCCCGAGATGTTG 1

RESULT 397
 US-09-371-772B-1078
 ; Sequence 1078, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; FILE REFERENCE: MEHB00.876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1078
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-371-772B-1078

RESULT 398
 US-09-371-772B-1506
 ; Sequence 1506, Application US/09371772B
 ; Patent NO. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MEBH00.876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371.772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1506
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-371-772B-1506

```

|:| | |:| |:| |:|
Db      1  CUGCCGUCGCCCTGUG  17

RESULT 399
US-09-371-772B-1607
; Sequence 1607, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1607
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1607

```

RESULT 400
US-09-371-772B-1678
; Sequence 1678, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions R
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1678
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1678

```

Query Match      0.98; Score 12.2; DB 1; Length 17;
Best Local Similarity 23.5%; Pred. No. 2.1e+03;
Matches 4; Conservative 10; Mismatches 3; Indels 0; Gaps 0;

Qy      1142 CCCTTTTTCCTTTTGG 1158
          ||::: : : ::::|

```


RESULT 405

US-09-371-772B-3213/c
; Sequence 3213, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3213
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3213

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1327 GTAGATCTGTGTTTCA 1343
DB 17 GTAGATCTGAGTTTCA 1

RESULT 406

US-09-371-772B-3387
; Sequence 3387, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3387
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3387

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.1e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 234 TCAGGCATCTGCATCTG 250
DB 1 UCAAGCCUCUCGCAUTUG 17

RESULT 407

US-09-371-772B-3660
; Sequence 3660, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3660
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3660

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 941 AGAGGTGTGAGCGCAGA 957
DB 1 AGAGGUACAGAGCAGA 17

RESULT 408

US-09-371-772B-4161
; Sequence 4161, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4161
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-4161

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 143 CGCTCGGCTCCGCTCCG 159
DB 1 CUCUGGCUCCUCCCG 17

RESULT 409

US-09-371-772B-4457/c
; Sequence 4457, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4457
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4457

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1327 GTAGATCTTGCTTCA 1343
||| ||||| |||||
DB 17 GTAAATCTGGGGTTCA 1

RESULT 410
US-09-371-772B-4643/c
; Sequence 4643, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4643
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4643

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1079 CTCCTCAGTGAGTGT 1095
||||| ||||| |||||
DB 17 CTCCTCTGTGACTCTT 1

RESULT 411
US-09-371-772B-4722

; Sequence 4722, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4722
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4722

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 54.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 235 CAGGCATCTGCATCTGG 251
||| ||||| |||||
DB 1 CAAGCAUCAGCAUUGG 17

RESULT 412
US-09-371-772B-5116/c
; Sequence 5116, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5116
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5116

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 956 GACTGCAGGACTGACCC 972
||||| ||||| |||||
DB 17 GGCTGCAGGCTGCGCC 1

RESULT 413
US-09-371-772B-5579/c
; Sequence 5579, Application US/09371772B

```
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5579

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGAAGT 1162
DB 17 TTTTCTTTTGAATT 1

RESULT 414
US-09-371-772B-6296
; Sequence 6296, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6296
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-6296

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 2.1e+02;
Matches 5; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 1145 TTTTCTTTTGAAG 1161
DB 1 UUUUGUUCUUUGAAG 17

RESULT 415
US-09-371-772B-6439/c
; Sequence 6439, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6439
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-6439

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 742 CCGCATGTTGCTGACTT 758
DB 17 CTGCAAGTTGCTGCTT 1

RESULT 417
US-09-371-772B-6701/c
; Sequence 6701, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6439
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-6439

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 299 CTGCTGCGGGCTGCA 315
DB 17 CTGCTCAGTGGGCTGCA 1

RESULT 416
US-09-371-772B-6624/c
; Sequence 6624, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6624
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-6624

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 742 CCGCATGTTGCTGACTT 758
DB 17 CTGCAAGTTGCTGCTT 1

RESULT 417
US-09-371-772B-6701/c
; Sequence 6701, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
```

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Growth of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MEHB00, 876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 6701
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-6701

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 260 TCTGGGCTGGCTGATC 276
||| |||||
Db 17 TCCAGAGCTGGCTGAGC 1

RESULT 418
PCT-US95-06266-87
Sequence 87, Application PC/TUS9506266
GENERAL INFORMATION:
APPLICANT: Dehlinger & Associates
TITLE OF INVENTION: Detection of Viral Antigens Coded by Reverse Reading Frames
NUMBER OF SEQUENCES: 157
CORRESPONDENCE ADDRESS:
ADDRESS: Dehlinger & Associates
STREET: 350 Cambridge Avenue, Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/06266
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/246,985
FILING DATE: 20-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,561
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/329,729
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/344,271
FILING DATE: 23-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/357,509
FILING DATE: 16-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/389,886
FILING DATE: 15-FEB-1995

ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0202.41
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: cDNA to mRNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Primer PGEX-R
PCT-US95-06266-87

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 625 GACCAGCTCCAGGAGCT 641
||| |||||
Db 1 GACCGTCTCCGGGAGCT 17

RESULT 419
PCT-US96-09641-17
Sequence 17, Application PC/TUS9609641
GENERAL INFORMATION:
APPLICANT: Slater, Michael R.
APPLICANT: Huang, Fen
APPLICANT: Hartnett, James R.
APPLICANT: Bolchakova, Elena
APPLICANT: Storts, Douglas R.
APPLICANT: Otto, Paul
TITLE OF INVENTION: THERMOPHILIC DNA POLYMERASES FROM THERMOTOGA NEAPOLITANA
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Medlen & Carroll
STREET: 220 Montgomery Street, Suite 2200
CITY: San Francisco
STATE: California
COUNTRY: United States Of America
ZIP: 94104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/09641
FILING DATE: 31-MAY-1996
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Ingolia, Diane E.
REGISTRATION NUMBER: 40,027
REFERENCE/DOCKET NUMBER: PRMG-02185
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 705-8410
TELEFAX: (415) 397-8338
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US96-09641-17

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1199 GACCTTCACACCTCCCC 1215
|||||
Db 1 GACCTTGACAGCTCCTC 17

RESULT 420
US-08-584-040-3044/c
; Sequence 3044, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3044:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3044

Query Match 0.9%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1027 CAAAGTGCAGCTGACTC 1043
|||||
Db 18 CAAAAGCAGCTGGCTC 2

RESULT 421
US-09-371-772B-1472/c

; Sequence 1472, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1472
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1472

Query Match 0.9%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1027 CAAAGTGCAGCTGACTC 1043
|||||
Db 18 CAAAAGCAGCTGGCTC 2

RESULT 422
US-08-214-603-11/c
; Sequence 11, Application US/08214603
; Patent No. 5596091
; GENERAL INFORMATION:
; APPLICANT: SWITZER, Christopher
; TITLE OF INVENTION: NOVEL ANTISENSE OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/214,603
; FILING DATE: 18-MAR-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Kezer, William B.
; REGISTRATION NUMBER: 37,369
; REFERENCE/DOCKET NUMBER: 2307E-052100US
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Oligodeoxynucleotide"

US-08-214-603-11

Query Match 0.9%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTT 1155
Db 12 TTTTTCCTTT 1

RESULT 423
US-08-242-664-14/c
; Sequence 14, Application US/08242664
; Patent No. 5571937
; GENERAL INFORMATION:
; APPLICANT: Watanabe, Kyoichi A.
; APPLICANT: Ren, Wu-Yun
; APPLICANT: Weil, Roger
; TITLE OF INVENTION: Complementary DNA and Toxins
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10112

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/242,664
FILING DATE: May 12, 1994
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)

US-08-242-664-14

Query Match 0.9%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1145 TTTTTCCTTT 1156
Db 13 TTTTTCCTTT 2

RESULT 424
US-08-484-138-14/c
; Sequence 14, Application US/08484138
; Patent No. 5652350
; GENERAL INFORMATION:
; APPLICANT: Watanabe, Kyoichi A.
; APPLICANT: Ren, Wu-Yun
; APPLICANT: Weil, Roger
; TITLE OF INVENTION: Complementary DNA and Toxins
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,138
FILING DATE: June 7, 1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-Z/JPW/MJG
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)

US-08-484-138-14

Query Match 0.9%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1145 TTTTTCCTTT 1156
Db 13 TTTTTCCTTT 2

RESULT 425
PCT-US95-06379-14/c
; Sequence 14, Application PC/TUS9506379
; GENERAL INFORMATION:
; APPLICANT: Watanabe, Kyoichi A.
; APPLICANT: Ren, Wu-Yun
; APPLICANT: Weil, Roger
; TITLE OF INVENTION: Complementary DNA and Toxins
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/06379
FILING DATE: May 13, 1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-278-0400
TELEFAX: 212-391-0526
INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:
 LENGTH: 13 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 PCT-US95-06379-14

Query Match 0.9%; Score 12; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTT 1156
 13 TTTTTCCTTTT 2

RESULT 426
 US-08-146-010A-8
 ; Sequence 8, Application US/08146010A
 ; Patent No. 5591577
 ; GENERAL INFORMATION:
 ; APPLICANT: TSUCHIYA, MAKOTO
 ; APPLICANT: MARIYA, MIKO
 ; APPLICANT: MIWA, KIYOSHI
 ; TITLE OF INVENTION: MOBILE GENETIC ELEMENT ORIGINATED FROM
 ; TITLE OF INVENTION: BREVI BACTERIUM STRAIN
 ; NUMBER OF SEQUENCES: 9
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT
 ; STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, FOURTH FLOOR
 ; CITY: ARLINGTON
 ; STATE: VIRGINIA
 ; COUNTRY: USA
 ; ZIP: 22202

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/146.010A
 FILING DATE: 12-NOV-1993
 CLASSIFICATION: 435

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: JP 52694/92
 FILING DATE: 11-MAR-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: OBLON, NORMAN F
 REGISTRATION NUMBER: 24,618
 REFERENCE/DOCKET NUMBER: 10-649-0
 TELEPHONE: (703) 413-3000
 TELEFAX: (703) 413-2220
 TELEX: 248855 OPAT UR
 INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:
 LENGTH: 14 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 ORIGINAL SOURCE:
 ORGANISM: Brevibacterium lactofermentum
 STRAIN: AJ2256
 US-08-146-010A-8

Query Match 0.9%; Score 12; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 963 GGACTGACCCCT 974
 13 TTTTTCCTTTT 2

Db 2 GGACTGACCCCT 13

RESULT 427

US-08-683-839B-15/c
 ; Sequence 15, Application US/08683839B
 ; Patent No. 5744326
 ; GENERAL INFORMATION:

APPLICANT: ILL, Charles . R. et al.
 TITLE OF INVENTION: Use of Viral Cis-Acting Post-Transcriptional
 ; TITLE OF INVENTION: Regulatory Sequences To Increase Expression of
 ; TITLE OF INVENTION: Introns Genes Containing Near-Consensus Splice Sites
 ; NUMBER OF SEQUENCES: 18
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: LAHIVE & COCKFIELD
 ; STREET: 60 State Street, suite 510
 ; CITY: Boston
 ; STATE: Massachusetts
 ; COUNTRY: USA
 ; ZIP: 02109-1875

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/683,839B
 FILING DATE: 11-MARCH-1996
 CLASSIFICATION: 435

PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Remillard, Jane E.
 REGISTRATION NUMBER: 38,872
 REFERENCE/DOCKET NUMBER: TTI-138
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (617)227-7400
 TELEFAX: (617)227-5941

INFORMATION FOR SEQ ID NO: 15:
 LENGTH: 14 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: CDNA
 US-08-683-839B-15

Query Match 0.9%; Score 12; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1125 TGAAGAGAGAG 1136

Db 12 TGAAGAGAGAG 1

RESULT 428

US-08-674-168-10
 ; Sequence 10, Application US/08674168
 ; Patent No. 580414
 ; GENERAL INFORMATION:

APPLICANT: MORIYA, Mika
 APPLICANT: MATSUI, Hiroshi
 APPLICANT: YOKOZAKI, Kenzo
 APPLICANT: HIRANO, Seiko
 APPLICANT: HAYAKAWA, Atsushi
 APPLICANT: IZUI, Masako
 APPLICANT: SUGIMOTO, Masakazu
 ; TITLE OF INVENTION: METHOD OF AMPLIFYING GENE USING
 ; TITLE OF INVENTION: ARTIFICIAL TRANSPOSON
 ; NUMBER OF SEQUENCES: 32
 ; CORRESPONDENCE ADDRESS:

ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESS: P.C.
STREET: 1755 JEFFERSON DAVIS HIGHWAY, SUITE # 400
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/674,168
FILING DATE: 01-JUL-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7-166541
FILING DATE: 30-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 10-810-0
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Brevibacterium lactofermentum
STRAIN: AJ12036
US-08-674-168-10

Query Match 0.9%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 963 GGACTGACCCCT 974
Db 2 GGACTGACCCCT 13

RESULT 429
US-08-846-021A-14
Sequence 14, Application US/08846021A
Patent No. 5948682
GENERAL INFORMATION:
APPLICANT: Moloney, Maurice M.
TITLE OF INVENTION: Preparation of Heterologous Proteins on
TITLE OF INVENTION: Oil Bodies
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: BERESKIN & PARR
STREET: 40 King Street West
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5H 3Y2
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/846,021A

FILING DATE: April 25, 1997
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Gravelle, Micheline
REGISTRATION NUMBER: 40,261
REFERENCE/DOCKET NUMBER: 9369-039
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 364-7311
TELEFAX: (416) 361-1398
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-846-021A-14

Query Match 0.9%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 393 GGCAGCAATGCG 404
Db 2 GGCAGCAATGCG 13

RESULT 430
US-08-365-189-10
Sequence 10, Application US/08365189
Patent No. 5514576
GENERAL INFORMATION:
APPLICANT: Bower, Patricia A.
TITLE OF INVENTION: Cloned Pullulanase
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Quarles & Brady
STREET: 411 East Wisconsin Avenue
CITY: Milwaukee
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53202-4497
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/365,189
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/132,648
FILING DATE: October 5, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Ryser, David G.
REGISTRATION NUMBER: 36,407
REFERENCE/DOCKET NUMBER: 66-005-9367-4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (414) 277-5717
TELEFAX: (414) 271-3552
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 1..15
US-08-365-189-10

```
Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      831 GCTGAAGCTTTC 842
DB      4 GCTGAAGCTTTC 15

RESULT 431
US-08-208-886C-29/c
; Sequence 29, Application US/08208886C
; Patent No. 5597710
; GENERAL INFORMATION:
; APPLICANT: Dalié, Barbara
; APPLICANT: Miller, Kenneth
; APPLICANT: Murgolo, Nicholas
; APPLICANT: Tindall, Stephen
; TITLE OF INVENTION: Humanized Monoclonal Antibodies Against Human Interleukin-4
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033-0530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 7.1a
; SOFTWARE: Microsoft Word 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/208,886C
; FILING DATE: March 10, 1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Foulke, Cynthia L.
; REGISTRATION NUMBER: 32,364
; REFERENCE/DOCKET NUMBER: JB0429
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 908 298 2987
; TELEFAX: 908 298 5388
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-208-886C-29

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      463 AGCAGCCTGCAG 474
DB      15 AGCAGCCTGCAG 4

RESULT 432
US-08-704-744-29/c
; Sequence 29, Application US/08704744
; Patent No. 5705154
; GENERAL INFORMATION:
; APPLICANT: Dalié, Barbara
; APPLICANT: Miller, Kenneth
; APPLICANT: Murgolo, Nicholas
; APPLICANT: Tindall, Stephen
; TITLE OF INVENTION: Humanized Monoclonal Antibodies Against Human Interleukin-4
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033-0530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
```

```
; NUMBER OF SEQUENCES: 90
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033-0530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 7.5.3
; SOFTWARE: Microsoft Word 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/704,744
; FILING DATE: 06-SEPT-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/208886
; FILING DATE: 10-MAR-1994
; APPLICATION NUMBER: PCT/US/95/02400
; FILING DATE: 08-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Foulke, Cynthia L.
; REGISTRATION NUMBER: 32,364
; REFERENCE/DOCKET NUMBER: JB0429K
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908) 298-2987
; TELEFAX: (908) 298-5388
; TELEX:
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-704-744-29

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      463 AGCAGCCTGCAG 474
DB      15 AGCAGCCTGCAG 4

RESULT 433
US-08-469-557-29/c
; Sequence 29, Application US/08469557
; Patent No. 5770403
; GENERAL INFORMATION:
; APPLICANT: Dalié, Barbara
; APPLICANT: Le, Hung
; APPLICANT: Miller, Kenneth
; APPLICANT: Murgolo, Nicholas
; APPLICANT: Nguyen, Hanh
; APPLICANT: Tindall, Stephen
; APPLICANT: Zavodny, Paul
; TITLE OF INVENTION: Cloning and Expression of
; TITLE OF INVENTION: Humanized Monoclonal Antibodies
; TITLE OF INVENTION: Against Human Interleukin-4
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033-0530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
```

OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: Microsoft Word 5.1A
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/469,557
FILING DATE: 06-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/290,793
FILING DATE: August 16, 1994
APPLICATION NUMBER: PCT/US93/01301
FILING DATE: 19-FEB-1992
APPLICATION NUMBER: US 07/841,659
FILING DATE: 19-FEB-1992
APPLICATION NUMBER: US 07/782,784
FILING DATE: 24-OCT-1991
APPLICATION NUMBER: US 07/499,327
FILING DATE: 21-MAY-1990
APPLICATION NUMBER: PCT/US88/03631
FILING DATE: 21-OCT-1988
APPLICATION NUMBER: US 07/655,966
FILING DATE: 14-FEB-1991
APPLICATION NUMBER: US 07/113,623
FILING DATE: 26-OCT-1987
APPLICATION NUMBER: US 06/881,553
FILING DATE: 03-JUL-1986
APPLICATION NUMBER: US 06/843,958
FILING DATE: 25-MAR-1986
APPLICATION NUMBER: US 06/799,668
FILING DATE: 19-NOV-1985
ATTORNEY/AGENT INFORMATION:
NAME: Foulke, Cynthia L.
REGISTRATION NUMBER: 32,364
REFERENCE/DOCKET NUMBER: 2409K7
TELECOMMUNICATION INFORMATION:
TELEPHONE: 908 298-2987
TELEFAX: 908-298-5388
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-469-557-29

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 463 AGCAGCCTGCAG 474
Db 15 AGCAGCCTGCAG 4

RESULT 434
US-08-290-793B-29/c
Sequence 29, Application US/08290793B
Patent No. 5863537
GENERAL INFORMATION:
APPLICANT: Dalie, Barbara
APPLICANT: Le, Hung
APPLICANT: Miller, Kenneth
APPLICANT: Murgolo, Nicholas
APPLICANT: Nguyen, Hanh
APPLICANT: Tindall, Stephen
APPLICANT: Zavodny, Paul
TITLE OF INVENTION: Cloning and Expression of
TITLE OF INVENTION: Humanized Monoclonal Antibodies
TITLE OF INVENTION: Against Human Interleukin-4
NUMBER OF SEQUENCES: 69
CORRESPONDENCE ADDRESS:
ADDRESSEE: Schering-Plough Corporation
STREET: 2000 Galloping Hill Road
CITY: Kenilworth

STATE: New Jersey
COUNTRY: USA
ZIP: 07033-0530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: Microsoft Word 5.1A
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/290,793B
FILING DATE: August 16, 1994
APPLICATION NUMBER: PCT/US93/01301
FILING DATE: 19-FEB-1992
APPLICATION NUMBER: US 07/841,659
FILING DATE: 19-FEB-1992
APPLICATION NUMBER: US 07/782,784
FILING DATE: 24-OCT-1991
APPLICATION NUMBER: US 07/499,327
FILING DATE: 21-MAY-1990
APPLICATION NUMBER: PCT/US88/03631
FILING DATE: 21-OCT-1988
APPLICATION NUMBER: US 07/655,966
FILING DATE: 14-FEB-1991
APPLICATION NUMBER: US 07/113,623
FILING DATE: 26-OCT-1987
APPLICATION NUMBER: US 06/881,553
FILING DATE: 03-JUL-1986
APPLICATION NUMBER: US 06/843,958
FILING DATE: 25-MAR-1986
APPLICATION NUMBER: US 06/799,668
FILING DATE: 19-NOV-1985
ATTORNEY/AGENT INFORMATION:
NAME: Foulke, Cynthia L.
REGISTRATION NUMBER: 32,364
REFERENCE/DOCKET NUMBER: 2409K7
TELECOMMUNICATION INFORMATION:
TELEPHONE: 908 298-2987
TELEFAX: 908-298-5388
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-290-793B-29

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 463 AGCAGCCTGCAG 474
Db 15 AGCAGCCTGCAG 4

RESULT 435
US-08-606-505B-62
Sequence 62, Application US/08606505B
Patent No. 6114601
GENERAL INFORMATION:
APPLICANT: KIKUCHI, Yasuhiro
APPLICANT: KIYOKAWA, Shigeto
APPLICANT: SHIMADA, Yukinisa
APPLICANT: OHBAYASHI, Masaya
APPLICANT: SHIMADA, Ritsuko
APPLICANT: OKINAKA, Yasushi
TITLE OF INVENTION: NOVEL PLANT GENES
NUMBER OF SEQUENCES: 67
CORRESPONDENCE ADDRESS:
ADDRESSEE: FITZPATRICK, CELLA, HARPER & SCINTO
STREET: 30 Rockefeller Plaza
CITY: New York

STATE: New York
COUNTRY: U.S.A.
ZIP: 10112-3801
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.50 inch, 720 Kb storage.
COMPUTER: IBM PS/IV
OPERATING SYSTEM: MS-DOS Ver3.30
SOFTWARE: PATENT AID Ver1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/606,505B
FILING DATE: 23-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP44963/92
FILING DATE: 02-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Perry, Lawrence S.
REGISTRATION NUMBER: 31865
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-218-2100
TELEFAX: 212-218-2200
INFORMATION FOR SEQ ID NO: 62 :
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
DESCRIPTION: Synthetic DNA
US-08-606-505B-62

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1233 TTTGGTCTGGA 1244
|||||
Db 4 TTTGGTCTGGA 15

RESULT 436
US-09-115-446-3
Sequence 3, Application US/09115446
Patent No. 6165719
GENERAL INFORMATION:
APPLICANT: Chandy, George K.
APPLICANT: Gargus, Jay J.
APPLICANT: Gutman, George
APPLICANT: Fantino, Emmanuelle
APPLICANT: Kalman, Katarin
TITLE OF INVENTION: hKCA3/KCNN3 SMALL CONDUCTANCE CALCIUM
TITLE OF INVENTION: ACTIVATED POTASSIUM CHANNEL: A DIAGNOSTIC
TITLE OF INVENTION: MARKER AND THERAPEUTIC TARGET
FILE REFERENCE: 07306/014001
CURRENT APPLICATION NUMBER: US/09/115,446
CURRENT FILING DATE: 1998-07-14
EARLIER APPLICATION NUMBER: 60/052,556
EARLIER FILING DATE: 1997-07-15
EARLIER APPLICATION NUMBER: 60/070,741
EARLIER FILING DATE: 1998-01-08
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 3
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-115-446-3

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1145 TTTTCTCTTTT 1156
|||||

Db 1 TTTTCTCTTTT 12

RESULT 437
US-09-177-359-26/c
Sequence 26, Application US/09177359B
Patent No. 6183963
GENERAL INFORMATION:
APPLICANT: SINNETT, Daniel
APPLICANT: LABUDA, Damian
TITLE OF INVENTION: DETECTION OF CYP1A1, CYP3A4, CYP2D6 AND
TITLE OF INVENTION: NAT2 VARIANTS BY PCR-ALLELE-SPECIFIC OLIGONUCLEOTIDE (ASO)
TITLE OF INVENTION: ASSAY
FILE REFERENCE: 12667-17"US" FC/ld
CURRENT APPLICATION NUMBER: US/09/177,359B
CURRENT FILING DATE: 1998-10-23
NUMBER OF SEQ ID NOS: 37
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO 26
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: cDNA for use as probes
US-09-177-359-26

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 257 ACCTCTGGGCT 268
|||||
Db 14 ACCTCTGGGCT 3

RESULT 438
US-09-616-990-62
Sequence 62, Application US/09616990
Patent No. 6232109
GENERAL INFORMATION:
APPLICANT: KIKUCHI, Yasuhiro
APPLICANT: KIYOKAWA, Shigeto
APPLICANT: SHIMADA, Yukihisa
APPLICANT: OHBAYASHI, Masaya
APPLICANT: SHIMADA, Ritsuko
APPLICANT: OKINAKA, Yasushi
TITLE OF INVENTION: NOVEL PLANT GENES
NUMBER OF SEQUENCES: 67
CORRESPONDENCE ADDRESS:
ADDRESSEE: FITZPATRICK, CELLA, HARPER & SCINTO
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10112-3801
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.50 inch, 720 Kb storage.
COMPUTER: IBM PS/IV
OPERATING SYSTEM: MS-DOS Ver3.30
SOFTWARE: PATENT AID Ver1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/616,990
FILING DATE: 14-Jul-2000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP44963/92
FILING DATE: 02-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Perry, Lawrence S.
REGISTRATION NUMBER: 31865
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-218-2100
TELEFAX: 212-218-2200
INFORMATION FOR SEQ ID NO: 62 :

```

;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; DESCRIPTION: Synthetic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 62
US-09-616-990-62
    Query Match          0.9%; Score 12; DB 1; Length 15;
    Best Local Similarity 100.0%; Pred. No. 1.8e+02;
    Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1233 TTTGGTGTGGA 1244
Db 4 TTTGGTGTGGA 15

RESULT 439
US-08-812-951B-1
; Sequence 1, Application US/08812951B
; Patent No. 6297006
; GENERAL INFORMATION:
; APPLICANT: Drmanac, Radoje T.
; APPLICANT: Drmanac, Snezana
; APPLICANT: Hou, Aaron
; APPLICANT: Houser, Brian
; TITLE OF INVENTION: Methods and Compositions for
; TITLE OF INVENTION: Detection or Quantification of Nucleic Acid Species
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McCutchen, Doyle, Brown & Enersen LLP
; STREET: Three Embarcadero Center
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/812,951B
; FILING DATE: 04-MAR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US08/784747
; FILING DATE: 16-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Kumamoto, Andrew A
; REGISTRATION NUMBER: 40,690
; REFERENCE/DOCKET NUMBER: 20411-701
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-393-2000
; TELEFAX: 415-393-2286
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-812-951B-2
    Query Match          0.9%; Score 12; DB 1; Length 15;
    Best Local Similarity 92.3%; Pred. No. 1.8e+02;
    Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1146 TTTTCTTTTGG 1158
Db 13 TTTTNTTTTGG 1

RESULT 441
US-08-784-747-2
; Sequence 2, Application US/08784747
; Patent No. 6309824
; GENERAL INFORMATION:
; APPLICANT: Drmanac, Radoje T.
; TITLE OF INVENTION: Methods and Compositions for
; TITLE OF INVENTION: Detection or Quantification of Nucleic Acid Species
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McCutchen, Doyle, Brown & Enersen LLP
; STREET: Three Embarcadero Center
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/812,951B
; FILING DATE: 04-MAR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US08/784747
; FILING DATE: 16-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Kumamoto, Andrew A
; REGISTRATION NUMBER: 40,690
; REFERENCE/DOCKET NUMBER: 20411-701
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-393-2000
; TELEFAX: 415-393-2286
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-812-951B-1
    Query Match          0.9%; Score 12; DB 1; Length 15;
    Best Local Similarity 92.3%; Pred. No. 1.8e+02;
    Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1146 TTTTCTTTTGG 1158
Db 3 TTTTNTTTTGG 15
```

;/ ZIP: 94111
;/ COMPUTER READABLE FORM:
;/ MEDIUM TYPE: Diskette
;/ COMPUTER: IBM Compatible
;/ OPERATING SYSTEM: DOS
;/ SOFTWARE: FastSeq for Windows Version 2.0
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/08/784,747
;/ FILING DATE: 16-JAN-1997
;/ CLASSIFICATION: 435
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER:
;/ FILING DATE:
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Kumamoto, Andrew A
;/ REGISTRATION NUMBER: 40,690
;/ REFERENCE/DOCKET NUMBER: 20411-709
;/ TELEPHONE: 415-393-2000
;/ TELEFAX: 415-393-2286
;/ TELEX:
;/ INFORMATION FOR SEQ ID NO: 2:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 15 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ US-08-784-747-2

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGG 1158
|||||
DB 3 TTTTNTTTTGG 15

RESULT 442
US-08-784-747-3/c
;/ Sequence 3, Application US/08784747
;/ Patent No. 6309824
;/ GENERAL INFORMATION:
;/ APPLICANT: Drmanac, Radoje T.
;/ TITLE OF INVENTION: Methods and Compositions for
;/ Detection or Quantification of Nucleic Acid Species
;/ NUMBER OF SEQUENCES: 13
;/ CORRESPONDENCE ADDRESS:
;/ ADDRESSEE: McCutchen, Doyle, Brown & Enersen LLP
;/ STREET: Three Embarcadero Center
;/ CITY: San Francisco
;/ STATE: CA
;/ COUNTRY: USA
;/ ZIP: 94111
;/ COMPUTER READABLE FORM:
;/ MEDIUM TYPE: Diskette
;/ COMPUTER: IBM Compatible
;/ OPERATING SYSTEM: DOS
;/ SOFTWARE: FastSeq for Windows Version 2.0
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/08/784,747
;/ FILING DATE: 16-JAN-1997
;/ CLASSIFICATION: 435
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER:
;/ FILING DATE:
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Kumamoto, Andrew A
;/ REGISTRATION NUMBER: 40,690
;/ REFERENCE/DOCKET NUMBER: 20411-709
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: 415-393-2000
;/ TELEFAX: 415-393-2286

;/ TELEX:
;/ INFORMATION FOR SEQ ID NO: 3:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 15 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ US-08-784-747-3

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGG 1158
|||||
DB 13 TTTTNTTTTGG 1

RESULT 443
US-09-409-778-9
;/ Sequence 9, Application US/09409778
;/ Patent No. 6472173
;/ GENERAL INFORMATION:
;/ APPLICANT: Yeung, George
;/ APPLICANT: Ford, John
;/ TITLE OF INVENTION: A NOVEL CHEMOKINE RECEPTOR OBTAINED FROM
;/ FILE OF INVENTION: A CDNA LIBRARY OF FETAL LIVER-SPLEEN
;/ FILE REFERENCE: 20411-742CON2 (now 28110/36057B)
;/ CURRENT APPLICATION NUMBER: US/09/409,778
;/ CURRENT FILING DATE: 1999-09-22
;/ PRIOR APPLICATION NUMBER: PCT/US99/12829
;/ PRIOR FILING DATE: 1999-06-29
;/ PRIOR APPLICATION NUMBER: US 09/236,166
;/ PRIOR FILING DATE: 1999-01-22
;/ PRIOR APPLICATION NUMBER: US 09/106,800
;/ PRIOR FILING DATE: 1998-06-26
;/ NUMBER OF SEQ ID NOS: 25
;/ SOFTWARE: FastSeq for Windows Version 3.0
;/ SEQ ID NO 9
;/ LENGTH: 15
;/ TYPE: DNA
;/ ORGANISM: Artificial Sequence
;/ FEATURE:
;/ OTHER INFORMATION: Exemplary oligonucleotide primer used in sequence assembly proc
;/ NAME/KEY: Misc feature
;/ LOCATION: (8)...(8)
;/ OTHER INFORMATION: n = A, T, C, G or 1-(2-deoxy-D-ribofuranosyl)-3-nitropyrrrole
;/ US-09-409-778-9

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGG 1158
|||||
DB 3 TTTTNTTTTGG 15

RESULT 444
US-09-409-778-10/c
;/ Sequence 10, Application US/09409778
;/ Patent No. 6472173
;/ GENERAL INFORMATION:
;/ APPLICANT: Ford, John
;/ APPLICANT: Yeung, George
;/ TITLE OF INVENTION: A NOVEL CHEMOKINE RECEPTOR OBTAINED FROM
;/ FILE OF INVENTION: A CDNA LIBRARY OF FETAL LIVER-SPLEEN
;/ FILE REFERENCE: 20411-742CON2 (now 28110/36057B)
;/ CURRENT APPLICATION NUMBER: US/09/409,778
;/ CURRENT FILING DATE: 1999-09-22
;/ PRIOR APPLICATION NUMBER: PCT/US99/12829
;/ PRIOR FILING DATE: 1999-06-29
;/ PRIOR APPLICATION NUMBER: US 09/236,166


```

; PRIOR FILING DATE: 1998-01-22
; PRIOR APPLICATION NUMBER: US 09/106,800
; PRIOR FILING DATE: 1998-06-26
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary oligonucleotide primer used in sequence assembly process
; NAME/KEY: misc feature
; LOCATION: (8)...(8)
; OTHER INFORMATION: n = A, T, C, G or 1-(2-deoxy-D-ribofuranosyl)-3-nitropyrrrole
US-09-409-778-10

```

```

RESULT 445
US-08-232-087A-5/c
; Sequence 5, Application US/08232087A
; Patent No. 5866372
;
; GENERAL INFORMATION:
; APPLICANT: Stein, Harald
; APPLICANT: D rkop, Horst
; APPLICANT: Latza, Ute
;
; TITLE OF INVENTION: Lymphoid CD30-Antigen
;
; NUMBER OF SEQUENCES: 11
;
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch & Birch, LLP
; STREET: 8110 Gatehouse Road, Suite 500 East
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: U.S.A.
;

```

```

Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0;

QY      576 GCAGGCCTCCG 587
      |||
Db      15 GCAGGCCTCCG 4

RESULT 446
US-08-882-649A-8
; Sequence 8, Application US/08882649A
; Patent No. 6344316
; GENERAL INFORMATION:
; APPLICANT: Lockhart, David J.
; Chee, Mark
; Gunderson, Kevin
; Chaogiang, Lai
; Wodicka, Lisa
; Cronin, Maureen T.
; Lee, Danny
; Tran, Huu M.
; Matsuzaki, Hajime
; McGall, Glenn H.
; TITLE OF INVENTION: NUCLEIC ACID ANALYSIS TECHNIQUES
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESS: Joe Liebeschuetz
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/882,649A
; FILING DATE: 25-Jun-1997
; CLASSIFICATION: 435-006.000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/010,471
; FILING DATE: 23-JAN-1996
; APPLICATION NUMBER: US 60/035,170
; FILING DATE: 09-JAN-1997
; APPLICATION NUMBER: PCT/US97/01603
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-019410US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: YES
; ; SEQUENCE DESCRIPTION: (ix) Features:
; ;
US-08-882-649A-8

Query Match 0.9%; Score 12; DB 1; Length 16
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels

QY      1141 GCCTTTTCTCTTT 1156
      |:|||||:|||||

```

Db 1 GVVTTTTTTTTTTTTT 16

RESULT 447

US-08-758-306-649

Sequence 649, Application US/08758306

Patent No. 5807743

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INTERLEUKIN-2 RECEPTOR

TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION

NUMBER OF SEQUENCES: 1379

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/758,306

FILING DATE: December 3, 1996

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 212/132

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 649:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-758-306-649

Query Match 0.9%; Score 12; DB 1; Length 17;

Best Local Similarity 66.7%; Pred. NO. 2.3e+02;

Matches 8; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 83 AATAGCAGTCTCT 94

Db 6 AAUAGCAGUUCU 17

RESULT 448

US-09-328-501-14

Sequence 14, Application US/09328501A

Patent No. 6258581

GENERAL INFORMATION:

APPLICANT: OKINO, No. 6258581omu

TITLE OF INVENTION: ITO, Makoto

FILE REFERENCE: 1422-0377P

CURRENT APPLICATION NUMBER: US/09/328,501A

CURRENT FILING DATE: 1999-06-09

EARLIER APPLICATION NUMBER: 10-234769 JAPAN

EARLIER FILING DATE: 1998-08-20

NUMBER OF SEQ ID NOS: 18

SOFTWARE: Patent In Ver. 2.1

SEQ ID NO 14

LENGTH: 17

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Designed

OTHER INFORMATION: oligonucleotide based on the amino acid sequence

OTHER INFORMATION: represented in SEQ ID NO:4.

FEATURE:

OTHER INFORMATION: any n or Xaa = Unknown

US-09-328-501-14

Query Match 0.9%; Score 12; DB 1; Length 17;

Best Local Similarity 62.5%; Pred. NO. 2.3e+02;

Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 629 AGTCCAGGAGCTCTG 644

Db 2 AGCTYCASRASCCTVG 17

RESULT 449

US-08-984-709A-45

Sequence 45, Application US/08984709A

Patent No. 6320032

GENERAL INFORMATION:

APPLICANT: Williams, Mark E.

APPLICANT: Stauderman, Kenneth A.

APPLICANT: Harpold, Michael M.

TITLE OF INVENTION: HUMAN CALCIUM CHANNEL COMPOSITIONS AND

TITLE OF INVENTION: METHODS

NUMBER OF SEQUENCES: 52

CORRESPONDENCE ADDRESS:

ADDRESSEE: Heller Ehrman White & McAuliffe

STREET: 4250 Executive Square, Suite 700

CITY: La Jolla

STATE: California

COUNTRY: US

ZIP: 92037

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/984,709A

FILING DATE: 02-DEC-1997

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Seidman, Stephanie L.

REGISTRATION NUMBER: 33,779

REFERENCE/DOCKET NUMBER: 24735-9815 (formerly 6362-9815)

TELECOMMUNICATION INFORMATION:

TELEPHONE: (619) 450-8400

TELEFAX: (619) 587-5360

INFORMATION FOR SEQ ID NO: 45:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: unknown

MOLECULE TYPE: cdna

HYPOTHETICAL: NO

ANTI-SENSE: NO

FRAGMENT TYPE:

ORIGINAL SOURCE:

US-08-984-709A-45

Query Match 0.9%; Score 12; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 323 ACTGATCATCTGG 338
| | | | | | | | | |
Db 1 AACTGYATACCTGG 16

RESULT 450

US-08-584-040-1844/c
; Sequence 1844, Application US/08584040
; Patent No. 6346398

GENERAL INFORMATION:

APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1844:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1844

Query Match 0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 909 CCTGGTCCTAAA 920
| | | | | | | | | |
Db 17 CCTGGTCCTAAA 6

RESULT 451

US-08-584-040-7538/c
; Sequence 7538, Application US/08584040
; Patent No. 6346398

GENERAL INFORMATION:

APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 7538:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7538

Query Match 0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 909 CCTGGTCCTAAA 920
| | | | | | | | | |
Db 17 CCTGGTCCTAAA 6

RESULT 452

US-09-537-720B-15/c
; Sequence 15, Application US/09537720B
; Patent No. 6376184

GENERAL INFORMATION:

APPLICANT: Laboratory of Molecular Biophotonics
TITLE OF INVENTION: Method for gene analysis
FILE REFERENCE: 400595
CURRENT APPLICATION NUMBER: US/09/537,720B
CURRENT FILING DATE: 2000-03-30
PRIOR APPLICATION NUMBER: JP12/22630
PRIOR FILING DATE: 2000-01-31
NUMBER OF SEQ ID NOS: 16
SOFTWARE: Patent in version 3.1
SEQ ID NO 15
LENGTH: 17

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Predicted Sequence
; NAME/KEY: misc_feature
; OTHER INFORMATION: Part of the template
US-09-537-720B-15

Query Match 0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1296 TCAGCCTGGCCC 1307
|||||
DB 14 TCAGCCTGGCCC 3

RESULT 453
US-08-937-067-17
; Sequence 17, Application US/08937067
; Patent No. 6433155
; GENERAL INFORMATION:
; APPLICANT: Umansky, Samuil
; APPLICANT: Melkonian, Hovsep
; TITLE OF INVENTION: A FAMILY OF GENES ENCODING
; TITLE OF INVENTION: APOPTOSIS-RELATED PEPTIDES; PEPTIDES ENCODED THEREBY AND
; TITLE OF INVENTION: METHODS OF USE THEREOF
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/08/937,067
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Lehnhardt, Susan K.
; REGISTRATION NUMBER: 33,943
; REFERENCE/DOCKET NUMBER: 23647-20018.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 813-5600
; TELEFAX: (650) 494-0792
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-937-067-17

Query Match 0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTCTCTTTGG 1158
|||||
DB 3 TTTTCTTTTNS 17

RESULT 454
US-09-777-710A-14
; Sequence 14, Application US/0977710A
; Patent No. 6489117
; GENERAL INFORMATION:

; APPLICANT: OKINO, No. 6489117omui et al.
; TITLE OF INVENTION: CERAMIDASE GENE
; FILE REFERENCE: 1422-0458P
; CURRENT APPLICATION NUMBER: US/09/777,710A
; CURRENT FILING DATE: 2001-02-07
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Designed oligonucleotide based on the amino acid sequence
; OTHER INFORMATION: represented in SEQ ID NO:4
US-09-777-710A-14

Query Match 0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.3e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 629 AGCTCAGGAGCTCTG 644
|||||
DB 2 AGCTCAGGAGCTCTG 17

RESULT 455
US-09-371-772B-389/c
; Sequence 389, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 389
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-389

Query Match 0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 909 CCTGGTCTCTAAA 920
|||||
DB 17 CCTGGTCTCTAAA 6

RESULT 456
US-09-371-772B-4638/c
; Sequence 4638, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

```
FILE REFERENCE: MEH00.876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 4638
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-4638

Query Match          0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 909 CCTGGTCCTAAA 920
DB 12 CCTGGTCCTAAA 1

RESULT 457
PCT-US91-03680-7
Sequence 7, Application PC/TUS9103680
GENERAL INFORMATION:
APPLICANT: Matteucci, Mark D.
APPLICANT: Krawczyk, Steven
TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
TITLE OF INVENTION: DUPLEX DNA
NUMBER OF SEQUENCES: 158
CORRESPONDENCE ADDRESS:
ADDRESSEE: Morrison & Foerster
STREET: 545 Middlefield Road, Suite 200
CITY: Menlo Park
STATE: California
COUNTRY: USA
ZIP: 94025
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/03680
FILING DATE: 19910524
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Murashige, Kate H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 4610-0011.40
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-327-7250
TELEFAX: 415-327-2951
TELEX: 706141
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: modified_base
LOCATION: 8
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "N4,N4-ethanocytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 14
OTHER INFORMATION: /mod_base= OTHER
```

```
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 17
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "1,3-propanediol"
PCT-US91-03680-7

Query Match          0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTT 1156
DB 1 TTTTTCCTTTT 13

RESULT 458
US-08-041-599-2
Sequence 2, Application US/08041599
Patent No. 5393877
GENERAL INFORMATION:
APPLICANT: McLEAN, MICHAEL J.
APPLICANT: HOLLAND, DAVID
APPLICANT: GARMAN, ANDREW J.
APPLICANT: SHEPPARD, ROBERT C.
TITLE OF INVENTION: SYNTHESIS OF OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: CUSHMAN, DARBY & CUSHMAN
STREET: 1100 NEW YORK AVENUE, N.W.
CITY: WASHINGTON
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/041,599
FILING DATE: 19930405
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: KOKULIS, PAUL N.
REGISTRATION NUMBER: 16,773
REFERENCE/DOCKET NUMBER: 202706/SBI36848/US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-861-3000
TELEFAX: 202-822-0944
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-041-599-2

Query Match          0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGA 1159
DB 1 TTTTTCCTTTTGA 15

RESULT 459
US-08-127-954-50
Sequence 50, Application US/08127954
Patent No. 5451512
```

```
;
; GENERAL INFORMATION:
; APPLICANT: Apple, Raymond J.
; APPLICANT: Bugawan, Teodorica L.
; APPLICANT: Erlich, Henry A.
; TITLE OF INVENTION: Methods and Reagents for HLA Class I A
; TITLE OF INVENTION: Locus DNA Typing
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/127,954
; FILING DATE:
; CLASSIFICATION: 436
; ATTORNEY/AGENT INFORMATION:
; NAME: Petry, Douglas A.
; REGISTRATION NUMBER: 35,321
; REFERENCE/DOCKET NUMBER: 8873
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2974
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 50:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-127-954-50

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 113 CGGAGACCGTCCACA 127
Db 1 CGGAGCCCGTCCACA 15

RESULT 460
US-08-337-025-2
; Sequence 2, Application US/08337025
; Patent No. 5552535
; GENERAL INFORMATION:
; APPLICANT: McLEAN, MICHAEL J.
; APPLICANT: HOLLAND, DAVID
; APPLICANT: GARMAN, ANDREW J.
; APPLICANT: SHEPPARD, ROBERT C.
; TITLE OF INVENTION: SYNTHESIS OF OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CUSHMAN, DARRY & CUSHMAN
; STREET: 1100 NEW YORK AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/337,025
```

```
;
; FILING DATE: 07-NOV-1994
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/041,599
; FILING DATE: 05-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: BIRD, DONALD J.
; REGISTRATION NUMBER: 25,323
; REFERENCE/DOCKET NUMBER: 202706/SBI36848/US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-861-3000
; TELEFAX: 202-822-0944
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; US-08-337-025-2

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1145 TTTTTCCTTTTTCGA 1159
Db 1 TTTTTCCTTTTTCGA 15

RESULT 461
US-08-276-099A-8
; Sequence 8, Application US/08276099A
; Patent No. 5591825
; GENERAL INFORMATION:
; APPLICANT: McKnight, Steven L
; APPLICANT: Hou, Jinzhao
; TITLE OF INVENTION: INTERLEUKIN-4 SIGNAL TRANSDUCERS AND
; TITLE OF INVENTION: BINDING ASSAYS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/276,099A
; FILING DATE: 15-JUL-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Osman, Richard Aron
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: A-59451-1/RAO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; TELEX: 910 277299
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; US-08-276-099A-8
```

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 AAGTTTCAGATGGG 849
Db 1 AAGTTTCAGAGGG 15

RESULT 462

US-08-182-968A-201
Sequence 201, Application US/08182968A
Patent No. 5610054

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/182,968A

FILING DATE: 13-JANUARY-1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/892,888

FILING DATE: 14-MAY-1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 205/277

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 201:

SEQUENCE CHARACTERISTICS:

LENGTH: 15

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-182-968A-201

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1190 TGAGTGTGACCTT 1204
Db 1 UGUGUGUAGGACCG 15

RESULT 463

US-08-291-932A-33/c

Sequence 33, Application US/08291932A

Patent No. 5658780

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: Draper, Kenneth G.

APPLICANT: McSwiggen, James

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NF-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/291,932A

FILING DATE: August 15, 1994

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

PRIOR APPLICATION DATA: including application

PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/245,466

FILING DATE: May 18, 1994

APPLICATION NUMBER: 07/987,132

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/157

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 33:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-291-932A-33

Query Match

Best Local Similarity 0.9%; Score 11.8; DB 1; Length 15;

Mismatches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GGCGAGTGTGAGGTGGA 20
Db 15 GGCGAGTGTGAGGTGGA 1

RESULT 464

US-08-291-932A-378/c

Sequence 378, Application US/08291932A

Patent No. 5658780

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

APPLICANT: Draper, Kenneth G.

APPLICANT: McSwiggen, James

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: NF-KB

NUMBER OF SEQUENCES: 830

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.
 ZIP: 90071-2066
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/291,932A
 FILING DATE: August 15, 1994
 CLASSIFICATION: 514
 PRIOR APPLICATION DATA: including application
 PRIOR APPLICATION DATA: described below:
 APPLICATION NUMBER: 08/245,466
 FILING DATE: May 18, 1994
 APPLICATION NUMBER: 07/987,132
 FILING DATE: December 7, 1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard J.
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 208/157
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 378:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-291-932A-378

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.9e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 528 GGAGGAGGAGCTGGG 542
 DB 15 GGAGGAGGAGCTGGG 1

RESULT 465
 US-08-334-847-570
 Sequence 570, Application US/08334847
 Patent No. 5693532
 GENERAL INFORMATION:
 APPLICANT: McSwiggen, James
 APPLICANT: Draper, Kenneth
 APPLICANT: Pavco, Pam
 APPLICANT: Woolf, Tod
 TITLE OF INVENTION: METHOD AND REAGENT FOR
 TITLE OF INVENTION: INHIBITING RESPIRATORY
 TITLE OF INVENTION: SYNCYTIAL VIRUS
 NUMBER OF SEQUENCES: 909
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071-2066
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/334,847

FILING DATE: No. 5693532ember 4, 1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard J.
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 209/032
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 570:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-334-847-570

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 20.0%; Pred. No. 1.9e+02;
 Matches 3; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTCTTTCTTTGG 1158
 DB 1 UUUUGUUCUUUUUGG 15

RESULT 466
 US-08-334-847-606
 Sequence 606, Application US/08334847
 Patent No. 5693532
 GENERAL INFORMATION:
 APPLICANT: McSwiggen, James
 APPLICANT: Draper, Kenneth
 APPLICANT: Pavco, Pam
 APPLICANT: Woolf, Tod
 TITLE OF INVENTION: METHOD AND REAGENT FOR
 TITLE OF INVENTION: INHIBITING RESPIRATORY
 TITLE OF INVENTION: SYNCYTIAL VIRUS
 NUMBER OF SEQUENCES: 909
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071-2066
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/334,847
 FILING DATE: No. 5693532ember 4, 1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard J.
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 209/032
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 606:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs

Two


```

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 541:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-541

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 924 GATGCAGATCTGGA 938
Db 15 GGTGCTGAICTGGA 1

RESULT 470
US-08-363-240A-658/c
; Sequence 658, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:

```

```

; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 658:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-658

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GGGCAGGCAGTTGAG 15
Db 15 GGCCAGGGAGTTGAG 1

RESULT 471
US-08-781-890-8
; Sequence 8, Application US/08781890
; Patent No. 5710266
; GENERAL INFORMATION:
; APPLICANT: McKnight, Steven L
; APPLICANT: Hou, Jiazhao
; TITLE OF INVENTION: INTERLEUKIN-4 SIGNAL TRANSDUCERS AND
; TITLE OF INVENTION: BINDING ASSAYS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOEBACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/781,890
; FILING DATE: 05-JAN-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/276,099
; FILING DATE: 15-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Osman, Richard Aron
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: A-59451-1/RAO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; TELEX: 910 277299
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear

```

```

; MOLECULE TYPE: cDNA
US-08-781-890-8

Query Match      0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      835 AGCTTTCAGATGGG 849
Db      1 AAGGTTTCAGAGGG 15

RESULT 472
US-08-471-033-34/c
; Sequence 34, Application US/08471033
; Patent No. 5770696
; GENERAL INFORMATION:
; APPLICANT: Warren, Gregory W
; APPLICANT: Koziel, Michael G
; APPLICANT: Mullins, Martha A
; APPLICANT: Nye, Gordon J
; APPLICANT: Carr, Brian
; APPLICANT: Desai, Nalini M
; APPLICANT: Kostichka, N. Kristy
; APPLICANT: Duck, Nicholas B
; APPLICANT: Estruch, Juan J
; TITLE OF INVENTION: No. 5770696el Pesticidal Proteins and Strains
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: NY
; COUNTRY: USA
; ZIP: 10532
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30B
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,033
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/314,594
; FILING DATE: 09-SEP-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/218,018
; FILING DATE: 23-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/037,057
; FILING DATE: 25-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Page, Gary M.
; REGISTRATION NUMBER: P-40,403
; REFERENCE/DOCKET NUMBER: CGC 1695/CIP3/DIV7 - SQLv3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-541-8582
; TELEFAX: 919-541-8689
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "reverse primer used to make
; DESCRIPTION: pCIB5526"
; HYPOTHETICAL: NO
US-08-471-033-34

Query Match      0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      826 ATGCAGCTGAGCTT 840
Db      15 AAGGAGCTGAGCTT 1

Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      826 ATGCAGCTGAGCTT 840
Db      15 AAGGAGCTGAGCTT 1

RESULT 473
US-08-292-620A-74
; Sequence 74, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-74

Query Match      0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      908 CCTGTGCTCTAAAGG 922
Db      1 CCGGGGCUAGAGG 15

```

RESULT 474

US-08-292-620A-105/c
; Sequence 105, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435

PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 105:

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-292-620A-105

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 308 GGGCTGCACTCCAT 322

Db 15 GGGCTGGACCCCAT 1

RESULT 475

US-08-292-620A-393/c
; Sequence 393, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435

PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 393:

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-292-620A-393

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 CCAGGTGTGAGCCCT 1274

Db 15 CCAGGTGTGAGTCCT 1

RESULT 476

US-08-292-620A-656/c
; Sequence 656, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF

;; TITLE OF INVENTION: INTRACELLULAR ADHESION
;; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
;; NUMBER OF SEQUENCES: 2390
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620A
;; FILING DATE: August 17, 1994
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 656:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-292-620A-656

two

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1260 CCAGGTTGAGCCCT 1274
Db 15 CCAGGCTGAGCTCT 1

RESULT 477
US-08-471-044-34/c
; Sequence 34, Application US/08471044
; Patent No. 5840868
; GENERAL INFORMATION:
; APPLICANT: Warren, Gregory W
; APPLICANT: Koziel, Michael G
; APPLICANT: Mullins, Martha A
; APPLICANT: Nye, Gordon J
; APPLICANT: Carr, Brian
; APPLICANT: Desai, Nalini M
; APPLICANT: Kostichka, N. Kristy
; APPLICANT: Duck, Nicholas B
; APPLICANT: Estruch, Juan J
; TITLE OF INVENTION: No. 5840868el Pesticidal Proteins and Strains
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne

;; STATE: NY
;; COUNTRY: USA
;; ZIP: 10532
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.30B
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/471,044
;; FILING DATE: 06-JUN-1995
;; CLASSIFICATION: 800
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/463,483
;; FILING DATE: 05-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/314,594
;; FILING DATE: 09-SRP-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/218,018
;; FILING DATE: 23-MAR-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/037,057
;; FILING DATE: 25-MAR-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Pace, Gary M.
;; REGISTRATION NUMBER: 40,403
;; REFERENCE/DOCKET NUMBER: CGC 1695/CIP3/DIV6 - SQLv3
;; TELEPHONE: 919-541-8582
;; TELEFAX: 919-541-8689
;; INFORMATION FOR SEQ ID NO: 34:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: other nucleic acid
;; DESCRIPTION: /desc = "reverse primer used to make
;; HYPOTHETICAL: NO
;; US-08-471-044-34

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 826 ATGCAGCTGAAGCTT 840
Db 15 AAGGAGCTGAAGCTT 1

RESULT 478
US-08-463-483A-34/c
; Sequence 34, Application US/08463483A
; Patent No. 5849870
; GENERAL INFORMATION:
; APPLICANT: Warren, Gregory W
; APPLICANT: Koziel, Michael G
; APPLICANT: Mullins, Martha A
; APPLICANT: Nye, Gordon J
; APPLICANT: Carr, Brian
; APPLICANT: Desai, Nalini M
; APPLICANT: Kostichka, N. Kristy
; APPLICANT: Duck, Nicholas B
; APPLICANT: Estruch, Juan J
; TITLE OF INVENTION: No. 5849870el Pesticidal Proteins and Strains
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: NY

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: Genomic DNA
DESCRIPTION: retinoblastoma gene (Accession #
DESCRIPTION: M33647, J02994) nucleotides 4062 to 4076
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
POSITION IN GENOME:
CHROMOSOME/SEGMENT: chromosome 13
MAP POSITION: 13q14.2
PUBLICATION INFORMATION:
AUTHORS: Friend, S H, Horowitz, J M, Gerber, M R,
AUTHORS: Wang X F, Bogenmann, E, Li, F P, Weinberg,
AUTHORS: R A.
TITLE: Deletions of a DNA sequence
TITLE: in retinoblastomas and mesenchymal tumors:
TITLE: Organization of the sequence and its encoded
TITLE: Protein
JOURNAL: Proceedings of the National Academy of
JOURNAL: Sciences, USA
VOLUME: 84
PAGES: 9059-9063
DATE: 1987
RELEVANT RESIDUES IN SEQ ID NO: 87 :FROM 1 TO 15
US-08-173-489C-87

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1202 CTTCCACCTCCCT 1216
| | | | |
Db 1 CTTCCCTCCCT 15

RESULT 481
US-08-471-046A-34/C
Sequence 34, Application US/08471046A
Patent No. 5866326
GENERAL INFORMATION:
APPLICANT: Warren, Gregory W
APPLICANT: Koziel, Michael G
APPLICANT: Mullins, Martha A
APPLICANT: Nye, Gordon J
APPLICANT: Carr, Brian
APPLICANT: Desai, Nalini M
APPLICANT: Kostichka, N. Kristy
APPLICANT: Duck, Nicholas B
APPLICANT: Estruch, Juan J
TITLE OF INVENTION: Method For Isolating Vegetative Insecticidal
TITLE OF INVENTION: Protein Genes
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5866326artis Corporation
STREET: 3054 Cornwalis Road
CITY: Research Triangle Park
STATE: NC

COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30B
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471,046A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/463,483
FILING DATE: 05-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/314,594
FILING DATE: 09-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/218,018
FILING DATE: 23-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/037,057
FILING DATE: 25-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Weigs, J Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: CGC1695/CIP3/DIV8 - SQLv4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "reverse primer used to make
HYPOTHETICAL: NO
US-08-471-046A-34

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 ATGCAGCTGAAGCTT 840
| | | | |
Db 15 AAGGAGCTGAAGCTT 1

RESULT 482
US-08-774-306A-201
Sequence 201, Application US/08774306A
Patent No. 5869253
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,306A
FILING DATE: December 26, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/227
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 201:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-306A-201

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1190 TGAGTGTGGACCTT 1204
:|:|:|:|:|:
Db 1 UGUGUGUGGACCGU 15

RESULT 483
US-08-470-566B-34/c
Sequence 34, Application US/08470566B
Patent No. 5872212
GENERAL INFORMATION:
APPLICANT: Warren, Gregory W
APPLICANT: Koziel, Michael G
APPLICANT: Mullins, Martha A
APPLICANT: Nye, Gordon J
APPLICANT: Carr, Brian
APPLICANT: Desai, Nalini M
APPLICANT: Kostichka, N. Kristy
APPLICANT: Duck, Nicholas B
APPLICANT: Estruch, Juan J
TITLE OF INVENTION: No. 5872212el Pesticidal Proteins and Strains
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5872212artis Corporation
STREET: 3054 Cornwallis Road
CITY: Research Triangle Park
STATE: NC
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30B
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/470,566B
FILING DATE: 06-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/463,483
FILING DATE: 05-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/314,594
FILING DATE: 09-SEP-1994

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/218,018
FILING DATE: 23-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/037,057
FILING DATE: 25-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Meigs, J. Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: CGC1695/CIP3/DIV4 - SOLV4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "reverse primer used to make
DESCRIPTION: PCIB5526"
HYPOTHETICAL: NO
US-08-470-566B-34

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 ATGCAGCTGAAGCTT 840
|:|:|:|:|:|:
Db 15 AAGGAGCTGAAGCTT 1

RESULT 484
US-08-585-684B-775/c
Sequence 775, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 775:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-775

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 GGAAGTAAGCAGCT 1171
Db 15 GGAAGCAAGCAGT 1

RESULT 485
US-08-585-684B-776/c
Sequence 776, Application US/08585684B
Patent No. 5877021

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 776:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-776

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 GGAAGTAAGCAGCT 1171
Db 15 GGAAGCAAGCAGT 1

RESULT 486

US-08-585-684B-1365/c
Sequence 1365, Application US/08585684B
Patent No. 5877021

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1365:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1365

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1155 TTGGAAGTAAGCAGC 1169
Db 15 TTGGAAGTACAGCTG 1

RESULT 487

US-08-585-684B-1376
Sequence 1376, Application US/08585684B
Patent No. 5877021

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1376

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 33.3%; Pred. No. 1.9e+02;
Matches 5; Conservative 8; Mismatches 2; Indels 0; Gaps 0;
QY 1109 TAGTTTCTGTGTTAA 1123
Db 1 UGGUUCUGUCUAA 15

RESULT 488
US-08-585-684B-2270
Sequence 2270, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2/51
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2270:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2270

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 929 CAGATCTGGAGAAGA 943
Db 1 CAGCUCUGAGAAGA 15

RESULT 489
US-08-854-041-4/c
Sequence 4, Application US/08854041
Patent No. 5916779
GENERAL INFORMATION:
APPLICANT: Pearson, Robert E.
APPLICANT: Dickson, Julie A.
APPLICANT: Mehropouyan, Majid
TITLE OF INVENTION: STRAND DISPLACEMENT AMPLIFICATION OF RNA
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: R. J. Rodrick, Becton Dickinson and Company
STREET: 1 Becton Drive
CITY: Franklin Lakes
STATE: NJ
COUNTRY: US
ZIP: 07417
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/854,041
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Fugit, Donna R.
REGISTRATION NUMBER: 32,135
REFERENCE/DOCKET NUMBER: P-3853
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-854-041-4

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 276 CAAAGAGGAAGCAGC 290
Db 15 CAATGAGGAAGCTGC 1

RESULT 490

US-08-485-133-7/c
; Sequence 7, Application US/08485133
; Patent No. 5976789
; GENERAL INFORMATION:
; APPLICANT: Allibert, Patrice A.
; APPLICANT: Cros, Philippe
; APPLICANT: Mach, Bernard F.
; APPLICANT: Mandrand, Bernard F.
; APPLICANT: Tiercy, Jean-Marie
; TITLE OF INVENTION: SYSTEM OF PROBES ENABLING HLA-DR TYPING
; TITLE OF INVENTION: TO BE PERFORMED, AND TYPING METHOD USING SAID PROBES
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OLIFF & BERRIDGE
; STREET: P.O. Box 19928
; CITY: Alexandria
; STATE: Virginia
; ZIP: 22320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/485,133
; FILING DATE: 7-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/030,143
; FILING DATE: 11-MAR-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Berridge, William P.
; REGISTRATION NUMBER: 30,024
; REFERENCE/DOCKET NUMBER: WPB 28596A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6400
; TELEFAX: 703-836-2787
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-485-133-7

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 782 TCTCCACAGTGCC 796
Db 15 TGTCCACAGGGCC 1

RESULT 491

US-08-469-334-34/c
; Sequence 34, Application US/08469334
; Patent No. 5990383
; GENERAL INFORMATION:
; APPLICANT: Warren, Gregory W
; APPLICANT: Kozziel, Michael G
; APPLICANT: Mullins, Martha A
; APPLICANT: Nye, Gordon J
; APPLICANT: Carr, Brian
; APPLICANT: Desai, Nalini M
; APPLICANT: Kostichka, N. Kristy
; APPLICANT: Duck, Nicholas B
; APPLICANT: Estruch, Juan J
; TITLE OF INVENTION: No. 5990383el Pesticidal Proteins and Strains

NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: NY
; COUNTRY: USA
; ZIP: 10532
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30B
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/469,334
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/463,483
; FILING DATE:
; APPLICATION NUMBER: US 08/314,594
; FILING DATE: 09-SEP-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/218,018
; FILING DATE: 23-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/037,057
; FILING DATE: 25-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spruill, W. Murray
; REGISTRATION NUMBER: 32,943
; REFERENCE/DOCKET NUMBER: CGC 1695/CIP3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-541-8615
; TELEFAX: 919-541-8615
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "reverse primer used to make
; DESCRIPTION: PCIB5526"
; HYPOTHETICAL: NO
; US-08-469-334-34

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 ATGCAGCTGAAGCTT 840
Db 15 AAGGAGCTGAAGCTT 1

RESULT 492

US-08-343-998-24
; Sequence 24, Application US/08343998A
; Patent No. 6020123
; GENERAL INFORMATION:
; APPLICANT: Sonigo, Pierre
; APPLICANT: Brechot, Christian
; APPLICANT: Courgnard, Valerie
; TITLE OF INVENTION: OLIGONUCLEOTIDE SEQUENCES FOR THE AMPLIFICATION OF THE
; TITLE OF INVENTION: GENOME OF THE RETROVIRUSES OF THE HIV-2 AND SIV TYPE,
; TITLE OF INVENTION: AND THEIR USES FOR IN VITRO DIAGNOSIS OF THE INFECTIONS
; TITLE OF INVENTION: DUE TO THESE VIRUSES
; FILE REFERENCE: 2356.0065-01
; CURRENT APPLICATION NUMBER: US/08/343,998A
; CURRENT FILING DATE: 1994-11-18
; EARLIER APPLICATION NUMBER: 07/820,600
; EARLIER FILING DATE: 1992-01-22

; EARLIER APPLICATION NUMBER: PCT/FR90/00394
; EARLIER FILING DATE: 1990-06-05
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 24
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Simian immunodeficiency virus
; FEATURE:
US-08-343-998-24

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 387 AGAGTGGCAGCAAT 401
DB 1 AGAGTGGCAGCACT 15

RESULT 493
US-08-832-021-25
; Sequence 25, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; FILE REFERENCE: JBP-382
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 25
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-25

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTCTCTTTTGA 1159
DB 1 TTTTCTCTTTTGA 15

RESULT 494
US-08-832-021-37
; Sequence 37, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; FILE REFERENCE: JBP-382
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 37
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-37

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTCTCTTTTGA 1159
DB 1 TTTTCTCTTTTGA 15

RESULT 495
US-08-832-021-41
; Sequence 41, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; FILE REFERENCE: JBP-382
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 41
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-41

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTCTCTTTTGA 1159
DB 1 TTTTCTCTTTTGA 15

RESULT 496
US-08-832-021-43
; Sequence 43, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; FILE REFERENCE: JBP-382
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-43

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 15

RESULT 497

US-08-832-021-45
Sequence 45, Application US/08832021

Patent No. 6045998

GENERAL INFORMATION:

APPLICANT: Combates, N.

APPLICANT: Pardinas, J.

APPLICANT: Parimoo, S.

APPLICANT: Prouty, S.

APPLICANT: Stenn, K.

TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

FILE REFERENCE: JBP-382

CURRENT APPLICATION NUMBER: US/08/832,021

CURRENT FILING DATE: 1997-04-02

NUMBER OF SEQ ID NOS: 64

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 45

LENGTH: 15

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-45

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1159
Db 1 TTTTTCCTTTTGG 15

RESULT 498

US-08-832-021-47

Sequence 47, Application US/08832021

Patent No. 6045998

GENERAL INFORMATION:

APPLICANT: Combates, N.

APPLICANT: Pardinas, J.

APPLICANT: Parimoo, S.

APPLICANT: Prouty, S.

APPLICANT: Stenn, K.

TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

FILE REFERENCE: JBP-382

CURRENT APPLICATION NUMBER: US/08/832,021

CURRENT FILING DATE: 1997-04-02

NUMBER OF SEQ ID NOS: 64

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 47

LENGTH: 15

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-47

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 15

RESULT 499

US-08-832-021-61
Sequence 61, Application US/08832021

Patent No. 6045998

GENERAL INFORMATION:

APPLICANT: Combates, N.

APPLICANT: Pardinas, J.

APPLICANT: Parimoo, S.

APPLICANT: Prouty, S.

APPLICANT: Stenn, K.

TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

FILE REFERENCE: JBP-382

CURRENT APPLICATION NUMBER: US/08/832,021

CURRENT FILING DATE: 1997-04-02

NUMBER OF SEQ ID NOS: 64

SOFTWARE: Patentin Ver. 2.0

SEQ ID NO 61

LENGTH: 15

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-61

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1159
Db 1 TTTTTCCTTTTGG 15

RESULT 500

US-09-300-529-34/c

Sequence 34, Application US/09300529

Patent No. 6066783

GENERAL INFORMATION:

APPLICANT: Warren, Gregory W

APPLICANT: Koziel, Michael G

APPLICANT: Mullins, Martha A

APPLICANT: Nye, Gordon J

APPLICANT: Carr, Brian

APPLICANT: Desai, Nalini M

APPLICANT: Kostichka, N. Kristy

APPLICANT: Duck, Nicholas B

APPLICANT: Estruch, Juan J

TITLE OF INVENTION: Genes Encoding Insecticidal Proteins

NUMBER OF SEQUENCES: 50

CORRESPONDENCE ADDRESS:

ADDRESSEE: No. 6066783artis Corporation

STREET: 3054 Cornwallis Road

CITY: Research Triangle Park

STATE: NC

COUNTRY: USA

ZIP: 27709

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30B

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/300,529

FILING DATE: TBA

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/469,334

FILING DATE: 06-JUN-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/463,483

FILING DATE: 05-JUN-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/314,594

FILING DATE: 09-SEP-1994

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/218,018
;; FILING DATE: 23-MAR-1994
;; PRIOR APPLICATION DATA: US 08/037,057
;; FILING DATE: 25-MAR-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Meigs, J. Timothy
;; REGISTRATION NUMBER: 38,241
;; REFERENCE/DOCKET NUMBER: S-19506L
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 919-541-8587
;; TELEFAX: 919-541-8689
;; INFORMATION FOR SEQ ID NO: 34:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: other nucleic acid
;; DESCRIPTION: /desc = "reverse primer used to make
;; HYPOTHETICAL: NO
;; US-09-300-529-34

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 ATGCAGCTGAAGCTT 840
Db 15 AAGGAGCTGAAGCTT 1

RESULT 501

;; US-09-064-156A-201
;; Sequence 201, Application US/09064156A
;; Patent No. 6132966
;; GENERAL INFORMATION:
;; APPLICANT: Draper, Kenneth G.
;; TITLE OF INVENTION: METHOD AND REAGENT FOR
;; TITLE OF INVENTION: INHIBITING HEPATITIS C
;; TITLE OF INVENTION: VIRUS REPLICATION
;; NUMBER OF SEQUENCES: 498
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/064,156A
;; FILING DATE: April 21, 1998
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/774,306
;; FILING DATE: December 26, 1996
;; APPLICATION NUMBER: 08/182,968
;; FILING DATE: January 13, 1994
;; APPLICATION NUMBER: 07/882,888
;; FILING DATE: May 14, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 234/083
;; TELECOMMUNICATION INFORMATION:

;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 201:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-064-156A-201

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1190 TGAGTGTGGACCTT 1204
Db 1 UGUGUGUGGACCGU 15

RESULT 502

;; US-09-071-845-74
;; Sequence 74, Application US/09071845
;; Patent No. 6132967
;; GENERAL INFORMATION:
;; APPLICANT: Susan Grimm
;; APPLICANT: Dan T. Stinchcomb
;; APPLICANT: James McSwiggen
;; APPLICANT: Sean Sullivan
;; APPLICANT: Kenneth G. Draper
;; TITLE OF INVENTION: RIBOZYME TREATMENT OF
;; TITLE OF INVENTION: DISEASES OR CONDITIONS
;; TITLE OF INVENTION: RELATED TO LEVELS OF
;; TITLE OF INVENTION: INTRACELLULAR ADHESION
;; NUMBER OF SEQUENCES: 2390
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/071,845
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620
;; FILING DATE: August 17, 1994
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 74:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-74

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 908 CCCTGGTCTTAAGG 922
DB 1 CCCGGGUCCUAGAGG 15

RESULT 503

US-09-071-845-105/c
Sequence 105, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071.845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 105:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-105

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 308 GGGCTGCAACTCCAT 322
DB 15 GGGCTGGAACCCAT 1

RESULT 504

US-09-071-845-393/c
Sequence 393, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 393:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-393

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 CCAGGTTGAGGCCT 1274
DB 15 CCAGGCTGAGTCCT 1

RESULT 505

US-09-071-845-656/c
; Sequence 656, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 656:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-656

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 CCAGGTGAGGCCT 1274
Db 15 CCAGGTGAGGTCT 1

RESULT 506
US-09-038-073-775/c
; Sequence 775, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 775:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-775

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 GGAAGTAAGCAGCT 1171
Db 15 GGAAGCAAGCAGGT 1

RESULT 507
US-09-038-073-776/c
; Sequence 776, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 776:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-776

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1157 GGAGTAAGCAGCT 1171
Db 15 GGAAGCAAGCAGCT 1

RESULT 508

US-09-038-073-1365/c
Sequence 1365, Application US/09038073
Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1376

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 33.3%; Pred. No. 1.9e+02;
Matches 5; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 1109 TAGTTTCTGTTTAA 1123
Db 1 UGGUUCUGUCUAA 15

INFORMATION FOR SEQ ID NO: 1365:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1365

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1155 TTGGAAGTAAAGCAG 1169
Db 15 TTGGAAGTACAGCTG 1

RESULT 509

US-09-038-073-1376
Sequence 1376, Application US/09038073
Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1376

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1376

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1376

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1376

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1376

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 33.3%; Pred. No. 1.9e+02;
Matches 5; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 1109 TAGTTTCTGTTTAA 1123
Db 1 UGGUUCUGUCUAA 15

RESULT 510
US-09-038-073-2270
; Sequence 2270, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2270:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-2270

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 929 CAGATCTGGAGAAGA 943
||| : : |||||
Db 1 CAGCUCUUGAGAAGA 15

RESULT 511
US-09-275-850-19
; Sequence 19, Application US/09275850A
; Patent No. 6261774
; GENERAL INFORMATION:
; APPLICANT: Pagratis, Nikos
; APPLICANT: Gold, Larry
; APPLICANT: Shatland, Timur
; APPLICANT: Javornik, Brenda
; TITLE OF INVENTION: Truncation SELEX Method
; FILE REFERENCE: NEX 79
; CURRENT APPLICATION NUMBER: US/09/275,850A
; CURRENT FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 351
; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 19
; LENGTH: 15
; TYPE: RNA
; ORGANISM: E. coli
US-09-275-850-19

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 719 CCCAGCAGCAGGGG 733
||||| : |||||
Db 1 CCCAGCACAGCGG 15

RESULT 512
US-09-344-888A-9/c
; Sequence 9, Application US/09344888A
; Patent No. 6291245
; GENERAL INFORMATION:
; APPLICANT: Kopetzki, Erhard
; APPLICANT: Schantz, Christian
; TITLE OF INVENTION: New Host-Vector System
; FILE REFERENCE: CD20315
; CURRENT APPLICATION NUMBER: US/09/344,888A
; CURRENT FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: EP98113156.8
; PRIOR FILING DATE: 1998-07-15
; PRIOR APPLICATION NUMBER: EP98119078.8
; PRIOR FILING DATE: 1998-10-09
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-344-888A-9

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 591 GCCCCCCCAGCGCT 605
||||| : |||||
Db 15 GCCCCCCCAGCGCT 1

RESULT 513
US-09-081-646-513/c
; Sequence 513, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 513
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-513

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 780:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-780

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 480 GGACTGCCGAGCG 494
Db 1 GGACUGCGGGAUGG 15

RESULT 521

US-08-291-932A-814
Sequence 814, Application US/08291932A
Patent No. 5658780
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RIBOZIME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NF-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466

Two

FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 814:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-814

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 480 GGACTGCCGAGCG 494
Db 1 GGACUGCGGGAUGG 15

RESULT 522

US-08-258-152-18/c
Sequence 18, Application US/08258152
Patent No. 5686279
GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
APPLICANT: ROBERTS, MARGO R.
APPLICANT: DULL, THOMAS J.
APPLICANT: ZSEBO, KRISZTINA M.
APPLICANT: QIN, LU
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
VIRUS AND HIGH EFFICIENCY RETROVIRAL TRANSDUCTION
TITLE OF INVENTION: OF MAMMALIAN CELLS
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/258,152
FILING DATE: 10-JUN-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-258-152-18

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1239 GCTGGACGTCGACAT 1253
|||||
Db 15 GCTGGACATGCCCT 1

RESULT 523

US-08-241-465B-17
Sequence 17, Application US/08241465B

Patent No. 5719125

GENERAL INFORMATION:

APPLICANT: FUJIO SUZUKI

APPLICANT: YUJI HIRAKI

APPLICANT: KAZUHIRO TAKAHASHI

APPLICANT: JUNKO SUZUKI

APPLICANT: JUN KONDO

APPLICANT: ATSUKO KOHARA

APPLICANT: AKIKO MORI

APPLICANT: EI YAMADA

TITLE OF INVENTION: HUMAN CHONDROMODULIN-I PROTEIN

NUMBER OF SEQUENCES: 21

CORRESPONDENCE ADDRESS:

ADDRESSEE: Wenderoth, Lind & Ponack

STREET: 805 Fifteenth Street, N.W., #700

CITY: Washington

COUNTRY: D.C.

ZIP: 20005

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/241,465B

FILING DATE: May 11, 1994

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Warren M. Cheek, Jr.

REGISTRATION NUMBER: 33,367

REFERENCE/DOCKET NUMBER:

TELEPHONE: (202) 371-8850

TELEFAX:

TELEX:

INFORMATION FOR SEQ ID NO: 17:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, Synthetic DNA

US-08-241-465B-17

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 420 CCTAGACAGGAC 434
|||||
Db 2 CCTAGACTGGATCAC 16

RESULT 524

US-08-465-485A-16/c

Sequence 16, Application US/08465485A

Patent No. 5831066

GENERAL INFORMATION:
APPLICANT: Read, John
TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT,
ADDRESSEE: P.C.
STREET: 1755 S. Jefferson Davis Hwy., Suite 400
CITY: Arlington
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22202

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/465,485A

FILING DATE: 05-JUN-1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/124,256

FILING DATE: 20-SEP-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/840,716

FILING DATE: 21-FEB-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/288,692

FILING DATE: 22-DEC-1988

ATTORNEY/AGENT INFORMATION:

NAME: Fortney, Andrew D.

REGISTRATION NUMBER: 34,600

REFERENCE/DOCKET NUMBER: 3335-070-55 CONT

TELECOMMUNICATION INFORMATION:

TELEPHONE: (408) 436-2070

TELEFAX: (408) 436-2075

INFORMATION FOR SEQ ID NO: 16:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

ANTI-SENSE: YES

US-08-465-485A-16

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 187 CCGCGCGCCCGCG 201
|||||
Db 15 CCGCGCGCGCTCCG 1

RESULT 525

US-08-076-299A-18/c

Sequence 18, Application US/08076299A

Patent No. 5834256

GENERAL INFORMATION:

APPLICANT: FINER, MITCHELL H.

APPLICANT: ROBERTS, MARGO R.

APPLICANT: DULL, THOMAS J.

APPLICANT: ZSEBO, KRISZTINA M.

APPLICANT: QIN, LU

TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER

TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL TRANSDUCTION

TITLE OF INVENTION: OF MAMMALIAN CELLS

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: CELL GENESYS, INC.

STREET: 322 LAKESIDE DRIVE

CITY: POSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/076,299A
FILING DATE: 11-JUN-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.0
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-076-299A-18

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1239 GCTGGACGTGGCCAT 1253
DB 15 GCTGGACATGGCCCT 1

RESULT 526
US-08-527-060-2/c
Sequence 2, Application US/08527060
Patent No. 5834440
GENERAL INFORMATION:
APPLICANT: Goldenberg, Tsvi
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT
TITLE OF INVENTION: AND/OR PREVENTION OF RESTENOSIS
NUMBER OF SEQUENCES: 35
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/527,060
FILING DATE: 12-SEP-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Mcmasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 480124.402C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-527-060-2

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 601 AGCCTGAAGCTGAC 615
DB 16 ATCCTGAAGACTGAC 2

RESULT 527
US-08-527-060-12
Sequence 12, Application US/08527060
Patent No. 5834440
GENERAL INFORMATION:
APPLICANT: Goldenberg, Tsvi
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT
TITLE OF INVENTION: AND/OR PREVENTION OF RESTENOSIS
NUMBER OF SEQUENCES: 35
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/527,060
FILING DATE: 12-SEP-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Mcmasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 480124.402C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-527-060-12

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 GACTCTTCCACGAC 1053
DB 1 GACTGTCCACGTC 15

RESULT 528
US-08-292-620A-1628/c
Sequence 1628, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:

```

; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggan
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1628:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1628

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 595 CCCACCAGCCTGAG 609
Db 15 CCCACCAGCCTGTAG 1

RESULT 529
US-08-438-582-18/c
; Sequence 18, Application US/08438582
; Patent No. 5858740
; GENERAL INFORMATION:
; APPLICANT: FINER, MITCHELL H.
; APPLICANT: ROBERTS, MARGO R.
; APPLICANT: DULL, THOMAS J.
; APPLICANT: ZSEBO, KRISTINA M.
; APPLICANT: QIN, LU
; TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION

```

two

```

; TITLE OF INVENTION: OF MAMMALIAN CELLS
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/438,582
; FILING DATE: 10-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/258,152
; FILING DATE: 10-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/076,299
; FILING DATE: 11-JUN-93
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I.
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELL 13.2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-358-9600 X131
; TELEFAX: 415-349-7392
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-438-582-18

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1239 GCTGGACGTGCCAT 1253
Db 15 GCTGGACATGCCCT 1

RESULT 530
US-08-282-197C-20
; Sequence 20, Application US/08282197C
; Patent No. 5871730
; GENERAL INFORMATION:
; APPLICANT: Brzezinski, Ryszard
; APPLICANT: Dery, Claude V
; APPLICANT: Beaulieu, Carole
; TITLE OF INVENTION: Thermostable Xylanase DNA, Protein and
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Steine, Kessler, Goldstein & Fox P.L.L.C.
; STREET: 1100 New York Ave., NW
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

```


APPLICATION NUMBER: US/08/282,197C
FILING DATE: 29-JUL-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Cimbala, Michele A.
REGISTRATION NUMBER: 33,851
REFERENCE/DOCKET NUMBER: 1050.0410000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-2600
TELEFAX: 202-371-2540
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: both
US-08-282-197C-20

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 73.3%; Pred. No. 2.3e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 530 AGGAGCAGCTGGTG 544
|||||
DB 2 AGGAGGAGCUGAUG 16

RESULT 531

US-08-137-024-2
Sequence 2, Application US/08137024
Patent No. 6005167

GENERAL INFORMATION:
APPLICANT: VAN TUNEN, Adrianus, J.
APPLICANT: VAN DER MEER, Ingrid M.
APPLICANT: MOL, Josephus N.M.
TITLE OF INVENTION: MALE-STERILE PLANTS, METHODS
TITLE OF INVENTION: FOR OBTAINING MALE STERILE
TITLE OF INVENTION: PLANTS AND RECOMBINANT DNA FOR
NUMBER OF SEQUENCES: 7

CORRESPONDENCE ADDRESS:
ADDRESSEE: Ladas & Parry
STREET: 26 West 61st Street
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10023

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette 3.50 inch, DS, DD 720
MEDIUM TYPE: Kb/720Kb
COMPUTER: IBM PC Compatible 286 SX 12 Mhz
OPERATING SYSTEM: DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/137,024
FILING DATE: 14-OCT-1993

CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/NL92/00075
FILING DATE: 15-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 91200910
FILING DATE: 16-APR-1991
ATTORNEY/AGENT INFORMATION:
NAME: MASS, Clifford, J.

REGISTRATION NUMBER: 30086
REFERENCE/DOCKET NUMBER: U-9373
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 708-1800
TELEFAX: (212) 246-8959
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: YES
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Petunia hybrida
US-08-137-024-2

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 387 AGAGTGGCAGCAAT 401
|||||
DB 2 AGAGTGCACAGAAAT 16

RESULT 532

US-08-817-145-8/c
Sequence 8, Application US/08817145
Patent No. 6025329

GENERAL INFORMATION:
APPLICANT: UTSUMI, Jun
APPLICANT: SUDO, Tetsuo
APPLICANT: TANAKA, Yasuhiko
APPLICANT: MATSUI, Mizuo
TITLE OF INVENTION: THERAPEUTIC AGENT FOR OPHTHALMIC
TITLE OF INVENTION: DISEASES
NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch, LLP.
STREET: P.O. Box 747
CITY: Falls Church
STATE: VA
COUNTRY: USA
ZIP: 22040-0747

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/817,145
FILING DATE: 02-JUL-1997

CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: MURPHY Jr., Gerald M.
REGISTRATION NUMBER: 28,977
REFERENCE/DOCKET NUMBER: 760-230P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Synthetic Primer"

US-08-817-145-8

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 625 GACCAGCTCCAGGAG 639
|||||
DB 16 GACGGCTCCAGGAG 2

```
RESULT 533
US-09-080-285-16/c
; Sequence 16, Application US/09080285
; Patent No. 6040181
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSER: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT,
; ADDRESSER: P.C.
; STREET: 1755 S. Jefferson Davis Hwy., Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/080,285
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/465,485
; FILING DATE: 05-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/124,256
; FILING DATE: 20-SEP-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/840,716
; FILING DATE: 21-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/288,692
; FILING DATE: 22-DEC-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Fortney, Andrew D.
; REGISTRATION NUMBER: 34,600
; REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 436-2070
; TELEFAX: (408) 436-2075
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
; US-09-080-285-16

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 187 CCCGCCGCCACCCG 201
Db 15 CCCGCCGCCGCTCCG 1

RESULT 534
US-09-071-845-1628/c
; Sequence 1628, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
```

```
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1628:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1628

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 595 CCCACCAGCTGAAG 609
Db 15 CCCACCAGCTGTAG 1

RESULT 535
US-09-266-596-18/c
; Sequence 18, Application US/09266596
; Patent No. 6218187
; GENERAL INFORMATION:
; APPLICANT: FINER, MITCHELL H.
; APPLICANT: DULL, THOMAS J.
; APPLICANT: ZSEBO, KRISTINA M.
; APPLICANT: COOKE, KEEGAN
; APPLICANT: FARSON, DEBORAH A.
; TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL TRANSDUCTION
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.
```

STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/266,596
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/517,488
FILING DATE: 21-AUG-1995
APPLICATION NUMBER: US 08/258,152
FILING DATE: 10-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-266-596-18

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1239 GCTGGACGTGGCCAT 1253
Db 15 GCTGGACATGGCCCT 1

RESULT 536
US-08-479-737-16/c
Sequence 16, Application US/08479737
Patent No. 6319494
GENERAL INFORMATION:
APPLICANT: Capon, Daniel J
Weiss, Arthur
Irving, Brian A
Roberts, Margo R
Zeebo, Kristina
TITLE OF INVENTION: CHIMERIC CHAINS FOR RECEPTOR ASSOCIATED
SIGNAL TRANSDUCTION PATHWAYS
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 Lakeside Drive
CITY: Foster City
STATE: California
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/479,737
FILING DATE: 07-JUN-1995
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/238,405
FILING DATE: 05-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Mandel, SaraLynn
REGISTRATION NUMBER: 31,853
REFERENCE/DOCKET NUMBER: Cell 5.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 358-9600
TELEFAX: (415) 358-0803
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-08-479-737-16

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1239 GCTGGACGTGGCCAT 1253
Db 15 GCTGGACATGGCCCT 1

RESULT 537
US-08-679-645-523
Sequence 523, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
APPLICANT: Edington, Brent E.
APPLICANT: McSwiggen, James A.
APPLICANT: Merlo, Patricia Ann Owens
APPLICANT: Guo, Lining
APPLICANT: Skokut, Thomas A.
APPLICANT: Young, Scott A.
APPLICANT: Folkerts, Otto
APPLICANT: Merlo, Donald J.
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
MODULATION OF GENE EXPRESSION
IN PLANTS
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645
FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 523:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-08-679-645-523

Query Match      0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 66.7%; Pred. No. 2.3e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      892 CTGCGGTACAGCGTG 906
Db      1 CUGCGGUUCAGCCUG 15

RESULT 538
US-08-475-442A-16/c
; Sequence 16, Application US/08475442A
; Patent No. 6407221
; GENERAL INFORMATION:
; APPLICANT: CAPON, DANIEL J
; APPLICANT: WEISS, ARTHUR
; APPLICANT: IRVING, BRIAN A
; APPLICANT: ROBERTS, MARGO R
; APPLICANT: ZSEBO, KRISTINA
; TITLE OF INVENTION: CHIMERIC CHAINS FOR
; RECEPTOR-ASSOCIATED SIGNAL TRANSDUCTION PATHWAYS
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,442A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/238,405
; FILING DATE: 05-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,194
; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/627,643
; FILING DATE: 14-DEC-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/09431
; FILING DATE: 12-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELLS.5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415)358-9600x131
; TELEFAX: (415)349-7392

```

```

; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-08-475-442A-16

Query Match      0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1239 GCTGGACGTGGCCAT 1253
Db      15 GCTGGACATGCCCT 1

RESULT 539
US-09-724-426-16/c
; Sequence 16, Application US/09724426
; Patent No. 6414134
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: Regulation of BCL-2 Gene Expression
; FILE REFERENCE: 10412-024
; CURRENT APPLICATION NUMBER: US/09/724,426
; CURRENT FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-724-426-16

Query Match      0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      187 CCGCGCGCCGCCG 201
Db      15 CCGCGCGCGCTCCG 1

RESULT 540
US-08-535-249-97
; Sequence 97, Application US/08535249
; Patent No. 6455689
; GENERAL INFORMATION:
; APPLICANT: Schlingensiepen, Georg-Ferdinand
; APPLICANT: Brysch, Wolfgang
; APPLICANT: Schlingensiepen, Karl-Hermann
; APPLICANT: Schlingensiepen, Reimar
; APPLICANT: Bogdahn, Ulrich
; TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
; immunosuppressive effect of transforming-growth-factor bet
; NUMBER OF SEQUENCES: 137
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/535,249
; FILING DATE:
; CLASSIFICATION: 514

```

```
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: EP 93 107 089.0
/ FILING DATE: 30-APR-1993
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: EP 93 107 849.7
/ FILING DATE: 13-MAY-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Player, William E.
/ REGISTRATION NUMBER: 31,409
/ REFERENCE/DOCKET NUMBER: 10577/P58418
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (202)638-6666
/ TELEFAX: (202) 393-5350
/ TELEX: RCA 248593 IDEA UR
/ INFORMATION FOR SEQ ID NO: 97:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: unknown
/ TOPOLOGY: unknown
/ MOLECULE TYPE: DNA (genomic)
/ ANTI-SENSE: YES
/ US-08-535-249-97

Query Match          0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1023 GTGCAAGTGCAGC 1037
Db 1 GTACAAAGTGCAGC 15

RESULT 541
US-09-916-228-14
/ Sequence 14, Application US/09916228
/ Patent No. 6498013
/ GENERAL INFORMATION:
/ APPLICANT: Velculescu, Victor
/ APPLICANT: Sparks, Andrew
/ APPLICANT: Kinzler, Kenneth
/ APPLICANT: Vogelstein, Bert
/ TITLE OF INVENTION: Serial analysis of transcript expression
/ TITLE OF INVENTION: using long tags
/ FILE REFERENCE: 00107.00172
/ CURRENT APPLICATION NUMBER: US/09/916,228
/ CURRENT FILING DATE: 2001-07-27
/ PRIOR APPLICATION NUMBER: 60/221,556
/ PRIOR FILING DATE: 2000-07-28
/ PRIOR APPLICATION NUMBER: 60/233,431
/ PRIOR FILING DATE: 2000-09-18
/ NUMBER OF SEQ ID NOS: 30
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 14
/ LENGTH: 16
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: tag or tag concatenamer
/ US-09-916-228-14

Query Match          0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 190 GCCGCCACCCGGAC 204
Db 1 GCCGCTCTCCCGAC 15

RESULT 542
US-09-944-411-18/c
/ Sequence 18, Application US/09944411
/ Patent No. 6506604
/ GENERAL INFORMATION:
/ APPLICANT: FINER, MITCHELL H.
/ DULL, THOMAS J.
/ ZSEBO, KRISTINA M.
/ COOKER, KERGAN
/ FARSON, DEBORAH A.
/ TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
/ VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTI
/ OF MAMMALIAN CELLS
/ NUMBER OF SEQUENCES: 48
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: CELL GENESYS, INC.
/ STREET: 322 LAKESIDE DRIVE
/ CITY: FOSTER CITY
/ STATE: CALIFORNIA
/ COUNTRY: USA
/ ZIP: 94404
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/944,411
/ FILING DATE: 04-Sep-2001
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/914,893
/ FILING DATE: <Unknown>
/ APPLICATION NUMBER: US 08/258,152
/ FILING DATE: 10-JUN-1994
/ APPLICATION NUMBER: US 08/076,299
/ FILING DATE: 11-JUN-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: KRUPEN, KAREN I.
/ REGISTRATION NUMBER: 34,647
/ REFERENCE/DOCKET NUMBER: CELL 13.3
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-358-9600 X131
/ TELEFAX: 415-349-7392
/ INFORMATION FOR SEQ ID NO: 18:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ SEQUENCE DESCRIPTION: SEQ ID NO: 18:
/ US-09-944-411-18

Query Match          0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1239 GCTGGACGTGGCCAT 1253
Db 15 GCTGGACATGGCCCT 1

RESULT 543
US-08-754-477A-38/c
/ Sequence 38, Application US/08754477A
/ Patent No. 6518411
/ GENERAL INFORMATION:
/ APPLICANT: Murray, Jeffrey
/ APPLICANT: Semina, Elena
/ TITLE OF INVENTION: RIEG COMPOSITIONS AND THERAPEUTIC
/ TITLE OF INVENTION: AND DIAGNOSTIC USES THEREFOR
/ NUMBER OF SEQUENCES: 139
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: FOLEY, HOAG & ELIOT LLP
/ STREET: One Post Office Square
```

;
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/754,477A
; FILING DATE: 22-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth E. 430
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: UIA-022.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 38:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; US-08-754-477A-38

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 720 CCAGCAGCGGGGCC 735
|||||
Db 16 CCAGGAGCGAGGCC 1

RESULT 544
US-09-060-299-420
; Sequence 420, Application US/09060299
; Patent No. 6545137
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: NO. 6545137el Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/060,299
; FILING DATE: 15-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-35
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 420:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-09-060-299-420

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5 AGGCAGTTGAGTGG 19
|||||
Db 1 AGGCAGTGCAGGCG 15

RESULT 545
US-09-402-923A-420
; Sequence 420, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: NO. 6555654el LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-Feb-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 420:

SEQUENCE CHARACTERISTICS:
 LENGTH: 16 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 SEQUENCE DESCRIPTION: SEQ ID NO: 420:

US-09-402-923A-420

Query Match 0.9%; Score 11.8; DB 1; Length 16;
 Best Local Similarity 86.7%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 5 AGGCAGTTGAGGTGG 19
 |||||
 Db 1 AGGCAGTTGAGGTGG 15

RESULT 546

US-09-371-772B-5660
 ; Sequence 5660, Application US/09371772B
 ; Patent No. 6566127

GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

FILE REFERENCE: MEBH00,876-J (237/198)
 CURRENT APPLICATION NUMBER: US/09/371,772B

CURRENT FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: PatentIn version 3.0

SEQ ID NO 5660

LENGTH: 16

TYPE: RNA

ORGANISM: Homo sapiens

US-09-371-772B-5660

Query Match 0.9%; Score 11.8; DB 1; Length 16;
 Best Local Similarity 60.0%; Pred. No. 2.3e+02;
 Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 299 CTGCTGTGGGGCTG 313
 |||||
 Db 2 CUGCUGGCGGCGUG 16

RESULT 547

US-09-371-772B-5661
 ; Sequence 5661, Application US/09371772B
 ; Patent No. 6566127

GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

FILE REFERENCE: MEBH00,876-J (237/198)
 CURRENT APPLICATION NUMBER: US/09/371,772B

CURRENT FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: PatentIn version 3.0

SEQ ID NO 5661

LENGTH: 16

TYPE: RNA

ORGANISM: Homo sapiens

US-09-371-772B-5661

Query Match 0.9%; Score 11.8; DB 1; Length 16;
 Best Local Similarity 60.0%; Pred. No. 2.3e+02;
 Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 300 TGCTGTGGGGCTGC 314
 |||||
 Db 1 UGCUGGCGGCGUGC 15

RESULT 548

PCT-US96-00331-19/c

Sequence 19, Application PC/TUS9600331
 GENERAL INFORMATION:

APPLICANT: GENTA INCORPORATED

TITLE OF INVENTION: METHODS AND COMPOSITION FOR

TITLE OF INVENTION: TREATING TUMOR CELLS

NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: California

ZIP: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US96/00331

FILING DATE: 10 JANUARY 1996

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/371,001

FILING DATE: 10 JANUARY 1995

ATTORNEY/AGENT INFORMATION:

NAME: BIGGS, SUZANNE L.

REGISTRATION NUMBER: 30,158

REFERENCE/DOCKET NUMBER: 218/068-PCT

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 19:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Other Nucleic Acid

ANTI-SENSE: Yes

PCT-US96-00331-19

Query Match 0.9%; Score 11.8; DB 1; Length 16;
 Best Local Similarity 86.7%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 487 CGGACGGTGTGCAG 501
 |||||
 Db 15 CGGACGATGTGCAG 1

RESULT 549

```

US-08-702-105A-33
; Sequence 33, Application US/08702105A
; Patent No. 5908839
; GENERAL INFORMATION:
; APPLICANT: Levitt, Roy C.
; APPLICANT: Maloy, W. Lee
; APPLICANT: Kari, U. Prasad
; APPLICANT: Nicolaides, Nicholas C.
; TITLE OF INVENTION: Asthma Associated Factors As Targets For
; TITLE OF INVENTION: Treating Atopic Allergies Including Asthma And Related
; TITLE OF INVENTION: Disorders
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; STREET: 1300 I Street N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/702,105A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/874,503
; FILING DATE: 13-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B.
; REGISTRATION NUMBER: 32984
; REFERENCE/DOCKET NUMBER: 05387.0056-01000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4400
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-702-105A-33

Query Match 0.9%; Score 11.6; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCGCAGC 819
Db 1 CTCCTCCCTGCAGCGCTACC 18

RESULT 550
US-08-702-110A-33
; Sequence 33, Application US/08702110A
; Patent No. 6037149
; GENERAL INFORMATION:
; APPLICANT: Levitt, Roy C.
; APPLICANT: Maloy, W. Lee
; APPLICANT: Kari, U. Prasad
; APPLICANT: Nicolaides, Nicholas C.
; TITLE OF INVENTION: Asthma Associated Factors As Targets For
; TITLE OF INVENTION: Treating Atopic Allergies Including Asthma And Related
; TITLE OF INVENTION: Disorders
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; STREET: 1300 I Street N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/702,105A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/874,503
; FILING DATE: 13-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B.
; REGISTRATION NUMBER: 32984
; REFERENCE/DOCKET NUMBER: 05387.0056-01000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4400
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-702-105A-33

Query Match 0.9%; Score 11.6; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCGCAGC 819
Db 1 CTCCTCCCTGCAGCGCTACC 18

```

```

; STREET: 1300 I Street N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/702,110A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/874,503
; FILING DATE: 13-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B.
; REGISTRATION NUMBER: 32984
; REFERENCE/DOCKET NUMBER: 05387.0056-01000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-702-110A-33

```

```

Query Match 0.9%; Score 11.6; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY 802 CGCTCCCTGCAGCGCAGC 819
Db 1 CTCCTCCCTGCAGCGCTACC 18

```

```

Search completed: January 8, 2004, 16:43:46
Job time : 17 secs

```